<SEC-DOCUMENT>0000950170-24-075875.txt : 20240621
<SEC-HEADER>0000950170-24-075875.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621073032
ACCESSION NUMBER:		0000950170-24-075875
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acasti Pharma Inc.
		CENTRAL INDEX KEY:			0001444192
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35776
		FILM NUMBER:		241058348

	BUSINESS ADDRESS:	
		STREET 1:		103 CARNEGIE CENTER
		STREET 2:		SUITE 300
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		609-649-9272

	MAIL ADDRESS:	
		STREET 1:		103 CARNEGIE CENTER
		STREET 2:		SUITE 300
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>acst-20240331.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-06-20T20:11:56.7481+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:acst="http://www.acastipharma.com/20240331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_28f1112b-def6-4587-b528-3cebd6c76aa4" name="dei:DocumentFiscalPeriodFocus" contextRef="C_779b151d-a506-4172-855a-bc523254a908">FY</ix:nonNumeric><ix:nonNumeric id="F_30be03b4-e4f4-4dce-949c-e09978481870" name="dei:AmendmentFlag" contextRef="C_779b151d-a506-4172-855a-bc523254a908">false</ix:nonNumeric><ix:nonNumeric id="F_a31b75df-fbc8-4aa6-92e5-db9704015b28" name="dei:EntityCentralIndexKey" contextRef="C_779b151d-a506-4172-855a-bc523254a908">0001444192</ix:nonNumeric><ix:nonNumeric id="F_7f7405dd-efe9-4caf-811f-fdb52e358109" name="dei:CurrentFiscalYearEndDate" contextRef="C_779b151d-a506-4172-855a-bc523254a908">--03-31</ix:nonNumeric><ix:nonFraction id="F_5b47b599-a873-4c0c-821a-222ef6337cf1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_728ff52a-c3c5-4df3-8d06-ae1526751ba6" name="us-gaap:CommitmentsAndContingencies" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" unitRef="U_USD" xsi:nil="true"/><ix:nonNumeric id="F_f132cd30-7902-4315-8127-ab7bcce7e6f9" name="us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques" contextRef="C_779b151d-a506-4172-855a-bc523254a908">0</ix:nonNumeric><ix:nonNumeric id="F_c1a9517d-f266-4d79-aeb0-1c8917bd2b32" name="us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6">0</ix:nonNumeric><ix:nonNumeric id="F_35eb60b8-303d-4e25-9601-0886d5998462" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" format="ixt-sec:duryear">0</ix:nonNumeric><ix:nonNumeric id="F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_779b151d-a506-4172-855a-bc523254a908">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acst-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="C_b74594a6-c75b-40ac-87aa-02fea55113f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02572285-4b65-41c8-8fa4-f3dc4a164d60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9938b6f-8e2c-45cd-b9a7-e5a38fc58fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-24</xbrli:startDate><xbrli:endDate>2023-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b554ace-39ee-4357-9ded-83838c05db04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c949238-1cb2-49d3-a7a9-6006bf23a15b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bab073f-8e03-425b-882d-ee0197687a29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3487dee3-4575-436c-8773-9c3b4bf9b897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:SoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_189b018a-6b9e-4d85-84a9-062a43fb0c41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84420b03-d4bf-41a4-a1dc-c3a81a813802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">acst:RKOSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76b72763-8a2d-4d7e-aea2-4b623c8e60f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91f3906a-c565-4e1c-b09c-103612aaa49a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e235b4c9-4adf-47cc-a3e3-c01fd379a76e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0ba7fe9-844a-4c36-9819-69617b6b15f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f34c5198-014f-4f67-a218-f5719b424883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7597480c-39df-45e1-9922-7010d9c4c72a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1eefc74f-a703-4dea-ae7e-ea4e331b81be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_407b0177-7169-41e6-882e-472705b1636f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYearTwoThousandFortyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16d16afb-4a44-408e-a2a5-100f7c0b1fbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faccd42d-8b25-4802-9d19-2b48cbbde167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:May2018PublicOfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dce797e5-6a6c-417b-b7d7-6195591f7d0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4f8e9bd-4546-4f0a-afa5-60be369c087e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c9a0299-cb67-4749-8a76-c93fb0ab71bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-19</xbrli:startDate><xbrli:endDate>2023-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_349e1080-b426-4ed9-a578-476efce50cf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f7e0aa5-ee77-4502-b721-627acdac5133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99120ca0-a7fe-43e2-936c-fcfed03ae232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05adfb7b-9ddc-4cc6-873f-b2dd8d56c9c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70f162d2-db64-4bf0-91a3-884865073097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1be0d73c-b1f4-423e-aa12-2a42820f8ecb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acst:WarrantsIssuedInMay2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_039d64a4-88b3-4aa8-9f0d-bfbbffcaad9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8187204f-303d-4869-a819-a4eb7d6028a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc813500-db81-42bc-be45-0769d86cdfbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_705dbe6d-a676-4e14-8f68-1447dd74db79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:September2023CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a51f099-2623-4ca7-bec5-744e473c2a07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_572273b4-60a1-4bad-97f2-b3aeeca1fc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cece337-a016-4efc-9a7d-ad4598442843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a24fef3-a068-4ca4-8dac-1a23822d569c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06ea57a9-3a97-4d7a-9bd1-eecd71be02df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9bbd593-6189-421e-8104-e8b8f59ded6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c5dc6d-7785-4018-a4a0-3981b25c8bab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c543260-cf22-4eb7-a1f7-51cc4741bc47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f8fe5fb-ef11-4634-a474-acca8f534421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3475cb4c-b4fd-423d-8077-b5c595ff8757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fea751d3-7614-4442-a3db-d6540fa51879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96f34336-bce0-4b05-bf5a-f6a008568ba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0238deb6-4fe5-4dd5-8a50-1ee0d936549a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d43202e2-7d88-42ec-9006-9b5d92669112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4272963-8b80-42bd-8469-469e87f57dc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f61b02f5-57f3-4c12-8cf6-ac25efbcbdaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95d10643-bfd0-4043-b9c9-ff71cc4ed89f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50bbc2ae-76a4-43e0-848e-139f93c827d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9c4389a-7f67-4bbf-a637-b694aeda8261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c869cf00-c0af-4b98-825d-27c8d211e38b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9de35410-3114-4f88-8550-bba2bee392fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ece0ac7f-6585-46e8-9205-a30ad7140159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a4ddfce-2b5b-46d2-8208-60d8a22d52e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f166744b-f3f7-45e1-bdd4-2768e6ef6d20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b87163d-8c7c-418f-bf82-a0fb5e3ddc84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acst:CommonClassDAndCommonClassEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2555b6e-b437-4ba8-9563-def690c61ff9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e7ece24-7a7f-426a-bbb4-52d87842bae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:Taxyear2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c54e8e1-ca7e-47f6-aaac-354c7f5c59dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cc0c4ab-5764-4050-862c-4ecc5ff57375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af2c1513-5cb1-454d-9540-187ad7be9278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c620743-7648-4a40-9f52-ad9e1ce7c425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31aacf07-7739-466d-9474-24f3d1e9ad89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4d697ac-eda3-4464-bee3-640ff429e5f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc8f5eed-e387-4957-ae1f-a00211fe78a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3eda1d7-9329-4b09-81c9-72ab4a9683c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8860ddc-a67b-4cbc-b6fe-22b8b851fe21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_212e94e2-e50a-4b7d-b58b-26d56a137061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c73f5261-e930-4ac2-9ecb-307f85b47d05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-14</xbrli:startDate><xbrli:endDate>2022-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6ef368e-0ee3-4ea0-acc8-95b6fb55d6e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee140fde-ec8b-4597-a458-9c1426a405b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8fa8a4a-743c-49ee-8a05-07e36d9b8934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5755bb0-b1b3-4e1a-b0d2-be4c6caa330f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46a52c6b-9951-44a8-8b8a-3cb9cb3e2439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58a0300e-46b5-4e90-9cfb-76e05e952710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b3364b9-6260-4b70-b7c1-3323e1ed6f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1661c524-65aa-434f-8b9c-ae631dd5b8bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_312bbb54-59d2-4300-b0d4-eef44282cdc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64eefdf8-8725-4487-9627-312c2276a125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32f95ce9-670d-452f-9fc1-58e64efe3142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f539434-13da-4ff9-88f7-5a546b91d0a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebcea23f-4694-41c8-85d2-30c548c5e8cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae60a243-9e5e-4f54-9f15-fb2ec877bb50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88cfac6a-e085-4d1e-9bee-16ee91a78d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3cca4b1-352c-4004-9c30-f04a2f7b79e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec4dd3d8-0001-4568-9915-fb4ca638ab8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36c24d42-fa01-40ca-a916-10d853ad79e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b745745-fcfd-4873-8e48-fa848811c654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d32a6e4-7a1f-4468-9246-d1db4a2f87d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2032Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56f5d179-a218-4d6e-93bf-c19733becaf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_684d5200-1c42-4272-8ca3-5608277c5be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b13b7d2-4aec-4346-9923-ef74e0f85053"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_422f9f9e-ac11-4222-817c-49c40bebb380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8143206-01c5-47e6-bf77-ccbbaa1a348e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_177feeb1-7b04-48ce-809a-866ea0b27de7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d061b65-1b50-45f5-aae5-b793fa09c563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c53e60b0-79a5-4d64-a657-f5b786c9594d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43242c92-e78b-4540-8623-9f75dbf73cb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:NoExpiryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4875e2a5-c34c-4bb6-b0fb-5d1c12cb8c02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7da55c0e-6ba5-4e9e-acd7-dac4568958a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a918cbd-dff3-4510-9992-8767c4195fdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46e5f6eb-b6a7-4f98-a854-ed3f302b7714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-25</xbrli:startDate><xbrli:endDate>2023-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6847874-0331-463a-bd4c-c694ab172b42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">acst:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8a2346d-c203-40c2-a5ab-e2216e6c3d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60ef9157-75f4-4a1e-b25c-2842ef0acc4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1b778e5-8b0d-438a-a6f2-684bd8df12a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f20daba8-2053-470f-8d6f-36c41659af0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c74a6eaf-0060-4554-9488-83e6d43a52c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77630b6d-9f63-49f0-aacd-228e5510fa1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7db0708e-187a-44e4-abc2-9ab65651e41b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec22031c-0a4b-4387-bbb7-0033acfa1768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eeacd49-7941-4477-961d-d7f222f3cc8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac3b545c-c1db-46c4-aa78-4fb7c590da00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5433bae-dcf1-457b-9735-b5bec1fca459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c54d6f0f-6fce-44a5-ad0b-79bf1eed26d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe78ca06-1c34-4828-b4ae-24b1dc14563f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_057790a0-605f-41ca-8ce9-91d483af8647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d2dbb68-f420-44ed-9aef-e0dcbd842219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_269f269e-95bb-4430-b89f-d436cbeaad91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15d1ffe6-b2f5-4746-93b3-3b9ddcb8c862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a6f8b28-b6c2-44d2-94e9-944ce97688d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_054f3d0b-11e9-4f9b-8d91-3b83f491df0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61d31cb9-015a-447b-92c1-edb57605af5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e9c3508-8c04-4935-ae0d-c619d66df6eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acst:CommonClassDAndCommonClassEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b379b9ec-28ea-4a40-b95f-8839111c5b29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8030229f-2b04-4173-a95b-ae174f4c06f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_779b151d-a506-4172-855a-bc523254a908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10f930e5-d54c-408c-9930-ba4f2a0de948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acst:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e835e3c2-21d5-4811-900e-7ca8a2f1e162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a12b334-af4e-4c1d-ad64-bc70258d8ef0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84b40618-5675-4dc0-9e64-a517f28f6d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_158d50e3-c6b0-4b7c-9cec-bc5c37a93fe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3dbe7f3-a4f8-4b41-ba66-ea50c892e380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-14</xbrli:startDate><xbrli:endDate>2023-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cec2bdb-71d8-4eef-a7e4-2a57bd60925d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a03babd-18d1-4097-a9d4-1044dab8ecf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f5f8bdc-5660-4849-adbb-453fc624895a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2dac555-c59d-4a9e-b6eb-37a8e4c83dd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_140a03c6-59fa-4092-bf9c-59104fc56516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3acbfd2e-cc52-456d-8a30-89f859728e78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d5eb575-72d3-4658-845e-185baceef441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">acst:ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c04ee66d-800b-4148-956d-a12fb82c62b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d6702e5-9571-48ee-81a7-d74ef46344e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecbe80f6-d6d3-483e-97b0-82b3081bda3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acst:CommonClassDAndCommonClassEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4569b27-2312-4bd8-be26-e61127f1dfc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_893afca7-27f1-4faa-8652-ebeea1283a01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b91b8c0b-647a-4df0-b491-de3b7226a402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:September2023CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2de077db-85fa-42b0-920e-a1103a07c7f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ede5bf9-460b-4689-8dc5-21171a08b231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_940b8ef1-f85d-4c61-b94a-bffc507b9e8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e0b6d2b-f94b-4c26-b5cb-495d338020d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba9a56ec-eeb4-420e-a520-410844ea86c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f951dabc-33fe-47d3-a362-7aa2e816d7cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:CommonWarrantAndPreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2b01b48-402b-4dc7-b752-a7f73d31bb54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e6bc244-b6c6-4d8b-a073-be202a4ef494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c11690fb-a2e6-428a-b417-46b840d84bbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67401b5c-e353-4b98-9f09-f2f145bc81df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe4fb9d8-fe31-4fd9-9a01-c7618803d7a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5dad982-0286-46ce-aa2c-9586c4730f1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_545ec182-f542-4e2b-9855-4b55b11f191b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-25</xbrli:startDate><xbrli:endDate>2023-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1756eb23-2e0b-48cb-9d20-d1c0db7eddbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d951ff5b-4e5d-465a-855a-f551e8825d5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f687fe2-5a55-4bed-a8a0-8cc695040f45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bf52d38-93c0-4416-ab44-ea0729cc861e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-25</xbrli:startDate><xbrli:endDate>2023-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7da7b073-43df-4431-96b2-512ccdc4cb73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec51c81d-0491-4f6a-87b8-469f68295a7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d1b1042-fd07-435a-9f9e-ae6291bd7e13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:May2018PublicOfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_005474d3-953e-419e-8e1d-8a618e56041f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97daaea2-edbc-4684-b715-e135f9491b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:Taxyear2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bc7c602-b685-4c20-b95a-4e946d0e035c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">acst:RKOSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd8d29d2-fb73-44c0-8b8f-697d5ef239fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_CadShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>acst:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:15pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f94b48a7-9f50-44b4-a7d8-23e21f3ee6a9" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_754da8a7-dd2a-4c14-8828-6e00f3f3be56" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_301b23d0-e74f-4da5-8764-fea95244e4dc" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b5498ba-66d3-458d-b977-782b9d2d70ad" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56988faa-83af-49e3-a290-db268700ab03" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:44.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.727%;"/>
    <td style="width:22.727%;"/>
    <td style="width:6.818%;"/>
    <td style="width:22.727%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the transition period from</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">to</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission file number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_044395f7-c0e5-4b88-a85e-ed56d74d5ae3" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-35776</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_881789a4-04e2-4516-93f1-06ac18820cfb" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></ix:nonNumeric></span></p>
  <p style="margin-left:0.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Qu&#233;bec, </span><span><ix:nonNumeric id="F_187d0bde-4b37-42dc-9903-f7ae2fdf2c78" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Canada</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a7a33f2d-1d33-468f-ad37-a48702fc3146" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">98-1359336</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation or organization)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:10.7pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer Identification Number)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f0fb4ef-102d-45e5-aa8d-313c8fd89b8e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103 Carnegie Center Suite 300</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9beb0724-e718-43d3-adb1-38e5ded54a22" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Princeton</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea5f32f2-b350-4de8-b5b6-d9a895204654" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New Jersey</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c29f70c2-91c3-4560-ad6f-9db64f31d2f3" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">08540</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4db0e6ed-2cc5-4b33-8c7a-1950d1aafb99" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">818</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31ff6fcd-a7cb-4f10-90ff-6199218f80bb" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">839-4378</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.96%;"/>
    <td style="width:34.08%;"/>
    <td style="width:32.96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:1.5pt solid #000000;padding-top:0.01in;border-left:1.5pt solid #000000;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:1.5pt solid #000000;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:1.5pt solid #000000;padding-top:0.01in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:1.5pt solid #000000;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:1.5pt solid #000000;padding-top:0.01in;border-right:1.5pt solid #000000;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:1.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.003in;border-left:1.5pt solid #000000;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9.5pt;"><ix:nonNumeric id="F_647e4899-67d6-45fc-bbb5-4fce133be173" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Shares, no par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9.5pt;"><ix:nonNumeric id="F_590a15bc-3e42-40be-bc1e-c5ab9883fa44" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ACST</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;border-right:1.5pt solid #000000;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9.5pt;"><ix:nonNumeric id="F_f3ce4ebd-b258-4576-ae4c-0131272fcb45" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;   </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c6ac46e-58ea-4bf6-88ba-16ce6ad1e6dc" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744;  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86a6f8fa-4ce7-4b97-ae56-c287eff40efd" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_483c7efd-36cf-48c6-b33c-2c4f2c2e3999" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7f31a44-298e-4304-8862-3698782b9a2e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:40%;"/>
    <td style="width:32%;"/>
    <td style="width:3%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4b8ca543-8ee3-47b5-bf9f-f0d13170bb47" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_96227b4d-db2e-412a-898e-043ba48a714e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:40%;"/>
    <td style="width:32%;"/>
    <td style="width:3%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_24cfae39-7561-400f-aa9f-c495cf96937b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes &#9744;   No </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57190108-c82c-456c-9bbe-838d1e63074b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5423cb69-f9f7-408a-8df5-144c61295096" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;        Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes &#9744;   No </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec62fee9-def4-4291-808f-5da6d7dc66a5" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting common shares held by non-affiliates of the registrant, based on the closing sale price of the registrant&#8217;s common shares on the last business day of its most recently com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pleted second fiscal quarter, as reported on the Nasdaq Stock Market LLC, was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cef15303-644e-4215-a272-3c44ade39d26" contextRef="C_d6ef368e-0ee3-4ea0-acc8-95b6fb55d6e2" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17,617,435</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The number of outstanding common shares of the registrant, no par value per share, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 21, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c38179b-0864-4f48-8562-40794ce9a1d3" contextRef="C_5f7e0aa5-ee77-4502-b721-627acdac5133" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,399,404</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auditor Firm Id: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f619f8e7-a6dc-4e47-8f6e-7b281c1833ba" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                  Auditor Name: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_417424aa-1a2a-41c1-828f-b9526c270c56" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                Auditor Location: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ffa285d-334a-4df8-a105-a7af42ceeb8b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Philadelphia, Pennsylvania, United States</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Former Auditor Firm Id: 1263   Auditor Name: Ernst &amp; Young LLP   Auditor Location: Montr&#233;al, QC, Canada</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM 10-K</span></p>
  <p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Fiscal Year Ended March 31, 2024</span></p>
  <p style="font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:1.037%;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.383%;"/>
    <td style="width:7.447%;"/>
    <td style="width:81.66%;"/>
    <td style="width:4.511%;"/>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1A</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">29</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_registrant_common_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">48</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">53</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">54</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 7A</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_f_s_supplementary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_accounts_f_d"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9A</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedure"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers_c_g"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">80</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Item 16.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item16_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains information that may be forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which we refer to in this Annual Report on Form 10-K as forward-looking information. Forward-looking information can be identified by the use of terms such as &#8220;may&#8221;,&#8221; &#8220;will&#8221;,&#8221; &#8220;should&#8221;,&#8221; &#8220;expect&#8221;,&#8221; &#8220;plan&#8221;,&#8221; &#8220;anticipate&#8221;,&#8221; &#8220;believe&#8221;,&#8221; &#8220;intend&#8221;,&#8221; &#8220;estimate&#8221;,&#8221; &#8220;predict&#8221;,&#8221; &#8220;potential&#8221;,&#8221; &#8220;continue&#8221; or other similar expressions concerning matters that are not statements about the present or historical facts. Forward-looking information in this Annual Report on Form 10-K includes, among other things, information or statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to build a premier, late-stage pharmaceutical company focused in rare and orphan diseases and, on developing and commercializing products that improve clinical outcomes using our novel drug delivery technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, and more convenient drug delivery that can result in increased patient compliance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential for our drug candidates to receive orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or regulatory approval under the Section 505 (b)(2) regulatory pathway under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the future prospects of our GTX-104 drug candidate, including but not limited to GTX-104&#8217;s potential to be administered to improve the management of hypotension in patients with aneurysmal subarachnoid hemorrhage (&#8220;aSAH&#8221;); GTX-104&#8217;s potential to reduce the incidence of vasospasm in aSAH patients resulting in better outcomes; the ability of GTX-104 to achieve a pharmacokinetic (&#8220;PK&#8221;) and safety profile similar to the oral form of nimodipine; GTX-104&#8217;s potential to provide improved bioavailability and the potential for reduced use of rescue therapies, such as vasopressors in patients with aSAH the timing and outcome of the Phase 3 safety study for GTX-104; our ability to ultimately file a new drug application (&#8220;NDA&#8221;) for GTX-104 under Section 505 (b)(2) of the FDCA; and the timing and ability to receive FDA approval for marketing GTX-104;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plan to prioritize the development of GTX-104;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plan to maximize the value of our de-prioritized drug candidates, GTX-102 and GTX-101, including through potential development, out-licensing or sale of those drug candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the future prospects of our GTX-102 drug candidate, including but not limited to GTX-102&#8217;s potential to provide clinical benefits to decrease symptoms associated with Ataxia Telangiectasia (&#8220;A-T&#8221;); GTX-102&#8217;s potential ease of drug administration; the timing and outcomes of a PK bridging study and Phase 3 efficacy and safety study for GTX-102; the timing of an NDA filing under Section 505 (b)(2) in connection with GTX-102; and the ability to receive FDA approval for marketing GTX-102;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the future prospects of our GTX-101 drug candidate, including but not limited to GTX-101&#8217;s potential to be administered to postherpetic neuralgia (&#8220;PHN&#8221;) patients to treat the severe nerve pain associated with the disease; assumptions about the biphasic delivery mechanism of GTX-101, including its potential for rapid onset and continuous pain relief for up to eight hours; and the timing and outcomes of single ascending dose/multiple ascending dose and PK bridging studies, and a Phase 2 and Phase 3 efficacy and safety study; the timing of an NDA filing under Section 505 (b)(2) for GTX-101; and the timing and ability to receive FDA approval for marketing GTX-101;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the quality of our clinical data, the cost and size of our development programs, expectations and forecasts related to our target markets and the size of our target markets; the cost and size of our commercial infrastructure and manufacturing needs in the United States, European Union, and the rest of the world; and our expected use of a range of third-party contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;) at multiple locations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expectations and forecasts related to our intellectual property portfolio, including but not limited to the probability of receiving orphan drug designation from the FDA for our leading pipeline drug candidates; our patent portfolio strategy; and outcomes of our patent filings and extent of patent protection;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position and duration of our patent rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our strategy, future operations, prospects and the plans of our management with a goal to enhance shareholder value</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need for additional financing, and our estimates regarding our operating runway and timing for future financing and capital requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectation regarding our financial performance, including our costs and expenses, liquidity, and capital resources;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our projected capital requirements to fund our anticipated expenses; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish strategic partnerships or commercial collaborations or obtain non-dilutive funding.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the forward-looking statements in this Annual Report on Form 10-K  are subject to a number of known and unknown risks, uncertainties and other factors many of which are beyond our control, that could cause our actual results and developments to differ materially from those that are disclosed in or implied by the forward-looking statements, including, among others:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we are heavily dependent on the success of our lead drug candidate, GTX-104;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we are subject to uncertainty relating to healthcare reform measures and reimbursement policies that, if not favorable to our drug candidates, could hinder or prevent our drug candidates&#8217; commercial success;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug products, if approved, we may be unable to generate any revenue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we are unable to differentiate our drug products from branded reference drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve products that compete with any of our drug products, our ability to successfully commercialize our drug products would be adversely affected</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our success depends in part upon our ability to protect our intellectual property for our drug candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property rights do not necessarily address all potential threats to our competitive advantage;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we do not have internal manufacturing capabilities, and if we fail to develop and maintain supply relationships with various third-party manufacturers, we may be unable to develop or commercialize our drug candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design, development, manufacture, supply, and distribution of our drug candidates are highly regulated and technically complex; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other risks and uncertainties identified in Item 1A. Risk Factors included in this Annual Report on Form 10-K.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the forward-looking statements in this Annual Report on Form 10-K are qualified by this cautionary statement. There can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the consequences or effects on our business, financial condition, or results of operations that we anticipate. As a result, you should not place undue reliance on the forward-looking statements. Except as required by applicable law, we do not undertake to update or amend any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are made as of the date of this annual report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We express all amounts in this Annual Report on Form 10-K in U.S. dollars, except where otherwise indicated. References to &#8220;$&#8221; and &#8220;U.S.$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; or &#8220;CAD$&#8221; are to Canadian dollars.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise indicated, references in this Annual Report on Form 10-K to &#8220;Acasti,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Acasti Pharma Inc. and its consolidated subsidiaries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Factor Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects and/or cause the price of our common shares to decline. For more information, see &#8220;Item 1A. Risk Factors&#8221; in this Form 10-K. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, the following:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors Relating to our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not achieve our publicly announced milestones on time, or at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are heavily dependent on the success of our lead drug candidate, GTX-104.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to maximize value from our de-prioritized drug candidates, GTX-102 and GTX-101, through development, out-licensing or sale.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to maintain our operations and advance our research and development and commercialization of GTX-104 without additional funding.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face potential product liability, and if claims are brought against us, we may incur substantial liability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Development, Testing and Commercialization of Our Products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our drug candidates receive regulatory approval in the United States, we may never obtain regulatory approval or successfully commercialize our products outside of the United States.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to uncertainty relating to healthcare reform measures and reimbursement policies which, if not favorable to our drug candidates, could hinder or prevent our drug candidates&#8217; commercial success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon attaining significant market acceptance of our drug candidates and drug products, if approved, among physicians, nurses, pharmacists, patients and the medical community.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate any revenue.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we obtain approval to commercialize any approved drug products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to differentiate our drug candidates from branded reference drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve generic products that compete with any of our drug candidates, our ability to successfully commercialize our drug candidates would be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA does not conclude that our drug candidates satisfy the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements for approval of any of our drug candidates under Section 505(b)(2) are not as we expect, the approval pathway for our drug candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and could jeopardize or delay our ability to obtain regulatory approval and commence drug product sales. We may also find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our drug candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our drug development strategy relies heavily upon the 505(b)(2) regulatory pathway, which requires us to certify that we do not infringe upon third-party patents covering approved drugs. Such certifications often result in third-party claims of intellectual property infringement, the defense of which can be costly and time consuming, and an unfavorable outcome in any such litigation may prevent or delay our development and commercialization efforts, which would harm our business.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to obtain regulatory approval for each of our drug candidates in each jurisdiction in which we intend to market such products, and the inability to obtain such approvals would limit our ability to realize their full market potential.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Relating to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part upon our ability to protect our intellectual property for our branded drug products and drug candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies for intangible assets prove to be incorrect, further impairment charges could result.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to manufacture commercial and clinical supplies of our drug candidates, and we intend to rely on third parties to manufacture commercial supplies of any approved drug products. The commercialization of any of our drug products could be stopped, delayed, or made less profitable if those third parties fail to provide us with sufficient quantities of active pharmaceutical ingredients, excipients, or drug products, or fail to do so at acceptable quality levels or prices or fail to maintain or achieve satisfactory regulatory compliance.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in maintaining development and commercialization collaborations, and any partner may not devote sufficient resources to the development or commercialization of our drug candidates or may otherwise fail in development or commercialization efforts, which could adversely affect our ability to develop certain of our drug candidates and our financial condition and operating results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Tax</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a significant risk that we may be classified as a PFIC for U.S. federal income tax purposes.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to use our net operating loss carry forwards to offset future taxable income for Canadian or U.S. federal income tax purposes.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Internal Revenue Service (&#8220;IRS&#8221;) may not agree that we should be treated as a foreign company for U.S. federal tax purposes.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Relating to Ownership of our Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to pay any cash dividends for the foreseeable future.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our common shares may be volatile.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to our technologies or drug candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to meet applicable listing requirements, Nasdaq may delist our common shares from trading, in which case the liquidity and market price of our common shares could decline.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may pursue opportunities or transactions that adversely affect our business and financial condition.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a Qu&#233;bec incorporated company, and U.S. investors may be unable to enforce certain judgments against us.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note Regarding Reverse Stock Split</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company effected a reverse stock split of its authorized and issued Class A common shares, no par value per share (the &#8220;Common Shares), at a ratio of 1-for-6, effective as of July 10, 2023, for the purpose of complying with Nasdaq Listing Rule 5550(a)(2). We have reflected the reverse stock split herein, unless otherwise indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Business</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by Acasti may be already approved in a target indication or could be repurposed for use in new indications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The existing well understood efficacy and safety profiles of these marketed compounds provides the opportunity for us to utilize the Section 505(b)(2) regulatory pathway under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) for the development of our reformulated versions of these drugs, and therefore may provide a potentially shorter path to regulatory approval. Under Section 505(b)(2), if sufficient support of a product&#8217;s safety and efficacy either through previous U.S. Food and Drug Administration ("FDA") experience or sufficiently within the existing and accepted scientific literature, can be established, it may eliminate the need to conduct some of the pre-clinical studies and clinical trials that new drug candidates might otherwise require.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our therapeutic pipeline consists of three unique clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions worldwide. These drug candidates aim to improve clinical outcomes in the treatment of rare and orphan diseases by applying proprietary formulation and drug delivery technologies to existing pharmaceutical compounds to achieve improvements over the current standard of care, or to provide treatment for diseases with no currently approved therapies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that rare disorders represent an attractive area for drug development, and there remains an opportunity for us to utilize already approved drugs that have established safety profiles and clinical experience to potentially address significant unmet medical needs. A key advantage of pursuing therapies for rare disorders is the potential to receive orphan drug designation (&#8220;ODD&#8221;) from the FDA. Our three drug candidates have received ODD status, provided certain conditions are met at new drug application ("NDA") approval. ODD provides for seven years of marketing exclusivity in the United States post-launch, provided certain conditions are met, and the potential for faster regulatory review. ODD status can also result in tax credits of up to 50% of clinical development costs conducted in the United States upon marketing approval and a waiver of the NDA fees, which we estimate can translate into savings of approximately $3.2 million for our lead drug candidate, GTX-104. Developing drugs for rare diseases can often allow for clinical trials that are more manageably scaled and may require a smaller, more targeted commercial infrastructure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The specific diseases targeted for drug development by us are well understood, although the patient populations suffering from such diseases may remain poorly served by available therapies or, in some cases, approved therapies do not yet exist. We aim to effectively treat debilitating symptoms that result from these underlying diseases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead drug candidate:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous ("IV") infusion in aneurysmal subarachnoid hemorrhage ("aSAH") patients to address significant unmet medical needs. The unique nanoparticle technology of GTX-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. IV delivery of GTX-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTX-104 has the potential to better manage hypotension in aSAH patients. GTX-104 has been administered in over 150 healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic ("PK") variability compared to oral nimodipine. On October 23, 2023, we enrolled our first patient in our pivotal Phase 3 safety trial to evaluate GTX-104 in patients hospitalized for aSAH. Patient enrollment in the STRIVE-ON Phase 3 trial is continuing, and potential NDA submission with the FDA is anticipated to occur in the first half of calendar 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other pipeline drug candidates:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-102, an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia (&#8220;A-T&#8221;), a complex orphan pediatric genetic neurodegenerative disorder usually diagnosed in young children, for which no FDA approved treatment currently exists.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-101, a topical bioadhesive film-forming bupivacaine spray for Postherpetic Neuralgia (&#8220;PHN&#8221;), which can be persistent and often causes debilitating pain following infection by the shingles virus. We believe that GTX-101 could be administered to patients with PHN to treat pain associated with the disease.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we announced the strategic decision to prioritize development of GTX-104 with a goal to advance the product candidate to commercialization, while conserving resources as much as possible to complete development efficiently. We estimate that the deferral of GTX-102 and GTX-101 clinical development could be at least three years from April 2023, given the timeline to complete the development and potential commercial launch of GTX-104. Further development of GTX-102 and GTX-101 will occur at such time as we obtain additional funding, or enter into strategic partnerships for license or sale with third parties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The decision to defer further development of GTX-102 and GTX-101 triggered a comprehensive impairment review of our intangible assets as of March 31, 2023. Given the extended timeline, we increased the discount rates used to value the related assets in order to recognize additional risks related to prioritizing one asset over the others, the financing for the projects given limited available resources and the need to preserve cash to advance GTX-104 as far as possible, potential competitor advances that could arise over three years, the general market depression affecting small cap development companies like us, and the prohibitively high dilution and expense of available funding in the capital markets. Increasing the discount rates significantly reduced the discounted cash flow values for each of the programs deferred. Accordingly, in the year ended March 31, 2023, we recorded impairment charges related to GTX-102 and GTX-101 of $22.7 million and $6.0 million respectively, together with further adjustments made to deferred taxes and goodwill directly related to those assets. The aggregate impairment charge was $33.5 million. We continue to believe that GTX-102 and GTX-101 may eventually provide significant value when development resumes and, if approved, commercialized successfully.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management team possesses significant experience in drug formulation and drug delivery research and development, clinical and pharmaceutical development and manufacturing, regulatory affairs, and business development, as well as being well-versed in late-stage drug development and commercialization. Importantly, our team is comprised of industry professionals with deep expertise and knowledge, including a world-renowned practicing neurosurgeon-scientist and respected authority in aSAH, as well as product development, chemistry, manufacturing and controls (&#8220;CMC&#8221;), planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for GTX-104, and drug commercialization.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-104 Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nimodipine was granted FDA approval in 1988, and is the only approved drug that has been clinically shown to improve neurological outcomes in aSAH patients. It is only available in the United States as a generic oral capsule and as a branded oral liquid solution called NYMALIZE&#153;, which is manufactured and sold by Arbor Pharmaceuticals (acquired in September 2021 by Azurity Pharmaceuticals). Nimodipine has poor water solubility and high permeability characteristics as a result of its high lipophilicity. Additionally, orally administered nimodipine has dose-limiting side-effects such as hypotension, poor absorption and low bioavailability resulting from high first-pass metabolism, and a narrow administration window as food effects lower bioavailability significantly. Due to these issues, blood levels of orally administered nimodipine can be highly variable, making it difficult to manage blood pressure in aSAH patients. Nimodipine capsules are also difficult to administer, particularly to unconscious patients or those with impaired ability to swallow. Concomitant use with CYP3A inhibitors is contraindicated (NIMODIPINE Capsule PI).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NIMOTOP&#153; is an injectable form of nimodipine that is manufactured by Bayer Healthcare. It is approved in Europe and in other regulated markets (but not in the United States). It has limited utility for aSAH patients because of its high organic solvent content, namely 23.7% ethanol and 17% polyethylene glycol 400 (NIMOTOP SmPC).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-104 is a clinical-stage, novel formulation of nimodipine for IV infusion in aSAH patients. It uses surfactant micelles as the drug carrier to solubilize nimodipine. This unique nimodipine injectable formulation is composed of a nimodipine base, an effective amount of polysorbate 80, a non-ionic hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection. GTX-104 is supplied as an aqueous concentrate that upon dilution with saline, dextrose or lactated ringer, is a ready-to-use infusion solution, which is stable and clear. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><img src="img181340459_0.jpg" alt="img181340459_0.jpg" style="width:504px;height:150px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key potential benefits of GTX-104 include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Novel nanoparticle technology facilitates aqueous formulation of insoluble nimodipine for a safe, standard peripheral IV infusion</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Better control of blood pressure and improved management of hypotension</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100% bioavailability</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eliminates or minimizes food effects and drug-to-drug interactions that impact the absorption of oral form of nimodipine </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lower inter and intra-subject variability as compared to oral nimodipine</span></div></div>
  <p style="margin-left:1.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-104 could provide a more convenient mode of administration as compared to generic nimodipine capsules or NYMALIZE&#153;. GTX-104 is administered as an IV infusion compared to oral administration via a nasogastric tube in unconscious patients every four hours for both nimodipine capsules and NYMALIZE&#153;. Therefore, GTX-104 could make a major contribution to patient care by potentially reducing the dosing associated nursing burden. More convenient, continuous, and consistent dosing can also reduce the risk of medication errors. In addition, as depicted in the charts below, two PK studies conducted by us have shown that GTX-104 has the potential to provide improved bioavailability and show reduced inter- and intra-subject variability compared to oral nimodipine, which is hypothesized to limit the risk of hypotension and to better achieve a desired therapeutic concentration. Following the capsule administration, the variability was observed higher as compared to IV infusion administration (nimodipine exposure variability at steady state observed 37.5% following oral capsule administration versus 15.5%, following GTX-104 IV infusion). Because of its IV formulation, we also expect GTX-104 to reduce certain drug-drug interactions and food effects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><img src="img181340459_1.jpg" alt="img181340459_1.jpg" style="width:563px;height:286px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the positive impact it has on recovery, physicians often must discontinue their patients from oral nimodipine, primarily as a result of hypotensive episodes that cannot be controlled by titrating the oral form of drug. Such discontinuation could potentially be avoided by administering GTX-104, which because of its IV administration, may reduce the complexity associated with the need for careful attention to the timing of nimodipine administration at least one hour before or two hours after a meal. Also, unconscious patients will likely receive more consistent concentrations of nimodipine when delivered via the IV route as compared to oral gavage or a nasogastric tube. More consistent dosing is expected to result in a reduction of vasospasm and a better, more consistent management of hypotension. As summarized in the table below, we also anticipate reduced use of rescue therapies, such as vasopressors, and expensive hospital resources, such as the angiography suite, are possible by more effectively managing blood pressure with GTX-104. Reduced incidences of vasospasm could result in shorter length of stay and better outcomes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><img src="img181340459_2.jpg" alt="img181340459_2.jpg" style="width:591px;height:302px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">About Aneurysmal Subarachnoid Hemorrhage (aSAH)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is rupture of an aneurysm. The result is a relatively uncommon type of stroke (aSAH) that accounts for about 5% of all strokes and has an incidence of six per 100,000 person years (Becske, 2018).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In contrast to more common types of ischemic stroke in elderly individuals, aSAH often occurs at a relatively young age, with approximately half the affected patients younger than 60 years old (Becske, 2018). Approximately 10% to 15% of aSAH patients die before reaching the hospital (Rinkel, 2016), and those who survive the initial hours post hemorrhage are admitted or transferred to tertiary care centers with high risk of complications, including rebleeding and delayed cerebral ischemia (&#8220;DCI&#8221;). Systemic manifestations affecting cardiovascular, pulmonary, and renal function are common and often complicate management of DCI. Approximately 70% of aSAH patients experience death or a permanent disability, and the mortality rate is about 8.7% at one week, 18.4% at three months, 22.9% at one year, and 29% at five years after the hemorrhage. Of those who survive the initial month, half remain permanently dependent on a caregiver to maintain daily living (Becske, 2018 and Steven 2020).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate that approximately 50,000 individuals experience aSAH each year in the U.S. based on third-party market research, and that total addressable market for aSAH is approximately $300 million in the U.S. There are an estimated 150,000 aSAH patients each year in China and approximately 55,000 patients in the European Union. The unmet needs in the treatment of aSAH and the potential of GTX-104 to address the limitations of the current standard of care were the subject of a Key Opinion Leader event we hosted on October 4, 2023.  In an independent market research survey we conducted of hospital administrators, critical and neuro intensive care physicians at institutions with Comprehensive or Advanced Stroke Center certification who are involved in purchasing decisions for their institutions/units, respondents reported 80% likelihood of  adopting an IV formulation of nimodipine (GTX-104), assuming 100% bioavailability, better safety, no food effects, effective hypotension management, potential hospital value and patient value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-104 Development Milestones</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we initiated our pivotal PK bridging trial to evaluate the relative bioavailability of GTX-104 compared to currently marketed oral nimodipine capsules in approximately 50 healthy subjects. The PK trial was the next required step in our proposed 505(b)(2) regulatory pathway for GTX-104.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Final results from this pivotal PK trial were reported in May 2022, and showed that the bioavailability of GTX-104 compared favorably with the oral formulation of nimodipine in all subjects, and no serious adverse events were observed for GTX-104.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All endpoints indicated that statistically there was no difference in exposures between GTX-104 and oral nimodipine over the defined time periods for both maximum exposure and total exposure. Plasma concentrations obtained following IV administration showed significantly less variability between subjects as compared to oral administration of capsules, since IV administration is not as sensitive to some of the physiological processes that affect oral administration, such as taking the drug with and without meals, variable gastrointestinal transit time, variable drug uptake from the gastrointestinal tract into the systemic circulation, and variable hepatic blood flow and hepatic first pass metabolism. Previous studies have shown these processes significantly affect the oral bioavailability of nimodipine, and therefore cause oral administration to be prone to larger inter- and intra-subject variability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The bioavailability of oral nimodipine capsules observed was only ~8% compared to 100% for GTX-104. Consequently, about one-twelfth the amount of nimodipine is delivered with GTX-104 to achieve the same blood levels as with the oral capsules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No serious adverse events and no adverse events leading to withdrawal were reported during the trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3 STRIVE-ON Randomized Safety Trial for GTX-104</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, we received a Type C written meeting response and clarifying feedback from the FDA on our proposed pivotal Phase 3 safety trial for GTX-104. The FDA provided additional comments on our development plan that, pending submission of the final clinical protocol and FDA approval, would allow us to proceed with a pivotal Phase 3 safety clinical trial in aSAH patients. On July 5, 2023, we announced the alignment with the FDA on our GTX-104 pivotal Phase 3 safety clinical trial protocol.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA concurred with the suitability of the 505(b)(2) regulatory pathway with the selected Reference Listed Drug NIMOTOP oral capsules ("NDA 018869"), and that our GTX-104-002 PK trial may have met the criteria for a scientific bridge.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The design of our Phase 3 safety clinical trial, which we have titled STRIVE-ON (Safety, Tolerability, Randomized, IV and Oral Nimodipine), is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in patients hospitalized for aSAH. Key trial design features include:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approximately 100 patients will be enrolled at an estimated 25 hospitals in the U.S.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary endpoint is safety and will be measured as comparative adverse events, including hypotension, between the two groups.  </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-104 will be administered as a continuous IV infusion of 0.15 mg/hour, and a 30-minute IV bolus of 4 mg every 4 hours. Oral nimodipine will be administered as 60 mg (two 30 mg capsules) every 4 hours. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both groups will receive their assigned GTX-104 or oral nimodipine for up to 21 consecutive days and will be evaluated from commencement of patient treatment through a 90-day follow-up period.  </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 23, 2023, we enrolled our first patient in our STRIVE-ON clinical trial. Patient enrollment in the STRIVE-ON Phase 3 trial is continuing, and potential NDA submission with the FDA is anticipated to occur in the first half of calendar 2025. We expect this safety trial to be the final clinical step required to seek FDA approval under the 505(b)(2) regulatory pathway.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-102 Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-102 is a novel, concentrated oral-mucosal spray of betamethasone intended to improve neurological symptoms of A-T for which there are currently no FDA-approved therapies. GTX-102 is a stable, concentrated oral spray formulation comprised of the gluco-corticosteroid betamethasone that, together with other excipients can be sprayed conveniently over the tongue of the A-T patient and is rapidly absorbed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">About Ataxia Telangiectasia</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A-T is a rare genetic progressive autosomal recessive neurodegenerative disorder that affects children, with the hallmark symptoms of cerebellar ataxia and other motor dysfunction, and dilated blood vessels (telangiectasia) that occur in the sclera of the eyes. A-T is caused by mutations in the ataxia telangiectasia gene, which is responsible for modulating cellular response to stress, including breaks in the double strands of DNA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img181340459_3.jpg" alt="img181340459_3.jpg" style="width:236px;height:283px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Children with A-T begin to experience balance and coordination problems when they begin to walk (toddler age), and ultimately become wheelchair-bound in their second decade of life. In pre-adolescence (between ages 5 and 8), patients experience oculomotor apraxia, dysarthria, and dysphagia. They also often develop compromised immune systems and are at increased risk of developing respiratory tract infections and cancer (typically lymphomas and leukemia) (U.S. National Cancer Institute A-T, 2015).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A-T is diagnosed through a combination of clinical assessment (especially neurologic and oculomotor deficits), laboratory analysis, and genetic testing. There is no known treatment to slow disease progression, and treatments that are used are strictly aimed at controlling the symptoms (e.g., physical, occupational or speech therapy for neurologic issues), or conditions secondary to the disease (e.g., antibiotics for lung infections, chemotherapy for cancer, etc.) (U.S. National Cancer Institute A-T, 2015). There are no FDA-approved therapeutic options currently available. Patients typically die by age 25 from complications of lung disease or cancer. According to a third-party report we commissioned, A-T affects approximately 4,300 patients per year in the United States and has a potential total addressable market of $150 million, based on the number of treatable patients in the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-102 - R&amp;D and Clinical Trials to Date</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have licensed the data from the multicenter, double-blinded, randomized, placebo-controlled crossover trial from Azienda Ospedaliera Universitaria Senese, Siena, Italy, where Dr. Zannolli et. al. studied the effect of oral liquid solution of betamethasone to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduce ataxia symptoms in patients with A-T. This oral liquid solution is not marketed in the United States, and therefore is not available for clinical use; currently, betamethasone is only available in the United States as an injectable or as a topical cream. This license gives us the right to reference the trial&#8217;s data in our NDA filing. On November 12, 2015, we submitted the data from the Zannolli trial to the FDA&#8217;s Division of Neurology at a pre-Investigational New Drug (&#8220;IND&#8221;) meeting and received guidance from the agency on the regulatory requirements to seek approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a multicenter, double-blind, randomized, placebo-controlled crossover trial conducted in Italy, Dr. Zannolli et al. studied the effect of an oral liquid solution of betamethasone on the reduction of ataxia symptoms in 13 children (between ages 2 to 8 years) with A-T. The primary outcome measure was the reduction in ataxia symptoms as assessed by the International Cooperative Ataxia Rating Scale (&#8220;ICARS&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the trial, oral liquid betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (the median percent decreases of ataxia symptoms of 28% and 31%, respectively). Adverse events in the trial were minimal, with no compulsory withdrawals and only minor side effects that did not require medical intervention. Clinical trial results in A-T patients administered oral betamethasone indicated that betamethasone significantly reduced ICARS total score relative to placebo (P = 0.01). The median ICARS change score (change in score with betamethasone minus change in score with placebo) was -13 points (95% confidence interval for the difference in medians was -19 to -5.5 points).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the Zannolli data, we believe that our GTX-102 concentrated oral spray has the potential to provide clinical benefits in decreasing A-T symptoms, including assessments of posture and gait disturbance and kinetic, speech and oculomotor functions. In addition, GTX-102 may ease drug administration for patients experiencing A-T given its application of 1-3x/day of 140&#181;L of concentrated betamethasone liquid sprayed onto the tongue using a more convenient metered dose delivery system, as these A-T patients typically have difficulty swallowing (Lefton-Grief, 2000).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-102 PK Data to Date:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-102 administered as a concentrated oral spray achieves similar blood levels at only 1/70th the volume of an oral solution of betamethasone. This more convenient mode of administration will be important for A-T patients who have difficulties swallowing large volumes of liquids.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img181340459_4.jpg" alt="img181340459_4.jpg" style="width:720px;height:357px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated a PK bridging trial of GTX-102 as compared to the oral liquid solution of betamethasone used in the Zannolli trial and against the injectable form of betamethasone that is approved in the U.S. in the third calendar quarter of 2022. The primary objectives of the PK bridging trial were to evaluate the bioavailability, pharmacokinetics and safety of GTX-102. In December 2022, we reported that the topline results of this trial met all primary outcome measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results showed that GTX-102 betamethasone blood concentrations were highly predictable and consistent based on AUC (the area under the concentration time curve up to 72 hours post-dose, extrapolated to infinity) and Cmax (the maximum concentration occurring between 0 hour to 72 hours after trial drug administration), indicating good linearity and dose-proportionality. GTX-102 betamethasone blood concentrations were within the same range of exposure as IM betamethasone, based on AUC. This IM formulation will serve as a bridge for GTX-102 in the context of the proposed 505(b)(2) regulatory pathway. GTX-102 betamethasone blood concentrations were also within the same range of exposure as Oral Solution ("OS"), based on AUC. This OS formulation was used by Zannolli and may serve as a clinical comparator for further clinical development. Furthermore, statistically there was no significant difference (p&gt;0.05) between GTX-102 administered at a fast rate (each spray immediately following the preceding one) vs. a slow rate (1 spray/minute), as indicated by Cmax and AUC. We believe this result is important because being able to use the fast or the slow rate of administration may provide greater flexibility for patients and caregivers. The Cmax of GTX-102 was within the same range of exposure as the OS, but the Cmax for the IM formulation was lower than both GTX-102 and the OS, as well as what has been reported previously for the IM in industry publications. It is important to note that achieving bioequivalence with the IM was not an objective of this trial, nor was it expected. Finally, of the 48 healthy adult subjects, no serious adverse events were reported, and the most frequent drug-related adverse effect was mild headache (4 cases).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The further clinical development of GTX-102 has been deprioritized in favor of our focus on development of GTX-104. However, we plan to collaborate with clinical experts to design the Phase 3 safety and efficacy protocol for GTX-102 and gain alignment with the FDA on the development path forward to maximize value. Further clinical development work will be contingent on additional funding for GTX-102 or the signing of a strategic partnership. It is also possible that we may out-license or sell our GTX-102 drug candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-101 Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GTX-101 is a non-narcotic, topical bio-adhesive film-forming bupivacaine spray designed to ease the symptoms of patients suffering with postherpetic neuralgia (&#8220;PHN&#8221;). GTX-101 is administered via a metered-dose of bupivacaine spray and forms a thin bio-adhesive topical film on the surface of the patient&#8217;s skin, which enables a touch-free, non-greasy application. It also comes in convenient, portable 30 ml plastic bottles. Unlike oral gabapentin and lidocaine patches which are used for the treatment of PHN, we believe that the biphasic delivery mechanism of GTX-101 has the potential for rapid onset of action and continuous pain relief for up to eight hours. No skin sensitivity was reported in a Phase 1 trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><img src="img181340459_5.jpg" alt="img181340459_5.jpg" style="width:429px;height:351px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">About Postherpetic Neuralgia (PHN)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PHN is neuropathic pain due to damage caused by the varicella zoster virus (&#8220;VZV&#8221;). Infection with VZV causes two distinct clinical conditions. Primary VZV infection causes varicella (i.e., chickenpox), a contagious rash illness that typically occurs among young children. Secondary VZV can reactivate clinically, decades after initial infection, to cause herpes zoster (&#8220;HZ&#8221;), otherwise known as shingles. Acute HZ arises when dormant virus particles, persisting within an affected sensory ganglion from the earlier, primary infection with VZV become reactivated when cellular immunity to varicella decreases. Viral particles replicate and may spread to the dorsal root, into the dorsal horn of the spinal cord, and through peripheral sensory nerve fibers down to the level of the skin. Viral particles also may circulate in the blood. This reactivation is accompanied by inflammation of the skin, immune response, hemorrhage, and destruction of peripheral and central neurons and their fibers. Following such neural degeneration, distinct types of pathophysiological mechanisms involving both the central and peripheral nervous systems may give rise to the severe nerve pain associated with PHN.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the rash associated with HZ typically heals within two to four weeks, the pain may persist for months or even years, and this PHN manifestation is the most common and debilitating complication of HZ. There is currently no consensus definition for PHN, but it has been suggested by the Centers for Disease Control and Prevention (&#8220;CDC&#8221;) that PHN is best defined as pain lasting at least three months after resolution of the rash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PHN is associated with significant loss of function and reduced quality of life, particularly in the elderly. It has a detrimental effect on all aspects of a patient's quality of life. The nature of PHN pain varies from mild to severe, constant, intermittent, or triggered by trivial stimuli. Approximately half of patients with PHN describe their pain as &#8220;horrible&#8221; or &#8220;excruciating,&#8221; ranging in duration from a few minutes to constant on a daily or almost daily basis (Katz, 2004). The pain can disrupt sleep, mood, work, and activities of daily living, adversely impacting the quality of life and leading to social withdrawal and depression. PHN is the number-one cause of intractable, debilitating pain in the elderly, and has been cited as the leading cause of suicide in chronic pain patients over the age of 70 (Hess, 1990).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current treatment of PHN most often consists of oral gabapentin (first line) and prescription lidocaine patches or antidepressants (second line), and refractory cases may be prescribed opioids to address persistent pain. Gabapentin and opioid abuse have continued to proliferate, and lidocaine patches are suboptimal for many reasons. An independent third-party market research firm we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commissioned interviewed more than 250 physicians who regularly treat PHN patients and found that approximately 40% of patients using lidocaine patches experience insufficient pain relief. Lidocaine patches are difficult to use, fall off, and look unsightly with possible skin sensitivity and irritation. Additionally, lidocaine patches can only be used for 12 hours and then need to be removed for 12 hours before being reapplied. Prescription lidocaine patches are only approved for PHN, and the market is currently made up of both branded and generic offerings. It is estimated that PHN affects approximately 120,000 patients per year in the United States. According to the third-party report, the total addressable market for GTX-101 could be as large as $2.5 billion, consisting of approximately $200 million for PHN pain and $2.3 billion for non-PHN pain indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-101 R&amp;D History and Clinical Trials Completed to Date</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have conducted four Phase I trials in healthy volunteers to assess the PK, safety and tolerability of GTX-101 and to determine the plasma levels of bupivacaine HCl administered as a single dose in various concentrations between 30 mg (three sprays) and 2100 mg (twenty sprays).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These trials confirmed that bupivacaine delivered as a topical spray (GTX-101) is well absorbed through the skin, as demonstrated in the graph below, while very little is absorbed systemically.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In all four trials, the administration of GTX-101 to healthy volunteers was safe and well tolerated. In addition, no evidence of skin irritation was observed at the application site following the spray administrations. The data below is from two separate trials of GTX-101 and the Lidoderm patch superimposed on each other.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><img src="img181340459_6.jpg" alt="img181340459_6.jpg" style="width:367px;height:317px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GTX-101 recent activities:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The data from the single dose Phase 1 clinical trial for GTX-101 was submitted to the FDA&#8217;s Division of Anesthesiology and feedback was received at a pre-IND meeting that informed the design of pre-clinical toxicology studies and a clinical and regulatory pathway to approval under section 505(b)(2). We completed a minipig skin sensitivity study in the second calendar quarter of 2022, and we initiated a single dose PK trial in healthy human volunteers in July 2022. Topline results from this single dose PK trial were reported in December 2022 and the results met all primary outcome measures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The median Tmax (the time of maximum concentration between 0 hour and 240 hours after study drug administration) of bupivacaine in plasma following GTX-101 single-dose topical applications ranged between 18 to 24 hours depending on dose, while the median Tmax following the subcutaneous injection of 10 mg of bupivacaine was only 23 minutes. This result suggests that bupivacaine delivered by GTX-101 remains in the skin for a long period of time, potentially inducing prolonged analgesic effect in the sprayed area. The exposure to bupivacaine based on Cmax (the maximum concentration occurring at Tmax between 0 hour and 240 hours after study drug administration) and AUC (the area under the concentration time curve, extrapolated to infinity) following GTX-101 topical application as a single-dose increased with increasing dose.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The systemic exposure to bupivacaine following a 200mg dose of GTX-101 was approximately 29-fold less than a single subcutaneous dose of 10mg of bupivacaine based on Cmax and approximately 6-fold less than a single subcutaneous dose of 10mg of bupivacaine based on AUC. We predict these lower blood levels will correspond to an increased safety margin for GTX-101 with regards to toxicity risk. Mean half-life ("T half") following GTX-101 single-dose topical applications ranged between 24 to 37 hours depending on dose, suggesting a slow elimination and potentially long duration of effect, while mean Tmax following the subcutaneous injection of 10 mg of bupivacaine was only 8 hours.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were only two adverse events judged as related to the study drug by the investigator for each of GTX-101 and the bupivacaine subcutaneous injection. Following GTX-101 topical application: headache (1 event = 3%) and numbness (1 event = 3%) at the sprayed area following bupivacaine subcutaneous injection: dizziness (1 event = 8%) and nausea (1 event = 8%).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The further development of GTX-101 has been deprioritized in favor of our focus on development of GTX-104. Pending additional funding for GTX-101 or the signing of a strategic partnership, we plan to follow this successful PK trial with the next step of the clinical development plan including a multiple ascending dose trial. Results from these non-clinical studies and clinical trials are required before the initiation of our Phase 2 program in PHN patients. It is also possible that we may out-license or sell our GTX-101 drug candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overall Commercialization Strategy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have worldwide commercialization rights for all our pipeline drug candidates and plan to maximize the value of each of our drug candidates over time. Currently, we have prioritized the development of GTX-104 over that of GTX-102 and GTX-101. If we receive regulatory approval for GTX-104 in the US, we may look to out-license its commercialization or consider self-commercialization including outsourcing sales to ensure efficient commercial management and maximize market penetration and financial returns. We may further seek commercial partnerships to fully exploit the market potential of GTX-104 in territories outside the US. It is possible that we out-license or sell GTX-102 and/or GTX-101 to the US and/or global markets to maximize value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing and Supply</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not own any manufacturing facilities. The manufacture of our pipeline of drug candidates is highly reliant on complex techniques and personnel aseptic techniques, which present significant challenges and require specialized expertise. Further, these processes undergo a high level of scrutiny by regulatory agencies. Consequently, we utilize a network of third-party CMOs for manufacturing our drug candidates. All CMOs are monitored and evaluated by us to assess compliance with regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We work with independent consultants to perform periodic quality audits of our manufacturers to review the manufacturing process for our drug candidates and to provide input on quality issues. All lots of the drug substance and drug product used in clinical supply are manufactured under current good manufacturing practices. We plan to continue to rely upon CMOs to manufacture clinical and commercial quantities once the product is approved. We have development agreements in place with these CMOs and we have personnel with pharmaceutical development and manufacturing experience who are responsible for the relationships with our CMOs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Portfolio</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a multi-layered intellectual property protection strategy, which we believe will create barriers to entry and solidify our position in the market. All of our clinical pipeline drug candidates have received orphan status designation from the FDA, which could result in 7 years of marketing exclusivity in the United States and 10 years in Europe, provided they receive the final marketing authorizations from the applicable government agencies, and they can meet the conditions for receiving such marketing exclusivity. In addition, we protect our drug candidates through a well-defined patent filing strategy. Our patent estate includes more than 40 granted and pending patents in various global jurisdictions, including 8 U.S. issued patents and 4 filed U.S. patent applications. We believe that our intellectual property portfolio, consisting primarily of composition and method-of-use patents, will protect the market value of our products by extending exclusivity beyond what is granted through the orphan designation. We intend to continue to build our patent portfolio by filing for patent protection on new developments with respect to our product candidates. We expect that these patents will, if and when issued, allow us to list our own patents in the Orange Book: Approved Drug Products with Therapeutic Equivalence issued by the FDA, to which potential competitors will be required to certify upon submission of their applications referencing our drug products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to manufacturing know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position. We may also rely on regulatory protections afforded through orphan drug status, data exclusivity, market exclusivity, and patent term extensions, where available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are actively seeking U.S. and international patent protection for a variety of technologies and intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel pharmaceutical products. We seek these protections, in part, through confidentiality and proprietary information agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual patents extend for varying periods depending on the date of filing or the date of issuance, and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than 5 years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. The actual protection afforded by a patent may vary on a product-by-product basis from country to country and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have several issued U.S. patents and patent applications as well as patents and patent applications in other jurisdictions. Five patents for GTX-104 have been granted in the United States. One patent for GTX-101 has been granted in Europe, China, Mexico, Japan and South Africa. One patent for GTX-102 has been granted in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Regulation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The FDCA and the FDA's implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record-keeping, reporting, distribution, import, export, sale, advertising and promotion of our product candidates. Although we focus on regulation in the U.S., because that is currently our primary focus, we may seek approval for, and market, our products candidates in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development and Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the FDCA, FDA approval of an NDA is required before any new drug can be marketed in the U.S. NDAs require extensive studies and submission of a large amount of data by the applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Testing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Before testing any compound in human patients in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the toxicity and dosing of the product. Certain animal studies must be performed in compliance with the FDA's Good Laboratory Practice (&#8220;GLP&#8221;) regulations and the U.S. Department of Agriculture's Animal Welfare Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IND Application</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Human clinical trials in the U.S. cannot commence until an IND application is submitted and becomes effective. A company must submit preclinical testing results to the FDA as part of the IND, and the FDA must evaluate whether there is an adequate basis for testing the drug in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND becomes effective 30 days following its receipt by the FDA, and the clinical trial proposed in the IND may begin. Once human clinical trials have commenced, the FDA may stop a clinical trial by placing it on "clinical hold" because of concerns about the safety of the product being tested, or for other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Clinical trials involve the administration of a drug to healthy human volunteers or to patients, under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA's bioresearch monitoring regulations and current Good Clinical Practice (&#8220;cGCP&#8221;) requirements, which establish standards for conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board (&#8220;IRB&#8221;) for each clinical site. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with, as applicable, regulations and guidelines for obtaining informed consent from the study patients, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with cGCP and the FDA is able to validate the data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A study sponsor is required to publicly post specified details about certain clinical trials and clinical trial results on government or independent websites (e.g., http://clinicaltrials.gov). Human clinical trials typically are conducted in three sequential phases, although the phases may overlap, be combined, or be subdivided in some cases:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase 1 clinical trials generally are intended to evaluate the safety, metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population and are designed to develop initial data regarding the product's effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential adverse events. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug's overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase 3 clinical development programs consist of expanded, multi-site, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen. Phase 3 data often form the core basis on which the FDA evaluates a drug&#8217;s safety and effectiveness when considering the product application.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The sponsoring company, the FDA, or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NDA Submission and Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The FDCA provides two pathways for the approval of new drugs through an NDA. An NDA under Section 505(b)(1) of the FD&amp;C Act is a comprehensive application to support approval of a product candidate that includes, among other things, data and information to demonstrate that the proposed drug is safe and effective for its proposed uses, that production methods are adequate to ensure its identity, strength, quality, and purity of the drug, and that proposed labeling is appropriate and contains all necessary information. A 505(b)(1) NDA contains results of the full set of preclinical studies and clinical trials conducted by or on behalf of the applicant to characterize and evaluate the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 505(b)(2) of the FDCA provides an alternate regulatory pathway to obtain FDA approval that permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely to some extent upon the FDA's findings of safety and effectiveness for an approved product that acts as the reference drug and submit its own product-specific data &#8212; which may include data from preclinical studies or clinical trials conducted by or on behalf of the applicant &#8212; to address differences between the product candidate and the reference drug. We are pursuing the Section 505(b)(2) regulatory approval pathway for GTX-104, with NIMOTOP oral capsules as the reference drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The submission of an NDA under either Section 505(b)(1) or Section 505(b)(2) generally requires payment of a substantial user fee to the FDA. However, such fees can be waived by the FDA for orphan drugs such as GTX-104.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product's identity, strength, quality, and purity. For some NDAs, the FDA may convene an advisory committee to seek insights and recommendations on issues relevant to approval of the application. Although the FDA is not bound by the recommendation of an advisory committee, the agency considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may determine that a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. Under the Pediatric Research Equity Act, certain applications for approval must also include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject drug in relevant pediatric populations. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are compliant with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements and adequate to assure consistent production of the product within required specifications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the FDA accepts an NDA submission which occurs, if at all, within 60 days after submission of the NDA &#8211; the FDA's goal for a non-priority review of an NDA is ten months. The review process can be and often is significantly extended, however, by FDA requests for additional information, studies, or clarification. After reviewing an NDA and the facilities where the product is manufactured, the FDA either issues an approval letter or a complete response letter (&#8220;CRL&#8221;) outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional preclinical or clinical data. Even if such additional information and data are submitted, the FDA may decide that the NDA still does not meet the standards for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining regulatory approval often takes several years, involves the expenditure of substantial resources, and depends on several factors, including the severity of the disease in question, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials. Additionally, as a condition of approval, the FDA may impose restrictions that could affect the commercial success of a drug or require post-approval commitments, including the completion within a specified time of additional clinical studies, which often are referred to as "Phase 4" or "post-marketing" studies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval modifications to the drug, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional preclinical studies or clinical trials, to be submitted in a new or supplemental NDA, which would require FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once approved, drug products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met or if safety or manufacturing problems occur after the product reaches the market, the FDA may at any time withdraw product approval or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials, changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution-related restrictions, if there are new safety information developments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Good Manufacturing Practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Companies engaged in manufacturing drug products, or their components must comply with applicable cGMP requirements and product-specific regulations enforced by the FDA and other regulatory agencies. Compliance with cGMP includes adhering to requirements relating to organization and training of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, quality control and quality assurance, packaging and labeling controls, holding and distribution, laboratory controls, and records and reports. The FDA regulates and inspects equipment, facilities, and processes used in manufacturing pharmaceutical products prior to approval. If, after receiving approval, a company makes a material change in manufacturing equipment, location, or process (all of which are, to some degree, incorporated in the NDA), additional regulatory review and approval may be required. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product. Failure to comply with applicable cGMP requirements and conditions of product approval may lead the FDA to take enforcement action or seek sanctions, including fines, issuance of warning letters, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval, seizure or recall of products, and criminal prosecution. Although we periodically monitor the FDA compliance of our third-party manufacturers, we cannot be certain that our present or future third-party manufacturers will consistently comply with cGMP and other applicable FDA regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising and Promotion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, advertising and promotion to healthcare professionals, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for "off-label" uses &#8211; that is, uses not approved by the FDA and not described in the product's labeling &#8211; because the FDA does not regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers' communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding off-label use. In addition to FDA restrictions on marketing of pharmaceutical products, state and federal fraud and abuse laws have been applied to restrict certain marketing practices in the pharmaceutical industry. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the way a company promotes or distributes a drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> NDA holders must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse drug experiences, and maintaining certain records.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hatch-Waxman Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Act&#8221;) establishes two abbreviated approval pathways for pharmaceutical products that are in some way follow-on versions of already approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Generic Drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> A generic version of an approved drug is approved by means of abbreviated NDA (&#8220;ANDA&#8221;), by which the sponsor demonstrates that the proposed product is the same as the approved, brand-name drug, which is referred to as the reference listed drug (&#8220;RLD&#8221;). Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (i) have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (ii) are intended for the same uses, and (iii) are bioequivalent. This is instead of independently demonstrating the proposed product's safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA previously found to be safe and effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">505(b)(2) NDAs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As discussed above, if a product is similar, but not identical, to an already approved product, it may be submitted for approval via an NDA under section 505(b)(2) of the FDCA. Unlike ANDA, this does not excuse the sponsor from demonstrating the proposed product's safety and effectiveness. Rather, the sponsor is permitted to rely to some degree on information from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference and must submit its own product-specific data of safety and effectiveness to an extent necessary because of the differences between the products. An NDA approved under 505(b)(2) may in turn serve as an RLD for subsequent applications from other sponsors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RLD Patents. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In an NDA, a sponsor must identify patents that claim the drug substance or drug product or a method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations, which is referred to as the Orange Book. The sponsor of an ANDA or 505(b)(2) application seeking to rely on an approved product as the RLD must make one of several certifications regarding each listed patent. A &#8220;Paragraph I&#8221; certification is the sponsor&#8217;s statement that patent information has not been filed for the RLD. A &#8220;Paragraph II&#8221; certification is the sponsor&#8217;s statement that the RLD&#8217;s patents have expired. A "Paragraph III" certification is the sponsor's statement that it will wait for the patent to expire before obtaining approval for its product. A "Paragraph IV" certification is an assertion that the patent does not block approval of the later product, either because the patent is invalid or unenforceable or because the patent, even if valid, is not infringed by the new product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory Exclusivities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Hatch-Waxman Act provides periods of regulatory exclusivity for products that would serve as RLDs for an ANDA or 505(b)(2) application. If a product is a "new chemical entity," or  &#8220;NCE&#8221; &#8212; generally meaning that the active moiety has never before been approved in any drug &#8212; there is a period of five years from the product's approval during which the FDA may not accept for filing any ANDA or 505(b)(2) application for a drug with the same active moiety. An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a Paragraph IV certification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product that is not an NCE may qualify for a three-year period of exclusivity if the NDA contains new clinical data, (other than bioavailability studies) derived from studies conducted by or for the sponsor, that were necessary for approval. In that instance, the exclusivity period does not preclude filing or review of an ANDA or 505(b)(2) application; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2) application until three years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that require submission of the clinical data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the FDA accepts for filing an ANDA or 505(b)(2) application containing a Paragraph IV certification, the applicant must within 20 days provide notice to the RLD or listed drug NDA holder and patent owner that the application has been submitted and provide the factual and legal basis for the applicant's assertion that the patent is invalid or not infringed. If the NDA holder or patent owner files suit against the ANDA or 505(b)(2) applicant for patent infringement within 45 days of receiving the Paragraph IV notice, the FDA is prohibited from approving the ANDA or 505(b)(2) application for a period of 30 months or the resolution of the underlying suit, whichever is earlier. If the RLD has NCE exclusivity and the notice is given and suit filed during the fifth year of exclusivity, the regulatory stay extends until 7.5 years after the RLD approval. The FDA may approve the proposed product before the expiration of the regulatory stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the RLD has NCE exclusivity and the notice is given and suit filed during the fifth year of exclusivity, the regulatory stay extends until 7.5 years after the RLD approval. The FDA may approve the proposed product before the expiration of the regulatory stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. A portion of the patent term lost during product development and FDA review of an NDA is restored if approval of the application is the first permitted commercial marketing of a drug containing the active ingredient. The patent term restoration period is generally one-half the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the NDA, plus the time between the date of submission of the NDA and the date of FDA approval of the product. The maximum period of restoration is five years, and the patent cannot be extended to more than 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60 days of approval. The U.S. Patent and Trademark Office in consultation with the FDA, reviews and approves the application for patent term restoration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Exclusivities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Section 505A of the FDCA provides for six months of additional exclusivity or patent protection if an NDA sponsor submits pediatric data that fairly responds to a written request from the FDA for such data. The data does not need to show that the product is effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA's request, additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection that cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents. When any product is approved, we will evaluate seeking pediatric exclusivity as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Orphan Drug Act provides incentives for the development of drugs intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals in the U.S. If a sponsor demonstrates that a drug product qualifies for orphan drug designation, the FDA grants ODD to the product for that use. The benefits of ODD include research and development tax credits and exemption from user fees. A drug that is approved for the orphan drug designated indication generally is granted seven years of orphan drug exclusivity. During that period, the FDA generally may not approve any other application for the same product for the same indication, although there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All our clinical-stage product candidates &#8211; GTX-104, GTX-102, and GTX-101 &#8211; have an ODD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended (the "Affordable Care Act"), is a sweeping measure intended to expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. This law substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, benefits for patients within a coverage gap in the Medicare Part D prescription drug program (commonly known as the "donut hole"), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicaid Drug Rebate program, expansion of the Public Health Service Act's 340B drug pricing program (340B Program), fraud and abuse, and enforcement. These changes impact existing government healthcare programs and have resulted in the development of new programs, including Medicare payment for performance initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some states have elected not to expand their Medicaid programs to individuals with an income of up to 133% of the federal poverty level, as is permitted under the Affordable Care Act. For each state that does not choose to expand its Medicaid program, there may be fewer insured patients overall, which could impact our sales of product candidates for which we receive regulatory approval, and our business and financial condition. Where new patients receive insurance coverage under any of the new Medicaid options made available through the Affordable Care Act, the possibility exists that manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, a decision that could impact manufacturer revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain provisions of the Affordable Care Act have been subject to judicial challenges, as well as efforts to modify them or to alter their interpretation and implementation. For example, on December 22, 2017, the U.S. government signed into law comprehensive tax legislation, referred to as the Tax Cuts and Jobs Act, which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount for pharmaceutical manufacturers who participate in Medicare Part D from 50% to 70% off the negotiated price effective as of January 1, 2019. The Inflation Reduction Act of 2022 replaces the Part D coverage gap discount program with a new Part D manufacturer discount program beginning in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is unclear how efforts to modify or invalidate the Affordable Care Act or its implementing regulations, or portions thereof, will affect the Affordable Care Act or our business. Additional legislative changes, regulatory changes, and further judicial challenges related to the Affordable Care Act remain possible. Any such changes could decrease the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it or its implementation may be modified in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our product candidates for which we receive regulatory approval or to successfully commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, on December 20, 2019, then-President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or &#8220;the CREATES Act.&#8221; The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic product developers access to samples of brand products. Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Privacy Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to laws and regulations covering data privacy and the protection of health-related and other personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant penalties), private litigation and/or adverse publicity that could negatively affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Corrupt Practices Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the U.S. Foreign Corrupt Practices Act of 1997 prohibits corporations and their intermediaries from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or political candidate to obtain or retain business or to otherwise influence a person working in that capacity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had a total of four full-time employees and utilized the services of three full-time consultants, all of whom are located in the United States. Our employees have significant prior experience within the pharmaceutical, and biotech industries. We continue to focus on building a high performing organization through our emphasis on accountability for results as measured by our performance development process. To help ensure that employees fully understand the Company&#8217;s long-term strategy, and how their work contributes to the Company&#8217;s success, we utilize a variety of channels to facilitate open and direct communication, including: regular calls with all employees, and ongoing update communications as needed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Developments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Announcement of appointment of Robert J. DelAversano as Principal Financial Officer</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 5, 2024, we announced the appointment of Robert J. DelAversano as Acasti's new Vice President, Finance, in which capacity he serves as our Principal Financial Officer and Principal Accounting Officer, succeeding Brian Ford, our former interim Chief Financial Officer. Mr. Ford continues to serve as a financial consultant on an as-needed basis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Certifying Accountant</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2023, the Audit Committee (the "Audit Committee") of our Board of Directors (the "Board") recommended to the Board and the Board approved the dismissal of Ernst &amp; Young LLP (Canada) ("E&amp;Y") as our independent registered public accounting firm. The report of E&amp;Y on our consolidated financial statements as of and for the fiscal year ended March 31, 2023 did not contain any adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles. On December 11, 2023, in connection with the dismissal of E&amp;Y, the Audit Committee recommended to the Board and the Board approved the engagement of KPMG LLP (U.S.) ("KPMG") as our new independent registered public accounting firm to audit the Company&#8217;s consolidated financial statements for the fiscal year ending March 31, 2024. The decision to engage KPMG was recommended by the Audit Committee, and approved by the Board, after taking into account KPMG&#8217;s location in the United States, the results of a competitive review process and other business factors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dosing of First Patient</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 23, 2023, we enrolled our first patient in our STRIVE-ON Phase 3 clinical trial. We expect this safety trial to be the final clinical step required to seek FDA approval under the 505(b)(2) regulatory pathway. Patient enrollment in the STRIVE-ON Phase 3 trial is continuing, and potential NDA submission with the FDA is anticipated to occur in the first half of calendar 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">September 2023 Private Placement Offering</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 24, 2023, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors in connection with a private placement offering of our securities (the &#8220;Offering&#8221;). Pursuant to the Purchase Agreement, we sold 1,951,371 Class A common shares, no par value per share (the &#8220;Common Shares&#8221;), at a purchase price of $1.848 per Common Share and pre-funded warrants (the &#8220;Pre-funded Warrants&#8221;) to purchase up to 2,106,853 Common Shares at a purchase price equal to the purchase price per Common Share less $0.0001. Pursuant to the Purchase Agreement, we also issued to such institutional and accredited investors common warrants (the &#8220;Common Warrants&#8221;) to purchase Common Shares, exercisable for an aggregate of 2,536,391 Common Shares (the &#8220;Warrant Shares&#8221;). Under the terms of the Purchase Agreement, for each Common Share and each Pre-funded Warrant issued in the Offering, an accompanying five-eighths (0.625) of a Common Warrant was issued to the purchaser thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Offering closed on September 25, 2023. Shore Pharma LLC, an entity that was controlled by Vimal Kavuru, the Chair of our Board of Directors, at the time of the Offering and SS Pharma LLC, the beneficial owners of 6.9% and 5.5%, respectively, of our Common Shares outstanding prior to the Offering, each a related party of ours, participated in the Offering. The net proceeds to us from the Offering were approximately $7.3 million, after deducting fees and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Purchase Agreement, we agreed to register for resale the Common Shares sold in the Offering and the Warrant Shares. On October 6, 2023, we filed a resale Registration Statement on Form S-3 with the SEC, registering the Common Shares sold in the Offering and the Warrant Shares for resale. The resale Registration Statement on Form S-3 was declared effective on October 16, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Announcement of compliance with the Nasdaq minimum bid price requirement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 24, 2023, we received written notice (the &#8220;Notification Letter&#8221;) from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that we had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Notification Letter was sent following the implementation of a 1-for-6 reverse split of our Common Shares (the &#8220;Reverse Stock Split&#8221;), which became effective on July 10, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse stock split</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2023, our Board approved an amendment to our Articles of Incorporation (the &#8220;Articles of Incorporation&#8221;) to implement the Reverse Stock Split. On July 4, 2023, we filed Articles of Amendment to our Articles of Incorporation with the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registraire des entreprises du Qu&#233;bec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to implement the Reverse Stock Split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Announcement of successful submission of pivotal GTX-104 Phase 3 safety study protocol with FDA and implementation of strategic realignment plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 8, 2023, we announced the successful submission to the FDA of GTX-104's full protocol of our pivotal Phase 3 safety trial and implementation of a strategic realignment plan to maximize shareholder value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key strategies implemented were:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prioritization of resources to GTX-104. On July 5, 2023, we announced alignment with the FDA on our GTX-104 pivotal Phase 3 safety trial protocol. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transformation of our operating model to be an agile biopharma reflecting our complete focus on GTX-104. In alignment with our new operating model, we brought on a highly experienced new management team with deep subject matter knowledge and direct, hands-on clinical trial experience in aSAH.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant extension of our cash runway. We believe our existing cash, cash equivalents, and short-term investments will be sufficient to fund our operations into the second calendar quarter of 2026.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of strategic alternatives to maximize value of de-prioritized pipeline assets, GTX-102 and GTX-101. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the transformation of our operating model, we appointed the following industry experts to our senior management team:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer. A world-renowned practicing neurosurgeon-scientist and respected authority in SAH, Dr. Macdonald is the former founder of a clinical-stage biotechnology company focused on subarachnoid hemorrhage.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Carrie D&#8217;Andrea, as VP Clinical Operations. Ms. D&#8217;Andrea is a highly experienced professional who has built and led the planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for a drug candidate for subarachnoid hemorrhage.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amresh Kumar, PhD, as VP Program Management. Mr. Kumar is an experienced drug development, CMC, and program management expert. Mr. Kumar was the former product leader of GTX-104 while at Grace Therapeutics, Inc. ("Grace Therapeutics&#8221;) (which was acquired by us).</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the realignment, the Company is a smaller, more focused organization, based in the United States, and concentrated on its development of its lead product GTX-104.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Structure</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acasti was incorporated on February 1, 2002 under Part 1A of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Companies Act </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Qu&#233;bec) under the name &#8220;9113-0310 Qu&#233;bec Inc.&#8221; On February 14, 2011, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Corporations Act </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Qu&#233;bec) (&#8220;QBCA&#8221;), came into effect and replaced the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Companies Act </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Qu&#233;bec). We are now governed by the QBCA. On August 7, 2008, pursuant to a Certificate of Amendment, we changed our name to &#8220;Acasti Pharma Inc.&#8221; We became a reporting issuer in the Province of Qu&#233;bec on November 17, 2008. On December 18, 2019, we incorporated a new wholly owned subsidiary named Acasti Innovation AG ("AIAG"), under the laws of Switzerland for the purpose of future development of our intellectual property and for global distribution of our products. AIAG currently does not have any operations. On August 27, 2021, Acasti completed its acquisition of Grace Therapeutics via a merger. Following completion of the merger, Grace became a wholly owned subsidiary of Acasti and was renamed Acasti Pharma U.S. Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K, and any amendments to these reports are filed, or will be filed, as applicable, with the SEC, and the Canadian Securities Administrators (&#8220;CSA&#8221;). These reports are available free of charge on our website, </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.acasti.com,</span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as soon as reasonably practicable after we electronically file such reports with or furnish such reports to the SEC and the CSA. Information contained on, or accessible through, our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this document is an inactive textual reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our filings with the SEC may be accessed through the SEC&#8217;s website at www.sec.gov and our filings with the CSA may be accessed through the CSA&#8217;s System for Electronic Document Analysis and Retrieval at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.sedar.com.</span></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Factors Relating to our Business</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not achieve our publicly announced milestones on time, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly announce the timing of certain events that we expect to occur, such as the anticipated timing of results from our clinical trials and the timing of an upcoming new drug application ("NDA&#8221;) filing. These statements are forward-looking and are based on the best estimate of management at the time relating to the occurrence of the events. However, the actual timing of these events may differ from what has been publicly disclosed. The timing of events such as completion of a clinical trial, discovery of a new product candidate, filing of an application to obtain regulatory approval, beginning of commercialization of products, completion of a strategic partnership, or announcement of additional clinical trials for a product candidate may ultimately vary from what is publicly disclosed. These variations in timing may occur as a result of different events, including the nature of the results obtained during a clinical trial or during a research phase, problems with a supplier or a distribution partner or any other event having the effect of delaying the publicly announced timeline. We undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as otherwise required by law. Any variation in the timing of previously announced milestones could have a material adverse effect on our business, financial condition or operating results and the trading price of our common shares.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are heavily dependent on the success of our lead drug candidate, GTX-104</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business and future success are substantially dependent on our ability to successfully and timely develop, obtain regulatory approval for, and commercialize our lead product candidate, GTX-104. Any delay or setback in the development of GTX-104 could adversely affect our business. Our planned development, approval and commercialization of GTX-104 may fail to be completed in a timely manner or at all. As part of our recent strategic realignment plan, we determined to focus primarily on the development of GTX-104, which concentrates the level of our drug development risk on one drug candidate. We cannot provide assurance that we will be able to obtain approval for GTX-104 or any other of our drug candidates from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or any foreign regulatory authority or that we will obtain such approval in a timely manner.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to maximize value from our de-prioritized drug candidates, GTX-102 and GTX-101, through either development, out-licensing or sale.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our GTX-102 and GTX-101 drug candidates are at an earlier development stage than GTX-104 and will require additional time and resources to develop. As part of our recent strategic realignment plan, we determined to focus primarily on the development of GTX-104 and to de-emphasize the development of GTX-102 and GTX-101. While we will continue to seek ways to maximize the value of GTX-102 and GTX-101, including through subsequent development, out-licensing or sale, we may not be successful in doing so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to maintain our operations and advance our research and development and commercialization of our GTX-104 lead drug candidate without additional funding.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred operating losses and negative cash flows from operations since our inception. To date, we have financed our operations through public offerings and private placements of securities, proceeds from exercises of warrants, rights and options, and receipt of research tax credits and research grant programs. Our cash and cash equivalents and short-term investments were $23.0 million as of March 31, 2024 and $27.9 million as of March 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current assets, as of March 31, 2024, are projected to support our current liabilities as at that date when combined with the projected level of our expenses for the next twelve months, including fully funding the completion of our Phase 3 program for GTX-104. We expect that additional time and capital will be required by us to file an NDA to obtain FDA approval for GTX-104 in the United States, to further scale up our manufacturing capabilities, and to complete marketing and other pre-commercialization activities. Consequently, we expect our existing cash and cash equivalents will be sufficient to fund our operations into the second calendar quarter of 2026. Based on the steps we are taking in our strategic realignment plan to focus primarily on the development of GTX-104 and to de-emphasize the development of GTX-102 and GTX-101, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the completion of our Phase 3 trials for GTX-104. To fully execute our business plan, we plan to raise the necessary capital primarily through additional securities offerings and multiple sources of non-dilutive capital, such as grants or loans and strategic alliances. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay the research and development and commercial launch of our GTX-104. If we determine to continue development of GTX-102 and GTX-101, significant additional funding will be needed. Unexpected negative results in our clinical programs for our lead drug candidate may affect our ability to raise additional capital and/or complete strategic development and/or distribution partnerships to support the commercial launch of our lead drug candidate. Additional funding from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third parties may not be available on acceptable terms or at all to enable us to continue with the research and development and commercialization of our lead drug candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our suppliers, third-party manufacturers and other contractors and consultants could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical pandemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to manufacture our drug candidate products. Our ability to obtain supplies of drug candidate products could be disrupted if the operations of our manufacturers and suppliers are affected by a man-made or natural disaster or other business interruption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the principal members of our executive team. While members of our executive team have significant industry experience, they have not been with the Company for long. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. Also, as part of our strategic realignment, we significantly reduced the number of our employees while we shift the base of our operations from Canada to the United States. As a result, in the process of shifting the base of our operations to the United States, we will have to recruit employees from the industry employment market in the United States. Recruiting and retaining qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives and other personnel in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. As we rebuild our organization in accordance with our strategic realignment, we may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit key executives or the loss of the services of any executive or key employee might impede the progress of our development and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations and our ability to compete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our drug development efforts are successful, we expect to expand our employee base to increase our managerial, scientific, engineering, operational, sales, marketing, financial and other resources and to hire more consultants and contractors. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate, and integrate additional employees, consultants and contractors. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product candidates. Our future financial performance and our ability to sell and commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential product liability, and if claims are brought against us, we may incur substantial liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of our product candidates in clinical trials, and the sale of any drug candidates for which we obtain marketing approval, exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment of our business reputation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical study participants</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs due to related litigation</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distraction of management&#8217;s attention from our primary business</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to patients or other claimants; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems, and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our drug product development and clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of drug product development or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs, and the development of our product candidates could be delayed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Development, Testing and Commercialization of Our Products</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if our drug candidates receive regulatory approval in the United States, we may never obtain regulatory approval or successfully commercialize our products outside of the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business plan is highly dependent upon our ability to obtain regulatory approval to market and commercialize our lead drug candidate, GTX-104 in the United States. As GTX-104 is currently the focus of our drug development program, the failure to commercialize it would have a material adverse effect on our ability to execute on our business plan and generate revenue. In addition, even if we obtain U.S. regulatory approvals to commercialize GTX-104, we may not be able to do so in other international jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to uncertainty relating to healthcare reform measures and reimbursement policies which, if not favorable to our drug candidates, could hinder or prevent our drug candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> commercial success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize our drug candidates successfully will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our drug candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for medical products. These restrictions and limitations influence the purchase of healthcare services and products. The cost containment measures that healthcare payors and providers are instituting and the effect of any healthcare reform could significantly reduce our revenues from the sale of any approved drug. We cannot provide any assurances that we will be able to obtain third-party coverage or reimbursement for our drug candidates in whole or in part.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, there have been a number of legislative and regulatory changes to the healthcare system in ways that could affect our future revenues and profitability and the future revenues and profitability of our potential customers. Under the prescription drug benefit, Medicare beneficiaries can obtain prescription drug coverage from private sector plans that are permitted to limit the number of prescription drugs that are covered in each therapeutic category and class on their formularies. If our products are not widely included on the formularies of these plans, our ability to market our products to the Medicare population could be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There also have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare costs to contain or reduce costs of healthcare may adversely affect one or more of the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we desire for our drug products, if any are approved</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenues and achieve profitability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the future revenues of our potential customers, suppliers and collaborators; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital to us.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these scenarios could harm our ability to market our products and generate revenues. It is also possible that other proposals having a similar effect will be adopted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our commercial success depends upon attaining significant market acceptance of our drug candidates and drug products, if approved, among physicians, nurses, pharmacists, patients and the medical community.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory approval for our drug product candidates, our drug product candidates may not gain market acceptance among physicians, nurses, pharmacists, patients, the medical community or third-party payors, which is critical to commercial success. Market acceptance of our drug candidates and any drug product for which we receive approval depends on a number of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of the drug candidate or drug product as well as competitive products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the drug product is approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration to patients of the drug candidate or drug product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of such drug candidate over alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any negative publicity related to our or our competitors&#8217; drug products that include the same active ingredient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of adverse side effects, including limitations or warnings contained in a drug product&#8217;s FDA-approved labeling; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our drug candidates or drug products, if approved, fail to achieve an adequate level of acceptance by physicians, nurses, pharmacists, patients, and the medical community, we will be unable to generate significant revenues, and we may not become or remain profitable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate any revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we intend to establish a small, focused, specialty sales and marketing organization to promote GTX-104, if approved for marketing in the United States, we currently have no such organization and the cost of establishing and maintaining such an organization may exceed the benefit of doing so. We believe that GTX-102 could also be marketed by a small, focused, specialty sales and marketing organization if and when we decide to resume development of GTX-102. Given the size of its potential market, we anticipate that commercializing GTX-101 would require entering into a strategic partnership with a larger marketing partner, if GTX-101 is approved by the FDA for marketing, and the ability to find any such strategic partnership would be uncertain. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we obtain approval to commercialize any approved drug products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our drug candidates are approved for commercialization, we may enter into agreements with third parties to market these drug products outside the United States. We expect that we will be subject to additional risks related to entering into international business relationships, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different regulatory requirements for drug approvals in foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to secure third-party marketing and selling agreements outside of the United States;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to differentiate our drug candidates from branded reference drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve generic products that compete with any of our drug candidates, our ability to successfully commercialize our drug candidates would be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe that our drug candidates will be clinically differentiated from branded reference drugs and their generic counterparts, if any, it is possible that such differentiation will not impact our market position. If we are unable to achieve significant differentiation for our product candidates against other drugs, the opportunity for our product candidates to achieve premium pricing and be commercialized successfully would be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to existing branded reference drugs and the related generic products, the FDA or other applicable regulatory authorities may approve generic products that compete directly with our drug candidates, if approved. Once an NDA, including a 505(b)(2) application, is approved, the product covered thereby becomes a &#8220;listed drug&#8221; which can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application (&#8220;ANDA&#8221;). The Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as our product candidate and that the generic product is bioequivalent to ours, meaning it is absorbed in the body at the same rate and to the same extent as our drug product. These generic equivalents, which must meet the same quality standards as branded pharmaceuticals, would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their drug products at lower prices. After the introduction of a generic competitor, a significant percentage of the sales of any branded drug product is typically lost to the generic drug product. Accordingly, competition from generic equivalents of our drug candidates would materially adversely impact our ability to successfully commercialize our drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. We expect to have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. If our competitors market products that are more effective, safer or less expensive than our drug products, if any, or that reach the market sooner than our drug products, if any, we may enter the market too late in the cycle and may not achieve commercial success. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or drug products developed by our competitors may render our drug products, if any, or drug candidates obsolete, less competitive or not economical.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We could incur substantial costs and disruption to our business and delays in the launch of our drug candidates if our competitors and/or collaborators bring legal actions against us, which could harm our business and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict whether our competitors or potential competitors, may bring legal actions against us based on our research, development, and commercialization activities, as well as any drug candidates or drug products resulting from these activities, claiming, among other things, infringement of their intellectual property rights, breach of contract or other legal theories. If we are forced to defend any such lawsuits, whether they are with or without merit or are ultimately determined in our favor, we may face costly litigation and diversion of technical and management personnel. These lawsuits could hinder our ability to enter the market early with our drug candidates and thereby hinder our ability to influence usage patterns when fewer, if any, of our potential competitors have entered such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market, which could adversely impact our potential revenue from such drug candidates. Some of our competitors have substantially greater resources than we do and could be able to sustain the cost of litigation to a greater extent and for longer periods of time than we could. Furthermore, an adverse outcome of a dispute may require us: to pay damages, potentially including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a party&#8217;s patent or other intellectual property rights; to cease making, licensing or using products that are alleged to incorporate or make use of the intellectual property of others; to expend additional development resources to reformulate our products or prevent us from marketing a certain drug; and to enter into potentially unfavorable royalty or license agreements in order to obtain the rights to use necessary technologies. Royalty or licensing agreements, if required, may be unavailable on terms acceptable to us, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to numerous complex regulatory requirements and failure to comply with these regulations, or the cost of compliance with these regulations, may harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research, testing, development, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, marketing, distribution, possession and use of our drug candidates, among other things, are subject to regulation by numerous governmental authorities in the United States and elsewhere. The FDA regulates drugs under the FDCA, and implementing regulations. Non-compliance with any applicable regulatory requirements can result in refusal of the governmental authority to approve products for marketing, criminal prosecution and fines, warning letters, product recalls or seizure of products, total or partial suspension of production, prohibitions or limitations on the commercial sale of products or refusal to allow the entering into of federal and state supply contracts. FDA and comparable governmental authorities have the authority to withdraw product approvals that have been previously granted. In addition, the regulatory requirements relating to our drug candidates and drug products, if any, may change from time to time and it is impossible to predict what the impact of any such changes may be.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the FDA does not conclude that our drug candidates satisfy the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements for approval of any of our drug candidates under Section</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">505(b)(2) are not as we expect, the approval pathway for our drug candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to seek FDA approval through the 505(b)(2) regulatory pathway for our lead drug candidate GTX-104. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA does not allow us to pursue the 505(b)(2) regulatory pathway for GTX-104, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our drug candidates would likely substantially increase. Moreover, an inability to pursue the 505(b)(2) regulatory pathway could result in new competitive products reaching the market faster than our drug candidates, which could materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the 505(b)(2) regulatory pathway for a drug candidate, we cannot assure you that we will receive the requisite or timely approvals for commercialization of such drug candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, it is possible that our competitors may file citizens&#8217; petitions with the FDA in an attempt to persuade the FDA that our drug candidates, or the clinical studies that support their approval, contain deficiencies. Such actions by our competitors could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing, even when utilizing the 505(b)(2) pathway, is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, even with active ingredients that have previously been approved by the FDA as safe and effective. The results of pre-clinical studies and early clinical trials of our drug candidates may not be predictive of the results of later stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our drug candidates are in various stages of development. Clinical trial failures may occur at any stage and may result from a multitude of factors both within and outside our control, including flaws in formulation, adverse safety or efficacy profile and flaws in trial design, among others. If the trials result in negative or inconclusive results, we or our collaborators may decide, or regulators may require us, to discontinue trials of our drug candidates or conduct additional clinical trials or pre-clinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. For these reasons, our future clinical trials may not be successful.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and could jeopardize or delay our ability to obtain regulatory approval and commence drug product sales. We may also find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in clinical trials of our drug candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to raise or delays in raising funding necessary to initiate or continue a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining regulatory approval to commence a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement with the FDA on final trial design;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a clinical hold for safety reasons or following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective contract manufacturing organizations (&#8220;CMOs&#8221;), or contract research organizations (&#8220;CROs&#8221;), and clinical trial sites, or failure by such CMOs to complete the manufacturing of clinical trial materials or CROs to follow and carry out the clinical study protocol at each site in accordance with the terms of our agreements with them;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining required institutional review board (&#8220;IRB&#8221;), approval at each site;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties or delays in having patients&#8217; complete participation in a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites electing to terminate their participation in one of our clinical trials, which would likely have a detrimental effect on subject enrollment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">time required to add new clinical sites; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays by our CMOs to produce and deliver sufficient supply of clinical trial materials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If initiation or completion of our planned clinical trials is delayed for any of the above reasons or other reasons, our development costs may increase, our regulatory approval process could be delayed and our ability to commercialize and commence sales of our drug candidates could be materially harmed, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, identifying and qualifying patients to participate in clinical trials of our drug candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our drug candidates as well as completion of required follow-up periods. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics or to complete our clinical trials in a timely manner. Patient enrollment is and completion of the trials are affected by a variety of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">severity and prevalence of the disease under investigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">design of the trial protocol;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">size of the patient population;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eligibility criteria for the trial in question;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived risks and benefits of the drug candidate under trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability of competing therapies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient referral practices of physicians; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to monitor patients adequately during and after treatment.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that none of our existing drug candidates or any drug candidates we may seek to develop will ever obtain regulatory approval in the United States or other jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our drug candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree that our changes to branded reference drugs meet the criteria for the 505(b)(2) regulatory pathway or foreign regulatory pathways;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective or comparable to its branded reference product for its proposed indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of any clinical trials we conduct may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may change significantly in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in us failing to obtain regulatory approval to market our drug candidates, which would harm our business, results of operations and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience using the 505(b)(2) regulatory pathway to submit an NDA or any similar drug approval filing to the FDA, and we cannot be certain that any of our drug candidates will receive regulatory approval. If we do not receive regulatory approvals for our drug candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our drug candidates, our revenue will be dependent, to a significant extent, upon the size of the markets in the territories for which we gain regulatory approval. If the markets for patients or indications that we are targeting are not as significant as we estimate, we may not generate significant revenue from sales of such drug products, if approved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our drug development strategy relies heavily upon the 505(b)(2) regulatory pathway, which requires us to certify that we do not infringe upon third-party patents covering approved drugs. Such certifications often result in third-party claims of intellectual property infringement, the defense of which will be costly and time consuming, and an unfavorable outcome in any litigation may prevent or delay our development and commercialization efforts which would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation or other proceedings to enforce or defend intellectual property rights are often complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from other aspects of our business and may result in unfavorable outcomes that could adversely impact our ability to launch and market our drug candidates, or to prevent third parties from competing with our drug products and drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, our commercial success depends in large part on our avoiding infringement of the patents and proprietary rights of third parties for existing approved drug products. Because we intend to utilize the 505(b)(2) regulatory pathway for the approval of our drug products and drug candidates, we rely in whole or in part on studies conducted by third parties related to those approved drug products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because patent applications can take many years to issue, there may be currently pending or subsequently filed patent applications which may later result in issued patents that may be infringed by our drug products or drug candidates. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our drug candidates, including the formulation, method of use, any method or process involved in the manufacture of any of our drug candidates, any molecules or intermediates formed during such manufacturing process or any other attribute of the final product itself, the holders of any such patents may be able to block our ability to commercialize our drug candidates unless we obtain a license under the applicable patents, or until such patents expire. In either case, such a license may not be available on commercially reasonable terms or at all.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may request and/or obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our drug candidates on a temporary or permanent basis. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of our drug candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our drug candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, principal investigators, consultants, commercial partners, and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates (1) the laws of the FDA and similar foreign regulatory bodies, including those laws requiring the reporting of true, complete, and accurate information to such regulatory bodies; (2) healthcare fraud and abuse laws of the United States and similar foreign fraudulent misconduct laws; and (3) laws requiring the reporting of financial information or data accurately. Specifically, the promotion, sales and marketing of health care items and services, as well as certain business arrangements in the healthcare industry are subject to extensive laws designed to prevent misconduct, including fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. It is not always possible to identify and deter employee and other third-party misconduct. The precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws. If any such actions are instituted against us, and we are not successful in defending ourselves, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are required to obtain regulatory approval for each of our drug candidates in each jurisdiction in which we intend to market such products, and the inability to obtain such approvals would limit our ability to realize their full market potential.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market drug products outside of the United States, we must comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction may adversely impact our ability to obtain regulatory approval in another jurisdiction. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our drug products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our drug products will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success also depends upon our ability and the ability of our future collaborators to develop, manufacture, market and sell our drug candidates and to use our proprietary technologies without infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing drug candidates. Because patent applications can take many years to issue, there may be currently pending applications,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our drug candidates of which we are not aware.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. In particular, the generic drug industry is characterized by frequent litigation between generic drug companies and branded drug companies. If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infringement and other intellectual property claims which, with or without merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial damages for infringement, including, but not limited to, treble damages, punitive damages, loss of profits and attorneys&#8217; fees, which we may have to pay if a court decides that the drug product or proprietary technology at issue infringes on or violates the third-party&#8217;s rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a license is available from the third-party, we may have to pay substantial royalties, fees and/or grant cross licenses to our technology; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">redesigning our drug candidates or processes so they do not infringe, which may not be possible or may require substantial funds and time.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not conducted an extensive search of patents issued to third parties, and no assurance can be given that third-party patents containing claims covering our drug  candidates, technology or methods do not exist, have not been filed, or could not be filed or issued. Because of the number of patents issued and patent applications filed in our technical areas or fields, we believe there is a significant risk that third parties may allege they have patent rights encompassing our products, technology, or methods. Other drug candidates that we may in-license or acquire could be subject to similar risks and uncertainties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed alleged confidential information or trade secrets of their other clients or former employers to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our drug candidates, many of whom were previously employed at or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any such litigation would be protracted, expensive, and potentially subject to an unfavorable outcome.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends in part upon our ability to protect our intellectual property for our branded products and drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success with respect to our drug products and drug candidates, depends on obtaining and maintaining patent protection in the United States and in other countries and trade secret protection for our drug candidates, proprietary technologies and their uses. Our ability to protect our drug products from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to evolving legal standards relating to patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to maintain, obtain and enforce patents is uncertain and involves complex legal and factual questions. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value and the scope of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we might not have been the first to file patent applications for these or similar inventions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that none of our or our licensors&#8217; pending patent applications will result in issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any patents we obtain, or our licensors&#8217; issued patents may not encompass commercially viable products, may not provide us with any competitive advantages, or may be challenged by third parties for lack of novelty, obviousness, lack of demonstrated or predicted utility, or other technical reasons related to the drafting of the patent itself;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any patents we obtain, or our in-licensed issued patents may not be valid or enforceable; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with certain of our employees, consultants, and advisors, third parties may still obtain this information, or we may be unable to protect our rights. Enforcing a claim that a third-party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secret information. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how, and we would not be able to prevent their use.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. Our existing license agreements impose, and we expect that future license agreements will impose, on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. Under these agreements, we must rely on our licensor to comply with their obligations under the primary license agreements under which such third-party obtained rights in the applicable intellectual property, where we may have no relationship with the original licensor of such rights. If our licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do at a reasonable cost or on reasonable terms, which may impact our ability to continue to develop and commercialize our drug candidates and companion diagnostic incorporating the relevant intellectual property. If we fail to comply with our obligations under our license agreements, or we are subject to a bankruptcy or insolvency, the licensor may have the right to terminate the license. In the event that any of our important technology licenses were to be terminated by the licensor, we would likely cease further development of the related program or be required to spend significant time and resources to modify the program to not use the rights under the terminated license.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our drug candidates and companion diagnostic. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make compounds that are similar to our drug candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies for intangible assets prove to be incorrect, further impairment charges could result.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We carry a significant amount of intangible assets on our consolidated balance sheet, associated with acquired in process research and development. In the ordinary course of business, circumstances may arise, including manifestation of any of the risks identified in this section, that could result in further recognition that the carrying values of our assets may not be recovered from future operations. Under such circumstances, it is possible we may be required to further impair our asset values to the extent that their remaining value after any such impairment can be recovered by our business going forward. Intangible assets with an indefinite useful life are subject to an impairment review at least annually.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our contract manufacturers may encounter manufacturing failures that could delay the clinical development or regulatory approval of our drug candidates, or their commercial production, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any performance failure on the part of any of our manufacturers could delay the clinical development or regulatory approval of our drug candidates. Our manufacturers may encounter difficulties involving, among other things, production yields, regulatory compliance, quality control and quality assurance, as well as shortages of qualified personnel. Approval of our drug candidates could be delayed, limited, or denied if the FDA does not approve and maintain the approval of our contract manufacturer&#8217;s processes or facilities. Moreover, our contract manufacturers may encounter difficulties that have a negative impact on our operations and business. Our manufacturers may encounter difficulties with the manufacturing processes required to manufacture commercial quantities of our drug candidates or the quantities needed for our pre-clinical studies or clinical trials. Such difficulties could result in delays in our pre-clinical studies, clinical trials, and regulatory submissions, in the commercialization of our drug candidates. Further, development of large-scale manufacturing processes may require additional validation studies, which the FDA must review and approve. If any of our manufacturers fail to deliver the required commercial quantities or quantities needed for our pre-clinical studies and clinical trials on a timely basis and upon terms that we find acceptable, we may be unable to meet demand for any of our drug candidates that are approved and could lose potential revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain changes in the manufacturing process or procedure, including a change in the location where the drug candidate is manufactured or a change of a third-party manufacturer, generally require prior FDA, or foreign regulatory authority, review and/or approval of the manufacturing process and procedures in accordance with current Good Manufacturing Practice (&#8220;cGMP&#8221;). We may need to conduct</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional pre-clinical studies and clinical trials to support approval of such changes. This review may be costly and time-consuming and could delay or prevent the launch of a drug candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with FDA laws and regulations regarding current good clinical practice (&#8220;GCP&#8221;), which are also required by the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities in the form of International Conference on Harmonization, guidelines for all of our drug candidates in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. While we have agreements governing activities of our CROs, we have limited influence over their actual performance. In addition, portions of the clinical trials for our drug candidates are expected to be conducted outside of the United States, which will make it more difficult for us to monitor CROs and perform visits of our clinical trial sites and will force us to rely heavily on CROs to ensure the proper and timely conduct of our clinical trials and compliance with applicable regulations, including GCP. Failure to comply with applicable regulations in the conduct of the clinical trials for our drug candidates may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to manufacture commercial and clinical supplies of our drug candidates, and we intend to rely on third parties to manufacture commercial supplies of any approved drug products. The commercialization of any of our drug products could be stopped, delayed, or made less profitable if those third parties fail to provide us with sufficient quantities of active pharmaceutical ingredients, excipients, or drug products, or fail to do so at acceptable quality levels or prices or fail to maintain or achieve satisfactory regulatory compliance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own any manufacturing facilities, and we do not currently, and do not expect in the future, to independently conduct any aspects of our product manufacturing and testing, or other activities related to the clinical development and commercialization of our drug candidates. We currently rely, and expect to continue to rely, on third parties with respect to these items, and control only certain aspects of their activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our drug candidate development and commercialization activities. Our reliance on these third parties reduces our control over these activities but does not relieve us of our responsibility to ensure compliance with all required legal, regulatory, and scientific standards and any applicable trial protocols. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, clinical trials required to support future regulatory submissions and approval of our drug candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More generally, manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up and validating initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state, and foreign regulations. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to make product candidates available for clinical trials and development purposes or to commercialize any of our product candidates in the United States would be jeopardized. Any delay or interruption in our ability to meet commercial demand may result in the loss of potential revenues and could adversely affect our ability to gain market acceptance for approved products. In addition, any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. Regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in establishing or maintaining development and commercialization collaborations, and any partner may not devote sufficient resources to the development or commercialization of our drug candidates or may otherwise fail in development or commercialization efforts, which could adversely affect our ability to develop certain of our drug candidates and our financial condition and operating results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products are expensive, we are exploring collaborations with third parties outside of the United States that have more resources and experience. In situations where we enter into a development and commercial collaboration arrangement for a drug candidate, we may also seek to establish additional collaborations for development and commercialization in territories outside of those addressed by the first collaboration arrangement for such drug candidate. There are a limited number of potential partners, and we expect to face competition in seeking appropriate partners. If we are unable to enter into any development and commercial collaborations and/or sales and marketing arrangements on acceptable terms, if at all, we may be unable to successfully develop and seek regulatory approval for our drug candidates and/or effectively market and sell future approved drug products, if any, in all of the territories outside of the United States where it may otherwise be valuable to do so.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are able to establish collaboration arrangements, any such collaboration may not ultimately be successful, which could have a negative impact on our business, results of operations, financial condition and prospects. If we partner with a third-party for development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third-party. It is possible that a partner may not devote sufficient resources to the development or commercialization of our drug candidate or may otherwise fail in development or commercialization efforts, in which event the development and commercialization of such drug candidate could be delayed or terminated, and our business could be substantially harmed. In addition, the terms of any collaboration or other arrangement that we establish may not prove to be favorable to us or may not be perceived as favorable, which may negatively impact the trading price of our common shares. In some cases, we may be responsible for continuing development of a product candidate or research program under a collaboration, and the payment we receive from our partner may be insufficient to cover the cost of this development. Moreover, collaborations and sales and marketing arrangements are complex and time consuming to negotiate, document and implement, and they may require substantial resources to maintain.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a number of additional risks associated with our dependence on collaborations with third parties, the occurrence of which could cause our collaboration arrangements to fail. Conflicts may arise between us and our partners, such as conflicts concerning the interpretation of clinical data, the achievement of milestones, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration. If any such conflicts arise, a partner could act in its own self-interest, which may be adverse to our interests. Any such disagreement between us and a partner could result in one or more of the following, each of which could delay or prevent the development or commercialization of our drug candidates and harm our business:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reductions in the payment of royalties or other payments we believe are due pursuant to the applicable collaboration arrangement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actions taken by a partner inside or outside our collaboration which could negatively impact our rights or benefits under our collaboration; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unwillingness on the part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Tax</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">There is a significant risk that we may be classified as a PFIC for U.S. federal income tax purposes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current or potential investors in our common shares who are U.S. Holders (as defined below) should be aware that, based on our most recent financial statements and projections and given uncertainty regarding the composition of our future income and assets, there is a significant risk that we may have been classified as a "passive foreign investment company" or "PFIC" for the 2023 taxable year and may be classified as a PFIC for our current taxable year and possibly subsequent years. Each current or potential investor who is a U.S. Holder should consult his, her or its own tax advisor regarding the U.S. federal, state and local, and non-U.S. tax consequences of the acquisition, ownership, and disposition of our common shares, the U.S. federal tax consequences of the PFIC rules, and the availability of any election that may be available to the holder to mitigate adverse U.S. federal income tax consequences of holding shares of a PFIC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules governing PFICs can have adverse tax effects on U.S. shareholders, which effects may be mitigated by making certain elections for U.S. federal income tax purposes, which elections may or may not be available. If we are a PFIC in any year, a U.S. shareholder in such year will be required to file an annual information return with the IRS on IRS Form 8621 regarding distributions received on their common shares, any gain realized on disposition of such common shares and any other information required by such form. Additionally, if we are classified as a PFIC in any taxable year with respect to which a U.S. shareholder owns common shares, we generally will</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to be treated as a PFIC with respect to such U.S. shareholder in all succeeding taxable years, regardless of whether we continue to meet the tests described above, unless the U.S. shareholder makes a &#8220;deemed sale election.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to use our net operating loss carry forwards to offset future taxable income for Canadian or U.S. federal income tax purposes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, Acasti Pharma U.S. had net operating loss carry forwards (&#8220;NOLs&#8221;) for U.S. federal income tax purposes of approximately $15.4 million, which have no expiry.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acasti Pharma U.S. underwent an &#8220;ownership change&#8221; within the meaning of Section 382 of the Code as a result of the merger with Grace Therapeutics, and therefore Acasti Pharma U.S. may become subject to an annual limit on the amount of NOLs that may be used to offset future taxable income of Acasti Pharma U.S. for U.S. federal income tax purposes. Such annual limit is generally equal to the product of (i) the total value of the loss company&#8217;s (in this case, Acasti Pharma U.S.) outstanding equity immediately prior to an &#8220;ownership change&#8221; (subject to certain adjustments); and (ii) the applicable federal long-term tax-exempt interest rate for the month that includes the &#8220;ownership change.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, we had NOLs for Canadian federal income tax purposes of approximately $130.1 million, which expire at various dates through 2043. The extent to which we can utilize any or all of our NOLs will depend on many factors, including the jurisdiction applicable to any of our future taxable revenue. In connection with our planned shift of our operations to the United States, we may not be able to justify the allocation of revenue to Canada sufficient to recover the tax benefits arising from NOLs and other tax credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to use NOLs will also depend on the amount of taxable income generated in future periods. The NOLs may expire before we can generate sufficient taxable income to use the NOLs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The IRS may not agree that we should be treated as a foreign Company for U.S. federal tax purposes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we are incorporated in Quebec, Canada, the IRS may assert that we should be treated as a U.S. Company (and, therefore, a U.S. tax resident) for U.S. federal tax purposes pursuant to Section 7874 of the U.S. Internal Revenue Code of 1986, as amended (the "Code"). For U.S. federal tax purposes, a Company generally is considered a tax resident in the jurisdiction of its organization or incorporation. Because we are an entity incorporated in Canada, we would generally be classified as a foreign Company (and, therefore, not a U.S. tax resident) for U.S. federal tax purposes. Section 7874 of the Code provides an exception under which a foreign Company may, in certain circumstances, be treated as a U.S. Company for U.S. federal tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Section 7874, if (1) former Grace Therapeutics shareholders owned (within the meaning of Section 7874) 80% or more (by vote or value) of our ordinary shares after the merger by reason of holding Grace Therapeutics  common stock (such ownership percentage, the "Section 7874 ownership percentage"), and (2) our "expanded affiliated group" did not have "substantial business activities" in Canada ("the substantial business activities test"), we will be treated as a U.S. Company for U.S. federal tax purposes. If the Section 7874 ownership percentage of the former Grace Therapeutics  shareholders after the merger was less than 80% but greater than or equal to 60%, and the substantial business activities test was not met, we and our U.S. affiliates may, in some circumstances, be subject to certain adverse U.S. federal income tax provisions (which, among other things, could limit their ability to utilize certain U.S. tax attributes such as NOLs to offset U.S. taxable income or gain resulting from certain transactions). The application of these rules could result in significant additional U.S. tax liability and limit our ability to restructure or access cash earned by certain of our non-U.S. subsidiaries, in each case, without incurring substantial U.S. tax liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the terms of the merger, the rules for determining share ownership under Section 7874 and certain factual assumptions, we believe that former Grace Therapeutics shareholders owned (within the meaning of Section 7874) less than 60% (by both vote and value) of our ordinary shares after the merger by reason of holding shares of Grace Therapeutics common stock. Therefore, under current law, we believe that we should not be treated as a U.S. Company for U.S. federal tax purposes and that Section 7874 should otherwise not apply to us or our affiliates as a result of the merger with Grace Therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to Our Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not expect to pay any cash dividends for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The continued operation and expansion of our business will require substantial funding. Accordingly, we do not anticipate that we will pay any cash dividends on our common shares for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend upon our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common shares may be volatile.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market prices for securities of pharmaceutical companies can fluctuate significantly. Factors such as the announcement to the public or in various scientific or industry forums of technological innovations; new commercial products; patents or exclusive rights obtained by us or others; disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; the commencement, enrollment or announcement of results of clinical trials we conduct, or changes in the development status of our drug candidates; results or delays of pre-clinical and clinical studies by us or others; any delay in our regulatory filings for our drug candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings; a change of regulations; additions or departures of key scientific or management personnel; overall performance of the equity markets; general political and economic conditions; publications; failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; research reports or positive or negative recommendations or withdrawal of research coverage by securities analysts; actual or anticipated variations in quarterly operating results; announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; public concerns over the risks of pharmaceutical products and dietary supplements; unanticipated serious safety concerns related to the use of our drug candidates or drug products; our access to financial resources, future sales of securities by us or our shareholders; and many other factors, many of which are beyond our control, could have considerable effects on the price of our common shares. The price of our common shares has fluctuated significantly in the past and there can be no assurance that the market price of our common shares will not experience significant fluctuations in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, securities of pharmaceutical companies often experience extreme price and volume fluctuations that are unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may negatively affect the market price of our common shares, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against pharmaceutical companies following periods of volatility in the market price of their securities. This type of litigation, if instituted against us, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to our technologies or drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to raise additional capital in the future in order to fully execute on our business plan. We may seek additional capital through a combination of public and private equity offerings, debt financings, and non-dilutive strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our shareholders. The incurrence of indebtedness by us would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or drug candidates, or grant licenses on terms unfavorable to us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to meet applicable listing requirements, Nasdaq may delist our common shares from trading, in which case the liquidity and market price of our common shares could decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common shares are currently listed on the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), but we cannot assure you that our securities will continue to be listed on Nasdaq in the future. On July 27, 2022, we received written notification from the Nasdaq Listing Qualifications Department for failing to maintain a minimum bid price of $1.00 per common share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2) - bid price (the &#8220;Minimum Bid Price Rule&#8221;). The Nasdaq notification had no immediate effect on the listing of our common shares, and we had 180 calendar days, or until January 23, 2023, to regain compliance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 24, 2023, we received notification from Nasdaq that we were eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the Minimum Bid Price Rule. We were granted the second extension because we meet the continued listing requirements for the market value of publicly held shares and all other initial listing standards for Nasdaq, except for the bid price requirement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 24, 2023, we received notification from Nasdaq that we had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The notification was sent following the implementation of a 1-for-6 reverse split of our common shares which became effective on July 10, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with listing standards and Nasdaq delists our common shares, we and our shareholders could face significant material adverse consequences, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a limited availability of market quotations for our common shares;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced liquidity for our common shares;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination that our common shares are &#8220;penny stock,&#8221; which would require brokers trading in our common shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common shares; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may pursue opportunities or transactions that adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, in the ordinary course of our business, regularly explores potential strategic opportunities and transactions. These opportunities and transactions may include strategic joint venture relationships, significant debt or equity investments in us by third parties, the acquisition or disposition of material assets, the licensing, acquisition or disposition of material intellectual property, the development of new drug candidates, the sale of our common shares and other similar opportunities and transactions. The public announcement of any of these or similar strategic opportunities or transactions might have a significant effect on the price of our common shares. Our policy is to not publicly disclose the pursuit of a potential strategic opportunity or transaction unless we are required to do so by applicable law, including applicable securities laws relating to periodic disclosure obligations. There can be no assurance that investors who buy or sell common shares are doing so at a time when we are not pursuing a particular strategic opportunity or transaction that, when announced, would have a significant effect on the price of our common shares.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any such future corporate development may be accompanied by certain risks, including exposure to unknown liabilities of the strategic opportunities and transactions, higher than anticipated transaction costs and expenses, the difficulty and expense of integrating operations and personnel of any acquired companies, disruption of our ongoing business, diversion of management&#8217;s time and attention, and possible dilution to shareholders. We may not be able to successfully overcome these risks and other problems associated with any future acquisitions and this may adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a Qu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#233;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bec incorporated company, and U.S. investors may be unable to enforce certain judgments against us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a company existing under the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Corporations Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Qu&#233;bec), and certain of our assets are located outside the United States. As a result, it may be difficult to effect service within the United States upon us. Execution by U.S. courts of any judgment obtained against us in U.S. courts may be limited to assets located in the United States. It may also be difficult for holders of our securities who reside in the United States to realize in the United States upon judgments of U.S. courts predicated upon civil liability of us under the U.S. federal securities laws. There may be doubt as to the enforceability in Canada against non-U.S. entities, in original actions or in actions for enforcement of judgments of U.S. courts, of liabilities predicated solely upon U.S. federal or state securities laws.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolved Staff Comments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent on third-party provided software applications and computing infrastructure to conduct key operations. We depend on both our own procured systems, networks, and technology as well as the systems, networks and technology of our contractors, consultants, vendors and other business partners.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the importance of cybersecurity to our business, we maintain a robust cybersecurity program as well as cybersecurity policies and processes to support our controls and our preparedness for treatment of identified information security risks. We also undergo annual evaluations of our cybersecurity program, conducted by our cybersecurity external advisory firm.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity program evaluation identified various risks and issues that we continue to mitigate to further improve our program. This includes:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establishing a cybersecurity training program for users. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Implementing a third-party risk management program to support our existing Third-Party Risk Management Policy and process to assess the risks associated with our critical third-party vendor engagements.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Testing our Cybersecurity Incident Response Plan. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establishing additional processes for identifying cybersecurity threats and vulnerabilities within the environment in which we operate. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enhancing our technical security management safeguards and configurations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Process for Assessing, Identifying and Managing Material Risks from Cybersecurity Threats</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of a cybersecurity incident, we maintain a Cybersecurity Incident Response Plan. Pursuant to the plan and its escalation protocols, designated personnel are responsible for assessing the severity of an incident and associated threat, containing the threat, remediating the threat, including recovery of data and access to systems, analyzing any reporting obligations associated with the incident, and performing post-incident analysis and program enhancements. We have a relationship with various law firms to assist with advisory on legal aspects of containing incidents and communicating accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management Oversight</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The controls and processes employed to assess, identify and manage material risks from cybersecurity threats are implemented and overseen by our information technology (&#8220;IT&#8221;) contractor. Our IT consultant leverages their over 35 years of experience. Our IT consultant is responsible for the day-to-day management of the cybersecurity program, including the prevention, detection, investigation, response to, and recovery from cybersecurity incidents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board Oversight</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our Board of Directors (the &#8220;Board&#8221;) has overall responsibility for risk oversight, the Audit Committee of the Board (the &#8220;Audit Committee&#8221;) oversees cybersecurity risk matters. The Audit Committee is responsible for reviewing, monitoring, reporting and, where appropriate, providing recommendations to the Board regarding compliance with our internal policies and its progress in remedying any material deficiencies, including those related to our security policies, including the physical safeguarding of corporate assets and security of our networks and information systems. The Audit Committee receives quarterly updates regarding the cybersecurity program, including top threats and risks, and updates on the cybersecurity roadmap.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cybersecurity Risks</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a Risk Management Policy that governs the process in which we identify cybersecurity risks, and quantify and evaluate their associated impacts and risk levels. A Cybersecurity Risk Register is also leveraged to track identified cybersecurity risks to date and update treatment of such risks accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information, see &#8220;Item 1A&#8212;Risk Factors.&#8221; In the last two reporting years, we did not experience any material cybersecurity incidents or threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Properties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our head office and operations are located at 103 Carnegie Center Suite 300 Princeton, New Jersey, 08540.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal Proceedings</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we are at times subject to various legal proceedings and disputes. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our financial position, results of operations, or cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our financial position, results of operations, or cash flows. We are not currently a party to any legal proceedings that, in the opinion of management, are likely to have a material adverse effect on our business.</span></p>
  <p style="margin-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety Disclosures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;" id="item_5_market_registrant_common_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities Market Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common shares are traded on the Nasdaq Capital Market under the symbol &#8220;ACST.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Holders</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 21, 2024, there were 95 holders of record of our common shares. The actual number of our shareholders is greater than this number of record holders because most of our shareholders are beneficial owners whose shares are held in street name by brokers and other nominees.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not anticipate paying any cash dividend on our common shares in the foreseeable future. We presently intend to retain any future earnings to finance the expansion and growth of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors the board of directors deems relevant. In addition, the terms of any future debt or credit facility may preclude us from paying dividends.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Taxation</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of certain U.S. federal income tax considerations arising from and relating to the acquisition, ownership, and disposition of our common shares to a U.S. Holder (as defined below) as capital assets.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This summary provides only general information and does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences that may apply to a U.S. Holder as a result of the acquisition, ownership, and disposition of our common shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences applicable to that U.S. Holder. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal, state and local, and non-U.S. tax consequences arising from or relating to the acquisition, ownership, and disposition of our common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No legal opinion from U.S. legal counsel or ruling from the IRS, has been requested, or will be obtained, regarding the U.S. federal income tax consequences to U.S. Holders of the acquisition, ownership, and disposition of our common shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Scope of this Disclosure</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Authorities</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This summary is based on the Code, U.S. Treasury Regulations promulgated thereunder (whether final, temporary or proposed), published IRS rulings, judicial decisions, published administrative positions of the IRS, and the Convention between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the Canada-U.S. Tax Treaty), in each case, as in effect as of the date of this report. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive basis. Unless otherwise discussed, this summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Holders</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this summary, a &#8220;U.S. Holder&#8221; is a beneficial owner of common shares that, for U.S. federal income tax purposes, is (a) an individual who is a citizen or resident of the United States, (b) a company, or other entity classified as a company for U.S. federal income tax purposes, that is created or organized in or under the laws of the U.S., any state in the United States or the District of Columbia, (c) an estate if the income of such estate is subject to U.S. federal income tax regardless of the source of such income, or (d) a trust if (i) such trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes or (ii) a U.S. court is able to exercise primary supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of such trust.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This summary does not address the U.S. federal income tax consequences applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, the following U.S. Holders: (a) U.S. Holders that are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax deferred accounts; (b) U.S. Holders that are financial institutions, insurance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">companies, real estate investment trusts, or regulated investment companies; (c) U.S. Holders that are dealers in securities or currencies or U.S. Holders that are traders in securities that elect to apply a mark-to-market accounting method; (d) U.S. Holders that have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) U.S. Holders subject to the alternative minimum tax provisions of the Code; (f) U.S. Holders that own common shares as part of a straddle, hedging transaction, conversion transaction, integrated transaction, constructive sale, or other arrangement involving more than one position; (g) U.S. Holders that acquired common shares through the exercise of employee stock options or otherwise as compensation for services; (h) U.S. Holders that hold common shares other than as a capital asset within the meaning of Section 1221 of the Code; (i) U.S. Holders that beneficially own (directly, indirectly or by attribution) 10% or more of our equity securities (by vote or value); and (j) U.S. expatriates. U.S. Holders that are subject to special provisions under the Code, including U.S. Holders described above, should consult their own tax advisor regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences arising from and relating to the acquisition, ownership, and disposition of the common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax consequences to that partnership and the partners of that partnership generally will depend on the activities of the partnership and the status of the partners. Partners of entities that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership and disposition of the common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Consequences Other than U.S. Federal Income Tax Consequences Not Addressed</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This summary does not address the U.S. estate and gift, alternative minimum, state, local or non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of our common shares. Each U.S. Holder should consult its own tax advisor regarding the U.S. estate and gift, alternative minimum, state, local and non-U.S. tax consequences arising from and relating to the acquisition, ownership, and disposition of our common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Assumptions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding that Acasti is organized under Qu&#233;bec law, if (1) former Grace Therapeutics shareholders owned (within the meaning of Section 7874 of the Code) 80% or more (by vote or value) of our ordinary shares after the merger by reason of holding Grace Therapeutics common stock (such ownership percentage, the &#8220;Section 7874 ownership percentage&#8221;), and (2) our &#8220;expanded affiliated group&#8221; did not have &#8220;substantial business activities" in Canada (&#8220;the substantial business activities test&#8221;), we will be treated as a U.S. company for U.S. federal tax purposes. If the Section 7874 ownership percentage of the former Grace Therapeutics shareholders after the merger was less than 80% but greater than or equal to 60%, and the substantial business activities test was not met, we and our U.S. affiliates may, in some circumstances, be subject to certain adverse U.S. federal income tax provisions (which, among other things, could limit their ability to utilize certain U.S. tax attributes such as NOLs to offset U.S. taxable income or gain resulting from certain transactions).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the terms of the merger, the rules for determining share ownership under Section 7874 of the Code and certain factual assumptions, we believe that former Grace Therapeutics shareholders owned (within the meaning of Section 7874 of the Code) less than 60% (by both vote and value) of our ordinary shares after the merger by reason of holding shares of Grace Therapeutics common stock. Therefore, under current law, we believe that we should not be treated as a U.S. company for U.S. federal tax purposes and that Section 7874 of the Code should otherwise not apply to us or our affiliates as a result of the merger with Grace Therapeutics. The remainder of the discussion in this section, &#8220;Taxation&#8221;, assumes that Acasti is and at all times has been properly classified as a non-U.S. company for U.S. federal income tax purposes.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Federal Income Tax Considerations of the Acquisition, Ownership, and Disposition of Common Shares</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distributions on Common Shares</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company Rules&#8221; below, a U.S. Holder that receives a distribution, including a constructive distribution or a taxable stock distribution, with respect to the common shares generally will be required to include the amount of that distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of our current or accumulated &#8220;earnings and profits,&#8221; (as computed for U.S. federal income tax purposes). To the extent that a distribution exceeds our current and accumulated &#8220;earnings and profits&#8221;, the excess amount will be treated (a) first, as a tax-free return of capital to the extent of a U.S. Holder&#8217;s adjusted tax basis in the common shares with respect to which the distribution is made (resulting in a corresponding reduction in the tax basis of those common shares) and, (b) thereafter, as gain from the sale or exchange of those common shares (see the more detailed discussion at &#8220;&#8212;Disposition of Common Shares&#8221; below). We do not intend to calculate our current or accumulated earnings and profits for U.S. federal income tax purposes and, therefore, will not be able to provide U.S. Holders with that information. U.S. Holders should therefore assume that any distribution by us with respect to our common shares will constitute a dividend. However, U.S. Holders should consult their own tax advisors regarding whether distributions from us should be treated as dividends for U.S. federal income tax purposes. Dividends paid on our common shares generally will not be eligible for the &#8220;dividends received deduction&#8221; allowed to companies under the Code with respect to dividends received from U.S. companies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A dividend paid by us generally will be taxed at the preferential tax rates applicable to long-term capital gains if, among other requirements, (a) we are a &#8220;qualified foreign company&#8221; (as defined below), (b) the U.S. Holder receiving the dividend is an individual, estate, or trust, and (c) the dividend is paid on common shares that have been held by the U.S. Holder for at least 61 days during the 121-day period beginning 60 days before the &#8220;ex-dividend date&#8221; (i.e., the first date that a purchaser of the common shares will not be entitled to receive the dividend).</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the rules described in the preceding paragraph, we generally would be a &#8220;qualified foreign Company&#8221;(&#8220;QFC&#8221;), if (a) we are eligible for the benefits of the Canada-U.S. Tax Treaty, or (b) our common shares are readily tradable on an established securities market in the United States, within the meaning provided in the Code. However, even if we satisfy one or more of the requirements, we will not be treated as a QFC if we are classified as a PFIC (as discussed below) for the taxable year during which we pay the applicable dividend or for the preceding taxable year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisor regarding the application of those rules to them in their particular circumstances. Even if we satisfy one or more of the requirements, as noted below. Thus, there can be no assurance that we will qualify as a QFC.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disposition of Common Shares</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company Rules&#8221; below, a U.S. Holder will recognize gain or loss on the sale or other taxable disposition of common shares (that is treated as a sale or exchange for U.S. federal income tax purposes) equal to the difference, if any, between (a) the U.S. dollar value of the amount realized on the date of the sale or disposition and (b) the U.S. Holder&#8217;s adjusted tax basis (determined in U.S. dollars) in the common shares sold or otherwise disposed of. Any such gain or loss generally will be capital gain or loss, which will be long-term capital gain or loss if the common shares are held for more than one year. A U.S. Holder's initial tax basis in the common shares generally will equal the U.S. dollar cost of such common shares. Each U.S. Holder should consult its own tax advisor as to the tax treatment of dispositions of common shares in exchange for Canadian dollars.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company Rules&#8221; below, preferential tax rates apply to long-term capital gains of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gains of a U.S. Holder that is a company. Deductions for capital losses are subject to complex limitations.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Passive Foreign Investment Company Rules</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are or become a PFIC, the preceding sections of this summary may not describe the U.S. federal income tax consequences to U.S. Holders of the acquisition, ownership, and disposition of our common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Passive Foreign Investment Company Status</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Special, generally unfavorable, rules apply to the ownership and disposition of the stock of a PFIC. For U.S. federal income tax purposes, a non-U.S. company is classified as a PFIC if:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at least 75% of its gross income for the taxable year is &#8220;passive&#8221; income (referred to as the &#8220;income test&#8221;); or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at least 50% of the average value of its assets held during the taxable year is attributable to assets that produce passive income or are held for the production of passive income (referred to as the &#8220;asset test&#8221;).</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Passive income generally includes the following types of income:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dividends, royalties, rents, annuities, interest, and income equivalent to interest; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net gains from the sale or exchange of property that gives rise to dividends, interest, royalties, rents, or annuities and certain gains from the commodities transactions.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining whether we are a PFIC, we will be required to take into account a pro rata portion of the income and assets of each company in which we own, directly or indirectly, at least 25% by value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described above, PFIC status of a non-U.S. company depends on the relative values of certain categories of assets and the relative amount of certain kinds of income for a taxable year. Therefore, our status as a PFIC for any given taxable year depends upon the financial results for such year and upon relative valuations, which are subject to change and beyond our ability to predict or control. Based on our most recent financial statements and projections and given uncertainty regarding the composition of our future income and assets, there is a significant risk that we may have been classified as a PFIC for the taxable year that ended on March 31, 2024 and may be classified as a PFIC for our current taxable year and possibly subsequent years. However, PFIC status is fundamentally factual in nature, depends on the application of complex U.S. federal income tax rules (which are subject to differing interpretations), generally cannot be determined until the close of the taxable year in question and is determined annually. Accordingly, there can be no assurance that we will not be a PFIC in our current taxable year or subsequent years. The PFIC rules are complex, and each U.S. Holder should consult its tax advisor regarding the application of the PFIC rules to us.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Default PFIC Rules Under Section 1291 of the Code.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, if we are or have been treated as a PFIC for any taxable year during a U.S. Holder&#8217;s holding period of common shares, subject to the special rules described below applicable to a U.S. Holder who makes a Mark-to-Market Election or a QEF Election (each as defined below), any &#8220;excess distribution&#8221; with respect to the common shares would be allocated ratably over the U.S. Holder&#8217;s holding period. The amounts allocated to the taxable year of the excess distribution and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or companies in that taxable year, as appropriate, and an interest charge would be imposed on the amount allocated to that taxable year. Distributions made in respect of common shares during a taxable year will be excess distributions to the extent they exceed 125% of the average of the annual distributions on common shares received by the U.S. Holder during the preceding three taxable years or the U.S. Holder&#8217;s holding period, whichever is shorter. In addition, dividends generally will not be qualified dividend income if we are a PFIC in the taxable year of payment or the preceding year.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, if we are treated as a PFIC for any taxable year during which a U.S. Holder owns common shares, any gain on the disposition of the common shares would be treated as an excess distribution and would be allocated ratably over the U.S. Holder&#8217;s holding period and subject to taxation in the same manner as described in the preceding paragraph and would not be eligible for the preferential long-term capital gains rate.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain elections (including the Mark-to-Market Election and the QEF Election, as defined and discussed below) may sometimes be used to mitigate the adverse impact of the PFIC rules on U.S. Holders, but these elections may accelerate the recognition of taxable income and have other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each current or prospective U.S. Holder should consult its own tax advisor regarding potential status of us as a PFIC, the possible effect of the PFIC rules to such holder in his, her or its particular circumstances, information reporting required if we were treated as a PFIC and the availability of any election that may be available to the U.S. holder to mitigate adverse U.S. federal income tax consequences of holding shares in a PFIC.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">QEF Election.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A U.S. Holder of common shares in a PFIC generally would not be subject to the PFIC rules discussed above if the U.S. Holder had made a timely and effective election (a &#8220;QEF Election&#8221;) to treat us as a &#8220;qualified electing fund&#8221; (a &#8220;QEF&#8221;). Instead, such U.S. Holder would be subject to U.S. federal income tax on its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">pro rata </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share of our (i) net capital gain, which would be taxed as long-term capital gain to such U.S. Holder, and (ii) ordinary earnings, which would be taxed as ordinary income to such U.S. Holder, in each case regardless of whether such amounts are actually distributed to such U.S. Holder. However, a U.S. Holder that makes a QEF Election may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a company, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A U.S. Holder that makes a timely and effective QEF Election generally (a) may receive a tax-free distribution from us to the extent that such distribution represents our &#8220;earnings and profits&#8221; that were previously included in income by such U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the common shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, for U.S. federal income tax purposes, a U.S. Holder that makes a timely QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of the common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first taxable year in the U.S. Holder&#8217;s holding period for the common shares in which we are a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such first year. If a U.S. Holder makes a QEF Election after the first taxable year in the U.S. Holder&#8217;s holding period for the common shares in which we are a PFIC, then, in addition to filing the QEF Election documents, a U.S. Holder may elect to recognize gain (which will be taxed under the rules discussed under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Default PFIC Rules Under Section 1291 of the Code</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) as if the common shares were sold on the qualification date. The &#8220;qualification date&#8221; is the first day of the first taxable year in which we are a QEF with respect to such U.S. Holder. The election to recognize such gain can only be made if such U.S. Holder&#8217;s holding period for the common shares includes the qualification date. By electing to recognize such gain, such U.S. Holder will be deemed to have made a timely QEF Election. In addition, under very limited circumstances, it is possible that a U.S. Holder might make a retroactive QEF Election if such U.S. Holder failed to file the QEF Election documents in a timely manner. If a U.S. Holder fails to make a QEF Election for the first taxable year in the U.S. Holder&#8217;s holding period for the common shares in which we are a PFIC and does not elect to recognize gain as if the common shares were sold on the qualification date, such holder will not be treated as having made a &#8220;timely&#8221; QEF Election and will continue to be subject to the special adverse taxation rules discussed above under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Default PFIC Rules Under Section 1291 of the Code</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A QEF Election will apply to the taxable year for which such QEF Election is made and to all subsequent taxable years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent taxable year, we cease to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those taxable years in which we are not a PFIC. Accordingly, if we become a PFIC in another subsequent taxable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">year, the QEF Election will be effective, and the U.S. Holder will be subject to the rules described above during any such subsequent taxable year in which we qualify as a PFIC.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A U.S. Holder cannot make and maintain a valid QEF Election unless we provide certain U.S. tax information necessary to make such an election. On an annual basis, we intend to use commercially reasonable efforts to make available to U.S. Holders, upon their written request (a) timely information as to our status as a PFIC, and (b) for each year in which we are a PFIC, information and documentation that a U.S. Holder making a QEF Election with respect to us is required to obtain for U.S. federal income tax purposes. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a QEF Election with respect to us.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mark-to-Market Election.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A U.S. Holder of common shares in a PFIC would not be subject to the PFIC rules discussed above under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Default PFIC Rules Under Section 1291 of the Code</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; if the U.S. Holder had made a timely and effective election to mark the PFIC common shares to market (a &#8220;Mark-to-Market Election&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A U.S. Holder may make a Mark-to-Market Election with respect to the common shares only if such shares are marketable stock. Such shares generally will be &#8220;marketable stock&#8221; if they are regularly traded on a &#8220;qualified exchange,&#8221; which is defined as (a) a national securities exchange that is registered with the SEC, (b) the national market system established pursuant to section 11A of the Exchange Act, or (c) a non-U.S. securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such non-U.S. exchange has trading volume, listing, financial disclosure, surveillance, and other requirements, and the laws of the country in which such non-U.S. exchange is located, together with the rules of such non-U.S. exchange, ensure that such requirements are actually enforced and (ii) the rules of such non-U.S. exchange ensure active trading of listed stocks. Our common shares will generally be treated as &#8220;regularly traded&#8221; in any calendar year in which more than a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de minimis </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">quantity of common shares is traded on a qualified exchange for at least 15 days during each calendar quarter. Each U.S. Holder should consult its own tax advisor with respect to the availability of a Mark-to-Market Election with respect to the common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, a U.S. Holder that makes a timely Mark-to-Market Election with respect to the common shares will include in ordinary income, for each taxable year in which we are a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the common shares as of the close of such taxable year over (b) such U.S. Holder&#8217;s tax basis in such shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the lesser of (a) the excess, if any, of (i) such U.S. Holder&#8217;s adjusted tax basis in the common shares over (ii) the fair market value of such shares as of the close of such taxable year or (b) the excess, if any, of (i) the amount included in ordinary income because of such Mark-to-Market Election for prior taxable years over (ii) the amount allowed as a deduction because of such Mark-to-Market Election for prior taxable years. If a U.S. Holder makes a Mark-to-Market Election after the first taxable year in which we are a PFIC and such U.S. Holder has not made a timely QEF Election with respect to us, the PFIC rules described above under &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Default PFIC Rules Under Section 1291 of the Code</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; will apply to certain dispositions of, and distributions on, the common shares, and the U.S. Holder&#8217;s mark-to-market income for the year of the election. If we were to cease being a PFIC, a U.S. Holder that marked its common shares to market would not include mark-to-market gain or loss with respect to its common shares for any taxable year that we were not a PFIC.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A U.S. Holder that makes a Mark-to-Market Election generally will also adjust such U.S. Holder&#8217;s tax basis in his common shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of the common shares subject to a Mark-to-Market Election, any gain or loss on such disposition will be ordinary income or loss (to the extent that such loss does not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior taxable years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior taxable years). A Mark-to-Market Election applies to the taxable year in which such Mark-to-Market Election is made and to each subsequent taxable year unless the common shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a Mark-to-Market Election with respect to the common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we were to be treated as a PFIC in any taxable year, a U.S. Holder will generally be required to file an annual report with the IRS containing such information as the U.S. Treasury Department may require.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each U.S. Holder should consult its own tax advisor regarding our potential status as a PFIC, the possible effect of the PFIC rules to such holder and information reporting required if we were a PFIC, as well as the availability of any election that may be available to the holder to mitigate adverse U.S. federal income tax consequences of holding shares in a PFIC.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Receipt of Foreign Currency</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amount of a distribution paid in Canadian dollars or Canadian dollar proceeds received on the sale or other taxable disposition of common shares will generally be equal to the U.S. dollar value of the currency on the date of receipt. If any Canadian dollars received with respect to the common shares are later converted into U.S. dollars, U.S. Holders may realize foreign currency gain or loss on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conversion. Any gain or loss generally will be treated as ordinary income or loss and generally will be from sources within the United States for U.S. foreign tax credit purposes. Each U.S. Holder should consult its own tax advisor concerning the possibility of foreign currency gain or loss if any such currency is not converted into U.S. dollars on the date of receipt.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Tax Credit</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to certain limitations, a U.S. Holder who pays (whether directly or through withholding) Canadian or other non-U.S. income tax with respect to the common shares may be entitled, at the election of the U.S. Holder, to receive either a deduction or a credit for Canadian or other non-U.S. income tax paid. Dividends paid on common shares generally will constitute income from sources outside the United States. Any gain from the sale or other taxable disposition of the common shares by a U.S. Holder generally will constitute U.S. source income. The foreign tax credit rules (including the limitations with respect thereto) are complex, and each U.S. Holder should consult its own tax advisor regarding the foreign tax credit rules, having regard to such holder&#8217;s particular circumstances.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Information Reporting; Backup Withholding</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, information reporting and backup withholding will apply to distributions on, and the payment of proceeds from the sale or other taxable disposition of, the common shares unless (i) the U.S. Holder is a company or other exempt entity, or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number, certifies that the U.S. Holder is not subject to backup withholding and otherwise complies with the applicable requirements of the backup withholding rules.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Backup withholding is not an additional tax. Any amount withheld generally will be creditable against a U.S. Holder&#8217;s U.S. federal income tax liability or refundable to the extent that it exceeds such liability provided the required information is provided to the IRS in a timely manner.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain categories of U.S. Holders must file information returns with respect to their investment in a non-U.S. company. For example, certain U.S. Holders must file IRS Form 8938 with respect to certain &#8220;specified foreign financial assets&#8221; (such as the common shares) with an aggregate value in excess of US$50,000 (and, in some circumstances, a higher threshold). Failure to do so could result in substantial penalties and in the extension of the statute of limitations with respect to such holder&#8217;s U.S. federal income tax returns. Each U.S. Holder should consult its own tax advisor regarding application of the information reporting and backup withholding rules to it in connection with an investment in our common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Medicare Contribution Tax</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Holders that are individuals, estates or certain trusts generally will be subject to a 3.8% Medicare contribution tax on, among other things, dividends on, and capital gains from the sale or other taxable disposition of, common shares, subject to certain limitations and exceptions. Each U.S. Holder should consult its own tax advisor regarding possible application of this additional tax to income earned in connection with an investment in our common shares.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuer Repurchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Reserved</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following discussion should be read in conjunction with our consolidated financial statements and notes thereto found elsewhere in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K. We caution readers not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis only as of the date of this Annual Report on Form 10-K. We undertake no obligation to update forward-looking statements which reflect events or circumstances occurring after the date of this Annual Report on Form 10-K, unless required by applicable securities laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This management&#8217;s discussion and analysis (&#8220;MD&amp;A&#8221;) is presented in order to provide the reader with an overview of the financial results and changes to our financial position as at March 31, 2024 and for the year then ended. This MD&amp;A explains the material variations in our operations, financial position and cash flows for the years ended March 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market data, and certain industry data and forecasts included in this MD&amp;A were obtained from internal surveys and market research conducted by third parties hired by us, publicly available information, reports of governmental agencies and industry publications, and independent third-party surveys. We have relied upon industry publications as our primary sources for third-party industry data and forecasts. Industry surveys, publications and forecasts generally state that the information they contain has been obtained from sources believed to be reliable, but that the accuracy and completeness of that information are not guaranteed. We have not independently verified any of the data from third-party sources or the underlying economic assumptions they have made. Similarly, internal surveys, industry forecasts and market research, which we believe to be reliable based upon management or contracted third parties&#8217; knowledge of our industry, have not been independently verified. Our estimates involve risks and uncertainties, including assumptions that may prove not to be accurate, and these estimates and certain industry data are subject to change based on various factors, including those discussed in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This MD&amp;A should be read in conjunction with our consolidated financial statements for the years ended March 31, 2024 and 2023 included elsewhere in this Annual Report on Form 10-K. Our annual financial statements were prepared in accordance with U.S. GAAP.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assets as at March 31, 2024, include cash and cash equivalents of $23.0 million and intangible assets and goodwill of $49.3 million. Our current liabilities were $1.7 million as of March 31, 2024 and are comprised primarily of amounts due to or accrued for creditors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse stock split</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2023, our Board of Directors approved an amendment to our Articles of Incorporation to implement a reverse stock split of our common shares, at a ratio of 1-for-6 (the &#8220;Reverse Stock Split&#8221;). On July 4, 2023, we filed Articles of Amendment to our Articles of Incorporation with the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registraire des entreprises du Qu&#233;bec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to implement the Reverse Stock Split. All references in this MD&amp;A to number of common shares, warrants and options, and number of shares outstanding have been adjusted to reflect the Reverse Stock Split, which became effective on July 10, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the year ended March 31, 2024, and 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended March 31, 2024 and 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.252%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.362%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.362%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.022%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31,<br/>2024</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31,<br/>2023</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase (Decrease)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="11" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses, net of government assistance</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,683</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,289</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,432</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,182</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">661</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(409</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring cost</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,485</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,485</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,682</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28,682</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of assets held for sale</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss from operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,852</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(52,155</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(39,303</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(16</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of derivative warrant liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,728</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,738</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income and other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">911</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">665</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,832</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,710</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,853</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(42,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29,576</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net loss of $12.9 million or $1.35 loss per share for the year ended March 31, 2024, decreased by $29.6 million from the net loss of $42.4 million or $5.71 loss per share for the year ended March 31, 2023. The decrease in net loss was primarily due to asset impairments, net of income tax benefit, totaling $25.3 million during the year ended March 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fees paid to external service providers such as contract research organizations ("CROs") and contract manufacturing organizations ("CMOs") related to clinical trials, including contractual obligations for clinical development, clinical sites, manufacturing and scale-up, and formulation of clinical drug supplies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fees paid to contract service providers related to drug discovery efforts including chemistry and biology services; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">salaries and related expenses for research and development personnel, including expenses related to stock options.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record research and development expenses as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development during the year ended March 31, 2024 was focused primarily on our clinical development programs for our GTX-104 drug candidate. Research and development expenses during the year ended March 31, 2023, were focused primarily on our clinical development programs GTX-104, GTX-102, and GTX-101 drug candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.051%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:16.297%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:11.918%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:16.297%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:center;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase (Decrease)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="11" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total third-party research and development expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,576</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,704</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,128</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government grants &amp; tax credits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Salaries and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">844</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,742</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(898</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense before stock-based compensation and depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,475</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,281</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,806</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(393</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and loss on disposal</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,683</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(5,289</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total third-party research and development expenses are calculated before salaries and benefits, depreciation, write-off of equipment and stock-based compensation. Because there is no standard method endorsed by U.S. GAAP, the results may not be comparable to similar measurements presented by other public companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total third-party research and development expenses for the year ended March 31, 2024, were $3.6 million, compared to $7.7 million for the year ended March 31, 2023. This decrease of $4.1 million was primarily due to the restructuring to align our organizational and management cost structure to prioritize resources to GTX-104, thereby reducing losses to improve cash flow and extend available cash resources. Our clinical development programs for GTX-102, and GTX-101 were de-prioritized in the current year compared to the prior year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government grants and tax credits of $55 thousand for the year ended March 31, 2024, decreased by $220 thousand compared to $(165) thousand for the year ended March 31, 2023. The changes within government grants and tax credits were due to adjustments of provisions regarding the estimated realizability of credits receivable after assessments and correspondence from tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Salaries and benefits of $844 thousand for the year ended March 31, 2024, decreased by $898 thousand compared to $1.7 million for the year ended March 31, 2023. The decrease was primarily due to a reduction in research and development headcount due to the restructuring.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation of $198 thousand for the year ended March 31, 2024, decreased by $393 thousand compared to $591 thousand for the year ended March 31, 2023. The decrease was primarily due to a reduction in research and development headcount due to the restructuring.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, and support functions, including professional fees for auditing, tax, consulting, rent and utilities and insurance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.86%;"/>
    <td style="width:1.88%;"/>
    <td style="width:1%;"/>
    <td style="width:9.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1.88%;"/>
    <td style="width:1%;"/>
    <td style="width:9.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.88%;"/>
    <td style="width:1%;"/>
    <td style="width:17.64%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:center;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase (Decrease)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="11" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Salaries and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,164</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,362</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,198</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,188</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,013</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,175</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,343</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,053</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(710</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expense before stock-based compensation and depreciation </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,695</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(733</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">697</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(426</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and loss on disposal</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6,432</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(1,182</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative sub-total expenses is calculated before stock-based compensation and depreciation. Because there is no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">standard method endorsed by U.S. GAAP, the results may not be comparable to similar measurements presented by other public companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $5.7 million before stock-based compensation and depreciation expense for the year ended March 31, 2024, a decrease of $733 thousand from $6.4 million for the year ended March 31, 2023. The decrease was primarily a result of decreased salaries and benefits due to a reduction in general and administrative headcount due to our restructuring and reorganization of our management structure offset by increased legal, tax, accounting and other professional fees related to the restructuring. Stock-based compensation of $697 thousand for the year ended March 31, 2024, decreased by $426 thousand compared to $1.1 million for the year ended March 31, 2023. The decrease was primarily due to a reduction in general and administrative headcount as a result of our restructuring.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and marketing</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses consist primarily of salaries and benefits, including share-based compensation, related to our commercial functions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.431%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.242%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sales and marketing expenses</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:center;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase (Decrease)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="11" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Salaries and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(408</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and Marketing expenses before stock-based compensation</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">564</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(330</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(79</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">252</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">661</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(409</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing sub-total expenses is calculated before stock-based compensation. Because there is no standard method endorsed by U.S. GAAP, the results may not be comparable to similar measurements presented by other public companies.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses before stock-based compensation expense were $234 thousand for the year ended March 31, 2024, compared to $564 thousand for the year ended March 31, 2023. The decrease of $330 thousand was primarily due to the reduction of headcount due to our restructuring and reorganization of our management structure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation of $18 thousand for the year ended March 31, 2024, decreased by $79 thousand, compared to $97 thousand for the year ended March 31, 2023. The decrease is primarily due to a reduction in sales and marketing headcount due to our restructuring.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 8, 2023, we announced our decision to terminate a substantial amount of our workforce as part of a plan intended to align our organizational and management cost structure to prioritize resources to GTX-104, thereby reducing losses to improve cash flow and extend available cash resources. We incurred $1.5 million of related costs primarily consisting of employee severance costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, we announced the strategic decision to prioritize development of GTX-104 with a goal to advance to commercialization, while conserving resources as much as possible to complete development efficiently. We estimated that the deferral could be 3 years from April 2023, given the timeline to complete the development and commercial launch of GTX-104. Further development of GTX-102 and GTX-101 will occur at such time as we obtain additional funding or enter into strategic partnerships.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The decision to defer further development triggered a comprehensive impairment review of our intangible assets in March 2023. Given the extended timeline, we increased the discount rates used to value the assets in order to recognize additional risks related to prioritizing one asset over the others, financing the projects given limited available resources and the need to preserve cash to advance GTX-104 as far as possible, potential competitor advances that could arise over three years, and the general market depression affecting small cap development companies like us and the prohibitively high dilution and expense of  available funding in the capital markets. Increasing the discount rates significantly reduced the discounted cash flow values for each of the programs deferred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, an impairment of intangible assets of $28.7 million resulted in the year ended March 31, 2023, compared to nil for the year ended March 31, 2024. In addition, an impairment of $4.8 million of goodwill resulted in the year ended March 31, 2023, compared</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to nil for the year ended March 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in fair value of derivative warrant liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in fair value of derivative warrant liabilities for the year ended March 31, 2024 of $2.7 million was mainly attributable to an increase in our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income was $911 thousand for the year ended March 31, 2024, compared to $246 thousand for the year ended March 31, 2023. The $665 thousand increase in our interest income was due to higher interest rates earned on average balances of cash and cash equivalents.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income tax benefit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax benefit was $1.8 million for the year ended March 31, 2024, compared to $9.5 million for the year ended March 31, 2023. In 2023, the impairment of $28.7 million of the intangible assets resulted in an income tax recovery of $8.6 million of the related deferred tax liability. In 2024, there was no such impairment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows and Financial Condition between the years ended March 31, 2024 and March 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, cash and cash equivalents were $23.0 million, a net decrease of $4.9 million compared to cash and cash equivalents of $27.9 million at March 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net cash used in operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended March 31, 2024 and 2023, our operating activities used cash of $12.3 million and $15.9 million, respectively, a decrease of $3.6 million.  The reduction in cash used in operating activities during 2024 was primarily due to our May 2023 restructuring, which resulted in lower third-party research and development expenses of $4.1 million, lower salaries and benefits expenses of $2.5 million, and lower other general and administrative expenses of $0.7 million.  In addition, during 2024, we earned higher interest income of $665 thousand.  These amounts were offset in part in 2024 by additional cash used of $1.5 million to fund operating assets and liabilities, restructuring costs of $1.5 million, higher professional fees of $1.2 million, primarily related to the restructuring and private placement, and reduced government grants and credits of $220 thousand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing activities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended March 31, 2024 our investing activities provided cash of $104 thousand compared to cash provided of $13.2 million for the year ended March 31, 2023. The decrease in cash provided was a result of a decrease in net maturities of short-term investments.</span></p>
  <p style="margin-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing activities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended March 31, 2024, was $7.4 million due to the net proceeds from our September 2023 Offering of $7.3 million compared to cash provided of $304 thousand during the year ended March 31, 2023 from our at-the-market (&#8220;ATM&#8221;) program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 24, 2023, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors in connection with a private placement offering of our securities (the &#8220;Offering&#8221;). Pursuant to the Purchase Agreement, sold 1,951,371 Class A common shares, no par value per share (the &#8220;Common Shares&#8221;), at a purchase price of $1.848 per Common Share and pre-funded warrants (the &#8220;Pre-funded Warrants&#8221;) to purchase up to 2,106,853 Common Shares at a purchase price equal to the purchase price per Common Share less $0.0001. Each Pre-funded Warrant is exercisable for one Common Share at an exercise price of $0.0001 per Common Share, was immediately exercisable, and will expire once exercised in full. Pursuant to the Purchase Agreement, we also issued to such institutional and accredited investors common warrants (the &#8220;Common Warrants&#8221;) to purchase Common Shares, exercisable for an aggregate of 2,536,391 Common Shares. Under the terms of the Purchase Agreement, for each Common Share and each Pre-funded Warrant issued in the Offering, an accompanying five-eighths (0.625) of a Common Warrant was issued to the purchaser thereof. Each whole Common Warrant is exercisable for one Common Share at an exercise price of $3.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per Common Share, was immediately exercisable, and will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) of a New Drug Application for our product candidate GTX-104 or (ii) five years from the date of issuance. The Offering closed on September 25, 2023. The net proceeds to us from the Offering were approximately $7.3 million, after deducting fees and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-the-Market ("ATM") Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2020, we entered into an amended and restated At Market Issuance Sales Agreement (the &#8220;Sales Agreement&#8221;) with B. Riley FBR, Inc., Oppenheimer &amp; Co. Inc. and H.C. Wainwright &amp; Co., LLC (collectively, the &#8220;Agents&#8221;) to amend our then existing at-the-market program (the "ATM Program"). Under the terms of the Sales Agreement, which had a three-year term, we could issue and sell from time to time, common shares of the Company ("Common Shares") having an aggregate offering price of up to $75 million through the Agents. Subject to the terms and conditions of the Sales Agreement, the Agents would use their commercially reasonable efforts to sell the Common Shares from time to time, based upon our instructions. We had no obligation to sell any of the Common Shares and could, at any time, suspend sales under the Sales Agreement. We and the Agents could terminate the Sales Agreement in accordance with its terms. Under the terms of the Sales Agreement, we provided the Agents with customary indemnification rights and the Agents were entitled to compensation at a commission rate equal to 3.0% of the gross proceeds from each sale of the Common Shares. The Sales Agreement expired pursuant to its terms on June 29, 2023. We intend to examine our financing strategies on a go-forward basis and may consider entering into a new at-the-market program in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended March 31, 2024, no Common Shares were sold under the ATM program. During the year ended March 31, 2023, 54,108 Common Shares were sold for total net proceeds of $304 thousand with commissions, legal expenses and costs related to the share sale amounting to $10 thousand. The Common Shares were sold at the prevailing market prices, which resulted in an average price of approximately $5.70 per share.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contractual obligations and commitments include trade payables, operating lease obligations, CMO and CRO agreements, as described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development contracts and contract research organizations agreements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize CMOs, for the development and production of clinical materials and CROs to perform services related to our clinical trials. Pursuant to the agreements with CMOs and CROs, we have either the right to terminate the agreements without penalties or under certain penalty conditions. As of March 31, 2024, we have no commitments with CMOs and $6.0 million of commitments for the next twelve months to CROs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raw krill oil supply contract</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 25, 2019, we entered into a supply agreement with Aker BioMarine Antarctic AS. (&#8220;AKBM&#8221;) to purchase raw krill oil product for a committed volume of commercial starting material for CaPre, one of our former drug candidates, for a total fixed value of $3.1 million based on the value of krill oil at that time. As of March 31, 2022, the remaining balance of commitment amounted to $2.8 million. During the second calendar quarter of 2022, AKBM informed us that AKBM believed it had satisfied the terms of the supply agreement as to their obligation to deliver the remaining balance of raw krill oil product, and that we were therefore required to accept the remaining product commitment. We disagreed with AKBM&#8217;s position and believed that AKBM was not entitled to further payment under the supply agreement. Accordingly, no liability was recorded by us. The dispute remained unresolved as of both March 31, 2023 and 2022. On October 18, 2023, we entered into an agreement with AKBM to settle any and all potential claims regarding amounts due under the supply agreement (the &#8220;Settlement Agreement&#8221;). Pursuant to the terms of the Settlement Agreement, in exchange for a release and waiver of claims arising out of the supply agreement by AKBM and any of AKBM&#8217;s affiliates, we agreed to the following: (a) AKBM retained ownership of all raw krill oil product, including amounts previously delivered to us; (b) AKBM acquired and took ownership of all of our production equipment related to the production of CaPre; (c) AKBM acquired and took ownership of all of our data from research, clinical trials and pre-clinical studies with respect to CaPre; and (d) AKBM acquired and took ownership over all of our rights, title and interest in and to all intellectual property rights, including all patents and trademarks, related to CaPre owned by us. Further, AKBM acknowledged that the CaPre assets were transferred on an &#8220;as is&#8221; basis, and in connection therewith we disclaimed all representations and warranties in connection with the CaPre assets, including any representations with respect to performance or sufficiency. The value of the raw krill oil previously delivered to us, the production equipment, and the intellectual property rights related to CaPre were fully impaired in prior reporting periods and had a carrying value of nil as of March 31, 2023. As of March 31, 2024, no liability was recorded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates and Measurement of Uncertainty</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates are based on management&#8217;s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions include the measurement of stock-based compensation, derivative warrant liabilities, accruals for research and development contracts and contract organization agreements, and valuation of intangibles and goodwill. Estimates and assumptions are also involved in determining which research and development expenses qualify for research and development tax credits and in what amounts. We recognize the tax credits once we have reasonable assurance that they will be realized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Accounting Policies</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Intangible Assets and Goodwill</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a business combination, the fair value of in-process research and development ("IPR&amp;D") acquired is capitalized and accounted for as indefinite-lived intangible assets, and not amortized until the underlying project receives regulatory approval, at which point the intangible assets will be accounted for as definite-lived intangible assets or discontinued. If discontinued, the intangible assets will be written off. R&amp;D costs incurred after the acquisition are expensed as incurred.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our IPR&amp;D and Goodwill was $49.3 million as of March 31, 2024, which represents 67% of total assets. Goodwill and indefinite lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeds the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The nature of the assumptions in the intangible asset's impairment tests are considered critical due to a high level of subjectivity and judgment necessary to account for highly uncertain matters, and the impact of the assumptions on our financial condition and our operating performance could be material.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We test goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. We test indefinite lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. Events that could result in an impairment, or trigger an interim impairment assessment, include the decision to discontinue the development of a drug, the receipt of additional clinical or nonclinical data regarding our drug candidates or a potentially competitive drug candidates, changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug candidates and increases in our weighted average cost of capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual IPR&amp;D projects and goodwill are tested for impairment on an annual basis in the fourth quarter, and in between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of each technology or our reporting unit below its carrying value. We identified the strategic realignment plan announced on April 4, 2023 to prioritize resources to GTX-104, from GTX-101 and GTX-102 triggered a comprehensive impairment review of our intangible assets and have considered these facts in our annual impairment test. Deferral of development for GTX-101 and 102 extended the cash runway from existing resources and also reduced the values in the discounted cashflow due to the deferral. The result of the impairment assessment resulted in the following activity between March 31, 2023 and March 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.52%;"/>
    <td style="width:8.4%;"/>
    <td style="width:1%;"/>
    <td style="width:17.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.88%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.88%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.34%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-104</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-102</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-101</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="11" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets &#8211; in-process research and development</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,908</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,307</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,810</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,712</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,970</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28,682</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,196</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,337</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">41,128</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,196</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,337</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">41,128</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impairment of $28.7 million of the identified intangible assets recorded for the year ended March 31, 2023 resulted in a recovery of $8.6 million of the related deferred tax liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.68%;"/>
    <td style="width:11.52%;"/>
    <td style="width:1%;"/>
    <td style="width:25.8%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Goodwill</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,964</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,826</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8,138</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8,138</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair values of our intangible assets were determined using the multi-period excess earnings method, which is a valuation methodology that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The projected discounted cash flow models used to estimate the fair value of assets of our IPR&amp;D reflect significant assumptions and are Level 3 unobservable data regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Probability of clinical success of research and development and obtaining regulatory approval. This estimate was based on various publicly available studies conducted by third parties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forecasted net sales from up-front and milestone payments, royalties and product sales. Comparable market transactions were used to estimate milestone and royalty revenues. The addressable market and patient acquisition rates were estimated based on studies we commissioned a third-party to conduct. The estimated sales prices of our technologies are based on competitors with similar drug products. We have made estimates related to deductions expected to be provided based on conventional commercial models to access the market; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discount rate reflecting our weighted average cost of capital and specific risk inherent in the underlying assets.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The projected discounted cash flow model used to estimate the fair value of our reporting unit and intangible assets as of March 31, 2024 includes a significant assumption related to each project's probability of clinical success, which is reflected in the cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The projected discounted cash flow model used to estimate the fair value of our reporting unit and the intangibles as of March 31, 2024, includes a significant assumption related to each project's projected net sales levels, which is reflected in the cash flows. Based on our fair value assessment, an impairment loss of GTX-101, GTX-102 and GTX-104 would result if the net sales assumptions decreased more than approximately 32.3%, 21.0% and 50.7% respectively, for each year, all other assumptions remaining constant. We believe that the net sales assumptions developed were applied with a conservative framework such as the exclusion of addressable markets outside the United States, which markets we expect to provide revenue upside if and when GTX-101, GTX-102 and GTX-104 are approved by the FDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The valuation of our IPR&amp;D has significant measurement uncertainty given the risks and uncertainties associated with the timely and successful completion of the development and commercialization of drug candidates. We engaged a third-party valuation firm to assist us with the valuation of the IPR&amp;D and goodwill. Assumptions are difficult to make accurately and were mainly derived from life science studies, industry data, and peer company information that our management believes represent appropriate comparable data. Estimates of value are required to be discounted to account for risks related to the inherent uncertainties of the overall development and commercialization processes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impairment assessment is sensitive to changes in forecasted cash flows, our selected discount rates as well as the implied control premiums. Changes to our assumptions, in particular changes in technological feasibility or changes in the regulatory approval process could materially affect the estimation of the fair value and could result in impairment charges in future quarters.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Credit Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are all invested in accordance with the Company&#8217;s Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which risk is managed by dealing only with highly rated Canadian and U.S. institutions. The Company maintains its cash and cash equivalents at accredited financial institutions in amounts that exceed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates. Our exposure to interest rate risk as at March 31, 2024 was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.08%;"/>
    <td style="width:1.84%;"/>
    <td style="width:49.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term fixed interest rate</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our capacity to reinvest the short-term amounts with equivalent return will be impacted by variations in short-term fixed interest rates available on the market. Management believes the risk we will realize a loss as a result of the decline in the fair value of our short-term investments is limited because these investments have short-term maturities and are held to maturity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contractual obligations related to financial instruments and other obligations and liquidity resources are presented in the liquidity and capital resources of this MD&amp;A.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred operating losses and negative cash flows from operations in each year since our inception. We expect to incur significant expenses and continued operating losses for the foreseeable future. We expect our expenses will increase substantially in connection with our ongoing activities, particularly as we advance clinical development for our drug candidates in our pipeline; continue to engage contract manufacturing organizations to manufacture our clinical study materials and to ultimately develop large-scale manufacturing capabilities in preparation for commercial launch; seek regulatory approval for our drug candidates; and add personnel to support our drug product development and future drug product launch and commercialization.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to generate revenue from product sales unless and until we successfully complete drug development and obtain regulatory approval, which we expect will take several years and is subject to significant uncertainty. To date, we have financed our operations primarily through public offerings and private placements of our common shares, warrants and convertible debt and with the proceeds from research tax credits. Until such time that we can generate significant revenue from drug product sales, if ever, we will require additional financing, which we expect to be sourced from a combination of public or private equity offerings or debt financing's or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require us to relinquish certain rights related to our technologies or drug product candidates. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to have sufficient cash resources to satisfy our objectives into the second calendar quarter of 2026, which is 22 months from the issuance date of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. We require additional capital to fund our daily operating needs beyond that time. We plan to raise additional capital prior to that time in order to maintain adequate liquidity. Negative results from studies, if any, and depressed prices of our common shares could impact our ability to raise additional financing. Raising additional equity capital is subject to market conditions not within our control. If we do not raise additional funds in this time period, we may not be able to realize our assets and discharge our liabilities in the normal course of business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Accounting Changes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considered recent accounting pronouncements and concluded that they are either not applicable to our business or that the effect is not expected to be material to our consolidated financial statements as a result of future adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosure About Market Risk</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a smaller reporting company, we are not required to provide this information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_f_s_supplementary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See our consolidated financial statements beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_accounts_f_d"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_and_procedure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls and Procedures Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the end of the period covered by this Annual Report on Form 10-K, our management, with the participation of our chief executive officer (&#8220;CEO&#8221;) and principal financial officer (&#8220;PFO&#8221;), has performed an evaluation of the effectiveness of our disclosure controls and procedures within the meaning of Rules 13a-15 (e) and 15d-15(e) of the Exchange Act. Based upon this evaluation, our management has concluded that, as of March 31, 2024, our existing disclosure controls and procedures were effective. It should be noted that while the CEO and PFO believe that our disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect the disclosure controls and procedures to be capable of preventing all errors and fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Report on Internal Controls over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our CEO and PFO, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of our consolidated financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management conducted an assessment of the design and operation effectiveness of our internal control over financial reporting as of March 31, 2024. In making this assessment, we used the criteria established within the Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment, our management has concluded that, as of March 31, 2024, our internal control over financial reporting was effective.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No changes were made to our internal controls over financial reporting that occurred during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a non-accelerated filer under the Exchange Act and not required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. Therefore, this Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding our management&#8217;s assessment of internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024, no director or officer of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7aa17690-c5e9-411c-9877-775c4fa8307b" contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f7a5ec93-3749-45cc-b42c-bec11e258a09" contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79d57a1d-61f6-4556-a914-dca7eea3620b" contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_c97924e7-cc8e-4deb-94cf-aa2930c041fe" contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers_c_g"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth information with respect to our current directors and executive officers:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.597%;"/>
    <td style="width:1.06%;"/>
    <td style="width:4.999%;"/>
    <td style="width:2%;"/>
    <td style="width:39.852%;"/>
    <td style="width:1.04%;"/>
    <td style="width:18.756%;"/>
    <td style="width:1.04%;"/>
    <td style="width:16.657%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07847222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Age</span></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Position(s) held within Acasti</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">In Office Since</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current Term to Expire</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.05pt;vertical-align:top;"><p style="margin-left:0.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:0.05pt;vertical-align:top;"><p style="margin-left:0.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.05pt;vertical-align:top;"><p style="margin-left:0.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vimal Kavuru</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11597222222222221in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 2021</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.1pt;vertical-align:top;"><p style="margin-left:0.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">A. Brian Davis</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11597222222222221in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director, Chairman of Audit Committee and Chairman of Governance and Human Resources Committee</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.1pt;vertical-align:top;"><p style="margin-left:0.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S. George Kottayil</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11597222222222221in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.1pt;vertical-align:top;"><p style="margin-left:0.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Edward Neugeboren</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11597222222222221in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.1pt;vertical-align:top;"><p style="margin-left:0.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prashant Kohli</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11458333333333333in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEO since April 2023, director since October 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.1pt;vertical-align:top;"><p style="margin-left:0.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert J. DelAversano</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11458333333333333in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President, Finance, Principal Financial Officer and Principal Accounting Officer</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.15pt;vertical-align:top;"><p style="margin-left:0.15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dr. R. Loch Macdonald</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11458333333333333in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Medical Officer</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.15pt;vertical-align:top;"><p style="margin-left:0.15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrie D'Andrea</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11458333333333333in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VP Clinical Operations</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.15pt;vertical-align:top;"><p style="margin-left:0.15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:0.2pt;vertical-align:top;"><p style="margin-left:0.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amresh Kumar</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.11458333333333333in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VP of Program Management</span></p></td>
    <td style="text-indent:0.35pt;vertical-align:top;"><p style="margin-left:0.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.3pt;vertical-align:top;"><p style="margin-left:0.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.15pt;vertical-align:top;"><p style="margin-left:0.15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a brief biography of our current directors and executive officers:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vimal Kavuru</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kavuru has created and led several pharmaceutical companies. Mr. Kavuru brings, in his vision and management, a broad-based understanding of the global pharmaceutical industry with expertise in strategic planning, product and business development, and operations. In addition to previously serving as the Chairman of the Grace Therapeutics Inc. (&#8220;Grace Therapeutics&#8221;) board of directors, Mr. Kavuru is the Founder, Chairman and Chief Executive Officer of Rising Pharma Holdings, Inc., a U.S. generic pharmaceutical company, and Acetris Pharma Holdings, LLC, a generic pharmaceutical company serving U.S. government agencies, positions Mr. Kavuru has held since January 2013 and January 2016, respectively. Previously, Mr. Kavuru founded Citron Pharma and Lucid Pharma, each of which were sold to Aceto Corporation in 2016, Casper Pharma LLC, an emerging specialty brand pharmaceutical company, and Gen-Source RX, a national distributor of generic pharmaceuticals that was acquired by Cardinal Health in 2014. In 2007, Mr. Kavuru also co-founded Celon Labs, a specialty oncology and critical care pharmaceutical company that was acquired by Zanzibar Pharma Limited, a portfolio company of CDC Group. Mr. Kavuru was initially elected to the Board as a nominee of former shareholders of Grace Therapeutics in connection with Acasti&#8217;s acquisition of Grace Therapeutics. He is a registered pharmacist in the state of New York, holds a B.S. in Pharmacy from HKE College of Pharmacy, Bulgarga, India, and attended Long Island University, Brooklyn, New York with specialization in industrial pharmacy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A. Brian Davis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Davis has nearly three decades of experience as a Chief Financial Officer and other executive financial positions in commercial and development-stage publicly traded life science companies.  Mr. Davis has extensive knowledge and background related to public company accounting and financial reporting rules and regulations as well as the evaluation of financial results, internal controls and business processes. Since December 2021, Mr. Davis has been the Chief Financial Officer of XyloCor Therapeutics, Inc., a clinical-stage gene therapy company developing potential therapies for patients with cardiovascular disease.  Mr. Davis was the Chief Financial Officer of Verrica Pharmaceuticals Inc., a publicly traded, NDA-stage dermatology therapeutics company, from October 2019 to July 2021. Prior to joining Verrica, Mr. Davis was the Chief Financial Officer of Strongbridge Biopharma plc, a public commercial-stage biopharmaceutical company, from March 2015 to September 2019. Mr. Davis was previously the Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company until Tengion, Inc. filed for bankruptcy in December 2014, and Neose Technologies, Inc., a publicly traded biopharmaceutical company. Mr. Davis is licensed as a certified public accountant, and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School at the University of Pennsylvania.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">S. George Kottayil</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Kottayil has over two decades of experience in the pharmaceutical industry with specific expertise in product development and drug delivery. He has several approved patents to his credit and is an inventor on multiple FDA approved drug products, a few that have achieved significant success. He co-founded two pharmaceutical drug development and drug delivery technology companies and was CEO and a member of each of their boards of directors. Most recently, from October 2014, he co-founded and was CEO and director of Grace Therapeutics, a drug delivery company with a focus on rare and orphan disease which was acquired by Acasti in August 2021. Dr. Kottayil served as Acasti&#8217;s Chief Operating Officer from September 2021 to May 2023. Dr. Kottayil has held senior positions in product development, business operations and general management at small to medium life science companies, successfully advancing drug products from bench to FDA approval and launch. He directed business operations at Unimed Pharmaceuticals Inc., a division of Solvay Pharmaceuticals, now Abbvie, from January 1993 to June 2002, and played a key role in product development and obtaining FDA approval for the company&#8217;s NDA products. Dr. Kottayil graduated with a Ph.D. in Organic and Medicinal Chemistry from the University of Kentucky.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Edward Neugeboren</span></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Neugeboren has over three decades of healthcare experience in pharmaceutical operations, business development, corporate management, investment banking, asset management and institutional equity research. Since January of 2016, Mr. Neugeboren has served as the Chief Strategy Officer of Cronus Pharma, LLC, a fully integrated research and development, manufacturing and sales, and marketing pharmaceutical company. Mr. Neugebroren leads Cronus Pharma&#8217;s commercial operations, strategic planning and acquisitions and is also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing. Previously, Mr. Neugeboren was the Chief Strategy Officer for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company and Casper Pharma, LLC, a specialty pharmaceutical company. Additionally, Mr. Neugeboren is Founder and Managing Partner of QuadView Healthcare Advisors, previously named ArcLight Advisors, LLC, a healthcare investment banking and business development firm. Mr. Neugeboren was previously a Managing Director of Ledgemont Capital Group, LLC, an investment banking firm providing strategic and financial advisory services to emerging healthcare and technology companies. Mr. Neugeboren was also a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Mr. Neugeboren holds Series 24, 7 and 63 FINRA security licenses and has graduated with a BA in Economics from Union College.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prashant Kohli</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prashant Kohli has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Prior to joining Acasti in August 2021, Mr. Kohli was VP, Commercial Operations of Grace Therapeutics since December 2017.  He has expertise crafting go-to-market plans for products with unique value proposition that address critical unmet needs. He has built, deployed, and led sales and marketing from the ground-up with significant experience in organization design, recruiting, performance management, incentive compensation, and P&amp;L accountability. He has successfully implemented evidence-based, consultative-selling model that is rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers. He has also designed strategic marketing plans that generate leads and increase share-of-voice, augmenting the salesforce with digital tactics that increase reach and frequency. He has extensive commercial experience with specialty and small molecule drugs including in rare and orphan diseases. Prashant has worked at Archi-Tech Systems, Cardinal Health, IMS Health, Rosenbluth, and Dun &amp; Bradstreet. He has a BA in Computer Science and Math from Augustana College and an MBA from The Wharton School.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Robert J. DelAversano</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. DelAversano, is a certified public accountant and has over twenty-five years of experience in accounting including thirteen years in public accounting. Mr. DelAversano joined the Company in November 2023 as Vice President, Finance. From 2018 to July 2023, Mr. DelAversano worked in roles of increasing seniority at OncoSec Medical Incorporated (&#8220;OncoSec&#8221;), a clinical-stage immuno-oncology company, which positions included Vice President of Finance, Principal Accounting Officer and Controller, and Executive Director of Finance, where he had global responsibility for accounting, external financial reporting, and financial controls covering all aspects of OncoSec&#8217;s business. Prior to joining OncoSec, Mr. DelAversano was the Director of Financial Reporting and Taxation at Brio Financial Group (&#8220;Brio&#8221;), where he served as the firm&#8217;s Director of Financial Reporting and Taxation, consulting with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC and oversaw its accounting and tax practice with industry focuses in manufacturing, wholesalers and medical devices services. Mr. DelAversano received a B.S. in Accounting from Rider University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dr. R. Loch Macdonald</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Macdonald is a world-renowned practicing neurosurgeon-scientist and respected authority in subarachnoid hemorrhage. Dr. Macdonald was as Professor, Department of Surgery, Division of Neurosurgery at the University of Toronto from January 2007 until December 2019, and was Head, Division of Neurosurgery, St. Michael's Hospital, University of Toronto from January 2007 until</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2015. He was Professor, Department of Neurological Surgery, Barrow Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, from April 2018 until August 2018; Fellow, Department of Neurosurgery, University of Illinois Hospitals in Chicago, Illinois from December 2018 until June 2019; Clinical Professor, Department of Neurological Surgery, University of California San Francisco Fresno, in Fresno, California from July 2019 until September 2021; and from October 2021 to the present has been Neurosurgeon, Community Physicians Group, Community Neurosciences Institute, Community Regional Medical Center and Medical Director of Neurosciences Research, Community Health Partners. Dr Macdonald was also a founder of Edge Therapeutics, Inc. in 2009, where he was a member of the board of directors between 2009 and 2018 and was Chief Scientific Officer between 2011 and 2018. Dr. Macdonald completed his medical degree at the University of British Columbia, Vancouver, British Columbia and his PhD in Experimental Surgery at the University of Alberta in Edmonton, Alberta. He completed his Neurosurgery residency at the University of Toronto.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Carrie D&#8217;Andrea</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. D&#8217;Andrea is a highly experienced professional with 25 years of experience in the pharmaceutical and biotechnology industry who has built and led the planning, implementation, management, and execution of global Phase 2 and Phase 3 trials for a drug candidate for subarachnoid hemorrhage. Ms. D'Andrea was the Vice President of Clinical Operations for Edge Therapeutics Inc. from October 2014 until March 2019 and for EryDel SpA from October 2020 until April 2021. Ms. D&#8217;Andrea was a clinical operations consultant at Aegle Research from July 2021-August 2022 and Praxis Precisions Medicines from September 2022-May 2023. Ms. D&#8217;Andrea was named a Healthcare Businesswomen&#8217;s Association Rising Star in 2009 and Ms. D'Andrea received her master's degree in Pharmaceutical Quality and Regulatory Affairs from Temple University and teaches Clinical Trial Design and Operations at Rutgers University in the Master of Business and Science Program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amresh Kumar</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kumar is an experienced drug development, CMC, and program management expert supporting investigational and marketed products for rare diseases and neurology. Mr. Kumar is the former product leader of GTX-104 while at Grace Therapeutics (which was acquired by the Company in August 2021). Mr. Kumar acted as the Sr. Director of Program Management at Foresee Pharmaceuticals Inc. from April 2022 until May 2023 and as Program Leader and Associate Director - R&amp;D at Grace Therapeutics between March 2015 and January 2022. Mr. Kumar received a PhD in Pharmaceutical Science from Sunrise University, India, focusing on complex injectable drug delivery systems of highly soluble oncology drugs. He has published many research articles and has more than 10 granted patents and many patent applications worldwide to his credit.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cease Trade Orders, Bankruptcies, Penalties or Sanctions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the knowledge of Acasti, none of our current directors or executive officers are, or have been, as at the date of this Annual Report on Form 10-K or within the 10 years prior to the date of this Annual Report on Form 10-K, a director, or executive officer of any Company (including Acasti) that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	was subject to a cease trade order, an order similar to a cease trade order, or an order that denied the relevant Company access to any exemption under applicable securities legislation, that was in effect for a period of more than 30 consecutive days that was issued while the director or executive officer was acting in the capacity as director or executive officer; or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	was subject to an order that was issued after the director or executive officer ceased to be a director, CEO or CFO and which resulted from an event that occurred while that person was acting in the capacity as director, CEO or CFO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the knowledge of Acasti, other than Mr. Davis, who was previously the CFO at Tengion, Inc., a publicly traded regenerative medicine company, when it filed for bankruptcy in December 2014, none of Acasti&#8217;s current directors or executive officers:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	are, or have been, as at the date of this Annual Report on Form 10-K or within the 10 years prior to the date of this Annual Report on Form 10-K, a director or executive officer of any Company (including Acasti) that, while that person was acting in that capacity, or within two years of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	have, within the 10 years prior to the date of this Proxy Statement/Prospectus, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the director or director nominee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the knowledge of Acasti, no current director or executive officer has been subject to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority; or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)	any other penalties or sanctions imposed by a court or regulatory body.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Family Relationships</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no family relationships between any directors or officers of the Company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delinquent Section 16(a) Reports</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 16(a) of the Exchange Act requires the Company&#8217;s directors, executive officers and greater-than-10% stockholders to file forms with the SEC to report their ownership of Company securities and any changes in ownership. We have reviewed all forms filed electronically with the SEC. Based on that review and on written information given to us by our officers and directors, we believe that all of our directors, officers and greater-than-10% stockholders filed the required reports on a timely basis under Section 16(a) during 2022, except for Mr. Macdonald, who on May 26, 2023 filed a Form 3 that was due May 18, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board adopted a Code of Business Conduct and Ethics (&#8220;Code of Conduct&#8221;), for our directors, officers and employees on May 31, 2007, as amended from time to time. Our Code of Conduct can be found on SEDAR at www.sedar.com and on our website on www.acasti.com. A copy of the Code of Conduct can also be obtained by contacting our corporate secretary. We intend to disclose future amendments to or waivers from certain provisions of our Code of Conduct provisions on our website. Since its adoption by the Board, any breach of the Code of Conduct must be brought to the attention of the Board by our CEO or other senior executives. No report has ever been filed which pertains to any conduct of a director or executive officer that constitutes a breach to our Code of Conduct.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board actively monitors compliance with the Code Conduct and promotes a business environment where employees are encouraged to report malfeasance, irregularities, and other concerns. The Code of Conduct provides for specific procedures for reporting non-compliant practices in a manner which, in the opinion of the Board, encourages and promotes a culture of ethical business conduct.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board has also adopted a disclosure policy, insider trading policy, majority voting policy, management and board compensation policies, and a whistle blower policy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Civil Code of Qu&#233;bec, to which we are subject as a legal person incorporated under the Business Corporations Act (Qu&#233;bec) (L.R.Q., c. S-31), a director must immediately disclose to the board any situation that may place him or her in a conflict of interest. Any such declaration of interest is recorded in the minutes of proceedings of the Board. In such instances, the director abstains, except if otherwise required, from the discussion and voting on the question. In addition, it is our policy that an interested director recuse himself or herself from the decision-making process pertaining to a contract or transaction in which he or she has an interest.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audit Committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The audit committee of the Board (the "Audit Committee") is responsible for assisting the Board in fulfilling its oversight responsibilities with respect to financial reporting, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing our procedures on overall financial reporting and internal control framework;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing and approving the engagement of our external auditor;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.231%;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing annual and quarterly financial statements and all other material continuous disclosure documents, including our annual and quarterly reports;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assessing our financial and accounting personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assessing our accounting policies;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing our risk management procedures; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reviewing any significant transactions outside our ordinary course of business and any pending litigation involving us.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee has direct communication channels with our management performing financial functions and our external auditor to discuss and review such issues as the Audit Committee may deem appropriate. The Audit Committee is composed of Mr. Davis, as Chairperson, Mr. Kavuru and Mr. Neugeboren. Each of Mr. Davis, Mr. Kavuru and Mr. Neugeboren is &#8220;financially literate&#8221; and &#8220;independent&#8221; within the meaning of the Exchange Act and applicable Nasdaq rules concerning director independence.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee&#8217;s charter can be found on the Company&#8217;s website at https://www.acasti.com/en/investors/corporate-governance/governance-documents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audit Committee Financial Expert</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board has determined that Mr. Davis is an &#8220;audit committee financial expert,&#8221; as defined by applicable regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The SEC has indicated that the designation of Mr. Davis as an audit committee financial expert does not make him an &#8220;expert&#8221; for any purpose, impose any duties, obligations or liability on Mr. Davis that are greater than those imposed on members of the Audit Committee and Board who do not carry this designation, or affect the duties, obligations or liability of any other member of the Audit Committee or Board.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executive Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive compensation program is intended to attract, motivate and retain high-performing senior executives, encourage and reward superior performance, and align the executives&#8217; interests with ours as well as those of our shareholders by providing compensation that is competitive with the compensation received by executives employed by comparable companies, and ensuring that the achievement of annual objectives is rewarded through the payment of bonuses, and providing executives with long-term incentives through the grant of stock options.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our governance and human resources committee (&#8220;GHR&#8221;) committee, has authority to retain the services of independent compensation consultants to advise its members on executive and Board compensation and related matters, and to determine the fees and the terms and conditions of the engagement of those consultants. During our fiscal year ended March 31, 2022, the GHR committee retained compensation consulting services from FW Cook to review our executive compensation programs, including base salary, short-term and long-term incentives, total cash compensation levels and total direct compensation of certain senior positions, against those of a peer group of 20 broadly similar size, as measured by market capitalization (peer market cap all averaged less than $500M in 2021), biotechnology and pharmaceutical companies listed or headquartered in North America. The consultants also reviewed Board compensation, including advisory fees and equity incentives. All of the services provided by the consultants were provided to the GHR committee. The GHR committee assessed the independence of the consultants and concluded that its engagement of the consultants did not raise any conflict of interest with us or any of our directors or executive officers. The GHR committee continued to rely on the review of FW Cook performed during the fiscal year ended March 31, 2022 and did not retain the services of FW Cook during the fiscal year ended March 31, 2023 and, during the fiscal year ended March 31, 2024, retained the services of Pearl Meyer to review our executive compensation programs for the current fiscal year.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation for our Chief Executive Officer (&#8220;CEO&#8221;) paid during the fiscal year ended March 31, 2024 was below the peer company median based on FW Cook&#8217;s review conducted during the fiscal year ended March 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Fixed and Variable Pay Components</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation of our named executive officers (&#8220;NEOs"), is revised each year and has been structured to encourage and reward executive officers on the basis of short-term and long-term corporate performance. For the year ended March 31, 2024, our NEOs consisted of Prashant Kohli, our current CEO, Jan D&#8217;Alvise, our former CEO, Amresh Kumar, Vice President &#8211; Program Management, Carrie D&#8217;Andrea, Vice President &#8211; Clinical Operations, Pierre Lemieux, our former Chief Operations Officer (Canada), and Brian Ford, our former interim Chief Financial Officer.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the context of its analysis of compensation for our fiscal year ended March 31, 2024, the following components were examined by the GHR committee:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">base salary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">short term incentive plan, consisting of a cash bonus;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">long term incentive plan, consisting of stock options and equity incentive grants based on performance and/or time vesting conditions; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other elements of compensation, consisting of group benefits and perquisites.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For executives, more than half of their target compensation (base salary + target STIP awards + target LTIP awards) is considered &#8220;at risk.&#8221; We believe this mix results in a strong pay-for-performance relationship and alignment with shareholders and is competitive with other firms of comparable size in similar fields. The CEO (or any person acting in that capacity) makes recommendations to the GHR committee as to the compensation of our executive officers, other than the CEO, for review and approval by the Board. The GHR committee makes recommendations to the Board as to the compensation of the CEO, for approval. The CEO&#8217;s salary is based on comparable market consideration, and the GHR committee&#8217;s assessment of the CEO's performance, with regard to our financial performance, and progress in achieving key strategic business goals.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Qualitative factors beyond the quantitative financial metrics are also a key consideration in determination of individual executive compensation payments. How executives achieve their financial results and demonstrate leadership consistent with our values are key to individual compensation decisions.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Base Salary</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to be competitive over time with comparator companies and to attract and retain top talent. The GHR committee reviews compensation matters periodically to help ensure that it meets this strategic imperative. Base salary is set to reflect an individual&#8217;s skills, experience, and contributions within a salary structure consistent with peer group data. Base salary structure is revised annually by the GHR committee as financial and market conditions evolve.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short Term Incentive Plan (STIP)</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Short-Term Incentive Plan (&#8220;STIP"), provides for potential rewards when a threshold of corporate performance is met compared to the Board&#8217;s primary stated objectives for the fiscal year. Corporate performance is assessed against a table of weighted performance categories and sub-goals within each weighted category, which assessment of goal achievement funds the corporate bonus pool.  These performance goals take into account the achievement of corporate milestones within timelines and budget and individual objectives determined annually by the Board according to short-term priorities.  The corporate bonus pool is allocated based on achievement of personal objectives assessed through a performance grid, with pre-specified, objective performance criteria. For the most senior participants in the STIP, greater weight is assigned to corporate objectives. Target payout is expressed as a percentage of base salary, and is determined by benchmarking against peer group data. Annual salary for STIP purposes is the annual salary in effect at the end of the plan year (i.e., prior to any annual salary increases awarded for the subsequent year).</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The STIP is a variable compensation plan, and all STIP payments are subject to Board approval. Participants must be employed by us at the end of the fiscal year to qualify.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long Term Incentive Plan (LTIP)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Long Term Incentive Plan (&#8220;LTIP&#8221;) has been adopted as a reward and retention mechanism. Participation is determined annually at the discretion of the Board. The Acasti Pharma Inc. Stock Option Plan (the &#8220;Stock Option Plan&#8221;) is intended to align the long-term interests of participants with those of shareholders, in order to promote creation of shareholder value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GHR committee determines the number of stock options to be granted to a participant based on peer group data and taking into account corporate performance and the employee&#8217;s level in the organization. The LTIP calculation for NEOs is determined by both reviewing grant values and a dilution- based methodology that considers the annual grant rate as a percent of shares outstanding.  All grants to NEOs during the fiscal year ended March 31, 2024, had a grant value that was below the median of the peer data prepared by FW Cook during the fiscal year ended March 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our directors and executive officers are not permitted to purchase financial instruments, such as prepaid variable forward contracts, equity swaps, collars or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities granted as compensation or held, directly or indirectly, by the director or officer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Plan</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Stock Option Plan was adopted by the Board on October 8, 2008, and has been amended from time to time, as most recently amended on September 28, 2022. The amendment provided for a change to the existing limits for common shares reserved for issuance under the Stock Option Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Stock Option Plan continues to provide for the granting of options to purchase common shares. The exercise price of the stock options granted under the Stock Option Plan may not be lower than the closing price of the common shares on the Nasdaq Stock Market LLC ("Nasdaq&#8221;) at the close on the day preceding the grant. The maximum number of common shares that may be issued upon exercise of options granted under the amended Stock Option Plan shall not exceed 20% of the aggregate number of issued and outstanding shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company as of July 28, 2022. The terms and conditions for acquiring and exercising options are set by the Board, subject among others, to the following limitations: the term of the options cannot exceed ten years and (i) all options granted to a director will be vested evenly on a monthly basis over a period of at least 12 months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period of at least 36 months.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total number of shares issued to any one consultant within any twelve-month period cannot exceed 2% of the Company&#8217;s total issued and outstanding shares (on a non-diluted basis). The Company is not authorized to grant within any twelve-month period such number of options under the Stock Option Plan that could result in a number of common shares issuable pursuant to options granted to (a) related persons exceeding 2% of the Company&#8217;s issued and outstanding common shares (on a non-diluted basis) on the date an option is granted, or (b) any one eligible person in a twelve-month period exceeding 2% of the Company&#8217;s issued and outstanding common shares (on a non-diluted basis) on the date an option is granted.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant of options is part of the long-term incentive component of executive and director compensation and an essential part of the Company&#8217;s compensation framework. Qualified directors, employees and consultants may participate in the  Stock Option Plan, which is designed to encourage option holders to link their interests with those of the Company&#8217;s shareholders, in order to promote an increase in shareholder value. As of March 31, 2024, four employees and three non-employee directors were eligible to receive awards under the Stock Option Plan. Awards and the determination of any exercise price are made by the Board, after recommendation by the GHR committee. Awards are established, among other things, according to the role and responsibilities associated with the participant&#8217;s position and his or her influence over appreciation in shareholder value. Any award grants a participant the right to purchase a certain number of common shares during a specified term in the future, after a vesting period and/or specific performance conditions, at an exercise price equal to at least 100% of the market price (as defined below) of the Company&#8217;s common shares on the grant date. The &#8220;market price&#8221; of common shares as of a particular date generally means the closing price per common share on Nasdaq. Previous awards may sometimes be taken into account when new awards are considered.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with the Stock Option Plan, all of an option holder&#8217;s options will immediately fully vest on the date of a Change of Control event (as defined in the Stock Option Plan), subject to the terms of any employment agreement or other contractual arrangement between the option holder and the Company.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, in no case will the grant of options under the Stock Option Plan, together with any proposed or previously existing security-based compensation arrangement, result in (in each case, as determined on the grant date) the grant to any one consultant within any 12-month period, of options reserving for issuance a number of common shares exceeding in the aggregate 2% of the Company&#8217;s issued and outstanding common shares (on a non-diluted basis); or the grant to any one employee, director and/or consultant that provides investor relations services, within any 12-month period, of options reserving for issuance a number of Common shares exceeding in the aggregate 2% of the Company&#8217;s issued and outstanding common shares (on a non-diluted basis).</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options granted under the Stock Option Plan are non-transferable and are subject to a minimum vesting period of 36 months for management, and 12 months for non-executive Board members, in each case with gradual and equal vesting on no less than a quarterly basis, in the case of management, and monthly in the case of non-executive Board members. Options are exercisable, subject to vesting and/or performance conditions, at a price equal to the closing price of the common shares on Nasdaq, on the day prior to the grant of such options. In addition, and unless otherwise provided for in the relevant agreement between the Company and the holder, options will also lapse upon termination of employment or the end of the business relationship with the Company except that they may be exercised for 90 days after termination, ceasing to hold office or the end of the business relationship (30 days for investor relations services employees), in each case to the extent that they will have vested on such date of termination of employment, end of the business relationship or ceasing to hold office, as applicable, except in the case of death, disability or retirement, in which case this period is extended to 12 months.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the approval of relevant regulatory authorities, including Nasdaq, if applicable, and compliance with any conditions attached to that approval (including, in certain circumstances, approval by disinterested shareholders), if applicable, the Board has the right to amend or terminate the Stock Option Plan. However, unless option holders&#8217; consent to the amendment or termination of the Stock Option Plan in writing, any such amendment or termination of the Stock Option Plan cannot affect the conditions of options that have already been granted and that have not been exercised under the Stock Option Plan.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there were 1,483,140 common shares reserved for issuance under the Stock Option Plan and Equity Incentive Plan (as defined below) and 721,793 options outstanding under the Stock Option Plan.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 22, 2013, the Acasti Pharma Inc. Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;) was adopted by the Board in order to, among other things, provide us with a share-related mechanism to attract, retain and motivate qualified directors, employees and consultants. The adoption of the Equity Incentive Plan was initially approved by shareholders on June 27, 2013, and has been amended from time to time, as most recently amended on August 4, 2022, and approved by shareholders on September 28, 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eligible persons may participate in the Equity Incentive Plan. &#8220;Eligible persons&#8221; under the Equity Incentive Plan consist of any director, officer, employee, or consultant (as defined in the Equity Incentive Plan) of our Company or a subsidiary. A participant is an eligible person to whom an award has been granted under the Equity Incentive Plan. The Equity Incentive Plan provides us with the option to grant to eligible persons bonus shares, restricted shares, restricted share units, performance share units, deferred share units and other share-based awards.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board has the discretion to determine that any unvested or unearned restricted share units, deferred share units, performance share units or other share-based awards or restricted shares subject to a restricted period outstanding immediately prior to the occurrence of a change in control will become fully vested or earned or free of restriction upon the occurrence of a change in control. The Board may also determine that any vested or earned restricted share units, deferred share units, performance share units or other share-based awards will be cashed out based on the market price of our common shares as of the date a change in control is deemed to have occurred, or as of such other date as the Board may determine prior to the change in control. Further, the Board has the right to provide for the conversion or exchange of any restricted share unit, deferred share unit, performance share unit or other share-based award into or for rights or other securities in any entity participating in or resulting from the change in control.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Equity Incentive Plan is administered by the Board and the Board has sole and complete authority, in its discretion, to determine the type of awards under the Equity Incentive Plan relating to the issuance of common shares (including any combination of bonus shares, restricted share units, performance share units, deferred share units, restricted shares or other share-based awards) in such amounts, to such persons and under such terms and conditions as the Board may determine, in accordance with the provisions of the Equity Incentive Plan and the recommendations made by the GHR committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to the adjustment provisions provided for in the Equity Incentive Plan and the applicable rules and regulations of all regulatory authorities to which we are subject (including any stock exchange), the total number of common shares reserved for issuance pursuant to awards granted under the Equity Incentive Plan will be equal to a number that will not exceed 20% of the issued and outstanding common shares as of July 28, 2022, which number shall include common shares issuable pursuant to options issued under the stock option plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there were 1,483,140 common shares reserved for issuance under the Equity Incentive Plan and Stock Option Plan and no awards outstanding under the Equity Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Forms of Compensation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Retirement Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We sponsor a voluntary Registered Retirement Savings Plan ("RRSP"), matching program, which is open to all eligible employees, including NEOs, who reside in Canada. The RRSP matching program matches employees&#8217; contributions up to a maximum of $1,500 per fiscal year for eligible employees who participate in the program. We currently have no eligible employees who reside in Canada. We have also implemented a 401K plan for US employees. Because of the size of our current employee population in the US and to assure passage of anti-discrimination testing, the 401K plan has a &#8220;safe harbor&#8221; provision which provides a contribution of 3% of salary to the 401K accounts of all eligible US employees, including NEOs who reside in the US.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Benefits and Perquisites. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive employee benefit program also includes life, medical, dental and disability insurance. These benefits and perquisites are designed to be competitive overall with equivalent positions in comparable organizations. We do not have a pension plan for employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Governance</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation of our executive officers and directors is recommended to the Board by the GHR committee. In its review process, the GHR committee informally reviews executive and corporate performance on a quarterly basis, with input from management. Annually, the GHR committee conducts a more formal review and assessment of executive and corporate performance. The GHR committee is composed of the following members: Mr. Kavuru (Chairman), Mr. Davis and Mr. Neugeboren, each of whom is independent within the meaning of applicable Nasdaq rules. The GHR committee establishes management compensation policies and oversees their general implementation. All members of the GHR committee have direct experience which is relevant to their responsibilities as GHR committee members. All GHR committee members are or have held senior executive or director roles within significant businesses in our industry, some also having public companies experience, and have a level of financial understanding which allows them to assess the costs versus benefits of compensation plans. The GHR committee&#8217;s members&#8217; combined experience in our sector provides them with a good understanding of our success factors and risks, which are highly relevant to determining metrics for measuring success.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not believe that our compensation program results in unnecessary or inappropriate risk taking, including risks that are likely to have a material adverse effect on us. Payments of bonuses, if any, are not made unless performance goals are met.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2024 Summary Compensation Table</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the compensation information for NEOs, which includes all persons who served as our principal executive officer during the fiscal year ended March 31, 2024, our two most highly compensated executive officers other than our principal executive officer, who were serving as executive officers as of March 31, 2024, and two individuals who would have been our most highly compensated executive officers but for the fact that they were no longer serving as executive officers as of March 31, 2024.</span></p>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.034%;"/>
    <td style="width:1.741%;"/>
    <td style="width:12.447%;"/>
    <td style="width:1.741%;"/>
    <td style="width:1%;"/>
    <td style="width:10.008%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.008%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.008%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.008%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.008%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and<br/>Principal<br/>Position</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Salary ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Bonus ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option Awards ($)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;min-width:fit-content;">(1) (2)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Other Compensation ($)(3)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Compensation ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jan D'Alvise (4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,577</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">579,450</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631,027</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Former President and CEO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">494,761</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,642</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">426,799</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,132,202</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Prashant Kohli (5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">399,970</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">387,660</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987,630</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">379,370</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,270</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,103</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">511,743</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amresh Kumar (6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">243,269</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,500</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,250</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">378,019</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VP Program Management</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrie D'Andrea (7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">248,250</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,500</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,250</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383,000</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VP Clinical Operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pierre Lemieux (8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,558</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">347,316</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431,874</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Former COO, Canada and CSO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">304,450</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111,585</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,753</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">541,788</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Brian Ford (9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177,689</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,588</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,203</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">521,480</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Former Interim CFO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">278,825</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,522</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,753</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,100</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calculated in accordance with Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, &#8220;Compensation &#8212; Stock Compensation.&#8221; The fair value of stock options is estimated at the grant date using the Black-Scholes option pricing model. This model requires the input of a number of parameters, including share price, share exercise price, historical volatility, expected term risk-free interest rates and expected dividend yields. Although the assumptions used reflect management&#8217;s best estimates, they involve inherent uncertainties based on market conditions generally outside of the Company's control. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of the option-based awards granted on June 22, 2022, was $4.56 (after accounting for the Company&#8217;s 1-for-6 reverse stock split, which was effective on July 10, 2023 (the &#8220;Reverse Stock Split&#8221;)). </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other compensation consist of severance payments made.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. D&#8217;Alvise ceased to be the Company&#8217;s President and CEO effective April 4, 2023.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kohli, the Company&#8217;s former Chief Commercial Officer, was appointed CEO effective April 4, 2023.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kumar was appointed VP of Program Management effective May 8, 2023. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ms. D'Andrea was appointed VP of Clinical Operations effective May 8, 2023. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Lemieux ceased to be the Company's Chief Operating Officer (Canada) effective May 8, 2023.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Ford ceased to be the Company&#8217;s Chief Financial Officer on May 8, 2023, and was appointed as the Company&#8217;s interim Chief Financial Officer. On January 5, 2024, we announced the appointment of Robert J. DelAversano as the Company's new Principal Financial Officer, succeeding Mr. Ford. Mr. Ford continues to serve as a financial consultant on an as-needed basis.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Outstanding Equity Awards at March 31, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables provide information about the number and value of the outstanding option-based awards held by the NEOs as of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:41.908%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.441%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.441%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.882%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.401%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:14.883%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="17" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option awards</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/><br/><br/><br/><br/><br/><br/>Name</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of securities underlying unexercised options (#)<br/>exercisable</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of securities underlying<br/>unexercised options (#) unexercisable</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity incentive<br/>plan awards: Number of securities underlying unexercised unearned options<br/>(#)</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option exercise<br/>price ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option expiration date</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jan D'Alvise, Former President and CEO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Prashant Kohli, CEO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,515</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,169</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 12, 2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,206</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 22, 2032</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,084</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.64</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 14, 2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,668</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.13</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 19, 2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amresh Kumar, VP Program Management</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.64</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 14, 2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrie D'Andrea, VP Clinical Operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.64</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 14, 2033</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pierre Lemieux, Former COO, Canada</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Brian Ford, Former Interim CFO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,994</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.90</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 12, 2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,044</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,456</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.34</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 22, 2032</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The option awards and exercise prices listed above have been adjusted to account for the Reverse Stock Split. The option awards listed in the table above vest with respect to 1/12 on each quarterly anniversary thereafter over the following three years, subject to the executive officer&#8217;s continuous service with the Company through the vesting date. The option awards listed above will be cancelled 90 days after termination date, as per the Stock Option Plan.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employment Agreements with Named Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Jan D&#8217;Alvise, Former President and CEO</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 1, 2016, the Company entered into an executive employment agreement with Ms. D&#8217;Alvise. Pursuant to her executive employment agreement, Ms. D&#8217;Alvise&#8217;s annual base salary was set at $330,000 and she was eligible to receive annual performance bonuses based on a target amount of 50% of her annual base salary with a maximum of up to 80% of her annual base salary. In accordance with the terms and provisions of the executive employment agreement the Company entered into with Ms. D&#8217;Alvise, the Company had the right to terminate the executive&#8217;s employment at any time for &#8220;good and sufficient cause&#8221;, as defined in the employment agreement, without notice or severance. The Company had the right to terminate the executive&#8217;s employment at any time without cause or upon a Change of Control, as defined in the Stock Option Plan, by providing the executive with sixty days&#8217; notice of termination and payment equal to twelve months&#8217; base salary plus any bonus payable. The executive was able to resign from employment upon providing the Company with at least sixty days&#8217; advance written notice. The executive was able to terminate employment with &#8220;good reason&#8221;, as defined in the executive employment agreement, in which case the Company would be required to make payment equal to twelve months&#8217; base salary plus any bonus payable. Ms. D&#8217;Alvise ceased to be the Company&#8217;s President and CEO effective April 4, 2023.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prashant Kohli, Chief Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kohli became Chief Executive Officer of Acasti on April 4, 2023. Pursuant to his employment arrangement, Mr. Kohli&#8217;s annual base salary is set at $400,000 and he is eligible to receive annual performance bonuses of up to 50% of his annual base salary. In accordance with the terms of Mr. Kohli&#8217;s employment arrangement, his employment could be terminated by the Company or by Mr. Kohli at any time with or without cause.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amresh Kumar, VP Program Management</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 8, 2023 we entered into a employee agreement with Amresh Kumar, pursuant to which he is entitled to an annual salary of  $275,000 and he is eligible to receive annual performance bonuses of up to 30% of his annual base salary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Carrie D&#8217;Andrea, VP Clinical Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 8, 2023 we entered into a consulting agreement with Carrie D'Andrea (&#8220;Ms. D&#8217;Andrea's Consulting Agreement&#8221;). Ms. D&#8217;Andrea&#8217;s Consulting Agreement provides, among other things, that Ms. D'Andrea will serve as a non-employee vice-president of clinical operations on a full-time basis, in exchange for a fee of $18,000 per month. There is no arrangement or understanding between Ms. D&#8217;Andrea and any other persons pursuant to which Ms. D&#8217;Andrea was selected as an officer. On July 1, 2023, we entered into an employment agreement with Ms. D'Andrea, pursuant to which she is entitled to an annual salary of $275,000 and she is eligible to receive annual performance bonuses of up to 30% of her annual base salary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pierre Lemieux, Former COO (Canada)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 26, 2017, the Company entered into an executive employment agreement with Dr. Pierre Lemieux. Pursuant to his executive employment agreement, Dr. Lemieux&#8217;s annual base salary was set at CAD$253,700 and he was eligible to receive annual performance bonuses of up to 40% of his annual base salary. In accordance with the terms and provisions of Dr. Lemieux&#8217;s executive employment agreement, the Company had the right to terminate the executive&#8217;s employment at any time for &#8220;good and sufficient cause&#8221;, as defined in the employment agreement, without notice or severance. The Company had the right to terminate the executive&#8217;s employment at any time without cause or upon a Change of Control, as defined in the Stock Option Plan, by providing the executive with thirty days&#8217; notice of termination and payment equal to twelve months&#8217; base salary plus any bonus payable. The executive was entitled to resign from employment upon providing us with at least sixty days' advance written notice. The executive was able to resign from employment upon providing the Company with at least sixty days&#8217; advance written notice. The executive was able to terminate employment with &#8220;good reason&#8221;, as defined in the executive employment agreement, in which case the Company would be required to make payment equal to twelve months&#8217; base salary. Dr. Lemieux ceased to be the Company's Chief Operating Officer (Canada) effective May 8, 2023. Dr. Lemieux received total payments of $431,874 upon termination, that included a one-time separation payment of $347,316.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brian Ford, Interim CFO</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 13, 2021, we entered into an executive employment agreement with Mr. Ford. Pursuant to his executive employment agreement, Mr. Ford&#8217;s annual base salary was set at CAD$350,000 and he was eligible to receive annual performance bonuses of up to 40% of his annual base salary. In accordance with the terms and provisions of the executive employment agreement we entered into with Mr. Ford, we were entitled to terminate his employment at any time with cause. We were entitled to terminate the executive&#8217;s employment without cause by providing the executive employee, with either a payment equal to six months of base salary, plus two months of base salary for each completed year of service, to a maximum of twelve months in total, or a payment equal to twelve months of base salary in the event that such a termination occurs within three months following a change of control, as defined in our stock option plan. The executive was entitled to resign from employment and upon providing us with at least eight weeks of advance written notice. Effective May 8, 2023, Mr. Ford employment as the Company&#8217;s Chief Financial Officer was terminated and he is entitled to severance payment in accordance with the terms of his executive employment agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clawback Policy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a compensation recoupment, or clawback, policy, which we adopted to comply with Nasdaq listing standards implementing Exchange Act Rule 10D-1. The clawback policy includes mandatory recoupment of excess incentive-based compensation received by a covered executive (including the Named Executive Officers) on or after October 2, 2023 in the event of a restatement of the Company&#8217;s consolidated financial statements due to material non-compliance with any financial reporting requirement under federal securities laws, as required by Exchange Act Rule 10D-1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Executive Director Compensation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our non-executive directors&#8217; compensation consists of an annual fixed compensation of $60,000 for the chairman of the Board and $35,000 for the other non-executive Board members. In addition, the chairperson of the Audit Committee and the chairperson of the GHR committee receive additional compensation of $15,000 and $12,000, respectively, while members of the Audit Committee and the GHR committee receive additional compensation of $7,500 and $6,000, respectively. The directors are also entitled to a fee of $1,000 per non-regularly scheduled Board meeting as well as a reimbursement for traveling and other reasonable expenses properly incurred by them in attending meetings of the Board or any committee or in otherwise serving us, in accordance with our policy on travel and expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following their first election to our Board, non-executive directors are eligible to receive an initial equity grant of up to 150% of their annual cash retainer worth of stock options vesting monthly in equal installments over a 12-month period, subject to the other terms and conditions set forth under the heading &#8220;Stock Option Plan.&#8221; In addition to their initial grant, non-executive directors are eligible to receive an annual equity-based award equal to 100% of their total annual cash retainer vesting monthly in equal installments over a 12-month period. These awards will be granted at the same time that we are performing our annual performance review for our employees, subject to availability of common shares and subject to the terms and conditions described under the headings &#8220;Stock Option Plan&#8221; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;Equity Incentive Plan.&#8221; The level of these awards are intended to be consistent with equivalent awards by comparable companies obtained from our benchmarking exercise and in accordance with the recommendations obtained from our independent compensation consultant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth compensation for each non-executive director for the fiscal year ended March 31, 2024. Mr. Kohli does not receive any additional compensation for his service as a director. Information regarding the compensation for Mr. Kohli is reflected in the &#8220;2024 Summary Compensation Table&#8221; set forth above.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total compensation for our non-executive directors during fiscal year ended March 31, 2024, was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.014%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.723%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fees earned or paid in cash<br/>($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock awards<br/>($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Option awards<br/>($) </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-equity incentive plan compensation<br/>($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nonqualified deferred compensation earnings<br/>($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All other compensation<br/>($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vimal Kavuru </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,332</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127,432</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Donald Olds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,972</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,372</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Derby </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,378</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,778</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Brian Davis </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,600</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,897</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,497</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">George Kottayil </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,897</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,897</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Edward Neugeboren</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,897</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,997</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calculated in accordance with FASB ASC Topic 718, &#8220;Compensation &#8212; Stock Compensation.&#8221; The fair value of stock options is estimated at the grant date using the Black-Scholes option pricing model. This model requires the input of a number of parameters, including share price, share exercise price, expected share price volatility, expected time until exercise and risk-free interest rates. Although the assumptions used reflect management&#8217;s best estimates, they involve inherent uncertainties based on market conditions generally outside of the Company's control.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kavuru had 37,017 option awards outstanding at March 31, 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Olds and Mr. Derby did not stand for re-election at the Company's 2023 Annual General Meeting held on October 10, 2023. Mr. Olds and Mr. Derby had 30,939 and 26,667 option awards outstanding at March 31, 2024, respectively.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Davis, Mr. Kottayil, and Mr. Neugeboren each had 22,500 option awards outstanding at March 31, 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 402(v) Pay Versus Performance</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the GHR committee view the link between the Company&#8217;s performance and named executive officer pay. This disclosure is intended to comply with the requirements of Item 402(v) of Regulation S-K applicable to &#8220;smaller reporting companies.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Required Tabular Disclosure of Pay Versus Performance</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and certain financial performance of the Company. The following table sets forth information concerning Compensation Actually Paid (&#8220;CAP&#8221;) to our Principal Executive Officers (&#8220;PEO&#8221;) and non-PEO NEOs versus our total shareholder return (&#8220;TSR&#8221;) and net income (loss) performance results for the fiscal years ended March 31, 2024, 2023, and 2022. The amounts set forth below under the headings &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to Non-PEO NEOs&#8221; have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term CAP is required by the SEC&#8217;s rules and as a result of the calculation methodology required by the SEC, such amounts  differ from compensation actually received by the individuals and the compensation decisions described in the &#8220;Executive Compensation Summary&#8221; section above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 CAP to our PEO and the average CAP to our non-PEO NEOs reflects the following adjustments required by the applicable SEC rules from the total compensation reported in the Summary Compensation Table (&#8220;SCT&#8221;):</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.558%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.638%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.678%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.638%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.638%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.638%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.638%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.518%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.058%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Summary compensation table total for PEO 1 ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Compensation actually paid to PEO 1 ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Summary compensation table total for PEO 2 ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Compensation actually paid to PEO 2 ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average summary compensation table total for non-PEO NEOs ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average compensation actually paid to non-PEO NEOs ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value of initial fixed $100 investment based on: Total shareholder return (TSR) ($)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net income (loss) ($ in 000s)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(a)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(b)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(c)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(d)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(e)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(f)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(g)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(h)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(i)</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987,630</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,224,297</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428,593</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">718,671</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.11</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,853</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,132,202</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">705,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">511,743</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454,640</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">504,564</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">596,611</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(42,429</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546,663</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">445,161</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">655,256</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">729,703</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">766,415</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,819</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Our Total Shareholder Return (&#8220;TSR&#8221;) for each of the applicable fiscal years is calculated based on a fixed investment of $100 at the applicable measurement point (March 31, 2021) on the same cumulative basis as is used in Item 201(e) of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) Net loss is as reported in our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2024 CAP to our PEOs and the average CAP to our non-PEO NEOs reflects the following adjustments required by the applicable SEC rules from the total compensation reported in the SCT:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.604%;"/>
    <td style="width:1.299%;"/>
    <td style="width:1%;"/>
    <td style="width:9.832%;"/>
    <td style="width:1%;"/>
    <td style="width:1.299%;"/>
    <td style="width:1%;"/>
    <td style="width:9.832%;"/>
    <td style="width:1%;"/>
    <td style="width:1.299%;"/>
    <td style="width:1%;"/>
    <td style="width:9.832%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PEO 1</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PEO 2</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average of Non-PEO NEOs</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Reported in 2024 SCT</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987,630</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">428,593</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: value of equity award reported in the SCT</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(387,660</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(221,088</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: year-end value of equity awards granted in 2024 that are unvested and outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">201,041</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120,473</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: change in fair value (from prior year-end) of prior year equity awards that are unvested and outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,482</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,187</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: fair market value of equity awards granted in 2024 and that vested in 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">229,097</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127,068</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: change in fair value (from prior year-end) of prior year equity awards that vested in 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,707</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123,438</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation Actually Paid for 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">631,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,224,297</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">718,671</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Actually Paid and Net Income (Loss)</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the nature of our consolidated financial statements and primary focus on research and development of novel therapies, we have not historically utilized net income (loss) as a performance measure for our executive compensation program. As a result, we do not believe there is any meaningful relationship between our net loss and compensation actually paid to our NEOs during the periods presented.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Actually Paid and TSR</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not utilize TSR in our executive compensation program. However, we do utilize several other performance measures to align executive compensation with performance. As described in more detail above, part of the compensation NEOs are eligible to receive consists of annual performance-based cash bonuses that are designed to provide appropriate incentives to the Company&#8217;s executives to achieve defined annual corporate goals and to reward executives for individual achievement towards these goals, subject to certain employment criteria. Additionally, the Board views stock options, which are an integral part of our executive compensation program, as related to company performance although not directly tied to TSR, because they provide value only if the market price of our common shares increase, and if the executive officer continues in the Company&#8217;s employment over the vesting period. These stock option awards align the Company&#8217;s executive officers&#8217; interests with those of its shareholders by providing a continuing financial incentive to maximize long-term value for Shareholders and by encouraging the Company&#8217;s executive officers to continue in employment for the long-term.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following graphs sets forth the relationship between CAP to our PEO 1, CAP to our PEO 2, the average of CAP to our Non-PEO NEOs, and the Company's net loss TSR over the period covering 2024, 2023, and 2022.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img181340459_7.jpg" alt="img181340459_7.jpg" style="width:651px;height:386px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img181340459_8.jpg" alt="img181340459_8.jpg" style="width:650px;height:384px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters Equity Compensation Plan Information</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth certain information regarding the Company&#8217;s equity compensation plans as of March 31, 2024:</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.36%;"/>
    <td style="width:1%;"/>
    <td style="width:1.24%;"/>
    <td style="width:1%;"/>
    <td style="width:10.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.36%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/><br/><br/><br/><br/>Plan category</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(a) Number of<br/>securities to be<br/>issued upon<br/>exercise of<br/>outstanding<br/>options, warrants<br/>and rights</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(b) Weighted-<br/>average exercise<br/>price of outstanding<br/>options, warrants<br/>and rights</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(c) Number of<br/>securities remaining<br/>available for future<br/>issuance under equity<br/>compensation plans<br/>(excluding securities<br/>reflected in column (a))</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans approved by security holders (Stock Option Plan)(1):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">721,793</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.68</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761,347</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans approved by security holders (Equity Incentive Plan)(2):</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans not approved by security holders:</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">721,793</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.68</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761,347</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes:</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total number of common shares reserved for issuance under the Company&#8217;s Stock Option Plan is limited by the number of awards that are outstanding under the Company&#8217;s Equity Incentive Plan such that the total number of common shares available for issuance under both stock-based compensation plans shall not exceed 1,483,140. A summary of certain material provisions of the Company&#8217;s stock option plan is available under &#8220;Item 11. Executive Compensation &#8211; Summary of our Compensation Programs &#8211; Stock Option Plan.&#8221;</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total number of common shares reserved for issuance under the Company&#8217;s Equity Incentive Plan is limited by the number of options that are outstanding under the Stock Option Plan such that the total number of common shares available for issuance under both stock-based compensation plans shall not exceed 1,483,140. A summary of certain material provisions of the Equity Incentive Plan is available under &#8220;Item 11. Executive Compensation &#8211; Summary of our Compensation Programs &#8211; Equity Incentive Plan.&#8221;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security Ownership of Certain Beneficial Owners</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth certain information regarding beneficial ownership of our common shares as of  May 31, 2024 by each director and the named executive officers identified above, and all directors and executive officers as a group. Beneficial ownership is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. All common shares have the same voting rights.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the purposes of calculating percentage ownership, as of May 31, 2024, 9,399,404 common shares were issued and outstanding, and, for any individual who beneficially owns common shares represented by options exercisable within 60 days of May 31, 2024, these shares are treated as if outstanding for that person, but not for any other person.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.413%;"/>
    <td style="width:1.24%;"/>
    <td style="width:1%;"/>
    <td style="width:29.054%;"/>
    <td style="width:1%;"/>
    <td style="width:1.24%;"/>
    <td style="width:1%;"/>
    <td style="width:29.054%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Address<br/>of Beneficial Owner (1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount and Nature<br/>of Beneficial Ownership</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percentage of<br/>Common Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prashant Kohli (2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168,775</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.40%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amresh Kumar (3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,763</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrie D'Andrea (4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,645</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Brian Davis (5)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,430</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vimal Kavuru  (6)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">460,215</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.88%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">George Kottayil (7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">507,128</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.39%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Edward Neugeboren (8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,325</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Brian Ford (9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,324</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jan D'Alvise</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pierre Lemieux</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SS Pharma LLC (10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">931,743</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.91%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shore Pharma LLC (11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,188,076</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.64%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AIGH Capital Management, LLC, AIGH Investment Partners LLC, and Orin Hirschman (12)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">567,812</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bank of America Corporation (13)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">494,698</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.26%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rajitha Grace 2018 Irrevocable Trust (14)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">781,592</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.32%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Directors and officers as a group (9 persons)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,270,771</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.13%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Less than 1%.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes:</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise indicated, the address of each of the executive officers and directors named above is 103 Carnegie Center Suite 300 Princeton, New Jersey 08540</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 147,418 common shares that Prashant Kohli may acquire through the exercise of share options within 60 days hereof, with exercise prices ranging between $2.13 and $9.90. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 15,645 common shares that Amresh Kumar may acquire through the exercise of share options within 60 days hereof, with exercise price of $2.64. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 15,645 common shares that Carrie D'Andrea may acquire through the exercise of share options within 60 days hereof, with exercise price of $2.64.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 12,430 common shares that Brian Davis may acquire through the exercise of share options within 60 days hereof, with exercise price of $2.13.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 426,323 common shares held by Kavuru 2017 Grace Therapeutics for which Vimal is trustee, and 33,892 common shares that Vimal Kavuru may acquire through the exercise of share options within 60 days hereof, with exercise prices ranging between $2.13 and $9.90. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 494,698 common shares, of which 124,344 shares are held directly by Kottayil Grace Pharma LLC by which Mr. Kottayil is a Manager and Member of, and 12,430 common shares that George Kottayil may acquire through the exercise of share options within 60 days hereof, with exercise price of $2.13.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 37,895 common shares and 12,430 common shares that Edward Neugeboren may acquire through the exercise of share options within 60 days hereof, with exercise price of $2.13.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 58,324 common shares that Brian Ford may acquire through the exercise of share options within 60 days hereof, with exercise prices ranging between $5.05 and $9.90. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal office and business address of SS Pharma LLC is 330 S Poplar Ave, Suite 103-I, Pierre, SD 57501.  SS Pharma LLC is a holding company owned by Rajitha Grace 2023 Grantor Trust. Information was provided by our transfer agent, Computershare Investor Services Inc.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal office and business address of Shore Pharma LLC is 330 S Poplar Ave, Suite 103-I, Pierre, SD 57501. Shore Pharma LLC is a holding company owned by The ANSUSHRA 2023 Grantor Trust. Information was provided by our transfer agent, Computershare Investor Services Inc.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal office and business address of AIGH Capital Management, LLC, AIGH Investment Partners LLC, and Orin Hirschman is 6006 Berkeley Avenue Baltimore, MD 21209. Mr. Hirschman, is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held through AIGH CM, </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">directly by AIGH LLC and Mr. Hirschman and his family directly. Information obtained from Schedule 13-G filed on March 27, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal office and business address of Bank of America Corporate Center is 100 N Tryon Street Charlotte, NC 28255. Information obtained from Schedule 13-G filed on December 31, 2023. </span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal office and business address of Rajitha Grace 2018 Irrevocable Trust is 330 S Poplar Ave, Suite 103-I, Pierre, SD 57501. Information was provided by our transfer agent, Computershare Investor Services Inc.</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Control</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There existed no change in control arrangements at March 31, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions and Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related Party Transaction</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As set forth in its charter, the Audit Committee is tasked with the review and approval of any proposed transactions with related persons of the Company. After initial review and approval of any proposed transaction with a related person, the Audit Committee continues to oversee and review any such transactions on a quarterly basis to ensure that such transaction continues to fall within the parameters of such initial approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than as set forth below, since April 1, 2022, there were no transactions or any currently proposed transactions in which the Company was or is to be a participant and the amounts exceeds $120,000, and in which any related person had or will have a direct or indirect interest.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 24, 2023, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors in connection with a private placement offering of our securities (the &#8220;Offering&#8221;). Pursuant to the Purchase Agreement, sold 1,951,371 Class A common shares, no par value per share (the &#8220;Common Shares&#8221;), at a purchase price of $1.848 per Common Share and pre-funded warrants (the &#8220;Pre-funded Warrants&#8221;) to purchase up to 2,106,853 Common Shares at a purchase price equal to the purchase price per Common Share less $0.0001. Each Pre-funded Warrant is exercisable for one Common Share at an exercise price of $0.0001 per Common Share, was immediately exercisable, and will expire once exercised in full. Pursuant to the Purchase Agreement, we also issued to such institutional and accredited investors common warrants (the &#8220;Common Warrants&#8221;) to purchase Common Shares, exercisable for an aggregate of 2,536,391 Common Shares. Under the terms of the Purchase Agreement, for each Common Share and each Pre-funded Warrant issued in the Offering, an accompanying five-eighths (0.625) of a Common Warrant was issued to the purchaser thereof. Each whole Common Warrant is exercisable for one Common Share at an exercise price of $3.003 per Common Share, was immediately exercisable, and will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) of a New Drug Application for our product candidate GTX-104 or (ii) five years from the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Offering closed on September 25, 2023. The net proceeds to us from the Offering were approximately $7.3 million, after deducting fees and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shore Pharma LLC, an entity controlled by Vimal Kavuru, the Chair of our Board, and SS Pharma LLC, the beneficial owners of 6.9% and 5.5%, respectively, of the Common Shares prior to the Offering, each a related party of Acasti, participated in the Offering. Each of Shore Pharma LLC and SS Pharma LLC purchased $1,250,000 of securities from us in the Offering.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Independence</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors (the "Board") believes that, in order to maximize its effectiveness, the Board must be able to operate independently. A majority of directors must satisfy the applicable tests of independence set forth in the Nasdaq rules and promulgated by the SEC, such that the Board complies with all independence requirements under applicable corporate and securities laws and stock exchange requirements applicable to us. No director will be independent unless the Board has affirmatively determined that the director has no material relationship with us or any of our affiliates, either directly or indirectly or as a partner, shareholder or officer of an organization that has a relationship with us or our affiliates. Such determinations will be made on an annual basis and, if a director joins the board of directors between annual meetings, at such time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board determined that Mr. Kavuru, Mr. Davis and Mr. Neugeboren are independent within the meaning of the Nasdaq rules. In making its independence determination, the Board considered Mr. Kavuru&#8217;s participation in the Offering, as described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chairman of the Board</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mr. Kavuru acts as chairman of the Board. His duties and responsibilities consist of the oversight of the quality and integrity of the Board&#8217; practices.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board Mandate</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board is responsible for overseeing management in carrying out the business and affairs of the Company. Directors are required to act and exercise their powers with reasonable prudence in the best interests of the Company. The Board agrees with and confirms its responsibility for overseeing management's performance in the following particular areas:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approving and monitoring the Company&#8217;s compliance procedures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing and developing the Company&#8217;s corporate governance principles and committees;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating the strategic plan of the Company;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identification and oversight of the principal risks associated with the business of the Company and application of appropriate systems to manage and mitigate such risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">planning for succession of management;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company's policies regarding communications with its shareholders and others; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the integrity of the internal controls and management information systems of the Company.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In carrying out its mandate, the Board relies primarily on management to provide it with regular detailed reports on the operations of the Company and its financial position. The Board reviews and assesses these reports and other information provided to it at meetings of the Board and/or of its committees. At least annually, the Board approves a strategic plan for the Company, taking into account, among other things, the opportunities and risks of the Company&#8217;s business, its risk appetite, emerging trends, and the competitive environment in the industry.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Position Descriptions</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A written position description has been approved for the chairs of each committee of the Board. The primary role and responsibility of the chair of each committee of the Board is to: (i) in general, ensure that the committee fulfills its mandate, as determined by the Board and in accordance with the committee&#8217;s charter; (ii) chair meetings of the committee; (iii) report to the Board; and (iv) act as liaison between the committee and the Board and our management.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board has adopted a written position description for the chairman of the Board. The chairman of the Board is responsible for leading the board to fulfill its duties under the Board&#8217;s mandate as independent of management and acting as an advisor to the chief executive officer. The chairman&#8217;s duties include, but are not limited to, setting meeting agendas, approving and supervising management&#8217;s progress towards achieving strategic goals, chairing meetings and working with the respective committee and management to ensure, to the greatest extent possible, the effective functioning of the committee and the Board. The chairman must oversee that the relationship between the Board, management of the Company, the Company&#8217;s shareholders and other stakeholders are effective, efficient, and further to the best interests of the Company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orientation and Continuing Education</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We provide orientation for new appointees to the Board and committees in the form of informal meetings with members of the Board and senior management, complemented by presentations on the main areas of our business. The Board does not formally provide continuing education to its directors, as directors are experienced members. The Board relies on third-party professional assistance, when judged necessary, in order to be educated/updated on a particular topic.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nomination of Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board receives recommendations from the GHR committee, but retains responsibility for managing its own affairs by, among other things, giving its approval for the composition and size of the Board, and the selection of candidates nominated for election to the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GHR committee initially evaluates candidates for nomination for election as directors, having regard to the background, diversity, employment, and qualifications of possible candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The selection of the nominees for the Board is made by the other members of the Board, based on our needs and the qualities required for the Board, including ethical character, integrity and maturity of judgment of the candidates; the level of experience of the candidates; their ideas regarding the material aspects of our business; the expertise of the candidates in fields relevant to us while complementing the training and experience of the other members of the Board; the will and ability of the candidates to devote the necessary time to their duties to the Board and its committees; the will of the candidates to serve on the Board for numerous consecutive financial periods; and the will of the candidates to refrain from engaging in activities which conflict with the responsibilities and duties of a director. The Board researches the training and qualifications of potential new directors which seem to correspond to the selection criteria of the Board and, depending on the results of said research, organizes meetings with the potential candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the case of incumbent directors whose terms of office are set to expire, the Board will review such directors&#8217; overall service to us during their term of office, including the number of meetings attended, level of participation, quality of performance and any transactions of such directors with us during their term of office.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may use various sources in order to identify the candidates for the Board, including our own contacts and the references of other directors, officers, advisors and executive placement agencies. We will consider director candidates recommended by shareholders and will evaluate those director candidates in the same manner in which we evaluate candidates recommended by other sources. In making recommendations for director nominees for the annual meeting of shareholders, we will consider any written recommendations of director candidates by shareholders received by our corporate secretary not later than 120 days before the anniversary of the previous year&#8217;s annual meeting of shareholders. Recommendations must include the candidate&#8217;s name, contact information and a statement of the candidate&#8217;s background and qualifications, and must be mailed to us. Following the selection of the candidates by the board of directors, we will propose a list of candidates to the shareholders, for our annual meeting of shareholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board does not have a separate nominating committee and has not adopted any formal written director term limit policy. Proposed nominations of director candidates are evaluated by our GHR committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GHR Committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The mandate of the GHR committee consists of the evaluation of the proposed nominations of senior executives and director candidates to our Board; recommending for board approval, if appropriate; revisions of our corporate governance practices and procedures; developing new charters for any new committees established by the Board; monitoring relationships and communication between management and the Board; monitoring emerging best practices in corporate governance and oversight of governance matters; and assessing the Board and its committees. The GHR committee is also in charge of establishing the procedures which must be followed by us to comply with applicable requirements of Nasdaq regarding corporate governance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GHR committee has the responsibility of evaluating the compensation, performance incentives as well as the benefits granted to our management in accordance with their responsibilities and performance as well as to recommend the necessary adjustments to our Board. The GHR committee also reviews the amount and method of compensation granted to the directors. The GHR committee may retain an external firm in order to assist it during the execution of its mandate. The GHR committee considers time commitment, comparative fees, and responsibilities in determining compensation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GHR committee&#8217;s charter can be found on the Company&#8217;s website at https://www.acasti.com/en/investors/corporate-governance/governance-documents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Periodic Assessments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board, its committees and each director are subject to periodic evaluations of their efficacy and contribution. The evaluation procedure consists of identifying any shortcomings and implementing adjustments proposed by directors at the beginning and during meetings of the Board and of each of its committees. Among other things, these adjustments deal with the level of preparation of directors, management and consultants employed by us, the relevance and sufficiency of the documentation provided to directors and the time allowed to directors for discussion and debate of items on the agenda.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Term Limits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board actively considers the issue of term limits from time to time. At this time, the Board does not believe that it is in our best interests to establish a limit on the number of times a director may stand for election. While such a limit could help create an environment where fresh ideas and viewpoints are available to the Board, a director term limit could also disadvantage us through the loss of the beneficial contribution of directors who have developed increasing knowledge of, and insight into, us and our operations over a period</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of time. As we operate in a unique industry, it is difficult to find qualified directors with the appropriate background and experience and the introduction of a director term limit would impose further difficulty.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policies Regarding the Representation of Women on the Board and Among Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not adopted a formal written policy regarding diversity amongst executive officers and members of the Board, including mechanisms for Board renewal, in connection with, among other things, the identification and nomination of women directors. Nevertheless, we recognize that gender diversity is a significant aspect of diversity and acknowledge the important role that women with appropriate and relevant skills and experience can play in contributing to the diversity of perspective on the Board.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rather than considering the level of representation of women for directorship and executive officer positions when making Board or executive officer appointments, we consider all candidates based on their merit and qualifications relevant to the specific role. While we recognize the benefits of diversity at all levels within our organization, we do not currently have any targets, rules or formal policies that specifically require the identification, consideration, nomination, or appointment of candidates for directorship or executive management positions or that would otherwise force the composition of our Board and executive management team.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accounting Fees and Services Audit Fees</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current independent registered public accounting firm is KPMG LLP, U.S. ("KPMG").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change in Accountant</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2023, the Audit Committee (the &#8220;Audit Committee&#8221;) of the Company's Board of Directors (the "Board") recommended to the Board and the Board approved the dismissal of Ernst &amp; Young LLP (Canada) ("E&amp;Y") who had been serving as the Company&#8217;s independent registered public accounting firm since February 22, 2023. The report of E&amp;Y on the consolidated financial statements of the Company as of and for the fiscal year ended March 31, 2023 did not contain any adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles. On December 11, 2023, in connection with the Company&#8217;s dismissal of E&amp;Y, the Audit Committee recommended to the Board and the Board approved the engagement of KPMG as its new independent registered public accounting firm to audit the Company&#8217;s consolidated financial statements for the fiscal year ending March 31, 2024. The decision to engage KPMG was recommended by the Audit Committee, and approved by the Board, after taking into account KPMG&#8217;s location in the United States, the results of a competitive review process and other business factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to our engagement of E&amp;Y on February 22, 2023, KPMG LLP, Montreal, Quebec, Canada (&#8220;KPMG Canada&#8221;) was previously our independent registered public accounting firm. On February 22, 2023, the Audit Committee and Board approved the dismissal of KPMG Canada as our independent registered public accounting firm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Independent Registered Public Accounting Firm Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audit Fees</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;Audit fees&#8221; consist of fees for professional services for the audit of our annual financial statements and fees related to securities filings. Audit fees for KPMG were $300 thousand for the fiscal year ended March 31, 2024. Our previous independent registered public accounting firms were E&amp;Y, which audited our annual financial statements for our fiscal year ended March 31, 2023, and KPMG Canada, which audited our annual financial statements for our fiscal year ended March 31, 2022. Audit fees for E&amp;Y were CAD $143 thousand and CAD $425 thousand for the fiscal years ended March 31, 2024 and March 31, 2023, respectively. Audit fees for KPMG Canada, were nil and CAD $64 thousand for the fiscal years ended March 31, 2024 and March 31, 2023, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Audit-Related Fees</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;Audit-related fees&#8221; consist of fees for professional services that are reasonably related to the performance of the audit or review of our financial statements, and which are not reported under &#8220;Audit Fees&#8221; above. KPMG Canada, billed nil and CAD $52 thousand for audit related fees for the fiscal years ended March 31, 2024, and March 31, 2023, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Fees</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;Tax fees&#8221; consist of fees for professional services for tax compliance, tax advice and tax planning. E&amp;Y billed CAD $47 thousand and nil for tax fees for the fiscal years ended March 31, 2024, and March 31, 2023, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">All Other Fees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;Other fees&#8221; include all other fees billed for professional services other than those mentioned hereinabove. We incurred no other fees for the fiscal years ended March 31, 2024 and March 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pre-Approval Policies and Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee approves all audit, audit-related services, tax services and other non-audit related services provided by the external auditors in advance of any engagement. Under the Sarbanes-Oxley Act of 2002, audit committees are permitted to approve certain fees for non-audit related services pursuant to a de minimus exception prior to the completion of an audit engagement. Non-audit related services satisfy the de minimus exception if the following conditions are met:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the aggregate amount of all non-audit services that were not pre-approved is reasonably expected to constitute no more than five per cent of the total amount of fees paid by us and our subsidiaries to our external auditors during the fiscal year in which the services are provided;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our subsidiaries, as the case may be, did not recognize the services as non-audit services at the time of the engagement; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the services are promptly brought to the attention of the audit committee and approved, prior to the completion of the audit, by the audit committee or by one or more of its members to whom authority to grant such approvals had been delegated by the audit committee.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the services described above under &#8220;Principal Accounting Fees and Services&#8221; were approved by the Audit Committee pursuant to the de minimus exception.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;" id="item_15_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Financial Statement Schedules</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)(1) Financial Statements&#8212;The consolidated financial statements included in Item 8 are filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)(2) Financial Statement Schedules&#8212;All schedules have been omitted because they are not applicable or required, or the information required to be set forth therein is included in the consolidated financial statements or notes thereto included in Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)(3) Exhibits&#8212;The exhibits required by Item 601 of Regulation S-K are listed in paragraph (b) below.</span></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Exhibits&#8212;The exhibits listed on the Exhibit Index below are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.</span></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBITS INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1.98%;"/>
    <td style="width:89.02%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000117184321003288/exh_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger dated as of May 7, 2021 among Acasti Pharma Inc., Acasti Pharma U.S., Inc. and Grace Therapeutics Inc. (incorporated by reference to Exhibit 2.1 from Form 8-K filed with the SEC on May 7, 2021)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023052416/acst-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Articles of Incorporation, as amended (incorporated by reference to Exhibit 4.1 from Form S-3 (File No. 333-274899) filed with the SEC on October 6, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023041595/acst-ex3_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated General By-Law (incorporated by reference to Exhibit 3.4 from Form 10-Q (File No. 001-35776) filed with the SEC on August 11, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000119312513378663/d596972dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Advance Notice bylaw No. 2013-1 (incorporated by reference to Exhibit 4.3 from Form S-8 (File No. 333-191383) filed with the Commission on September 25, 2013)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000119312514228010/d732577dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen Certificate for Common Shares of Acasti Pharma Inc. (incorporated by reference to Exhibit 2.1 from Form 20-F (File No. 001-35776) filed with the Commission on June 6, 2014)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017022011842/acst-ex4_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities (incorporated by reference to Exhibit 4.6 from Form 10-K (File No. 001-35776) filed with the SEC on June 21, 2022)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/acst-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Warrant, dated September 25, 2023 (incorporated by reference to Exhibit 4.1 from Form 8-K (File No. 001-35776) filed with the SEC on September 26, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/acst-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant, dated September 25, 2023 (incorporated by reference to Exhibit 4.2 from Form 8-K (File No. 001-35776) filed with the SEC on September 26, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017022017938/acasti_def14a_2022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Acasti Pharma Inc. Stock Option Plan, as amended August 4, 2022 (incorporated by reference from Schedule A to the definitive proxy statement filed with the SEC on August 31, 2022)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023041595/acst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement for Employees under the Acasti Pharma Inc. Stock Option Plan (incorporated by reference to Exhibit 10.1 from Form 10-Q (File No. 001-35776) filed with the SEC on August 11, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023041595/acst-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement for Non-Employee Directors under the Acasti Pharma Inc. Stock Option Plan (incorporated by reference to Exhibit 10.2 from Form 10-Q (File No. 001-35776) filed with the SEC on August 11, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017022017938/acasti_def14a_2022.htm#schedule_b_equity_incentive_plan"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Acasti Pharma Inc. Equity Incentive Plan, as amended August 4, 2022 (incorporated by reference from Schedule B to the definitive proxy statement filed with the SEC on August 31, 2022)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/acst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter by and between Robert J. DelAversano and the Company, dated November 21, 2023 (incorporated by reference to Exhibit 10.1 from Form 8-K (File No. 001-35776) filed with the Commission on January 8, 2024)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1.98%;"/>
    <td style="width:89.02%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023054637/acst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Settlement Agreement, dated October 18, 2023, by and between the Company and Aker BioMarine Antarctic AS (incorporated by reference to Exhibit 10.1 from Form 8-K (File No. 001-35776) filed with the SEC on October 23, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/acst-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Securities Purchase Agreement, dated September 24, 2023, by and between Acasti Pharma Inc. and each of the Purchasers signatory thereto (incorporated by reference to Exhibit 10.1 from Form 8-K (File No. 001-35776) filed with the SEC on September 26, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1444192/000095017023003847/acst-20230222.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter from KPMG LLP (Canada), dated February 22, 2023 (incorporated by reference to Exhibit 16.1 from Form 8-K (File No. 001-35776) filed with the SEC on February 22, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1444192/000095017023070574/acst-ex16_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter from Ernst &amp; Young LLP (Canada), dated December 15, 2023 (incorporated by reference to Exhibit 16.1 from Form 8-K (File No. 001-35776) filed with the SEC on December 15, 2023)</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.7pt;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of KPMG LLP, an Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex23_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Ernst &amp; Young LLP, an Independent Registered Public Accounting Firm.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="acst-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Acasti Pharma Inc. Incentive Compensation Recoupment Policy</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed or furnished herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Management contract, compensatory plan or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item16_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form 10-K Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54%;"/>
    <td style="width:5%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: June 21, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ACASTI PHARMA INC.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;/s/ Prashant Kohli</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prashant Kohli</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title: Chief Executive Officer and</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26%;"/>
    <td style="width:1%;"/>
    <td style="width:42.2%;"/>
    <td style="width:2%;"/>
    <td style="width:28.8%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Prashant Kohli</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prashant Kohli</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert DelAversano</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert DelAversano</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Brian Davis</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Brian Davis</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/Vimal Kavuru</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vimal Kavuru</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;/s/Edward Neugeboren</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Edward Neugeboren</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26%;"/>
    <td style="width:1%;"/>
    <td style="width:42.2%;"/>
    <td style="width:2%;"/>
    <td style="width:28.8%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;/s/George Kottayil</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">George Kottayil</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:1.427%;font-size:10pt;margin-top:6.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended March 31, 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:95%;"/>
    <td style="width:5%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:7.9pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#independent_registered_public_accounting"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reports of Independent Registered Public Accounting Firms</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:7.9pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:7.9pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:7.9pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_sharehold_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of  Shareholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:7.9pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:7.9pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0065cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="independent_registered_public_accounting"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To the Shareholders and Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Acasti Pharma Inc.: 	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have audited the accompanying consolidated balance sheet of Acasti Pharma Inc. and subsidiaries (the Company) as of March 31, 2024, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2024, and the results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles. 	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. 	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ KPMG LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">		 		 </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Philadelphia, Pennsylvania</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 21, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To the Shareholders and the Board of Directors of Acasti Pharma Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have audited the accompanying consolidated balance sheet of Acasti Pharma Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(the &#8220;Company&#8221;) as of March 31, 2023, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for the year ended March 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at March 31, 2023 and the results of its operations and its cash flows for the year ended March 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.<br/><br/>Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We served as the Company&#8217;s auditor in 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Montr&#233;al, Canada</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">June 23, 2023, except for the effects of the reverse stock split described in Note 1, as to which the date is June 21, 2024</span></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.814%;"/>
    <td style="width:1.06%;"/>
    <td style="width:1%;"/>
    <td style="width:13.643%;"/>
    <td style="width:1%;"/>
    <td style="width:1.06%;"/>
    <td style="width:1%;"/>
    <td style="width:12.422%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Expressed in thousands except share data)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8b6e2f9-fac6-4dfc-8041-5795d6fd541f" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbea8ab7-7e54-4078-a853-7d045efaa28d" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,875</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce28fee2-b8be-4fe3-a787-cf5b295a57a6" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33067008-7d00-4242-8c4f-9f5408f0f1ed" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa0ba1d-8783-422b-b792-5e2a0367907c" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f81f7ff2-237f-4544-a181-24752cfc5c4a" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a0bc188-42db-4bfd-8028-8d4413ddc0c1" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c57f66b-3ea2-4396-8324-4ee88a224ee8" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">598</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fe6e41c-8f16-4e86-b1b4-62ea2592c055" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0a997bb-f94e-4c2f-a71a-916101b4574c" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,290</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ceebdd0-857b-4a53-b434-2e059ac05af5" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90bdaa39-4951-4b43-82e0-f71e0937fccf" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e15d70b2-682e-481f-abf4-edea795b056a" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:MachineryAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc902d1a-260c-4591-90d0-9de9b4ea09be" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:MachineryAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_512f8538-c335-4bdb-9fdb-cedc02856e28" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b70f597-6a81-41e1-9a23-4b5ac45d4741" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a767e75a-7974-4d9a-9ff8-fef612159eff" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32ff4297-079e-4f23-8de5-8244b11ae4b7" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a409fbee-8aa5-40f7-828b-748d3a9413d5" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d79115a-072b-40d5-b679-8875c52cafd5" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities and Shareholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade and other payables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0de51f18-b51c-4f32-a035-f2608c14f691" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aead05b2-e490-4163-8981-3a7c2f577544" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b58dff05-0f99-47bb-bff5-0c560e287b81" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_425a5ccc-e88f-405e-95c2-1fce1ea34ae6" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2b397c6-8fb9-49c1-8fe8-dac2acfb6564" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1dad234-1939-4ccf-8e63-5fdb6bacb048" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative warrant liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8451d809-9657-4bf7-97a4-10ccf6df9398" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5769ccb1-09fb-416c-a316-1a3970270786" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a6a03bf-686c-4be6-b674-fc51445dddd5" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd32b2fd-f9b1-4054-b8f2-7df4c2c4395c" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f8d0c2c-762c-41e5-9170-301e260b0330" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,514</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d90e15e2-146a-4124-8ddd-8b26b7f20247" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee3cfcd-6a55-4146-b9ba-0698d412b541" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,557</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5da3a21-027c-4350-a8bd-61d72ccf3d75" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,168</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_5b47b599-a873-4c0c-821a-222ef6337cf1;"><span style="-sec-ix-hidden:F_728ff52a-c3c5-4df3-8d06-ae1526751ba6;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shareholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common shares, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65c912b5-f55b-4144-9f98-c93599fc8208" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8ac6fecc-85b4-4cce-9fed-5b0158884c53" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value per share; unlimited shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34abc4b5-5986-4a2c-82fb-7cf4d540e54b" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca05976c-246d-41d6-851b-051ff4dde384" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,399,404</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b356fff-634d-4dd7-9f2a-fc8936317972" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d175764e-8a0a-4896-a081-3de06981ceb8" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,435,533</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2024 and 2023,<br/>respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69394f00-5da5-4d5f-a1bb-145b2a15fc53" contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a0cffcf-c29e-4953-bb89-79f84fce093e" contextRef="C_fe78ca06-1c34-4828-b4ae-24b1dc14563f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class B, C, D and E common shares, no par value per share; unlimited shares authorized; none issued and outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9a67e0b-f0f6-43c5-b157-89b155a9a03b" contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03b8f92d-3092-4c1b-9c95-84f9f333273e" contextRef="C_61d31cb9-015a-447b-92c1-edb57605af5b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc43b150-6f96-432d-97d7-15d27bbb41d8" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d7d4b86-c60d-4c1b-a1c4-37beee7a4d56" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9da5cfbd-a113-426a-9a4b-8b787091135d" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe502441-1ef3-443d-91a8-0ff8243d098c" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2910d2da-7fd8-4601-a432-9cfc77a50ab6" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">211,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d03f4c15-9567-4c26-8fa2-91bb4fc98bfd" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198,266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shareholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5aeecff8-390c-4cf7-8855-0b7e0255bfe6" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_170bc865-1dcf-4593-a40e-f2b6870096b5" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and shareholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f335ddae-3a0a-4d6b-b83b-02231e683fce" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f94a8842-7872-4607-a394-e07b37c72560" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="consolidated_statements_of_loss"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:70.606%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:11.838%;"/>
    <td style="width:1%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:11.278%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Expressed in thousands, except share and per data)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses, net of government assistance</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a393acfd-7e5f-4bb1-a4a2-e4fa1bce4711" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,683</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c171a54d-b429-430e-8178-c546d34cad7e" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_935e7797-acd3-41a3-a505-b1ba8088e890" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90f73755-d1ae-4e81-9b2f-46a1f8b71ac3" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35728812-3994-473d-9b5f-bf2535e53da5" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3dd8f4c-f66a-4607-9709-9c264c59bd46" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring cost</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00a4f209-d014-460a-975f-96971da7a6d9" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:RestructuringAndRelatedCostIncurredCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,485</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac51bc97-b288-4b81-9585-3ee9dca5f6e9" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_396a5d42-823e-439d-99d4-41237b5c4222" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03e34163-46ee-461d-924f-a8fc68a27977" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d14643ff-03d0-48d0-8e1b-762ede3220b8" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ImpairmentOfGoodwill1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2653a6a-fee4-443e-9dc6-3dadc1f064dd" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfGoodwill1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,826</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of assets held for sale</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99e9d8f3-b1d1-4871-a552-b240524f4a15" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ImpairmentOfAssetHeldForSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78de28b7-fff0-4b0e-800e-e7cd0abbf319" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfAssetHeldForSale" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss from operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcaa3478-2e89-405b-8efe-f420633b4e49" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e511a3a8-000f-4cdc-8917-f8ee241a024a" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,155</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign exchange loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87354a79-68ad-4674-819a-159e2bba1817" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86526664-2d6f-4877-9a84-c100ac19d3ac" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of derivative warrant liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90d92c18-bd29-4885-b8f8-100a63f1a618" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,728</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b5668c4-3efe-41a6-b2e9-77909fdd1dec" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income and other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20542c4d-4c2c-4d0f-9921-ce59c67f1976" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0d46f15-3ac5-4531-97eb-23c19afcf443" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b08487c-6e08-452f-8a34-35c3c2e7315c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a38c5468-3049-4335-a4bc-72726423ccbd" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income tax benefit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95fc2343-895c-4484-a176-e119e1f303da" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1810b8b-1fde-4400-86a4-11fbb1a32563" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">51,971</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef04568a-57c1-4b38-ac14-c43acca8e743" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,832</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5db507f8-2cb0-4660-b563-6ff3eb05185b" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,542</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net loss and total comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfd8a552-da2a-4b78-8af6-688767662832" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06f2168f-2b39-4e0e-9100-8f24fc99f4a3" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Basic and diluted loss per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb270ec0-318d-4ee1-a029-3fe1bab9429d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7b95d840-d1ce-4b54-b215-9e50116b466f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.35</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd81ffd0-f4bb-46f5-beb3-fe608b5f88c8" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cb0ee9c3-11a7-4ce7-8a7f-a083261d14ab" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">5.71</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted average number of shares outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42225bb8-a9e8-4a47-a23e-c17e2a0dc8bb" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_79e6c010-0839-43b8-bcfd-29c764fc1614" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,529,123</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8676243-e2c1-4c0e-8ccd-7ccbc65868ba" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_04799b2e-e1b9-43a5-918a-9b6ca70566a7" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,435,472</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_statements_sharehold_equity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of  Shareholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.021%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:8.232999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:8.232999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:8.232999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:8.232999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:8.232999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:0.999%;"/>
    <td style="width:1%;"/>
    <td style="width:8.812999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common shares</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shareholders' equity</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Expressed in thousands expect share data)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab3092f6-982d-43ec-80c5-8e5dd9c03746" contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,435,533</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71412c82-1eb4-48ed-adc8-3cc4ac0df2bd" contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3ed298c-ce79-479c-89f2-b5a704c7f57b" contextRef="C_2f539434-13da-4ff9-88f7-5a546b91d0a2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b0e6af8-2b11-454a-bc49-dbe2a5b8bdf2" contextRef="C_b1b778e5-8b0d-438a-a6f2-684bd8df12a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea6cf7ad-1e1e-4119-86ec-6eafa700429f" contextRef="C_70f162d2-db64-4bf0-91a3-884865073097" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198,266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efb39ac6-6635-4769-9adb-c83b2a765c15" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and total comprehensive loss for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_590b42a5-d061-4ff6-910b-3a7d3f5568fd" contextRef="C_c54d6f0f-6fce-44a5-ad0b-79bf1eed26d3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a336dfa3-cbb2-4235-95da-f5e3b46f4186" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b04aab5-45dd-4216-89bd-359b41d0d4e2" contextRef="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7d2e839-dce5-4af6-82d1-e6055ad6a992" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common shares and pre-funded warrants through private placement, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23d7ad6b-d557-4d79-bbff-a1a3db317ebe" contextRef="C_0cece337-a016-4efc-9a7d-ad4598442843" name="acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,951,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c53a4233-2f19-4c4f-b34d-d17460d34bab" contextRef="C_0cece337-a016-4efc-9a7d-ad4598442843" name="acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,744</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d284088d-0f23-48bd-b1bd-b205048b64b0" contextRef="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2" name="acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,963</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63e1efe8-df07-48a9-815c-3712e4530584" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,707</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common shares upon the exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fe1e1ee-1842-4659-9a6b-1486f969f83e" contextRef="C_0cece337-a016-4efc-9a7d-ad4598442843" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a39db27-3fd8-48dc-8640-b47a8e07aaee" contextRef="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee04366e-1c58-4e66-a480-e8080d985305" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eac8188-85fc-45c7-89fb-3cf34d7d524a" contextRef="C_1eefc74f-a703-4dea-ae7e-ea4e331b81be" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,399,404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7e6231d-800b-4523-bef9-2d6bbcc18d9a" contextRef="C_1eefc74f-a703-4dea-ae7e-ea4e331b81be" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ca39c3-841c-4a6d-ad87-003d2804bda3" contextRef="C_4cc0c4ab-5764-4050-862c-4ecc5ff57375" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b1833ed-0f1e-4ffc-a819-20713d3af0dc" contextRef="C_f4f8e9bd-4546-4f0a-afa5-60be369c087e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2cc1d4f-54e2-4690-9d54-cfaadc3ccd80" contextRef="C_f9bbd593-6189-421e-8104-e8b8f59ded6a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">211,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a7a448-dd2b-4b5e-a030-917d85f8629a" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.047%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.237%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.237%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.237%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.237%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.197%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.816%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common shares</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other<br/>comprehensive loss</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shareholders' equity</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Expressed in thousands expect share data)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cce119d-4671-4f48-a575-27d62e90422e" contextRef="C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,381,425</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_722a45ce-0c51-4aa6-a2a7-74619297ae4f" contextRef="C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6108cdaf-33b6-4360-8ab8-497079a7a0ef" contextRef="C_5e0b6d2b-f94b-4c26-b5cb-495d338020d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f851220-ad57-4f9b-a63f-a9b2089074ab" contextRef="C_f20daba8-2053-470f-8d6f-36c41659af0c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e80ecb25-ae67-413a-9dee-f46b7aec1063" contextRef="C_7f5f8bdc-5660-4849-adbb-453fc624895a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">155,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e884d014-2bed-45dd-aa37-4c5d3a7f49be" contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,270</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and total comprehensive loss for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e4cca5-6ea2-46a8-9ec0-bc4d8c0c1286" contextRef="C_95d10643-bfd0-4043-b9c9-ff71cc4ed89f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7b4d33e-b5d6-43ba-986b-5dc652d54f82" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12a9e382-0bcf-4d96-a4d1-bd04a15ea7f3" contextRef="C_212e94e2-e50a-4b7d-b58b-26d56a137061" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa97c3de-5496-4fad-ae1c-8174cc98c51e" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd375725-a618-40b2-814a-afbc867d30f5" contextRef="C_f4272963-8b80-42bd-8469-469e87f57dc8" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2126bf56-0e0b-49d0-a7e1-9b73d6e3a08c" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net proceeds from shares issued under the at-the-market (ATM) program</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00957bbb-30ef-462a-9e3b-54e425e5ebef" contextRef="C_572273b4-60a1-4bad-97f2-b3aeeca1fc06" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">54,108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7976509c-f302-49a7-b64a-58ec0af96954" contextRef="C_572273b4-60a1-4bad-97f2-b3aeeca1fc06" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_957d4a05-4849-43a2-b7c9-18e55f0aff11" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6187ea08-ea04-42ba-8f0e-8c6c98d1d642" contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,435,533</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46c5dbc0-f30e-4765-9927-fb0ca10565cd" contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_803a9196-9613-46fe-ad76-879d26772c81" contextRef="C_2f539434-13da-4ff9-88f7-5a546b91d0a2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3650c96-b1f5-42f6-bcd4-7b1cf4e10d62" contextRef="C_b1b778e5-8b0d-438a-a6f2-684bd8df12a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_956254cf-30c8-490e-b319-e092c4109d61" contextRef="C_70f162d2-db64-4bf0-91a3-884865073097" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198,266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd2959b-c206-49e0-a781-d27dba2cc9c4" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="margin-left:0.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.806%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:12.537%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:11.418%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(Expressed in thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a41cbbe-9e97-4c57-b54e-f9d5f4bf51c5" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff7682ff-0143-442c-a118-fab780748bf7" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation of equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fe34ff0-3c99-4215-9603-194dff18a36d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a4df0cc-40f7-4b81-a3b2-6c9b7a519802" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on sale of equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a658bff5-02a7-4463-b5d0-f6d76ed9a997" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6736bd66-96b9-4a65-8a6f-18a450afda7c" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7907314a-a8d5-4f69-a393-70181723642c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d8b03c7-bfc5-4831-bfce-fd56b60b328e" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_589929ed-a65e-4e06-ae89-011902e3d5f7" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ImpairmentOfGoodwill1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6a9a72e-b5b5-4a98-b9ff-8cedd837f6ea" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfGoodwill1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,826</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of assets held for sale</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_237b34c7-5b2e-4b71-88f3-a8fb22b30e9f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ImpairmentOfAssetHeldForSale" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bce967e9-87de-48c4-8618-d9584d37816a" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfAssetHeldForSale" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b84b7168-2a28-49d9-ae97-d0ae57442e62" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da4cdb14-46f3-4016-874c-76946e1b69fb" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa3108da-de96-42af-8c2f-d5075917b828" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,728</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb3150cf-f7d4-4250-a8a5-24dd2e8011d7" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income tax benefit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49493f1a-467b-46c5-94dd-3f7a1d8d56b5" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,832</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aef0335-2abd-4a9a-9541-2b93ff2238b9" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,542</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized foreign exchange (gain) loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a476df59-d139-4f4e-98ed-ceca003c9064" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85660b60-05aa-4d2e-b2c7-8f99d1406d8f" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c996dc32-1da9-41b6-82a1-2bf96fa4140f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed835153-6c1b-4b2b-b1e6-397af1ac7946" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02a46509-cfba-4f4b-a6cb-f0989397b1f6" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fb715b6-abe0-439e-bdd0-2b36f357e330" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ef3c4fc-4c03-4d58-9941-202c50914fff" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84fba7b3-8968-4141-9627-37f55222a688" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade and other payables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fd9cefd-bace-434e-b794-307e5064f2b0" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_016e9183-4bb3-4081-86c8-535a37f7409a" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da710870-05b0-4d06-8159-19729418c3f9" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e401705f-9371-443c-b430-b2faddbc569a" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0158e332-bdc3-48db-a7de-52d1b40721ff" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bffeb912-5271-460b-8051-45b38fdfc206" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f7ece7b-e32c-4f11-bd9f-127f07e5cbab" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df86e38d-01cd-4e16-b1c7-d68074a7acf3" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c19b7458-7f25-43ed-8acc-421bc8958f7f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c647b55b-05d1-451c-b86c-595d889dc25f" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94c0a30a-1f5f-4da9-85ed-fcbfba0f6694" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,554</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c68746b9-5557-4f2e-9618-a0245367e901" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,015</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturity of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c9efc1d-5f73-4a3f-8e7f-dfcf78ddff98" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,569</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb6c5c9a-4490-44a3-bea8-097189e67f19" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cd913eb-49bb-4929-bf60-d4d8e222bc1c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_119e8790-5cd0-4239-a69a-56b406484bbd" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net proceeds from issuance of common shares and warrants from private placement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de1275d-504b-453f-9ac8-5616b4b75fe6" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd088a98-76c8-481c-9595-98c4bfe10453" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common shares from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e8b0838-224e-457d-8d78-576fcce504a6" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cf9bae8-1042-4e7a-a90c-741720ec562f" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net proceeds from shares issued under the at-the-market (ATM) program</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd669dd3-ef7b-44ee-a414-00f343cf4506" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ad8db12-df24-4fc0-9ff3-931f19d9f5d6" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13ccfd91-0f21-496e-81d5-3a5f397500a6" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1290b572-2ef3-4370-a4b5-6b49f1f55b91" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate fluctuations on cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d0666ab-01b6-4ec1-bed3-c35a3a01b75f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:EffectOfTranslationEffectOnCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cd88749-6b7a-40ad-8d91-1ce4f45ea878" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:EffectOfTranslationEffectOnCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7710c4d-38c9-4c4a-a0b1-3dcdf39b0f85" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,870</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26fd3b1a-ac8c-4f20-8f0a-9260f5a7d253" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d7eb82a-7229-4fd8-8049-243de83a3dd3" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,875</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed780434-4458-4788-82c3-95df774531a9" contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a48e5d56-cbd0-486e-96f2-2baea2a72ef2" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22c40f7b-e5fa-4fdb-98d2-19207c5a7504" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,875</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents are comprised of:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf3c451b-8149-4008-9f87-3f63994b9938" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb9bf14a-0fd3-4d36-81d5-c046149015af" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b2453b4-ea0b-47ff-bb6a-2576aa8a971e" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b035eb0f-3d98-458d-9745-cd67c19b6a85" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Expressed in thousands except share and per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80ec9d93-58fa-43a6-aded-d2d676a07399" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acasti Pharma Inc. (&#8220;Acasti&#8221; or the &#8220;Company&#8221;) is incorporated under the Business Companies Act (Qu&#233;bec) (formerly Part 1A of the Companies Act (Qu&#233;bec)). The Company is domiciled in Canada and its principal executive office is located at 103 Carnegie Center Suite 300 Princeton, New Jersey 08540.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Class A common shares, no par value per share (&#8220;Common Shares&#8221;), are listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) and, through March 27, 2023, the Company's Common Shares were also listed on the TSX Venture Exchange (&#8220;TSXV&#8221;), in each case, under the symbol &#8220;ACST&#8221;. On March 13, 2023, the Company received approval to voluntarily delist from the TSXV. Effective as at the close of trading on March 27, 2023, the Company's Common Shares are no longer listed and posted for trading on the TSXV.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, the Company completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (&#8220;Grace Therapeutics&#8221;), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Company is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and developing and commercializing products that improve clinical outcomes using its novel drug delivery technologies. The Company seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Company for further development may be already approved in the target indication or could be repurposed for use in new indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses and negative cash flows from operations in each year since its inception. The Company expects to incur significant expenses and continued operating losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company implemented a strategic realignment plan to enhance shareholder value that resulted in the Company engaging a new management team, streamlining its research and development activities and greatly reducing its workforce. Following the realignment, the Company is a smaller, more focused organization, based in the United States, and concentrated on its development of its lead product GTX-104. Further development of GTX-102 and GTX-101 will occur at such time when the Company is able to secure additional funding, or enters into strategic partnerships for license or sale with third parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 24, 2023, the Company entered into a securities purchase agreement with certain institutional and accredited investors. Gross proceeds to the Company from this private placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cec8059-ee9e-4e1f-979b-946a0b7592e5" contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, before deducting fees and expenses. The Company issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00472827-c20b-4281-ab50-115659bb94c1" contextRef="C_ebcea23f-4694-41c8-85d2-30c548c5e8cd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,951,371</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, pre-funded warrants (the "Pre-funded Warrants") to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a8e1877-3bc7-4622-bcdc-fa0f5af08408" contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3" name="acst:PurchaseOfPreFundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,106,853</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, each at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d42e8ef-f05a-465d-b41b-0791d50e56af" contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3" name="acst:PurchasePricePerCommonShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.8481</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share and accompanying common warrants (the "Common Warrants" and, together with the Pre-funded Warrants, the "Warrants") to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd6bce94-c818-4f99-88f2-c7ff770614aa" contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3" name="acst:PurchaseOfCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,536,391</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares. The Company currently intends to use the net proceeds from the private placement for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, pre-commercial planning, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents, will be sufficient to fund the Company&#8217;s operations into the second calendar quarter of 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will require additional capital to fund its daily operating needs beyond that time. The Company does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Company expects will take several years and is subject to significant uncertainty. To date, the Company has financed its operations primarily through public offerings and private placements of its Common Shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Company can generate significant revenue from drug product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financing or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Company to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy. The Company plans to raise additional capital in order to maintain adequate liquidity. Negative results from studies or trials, if any, or depressed prices of the Company&#8217;s stock could impact the Company&#8217;s ability to raise additional financing. Raising additional equity capital is subject to market conditions that are not within the Company&#8217;s control. If the Company is unable to raise additional funds, the Company may not be able to realize its assets and discharge its liabilities in the normal course of business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">7</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with government regulations, protection of proprietary technology, dependence on third-party contractors and consultants and potential product liability, among others.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse stock split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2023, the Board of Directors of the Company approved an amendment to the Company's Articles of Incorporation to implement a reverse stock split of the Company's Common Shares, at a ratio of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25a88d5f-f706-45d9-9852-8c6674c45b93" contextRef="C_f6847874-0331-463a-bd4c-c694ab172b42" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Reverse Stock Split&#8221;). On July 4, 2023, the Company filed Articles of Amendment to its Articles of Incorporation with the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registraire des entreprises du Qu&#233;bec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to implement the Reverse Stock Split. All references in these financial statements to number of Common Shares, warrants and options, price per share and weighted-average number of shares outstanding have been adjusted to reflect the Reverse Stock Split, which became effective on July 10, 2023.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b725ae7b-bab1-4a35-9335-cad2e1cfb693" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of significant accounting policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c259ea7-0066-4418-9f9b-c8c173f9ad5a" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of presentation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). All intercompany transactions and balances are eliminated on consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e64e5c19-bcd0-48e8-a1bf-be57b24bb436" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates are based on management&#8217;s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions include the measurement of stock-based compensation, derivative warrant liabilities, accruals for research and development contracts and contract organization agreements, and valuation of intangibles and goodwill. Estimates and assumptions are also involved in determining the extent to which research and development expenses qualify for research and development tax credits. The Company recognizes tax credits once it has reasonable assurance that they will be realized.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67dbe5fe-e7ee-494e-8b67-e9df96aa2c5e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash equivalents</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents comprise of highly liquid investments purchased with original maturities of 90 days or less. Cash equivalents consist of guaranteed investment certificates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f876a62-7b0b-41e3-b99c-451ffc34642a" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equipment</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is recognized on a declining basis over the estimated useful lives of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not yet in service, from the date they are ready for their intended use.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9679d4bb-39a5-437b-b47d-911a42473dbe" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible assets - acquired in-process research and development</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a business combination, the fair value of in-process research and development (&#8220;IPR&amp;D&#8221;) acquired is capitalized and accounted for as indefinite-lived intangible assets, and not amortized until the underlying project receives regulatory approval, at which point the intangible assets will be accounted for as definite-lived intangible assets and amortized over the remaining useful life or discontinued. If discontinued, the intangible asset will be written off. Research and development (&#8220;R&amp;D&#8221;) costs incurred after the acquisition are expensed as incurred.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method, which is a valuation methodology that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The significant assumptions used in the valuation are the discount rate, the probability of clinical success of research and development programs, obtaining regulatory approval and forecasted net sales, including milestone payments and royalty revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">8</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e774c604-7d67-4404-a9c5-1a59c570fe15" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews the recoverability of its finite long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not be recoverable. The carrying amount is first compared with the undiscounted cash flows. If the carrying amount is higher than the sum of undiscounted cash flows, then the Company determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the difference by which the carrying amount of the asset group exceeds the estimated fair value of the asset group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeds the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than it's carrying amount, a quantitative impairment test is performed.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's annual impairment test is performed in the fourth quarter of the fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6be5a000-2d91-4598-8747-5771e4af0f95" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development costs</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and developments expenditures are expensed as incurred. These costs consist of employees&#8217; salaries and benefits related to research and development activities, contractors and consultants that conduct the Company&#8217;s clinical trials, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fdd032e-3665-4bfa-92ee-c217e66c00e0" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has in place a stock option plan for directors, officers, employees, and consultants of the Company, with grants under the stock option plan approved by the Company&#8217;s Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant.  The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company measures the cost of such awards based on the fair value of the award at grant date and recognizes stock-based compensation expense in the Consolidated Statements of Operations and Comprehensive Loss on a tranche by tranche basis. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including fair value of the Common Shares at the grant date, expected term, historical volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior in determining compensation expense. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may be required in future periods.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ae27b0a-e97d-46a3-b2ef-59c7382b7758" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:GovernmentGrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government grants</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45d51790-a41a-4db2-9389-68aa18f4e0f5" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic environment. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company&#8217;s lease expense is recognized in research and development expenses. The Company does not have financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with FASB ASC 842&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;Topic 842&#8221;), components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27be16ec-393d-4f46-88a0-e4ab6e41a236" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes comprises current and deferred taxes. The provision for income taxes is computed using the asset and liability method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realized (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Company has the right to set off the amount owed by with the amount owed by the other party, the Company intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses, and tax credits, reduced by a valuation allowance. A valuation allowance is recorded to reduce the carrying amount of deferred income tax assets when it is more likely than not that these assets will not be realized.  tax benefits related to tax positions not deemed to meet the &#8220;more-likely-than-not&#8221; threshold are not permitted to be recognized in the consolidated financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ebb31c3-3014-4468-b7aa-88db6557cbae" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings per share</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company presents basic and diluted earnings per share ("EPS") data for its Common Shares. Basic EPS is calculated by dividing the net income or loss attributable to the holders of Common Shares by the weighted average number of Common Shares outstanding during the year. Diluted EPS is determined by adjusting the net income or loss attributable to the holders of Common Shares and the weighted average number of Common Shares outstanding adjusted for the effects of all dilutive potential </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares, which comprise warrants and share options granted to employees. The basic and diluted EPS are the same due to loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19d00885-54dd-4d70-8433-01768adbe09e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment reporting</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdff9c43-7d69-4c4d-89b4-063ea832a471" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NumberOfReportableSegments" unitRef="U_Vote" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable operating segment: the development and commercialization of pharmaceutical applications of its patent portfolio and licensed rights. The majority of the Company&#8217;s assets are located in Canada and the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da4419ac-4431-4405-aaf3-5049ba0f3c73" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative warrant liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative warrant liabilities are recognized initially at fair value. Subsequent to initial recognition, derivative warrant liabilities are measured at fair value, with changes in fair value are recognized in the Consolidated Statement of Operations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c36f0f2d-a4f0-4c8b-8510-45cee84aab52" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value measurements</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of the Company&#8217;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below:</span></p><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: defined as observable inputs such as quoted prices in active markets.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions.</span></div></div><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">10</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d85ce098-efbd-415f-aff1-281698feeddb" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are all invested in accordance with the Company&#8217;s Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which risk is managed by dealing only with highly rated Canadian and U.S. institutions. The Company maintains its cash and cash equivalents at accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_677ac61f-77cc-4515-b095-cb23a25a8289" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent accounting pronouncements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the consolidated financial statements as a result of future adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42ad632b-b375-45d3-8c7a-fec47c42e16f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair value measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fef1530-7154-4dd3-9773-8fbc25066e3b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.203%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:11.435%;"/>
        <td style="width:1%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:8.477%;"/>
        <td style="width:1%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:11.056%;"/>
        <td style="width:1%;"/>
        <td style="width:1.479%;"/>
        <td style="width:1%;"/>
        <td style="width:11.435%;"/>
        <td style="width:1%;"/>
        <td style="width:1.479%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quoted prices in active markets (Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Guaranteed investment certificates and term deposits<br/>&#160;&#160;&#160;classified as cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7723e47-a56e-4be6-bb22-779ed52e9119" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,725</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd842b07-69d4-45a2-99b0-637d2d25961f" contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,725</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b5e912a-10c6-4bd1-a248-39926e0454c6" contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edba0203-cbd3-4f0d-9842-6cec9e620682" contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03ba9a99-86da-417e-9451-1f7b7ababb26" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,725</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac570e2a-59b6-4f54-955e-7488d33e4968" contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,725</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c16def0-d7a5-4a02-859b-d753d06eea45" contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44540058-a391-4fec-9715-e97bf3e15745" contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Derivative warrant liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caf8a656-4e7f-417f-aa93-f18db75d6131" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a8e54f2-4a12-48e0-9f65-b7c12c9b4159" contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e415c239-1d00-49a6-88d5-2e6dc408f20c" contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c79e0ddb-48e7-4319-831b-b994bb57e2f5" contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a69737-96d5-47fe-a6a7-5c44ebe725ea" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_096004b5-bacb-4a3e-9ae7-561fcdb66e80" contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1db195b-3589-4ed5-9ff2-2a76456e289d" contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_885056be-521e-4442-8452-033ac151a647" contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of March 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.058%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:11.405%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:8.323%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:11.024%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1%;"/>
        <td style="width:11.405%;"/>
        <td style="width:1%;"/>
        <td style="width:1.541%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quoted prices in active markets (Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Term deposits classified as cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e13c5d88-8f1a-47f1-84af-c7702c27a991" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,072</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf48f553-93e3-418d-a451-3166722a0500" contextRef="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,072</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acf5e38b-3a41-4c35-844c-5bc4ccb345d9" contextRef="C_3475cb4c-b4fd-423d-8077-b5c595ff8757" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d82e6e3c-0c92-4431-89ab-2663a3e5805a" contextRef="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c" name="acst:GuaranteedInvestmentCertificatesAndTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Guaranteed investment certificate classified as a<br/>&#160;&#160;&#160;short-term investment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17506f3c-f0be-48ee-95d6-35dfe4a64359" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OtherShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_900f02bb-a6e1-42f7-9067-a97588f8a34a" contextRef="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970" name="us-gaap:OtherShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dc9f73c-3f26-4614-86b3-79e27ce51fc1" contextRef="C_3475cb4c-b4fd-423d-8077-b5c595ff8757" name="us-gaap:OtherShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_469b92a0-6b9c-44e1-8994-962971e68645" contextRef="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c" name="us-gaap:OtherShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a81c8e58-c071-4305-ab7a-e814ad636eb8" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,087</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c24cd06-b4ac-44f3-94e9-3983a1902ddc" contextRef="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,087</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fba3f056-1499-46f4-97b6-a4e9fe2b1ffa" contextRef="C_3475cb4c-b4fd-423d-8077-b5c595ff8757" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a7f795f-6d70-4361-b950-c22a53020677" contextRef="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f132cd30-7902-4315-8127-ab7bcce7e6f9;"><span style="-sec-ix-hidden:F_c1a9517d-f266-4d79-aeb0-1c8917bd2b32;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> changes in valuation techniques or transfers between Levels 1, 2 or 3 during the years ended March 31, 2024 and 2023. The Company&#8217;s derivative warrant liabilities are measured at fair value on a recurring basis using unobservable inputs that are classified as Level 3 inputs. Refer to Note 10(b) for the valuation techniques and assumptions used in estimating the fair value of the derivative warrant liabilities.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a67e05b-e3d9-421c-b07c-3f105ad0e87e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" escape="true" continuedAt="F_5a67e05b-e3d9-421c-b07c-3f105ad0e87e_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Receivables</span></p><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00751df3-3ea4-4b24-a170-e94234ad03f6" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales tax receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c284f9e1-ed45-464a-895b-9b08d1e27c2f" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:SalesTaxReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df88d46a-cd8d-49d1-9a1a-249f97286584" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:SalesTaxReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government assistance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dd115e4-2e9d-4092-9a41-0522a9cef1d0" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:GrantsAndInvestmentTaxCreditReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">356</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_616012ab-ee5e-4770-b620-1a574f4c61f8" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:GrantsAndInvestmentTaxCreditReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d99bc33-8148-4277-afe1-a93a97977663" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fea952e6-cdf2-49d8-a93c-26938e514655" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e59b84f-3ecf-4669-b2d2-c8f8a1e76abf" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9cf3f61-2291-4588-8e32-3f73c902bd4f" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_610729d6-1b22-4a62-b620-7d5877766fd4" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a30fda9f-3037-4cba-aab9-5bf6d6623c1a" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_5a67e05b-e3d9-421c-b07c-3f105ad0e87e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government assistance is comprised of research and development investment tax credits from the Qu&#233;bec provincial government, which relate to quantifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0411cb57-7abf-4e96-9e38-2cb785fd397b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Equipment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95af6580-dd2a-434f-90c8-850747b24b73" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of equipment, net:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.12%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.9%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated<br/>depreciation</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Write-off</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net book<br/>value</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b046a7cc-4d5b-434b-b5cc-bb3547f85a11" contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec1015bc-213e-4a86-9a12-cb81726e310d" contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c19e8e98-fdde-468e-966b-6bec217617cb" contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4b5818c-a2b8-4819-9780-59e058cf44e7" contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea13c184-75c0-4c9c-8a74-7eed3ba9c701" contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76bc1df2-b5cc-413b-ba86-99ae915f3ee6" contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de3d0dfd-4bfb-46e2-b683-1cb4ccdb141d" contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d023ad50-6481-41bd-81c2-aadf0beaad28" contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aca4f77c-7588-4bed-b6c4-7b962075344e" contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">571</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39e3eb7b-5c02-4ca5-85fc-af3519ed82f0" contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d87309f4-844a-458b-bd02-014fbac77eee" contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6f54433-d3d7-4861-9574-c76f1643eb65" contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54356db1-0e83-4605-af80-d02343b930eb" contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e43ca8a-19d2-493c-98ac-c39074460821" contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a32f02-dfdf-461d-bec3-b8066cec96b9" contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc5cf637-f250-40a8-8616-becf48a8b64b" contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_205041de-d661-41c7-928e-150a2c2a66e0" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cca200e-8804-4d69-ba71-6f0269a38c71" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">608</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f1bfb36-40eb-4a91-8847-77fd4b31f6bd" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0272365-6bf5-41b2-999b-ba5154718e5d" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.12%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.9%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated<br/>depreciation</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Write-off</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net book<br/>value</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2600502f-f188-4986-a9b4-e0c60d72e62e" contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8ea8292-5120-4bbe-82c2-648fc6b673f6" contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_212b07a1-2585-4cec-a817-adfd97022237" contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e322f95-7ddf-49d4-8540-002da5740af6" contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_050cc712-09b0-47d0-8d4c-4205b8f62969" contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b28aab32-8853-4908-af1e-36dd8de7683c" contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be93c53c-b0bd-47dd-a2ef-1a82a02ddd42" contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ced1ffc8-cf1b-42a8-9e78-8d91f5d853f5" contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b3b4e2-d8fc-46c1-87aa-d5ac8c4cd0f5" contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">586</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a04b1b25-774d-4484-8aad-ddee9c22ac02" contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">512</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fffb1f6a-c18b-4a07-8533-c43f319eb7b1" contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f0e7c79-8b86-4a58-b353-16b4cfce7e38" contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_679f4231-d50a-4908-9c5d-e1ed5b9e77f2" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12e5f409-8969-4c76-bd8c-90f02033e282" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8d7d751-7e55-4f62-8eff-d736c0314cfa" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:WriteOff" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4529ff8f-bd51-4107-ae6a-3af0679df53b" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c40fa15-0f97-409c-a641-897a2176066d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6d69755-6fae-495b-aa8c-f85e91fc892d" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_37cd78ab-9819-4744-bada-4ff3ea975808" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Intangible assets and goodwill</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual IPR&amp;D projects and goodwill are tested for impairment on an annual basis in the fourth quarter, and in between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of each technology or our reporting unit below its carrying value. In April 2023, the Company announced its strategic realignment plan to prioritize resources to GTX-104, from GTX-101 and GTX-102 triggering a comprehensive review as of March 31, 2023. The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method. </span><span><ix:nonNumeric id="F_ba8197c4-b282-44be-b0d3-31d41ea2712f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true" continuedAt="F_ba8197c4-b282-44be-b0d3-31d41ea2712f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of the reporting unit was determined using the projected discounted cash flow model. The impairment assessments resulted in the following activity during the years ended March 31, 2024 and 2023: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ba8197c4-b282-44be-b0d3-31d41ea2712f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.52%;"/>
        <td style="width:8.4%;"/>
        <td style="width:1%;"/>
        <td style="width:17.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:6.88%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:6.88%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7.34%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-104</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-102</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-101</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets &#8211; in-process research and development</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_584549cc-ec87-4318-b6f0-c46aee6f26a2" contextRef="C_c4d697ac-eda3-4464-bee3-640ff429e5f1" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67d8690a-1c7b-48bb-8c19-d81860362d84" contextRef="C_99120ca0-a7fe-43e2-936c-fcfed03ae232" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02940392-f4a9-4e60-9fed-48d01709931e" contextRef="C_e2b01b48-402b-4dc7-b752-a7f73d31bb54" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,307</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50c017fc-8715-436d-b2b1-e43a48c2c363" contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,810</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56f78b73-44f8-4a85-8a95-2c6a401efe80" contextRef="C_7da7b073-43df-4431-96b2-512ccdc4cb73" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd28ed4f-eee4-4830-a5e4-a1e04db997c6" contextRef="C_16d16afb-4a44-408e-a2a5-100f7c0b1fbb" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,712</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c94791f-026d-47bd-b6b5-11b3a9ec4052" contextRef="C_2c54e8e1-ca7e-47f6-aaac-354c7f5c59dd" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a40435e1-9588-4c44-883f-3628faa8131b" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8df05f7e-025b-43a5-8ee3-ae0cc5583652" contextRef="C_8c949238-1cb2-49d3-a7a9-6006bf23a15b" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4c904fb3-a2ed-4b3a-82ca-ecb4d1d865e0" contextRef="C_0d061b65-1b50-45f5-aae5-b793fa09c563" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,196</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_0de7b709-3cf7-420a-b204-1a5cb4b12bc1" contextRef="C_189b018a-6b9e-4d85-84a9-062a43fb0c41" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,337</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ca5b14ec-6228-4fca-a053-fe35d46b8fd4" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,128</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac3d3bf4-d0c2-4236-91e3-34a8a84c29b2" contextRef="C_f3eda1d7-9329-4b09-81c9-72ab4a9683c2" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ee587e9-bc8f-47cd-9d82-340cb8e0d9bb" contextRef="C_58a0300e-46b5-4e90-9cfb-76e05e952710" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b29b39dc-4901-4790-9760-7c793e609b9d" contextRef="C_67401b5c-e353-4b98-9f09-f2f145bc81df" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2201893-8c2f-420e-b707-821c0438706a" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_47771f4e-ee7d-4e8d-88c9-816c08026dca" contextRef="C_5c543260-cf22-4eb7-a1f7-51cc4741bc47" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9f9043db-8d98-40c2-b535-5f9d6505c035" contextRef="C_b8860ddc-a67b-4cbc-b6fe-22b8b851fe21" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,196</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_790c340f-049f-48ed-8063-8dc3759910e2" contextRef="C_5eeacd49-7941-4477-961d-d7f222f3cc8f" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,337</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f92bbd71-e350-494d-89e5-6f783ef10143" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,128</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ae3d634-09e9-48e4-9f99-bee81d6cd39c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfGoodwillTextBlock" escape="true" continuedAt="F_7ae3d634-09e9-48e4-9f99-bee81d6cd39c_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impairment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d08c83e9-843f-4b57-8d19-c1ceb3da11eb" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,682</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the intangible assets resulted in a recovery of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07a76a05-60e5-42c7-aea8-fe093a628ec1" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:ImpairmentRelatedDeferredTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,633</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the related deferred tax liability.</span></ix:nonNumeric></span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">12</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7ae3d634-09e9-48e4-9f99-bee81d6cd39c_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.68%;"/>
        <td style="width:11.62%;"/>
        <td style="width:1%;"/>
        <td style="width:25.7%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Goodwill</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57ff17a6-56ea-4370-acaa-6131ced19bd0" contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,964</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a707a420-a376-4cd8-9992-d8e5b5e4b2d7" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ImpairmentOfGoodwill1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,826</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_04db077a-2427-429d-9e59-f22ce0a21535" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81071468-52ef-4fd0-8f8a-abac857db10c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ImpairmentOfGoodwill1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ab9d40f0-42ae-443a-9da0-5726b81e6298" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The multi-period excess earnings method models used to estimate the fair value of assets of our IPR&amp;D reflect significant assumptions and are level 3 unobservable data regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Probability of clinical success of research and development and obtaining regulatory approval;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forecasted net sales from up-front and milestone payments, royalties and product sales; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discount rate reflecting our weighted average cost of capital and specific risk inherent in the underlying assets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's IPR&amp;D projects, consistent with others in our industry, have risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. It is not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5591cf4-030a-4f11-b2be-23e4c65e0a20" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Trade and other payables</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_863d2812-d061-42c9-b741-bf5309a38ace" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1a1d112-95bc-4ef5-a172-c8e3d67564e1" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccountsPayableTradeCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,007</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad71fe9b-53b8-4e69-84a8-1110442412f5" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccountsPayableTradeCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,242</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities and other payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_561ccd08-8fe1-41d1-9e5e-ccb88edb1713" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91bd0fd2-aaf1-4504-a26d-22a92f2ec3ca" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">946</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee salaries and benefits payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7cc40ad-fc70-444f-8289-d0fd702fe3f6" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e148ec4-2973-4f79-967f-9aed4d224bc0" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total trade and other payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2659f050-f9eb-4163-b17d-7f4d028ca433" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,684</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13ceec25-ad8c-4a30-8019-9eef433b6fc0" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab33d169-65d4-469f-9974-712967085d97" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically entered into lease arrangements for its research and development and quality control laboratory facility located in Sherbrooke, Qu&#233;bec. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10c309e4-777a-472f-b8a6-870edb6d5365" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, the Company renewed the lease agreement effective April 1, 2022, resulting in a commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d1f278a-b1a8-4a28-94b1-35086364f21d" contextRef="C_c73f5261-e930-4ac2-9ecb-307f85b47d05" name="us-gaap:PaymentsForRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">556</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b934036a-3c52-443d-86f4-e0d3a4e798a4" contextRef="C_0238deb6-4fe5-4dd5-8a50-1ee0d936549a" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month base lease term with an option to renew for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18d4d07f-1c55-459e-a1a7-3e00bc5a25d6" contextRef="C_0238deb6-4fe5-4dd5-8a50-1ee0d936549a" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month term. In April 2023, the Company elected not to renew the additional 48-month option to renew, and terminated the lease on March 31, 2024.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fc3ee98-75de-4cbb-a6a6-88f9ec97cf6d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:SupplementalBalanceSheetInformationTableTextblock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to leases was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.914%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.662%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e0542e2-ca3a-4a1f-a5d2-91d0250a47f4" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4891581-281c-45d8-80c6-37ea51ea5d04" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e81e2e4-7e19-4b31-88ad-19bb5394b2e8" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1fc8b7-5602-4fe7-aecc-6f8cc824c015" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, long-term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b108ce8-6a49-44b4-a92a-947b96f2be1d" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f4fa3b4-0657-414b-8a56-50a791732f03" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac05bc6c-eddc-4cc5-a783-7924645add4a" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c7cde41-cbe9-46f3-bed0-e425dd22badd" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13becb46-7267-408a-b935-eec3348dc7ae" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:LeaseExpenseTableTextblock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental lease expense related to leases is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">13</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.792%;"/>
        <td style="width:1.939%;"/>
        <td style="width:1%;"/>
        <td style="width:10.916%;"/>
        <td style="width:1%;"/>
        <td style="width:1.939%;"/>
        <td style="width:1%;"/>
        <td style="width:10.416%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79cb0979-a860-4fea-901e-b5dfdb9d3c7d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c45c387-949a-4c22-a1e9-ac373ee5942b" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd4b7bac-bd0e-4b5a-9f76-3dfba16f6f1b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ca2c7d0-d913-453f-99db-0a660f36a273" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faec340f-b632-4906-9d4a-e3b094ff3904" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the year ended March 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.235%;"/>
        <td style="width:6.564%;"/>
        <td style="width:1%;"/>
        <td style="width:26.202%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows for operating lease</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c5161fb-5324-41e9-832d-2f12a6b7240a" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_35eb60b8-303d-4e25-9601-0886d5998462;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9d86de-aa35-4938-9622-a4b5902846db" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the Company's lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As of March 31, 2024, there were no future minimum lease payments.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80656a46-cb17-48f1-9fec-a1fc4245b81d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Shareholders' equity</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Authorized capital stock</span></p><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class A common shares ("Common Shares"), voting (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e19a8a-dfd5-4f5f-881d-2983902aa5ee" contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e" name="acst:CommonStockVotesPerShare" unitRef="U_Vote" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote per share), participating and without par value. As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16885fc0-72dc-46d8-a853-afe8fcac6684" contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d2e35779-9d40-4b59-9fb3-2b3c45460c77" contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,399,404</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares issued and outstanding. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class B common shares, voting (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5b9b467-7475-46fd-b792-eeb13cc166dd" contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459" name="acst:CommonStockVotesPerShare" unitRef="U_Vote" decimals="0" format="ixt-sec:numwordsen">ten</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> votes per share), non-participating, without par value and maximum annual non-cumulative dividend of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b291eccb-18e2-4814-b3fa-5ff48893fc3c" contextRef="C_7da55c0e-6ba5-4e9e-acd7-dac4568958a6" name="acst:CommonStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the amount paid per share. Class B common shares are convertible, at the holder&#8217;s discretion, into Common Shares, on a one-for-one basis, and Class B common shares are redeemable at the holder&#8217;s discretion for CAD $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cda849be-1ba2-4d57-b6fe-24029b5699ce" contextRef="C_7da55c0e-6ba5-4e9e-acd7-dac4568958a6" name="acst:CommonStockRedemptionPricePerShare" unitRef="U_CadShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to certain conditions. As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3aefeff5-bb1e-4bdd-9e98-6e772dd8396a" contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2227e7d4-cd34-4c78-a93e-1011dee774bf" contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B common shares issued and outstanding.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class C common shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d54c5e4-80f3-4dc5-870a-165ff1419ad5" contextRef="C_940b8ef1-f85d-4c61-b94a-bffc507b9e8b" name="acst:CommonStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the amount paid per share. Class C common shares are convertible, at the holder&#8217;s discretion, into Common Shares, on a one-for-one basis, and Class C common shares are redeemable at the holder&#8217;s discretion for CAD $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1c3f8a-f605-4f90-8bf0-5ab6d446033e" contextRef="C_940b8ef1-f85d-4c61-b94a-bffc507b9e8b" name="acst:CommonStockRedemptionPricePerShare" unitRef="U_CadShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to certain conditions. As of March 31, 2024, there were no Class C common shares issued and outstanding.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class D and E common shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fa7f6cf-7b2f-47cd-a844-67fec8cdf342" contextRef="C_0e9c3508-8c04-4935-ae0d-c619d66df6eb" name="acst:CommonStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80aeda92-656f-4e58-90bc-efbf2e10dcd9" contextRef="C_ecbe80f6-d6d3-483e-97b0-82b3081bda3a" name="acst:CommonStockDividendRatePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the amount paid per share. Class D and E common shares are convertible, at the holder&#8217;s discretion, into Common Shares, on a one-for-one basis, and Class D and E common shares are redeemable for the price paid for such shares, plus a redemption premium described in the Company's Articles of Incorporation, as amended, at the holder&#8217;s discretion, subject to certain conditions. As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f3ea7ee-ca2e-42e2-a3d4-f036de88f8f8" contextRef="C_8b87163d-8c7c-418f-bf82-a0fb5e3ddc84" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class D or E common shares issued and outstanding.</span></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors in connection with a private placement of the Company's securities (the &#8220;Offering&#8221;). Pursuant to the Purchase Agreement, the Company agreed to offer and sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e98117c0-417b-4450-a62b-d77f5471c235" contextRef="C_e235b4c9-4adf-47cc-a3e3-c01fd379a76e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,951,371</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b54dd909-2a6e-4c73-baf4-d918e28d5158" contextRef="C_f951dabc-33fe-47d3-a362-7aa2e816d7cb" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">1.848</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share and Pre-funded Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_907538a8-78df-4825-8e8e-38c0dc861dbc" contextRef="C_ee140fde-ec8b-4597-a458-9c1426a405b4" name="acst:StockIssuedSharesWarrantsExercisableShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,106,853</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at a purchase price equal to the purchase price per Common Share less $0.0001. Each Pre-funded Warrant is exercisable for one Common Share at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ac9b014-3cec-4b45-adc0-0e308a67629c" contextRef="C_ee140fde-ec8b-4597-a458-9c1426a405b4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share, is immediately exercisable, and will expire once exercised in full. Pursuant to the Purchase Agreement, the Company also issued to such institutional and accredited investors Common Warrants to purchase Common Shares, exercisable for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d282019-fe01-4852-8eba-37d97d1fc2a0" contextRef="C_f951dabc-33fe-47d3-a362-7aa2e816d7cb" name="acst:StockIssuedSharesWarrantsExercisableShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,536,391</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares. Under the terms of the Purchase Agreement, for each Common Share and each Pre-funded Warrant issued in the Offering, an accompanying five-eighths (0.625) of a Common Warrant was issued to the purchaser thereof. Each whole Common Warrant is exercisable for one Common Share at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d36413c2-fafd-4314-9275-6f91fb0fe876" contextRef="C_ac3b545c-c1db-46c4-aa78-4fb7c590da00" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share, is immediately exercisable, and will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company&#8217;s product candidate GTX-104 or (ii) five years from the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Offering closed on September 25, 2023. The Offering included the issuance of Common Shares, Pre-funded Warrants, and Common Warrants to related parties Shore Pharma LLC, an entity that was controlled by Vimal Kavuru, the Chair of our Board of Directors, at the time of the Offering and SS Pharma LLC, resulting in proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7afb694-0392-4366-ae1c-8a3eca189249" contextRef="C_46e5f6eb-b6a7-4f98-a854-ed3f302b7714" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The net proceeds to the Company from the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95dd7046-4310-44a5-b2c0-3786e5637dfc" contextRef="C_545ec182-f542-4e2b-9855-4b55b11f191b" name="acst:ProceedsFromIssuanceOfCommonStockNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,338</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after deducting fees and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-the-Market (&#8220;ATM&#8221;) Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2020, the Company entered into an amended and restated sales agreement (the &#8220;Sales Agreement&#8221;) with B. Riley FBR, Inc. (&#8220;B.Riley&#8221;), Oppenheimer &amp; Co. Inc. and H.C. Wainwright &amp; Co., LLC (collectively, the &#8220;Agents&#8221;) to amend the Company&#8217;s existing ATM program. Under the terms of the Sales Agreement, which had a three-year term, the Company could issue and sell from time to time, Common Shares having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e49c9a1-16e4-42ee-a09f-c6e7c2c39c50" contextRef="C_d3cca4b1-352c-4004-9c30-f04a2f7b79e5" name="acst:AtthemarketSalesAgreementCommonStockMaximumAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through the Agents. Subject to the terms and conditions of the Sales Agreement, the Agents would use their commercially reasonable efforts to sell the Common Shares from time to time, based upon the Company&#8217;s instructions. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce25f896-a1de-40da-be30-1a8c7247ce09" contextRef="C_312bbb54-59d2-4300-b0d4-eef44282cdc6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> obligation to sell any of the Common Shares and could, at any time, suspend sales under the Sales Agreement. The Company and the Agents could terminate the Sales Agreement in accordance with its terms. Under the terms of the Sales Agreement, the Company provided the Agents with customary indemnification rights and the Agents were entitled to compensation at a commission rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05186156-45b0-458b-8a7a-c3f326f116ef" contextRef="C_f8a2346d-c203-40c2-a5ab-e2216e6c3d61" name="acst:AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds from each sale of the Common Shares. The Sales Agreement expired pursuant to its terms on June 29, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdac8770-2c49-4ace-9abb-128309cc0c54" contextRef="C_b379b9ec-28ea-4a40-b95f-8839111c5b29" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares were sold under the ATM program. During the year ended March 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c2fbded-ed25-40d3-ae02-8b627da96571" contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">54,108</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares were sold for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_408e6049-2b61-4035-9def-39842cefa368" contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d" name="acst:ProceedsFromIssuanceOfCommonStockNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with commissions, legal expenses and costs related to the share sale amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c8c728f-4d2e-480a-abd4-08b4289dcdba" contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Common Shares were sold at the prevailing market prices, which resulted in an average price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d277fd60-53dc-4c18-b704-ac056663f377" contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d" name="acst:SaleOfStockAveragePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 9, 2023, warrants issued pursuant to the Company&#8217;s May 2018 Canadian public offering to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fc3cf13-bd9f-415b-b9af-ccc3a970fcd1" contextRef="C_1be0d73c-b1f4-423e-aa12-2a42820f8ecb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">137,370</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at an exercise price of CAD $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4492d757-2728-47c5-9a39-77303fd2a72b" contextRef="C_1be0d73c-b1f4-423e-aa12-2a42820f8ecb" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_CadShare" scale="0" decimals="2" format="ixt:num-dot-decimal">62.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As further discussed above, on September 25, 2023, the Company issued Warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6349346e-afe1-4697-a898-37957ba0f41f" contextRef="C_0f687fe2-5a55-4bed-a8a0-8cc695040f45" name="acst:StockIssuedSharesWarrantsExercisableShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,643,244</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares in the Offering pursuant to the terms of the Purchase Agreement entered into with certain institutional and accredited investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Common Warrants issued as a part of the Offering are derivative warrant liabilities given the warrant indenture did not meet the fixed-for-fixed criterion and that the Common Warrants are not indexed to the Company&#8217;s own stock. Proceeds were allocated amongst Common Shares, Pre-funded Warrants, and Common Warrants by applying the residual method, with fair value of the Common Warrants determined using the Black-Scholes model, resulting in an initial warrant liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3ce7134-7725-44cb-90ab-cd61f0cac685" contextRef="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,631</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff548283-8d26-46fa-9b9c-bf212545825b" contextRef="C_8bf52d38-93c0-4416-ab44-ea0729cc861e" name="acst:PaymentOfIssuanceCostsCommonWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of issuance costs allocated to Common Warrants. Accordingly, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_551bcbf6-c313-49dc-956e-e16197b4c49d" contextRef="C_d2dac555-c59d-4a9e-b6eb-37a8e4c83dd5" name="acst:ProceedsFromCommonShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,822</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7319e40-30c8-4576-91e5-94991b3cc60d" contextRef="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3" name="acst:ProceedsFromCommonShares" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,047</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of gross proceeds were allocated to Common Shares and Pre-funded Warrants, respectively; and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daa2e5f9-4ccc-4dfd-8f17-f42fa8505515" contextRef="C_d2dac555-c59d-4a9e-b6eb-37a8e4c83dd5" name="acst:PaymentOfIssuanceCostsCommonWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b3468a7-4c15-4597-ad9e-2a9c14d24804" contextRef="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3" name="acst:PaymentOfIssuanceCostsCommonWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of issuance costs were allocated to Common Shares and Pre-funded Warrants, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03ef08bb-81cf-4cd8-924e-b449c7d6be20" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:</span></p><p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.093%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:12.823%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:16.063%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d746cbeb-7243-47ec-9e29-08b9c61aa68e" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5667fc5-ed46-4e02-9475-32cfa7b87ac8" contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued during the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d828868-bfc3-4945-9314-a0518334a72b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,631</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ba49b4d-ee1a-4100-989e-9b8cbe6c95e8" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0114d19e-6f70-440e-bdb4-d3be58837d85" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,728</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d5b5456-bec4-46e8-a32d-0a1665dec66e" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_722db4e3-2bb4-4fda-aa86-9430a89813c0" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df4c70dc-23f7-4288-9330-58149e802f26" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d0339a6-2442-439e-af2c-295eec604dff" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrant liability was determined based on the fair value of warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) five years from the date on issuance.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">15</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.806%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.558%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.558%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 25, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecdc3257-0028-4710-a19f-62ca53254a06" contextRef="C_1756eb23-2e0b-48cb-9d20-d1c0db7eddbb" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5050435c-ed16-42bb-970b-efbe6e970490" contextRef="C_3d6702e5-9571-48ee-81a7-d74ef46344e1" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">4.69</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c7b3fae-382a-40af-969b-4934b6a8b523" contextRef="C_6bab073f-8e03-425b-882d-ee0197687a29" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">1.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ccdc7e6-f912-4155-9406-7e2c2e937ec9" contextRef="C_1b554ace-39ee-4357-9ded-83838c05db04" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">3.43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected warrant life</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de062e5-9442-4883-a61e-f0ddb7c5196f" contextRef="C_dce797e5-6a6c-417b-b7d7-6195591f7d0e" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">2.54</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddb1c87f-fc42-4447-b0a8-c84f8465dcd9" contextRef="C_0a51f099-2623-4ca7-bec5-744e473c2a07" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">2.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3de93ea5-e3f7-4075-bac6-bdd8adadb5be" contextRef="C_9de35410-3114-4f88-8550-bba2bee392fb" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73eb6b89-448a-454d-a293-e12a54796947" contextRef="C_684d5200-1c42-4272-8ca3-5608277c5be4" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8822377b-29b7-4251-b937-189750368863" contextRef="C_15d1ffe6-b2f5-4746-93b3-3b9ddcb8c862" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">80.90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b407157c-81be-408e-a090-6896ef040e9f" contextRef="C_77630b6d-9f63-49f0-aacd-228e5510fa1f" name="us-gaap:DerivativeLiabilityMeasurementInput" unitRef="U_USD" scale="2" decimals="0" format="ixt:num-dot-decimal">85.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions were prorated based on the probability of the warrant liability expiring on the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 and of it expiring on five years from the date of issuance. The weighted-average fair values of the Common Warrants were determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5390b8d0-1f6d-44ad-bf46-26b10aae63bf" contextRef="C_b9938b6f-8e2c-45cd-b9a7-e5a38fc58fcd" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc1f4499-dc5c-4cfa-935f-cc4aa3506f01" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Warrant, as of September 25, 2023 and March 31, 2024, respectively. The risk-free interest rate at the issue date and on the reporting date of March 31, 2024 was based on the interest rate corresponding to the U.S. Treasury rate issue with a remaining term equal to the expected term of the warrants. The expected volatility was based on the historical volatility for the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, the Company had outstanding Common Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332a6fbe-c1b5-4341-a44a-d60b5a6ad302" contextRef="C_2f8fe5fb-ef11-4634-a474-acca8f534421" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,536,391</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90e3156a-9ce7-4b78-8b65-429caf1e9746" contextRef="C_2f8fe5fb-ef11-4634-a474-acca8f534421" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all of which were classified as derivative warrant liability. At March 31, 2024, the Company had outstanding Pre-funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c277107-0ec7-4cf2-a507-cbd5483c861a" contextRef="C_bd8d29d2-fb73-44c0-8b8f-697d5ef239fa" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,106,853</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d34ab21-a4fe-4a8c-be22-589e78f2e190" contextRef="C_bd8d29d2-fb73-44c0-8b8f-697d5ef239fa" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all of which were classified within shareholders' equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f732fd72-aa18-4ffd-ba85-9fc187876fa2" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ClassOfWarrantOrRightExercisedDuringPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a7ed3d3a-77ed-411e-956e-c0026ae79398" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ClassOfWarrantOrRightExercisedDuringPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants were exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30e5ebfd-56af-47ef-be6e-1f2850a61e6a" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stock-based compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, the Company had in place a stock option plan for directors, officers, employees, and consultants of the Company (&#8220;Stock Option Plan&#8221;). As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_522d0f12-26b0-41c0-8d2c-06d0707366cb" contextRef="C_64eefdf8-8725-4487-9627-312c2276a125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">738,725</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> awards available under the plan for issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Stock Option Plan provides for the granting of options to purchase Common Shares. Under the terms of the Stock Option Plan, the exercise price of the stock options granted under the Stock Option Plan may not be lower than the closing price of the Company&#8217;s Common Shares on the Nasdaq Capital Market at the close of such market the day preceding the grant. The maximum number of Common Shares that may be issued upon exercise of options granted under the amended Stock Option Plan shall not exceed 20% of the aggregate number of issued and outstanding shares of the Company as of July 28, 2022. The terms and conditions for acquiring and exercising options are set by the Company&#8217;s Board of Directors, subject to, among others, the following limitations: the term of the options cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16a26f4a-c701-4066-92e7-af928dca8385" contextRef="C_c11690fb-a2e6-428a-b417-46b840d84bbd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and (i) all options granted to a director will be vested evenly on a monthly basis over a period of at least twelve (12) months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period of at least thirty-six (36) months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total number of options issued to any one consultant within any twelve-month period cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f2e9dfc-9d14-4e53-bbb3-811984c6ffb0" contextRef="C_10f930e5-d54c-408c-9930-ba4f2a0de948" name="acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s total issued and outstanding Common Shares (on a non-diluted basis). The total number of options issued within any twelve-month period to all directors, employees and/or consultants of the Company (or any subsidiary of the Company) conducting investor relations services, cannot exceed in the aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e9bd747-4684-427c-b859-cb87ebeb08ba" contextRef="C_5ede5bf9-460b-4689-8dc5-21171a08b231" name="acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s issued and outstanding Common Shares (on a non-diluted basis), calculated at the date an option is granted to any such person.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96deb89c-cf0f-4d0e-9a0a-e7560ee6d4ed" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes information about activities within the Stock Option Plan for the year ended March 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.658%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of<br/>options</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average<br/>exercise price</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining Contractual Term (years)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aggregate Intrinsic Value (in thousands)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0470be4d-3601-4701-94c4-da3e42fb157f" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">740,957</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1bed01f-af21-4e19-8c14-ad15f4abec3e" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.60</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_13069142-830c-446d-bcc4-7e96d8fa2bd5" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.19</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_810feec9-badf-403f-ae76-0795ade0af51" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,121</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_292843b9-d909-4744-b505-6303c05ae846" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">607,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dae2363-919b-43e4-87f2-23b3ba6e521f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f62f86f3-e301-4978-8bb7-e576fea508e4" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4308a96-32f8-4190-acbb-c8e4028aa40c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26a36488-5c72-4018-88c8-40ac7aff6bb5" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">614,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31c4aec7-788c-4688-b56e-3b73c13f80e9" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.89</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a01ddb0-649a-4c97-ac94-264ea3f9aa46" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">721,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94fd98ea-31f7-4868-baa6-c08f232d7552" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ec819210-e5a3-428a-81b3-4b9e0b7730dd" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.08</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce72484a-5c36-49a8-948f-f0cd48a2cf32" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_965aef49-d047-492b-9f3f-bf6e16de1bd6" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">312,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2256f74-5f41-45f7-9f20-d715fbc9bf17" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2e084d6f-2049-42ae-9bba-0a62c32067ff" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.84</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03bfb341-9da8-4167-8718-ecdb9047c6a7" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">16</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forfeited and cancelled options were as a result of the Company's restructuring that occurred during the year ended March 31, 2024. On July 14, 2023, the Company's Board of Directors approved the grant of options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95ac1ca4-f443-4581-bb23-c9f49739fc4f" contextRef="C_b3dbe7f3-a4f8-4b41-ba66-ea50c892e380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">446,502</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb608872-7bf6-4d86-bef1-e905dfbf2709" contextRef="C_7db0708e-187a-44e4-abc2-9ab65651e41b" name="acst:StockOptionsExercisePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share under the Company's Stock Option Plan. On December 19, 2023, the Company's Board of Directors approved the grant of options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9ba785a-0272-4859-8e75-d3d3f3d2c669" contextRef="C_3c9a0299-cb67-4749-8a76-c93fb0ab71bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">161,168</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cce1b0e3-865f-4c60-887b-7c03d229ab04" contextRef="C_a0ba7fe9-844a-4c36-9819-69617b6b15f6" name="acst:StockOptionsExercisePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share under the Company's Stock Option Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97a2f332-c9ed-49e8-b6b6-af87d5d5caab" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of awards for options granted during the years ended March 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f940eee-b29d-4f72-9679-f8dbe064ecb3" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57b61dce-7413-408d-94eb-c0c9b0da33e1" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.365%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:14.225999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:4.702%;"/>
        <td style="width:1%;"/>
        <td style="width:14.225999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d410b1c-dc22-4a2c-84b4-9ea8af57e1e2" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c51dc73-47de-46d4-ae55-42e9a8e566cf" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a145051-715a-49bb-909f-095a77f5f610" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:SharesPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_823c3bd9-874e-486d-9096-b81c6cc03087" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:SharesPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8f4898-bd87-445d-b5f2-060c3cd926da" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15721004-9f9c-4f7b-b36c-cb9e3907cfde" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2dac9e8-7de5-48a7-ba33-0eeb8854ab50" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06324bcc-ccf1-43c8-a84f-008ee5855fec" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Estimated life (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e1198380-9720-4be8-8169-8a331754c0ce" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.62</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_23b3ab7e-ffa3-4944-b412-114eefe2e85a" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.73</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd74c782-44c0-4586-b6fa-8bfee3b33644" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">117.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d5bf154-7863-4d69-9c53-2a0ac3e98a71" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">117.56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aeb6ee98-e530-4e0b-a4a0-43b84c07511c" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized under ASC 718 related to the stock option plan is summarized as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_484adae7-ef82-4650-9976-449e5cc150d5" contextRef="C_06ea57a9-3a97-4d7a-9bd1-eecd71be02df" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812b5e1b-30cb-462f-b9f4-a521dfd33265" contextRef="C_05adfb7b-9ddc-4cc6-873f-b2dd8d56c9c5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e412656-610a-4048-9470-e78b2263e9b1" contextRef="C_057790a0-605f-41ca-8ce9-91d483af8647" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">697</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42f97f13-85e4-406b-8869-55c60cf86a9a" contextRef="C_60ef9157-75f4-4a1e-b25c-2842ef0acc4f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17f830ce-a7b7-4c0f-8327-c03e39a9c85f" contextRef="C_1661c524-65aa-434f-8b9c-ae631dd5b8bf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea97d6f-eccd-4915-9f5f-c0f24c7341e0" contextRef="C_ba9a56ec-eeb4-420e-a520-410844ea86c8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63d34cb2-d5a4-473c-8b73-544e4ff15ac3" contextRef="C_c11690fb-a2e6-428a-b417-46b840d84bbd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">913</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d8e7475-b217-4879-8bf2-9830050be4d3" contextRef="C_158d50e3-c6b0-4b7c-9cec-bc5c37a93fe6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25ae8449-c375-4d37-8586-59af6b036efa" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">467</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total unrecognized compensation cost, related to non-vested stock options, which is expected to be recognized over a remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8790623a-24a4-4c92-a471-7bc28e0b2da3" contextRef="C_c11690fb-a2e6-428a-b417-46b840d84bbd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity incentive plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company established an equity incentive plan (the &#8220;Equity Incentive Plan&#8221;) for employees, directors, and consultants. The Equity Incentive Plan provides for the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371a7a72-9da0-42c4-aaf5-c90302554fbe" contextRef="C_177feeb1-7b04-48ce-809a-866ea0b27de7" name="acst:IssuanceOfRestrictedShareUnit" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,483,140</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> restricted share units, performance share units, restricted shares, deferred share units and other stock-based awards, subject to restricted conditions as may be determined by the Board of Directors. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ca698cd-dd09-4cc9-bf66-7e8f721aa6d6" contextRef="C_2b3364b9-6260-4b70-b7c1-3323e1ed6f70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such awards outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_870c3b04-8853-4fa9-b148-956658bb2207" contextRef="C_177feeb1-7b04-48ce-809a-866ea0b27de7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation was recognized for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af51f1f3-f0d1-4730-9fc6-47b2d110a98f" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Loss per share</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has generated a net loss for all periods presented, therefore diluted loss per share is the same as basic loss per share since the inclusion of potentially dilutive securities would have had an anti-dilutive effect. All currently outstanding options and warrants could potentially be dilutive in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91c24cda-deef-4752-b205-7879b2d93ce8" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential Common Shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:13.383%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:13.383%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_625fe63d-8baa-4f1f-8173-61be353da0b3" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">721,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4019089-c329-47d2-b224-5ea8ac0716e3" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">740,974</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2023 Common Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df2a4074-bdb5-4f2d-9992-71a2946c77e1" contextRef="C_b91b8c0b-647a-4df0-b491-de3b7226a402" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,536,391</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_352cb096-4430-417c-a7d5-6a7ebd7b4fa5" contextRef="C_705dbe6d-a676-4e14-8f68-1447dd74db79" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2018 public offering warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_654d5580-812a-4b4a-82b8-bb39860c55f6" contextRef="C_9d1b1042-fd07-435a-9f9e-ae6291bd7e13" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85c2a17a-4969-409d-80fc-df653ed68448" contextRef="C_faccd42d-8b25-4802-9d19-2b48cbbde167" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">137,370</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share is calculated based upon the weighted-average number of Common Shares outstanding during the period. Common Shares underlying the Pre-funded Warrants are included in the calculation of basic and diluted earnings per share.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_862e7ab9-3a34-4d19-a3f2-9b5b562b0e0d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef10f918-2889-4654-89a5-8ce35373b322" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax (benefit) expense:</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_466102b6-644a-412f-93a0-a0484271c850" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0978d29-704f-44ca-bfe4-59402d0594b6" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_322ca3b1-71eb-4c97-8ffc-4068c75ff74d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,834</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_963f901f-7e5e-4d45-9d85-c8e45e7d567d" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0fb6690-9bcc-4f71-8966-cefe4b434371" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,832</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f46350b9-8752-4d8b-9c85-38201db7b234" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5692daf5-8440-42bb-81c0-5d9d609de661" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation between tax expense and the product of accounting income multiplied by the basic income tax rate for the years ended March 31, 2024 and 2023 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at Canadian Rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc016227-10dc-4636-aa4b-30633ab1da54" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,891</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_060e2710-94ab-469f-af5d-abc151a36aad" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,772</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Difference in foreign tax rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89d3def7-610e-4f99-bf23-ce830902ba07" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69ccffe6-51a2-45d2-abae-0d148e73b24c" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e39ee98-2d37-42b3-a867-058087540b5b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9f40f38-9b9a-40e1-ac9e-7908b5cd37de" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible change in fair value of warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49507995-bc5e-426b-8239-bd1761a892db" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:IncomeTaxReconciliationNondeductibleChangeInFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_209038bb-61e9-467a-b1a7-24855688f644" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:IncomeTaxReconciliationNondeductibleChangeInFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible transaction costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96cbc6fd-9e7c-4d66-8421-827bddd96701" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e3f0496-6c3a-4ecc-97b6-f958e0eb9a16" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible goodwill impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84a611c8-ab29-4c5b-8b12-2031ede759dc" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51cf58ca-cd82-4ff3-8403-36288083918d" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-deductible items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_015ee501-cbd4-4ba8-97f7-76a2e5bdb964" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b37270c-29f8-44ce-adff-c2a5aff6a284" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-refundable federal investment tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_220f7619-f6f1-4a9e-97ba-b0eb51b1110d" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:NonRefundableFederalItc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5842937c-13e1-44a1-9f76-a0ed39042d1a" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:NonRefundableFederalItc" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">642</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State non income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e37e043-bfd2-4d01-89b8-6eb22ae9c8be" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:StateNonIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41e342fd-dc08-480b-acb2-999abca94a61" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:StateNonIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in tax rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77aa42d1-b398-4521-90b5-48895b4ff6ad" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ChangeInTaxRates" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">486</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d45d34e-f984-40db-b013-058dafe61091" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:ChangeInTaxRates" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_003df1ef-5c42-4de6-b290-296372e3312e" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:IncomeTaxReconciliationUnrecognizedTemporaryDifferences" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3b1598e-9498-47b2-a269-c83fd741de1d" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="acst:IncomeTaxReconciliationUnrecognizedTemporaryDifferences" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,263</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c672d5f-d767-4e68-b261-807809237022" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23949054-8d71-4597-98bf-770950add215" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcb845de-9223-4a77-a285-a62aa4b8bf24" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,832</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93a9b9a3-2093-4520-8ada-9b13812568af" contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2210309b-533a-4792-9fa5-f63986a09702" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net deferred income tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, and 2023 were comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax losses carried forward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dbc0412-71b7-475a-b78f-8ddd3fe5bd6d" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,659</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f2dd6d9-3b66-46af-9988-57b58c88b12b" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a57028-81da-4ffa-8a42-6a08000c9ed7" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:DeferredTaxAssetsResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6be1afca-1cde-459a-a5ec-8a79041fe190" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:DeferredTaxAssetsResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property, plant and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e91a906b-1d0a-4d53-94ee-80564108bd54" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_985f9c98-88b6-49ac-9771-dbf3ff9c5f56" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a4251fa-a13c-4d9a-a7ec-ac04d712f6ce" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cccfb39-7ffd-4de1-992e-1a3ad3db46a3" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f173424-0f5b-4ba8-b7bf-4e2e2330f466" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:DeferredTaxAssetsOperatingLeaseRightOfUseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4d50446-2cff-42cf-aa8e-8dff4ea86c10" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:DeferredTaxAssetsOperatingLeaseRightOfUseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9381bd9-6f61-4c77-a83d-bcf813cdc25b" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:DeferredTaxAssetsFinancingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_331485ee-c4d1-4a8b-94de-e5bc63393aa4" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:DeferredTaxAssetsFinancingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net federal investment tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_433de766-5749-4677-99ac-7fbda787eb2d" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:NetFederalInvestmentTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b33c5f1a-5eb2-47e7-8425-2ec7e6aeaa30" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:NetFederalInvestmentTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,950</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other deductible temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7f520d3-e98f-4b40-8ce5-6a4e831c569d" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d92c162e-96d1-4d25-ade3-70655854b61c" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred income tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ccb6f08-44ad-45e9-8f6a-b343d31ce0a5" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,139</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_042819bb-25c1-4553-9de9-11db6ce6de2b" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed707819-1ecc-42b5-a916-908474fc5fbc" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,284</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06390abc-06a5-4526-9856-503341375046" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15edd0d0-8bb8-447a-b001-ca4e623949e5" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,369</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_040f707b-b53f-4f54-8d37-f364a1cdb2d6" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,198</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e475003a-3d0a-48ff-bcc3-c063ebd1ecbc" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:DeferredTaxAssetsOperatingLeaseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a63e1d30-a46d-4785-a1b8-0d2d8125df98" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:DeferredTaxAssetsOperatingLeaseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other taxable temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_636dc255-d3a3-4393-8752-47bf52a5d998" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b58711d8-b3ec-41ac-80bb-c7bd9253fad3" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32eaa2d0-2223-4f56-a805-d3c76b43f56c" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,369</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b3836c6-e73a-4509-b682-f9b05ece7217" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,326</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93452294-71ee-406f-ab94-312ce52a2491" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,514</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1150a054-e245-4efb-81fc-8e6051044257" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,347</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea58e452-c9c3-4623-b5b4-c5f63efcdc23" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" escape="true" continuedAt="F_ea58e452-c9c3-4623-b5b4-c5f63efcdc23_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">18</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years&#8217; taxable income, were as follows:</span></p><p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.552%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.302%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.062%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.082%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provincial</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax losses carried forward</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00bff84b-8021-496c-bf3d-9d624b1a98e3" contextRef="C_422f9f9e-ac11-4222-817c-49c40bebb380" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">571</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_815aeaab-9b34-483d-b26f-ac780d989ccb" contextRef="C_b2555b6e-b437-4ba8-9563-def690c61ff9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">571</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d065580-d918-4a59-82cb-b59308d0d90c" contextRef="C_4d2dbb68-f420-44ed-9aef-e0dcbd842219" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e20bbce0-3ed8-4881-a0fc-eba023a04c99" contextRef="C_84b40618-5675-4dc0-9e64-a517f28f6d53" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3df05750-edeb-4068-be62-d9ba1172545b" contextRef="C_31aacf07-7739-466d-9474-24f3d1e9ad89" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fda3a1b6-7999-42d0-b9a9-aeb7e2e50a76" contextRef="C_c74a6eaf-0060-4554-9488-83e6d43a52c0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,651</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2031</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66419725-6338-4a5b-8ff4-fe7028c6d0b1" contextRef="C_02572285-4b65-41c8-8fa4-f3dc4a164d60" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,810</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1463a0a0-8205-4414-b6be-ce9d20bece1a" contextRef="C_005474d3-953e-419e-8e1d-8a618e56041f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,794</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9770955-5715-47a9-9fee-8b83158c913c" contextRef="C_36c24d42-fa01-40ca-a916-10d853ad79e5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,484</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9991ee92-0203-4551-ae02-75f136d52468" contextRef="C_3d32a6e4-7a1f-4468-9246-d1db4a2f87d2" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2033</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bc8fe74-4ae8-4574-8d85-199ed3015615" contextRef="C_b4569b27-2312-4bd8-be26-e61127f1dfc1" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24148da4-5172-4967-9d07-54e0e2324c65" contextRef="C_7597480c-39df-45e1-9922-7010d9c4c72a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2034</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fd95855-5df7-4a0a-8590-5a41bf00a9f8" contextRef="C_5a12b334-af4e-4c1d-ad64-bc70258d8ef0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,678</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b1c4483-1605-4bea-baaa-130c780dee31" contextRef="C_1a24fef3-a068-4ca4-8dac-1a23822d569c" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,568</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2035</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cf2c1ae-1f18-4ddd-93ed-a09de4ea04cc" contextRef="C_76b72763-8a2d-4d7e-aea2-4b623c8e60f6" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2246d5b6-5069-4948-b33b-b4c725b5bcc4" contextRef="C_0a03babd-18d1-4097-a9d4-1044dab8ecf4" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2036</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e117e19-a064-403f-b1d8-5609dbb2592b" contextRef="C_d951ff5b-4e5d-465a-855a-f551e8825d5b" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,470</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0693be59-69e7-4c3c-9613-815203b7e985" contextRef="C_269f269e-95bb-4430-b89f-d436cbeaad91" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,371</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2037</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b5eb55c-f156-42fc-9be1-f2aa564d807c" contextRef="C_f166744b-f3f7-45e1-bdd4-2768e6ef6d20" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_994d3ad0-e40b-40ea-91ad-538bb958fa48" contextRef="C_d43202e2-7d88-42ec-9006-9b5d92669112" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2038</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b11d2ede-91b1-427a-ae30-d76f7ac89963" contextRef="C_dc8f5eed-e387-4957-ae1f-a00211fe78a5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,856</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ef4976d-65c9-43e2-80b1-baa932065aa5" contextRef="C_039d64a4-88b3-4aa8-9f0d-bfbbffcaad9d" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,821</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2039</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3415dbe-e0a3-4d5a-8c27-72636bf00c93" contextRef="C_91f3906a-c565-4e1c-b09c-103612aaa49a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a3f1917-73ad-4e6d-bd86-7c97e3e574f1" contextRef="C_32f95ce9-670d-452f-9fc1-58e64efe3142" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2040</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_267ecc56-6fd2-4264-acfa-8d6312884272" contextRef="C_c869cf00-c0af-4b98-825d-27c8d211e38b" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,576</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8325669-44cb-4fc8-b7d0-de310508a985" contextRef="C_893afca7-27f1-4faa-8652-ebeea1283a01" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2041</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38d49d49-f55f-4be2-8931-04d38c7fcbd7" contextRef="C_8030229f-2b04-4173-a95b-ae174f4c06f6" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39087ccc-59db-4baa-b826-f2fbcdb80b96" contextRef="C_56f5d179-a218-4d6e-93bf-c19733becaf9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2042</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b20b56-ec9a-4ace-949a-37325210333d" contextRef="C_4cec2bdb-71d8-4eef-a7e4-2a57bd60925d" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,417</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00d3d89c-75e5-4a5d-a4b5-c2aaea459c52" contextRef="C_c04ee66d-800b-4148-956d-a12fb82c62b1" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,416</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2043</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1433b98-2097-4d52-9a93-c01d66f102e5" contextRef="C_4e7ece24-7a7f-426a-bbb4-52d87842bae5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,568</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b67d918-aba2-4c72-b2eb-cca198acea72" contextRef="C_97daaea2-edbc-4684-b715-e135f9491b08" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2044</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e9b7de3-78b2-46c3-a319-343ccbf0a92b" contextRef="C_ec4dd3d8-0001-4568-9915-fb4ca638ab8e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b8f95c5-b7b0-4382-9f44-0202c5b505bd" contextRef="C_054f3d0b-11e9-4f9b-8d91-3b83f491df0f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No expiry</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_061f6c13-939c-4333-835b-73691635a655" contextRef="C_43242c92-e78b-4540-8623-9f75dbf73cb9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,443</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db346469-1519-4f64-ae31-ce6a2111bf54" contextRef="C_2de077db-85fa-42b0-920e-a1103a07c7f4" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,695</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_370e0cb6-4dc8-4347-b8d1-3b3fc6c02cc6" contextRef="C_b74594a6-c75b-40ac-87aa-02fea55113f7" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,205</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44f1a04d-ab5b-4e67-a2a8-dcde12fe9d61" contextRef="C_6a6f8b28-b6c2-44d2-94e9-944ce97688d9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,443</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses, without time limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3db7e90f-9a2d-4ee7-bf52-591d9cde8bcc" contextRef="C_46a52c6b-9951-44a8-8b8a-3cb9cb3e2439" name="acst:TaxCreditCarryforwardNotSubjectToTimeLimitation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a45b06c8-ddb5-45f8-98be-27024136eaa7" contextRef="C_f8fa8a4a-743c-49ee-8a05-07e36d9b8934" name="acst:TaxCreditCarryforwardNotSubjectToTimeLimitation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,887</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97ab70cf-3f66-48de-876f-54e663e74e4c" contextRef="C_2de077db-85fa-42b0-920e-a1103a07c7f4" name="acst:ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,922</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_237d0d44-da18-487f-b3dc-487c4436e512" contextRef="C_b74594a6-c75b-40ac-87aa-02fea55113f7" name="acst:ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized tax benefits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect a significant change to the amount of unrecognized tax benefits over the next 12 months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter the timing or amount of taxable income or deductions, of the allocation of income among tax jurisdictions, and these adjustments could differ from the amount accrued. The Company&#8217;s federal and provincial income tax returns filed for all years remain subject to examination by the taxation authorities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government assistance</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government assistance is comprised of research and development investment tax credits receivable from the Quebec provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_120e1218-7603-4dcc-8d04-6ae0ca2348ef" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="acst:ScheduleOfGovernmentAssistanceTableTextBlock" escape="true" continuedAt="F_120e1218-7603-4dcc-8d04-6ae0ca2348ef_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the years ended March 31, 2024 and 2023, the Company recorded ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4b53243-b9a1-4c80-a9ba-86b632fa71c4" contextRef="C_e5dad982-0286-46ce-aa2c-9586c4730f1e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3551d3c3-344e-49ac-a2c8-799d2043bed5" contextRef="C_88cfac6a-e085-4d1e-9bee-16ee91a78d75" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, as a reduction of research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_120e1218-7603-4dcc-8d04-6ae0ca2348ef_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.463%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b380a90-2b22-486c-b398-1c3bab1326d6" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="acst:InvestmentTaxCreditReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">356</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbf656be-72ce-4374-93fe-73093a2d3b32" contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386" name="acst:InvestmentTaxCreditReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ea58e452-c9c3-4623-b5b4-c5f63efcdc23_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized Canadian federal investment tax credits may be used to reduce future Canadian federal income tax and expire as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">19</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.36%;"/>
        <td style="width:1%;"/>
        <td style="width:16.403%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2029</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ba9341e-3dcd-4c8f-99cf-087ca8042f82" contextRef="C_3c620743-7648-4a40-9f52-ad9e1ce7c425" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8ab8348-293b-468e-b889-b51e859ec3a9" contextRef="C_349e1080-b426-4ed9-a578-476efce50cf6" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2031</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ef14aa8-7540-4201-8736-af891556d935" contextRef="C_23c5dc6d-7785-4018-a4a0-3981b25c8bab" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9cc4717-be8c-463b-94dc-851ea7e235c1" contextRef="C_fea751d3-7614-4442-a3db-d6540fa51879" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2033</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1654673d-4eb2-42b5-be1c-b3f2c979d4e0" contextRef="C_f61b02f5-57f3-4c12-8cf6-ac25efbcbdaf" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2034</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dbdf802-3283-4e9a-8030-56000f06a4f6" contextRef="C_8187204f-303d-4869-a819-a4eb7d6028a3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2035</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcd4efc7-78ba-4790-a759-3525b7f8f6b5" contextRef="C_2b13b7d2-4aec-4346-9923-ef74e0f85053" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">415</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2036</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a8cb890-e8d6-4f0c-a9a1-04b2b0d2fda6" contextRef="C_4875e2a5-c34c-4bb6-b0fb-5d1c12cb8c02" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2037</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4140a65-13e2-494b-ab27-fc1463b7b71d" contextRef="C_6e6bc244-b6c6-4d8b-a073-be202a4ef494" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2038</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3df023c2-dd40-4186-b939-c8340c2a39ad" contextRef="C_7a4ddfce-2b5b-46d2-8208-60d8a22d52e4" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2039</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66094681-b8f3-4e6d-a73f-714024d5968c" contextRef="C_e835e3c2-21d5-4811-900e-7ca8a2f1e162" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">355</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2040</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a83e580a-1ef2-467d-8167-2419c7998c79" contextRef="C_f34c5198-014f-4f67-a218-f5719b424883" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2041</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a112cd4c-ba55-4614-89f9-108234316481" contextRef="C_ae60a243-9e5e-4f54-9f15-fb2ec877bb50" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2042</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d454996-a2df-4f5c-b0bf-12b46127f19e" contextRef="C_fe4fb9d8-fe31-4fd9-9a01-c7618803d7a7" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2043</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9d28030-d999-4336-94e5-a045973daf1a" contextRef="C_407b0177-7169-41e6-882e-472705b1636f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">614</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2044</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a3f80d7-0327-4221-994b-d47dc7e819fb" contextRef="C_d8143206-01c5-47e6-bf77-ccbbaa1a348e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b149d98-d84d-4697-bd7d-09aa7cef1f43" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,922</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a088edfa-6943-41d7-ab43-0b859ea9f84b" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and contingencies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development contracts and contract research organizations agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes contract manufacturing organizations (&#8220;CMOs&#8221;) for the development and production of clinical materials and contract research organizations (&#8220;CROs&#8221;) to perform services related to its clinical trials. Pursuant to the agreements with these CMOs and CROs, the Company has either the right to terminate the agreements without penalties or under certain penalty conditions. As of March 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9589f0c-c89f-40e9-b9af-ed2062611ed3" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:CommitmentsToCompleteContractsInProcess"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commitments from CMOs and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca84f847-746d-452e-b252-e1724f974c98" contextRef="C_7d5eb575-72d3-4658-845e-185baceef441" name="us-gaap:CommitmentsAndContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,020</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ommitments for the next twelve months to CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raw krill oil supply contract</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 25, 2019, the Company signed a supply agreement with Aker BioMarine Antarctic AS. (&#8220;AKBM&#8221;) to purchase raw krill oil product for a committed volume of commercial starting material for CaPre, one of the Company&#8217;s former drug candidates, for a total fixed value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae27e377-5e52-4fed-a64b-c478965dc240" contextRef="C_1bc7c602-b685-4c20-b95a-4e946d0e035c" name="us-gaap:PurchaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on the value of krill oil at that time. As of March 31, 2022, the remaining balance of commitment amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df902af5-e549-4476-b707-1e309d05d6d3" contextRef="C_84420b03-d4bf-41a4-a1dc-c3a81a813802" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the second calendar quarter of 2022, AKBM informed the Company that AKBM believed it had satisfied the terms of the supply agreement as to their obligation to deliver the remaining balance of raw krill oil product, and that the Company was therefore required to accept the remaining product commitment. The Company disagreed with AKBM&#8217;s position and believed that AKBM was not entitled to further payment under the supply agreement. Accordingly, no liability was recorded by the Company. The dispute remained unresolved as of both March 31, 2023 and 2022. On October 18, 2023, the Company entered into an agreement with AKBM to settle any and all potential claims regarding amounts due under the supply agreement (&#8220;Settlement Agreement&#8221;). Pursuant to the terms of the Settlement Agreement, in exchange for a release and waiver of claims arising out of the supply agreement by AKBM and any of AKBM&#8217;s affiliates, the Company and AKBM agreed to the following: (a) AKBM retained ownership of all raw krill oil product, including amounts previously delivered to the Company, (b) AKBM acquired and took ownership of all production equipment related to the production of CaPre, (c) AKBM acquired and took ownership of all data from research, clinical trials and pre-clinical studies with respect to CaPre, and (d) AKBM acquired and took ownership over all rights, title and interest in and to all intellectual property rights, including all patents and trademarks, related to CaPre owned by the Company. Pursuant to the terms of the Settlement Agreement, AKBM acknowledged that the CaPre assets were transferred on an &#8220;as is&#8221; basis, and in connection therewith the Company disclaimed all representations and warranties in connection with the CaPre assets, including any representations with respect to performance or sufficiency. The value of the raw krill oil previously delivered to the Company, the production equipment, and the intellectual property rights related to CaPre were fully impaired in prior reporting periods and had a carrying value of nil as of March 31, 2023. As of March 31, 2024, no liability was recorded by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal proceedings and disputes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes. The Company assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, the Company records a liability in its consolidated financial statements. These legal contingencies may be adjusted to reflect any relevant developments. Where a loss is not probable or the amount of loss is not estimable, the Company does not accrue legal contingencies. While the outcome of legal proceedings is inherently uncertain, based on information currently available, management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to the Company&#8217;s financial position, results of operations, or cash flows.  </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b626f744-09b3-4e6a-b5dd-b379f52530ea" contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reserves or liabilities have been accrued as at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9321f402-d6da-4101-b818-ae5c27ac6e17" contextRef="C_779b151d-a506-4172-855a-bc523254a908" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Restructuring Costs</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 8, 2023, the Company communicated its decision to terminate a substantial amount of its workforce as part of a plan that intended to align the Company&#8217;s organizational and management cost structure to prioritize resources to GTX-104, thereby reducing losses to improve cash flow and extend available cash resources. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0508ab2d-cde0-44fa-bdbf-bfa6d90bd73b" contextRef="C_d5755bb0-b1b3-4e1a-b0d2-be4c6caa330f" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,485</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of costs primarily consisting of employee severance costs and legal fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>acst-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acasti Pharma Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LIST OF SUBSIDIARIES</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.32%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jurisdiction of Incorporation</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent Owned</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acasti Pharma U.S., Inc.</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">New Jersey, United States</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>acst-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (Nos. 333-191383, 333-227476 and 333-274228) on Form S-8 and (No. 333-274899) on Form S-3 of our report dated June 21, 2024, with respect to the consolidated financial statements of Acasti Pharma Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Philadelphia, Pennsylvania<br>June 21, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>acst-ex23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html>
 <head>
  <title>EX-23.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-191383, No. 333-227476 and No. 333-274228) pertaining to the Stock Option Plan and Equity Incentive Plan of Acasti Pharma Inc. and in the Registration Statement (Form S-3 No. 333-274899) of Acasti Pharma Inc. of our report dated June 23, 2023, except for the effects of the reverse stock split described in Note 1, as to which the date is June 21, 2024, with respect to the consolidated financial statements of Acasti Pharma Inc. included in this Annual Report (Form 10-K) for the year ended March 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Montr&eacute;al, Canada</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 21, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>acst-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">I, Prashant Kohli, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Acasti Pharma Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Date: June 21, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30%;"></td>
    <td style="width:70%;"></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/  Prashant Kohli</font></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>acst-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">I, Robert DelAversano, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Acasti Pharma Inc.;</font></div></div>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Date: June 21, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30%;"></td>
    <td style="width:70%;"></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert DelAversano</font></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>acst-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) in connection with the Annual Report on Form 10-K of Acasti Pharma Inc. for the annual period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer hereby certifies, to such officer&#x2019;s knowledge, that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.5%;"></td>
    <td style="width:97.5%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.5%;"></td>
    <td style="width:97.5%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Acasti Pharma Inc.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.24%;"></td>
    <td style="width:20.38%;"></td>
    <td style="width:73.38%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">Prashant Kohli</font></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prashant Kohli</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 21, 2024</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Report pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed &#x201c;filed&#x201d; by Acasti Pharma Inc. for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>acst-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) in connection with the Annual Report on Form 10-K of Acasti Pharma Inc. for the annual period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer hereby certifies, to such officer&#x2019;s knowledge, that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.5%;"></td>
    <td style="width:97.5%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.5%;"></td>
    <td style="width:97.5%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Acasti Pharma Inc.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.24%;"></td>
    <td style="width:20.38%;"></td>
    <td style="width:73.38%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert DelAversano</font></p></td>
    <td style="vertical-align:top;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert DelAversano</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">June 21, 2024</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Report pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed &#x201c;filed&#x201d; by Acasti Pharma Inc. for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>acst-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Acasti Pharma Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recovery Policy</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted by the Board of Directors (the &#x201c;Board&#x201d;) of Acasti Pharma Inc. (the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">on November 10, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Company and its shareholders and essential to the Company&#x2019;s success. The Board is therefore adopting this Incentive Compensation Recovery Policy (this &#x201c;Policy&#x201d;) to provide for the recovery of certain incentive compensation in the event of an Accounting Restatement. This Policy is intended to foster a culture of compliance and accountability, to reward integrity, and to reinforce the Company&#x2019;s pay-for-performance compensation philosophy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statement of Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company is required to prepare an Accounting Restatement, except as otherwise set forth in this Policy, the Company shall recover, reasonably promptly, the Excess Incentive Compensation received by any Covered Executive during the Recoupment Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to all Incentive Compensation received during the Recoupment Period by a person (a) after beginning service as a Covered Executive, (b) who served as a Covered Executive at any time during the performance period for that Incentive Compensation and (c) while the Company has a class of securities listed on the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) or another national securities exchange or association. This Policy may therefore apply to a Covered Executive even after that person that is no longer a Company employee or a Covered Executive at the time of recovery.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation is deemed &#x201c;received&#x201d; for purposes of this Policy in the fiscal period during which the financial reporting measure specified in the Incentive Compensation award is attained, even if the payment or issuance of such Incentive Compensation occurs after the end of that period. For example, if the performance target for an award is based on total shareholder return or revenue for the year ended March 31, 2024, the award will be deemed to have been received in fiscal year 2023 even if paid in fiscal year 2024.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exceptions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company is not required to recover Excess Incentive Compensation pursuant to this Policy to the extent the Governance &amp; Human Resources Committee (the &#x201c;Committee&#x201d;) makes a determination that recovery would be impracticable for one of the following reasons (and the applicable procedural requirements are met):</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">after making a reasonable and documented attempt to recover the Excess Incentive Compensation, which documentation will be provided to Nasdaq to the extent required, the Committee determines that the direct expenses that would be paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered;</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">based on a legal opinion of counsel acceptable to the Nasdaq, the Committee determines that recovery would violate a home country law adopted prior to November 28, 2022; or </font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Committee determines that recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. For the avoidance of doubt, a restatement resulting solely from any one or more of the following is not an Accounting Restatement: retrospective application of a change in generally accepted accounting principles; retrospective revision to reportable segment information due to a change in the structure of an issuer&#x2019;s internal organization; retrospective reclassification due to a discontinued operation; retrospective application of a change in reporting entity, such as from a reorganization of entities under common control; retrospective adjustment to provisional amounts in connection with a prior business combination; and retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Company&#x2019;s Chief Executive Officer, President, Chief Financial Officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function, any other officer who performs a policy-making function for the Company, any other person who performs similar policy-making functions for the Company, and any other employee who may from time to time be deemed subject to this Policy by the Committee. For purposes of the foregoing, designation by the Board as an &#x201c;Executive Officer&#x201d; for purposes of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) shall constitute designation as a Covered Executive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Excess Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the amount of Incentive Compensation received during the Recoupment Period by any Covered Executive that exceeds the amount of Incentive Compensation that otherwise would have been received by such Covered Executive if the determination of the Incentive Compensation to be received had been determined based on restated amounts in the Accounting Restatement and without regard to any taxes paid.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation (including cash and equity compensation) that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. For purposes of this definition, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">financial reporting measure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is (i) any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements and any measure derived wholly or in part from such measures, or (ii) the Company&#x2019;s share price and/or total shareholder return. A financial reporting measure need not be presented within the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">financial statements or included in a filing with the commission. Incentive Compensation subject to this Policy may be provided by the Company or subsidiaries or affiliates of the Company (&#x201c;Company Affiliates&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoupment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years preceding the Trigger Date, and any transition period (that results from a change in the Company&#x2019;s fiscal year) of less than nine months within or immediately following those three completed fiscal years, provided that any transition period of nine months or more shall count as a full fiscal year.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trigger Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of: (a) the date the Board, the Audit Committee (or such other Committee of the Board as may be authorized to make such a conclusion), or the officer or officers of the Company authorized to take such action if action by the Board is not required concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement; in the case of both (a) and (b) regardless of if or when restated financial statements are filed.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy is intended to comply with Nasdaq Listing Rule 5608, Section 10D of the Exchange Act, and Rule 10D-1(b)(1) as promulgated under the Exchange Act, and shall be interpreted in a manner consistent with those requirements. The Committee has full authority to interpret and administer this Policy. The Committee&#x2019;s determinations under this Policy shall be final and binding on all persons, need not be uniform with respect to each individual covered by the Policy, and shall be given the maximum deference permitted by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee has the authority to determine the appropriate means of recovering Excess Incentive Compensation based on the particular facts and circumstances, which could include, but is not limited to, seeking direct reimbursement, forfeiture of awards, offsets against other payments, and forfeiture of deferred compensation (subject to compliance with Section 409A of the Internal Revenue Code).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to any limitations under applicable law, the Committee may authorize any officer or employee of the Company to take actions necessary or appropriate to carry out the purpose and intent of this Policy, provided that no such authorization shall relate to any recovery under this Policy that involves such officer or employee.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Committee cannot determine the amount of excess Incentive Compensation received by a Covered Executive directly from the information in the Accounting Restatement, such as in the case of Incentive Compensation tied to share price or total shareholder return, then it shall make its determination based on its reasonable estimate of the effect of the Accounting Restatement and shall maintain documentation of such determination, including for purposes of providing such documentation to Nasdaq.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except where an action is required by Nasdaq Listing Rule 5608, Section 10D of the Exchange Act or Rule 10D-1(b)(1) promulgated under the Exchange Act to be determined in a different matter, the Board may act to have the independent directors of the Board administer this policy in place of the Committee in any particular circumstance.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification or Advancement of Legal Fees</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the terms of any indemnification agreement, insurance policy, contractual arrangement, the governing documents of the Company or other document or arrangement, the Company shall not indemnify any Covered Executive against, or pay the premiums for any insurance policy to cover, any amounts recovered under this Policy or any expenses that a Covered Executive incurs in opposing Company efforts to recoup amounts pursuant to the Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Exclusive Remedy; Successors</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery of Incentive Compensation pursuant to this Policy shall not in any way limit or affect the rights of the Company to pursue disciplinary, legal, or other action or pursue any other remedies available to it. This Policy shall be in addition to, and is not intended to limit, any rights of the Company to recover Incentive Compensation from Covered Executives under any legal remedy available to the Company and applicable laws and regulations, including but not limited to the Sarbanes-Oxley Act of 2002, as amended, or pursuant to the terms of any other Company policy, employment agreement, equity award agreement, or similar agreement with a Covered Executive.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Executives and their successors, beneficiaries, heirs, executors, administrators, or other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy may be amended from time to time by the Committee of the Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to any Incentive Compensation received on or after October 2, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A &#x2013; BROAD FORM OF ACKNOLWEDGMENT AND AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INCENTIVE COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGMENT AND AGREEMENT</font></p>
  <p style="text-indent:6.849%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Acknowledgment and Agreement (this &#x201c;Agreement&#x201d;) is entered into as of the __ day of ______, 20[__], between Acasti Pharma Inc., a corporation incorporated under the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Corporations Act (Qu&eacute;bec)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;Company&#x201d;), and	[__] (the &#x201c;Executive&#x201d;), under the following circumstances:</font></p>
  <p style="text-indent:6.849%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Board of Directors of the Company (the &#x201c;Board&#x201d;) has adopted the Acasti Pharma Inc. Incentive Compensation Recovery Policy (the &#x201c;Policy&#x201d;);</font></p>
  <p style="text-indent:6.711%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Executive has been designated as a &#x201c;Covered Executive&#x201d; of the Company as defined in the Policy;</font></p>
  <p style="text-indent:6.711%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, in consideration of, and as a condition to the receipt of, future cash and equity-based awards, performance-based compensation, and other forms of cash or equity compensation made under the Company&#x2019;s Stock Option Plan, as amended, or the Company's Equity Incentive Plan, as amended, or any other incentive compensation plan or program of the Company, the Executive and the Company are entering into this Agreement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, defined terms used but not defined in this Agreement shall have the meanings set forth in the Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Company and the Executive hereby agree as follows:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Executive hereby acknowledges receipt of the Policy, to which this Agreement is attached, and the terms of which are hereby incorporated into this Agreement by reference. The Executive has read and understands the Policy and has had the opportunity to ask questions to the Company regarding the Policy.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Executive hereby acknowledges and agrees that the Policy shall apply to any Incentive Compensation as set forth in the Policy by the Board and that all such Incentive Compensation shall be subject to recovery under the Policy.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any applicable award agreement or other document setting forth the terms and conditions of any Incentive Compensation granted to the Executive by the Company&#x2019;s Board of Directors or the Compensation Committee of the Board of Directors (the &#x201c;Committee&#x201d;) shall be deemed to include the restrictions imposed by the Policy and shall incorporate it by reference. In the event of any inconsistency between the provisions of the Policy and the applicable award agreement or other document setting forth the terms and conditions of any Incentive Compensation granted to the Executive, the terms of the Policy shall govern unless the terms of such other agreement or other document would result in a greater recovery by the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Executive hereby acknowledges that, notwithstanding any indemnification agreement or other arrangement between the Company and the Executive, the Company shall not indemnify the Executive against, or pay the premiums for any insurance policy to cover, losses incurred under the Policy.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event it is determined by the Company that any amounts granted, awarded, earned or paid to the Executive must be forfeited or reimbursed to the Company, the Executive will promptly take any action necessary to effectuate such forfeiture and/or reimbursement.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement and the Policy shall survive and continue in full force and in accordance with their terms notwithstanding any termination of the Executive&#x2019;s employment with the Company and its affiliates.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement may be executed in two or more counterparts, and by facsimile or electronic transmission (such as PDF), each of which will be deemed to be an original but all of which, taken together, shall constitute one and the same Agreement.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement shall be governed by the laws of the Province of Qu&eacute;bec, without reference to principles of conflict of laws.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No modifications or amendments of the terms of this Agreement shall be effective unless in writing and signed by the parties hereto or their respective duly authorized agents. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of the Executive, and the successors and assigns of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Signature Page Follows]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="text-indent:6.081%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the parties hereto have executed this Agreement as of the day and year first above written.</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACASTI PHARMA INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By:_______________________________________</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name:<br>Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By:_______________________________________</font></p>
  <p style="margin-left:41.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name: <br>Title:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> MACROBUTTON DocID \\4133-1772-1420  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img181340459_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %7!(,# 2(  A$! Q$!_\0
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M &$6_P#0FKN*[\1B*D*CC';3HNQY^'P].I34I+77J^_J</\ \(%J7_0X:O\
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M />F:EJMAH]H;O4;J.V@!QOD; SZ4?6ZW?\ !?Y!]3H]OQ?^9R?_  @6I?\
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M+4O^APU?_OXW_P 51_P@6I?]#AJ__?QO_BJ[BBCZW6[_ (+_ "#ZG1[?B_\
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M(%J7_0X:O_W\;_XJNXHH^MUN_P""_P @^IT>WXO_ #.'_P"$"U+_ *'#5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^8'KCC-65UGQ/'J&J^&M2NK&2]-@UU;7D,)50.A#*30!Z!#/%<Q"6"1)(R2
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MY%"P_P"VG_HQJ*[J_P#%EZLX*'\*/HOR+G@+_D,^*O\ L(M_Z$U=O7$> O\
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MWTB[EU!5S+> N;0XP50=QWKTNB@#SC1? FJZ?;>&(IYK=FTJ]FGF9. ZL#C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHK*U_5WT33OM:V<MT X5DB&2 >]"U%)J*NS5S17#_\
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MIZK_ ,@>]_ZX/_Z":N=ZIZK_ ,@>]_ZX/_Z":J'Q(F?PLXCP1_R*%A_VT_\
M1C44>"/^10L/^VG_ *,:BNZO_%EZLX*'\*/HOR+G@+_D,^*O^PBW_H35V]<1
MX"_Y#/BK_L(M_P"A-7;UAB_XS^7Y(Z,'_!7S_-B TM%%<QTA1110 4444 %%
M%% !11S10 4444 %%)S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 444G- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(3(@E89"9Y(^E2YH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD*DU3IN4GI]YS,5O'X&U2:+5;".ZTF[F+QWIC#-$2>C>U>BVJ6WD*]JD8B<
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M]=N]5LK-9]*L$OI%;,D!DV,R=]IZ9^M5M"\6Z9KSO!"[V]]'Q+97*^7-&?\
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MBB@ HH->?^+OC!X:\)7K6,TDEW>)]^*W&=GL3ZT =MJ:2RZ5=QP'$S0N$/\
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MZEHW_$3_ )X^'_\ OJ6@ _X5GH'_ #TU/_P/E_QH_P"%9Z!_STU/_P #Y?\
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MK7MZ['= A@"#D'N*J:K_ ,@>]_ZX/_Z":FM;:.SM8K>+/EQKM7)R<"H=5_Y
M][_UP?\ ]!-*'Q(WE\+.(\$?\BA8?]M/_1C44>"/^10L/^VG_HQJ*[J_\67J
MS@H?PH^B_(N> O\ D,^*O^PBW_H35V]><>%M8MM)UK7Q<[_]*U<P1[1GYBS8
MS7H]88O^,_E^2.C!_P %?/\ -A1117,=(UT5UVNH8>A&:4  8I:* "@]***
M,BZ\-Z5>:G'J-Q:(]S'C#GO]1WK7Q113NV2HQC=I;A1BBBD41"VA68S+%&)6
M&"X49/XU+110 4444 %%%% !2&EK.L-:M=2U'4;&#?YNGR+'-D8&2NX8_ T
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M?#RW?6'N%O9%T^2<7#V8'RF3UKM:6A2:U+=&$DDUL9NLZ/;ZUI$VG7 Q'(N
M1U4CH167X:\)C0KF:[N+Q[V\D41B5Q]U!T KIJ*2DTK#=.+DI-:H.]4]5_Y
M][_UP?\ ]!-7.]4]5_Y ][_UP?\ ]!-.'Q(<_A9Q'@C_ )%"P_[:?^C&HH\$
M?\BA8?\ ;3_T8U%=U?\ BR]6<%#^%'T7Y'.'Y=4OI/[OB1/U9A7LU>.30RM9
M>*+B&)Y&M-:2X*H,G:LAS@?2NV7XC^'=HS/<9Q_S[/\ X5AB_P",_E^2.C!_
MP5\_S9UM%<G_ ,+&\.?\][C_ ,!G_P */^%C>'/^>]Q_X#/_ (5S'2=917)_
M\+&\.?\ />X_\!G_ ,*/^%C>'/\ GO<?^ S_ .% '645R?\ PL;PY_SWN/\
MP&?_  H_X6-X<_Y[W'_@,_\ A0!UE%<G_P +&\.?\][C_P !G_PH_P"%C>'/
M^>]Q_P" S_X4 =917)_\+&\.?\][C_P&?_"C_A8WAS_GO<?^ S_X4 =917)_
M\+&\.?\ />X_\!G_ ,*/^%C>'/\ GO<?^ S_ .% '645R?\ PL;PY_SWN/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$>*,3>.O#,
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M@^95!_O4_P /W=L/B-J*V4Z36M];K/N0Y (J[X!9-2\%16UU&LT<3O"0XR&
M/%;>E>&M(T2:673[-(9)/O,/3TK1N*NK'+3A.:C*]UOYD$_@[0;C5%U%]/B^
MTJ=V0, GU(K<Q@4M1RSQ0KNED2->F6;%9MMG4HQCLC#\0^+;3P_/!;/#-<W,
MP++%"N6VCO7)>)O$GA[Q+HS*;E[+4K4^=;F9"K*X[?C6UXUL)MMIXDTLA[S3
MCN(4Y\R,]16S91Z1XCTRVOVLK>995#?/&"0?2K5DDSFGSSE*%U_P!WAC49M6
M\.65[<(4EDC&X'N?6J7B3Q/-H]Y::?961N[ZZR40MM&![UT2(L:!$4*H&  ,
M 5A>)_#MKK]J@:X^S7D!W6]PK89#_A4JW-J:S4U3M%ZG-:Q;^+/$UD;"YT2T
M@C<C$KOEH_<>]=S96GD:9!:3L)MD01RW.[CG-<YX3\0WL]_<Z#K 1M1LU#":
M,Y69.Q^M;'B:UOKSP[>V^FR%+MX\(0<'Z9IRO?E(II6=17;_ *T.$\4V'A;2
M99)],U"2QU7DI'9,3N;T*BNY\,SZA=^'+.;54VWCQ_O 1U^HKB?#&I>&]",=
MKJ6E2:?J(P'GN4W;V]=QKTN.1)8UDC<.C#*L#D$4Y[6)PZ3;DFEY(X[Q+K<8
MO#H>C:?!>:I*,.3&"L(/=C6SX5T+_A'M"BL6D\R3)>1ATW'DX]JP;CPMK^G:
MW?:AX?U&V1;U]\B7$>2#['TIEMXA\1Z5XDL=*UK[%<B[) ^S\.GN1Z4VKJT1
M1ERSYJB?;R+NN^&=5N/$2:UH]]%!<>3Y+><NX*/45S?BC1;[2-(>_P!1\27L
M^H,P6VBB;:I<].*]2KSKQ/=-:>.K:[U*RN;FQMXMUJD*;@9/4T0DV[!B*<5%
MOO\ U<[G1Q=#1[,7S;KOR5\T_P"UCFKI4-UP1[UP%WXYUV"T?4!X;:&PC(+O
M/)AB/85W%C=+?6,%TJE5F0. >HR*B46M6;TZD9>ZNAF>+X;J?PIJ,5DI>=X2
M%4=3Z_I7'Z9J&OZGI5IHV@V4FGP0QA)KRX7!![[17I9I,!>G2A2LK"G1YI<U
M[' ^%([O3O&NH:2-1GO;>&!7E:8YQ(?2N^S7E]I?ZOHFNZY%!H\USJ=[<9BD
M(_=A.Q)K=TKPCJC7T6K:SK=R]\&W&&$XB4?W<5<UU9C0FTN6*OJ_D=I12"EK
M([ [U3U7_D#WO_7!_P#T$U<[U3U7_D#WO_7!_P#T$U4/B1,_A9Q'@C_D4+#_
M +:?^C&HH\$?\BA8?]M/_1C45W5_XLO5G!0_A1]%^1<\!?\ (9\5?]A%O_0F
MKMZXCP%_R&?%7_81;_T)J[>L,7_&?R_)'1@_X*^?YLX;XBZ!J&NW'AHV-J)T
MM-32>XR0 J =>>M85UX(N;V]\?#4($@L-2C5[:8D8R@R&]L$5ZM4<\$=S \,
MR!XI%*NK="#U%<QTGSYX;\)ZUXP^&6K:H66?5;J:)8=YP)(X2 %SZ'%=##H?
MBW6_%7]LWWAV/38AI$MFD:RJS%\8&<>IZ5Z]96-MIUI':V<$<%O&,)'&,!15
MB@#R@^!=5N?@A;^'EMXK?5HU60Q,1AV5L[21ZU332/$>M:['K^K:(NC6VDZ1
M-;A#*':=RA'&.@KV.F2Q)-&T<BAD<%64]"#VH ^?O!^C^)/$NB^$K)=&@M]*
ML+O[6=1$@)=0W3'7-;=QX'UV3P;XJLQIBF\O=7-Q;KN7+Q[LYS7L-E8VVGVJ
M6MI D$"?=C08 JQ0!XYXI\&:_J&L>(9[6Q+QW6D06T)WCYI%QD?I5;5OA]X@
MU2ZU=8[98UFT:WAB=G&'EC*DH?R->V8HH Y+P3>:_<VQCUGP]'I*V\21(1(&
M:4@8)XZ"N#\1W.L6WQ?U5M&T:/59GTM8VB9PI4'(R,]:]IJJNG6::@]^MO&+
MMUV-,%^8KZ9H \7C\&^,=#\-^']-BMIKFV19GO;>QN!$ZR.<J"Q_A'?%2>&O
M FOV=QX.^W:8!'87=S)<AG#A Q^4^]>W4E 'G.NZ5KMC\5=/\0:;I"W]E):?
M9)<2!##EOO'/M7HPI:* "N,^)^BW^O\ @Z2PTVW\^X:>)MF0/E# GK79T4 >
M;'PA=W/Q$N;JXLE729]#%F\@(QOXR,5P?@CPCJ/B+3/%-O+<I(UK;/I.GR_P
MXR3U_(5]"%000>AJK8:;9Z9"8;&VBMXF8L5C7 )/4T >.Z1H'C"[U?PB+[PW
M%8VNB PR3+,I:3Y<;L#M6UX9\$:G'\-M>T6[MTM+^^N+AHV)!RK'Y22.U>IT
M4 >+V'AWQ5K,_A;3M1T"/2[7P^WF2WGFJWG;1@! .>:YC3-,\2>)O#5_X?TW
M1('L;G66D;4C(!Y05\D$=<U]'$9&*K66G6FG1-%9V\<$;N798UP"QZFCJ!Y?
M/X,U<R>.@+%9/M]HD-FY(S*57'X553PWXF\.7_AC7K311J<EII0LKFR$H5XV
M]03Q7LF*3% 'A;^ ?%-OX9LI8]-@EU&36VU.6S\P!(EQPI-2W?A#Q3K>F^,=
M5N-&2SO-56&*WL%D!.$8$L3TKW#%% 'D&F:/XM\)^)M0DL_#T.J6^JK"?.>8
M*("  P8'J![5T7Q@S_PJW5<X!VIGT^\*[S%5[VPM=1M7M;R".>!_O1R#(- '
MC^GZ)XPU_6;#5GT:WTDZ9I306SB0,)Y&7Y2,=OK6=I?A#Q=<^(-+O]0TJ\5[
M>WN(KB:YNU??(R$ HH^ZN<5[Q'&L4:HBA448 '0"G4 >9Z;X/U)?@G<>'GM(
MX=4EM9$V$CEB21DUTO@(ZHGA.SMM7TK^SKBV18?+WAMX48W<=,UT]% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:XF1#
M!\6HGMT8B:R_TC X&.AS7;TSRUW[]J[L8W8YIIV(G#FMY.Y%)9VT\JRRV\3R
M+]UF4$BI\4M%(JPV21(HVDD8*BC+,3P!6#_PD?AS6HIK'^TK:19%*,A;&?SK
M2UBP_M31[NQW%//C*!AV-<%X3T?1M8L)=%U;38H]4TT^5(5&UF7LP-7%*UV8
MU9S4E%6U[_D:'@RYFTC6+WPK<RB:.$>=9R YS&>WX5W(15'  ^@K#T3PCI>@
M7,EQ9HYFD&TO(Y8@>@K=/2E-INZ*HPE&%I%2]O[*SC_TVXAB1N,2L!FO-]1N
M]/\ #.L1:CX9U*&2.XE"W&G(VX-D]5':KWC;3?LOB"'7-0L6U#21&(Y8QDF'
M_:Q72:'I/AF>WAU'2;.U9&&4D5>1_@:I6BKF$^:I/E5DU]_J;\;;XU;!&0#@
M]J\^O=(UGPYXCO=8L]-@U>VNFWLK?ZV+V&:]$KBK[Q/K&I:M=:5X;LHV:V;9
M/=3MA4/L.]*%[Z&E=1LK[]+&MX?\4V>O^9#''+;7<(_>VTRX9?\ $5+X@\.6
MOB&WB2>22&6%M\4L1PR&J/ASPO/INH3ZKJ5Y]KU*==K.!A5'H*Z8].!D^E)V
M3]TJ"E.%JB/-M<T6[\-:<]XWC"\1E_U4;@$NW8 5VWANYO;SP]97&H)LNGC!
M<8Q7F]IK&E?\)->7_BZ2X%Y#,5M[9HB8XU'0CUKT31_%.C:X[1:=>I+(HR8\
M8;'T-7-.VIA0E#G;3MY7*OC?3;[5O"]S9Z?S,Q4E,XWJ#RN?>L&SD\;SVL-G
M8Z99Z1;1($#2MN( ]J] ZUS'CW5+C2O#$SVQ*23,(?,[1AN":F+^R:UH)7J-
MM:="OX)UK4M1FU.SU":.Z^QR^6MU&N%<]Q77]:\^TGQ3X7\*Z3!IEE</?3 9
M<V\9<NYZDFNI\/>);+Q';RR6HDC>%]DL4JX9#[BB47>]@H5(V4'*[-C%<?XS
MTK4[B_TG4]-MEO&L9"QMV;&XGH:[&BI3L[FM2"G'E9PMIX0U#7;D7_BRY\S_
M )YV,38C3Z^M=AI^GVVF64=I:1^7!'PJYSBK6**;DV*%*,-5OW"BBBI- HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *;)&LJ,C@%6&"#W%.HH KV=E;V%NMO:PK%"O1%
M&!5BBB@+6V$S7 ?$6U'VO2;V\$DFDQR%+E$8C;GHW%:?C#7=2TVZTVQTTPQR
MWDA3SIONJ?2LK4+[Q8+">PU?P]%?P2H4,EJ_ZXK2"::9R5YQDG#7[B<> (S%
MOTC7KZVMYE^YOWJ5/UKJ=#T>'0M)AT^!F=(A]YNI/K5#P79W]AX6M+;405G7
M.$)R57/ -=#4RD]C2C3@DI)69#="4VLP@($Q0["?[V.*\J\-Z-I^MW,UIKM_
MJ$>MQN?-@>8J&YZKZBN_U[Q5IWA[RDNO->:7[D4*;F/X5PGB/68/$HBDTS0M
M3CU:-AY%SY17;SW/I5TTS'$2A=7U:Z'>Z)X7TS0/,:RB;S).'DD;<Q'U-:-[
M>6^GV<MW=2".")=SL>PHL1.+"W%U@W'EKYF/[V.:AUC2X-:TFXT^X)$4R[21
MU%9WN]3J2Y86@CB-2US4?&,$EEHN@"2VD&W[9>K@ >H%=CX<TEM$T&TT]YC,
MT*X+GN:Y0_\ "6^$+;Y5AU;2X%[?)(B"NPT75H-;TFWU"V!$4RY ;J#Z5<]M
M-C"C;GO+XC-\9ZY/H&@R75L@:9V$:,WW4)[FLCPK8Z+I[G4;O6+:]U><9DG>
M4?+GLOH*[*ZM(+V!H+F))8GZHPR#7 ^*=)\'Z%;A&TQ9+Z?B"WA)WL?7'841
MLURA64HR]II9=ST-'5U#(P93T(.0:"H/4 X]17/>"=,O=*\-PV]^3YI)<(3G
MRP>BUT50U9G1!N44VK' ^))3XB\60>'VE$6GV@%Q>,S8W^BUT+>+/#UI-':?
MVG;*_"JJMD#VIFL>#='UN^%Y=Q/YV-K%'*[A[XKD_%&CZ5#-9^%]%TZ$7MVP
M>23&3%&#R2:M<LK(Y9>TIN4]-?Z2/3%8, 5(((R".]+4%I +6TA@4DB- @)[
MX%3 UF=:V#;SFC%+10,**** #O5/5?\ D#WO_7!__035SO5/5?\ D#WO_7!_
M_0350^)$S^%G$>"/^10L/^VG_HQJ*/!'_(H6'_;3_P!&-17=7_BR]6<%#^%'
MT7Y%SP%_R&?%7_81;_T)J[>N(\!?\AGQ5_V$6_\ 0FKMZPQ?\9_+\D=&#_@K
MY_FPHHHKF.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFIO<1Z7=/:*&N%B8Q@
M_P!['%6Z0T":NCS'PY!XEU?24U.P\1LUSN(GMITRJ,#T]JV="T#7#XK;6]8-
MM'((/)(M_P#EI[FDM;";1OB/(MC$_P!AOX3+. /D5QW%=L*TE+L<M&DFO>O=
M/^F+5+5=1ATG2[F_G!,4"%V ZFKM075O#=VTMO<('AD4JZMT(-9HZG>VAQ4?
MBGQ+J5NLMIX95[69<J9)!AE/K5WP1H5_I(OY[V*.V%U+O2UC;*Q_2LE)+SX?
M7\4)G-WH%Q*$0,V7MR>@'M7H:D,H(Z$9K23LM-CFHQYI7FW=#JY+6?!L5Q?2
M:KINH2Z9>GEW1OD?_>%=;7E>KW"ZMXLN]/\ $FJW.GV,; 6\"95)1ZEJ4$[Z
M%8AQ44I*_P"'XF]X2\1:A=:S=Z+J$L%V]L@874'W6]C[UVO:LK0M)TC2[()I
M$42PMR70Y+?4]ZUJ4FF]"Z491C:3N9.NWNEZ5827NI1Q%%& &0%F/H*Y;PQI
M5UJWB(>)[JR33H%C,=M;HNUF4_Q-6UXN\.W&O06KVDZ1W-I+YL8D7*,?<5CW
ME[XYTFSDN[HZ4\$*[F_AR!51VTW,:G\2\EHNQW@J*YM8;R!H+B))8G&&1QD&
MJ/A[53K>AVVH&(Q&9<E#VK4J-F=*:DK]&<SK4FE^#]$FO+6PMXY?NQ*B %G/
M04SP;I#Z-I,EW?NHOKY_/N&8XP3T'X5>\3>'D\1:>EN9V@EBD$D<BC.UA[5A
M+\/#>/OUK7+^^_V-^Q?TJTURZLYY1FJEXQT6QVR2+(H9&#*>A!R*=67H>A6V
M@6;6EJ\S1%RP$K[MOL*U*S9TQNUJ%%%% PHHHH **** "BBB@ HHHH ****
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M'Y=VZ9<8Q^.*TGM=;'+0LI.+7O=[W->O.)[#6]%\7WVJC1AJOG']Q-OYB7T
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M;_T)J[>L,7_&?R_)'1@_X*^?YL****YCI"BBB@ HHHH **** "BBB@ HHHH
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MTLT*!"CP;LJ^>]=,*3MT-(.5O>5@HHHI%A1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %)2T4 4(](LHM5DU-( MW(FQG'<5?HHH$DEL%%%% PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]4]5_Y ][_U
MP?\ ]!-7.]4]5_Y ][_UP?\ ]!-5#XD3/X6<1X(_Y%"P_P"VG_HQJ*/!'_(H
M6'_;3_T8U%=U?^++U9P4/X4?1?D7/ 7_ "&?%7_81;_T)J[>N(\!?\AGQ5_V
M$6_]":NWK#%_QG\OR1T8/^"OG^;"BBBN8Z0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%=TLBHOJQP*QO%?B$>&_#-SK"0BY$.W"!L!LL!U_&@#<HK M_$9G\7-H7V;
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M6-7\6 ((DO([9K25C\K/'S@^V:6_B\3^+K2QT6\T3^SH8YHY+NY>4,K!#G"
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M-NTKCCUZ^]=Q10!Q]S\.='DT.STZVFN[.6RG^TP7L4N9UE/5RQ!R3WS3M*\
MV^F>(X=>DUC5+W4$A:%WNI0PD4]L8PN/;%==10!Q^E_#O3=-L=3TUKN\N]*O
MF9OL-PX,<)8Y.S R.3ZTRQ^'D$%Y;2W^N:OJEO:,'MK6\G!CC8=#P 6QVSFN
MSHH K:A86VJZ?/87L*S6TZ%)(VZ$&N2M/AK917-L;W6-6U*QM'$EM87<X:&,
MC[O &6QVR37;44 <QKW@R'6=234[75-0TG4!'Y3W%C(%,B?W6!!!QVK2\/\
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MOQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\
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M*/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\
M&BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\
M:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;_P#@2O\ C1_PF'BK_H7;?_P)
M7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_ / E
M?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P#
ME?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\
M E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;_P#@2O\ C1_PF'BK_H7;
M?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_
M / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW
M_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%V
MW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;_P#@2O\ C1_PF'BK
M_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z
M%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_
MZ%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_
M *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;_P#@2O\ C1_P
MF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO_P"!*_XT?\)A
MXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )
MAXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF
M'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;_P#@2O\
MC1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO_P"!*_XT
M?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1
M_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C
M1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;_P#@
M2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO_P"!
M*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+MO_X$
MK_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV_P#X
M$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?]"[;
M_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_T+MO
M_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_ $+M
MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7_0NV
M_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$P\5?
M]"[;_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3#Q5_
MT+MO_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,/%7_
M $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A,/%7
M_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @_P"$
MP\5?]"[;_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\@_X3
M#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R#_A,
M/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_R#_A
M,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P_P @
M_P"$P\5?]"[;_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?SO\/\
M@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_  _R
M#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_._P_
MR#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y_._P
M_P @_P"$P\5?]"[;_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P_>?S
MO\/\@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/WG\[_
M  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S#]Y_
M._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_S#]Y
M_._P_P @_P"$P\5?]"[;_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ_P P
M_>?SO\/\@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'_,/W
MG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(OQ_S
M#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\ (OQ_
MS#]Y_._P_P @_P"$P\5?]"[;_P#@2O\ C1_PF'BK_H7;?_P)7_&BBC]W_(OQ
M_P P_>?SO\/\@_X3#Q5_T+MO_P"!*_XT?\)AXJ_Z%VW_ / E?\:**/W?\B_'
M_,/WG\[_  _R#_A,/%7_ $+MO_X$K_C1_P )AXJ_Z%VW_P# E?\ &BBC]W_(
MOQ_S#]Y_._P_R#_A,/%7_0NV_P#X$K_C1_PF'BK_ *%VW_\  E?\:**/W?\
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..I4<IMON=5.DHP278_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img181340459_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> C,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY=ZS$BW4<$!G15DP)!C(PV#P?7FN8L_'^H>;HKZIX;-E9:P\<=K<QWJS9:0
MIE0H(SD4U!M70-I'=45236-,DU!K!-1LVO5SFW6=3(,?[.<T0ZQIEQ?/8P:C
M9RW:9WP).K2+CKE0<BE9CN7:*H_VUI1MHKG^T[/R)9?)CE\]=KR<_(#G!;@\
M=>*Y>?XDZ?9-?K>PK ]OJ?\ 9\:F=<RXQND.0-J@'GKCCUIJ+>PFTCMJ*SY-
M=TB*:"&35;%)9P&A1KA T@/0J,\@^U:%3884444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"W153^U-/_Y_K;_O\O\ C1_:FG_\_P!;?]_E_P : +=%5/[4T_\ Y_K;_O\
M+_C1_:FG_P#/];?]_E_QH MT54_M33_^?ZV_[_+_ (T?VII__/\ 6W_?Y?\
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MM_W^7_&@"W153^U-/_Y_K;_O\O\ C1_:FG_\_P!;?]_E_P : +=%5/[4T_\
MY_K;_O\ +_C1_:FG_P#/];?]_E_QH MT54_M33_^?ZV_[_+_ (T?VII__/\
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M;%;(UI;LCU"RD3:;#3K*3^\)(P*I*MS;6\\]]I-@$C4%0BCDYY_2NDK/UO\
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MN$03("CDDAC1<#JWM=,BDBCD@M$DE)6-6107(!) '?@$_05)_9UC_P ^=O\
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M%='6?K?_ "![G_=_K7&;FA11VHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD_Y\;'_P'6J]%%@+'VI/^?&Q_P# =:/M2?\ /C8_^ ZU7HHL!8^U)_SXV/\
MX#K1]J3_ )\;'_P'6J]%%@+'VI/^?&Q_\!UH^U)_SXV/_@.M5Z*+ 6/M2?\
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MEW.)HKJ-0U6,^&$0S>??7#M#YS.&D:V5]XW@,2K%VZ$]%],5R]6G<3*>O_\
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MK'_(UIY'K698?\AC5/K'_P"@F@#3HHR/6C(]: "BBB@ HHHH **** "BBB@
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M@P-G0[L_RK;L!ML(!G.$ ^]G]:KZW_R![G_=_K7&;FA11VHH **** "BBB@
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MJ_5#1/\ D!V/_7!/Y5?K$^W6P4444#"BBB@ HHHH *\.^.__ "%M'_ZX2?\
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M -!2BF:5+%-8-9O-'%*DIDC\Q@JN" "-QX!&T=?4\\<W/L3?\_-C_P"!T/\
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MW_71OYU%26P,*^M=#@AN/"^E+-$D@%I"0&&?X!7R57USX=_Y%G2O^O.+_P!
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M -<)/_0A7N->'?'?_D+:/_UPD_\ 0A6V'_B(BI\)Y)1117H',%%%% !1110
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MM=SIB1_EG Z29^4RKCY@>#R.*P/$>JPZQJ:W$*L%6%(RS@AG('4Y9CGMRQ.
M.:R**M12=R6VPHHHJA!1110!3U__ )&/4_\ K[E_]#-%&O\ _(QZG_U]R_\
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M"K@#TK*HHY4%V%%%%4(**** "BBB@"GK_P#R,>I_]?<O_H9HHU__ )&/4_\
MK[E_]#-%4MA,IW7_ !]S?]=&_G452W7_ !]S?]=&_G45"V!A7USX=_Y%G2O^
MO.+_ - %?(U?7/AW_D6=*_Z\XO\ T 5S8K9&M+=EZYMH[NW:&4$HW7!K#O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img181340459_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +T!<4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!#7D6GZM\2O'DL]WI=W)!;QMC]S((8U/\ =!ZL:=XJBN?^%)>%68-Y:O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M76_H<=X/+:9XXN]-1B8CYD>/]TY!_2M2^\3:OJFMRZ7X>C0"'(DF< ].#UX
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MQ1MMR,XX]_4TG%*3=N@X8B<J,8.4KN3V=KV\WL:GA[Q+JO\ PD+Z)K(C:89
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MRB[JS_(X;PO<^(I=(>TT.*-4CD+23OCDG^$9XK?\+^*KVZU231]8C5;M<[6
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M!RH&.GY_I44XMS2L=F+KQAAI55*RMNM=^QD7NJ>--)LDU*[>#R&(S&47Y<]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5Q_P 2M0O-,\)M<6-U+;3>>B^9&<'!
M[5V%<-\6/^1+;_KXC_K51^)"EL>3?\)EXF_Z#M]_W\H_X3+Q-_T';[_OY6)1
M739&%V;?_"9>)O\ H.WW_?RC_A,O$W_0=OO^_E8E%%D%V;?_  F7B;_H.WW_
M '\H_P"$R\3?]!V^_P"_E8E%%D%V;?\ PF7B;_H.WW_?RC_A,O$W_0=OO^_E
M8E%%D%V;?_"9>)O^@[??]_*/^$R\3?\ 0=OO^_E8E%%D%V;?_"9>)O\ H.WW
M_?RC_A,O$W_0=OO^_E8E%%D%V;?_  F7B;_H.WW_ '\H_P"$R\3?]!V^_P"_
ME8E%%D%V;?\ PF7B;_H.WW_?RC_A,O$W_0=OO^_E8E%%D%V;?_"9>)O^@[??
M]_*/^$R\3?\ 0=OO^_E8E%%D%V;?_"9>)O\ H.WW_?RC_A,O$W_0=OO^_E8E
M%%D%V;?_  F7B;_H.WW_ '\H_P"$R\3?]!V^_P"_E8E%%D%V;?\ PF7B;_H.
MWW_?RC_A,O$W_0=OO^_E8E%%D%V;?_"9>)O^@[??]_*/^$R\3?\ 0=OO^_E8
ME%%D%V;?_"9>)O\ H.WW_?RC_A,O$W_0=OO^_E8E%%D%V;?_  F7B;_H.WW_
M '\H_P"$R\3?]!V^_P"_E8E%%D%V;?\ PF7B;_H.WW_?RC_A,O$W_0=OO^_E
M8E%%D%V;?_"9>)O^@[??]_*/^$R\3?\ 0=OO^_E8E%%D%V;?_"9>)O\ H.WW
M_?RC_A,O$W_0=OO^_E8E%%D%V;?_  F7B;_H.WW_ '\H_P"$R\3?]!V^_P"_
ME8E%%D%V;?\ PF7B;_H.WW_?RC_A,O$W_0=OO^_E8E%%D%V;?_"9>)O^@[??
M]_*/^$R\3?\ 0=OO^_E8E%%D%V;?_"9>)O\ H.WW_?RC_A,O$W_0=OO^_E8E
M%%D%V;?_  F7B;_H.WW_ '\H_P"$R\3?]!V^_P"_E8E%%D%V;?\ PF7B;_H.
MWW_?RC_A,O$W_0=OO^_E8E%%D%V;?_"9>)O^@[??]_*/^$R\3?\ 0=OO^_E8
ME%%D%V;?_"9>)O\ H.WW_?RC_A,O$W_0=OO^_E8E%%D%V;?_  F7B;_H.WW_
M '\H_P"$R\3?]!V^_P"_E8E%%D%V>_?#74+S4_!\=S?7,MS.9Y%,DAR< \"N
MOKA_A/\ \B/'_P!?$O\ Z%7<5S2^)F\=@KDO']U<6NE6[V\TD3&;!*-C/%=;
M7&_$;_D#VW_7;^AJZ/\ $1P9HVL'4:['!?VSJ?\ S_W/_?PT?VSJ?_/_ '/_
M '\-4:*]+E78^!]M4_F?WE[^V=3_ .?^Y_[^&C^V=3_Y_P"Y_P"_AJC11RKL
M'MJG\S^\O?VSJ?\ S_W/_?PT?VSJ?_/_ '/_ '\-4:*.5=@]M4_F?WE[^V=3
M_P"?^Y_[^&C^V=3_ .?^Y_[^&J-%'*NP>VJ?S/[R]_;.I_\ /_<_]_#1_;.I
M_P#/_<_]_#5&BCE78/;5/YG]Y>_MG4_^?^Y_[^&C^V=3_P"?^Y_[^&J-%'*N
MP>VJ?S/[R]_;.I_\_P#<_P#?PT?VSJ?_ #_W/_?PU1HHY5V#VU3^9_>7O[9U
M/_G_ +G_ +^&C^V=3_Y_[G_OX:HT4<J[![:I_,_O+W]LZG_S_P!S_P!_#1_;
M.I_\_P#<_P#?PU1HHY5V#VU3^9_>7O[9U/\ Y_[G_OX:/[9U/_G_ +G_ +^&
MJ-%'*NP>VJ?S/[R]_;.I_P#/_<_]_#1_;.I_\_\ <_\ ?PU1HHY5V#VU3^9_
M>7O[9U/_ )_[G_OX:/[9U/\ Y_[G_OX:HT4<J[![:I_,_O+W]LZG_P _]S_W
M\-']LZG_ ,_]S_W\-4:*.5=@]M4_F?WE[^V=3_Y_[G_OX:/[9U/_ )_[G_OX
M:HT4<J[![:I_,_O+W]LZG_S_ -S_ -_#1_;.I_\ /_<_]_#5&BCE78/;5/YG
M]Y>_MG4_^?\ N?\ OX:/[9U/_G_N?^_AJC11RKL'MJG\S^\O?VSJ?_/_ '/_
M '\-']LZG_S_ -S_ -_#5&BCE78/;5/YG]Y>_MG4_P#G_N?^_AH_MG4_^?\
MN?\ OX:HT4<J[![:I_,_O+W]LZG_ ,_]S_W\-']LZG_S_P!S_P!_#5&BCE78
M/;5/YG]Y>_MG4_\ G_N?^_AH_MG4_P#G_N?^_AJC11RKL'MJG\S^\O?VSJ?_
M #_W/_?PT?VSJ?\ S_W/_?PU1HHY5V#VU3^9_>7O[9U/_G_N?^_AH_MG4_\
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M@C;_ /@*G^%'_"WO&G_01M__  %3_"N'HH]G#L'-+N=Q_P +>\:?]!&W_P#
M5/\ "C_A;WC3_H(V_P#X"I_A7#T4>SAV#FEW.X_X6]XT_P"@C;_^ J?X4?\
M"WO&G_01M_\ P%3_  KAZ*/9P[!S2[G<?\+>\:?]!&W_ / 5/\*/^%O>-/\
MH(V__@*G^%</11[.'8.:7<[C_A;WC3_H(V__ ("I_A1_PM[QI_T$;?\ \!4_
MPKAZ*/9P[!S2[G<?\+>\:?\ 01M__ 5/\*/^%O>-/^@C;_\ @*G^%</11[.'
M8.:7<[C_ (6]XT_Z"-O_ . J?X4?\+>\:?\ 01M__ 5/\*X>BCV<.P<TNYW'
M_"WO&G_01M__  %3_"C_ (6]XT_Z"-O_ . J?X5P]%'LX=@YI=SN/^%O>-/^
M@C;_ /@*G^%'_"WO&G_01M__  %3_"N'HH]G#L'-+N=Q_P +>\:?]!&W_P#
M5/\ "C_A;WC3_H(V_P#X"I_A7#T4>SAV#FEW.X_X6]XT_P"@C;_^ J?X4?\
M"WO&G_01M_\ P%3_  KAZ*/9P[!S2[G<?\+>\:?]!&W_ / 5/\*/^%O>-/\
MH(V__@*G^%</11[.'8.:7<[C_A;WC3_H(V__ ("I_A1_PM[QI_T$;?\ \!4_
MPKAZ*/9P[!S2[G<?\+>\:?\ 01M__ 5/\*/^%O>-/^@C;_\ @*G^%</11[.'
M8.:7<[C_ (6]XT_Z"-O_ . J?X4?\+>\:?\ 01M__ 5/\*X>BCV<.P<TNYW'
M_"WO&G_01M__  %3_"C_ (6]XT_Z"-O_ . J?X5P]%'LX=@YI=SN/^%O>-/^
M@C;_ /@*G^%'_"WO&G_01M__  %3_"N'HH]G#L'-+N=Q_P +>\:?]!&W_P#
M5/\ "C_A;WC3_H(V_P#X"I_A7#T4>SAV#FEW.X_X6]XT_P"@C;_^ J?X4?\
M"WO&G_01M_\ P%3_  KAZ*/9P[!S2[G<?\+>\:?]!&W_ / 5/\*/^%O>-/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBD/0T =3:?#[Q!>V%O>QI91PW">9%YUXD;%?7!-3?\*V\1>NE_\
M@PC_ ,:D\9)#)%X06X<QPG2XP[A=Q5=YR0.]7/%FB^$[3PAHMQ87[FY>WD,)
M%K@W7[S!+G/RD=*RYI:>?D79'-:[X6U7PY';2:C' ([G<(GAF616*XSR/J*Q
MJZ[6ACX8^$L?\_%[_P"AK7(U<6VM26@HHHJA!1110!]/?#'_ ))WI'_7(_\
MH1KKJY'X8_\ ).](_P"N1_\ 0C775Y<_B9UQV04445(PHHHH **** "BBB@
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M *%7<5RS^)G1'9!7&_$;_D#VW_7;^AKLJXWXC?\ ('MO^NW]#5T/XB.#-O\
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MD.CSSZZ=)5T$PD:/<?NY'_ZJJ-1-&=7"5(3<8JZYG%/NT9U%:-[HMU9:R=+
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M'_7(_P#H1KKJY'X8_P#).](_ZY'_ -"-==7ES^)G7'9!1114C"BBB@ HHHH
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M;FS\.:"(Y;@8:6Y4-M]\'.<=JX"J@K$R844459(4444 %%%% !1110 4444
M;S_\D_A_["I_]%&L&MY_^2?P_P#85/\ Z*-8-)#9T'A"SANM8:67RI)+:,RP
M6LC!?M$@^ZHSUYY(]JEUG5X9M%N=,FT;^S]0DN4FG" JC%01]P_=//;BH?"
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M?$_4=,NKJ1]3M,K9X7"R1E,L6[ X*UT^D?\ "0VWCLZ?:>'++3- MV8-<)$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWUAXG^R6LLV_3FA78N<N2"%^N*BI\(X[FEIOBOPI'+H.J75QJ*7^EV(MO(2
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MDURFOV\UIXBU&&XB>*47+DHXP1EB16D;<VC)=[:F=1116A)]/?#'_DG>D?\
M7(_^A&NNKD?AC_R3O2/^N1_]"-==7ES^)G7'9!1114C"BBB@ HHHH **** "
MBBB@ HHHH *X;XL?\B6W_7Q'_6NYKAOBQ_R);?\ 7Q'_ %JH?$A2V/"Z***Z
MCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'=_\)OH7_0!U/_P<2_XT?\)OH7_0!U/_ ,'$O^-<)14^SB/F9W?_  F^A?\
M0!U/_P '$O\ C1_PF^A?] '4_P#P<2_XUPE%'LXAS,[O_A-]"_Z .I_^#B7_
M !H_X3?0O^@#J7_@XE_QKA**/9Q#F9W@\<:$K C0=2R#G_D+R_XUS/B76SXB
M\0W6JF#R//(Q'NW;0!CKWZ5DT4U!)W0.3844450CZ>^&/_).](_ZY'_T(UUU
M<C\,?^2=Z1_UR/\ Z$:ZZO+G\3.N.R"BBBI&%%%% !1110 4444 %%%% !11
M10 5S7CG0;GQ%X=-A:211RF57W2D@8'T!KI:CF_U?XTT[.X-7/$_^%2ZY_S^
MZ?\ ]]O_ /$T?\*EUS_G]T__ +[?_P")KV.BK]K(CD1XY_PJ77/^?W3_ /OM
M_P#XFC_A4NN?\_NG_P#?;_\ Q->QT4>UD'(CQS_A4NN?\_NG_P#?;_\ Q-'_
M  J77/\ G]T__OM__B:]CHH]K(.1'CG_  J77/\ G]T__OM__B:/^%2ZY_S^
MZ?\ ]]O_ /$U['11[60<B/'/^%2ZY_S^Z?\ ]]O_ /$T?\*EUS_G]T__ +[?
M_P")KV.BCVL@Y$>.?\*EUS_G]T__ +[?_P")H_X5+KG_ #^Z?_WV_P#\37L=
M%'M9!R(\<_X5+KG_ #^Z?_WV_P#\31_PJ77/^?W3_P#OM_\ XFO8Z*/:R#D1
MXY_PJ77/^?W3_P#OM_\ XFC_ (5+KG_/[I__ 'V__P 37L=%'M9!R(\<_P"%
M2ZY_S^Z?_P!]O_\ $T?\*EUS_G]T_P#[[?\ ^)KV.BCVL@Y$>.?\*EUS_G]T
M_P#[[?\ ^)H_X5+KG_/[I_\ WV__ ,37L=%'M9!R(\<_X5+KG_/[I_\ WV__
M ,31_P *EUS_ )_=/_[[?_XFO8Z*/:R#D1XY_P *EUS_ )_=/_[[?_XFC_A4
MNN?\_NG_ /?;_P#Q->QT4>UD'(CQS_A4NN?\_NG_ /?;_P#Q-'_"I=<_Y_=/
M_P"^W_\ B:]CHH]K(.1'CG_"I=<_Y_=/_P"^W_\ B:/^%2ZY_P _NG_]]O\
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MS_0_]\FC_A7UU_S_ $/_ 'R:[ZBCZQ4[A_8>"_E_%G _\*^NO^?Z'_ODT?\
M"OKK_G^A_P"^37?44?6*G</[#P7\OXLX'_A7UU_S_0_]\FC_ (5]=?\ /]#_
M -\FN^HH^L5.X?V'@OY?Q9P/_"OKK_G^A_[Y-'_"OKK_ )_H?^^37?44?6*G
M</[#P7\OXLX'_A7UU_S_ $/_ 'R:/^%?77_/]#_WR:[ZBCZQ4[A_8>"_E_%G
M _\ "OKK_G^A_P"^31_PKZZ_Y_H?^^37?44?6*G</[#P7\OXLX'_ (5]=?\
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M !1110 4444 %%%% !1110 4444 68/]7^-25'!_J_QJ2@ J*?[H^M2U%/\
M='UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!9A_P!6*DJ.'_5BI* "H;CHM35#<=%H
M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"U%_JQ3Z9%_JQ3Z "BBB@ HHHH **** "BB
MB@ HHHH **** "HYO]7^-25'-_J_QH K4444 %%%% !1110 4444 %%%&#0
M4444 %%+@XSCBDH **** "BBB@ HHHH **** "BBB@ HHQ1@GH* "BCK10 4
M444 %%%% !1110 4444 %%&** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH LP?ZO\ &I*C@_U?XU)0 5%/]T?6I:BG^Z/K0!7HHHH **** "BB
MB@ HHHH ***,$]!0 448Q10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"> U TSQVVW!;5[W)QU^4UK?"O\ Y)EH?_7$_P#H1H =::UI&GZ_XLN9K^^
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M76J6ZPW%[%/-NAG1R-Z;.B@;N,=,4[7I[?5_$GB0ZMK%S80Z=IL=SIBQ71@
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M!.<Y*@]P,5SLFE7J>,+32,DWP\'M;9SUDQMZ_6N?TB738/A\EMJ'CW6+.6"
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M%=JYZGU)]S5NBG*3>X**04445(Q" P(8 @\$'O2(B1(J1HJ(HP%48 _"G44
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M'IFH&TZQ>\%XUE;-=#I,8E+C_@6,U9HH **** "BBB@ HHHH **** "BBB@
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M-WXCO9TCN-4_=Z=;22 ,MHA.TA<]6.6/U%+XM@CU+4+3PY9PI'<:I\^H7$:
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M>'T=2K+IMN"K#!!\M>"* -NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH LP?ZO\ &I*C@_U?XU)0 5%/]T?6I:BG^Z/K0!7HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"S#_JQ4E1P_P"K%24 %0W'1:FJ&XZ+0!!1110 4444 %%%% !1110
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M110 4FU=^_:N_P#O8Y_.EHH .^<#-(RJPPRJPZX89I:* #J<D"BBB@ HHHH
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M2Y#-@KM;V]* /6J*Y2_\<Q0:K+I>G:/J&K7UO&KW:6:C;;[AG:S,0-WM7/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/6%_;7XBNKF^MI \5S=W3RR+@$ 9)Z<GBNIHH H:SHUCK^ERZ;J4)EM92I=
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MSN-1M?!VJ3:7#%+<+;/D22^6%3:=S ^H'('>@#4MM1L;R62*UO+>>2+B18I
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MF28OM\H9' YP#FNO?QGXBTC[%>>)?#EO8Z3>2I%YT%UYDEN7^[YJD8 ]<=*
M.ZHKD-1\6:M/XDNM"\,:1!?W%BBM>7%U<&*&(L,J@(!)8CFN8\;^*-=O_AKJ
M3II$FFW=O<K;7RR3%=GSK@Q,!\ZMG'TS0!ZF\T4<D<;R(KR$A%+ %L>GK3ZX
M:XU"5=;\$1:UHMJ-3N9IUADBN&<6N(L[E/&XL.#GI6GH/BY-3TC5[O4(%LI]
M(GFANX@^0NP9# GLPY% '345P$'Q U/4+31[;3M"CFUS5(&O%M7G*Q06^["R
M2-C//' '6MCP]XHO+_6;O0=;TU-.UBVC6?9%+YD4T1XW(W7@]0: .D,T2S+"
MTB"5P2J%OF('4@4^O./&5]>V'Q4\+R:=IYOKM["ZCBA\P(N3CEF[*.]:-EXR
MUIKG6=(U#0X(-=L++[;###<%X;E.V&QD'/% ';45R-QX\MH_AS#XLAM_-,\:
M>5:[N6F9MOEY]<Y_*JVH>,]<C\5CPSIV@0W6H&PCNR[W!2*(L3N#'&<#&!CD
MYH [>BN/TOQQ@ZQ:^([)=+U#2(/M-PD<GF1O"1D/&W<=L>M9S^._$EOHZ^([
MKPK$GA\J)25NLW20GI(4QCISC/2@#T&BO+]3UC7[CXMZ&=,M;6XL9=/DEM0U
MV566)MNZ0C'##)P.XK>N/%NMZCKFH:;X4T2VOTTU_*NKF[N3"GFXR8TP#DCO
M0!V5%<'=_$N*W\$R:^NF2?:+:]6RN[%V^>*3=A@".OJ/6I4\8Z]8:UI5MX@\
M/06-CJLWD6TT-UYKQN1D+(,8&1Z4 =O3&FB65(FD02."50L,MCK@5P\WC77K
MW4=8C\/>'[:^M='G:WN?.N_+GD=1EO+0#IZ9ZU8N-6L[GQOX4\[1BMY>6<TL
M4T[%9+48&Y-O0Y[YH [.BN&3QEX@UJ:^F\+^'K:]TVSF: SW-T8FN'7[PB4
MY';)ZU'??$V&+PSHNM6&F371U&^%BUH6VR128;*^A.5Q^- '>T5QMAXLUN#Q
M39:'XDT2WL7U%':SFM;GSE+*,E&R!@X]*[*@ HHHH **** +,'^K_&I*C@_U
M?XU)0 5%/]T?6I:BG^Z/K0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC^,&L7C02"T?2K>-)BORLP<Y /K78DDC!)Q24 >/Q^$=4U?X1ZQI:VDB7O\
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ML=,#&?>O7PQ'0D4E '&^)K*ZG^(O@NYAMY)+>WDN3-(JY6/,>!D]LFNRHHH
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M !14275M),84N(6E'5%<$C\*EH **** "BBB@ HHI@EB,GEB6,O_ '0XS^5
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MX]Z]&H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTZXLXTMPIF602A5QO!7H/8UT5%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 68/\ 5_C4E1P?ZO\
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MQVD6Q<_O'Z9]!7!^-=<NK'QD;35]<U;0="^S*UI=Z?#N$LQ/S"1@IQCTK/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6HO]6*?3(O\
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MBF12Q3Q^9#+'*G3=&P8?F*%EB>1XTE1G3[ZJP)7ZCM0 ^BBB@ HHHH ****
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M%;E% '#WWAGQ%J%OHFKBXT^U\3:275-FYK>:)AM*-W&0!SV-:.CV/BNXUO\
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MG8 #ZDUP\[A_C;IK*Q*-HDC#WRPK,^+LFI2MX;TZ+3([NPNM5A5U>Y\L3O\
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M "BBB@ HHHH **** +47^K%/ID7^K%/H **** "BBB@ HHHH **** "BBB@
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MSN(I9LC"LWW1CKS6-JGAO5[C6O'L\5FS1:GI45O9MN'[V0*P*CGCDCK7HE%
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M'O6?X;T#5+'P+XBT^YM&CN[NYOG@C+#+K)G8>O>N[HH \:O(-;T"\^&EO;V
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M;:[MYF')$4JL?T- $]%%% !1110 4444 %%,$L1F,(E0R@;C&&&X#UQUQ3Z
M"BF&6(3"$RIYI&X1[AN(]<=<4DT\-M"TT\T<,2_>>1PJCZDT 245'!<0W4*S
M6\T<T3='C<,I_$5)0 4444 %%%% !137=(T9Y'5$499F. ![FE5E=0R,&5AD
M,IR"/8T +1110 4444 %%-=TC1GD=411EF8X 'N:565U#(P96&0RG((]C0 M
M%'09/2H1=VS)&XN8"DAVQL)!ASZ YY/TH FHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** +47^K%/ID7^K%/H **** "BBB@ HHHH **** "BBB@
MHHHH *CF_P!7^-25'-_J_P : *U%%% !117.>+/%UKX6M8R\9GNYL^5"#C('
M<GL*:5]$#=CHZ*\HL/BU?M=@7>E120=6%N3O4=R/6O3[&]M]1L8;RUD$D$RA
MT8=Q3E%QW$I)[%BBBBI&%.V-_=/Y5G:X[1^']2=&*NMK(58'!!VGFO*_#'AG
M2K_P)I^L7OC'6+.^EM?-DE.JG;&W/.TGVZ&@#V.BO.O"GCQK?X;:;JWB)Y[B
M\N)6M[<0Q9EO"&(4JO<D=_:NAT7QE;:KJYTBYT^^TO4_+\U+:]C"F5.Y0@D'
M'<4 =)000<$8KC9_B-IZSW?V73-5O;"S=H[G4+:#=#&PZXYRP'<@<5C^ _%<
M>G_#OP[/J<MS=2ZE>R6L<A)=MQD;&XDYQ@4 >E45E:EX@M-+UO2=)G24W&J/
M(D!094%!D[O2L6]^(5E#J-Y::?I.J:L+%MMW-8PAHXFZE<D_,P]!0!U]%<U<
M^.]"@\.66N1S2W-O?,$M(H(RTLS_ -P+ZCOZ4NB^,K;5=7.D7.GWVEZGY?FI
M;7L84RIW*$$@X[B@#I*""#@C%<;/\1M/6>[^RZ9JM[86;M'<ZA;0;H8V'7'.
M6 [D#BF_"B[GOOASIUS<7$EQ*[S9DD8LQ'F-CD\]* .TH((ZBN5U'QW:6>LW
M&F66EZEJL]H ;LV,098,\X))&6QV'-<SX2\:6UGX>\7>([V>[N-/AU4F,,"7
M1&V@ *>F">GUH ]0HKBU^)6G_P!F7>IR:5JT-A T8CN);?:MP';:I3/4=_I6
M[KGB*S\/Q:?)=I*POKJ.UB\M<X=^A/MQ0!KT5R^J>-[6PUJ;2++3-1U:\MD#
MW2V,880 ]-Q) S[=:M>%_%NF^+8+R;35N EK-Y,GGQ[#NQDC'MT^M &]@XSC
MBBN:U>YLH_'GAFVFN+Y+R9+K[/%$V() $&[S!WP.GO6<_P 2[!YKV"PT;5]0
MEL9GBN5MK?(CV]R<X.>P'- ';45YKXS^(+CPMH>I^'5O)+?4;N(&>*,<('PT
M1R>'/(Q[&NDU/QM:Z>UA;C2]2GU2^B,T>FQ1 S(@ZE^<*.W6@#INM'2N(O?%
MUOKW@;Q2]I'>6&H:?9S)/;SKY<L#^62#P?R(I^B>++:Q\/\ A/3I?M-]J^H:
M? XAA&^0+Y:[I9"3PON>M ':45RVI^.;6SUBXTJPTS4=7N[50UTMC$&6#/0,
M20-WL.:U]"UVP\1Z5'J.G2,T+DJ5==KQL."K#L1Z4 :5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %F#_ %?XU)4<'^K_ !J2@ J*
M?[H^M2U%/]T?6@"O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %F'_5BI*CA_U8J2@ J&XZ
M+4U0W'1: (**** "O#/B?XNU2_UV\T:PDFBL+#Y9_)R-S=RQ'8'BO<Z\C\56
MFL^#/&-YXAT^R^W:3J0_TR IN4YZAO3U!K:A;F(J;'(>'H/$.AZ)+XMBU(V5
MM$P$,5PY(O.>5"]Q[U[]I&HQZOHUGJ,2[4N85DV_W<CD5\]WL_B#XD:[%%;6
M;+ F(X((U(AMD]ST'UKZ$T?34T?1K/3HVW+;0K'N_O$#D_G5U^E]R:?EL7:*
M**YC4**** /.?C"MJ^CZ M]Y?V,ZU;B?S3A?+R=V[VQG-<UXTMO ]C9VDW@B
M6QC\2?:XA:)I<V7;YN=P4_=QZUV/Q/TV;5+'P_!%9R7<8UJV:=%C+@1Y^8L/
M[N.N:ZJST#1M,N#-8:38VTO_ #TA@56Q]0,T <Y-XMUJ_P!:O-+\.:-!>OIV
MU+VYN;CRHQ,1DQI@')'KT%<OXV\9ZAK7POU*>PLGL;JVN!::G$\^V2U8.O"D
M#Y@WKQP:T]-U"3P#XA\16VIZ;J,UCJ5\VH6EW9VS3AMP ,;;>C#'?K6/J6@:
MUJ7P\\9ZFVFS17FM7B7<%@1^]$2,N,C^\0"<=: .PU+Q;J.D6>D64FCQS>(=
M2)6"QBN/W:JO5VD(X4#';O4FD>++\^(#H'B#3(K'4'MVN;:2WG\V&X5?O '
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MU:YB-PL$<HC2.+^^[G[H]*Q=4\;:I/X8\0P1Z'<V.NZ?!F6!IUPB,#B9).C
M>@YH ]!HKE_A[?:C?^"-,EU*T:"00($=YA(9UV@^8<=,G/!YKJ* +,/^K%25
M'#_JQ4E !4-QT6IJAN.BT 04444 %'M110 @ 7[H ^@Q2T44 %%%% !1110
M9Q152]U2RTY[9+RY2%KJ40P!OXW/\(]ZMT &2.]&><]Z** %R<YR<TF2:*J7
MFIV6GS6D-W<I#)=R^3 K'F1^NT>] %O)S2Y.<Y.:2B@ R?6ER?4TE% !D^M&
M:** #)%+DYSGFDHH *,T44 &<4$YZT44 +D^II,GUHHH 7)/>C)]:2B@ SB@
MG/6BB@!<GU-)110 N3ZT9/K244 +DCO29-%%  23UI<GU-)10 N3ZTF2:**
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MFVMQ-&8Q<RM\V0#SM& ,^]=VOAQ5\<2>)?M)+/IXL?L^SC&_=NS^F*W.V.U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** +47^K%/ID7^K%/H **** "BBB@ HHHH **** "BBB@ HHHH *C
MF_U?XU)4<W^K_&@"M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %F#_ %?XU)4<'^K_ !J2
M@ J*?[H^M2U%/]T?6@"O1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %F'_5BI*CA_U8J2@
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MDJQQNQ[\59\$JL?COQY'&H6,7\1"J,#)C&3B@#NZ*** "BBB@ HHHH ****
M+,'^K_&I*C@_U?XU)0 5%/\ ='UJ6HI_NCZT 5Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH LP_P"K%25'#_JQ4E !4-QT6IJAN.BT 04444 %%%% !1110 4444 %%%%
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MO\:DJ.#_ %?XU)0 5%/]T?6I:BG^Z/K0!7HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"S#
M_JQ4E1P_ZL5)0 5#<=%J:H;CHM $%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6HO]6*?3
M(O\ 5BGT %%%% !1110 4444 %%%% !1110 4444 %1S?ZO\:DJ.;_5_C0!6
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"S!_J_P :DJ.#_5_C4E !44_W1]:EJ*?[H^M
M%>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** +,/^K%25'#_ *L5)0 5#<=%J:H;CHM $%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6HO]6*?3(O]6*?0 4444 %%%% !1110 4444 %%
M%% !1110 5'-_J_QJ2HYO]7^- %:BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +,'^K_&I*
MC@_U?XU)0 5%/]T?6I:BG^Z/K0!7HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img181340459_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Z 7$# 2(  A$! Q$!_\0
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MQ]*Z4-G'O5F0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO*BDADV)&1@IU YY!]3TKI/L%U_SS_\ 'A1_9]U_SS_\>%/E1,<34CLSE?\
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M%G*ZG(A_BC.?J#7LX1WA8^5QT;5+]SL:***ZCB"BBB@ HHS10 4444 %%%%
M!1110 4444 %%%% !1110 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
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M/MGVKG: "BBB@ HHHH *5#AP?0TE%#5QIV=S$M+8CQ&8\[<7)/ZDUVCMYOF
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M>#/3T[UK&<9J\3GJTI4I<D]&+> AYW)]$Z],^GY50K0OR0)?E_Y:+V^M9['
M)IMV5V3&+D[+<**A^TJ#AE('K4P((!!R#40K0G\+-*N'J4OC5B2&>6W?=#(\
M9]5;%;%KXGNHB%N8UF4?Q#AJPZ*T,3O++6[&\.U)=K_W7X-:&17F=;.F^()[
M4K'<YF@'&?XE^GK0!VE%0VUU%=PK+"X9&Z$5-0 4444 %%%% !1110 4444
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M.IS$W^L3/7W'O7=03)/"DL;;D<9!KS:NI\*WFZ.2T9N4^9/IW% '244@Z4M
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M**]L^2-+0)?+UJ#T;*_F*[NO.;.3RK^VDSC$B_SKT:@ HHHH **** "BBB@
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MN$RAY[@]13WB21<.H8>]4)--V-OMG*,.<&@#2HJE#=R*PCN4\MNS=C5T'(H
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M0#R=IP>/8\5;W9&>* ::W'T4@Y I: "BBB@ JO>VR7EK) _W7&/I[U8I",T
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M\81!U]2?4UCAZ<G-3MI^9TYA7A&FZ=[R?3L3T445Z)X!U_A9,:;(_P#>E/\
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MUS=0C_IHO\Z9!Z'!$(8(XAT10/RJ6C%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<IXM'^D6I_V
M6%=77+>+A^\M?HW]* .;HHHH **** "B@=:S;NZDCE"+G=G@>M8UJRIJ[1TX
M;#.NVD[6-*B@9*C/7'/UH)P#ZXK2^ES#E][E"BLR.[E>]6-58\_-QT%:=9T*
MRJINQT8G#.@TF[W"BBBMCE"BBB@ J:T_X_;?_KHO\ZAJ>R&;^V'_ $U7^= '
MHU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<OXM_UEK]&_I745RWB[[UI_P "_I0!S=%%% !1
M110 48Y!P,CVHHI6N--K8***DFC$8BYR6C#'VS3$1X ).!SUHHHI)6V&VWN%
M%%%,04444 %6+'_D(6W_ %U7^=5ZGL1G4;8?]-5_G0!Z-1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7,>+A_QZ'W:NGKF_%BDV]LY[.1^E '+4444 %%%% !1110 5/=\21CT
MB3^5058N_P#61GUB3^5 %>BBB@ HHHH **** "K.G#=JEJ/^FB_SJM5W2%+:
MQ: ?\],_E0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img181340459_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &_ X0# 2(  A$! Q$!_\0
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MP\<D8X'&,<]:;@[V7]:"4EU-B+XD^))?$EPKQ"]T^21X%T7R0(RG(" !2<C
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M<CI]Z^F:E:W\85GMI5E4/T)4YP:[;5(O _C/4[G5?[=GT;4;PAYH+Z'S(M^
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M ("O_A7UE11]9?8/9+N?)O\ PA_B;_H7M4_\!7_PH_X0_P 3?]"]JG_@*_\
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M\!G_ ,*=_P (MXA_Z 6I?^ S_P"%?3=%'UI]B?[/CW/F7_A%O$/_ $ M1_\
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MUK_H$7W_ 'X;_"E_X1[6O^@1??\ ?AO\*]ZHH^M2["_L&G_.SP;_ (1_6O\
MH$WW_?AO\*=_PC^L_P#0)O?^_#?X5[O11]:EV%_8%+^=GA(\/ZS_ - F]_[\
M-_A2_P!@:S_T"KW_ +\-_A7NM%/ZW+L+_5^E_.SPL:!K/_0*O?\ OPW^%+_8
M&L?] J]_[\-_A7N=%'UN787^KU+^=GAPT'6/^@5>_P#?AO\ "E_L'6/^@7>?
M]^&_PKW"BCZW+L+_ %=I?SL\0_L'5_\ H%WG_?AO\**]OHH^MR["_P!7*7\[
M"BBBN0^C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BJU_J-GI=M]IOKF*WAW!=\C8&3T%9G_  F?AO\ Z#5G
M_P!_!346]D*Z-RBL/_A,_#?_ $&K/_OX*/\ A,_#?_0:L_\ OX*?++L%T;E%
M8?\ PF?AO_H-6?\ W\%'_"9^&_\ H-6?_?P4<LNP71N45A_\)GX;_P"@U9_]
M_!1_PF?AO_H-6?\ W\%'++L%T;E%8?\ PF?AO_H-6?\ W\%'_"9^&_\ H-6?
M_?P4<LNP71N45A_\)GX;_P"@U9_]_!1_PF?AO_H-6?\ W\%'++L%T;E%8?\
MPF?AO_H-6?\ W\%'_"9^&_\ H-6?_?P4<LNP71N45A_\)GX;_P"@U9_]_!1_
MPF?AO_H-6?\ W\%'++L%T;E%8?\ PF?AO_H-6?\ W\%'_"9^&_\ H-6?_?P4
M<LNP71N45A_\)GX;_P"@U9_]_!1_PF?AO_H-6?\ W\%'++L%T;E%8?\ PF?A
MO_H-6?\ W\%'_"9^&_\ H-6?_?P4<LNP71N45A_\)GX;_P"@U9_]_!1_PF?A
MO_H-6?\ W\%'++L%T;E%8?\ PF?AO_H-6?\ W\%'_"9^&_\ H-6?_?P4<LNP
M71N45A_\)GX;_P"@U9_]_!1_PF?AO_H-6?\ W\%'++L%T;E%8?\ PF?AO_H-
M6?\ W\%'_"9^&_\ H-6?_?P4<LNP71N45A_\)GX;_P"@U9_]_!1_PF?AO_H-
M6?\ W\%'++L%T;E%8?\ PF?AO_H-6?\ W\%'_"9^&_\ H-6?_?P4<LNP71N4
M5A_\)GX;_P"@U9_]_!1_PF?AO_H-6?\ W\%'++L%T;E%8?\ PF?AO_H-6?\
MW\%'_"9^&_\ H-6?_?P4<LNP71N45A_\)GX;_P"@U9_]_!1_PF?AO_H-6?\
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M(JY0OEV/"\#\^*RK/Q^]]=Z;:PZ!>M-?6"WX0.H,<9D"'=G'(SGWH [/8O\
M='Y4;%_NC\JX:;XF6T$&H,VE7/FV4EJCQ>8F2)VV*<@XR".1^M4-7^(-W%JN
MG&RMI=D%S?6VH67R$NT,6\;7/;H<_A0!Z1L7^Z/RHV+_ '1^5<_<>+K2+0-(
MU6*"67^UGACM(>%9GE&5!/08&23[5@V7C&\\2^*]$MM+E^RZ9<V$E[*616D9
MDE$;1G/09R,CZT =]L7^Z/RHV+_='Y5QDGB*ZO?'.KZ/]J_L_3]'M(IYI0@+
MRM)DYR00$4#TY-9?B'7]5L_#FB:G8>((KK[9J5O9236\2>5(CNP9ER#SC'?
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MC^PM;_Z&V^_\!;?_ .(H Z&BN>_L+6_^AMOO_ 6W_P#B*/["UO\ Z&V^_P#
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MZW:PO#W_ "$/$'_81/\ Z*CK=JI[BCL%(02" <'UI:R-0\-:?J=V;FX:]$A
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M^%7L#.NG>*#=>8%%A]LF\]E,?FB0#S<;=@+=<]L9JY97GA+4/$-OI%LFO/\
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M>'9-#N_$<\T$D<E]J;S*SREQ(FT88#)QR6]^GH*ZVN>_X0K2/[^I?^#.X_\
MBZVK.TBL+2.U@\SRXQA?,D9V_%F))_$T 3UQ4O\ R4N[_P"O.W_G)7:UQ4O_
M "4N[_Z\[?\ G)51V8GT.T'04M(.@I:D9@^*?N:1_P!A2W_]"-;U8/BG[FD?
M]A2W_P#0C6]5/9"6X4445(PHHHH **** "BBB@#G?%_^IT?_ +"]K_Z'715S
MOB__ %.C_P#87M?_ $.NBH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH P?%W_ "!8O^OVU_\ 1Z5O5@^+O^0+
M%_U^VO\ Z/2MZJ^R+J%%%%2,PO#W_(0\0?\ 81/_ **CK=K"\/?\A#Q!_P!A
M$_\ HJ.MVJGN*.P5CZCKYT^[-N-(U6ZPH/F6UN'3GMG(YK8HJ1GC]KI&IPZ$
MVB3R^()=.CP]HBZ+&CP2+()$8MO.\ CH1SFKEA83V6HV&I&W\0RW\-Y-=W<I
MTM MR945&4*'^0;47&,]#ZUSNG>&/$<'@K4->:XFB:33[E1;QS7+7%P[/\ID
M5V(0KC(V =:]1\$7>J7>A2?VWYHU2*XDCN(V0*D9!^41X'S)M*D'DG)SZ4 <
M3KOA^TUV\O;R72_$45S/?0WD4B6 S%L15:/[_P RL$&??'I5:\\-R7MU?EX_
M$8M+A+U8;?\ LI/W)N@-YW;\M@C(S7LE% 'E<^F1SWTES_9WB%=]X;LJ-.7O
M;?9]OW_0[L_A6/+X/-YI?V:_3Q'<7,4=M%:S_P!E(@AC@#!5*JXW??;)R#T]
M*]LHH \W\,PP^&;QI[?1=>=6LH;3RQIX4#8SL6'SGJ7/';%=-_PEA_Z%W7O_
M  $'_P 57144 <[_ ,)8?^A=U[_P$'_Q5'_"6'_H7=>_\!!_\57144 <[_PE
MA_Z%W7O_  $'_P 51_PEA_Z%W7O_  $'_P 57144 <[_ ,)8?^A=U[_P$'_Q
M5'_"6'_H7=>_\!!_\57144 <[_PEA_Z%W7O_  $'_P 51_PEA_Z%W7O_  $'
M_P 52^*]FW3OM@D.E_:3]LV!C\OEMMW;><;]OXXK&O;R.'P3IJ:O'=7%V-B?
M9W9U#.5.WSF R% ^8GU'<X% ">([YM=M+<0Z5XBL;VTG6XM;J.Q5S'( 1RI;
M#*02"/>L2QTE;3PAK6AR67B2:75UD$UP; !8RR[?D3><#OC/7/2K+0W=IJ6G
M>3J$MY(4MS)<XF$D=NJ'S"HQM*G!.<YW'&"<5L^%98FTS5KS3GECB= T%K(7
M9X\*<.^[^-NI ]!GG- &#J]C)JVKP:J;;Q-#=V*QKII2P&VU(_UA*[\/O'!S
MCCBK=_;6%QI-U8V?A[Q#9_:[R*\FD%J9-SI(K]&?C.W''3-$-_XHM]L@O+VZ
MD46A$4L"A9&EC8R X4$ ,!CGY>]&G:MJ.H3W%C_:%Y=;8K:=_,@$9B<)(\B\
M*."RH,<XSCUH H/ITR:[>:G:0^)+<2-<3VL7]F(WV:XF4*\N=V6X'"G@$T:9
MHUK%HD>GZSH^OZG)"93%<K8>0P\Q<.6"R$.Q.26;/)J_+K&N6RZ-&MU?O<M%
M:2W'FQJ%D\QQY@"K'DX&<Y*[>.IJA#=Z@NFVD!U+4_L\<L374IMSOM6\XC ^
M7)&W.<[L  ]Z *">'+B.U,BGQ)_:V]0M]_9,>!$(3"$\O?@_(3\V<YY]JLZ=
MH%OI?BJTUBWT_P 1"*U1%2$Z:GF?+"(@OF[MWEX&=F,;N:U(KG5+K4]/FNKB
M^2WCN+<B98MGG1EKA59QM_B CR..H/&:Z;Q',EQ8:?-NEDTEYPUXUON),11L
M$[>=N[;G';VS0 ?\)8?^A=U[_P !!_\ %4?\)8?^A=U[_P !!_\ %5B6<MZN
MKPPZ7+>Q:$]R[1;(]Q95ARRKO!(0OC'3)R!Q5/2=5U?4M:M%FDO)+7SX)5$B
M\H2LP=6*HH[+E>0#CF@#I_\ A+#_ -"[KW_@(/\ XJC_ (2P_P#0NZ]_X"#_
M .*KHJ* .=_X2P_]"[KW_@(/_BJ/^$L/_0NZ]_X"#_XJKGB?[7_PC.H?8?-^
MT^2=GE??]]OOC.*P;*YL;?1=;R]XFC%V:T$(D\PQB-/,$?\ %]\L/J3B@#/\
M3R2:\]K<VFG>(=/O[99(TG&GK*K1R !T92PR#@'@@@@&J5OIT5MX/M_#ZZ=X
ME<17<=TT[V08LRR"3: 7X7C &3@>M+-%')HT%P+ADB\V>:"R6"2XB5RJ[("<
M@@]3Z99L$8YZ'Q-=:TEO;M937%HZ:;<7+QP1+)F91'L4Y!XR6X'6@#GI;.2;
MQ4?$AM?$W]HB8*I^PCRQ:8P;?;OQ@G+;NN[![5:EM[!;;2;:P\/^(;.#3M17
M4 GV4R;V"N"N6<D9WY_"C5M7UG3X;^.;4[Z""V$S6]T+96:2411.B-\F-N7D
M[#.W&>*O)=:I)?17RS7J02PSSO'#&&,GE*BHN&'&XES@8SQ0!RT6A7=I#?K8
MR>)[=YH&M;.0:8A:TA>4RNH.\;B2<!CC _.K<FBV5WX>BL+_ $779+Z&W-O#
M>V^G^2(UW;EQ$)"O!QUSG'O3H=7U*YNXFOM4U&WLH[@,MU%%YC*&@;*DB(*?
MF 'W2 > :D34==5[YGEO?[0FVF6Q:W/EB/[&I9QQP=X' /!XQS0!ES^&WN8/
MWB>)?M5R9EU*==+C'VN.5U=E"[L1_<4 C.!FM;3+*+3_ !G=>(Y-)UV:64.L
M48TJ.-D#[<[W4YDP% 7/0$]>M='X.F>$7T%Y=7#7,MT72.XX(7RT/RC XYK,
MU49GU;SA>?\ "0>>?[,*;_N8'E[,?+MSG=G_ &LT ;G_  EA_P"A=U[_ ,!!
M_P#%4?\ "6'_ *%W7O\ P$'_ ,57.:MJNNVNE32K=WXNYKB\$6V-5CC$;$1J
M/W;,V>"!CYO4"NE\)27,UE>S78D$DEV7PX(ZHAX!Z#.: &_\)8?^A=U[_P !
M!_\ %5MV5S]LLX[CR)H-XSY4Z[77ZCM4]% !7%2_\E+N_P#KSM_YR5VM<5+_
M ,E+N_\ KSM_YR54=F)]#M!T%+2#H*6I&8/BG[FD?]A2W_\ 0C6]6#XI^YI'
M_84M_P#T(UO53V0EN%%%%2,***QO%>NOX:\,7VLI9F[^R1F0Q"0)D#J<F@#9
MHKEM2\90VFHZ=I40MUOKR!;AVN)=D4*$A1DXY+,=JCO[5#HOCA-6UFUM#;".
M"^-T+1]V6/V=PC;A[]1CL* .OHKA-2^)-OI5S>23VN;"VNYK'S WSM-'#YIX
MZ8/*_7FMGPUXF;6[J\LKBW6&ZM8H)F"-E2DR;UZ]Q@@_2@ \7_ZG1_\ L+VO
M_H==%7+>+[RU$VBV9N81='5;5Q"9!O*[^NWKBNIH **** "BJMQJ>GVDZP7-
M];0RL 5CDE56.>!@$U:IM-:L HHHI %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 8/B[_D"Q?]?MK_ .CTK>K!\7?\@6+_ *_;7_T>
ME;U5]D74****D9A>'O\ D(>(/^PB?_14=;M87A[_ )"'B#_L(G_T5'6[53W%
M'8***Q]0UY]/NS;KHNJW0 !\VVA5D.>V2PJ1G/Z1\4-*U.Y6.:RO+**2&:>*
M:7RW#K$?G^6-F8'G@$#/:M2/Q]X8E2R9-45OMTC16ZB*3<S*0&!7;E<9&<XZ
MUR-AI%II7A>;2]-T#7;+49HRCZM;:?$EPQ+;LE@^3Z8STJ'2-&;2KE;C[%XE
M>8"Z^=+"*,AIPF67#X7!3(P._M0!U[?$;PFMF]VVKHL23>0VZ&0,'VE@-NW=
MR 2.,'%2Q>/_  K/975Y%K,$D%KY?FLJL?\ 6?<VC&6SSC;GH?2N#TOP_+87
M\5[<V_B:\N5F29Y'T^)2[+$\63A^I#Y).22.O-0W7A*WNM*2R?3?$F8K2TMH
MI#8QG:;<N0Q'F<Y\PY''UH [S_A8OAD7[VQO_E2R6^,_EMY9C8X&#C[WMUSQ
MUXJ=O'GAA19EM6C NT>2']V_*H2'+<?+M(.=V,=Z\^N/"L$VG_84TSQ%#;MI
MZ6<D<>GQ!7=)3*D@&_C#,<J.H/7O5_1-(BT41F/1M==EL9[1Q_9T01S*X8N5
M+D=@,'(/>@#KI?'NBG15U6R>:]MVD:,>7$4;Y8VD)P^WC:IY^E5]-^(>G7*2
M/JEG=Z*%M!?(U\$VR0$@;E*,PZLHQU^8<5R&F: UC83VL]IXFN%E2X55%C&D
M<1EC"91!)A<#<<#@ECTIJ>'YY[-H]5B\3WEQ%:I:V4RZ=#%]F5'5P0H<ACN1
M,Y[#'>@#O&\?>%ULK6[_ +60Q74C11;8G+%E^\"H7<N,C.0,9'K4\GC'0DO;
MZR6_1[NRA>::%0<A5&6 .,$@$9 .1GFO.[[P]/?:9Y$D'B,7TMVUY<WW]F0^
M8[E57,>''E8"+C:>W.:;_P (G:+K6I:@FE>(Q]MWDAK&-I$9\>8=^_G< 1C'
M\5 '50_$VREU5;-])OXHS=1V;7#-%A)7"X!7?OZL 2%Q5RT\?V5WJ,$0T[4(
M]/NKDVEMJ;QKY$TH)&!AMP!*L 2 "1[BN6?1+0:TVMP:%KT6K?VD;Y+L:?$6
M"%0K0GY_F0@'W!.13;;2;BVG@A6#Q0='L[@W5EIYL(<0RY)4E]^YE5F)"GVY
MXH [G1?%VGZ[K6J:7;),LNGOM+R* LP!*LR'/(#*5/N*WZ\I\.Z)!X9U2QU"
MST[Q;)-#!)!<">-76</AB0IDQ'\XW?+ZFNT_X2N3_H6M>_\  9/_ (N@#HJ*
MYW_A*Y/^A:U[_P !D_\ BZ/^$KD_Z%K7O_ 9/_BZ .BHKG?^$KD_Z%K7O_ 9
M/_BZ/^$KD_Z%K7O_  &3_P"+H T=;U2WTC3&N+F,R1LZQ!. &+G: 2< #)Y)
MXK%TW6= T6S3=;/IK3ECY;(TI=4 RP9=P,8!'.< 'MS3-3UZYOK/R8=$U^W?
M<&#?8XW5L=592_*GN./J*YC[-?031QV6D:S;P21W"W/E:=&J#S-@VQQ^9\G"
MDYR>>2#F@#O7\4Z.@G(N9'$$ABD,5O(X# $D#:IS@#)QG'?K5BSUO3;\QBUN
MTE\QRB[0>2%#^G]T@Y]Q7!W5J9M.6QBTKQ$D GDE,;V2.C!Q@!E\P;BO4$Y&
M>H-3Z%+)H^IF?_A'_$3QQ64%I'NMH_F9%"M)@/P2%0?\!H ]%ZC!I%544*JA
M5 P !@"N>_X2N3_H6M>_\!D_^+H_X2N3_H6M>_\  9/_ (N@#HJ*YW_A*Y/^
MA:U[_P !D_\ BZ/^$KD_Z%K7O_ 9/_BZ .BHKG?^$KD_Z%K7O_ 9/_BZ/^$K
MD_Z%K7O_  &3_P"+H Z*BN=_X2N3_H6M>_\  9/_ (NC_A*Y/^A:U[_P&3_X
MN@#HJ*YW_A*Y/^A:U[_P&3_XNC_A*Y/^A:U[_P !D_\ BZ &WVH>&-53SKLB
M=;=MBGRI/G+-MVK@?O 2N,#<#BK=KXFTN[O4M89LB1(VA?'RR%_,.T=P0(GR
M"!C%<4MM+'>2W<6EZ]%-YRSQ"+3HUC#@GYG0289B&*DC;GZTL=K);3)<VVF^
M(5NT=9?,DL(V4R9F+DKY@X;SVXSQ@=: .LMO&FDW5U)%'(XB1D'VB12D;!HV
MDR&/4!5.:E;QAH20K(UXPW,5"?9Y-_";SE-NX#;\V<8QS7$1:6BVL=I+I?B2
M2W"1JP^QQAF*PO%G._ R'SC'4>]64CF>\:]N],\037;HT;NMA&BE3'Y8POF'
M&,D]>2>PXH ]&C:&=([B/8ZLN8W'/RGG@^AXJ2N4T_Q ]AIMK9KX=U]Q;PI$
M'-J@+;0!G[_M5G_A*Y/^A:U[_P !D_\ BZ .BHKG?^$KD_Z%K7O_  &3_P"+
MH_X2N3_H6M>_\!D_^+H Z*BN=_X2N3_H6M>_\!D_^+K;LKDWEG'<&WFMRXSY
M4ZA77Z@$T 3UQ4O_ "4N[_Z\[?\ G)7:UQ4O_)2[O_KSM_YR54=F)]#M!T%+
M2#H*6I&8/BG[FD?]A2W_ /0C6]6#XI^YI'_84M__ $(UO53V0EN%%%%2,*R/
M$^B?\))X=O='-R;9+N,QO($#$*>N 3UK7HH X_5?A_;:PRM<WT@:2SCLKO9&
M )XTD#KC^ZV1UYX-$?@&"UD:2QU&>UDB2X6R=$4FU,[AW(S][D8&>@-=A10!
MQ]W\.]+O[F<W<LDEK//)=/!@#,TD7E,^?ISCL3GVK4T#PU#H4MU<"=[BYN4A
MCDE90OR1)L08'MG/J36Y10!S'B^W@+:-<&&,SC5;51)M&X#?TSUKIZYWQ?\
MZG1_^PO:_P#H==%0 4444 <[KEI;3>)O#SRV\4C>=,-SH"<"%R/UKHJP]8_Y
M&/P[_P!=YO\ T2];E;56^2'I^K$@HHHK$84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '%W+?$D33&VC\-&$,QC#--N*]L\8S7 ^#?$/Q6U/Q!J%
ML\,1"Y,@U.!HXH6SPJE1G/MSQS7MLUQ#;PR332*D<:EG8GH ,DUDZ7XOT#6K
MO[)IVIQ3S[2^Q0P.!U/(KOIYC"G"4)4HMO;0:P]2:<XIM+<YW5&^(@\+:SYB
M:7]M\@?9/[-+F3=N&[&_C.W./?%13207-EK<%G::FMM:Z:)(KIIY-LDNUB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.2*$2P(^Q78,ROD?O!\H !Z#WYIFG^&!IU_IXBP8+5I[EY  OF32?*0%'"J
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M %%%% !112-G:=O7'% &18^'K:QNS<1W5W)*J^7&99=_E1[MQC7(^Z3CKDX
MYXIT&@6L$UU/)/<W$L\1@,D\FXI'DG:IQTR>IR>!SQ7.>#(+O3KMX[NS.]H
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M7GDD>:9E'!D=BS8]LGBM"L7PJ[MHNTDF&.XGCMV)SF%9&"?H!^%;5 !1110
M5Q4O_)2[O_KSM_YR5VM<5+_R4N[_ .O.W_G)51V8GT.T'04M(.@I:D9@^*?N
M:1_V%+?_ -"--\;QQ3>$+^.62=%8+S;P+-(3N& J-P3G'6G>*?N:1_V%+?\
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MXW*/<4MK>VM]$9+2XBG0'!:-PP!_"@#$\7_ZG1_^PO:_^AUT5<[XO_U.C_\
M87M?_0ZA\8:?:W;Z/)-&S-_:$460[+\C'D<$9S@5I2@IS46["90\/_Z5\4_%
MMSU6WAM+8'T^4L?YUV]<1X!_TC5O&%_U$NL/$I]1&JJ/ZUV];XW2KR]E%?=%
M"CL9&I_\AW1/^NTO_HIJUZR-3_Y#NB?]=I?_ $4U:]<4=V=%7X8>GZLQ[O\
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MHJC6"))I)EC199  [@<MCID]\5@_VMXF_P"A7C_\&2?_ !-']K>)O^A7C_\
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M"\MA;QV\EI<-')'']TDX<,/]X,#]<UI5Q^G3>)[*6]GD\-0O/=SF5RNHK@
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MZA+=++H#1VUQ<1W12+5$!\U5V\Y0@J<*<'N,U,UAK;W,=Q)X>FD=62216U9
ML[I]QG 3DC Z8Z#@XH ZK0[N.\TJ-HX$MS$S0/"GW8W1BK*/8$<>U:-<?I$W
MB;3+#R6\-0O*\CS3.NHJ TCL68CY>F35[^UO$W_0KQ_^#)/_ (F@#HJ*YW^U
MO$W_ $*\?_@R3_XFMNSEN)K2.2ZMQ;SL,O$) ^T^FX=: )ZXJ7_DI=W_ ->=
MO_.2NUKBI?\ DI=W_P!>=O\ SDJH[,3Z':#H*6D'04M2,P?%/W-(_P"PI;_^
MA&LOQ]KS:=;0V']F07T%PCR7(EO5MBL2XSY9)!+\\ 8Z=:U/%/W-(_["EO\
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MZ_)*YB:!X9TCQ9?ZKXDU#3HY;>\G*VB-D91/E,GU8C]*]"CC2&)(HU"HBA5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZUV5KXHT:[=$COHUD=Y(T1_E9BC%6P/JIQZXJ6]UVRT]V6<R "U>Z5@O#HI
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MK:R-QP']2 /S++_WT/6@"K_:OB;_ *%F#_P9+_\ $4?VKXF_Z%F#_P &2_\
MQ%6)?%F@0.J2ZM:*S , 9!T/2K&HZ_I.DS+%?W\%O(R[U5VP2/7]* ,_^U?$
MW_0LP?\ @R7_ .(H_M7Q-_T+,'_@R7_XBKY\0Z0)A$=0@#E%D&6X*MC#9Z8^
M8<^XJNWB[0HR1+J5O'\VU=SCYN <CV^8?G[B@"#^U?$W_0LP?^#)?_B*/[5\
M3?\ 0LP?^#)?_B*O'Q'HP@\XZG:^5MW;_,&,;5;^3J?^!"HX/$^CW6TVU]'.
MID6-FC.0C,"5SZ9P0/?B@"K_ &KXF_Z%F#_P9+_\11_:OB;_ *%F#_P9+_\
M$58U;Q+::1*D<L%S-NMWNF:%5(2)" S')']X<#)]J6+Q)93:BMJJ3[&E,"7)
M3$32@9* YSG /;&01G- %;^U?$W_ $+,'_@R7_XBC^U?$W_0LP?^#)?_ (BK
MEIXBTR[L1=FY2WB,C1#[21&20>V?48(]00:K1>+=.>\D@E6>WC1IE%Q*%$;&
M(X?!!)X]P,T ,_M7Q-_T+,'_ (,E_P#B*/[5\3?]"S!_X,E_^(JW-XGT:&Q>
M\.H0M"L?F?*V21ACP.N?D?C_ &34NGZ[IFJ.8[.\CDE$:RM&#\RJP!&1^(^E
M &?_ &KXF_Z%F#_P9+_\16U9R7$MI')=6ZV\[#+Q+)O"GTW8&:S%\5Z1+?6=
MG;7(NI;J5XD\CY@I5=Q+'L,?GGBMJ@ KBI?^2EW?_7G;_P Y*[6N*E_Y*7=_
M]>=O_.2JCLQ/H=H.@I:0=!2U(S!\4_<TC_L*6_\ Z$:D\5:G>Z3X>OKRQM6F
MEBMY'#AE C(4D,0Q&1["H_%/W-(_["EO_P"A&IO%.K?V'X:O=1\F*;R4'R3/
ML3DA<L><*,Y/L*I[(2W(/#&K7NJ_VF;V,Q-!=")(SMRJ^5&W)7@\L3^-9'Q
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M-P*\$Y;Y1S52Z^'-E<"X$=UY*S>9D) H'S%_Y;S^5%[\.K6Z\W9>>5N8L@$
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MV50)&7)9"00%5<'CK\O6H/\ A&O"]MJ?V W5T;EX4@<$;N2N%+2;/E8J.%W
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M3Q374DD'$9E<'"[-@7@#@+T[^I-;E%% !7%2_P#)2[O_ *\[?^<E=K7%2_\
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MC9W%W:7:206[,DS8(\ME&6# \@@'D4 <!:FYN[R[^Q'5)KT:K>I<-(9##]F
M<;!GY",[  .=V>V:H11Z]!!I:Q6NHP3VB:<B1B*9BT8$8DQ@A$49D#!@S<>F
M*[^#Q/X:M[2.:"\@C@N6>562,@/R"TG3[N6!+].>M1IXRT\ZOJ5G*1%#8-'&
MT[;OWDC@$*B[?FX/8_ACF@#C[B#6$@U*TM5U.Y>9<M>*MQ#*A\]/E*L=C-M+
M8:/'"GC!K3.F:A9:K+-:)J6V'6H4@4RR,HMFC7S, D@J6+9)S@^F*ZI?$VBM
M):QIJ$3/=(9(@N3E0<$G X /!SC!ZU&OBW06M9;G^TX1#$4#,V1]\X0C(Y#'
M@$<&@#DO")UD>*+22XCOT@FLYOM:313;4E#(5#NYPS_?Y0!<=*$:YN?$FH_8
MVU.34HM;C5&W2&WCM@D9D4_P8P7XZ[B,5V#>*=%2S2[:_C\IY&C'RMNW+RPV
MXW @<GC@4D6MZ##?BU@N[59[MED_=])&<?*2PXW,%&,G)P,4 <#8:;J^C>&-
M/-C9ZH)I=*N!=0J[@B0/'LX.=C %\!1DC(':GZ?9:O<ZFMG*-2;3#JD#Y1)X
M4,1MY=X&]B^S>$!R1ENPS7H=[JL5GJ%G9;"\USO;K@1QH,LY/H,J/J:JCQ;H
M+6TUS_:4(AAV;V((X<[5(XY!/ (R#0!R-EH=]++IGVD:L5F>_P#M8:XE *AS
MY(;G@8QMZ5F7S^))+.UD:+5%OH;.S9"(IG>1^#)C:0B$<[M^2<<#D5Z,GB32
M)+N*U6]7SI2H52K##,,JI)&%8C^$X/M3-/\ $5I>>'+?6Y\VL$PSM<[B#NV@
M<=23T ]: .0NH]7^RZA]F36?^$B+76YT+" Q;CLVEOD^YM";>0W7O534M/UN
M\N(U\-?:[>U%U"UK)?Q2/Y,ODS"1L/\ ,%Y09/&X]Z[N7Q1HL%K%<R7Z+'*6
M"?*V[Y?O97&1COD<=Z9:^)K&YUFYTTLJ-')%'#)O!6X+Q>:-N/\ 9!_*@#BO
ML^JW4]C%!;ZU;V;"P6:*227<I$TGGAGSSQC+#J".V*2\MM;BN/L\BWW]DPSW
MB1 BX=@=R^5_JSO(V[]I)(_2NKN/&VE17TEK'*KA+4W)G8E8L"3RR"V#SD'\
MJT3XCT<7DUH;^(30ARXYP-HRPST) Y(!R* .!AT_6[;4C,8;_P#M&XDTMIIP
MK@2*N1(6VDJ,'&X9_2NB\(I(DL/VB/6!J'V8_P!H-<EO),VX9QNX)SNQLXV]
M>U:3^+M*DTVXOK&87D=M&L\RQY#"$_\ +101\RX!/'7!K2O-5L;"UCN;FX5(
MI2%C(RQD)Z!0.6..>* //K*6]FO[B;3AJT^HQZM>"<L[^4;=?, 12WR==@4=
M0WMFLZ&+7YXWBC755AN+:U:4)'.A23[0F\;G.2^PMN("C';BN_7Q/X:L8D*7
MUM$DZO<XC4\C<0[L ./FSN)Z'K3M2\6:;I][;60E$]S-<PV^R,_=,AX)/3..
M<9SB@#D=235H/$J"R@U&-;;4;:*,!)I=]M\@9MV?+$?+Y!#-GK[16NAZF=/M
M3*-8,LFD74L^ZXER;D,OE9YX8 M@?SQ7=:EK36FHV^FV=H;R_GC:;R_,"*D:
MD LS'.!D@# .36=J?BF^TSP_=ZM)H4H%EO\ M,4DX0X4 YC."'!SP>* .8BC
M\1S:Q&]T;Q;EIK4PD13$>3L3S <$1@9\S=N^;)XS\M9\.G:K9Z;:VL<%]!9Q
M17*[%CN&9;GSF(("$'.S&TGY.O>N[O/%+:,;637;);&TGW W2S^9'$X&55C@
M8W#.#ZC'4BM;2[Z6_P!,BO9[.2S,@+B&4Y=5S\I8#H2,'';.* .%_LW5I;76
M)[^YU&*[$EJB2B.1T9?*B,@\M&^X7#!BAR.<&MBT;69? &H+8VLMMJ*K.EH&
MD<E\$[77S?F7/8-T^E3P^-;>YL;NXAL+H/%?)80PS+Y;32,%*G!^ZIWYYYP,
MX[5*/$UW-#(+;1I);BW>6.[1IU5(2@!QO/7<&!''3.<8H Y.ZTN74)H4LK35
M6TE+S3Y%2Y\X.LHD/FL-QW !-N3TSDCG)KH/%,<R>)]"NEEOK>"**Y62XM+8
MS%2PCP"-C8S@]NU;#^(K1?#,6NJDK0311R11XP[E\!%QZDL!^-2+K^FB_33Y
M;J)+TX5HLDA7*[MF[&-V.<=<<XH \X6SUZ*SM4ECO$L-EVT#+#,)7E:8LDDB
M18*R,IR-V%R3T-6);'4[)]2=[6]:[NYK(W$RK+M9?) =F$9)(WC!5#GGKBNV
M7QAH#6JW*:BCQ/NV,B,VX*,L0 ,E1D9(X'K5C3M<@U+4=1M85REF(CYP8%91
M(F\$8[8H \]M-/UN[LKI+G^UR+>RU#[+_K8<OYBF$@9)SC.T$DXJS?V6O6RM
M%:"_-I(+&6[,C2N6R)/.(P=W41[@G..U=:GC?PW)'YB:M"R;/,W!6P4_OCCE
M1W;H.YK1.M::&=?MD68[A+5N>DK@%5^I#+^= 'FUWI.H36?G7%M>W#G3]3@M
M&$4N5#!/*3!);!^?;OP2,9[5>N[+4M+BEM+.#46LGBL2^7F=48[Q(QQER.$W
M*A';IS79KXIT-_M!&I08MU+2$D@8#;20?XANXXSS@=Z1O%.BK:+<F_3RV=DP
M$8N"O+ J!N&!C.1QD>HH \_\O6ET<-,=2F:WFNQ!;26UR@G7(,>UD8M&W9=V
MX8)[CC6*ZQ)JK.\.I1ZLVHPM!RY@2SVIO5B/D.!Y@.?F+8([5US^(M(CNH[9
MK^+S9-FW&2!O^YEAP-W;)&<C%,T[Q#:WN@'6)Q]EMP\B-YASC9(T?;U*\#W
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M7U]/-:.3^:T?\(GXNB_U'C^Y/M-I\3_X5E]3H=*J_P#)O\F+Z_6^TD_6,?\
M(M?\5[;_ /0!NQ_VUC)_F*/[9\8P?Z_PK;S#UM[]?Y,*J_V+\0HON>+=.FQ_
MSUTT#^34GV?XF0_=O_#5P/\ ;@F0_H:/J2^S67WO]8A]<B_BI1?R:_)HM_\
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M%YTMO%=_+MDEC#%E SD?<< D8)'TJI=>/[>RTBVU*ZTVXABN+?[4@DEC4F+
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M^(;91&JEMQ4>AK&$:G.W)Z=#U<5B,+/"4Z5&+4UJ_/2SZF3_ ,)KI']S4O\
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M_@MN/_B*UH+.UL)KRZ4[&NI!+,SOQN"J@Z].%%6Z .>_X372/[FI?^"VX_\
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M>6_G3W$+/(D4T@".S0I#AB%X&U!VZD_2K7A701X=\.6^FLX>0;GE<$G+,2<
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M WQ5@X.!PW3<3[9I/A_#JJ:_IXG64/'IEPNJ%\_\?!N25W?[6-Q'M[5ZG10
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MY4\?W1SQ76^ 4NUT*[^T!Q"VHW36@;_G@96V8_V>N/;%=++/# NZ:5(U]78
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MN<Y_PGEO_P! 36?^_"?_ !='_">6_P#T!-9_[\)_\771_8+?_GFOY4?8+?\
MYYK^5%UV"S[G.?\ ">6__0$UG_OPG_Q='_">6_\ T!-9_P"_"?\ Q==']@M_
M^>:_E1]@M_\ GFOY4778+/N<Y_PGEO\ ] 36?^_"?_%T?\)Y;_\ 0$UG_OPG
M_P 771_8+?\ YYK^5'V"W_YYK^5%UV"S[G.?\)Y;_P#0$UG_ +\)_P#%T?\
M">6__0$UG_OPG_Q==']@M_\ GFOY4?8+?_GFOY4778+/N<Y_PGEO_P! 36?^
M_"?_ !='_">6_P#T!-9_[\)_\771_8+?_GFOY4?8+?\ YYK^5%UV"S[G.?\
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M'_">6_\ T!-9_P"_"?\ Q==']@M_^>:_E1]@M_\ GFOY4778+/N<Y_PGEO\
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M(Q^5',NP6?<XO3O#=Y?ZC_:6KW#75V1M#LH58U_NHHX4?J>Y-=M;P);Q!$&
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img181340459_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (E I\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HJ*YNH+*V>XNIHX8(QEY)&"JH]R:KV
M&L:;JOF?V??VUWY>-_D2J^W/3.#QTIV=KA<NT5FW?B#1K"Z-M>:K96\XP3'+
M.JMSTX)K2!!&1THLT%PHHHI %%%4WU73XM133Y+ZW6]<96W,@#L/9>O8T6N!
M<HHHH **** "BBJEMJNGWMU-;6M[;S3P<2QQR!F3G'('3FBP%NBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%U:VUW1;35+3=Y%U&)$##D>H/N#D5R7BSXEPZ#K4>@Z5ID^KZPXR8(3@)D9
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MMTO;^M2W.237F>D>$OB%%X@U>XT34-,GTG68%W-;3'(8#&2#@>N<>GK6??\
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M:6^KKJS6%N=00;5N2@W@8QC/T)J_12YG>]PL@JEJ>D:=K-M]FU*R@NX>H29
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M;S>B.;^($?AK0[KPCIUWI-S=)$1#9&.Z*>4 4 SD'=V_*JGQ%_Y+)X,^L?\
MZ--,^-( \2>#P.@N#_Z''3_B+_R63P9]8_\ T::JGM%^3"6[7FCI/$/Q1M?#
MOBUO#\NE75S+Y2M&UN=S2.PRJ!<=SQG-9<'QFCBO[C3=5\-ZC9ZDF!#:K\[R
ML<;5Q@8)R#FLW4$5_P!I6QW#.+<$?41-3M0C23]I2P# '%MN'U$35*IT[6:^
MS<;E+OUL=+X6^):Z[XGF\/:EHUQI.HJI9(YFW;@!G!X&#CFNRU7_ )!%[_UP
MD_\ 037E-S_R<Q:?]>I_]$-7JVJ_\@B]_P"N$G_H)K&K&*E%Q6Z3+@VT[GSC
M\.M+\!W^DW<GBR[BANEGQ$'N6CRFT=A[YKVCP-HO@_2K:\OO"LR202D)/*)V
MD4%,G')XQNKSCX,^$- \1>']0GU?3(KN6.ZV(SE@0NT''!KU.[\+V>F>#=7T
MKP_9I:&YMY=B1D\R%,=_H!6^)FG)QN_T,Z4=$[(Y2Y^,0GOKF/P_X;O]7M+4
M_OKJ+(7'J %/'UQ75^&?&^F>*M GU33PX-NI\ZWDP'1@,X^A[&O//A!XO\/Z
M#X2N]/U6]AL+R"Y>219_E9P0!QZD8QCKQ4?PI@DNIO&FMP0M%IEV7$ (P&.7
M; ^@8?G2J48I2TM;KW'&;=M=S4L_C9_:D<0TSPO?75P9-LT:/E8E. I+!>Y)
MZXZ5L:Y\4K;0_%TWAZ31[NYN%C4Q&W.]I7900@7'OC/M6)\ (E7PKJ<H W/>
M8)]@B_XFJ[(K_M,?, =MN"/KY%#A3YY1MLF"E+E3ON:-M\9HQ>W.FZCX;U"V
MU9"%ALT^=Y6)X7H,'!!K6\)_$I/$/B.XT#4-(N-*U*)2RQ2MNW <D'@8.#GW
M%<RT:O\ M+C< =MMN'U\BA/^3F'_ .O;_P!H4.G3:T7V;@I2OOUL=)XB^)+Z
M;XC?0-%T&[UC4(DW2B+*JG0^ASU&3TYI-!^)RZY8ZPJZ'>1ZMIB%Y-/SN>3!
MP0O&<YXQBN:O_%FJ:]\0]4T(^(H/#-A8[E\THHDFVG'WFQC.<]>GK5'X0/ W
MQ)\2_9[^6^C,3;+J8Y>8>8/G/UZT>RBJ;;6J2?7_ (8.=N6C$^$/BK5;GQ'J
M<5UI]_?&_N%,UXS%EMMH<@/QQZ#I72_#>ZT*?QAXGCTO2[BTNDE/VF66X\Q9
M#YC=!CY><FL'X*:K86.J:_IUU=Q17ES=J(87.&D(WYP.^*;\,8I+CQ=X]AA;
M;+(9$1L]&+R '\ZJK%7GTT1,'I'YG1ZA\74;5[FP\.^'[W6Q:G]_-;YVC!P<
M84Y'N<9K?\+^/],\5Z->7MI')%<6:%KBTEP'3 )Z]P<'FO._@[XCT;PQIVKZ
M5K=U%IU_'=%V%P=NX!0,9]00>/>D\!9U;QAXWU^PC9-)E@G1'VX#LQW#] 3[
M9J9T8+F5K6Z]RHS;L[[FY:?&AM5TZ2;2?"VH7ES#EIHHSN2)!T8L%[\\8[5U
M_@CQK9>-](DO;6&2WDAD\N:&0Y*'J,'N"*XOX HH\(ZDX W->D$_1%J#X"\6
MOB(#_GZ3^34JM."4U%;6"$I75WN>PT445QFX4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNEV$%H)F#2")<;CZG\ZT:*7,^X604444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !114-U=0V5NT]PX2)?O.>B^YH FH!R.*PY[
MV<^(K6&*\46\J!Q#Y>3(,'+!NPZ9K6M6W0 _[3?^A&@":BBB@ HHHH ****
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M HR91T'Y$@UV%&,U[\)N$E)=#@J4U4@X/9E'1K:XLM&L[:[F\ZXBB59)/[Q
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MZA_T#+;_ +Z;_&O.<4N*]+ZI1_E/%_M#$_S'HO\ PM[4?^@9:_\ ?3?XT?\
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M>,@$66HD'H1:L0:UK*X%S;B0131CIME0H?R-==#FO9G%*W0L4445TD!1110
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M_P B@CK^/9O?_/\ D4$<'_!O?_/^10!O^&UVZ6_O<2G_ ,?-:]97AX8TP_\
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MA9)J-A<6<Q4AAMW+T##H1^-0Z/8)I.G1VH.Y\[I9 IVLYZ__ *JG^T1 8#@
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MN"=DEZ[)WWZMK\CF?/S6NS1L2#XIOAD9%I#D9Z?,]4-,:_/B:;S%9"Q+2@@
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MIMSYL.PGYE_E5ZN=T>5FO,$]JZ'-;T)<T#CQ$.2I86BDS2UL8!2$9!!Z4M%
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M?-;%R?W./[S*OYD"L7P><Z3<_P#7]<?^C#6Q<?-/;Q^K[S] /\<4AEBBBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,5]&G?5S>F6+;]I6;:%.=JQE,?7FGVJ2CQ
M1J#LH$;01;#Z_>S6O5"#3S%K-W?EU(GC1 H'(VY[_C0!?K OF5/&>FMY@#-;
MR)L^;YAP<\#!QCN>];]9<EE<2>)8+W:OV>*!HP=W.2<]/P% &I56_LEO[?R7
M=D&X'( .?SJU10!5MK&.UN+F="2]PX=\^PP*M444 <C87_V&2]DMMLPN-8\E
MR>V1STZXKKJQ!X= ()O')-[]K<E!\Q]/_KUMT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0TI-D5S
M[W4I_-C5^HX8A$& _B<M^9J2@ HHHH **** "BBB@ JFVJ6::F-.:;%T8_,"
M%3C;]>F?;.:N5R'B;PA=:[J37$-W'"A@$>"6R2#G!QQCGKC/'I0!TMIJ%M>P
MM+"_R!V3+<9()4X]L@U.94 R77&,]:X;_A7K;G43VR1E&VE8R&W$'!/., \C
MW+5+-X)NY(K!%N;4_9[5('\Q6;<0V<CGC&<CWQGI0!V%O>075M%<1N/+E7>I
M/&12QW4$V_RYD;8Y1L-T8=OK7$2_#Z>62'??H\: J4((&TKT]^=WX&IW\"R-
M806:W$,<<=[]I;RU*EUVXP?<=O:@#L_-3.-ZYSC&>],EN[>")I99XTC4;BQ8
M8 ]:X$^ M2&H([7D$J.5+RE"&C('WAS]XDD ^E/D^'<\L40\ZQ4^87D583MV
M[-H09.=N<G'N: .\CN8I4#JXP>F>#4M<.O@69KQ9YI[4A&$B[4;.[G'?HN?E
M].:[B@ HHHH **** "BBB@ HHHH *QO$\]W#HDHL$F>Z=E6,0D!LYR<$\= :
MV:* /,8?$GB#37;8JW/VN1Y562%QY0.X@9S[#@>GO6OK/B'5K6[EL%6)_P!W
M&"R0OEF9#D C@$\D>@6NWHH \^3Q5XA%S#91V,2?N]OG2QN065@K-C.2/\:E
M_P"$HUNUL[ _9UN9)FN'F)B92@0Y" ?W@OYUWE% 'G2^-]9-W+ UO#&R%L*]
MO)N( 7)X/1,DGU XI+CQ9K[K$FV* 3;F\P6KD(B[?F/.?FR>.P(KT+R8S<"?
M8/-"[ _?;G./TJ2@#B-,\1ZQ<7MO 8(A;B54EW12;E!P-NX]3R&STP<5V]%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5$ZSI:D@ZE9@C@@SK_ (U>K,;PYH;L6;1M.+$Y)-JF3^E-6ZDRYOLD
MO]MZ5_T$[+_P(7_&C^V]*_Z"=E_X$+_C4/\ PC6A?] 33?\ P%3_  H_X1K0
MO^@)IO\ X"I_A3]TG]YY$W]MZ5_T$[+_ ,"%_P :/[;TK_H)V7_@0O\ C4/_
M  C6A?\ 0$TW_P !4_PH_P"$:T+_ * FF_\ @*G^%'NA^\\B;^V]*_Z"=E_X
M$+_C1_;>E?\ 03LO_ A?\:A_X1K0O^@)IO\ X"I_A1_PC6A?] 33?_ 5/\*/
M=#]YY$W]MZ5_T$[+_P "%_QH_MO2O^@G9?\ @0O^-0_\(UH7_0$TW_P%3_"C
M_A&M"_Z FF_^ J?X4>Z'[SR)O[;TK_H)V7_@0O\ C1_;>E?]!.R_\"%_QJ'_
M (1K0O\ H":;_P" J?X4?\(UH7_0$TW_ ,!4_P */=#]YY$W]MZ5_P!!.R_\
M"%_QH_MO2O\ H)V7_@0O^-0_\(UH7_0$TW_P%3_"C_A&M"_Z FF_^ J?X4>Z
M'[SR)O[;TK_H)V7_ ($+_C1_;>E?]!.R_P# A?\ &H?^$:T+_H":;_X"I_A1
M_P (UH7_ $!--_\  5/\*/=#]YY$W]MZ5_T$[+_P(7_&C^V]*_Z"=E_X$+_C
M4/\ PC6A?] 33?\ P%3_  H_X1K0O^@)IO\ X"I_A1[H?O/(F_MO2O\ H)V7
M_@0O^-']MZ5_T$[+_P "%_QJ'_A&M"_Z FF_^ J?X4?\(UH7_0$TW_P%3_"C
MW0_>>1-_;>E?]!.R_P# A?\ &C^V]*_Z"=E_X$+_ (U#_P (UH7_ $!--_\
M 5/\*/\ A&M"_P"@)IO_ ("I_A1[H?O/(F_MO2O^@G9?^!"_XT?VWI7_ $$[
M+_P(7_&H?^$:T+_H":;_ . J?X4?\(UH7_0$TW_P%3_"CW0_>>1-_;>E?]!.
MR_\  A?\:/[;TK_H)V7_ ($+_C4/_"-:%_T!--_\!4_PH_X1K0O^@)IO_@*G
M^%'NA^\\B;^V]*_Z"=E_X$+_ (T?VWI7_03LO_ A?\:A_P"$:T+_ * FF_\
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MLO\ P(7_ !H_MO2O^@G9?^!"_P"-0_\ "-:%_P! 33?_  %3_"C_ (1K0O\
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MS*B*,EB4. !ZUY9-I>N:+\._!6O:;I5S-K6C1>5)9>4WF-'*A5E*XSP=IZ4
M4=5=M:^,NC:\9";:'6#I5JO8B*,M(W_?QB/PKO=0\6ZW?>)+[1/"NG6-PVG!
M?MMW?SM'$KL,B-0H))QU/05@2>%;W2!\-[.*VGG:SO'FOIDC+!7="SLQ'0%B
M>367J_A;2-)\=:Y>>)_#5_J>G:E(MS:7MDDLGE-C#1NL9R.>0<4 7/&?BW4M
M<^%OB2)+&*RU/3G^S:I \Y_=*<'?&P'S!N,9QQG\>BE\5ZGX?\):,EWIEO<:
MYJ#K;65G:SGRW.W(9G8#  Y/%<PGAJ2Z^&/BY=(\)OI']H(!:6S.[7%PB<AG
M5B=I.3@=?TJ3Q3I[^+_"WAG6TT#4+J'29BMYI<T;0SR1[0KE%R"2" 1CK0!U
M%CXLUS3_ !#8:/XJTZQ@_M+<MG=:?.TD9D49,;A@"#CH>AJAX?\ ''B?Q-K5
MS!I^@6:Z;8ZC)9W=U+<D':K8RBXY(')^H%8OA_1_#MYXOTQ_#G@>\@AMF,US
MJ&I+/"("/NK&KM\SY]L"NG^&-A=Z?IFO+>6LUN\NN7<J"5"I="PPPSU![&@"
M%?&'B77KR_?PIH^G3Z;8SM;F>_NFC:YD3[PC"@X /&6X-$WQ,AE\*Z?J&FZ;
M)/JNHW9L(-.D?:4N 2'5V[*N,D^F/6N%M?"V@>&KG4[#Q3X0U6_G^U22V=[8
MQS2I<QL<JOR-A7'3!Q6N?#6I:9X;\.Z]8>%Q9S:7J3WLNCVTK22&%UV,?F)S
M)M .,T 2:K?>(I?B;X%M?$6F6=O*D]S)%<64S212 PG*_, 0PP/8YKUVO+;W
M6;SQ9X^\'W5AH.K1:78W$S3W=U:-$ [1, ,'G [MTR0*Z)?AEX;3Q -;$=[]
MM%S]JS]MDV^9NW?=SC&>W2@"M<>+O$&J^(M2TWPKI-C<P:4PCN[F^N&C5Y2,
MF./:#R.Y/%8OPQUF*S\.>--;U*%[*./6[NYN(F^9HL(A9>.I'2IM/O;GX?\
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M2TCO+*97),\9.'R"."&XXI_AKQ+-XBU77DCMD33M.N_L<$X8DS.H_><=  2
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M=H<P@,[JI[D*"0/K0!T-4]5T]-6T>]TZ1V2.[@>!G7JH92"1^=<=XV\9>7X
MCU[PSJ44BR7<$:7$8#@J9 K#![]1ZUWC,$4LQPH&2: *.AZ5'H>A6&DPR/)'
M9VZ0*[]6"@ $^_%7Z\ET+QK)XL^(^HPVWBL6VGV;A;.PBM@1=J(RSNS,,C!^
MG2K_ /PDVIPP^ E@UZ+4X]3O9(;J\B@"+<J-W08^7&,<>E 'I=%<QJ/Q$\):
M2\L=[KEM')#,T$D8#,RNN-P( )XR.>E%Y\1?"%A+;1W.OV:FY19(R&+#:WW2
M2 0H/OB@#IZ*S[G7-,L]2L=/N+R-+N_W?98CUEVC)Q] :T* "BBB@ HHHH *
M*** "BBB@#$TGPU!I'B#7-7BGD>75WB>1& VH8TVC'U]ZVZ** "BBB@#E]8\
M&_V]XBM+^_U:ZDTVU=)DTL!1$94SM=CU//..F174444 %%%% !1110 4444
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MN[NWU2V"I!)Q<098>6>49EZCN"1D9!Z4 ;U%,BECGB66*19(V&5=#D$>QI]
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M,)!C#CHV">#U!KJ?#W@_3?#ANYH9+J[O;S'VF]O)C+-(!T!;L!V H \BL?\
MD@?A7_L-Q?\ I2]=HMC::]\;=5AUBWBNH]-TV$V,$X#HN\G>X4\9SQFM^+X?
M:)#X5L?#B_:OL%E<K=19E^?>'+C)QR,DU8\0>#-.\07UOJ#SWMCJ5NACCO;"
M<Q2A#U4GD%?8B@#"N+7P?X8TSQC'!?2VT!C$VHVEI+@VV], QJ!\C./UQTKS
MKQ?8W$7PM>:T\":?HNGVL<4EO>W%RAO!\R[6 1<[SGG+=S7K]CX$T*RT+4-(
M,,MS%J.3>S7,IDEN">[/UR.V.E9$OPGT2\L/L&IZCK6HVB)L@ANKXLD'& 5
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MP_96WB6\UZ/S?MMW D$N6^7:G3 ['FM6@ HHHH **** "BBB@ HHHH ****
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M^.-1\.;[9!9P1N)C<+F5VSE0/]D#FJFE^/H-:L/$TUJ+99=)EGCA3SPYF$:
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M['6%\ZV6/SEM2Y59G"Q@9 /. 2<>U7/ Q?PK\1?'NB:(6;3+2T:Y@@+%E28
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M%;:A;"&[^T)]JY<<;4&>>^6->I_\*]T-O#FIZ'(MQ)9ZC=O>2EI/G25B&RA
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M&2='W%3$@8;2#CJ>: .KHHK*CNM2/BB:T9+/^S%M1(CB3]_YN[!!7^[COZT
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MT/X:7,UW\-?#\]Q*TLK6B@NQR3C@9/T%7M#\*6.@>%SX?M9;A[4B4;Y&!?\
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M;B".",^E.UBW@;3KVY,,9G6UE592HW %3D ]<5<MK>&TMHK:WB6*") D<:#
M50, #\*+F!;JUFMW)"2H48CK@C% ')?"C_DEOA[_ *]O_9C3OB3HUUKWAA+*
MSN+9)_M<4@MKF39'>;3GR6/HWI[5N^'M#MO#>@6>CV;RO;VB>6C2D%B,D\D
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MX(VD8(N6(49.!W/% $U%5-+U&'5]+M=1MUD6&YC$J"5-K $9Y'8U;H ****
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ME&%SP.?45;^'^FZ[HOA>WTC7(;-&L56""2UE+B5 /O'(&#0!U5%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img181340459_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'O CT# 2(  A$! Q$!_\0
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MOPCIMC;>"-1O8880J7$>[;(,GD80_P Z]#^(VEWNL^ M3T_3K=I[J94$<:D
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M[B/8Q4]& ].GYBMJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!" 001D&O.4T?4]%L;K1)] &L:<96FM)5<
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M*=G>-XXS)Y4FY0"2H."O&13K3QY=)9WPO[2UDOHX[=[2*QE+K</.&\N(9'#
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M10 4444 %%%% !1110!R;?\ )7(_^P$__H]:ZRN3;_DKD?\ V G_ /1ZUUE
M!1110 4444 %%%% !1110 4444 %%%% &5XCU4:-H5S=@_O NR(>KG@?X_A5
M#P3I)TW04FE!^TW9\Z0GK@_='Y<_B:R_$^==\6Z;H*\P1'SKC'Y_R_\ 0J[<
M    8 Z"M7[L$NY3T1GZ[I2:SH]Q9/@,ZY1C_"PZ&L;P-JKW.FR:9=96\L&\
MME;KMZ#\NGX"NJKA?$\4GASQ#;>([0#RI6\NZC!QN_\ U@?F!13]Y<GW"NK:
MG=5Q'C?Q3%!8M8:==YNF;$K1'[B]QGUZ5&U]K?C*1HM.#6&E9PTS?>?_ !^@
M_$UOZ=X2TC3[)K?[,LYD7$DDHRS?X?A6D8PI-.IJ^W^9SRE*HK0V[GE&D+-J
M.J6UA)-.8;B55D5&ZC/)KV33=%T_28]EE;)&<8+XRQ^IZU!IGAK2=(G:>SM0
MDI_C9BQ'TSTK6IXC$>T=H["H4>1>]N%%%%<IT!1110 4444 <WKWA*WU-_ME
MFWV345.Y94X#'WQ_.JVB>*)HKO\ L?7U\B^0[4E;A9/3VR?7H:ZVLK7= M->
MM/*G7;*H_=S ?,A_J/:MX5$UR5-OR,I0:?-#?\S5HKBM'UV[T&]71/$!('2"
MZ)X([9/I[]N]=KG(R*BI3<'J5":D@HHHK,L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_Q5I;ZMJWD)MDD%@S11
M[\%7#CYL9[CBNPKEM8%I=>(XE36C8W4,!.5VXQNP06R.?8_6@"7PG8RVIOY6
ML#90S2*8HG.6&%YY/.,]/QKI*Q- F#S7L']J27[0L@+,HVC()^4@\_\ UJVZ
M "BBB@ HHHH **** "BBB@ HHHH Y-O^2N1_]@)__1ZUUE<FW_)7(_\ L!/_
M .CUKK* "BBB@ HHHH **** "BBB@ HHHH *9+*D,+RR':B*68^@%/KF?'>H
M&R\-R0H?WMTPA4#K@\G]!C\:J,>:20TKLH>!HGO[W4]?G7Y[F4I'GLO4_P#L
MH_"NUK.T+3QI6AVEG@!HXQOQ_>/)_4FJ/B3Q)'HL*P0KYVH3<10CG&>Y_P .
M]6TZD[1)G-+5DVO^([70;<%_WMR_^J@4\M[GT%85CX;O?$%R-3\2,P4C]U:*
M2NT>_I].OK5OP]X8DCN/[7UIOM&HR?,%;D1?_7_EVKJZMS5)<M/?O_D9*+GK
M/;M_F<!8W=QX&U0Z=?EI-(G8F"?&?+_SW'XUWD4L<\2RQ.KQN,JRG((J&_L+
M74[1[6[A66%^H/;W'H:\\URRUCP5:LVFZD[:?.Q0*WWHR>?Z'D8I655]G^9T
M:,],HKQGP[XNO].U:-[N\GFM';$RR,7X/4C/<=>*]4LM?TG4<?9;^!V/\);:
MWY'FIJ490!Q:-*BBBLB0HHHH **** "BBB@#/UG1K36[%K:Z7W20?>0^HKE]
M(UB[\-7ZZ)KC9MSQ;71Z8[<^G\OI7<50U?2+76K%K6Z3(/*N/O(?45M3J)+D
MGM^1E.#;YH[E\$$ @Y![T5PVFZM>>$[U=(UHE[)CBWNNP'^'\OI74V6N:9J,
MYAM+V&649^53R?IZTITI1U6J[CA44O)FA11161H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5R&MVFE0Z\NW1Y;Z]FB+M%
M&<*!N^\??-=?7+^)_LMO?VMY-K3Z?*J%$"1;BP)Y/'..G7CB@#0\/A4AF1='
M;35# X)!WGU_#%;%9.BJR/=12:I)?21L%8/'M\LXS^.<_I6M0 4444 %%%%
M%>\OK33K<W%[=06T((!DGD"+D]!D\57M-=TB_P#,^QZK8W/EJ7?R;A'VJ.I.
M#P/>K5U:VMY 8KNWAGASDI,@9>.^#7GGAO1+?Q!;^*==L;6VM8]4BETW3?+C
M"+]G0,N\[1_'(6;/H%H [FRUW2-2G,%CJMC=3 ;C'!<([ >N >E6+:^M+QI5
MM;J"=H6V2"*0,4;T..A]C7#:&LWA[4M+\.ZGHFF6ES?6CPV^H:8V=QC0%@^4
M5@2.<\BN;N=.N_"SM92W%K;LFDI;7<VFJV\6J.<RMD#]](3L0<X)9L\4 >O6
M=[:ZA;"YLYXYX"6421ME202#@_4$5/6'X8U&TNK"2PMM.FTUM-9;9[.8+F+Y
M05P5)!!4@Y!K<H Y-O\ DKD?_8"?_P!'K765R;?\E<C_ .P$_P#Z/6NLH **
M** "BBB@ HHHH **** "BBB@ KA]7_XG?Q!L-.'S06*^;*,]^&Y_\='XUVLL
MB0Q/+(<(BEF/H!7F7AWQ+I]C=:MJ]\[-=W+GRHE4DXZXST'8?A6]&,G=Q0<R
MBN9L[7Q)XAAT*RR )+N7B&+U/J?:J'ACP[+#(=8U8F74IOF ?GR@?Z_RZ55\
M,:3/JUZ?$FK8>20YMHST0=C_ (?G7:4YM4U[.._5_H8Q3F^>6W3_ #"BBBN<
MV"JVH:?;:I926EW$)(7ZCT]P>QJS10G8#G--\#Z)ILS2K T[$$#[00P /H,8
MIM[X$T&\R5MFMV/>!L?H<C]*Z6BK]I.][CNSBO\ A#M9T_G2/$$R@=(YLX_J
M/TI/[0\;:8<7.G07\8_BBQG]/\*[:BJ]JW\23'S=SC(OB'!$XCU+3+NT<]>,
MC]<&MBT\7Z#>8\O48D8_PRY0_K6Q)%',FR6-)%/\+*"*Q[OPAH5YDOIT2,?X
MHLH?THO3>ZL&AL1313IOBD213W1@13ZXR7X=VL;F33M1N[1S[Y'Z8/ZTS^QO
M&>GX^R:S%=H/X9NI_P"^@?YT<D7M(++N=M17$_\ "0^+-/!^WZ")U7J\&>GX
M%JEA^(NGA_+O;*[M7[@J& _D?TH]C+IJ'*SL:*Q;7Q;H5WCR]2A4GM)E#^N*
MUHIX9UW0RI(OJC C]*S<6MT38YWQW9SWGAIQ!'YC1R*[ #)V\YQ^=>6Z1.;3
M6+2<R&(),A9_09Y_3->\53O-*L;ZTEM9[:,QR_>PH!SZY]:ZJ&)5./(UH<U6
MASRYDRU'(DL:R1L&1AE64Y!%.KA+"]NO!>IC2]2=I-+F)-O<'^#Z_P!1^-=T
MK!E#*05(R".]85*?(^Z>QM"?,O,6BBBLRPHHHH **** "BBB@ HHHH ****
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M_E63+\.K%9#)8WUW:O[,"/Z']:[*BK56:V8^9G$_\(]XML!_H.OB=1T6?/\
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ML?R(_6H]DWLTR^4[:BN1M_B+H\AVW$5U;L.H=,X_(_TK7MO%&AW>!%J=OD]
M[;#^N*ETYK="LS7HID<L<R[HI%=3W4Y%/J!!1110 4444 %%%% !1110 444
M4 %%%% !1110 5R_B"SN'UZVNX](_M&%8"CH[*%!SD$ ]_\ &NHKE/$CPMK=
MI!J5S-;Z:T+$&,D!I<]#CVH U-"#!)MVC)IG(X4J=_7T]/ZUKUSGA.<R?VA%
M!/-<6$4P%M++G)X^8<]@:Z.@#SS4?#MR;F6\GTV:Z9KB=7V.2S*P'EL,=A7:
MZ+!+:Z+9P3($E2)0RCL<5PUW?36?B";[>]YYLAN$*#."I7$>S'UKN=%6X71;
M-;K=YXB7?O/S9QW]Z +U%%% !1110 4444 %%%% ')M_R5R/_L!/_P"CUKK*
MY-O^2N1_]@)__1ZUUE !1110 4444 %%%% !1110 52U74H=)TR>]F/RQKD#
M/WCV'XFKM>8>/]7>_O'L+<YM[/F4CH9#Q^F<?G6U&G[2=GL14DTM-WL:'@&.
M74M3U+6[GYI&.Q6]SR<?08'XUW]87@[3_P"SO#%G&1AY5\U\^K<C],5NTJT^
M:;8XP4%9!1116104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 8GB3P[#KMH,'RKR+F&8=CZ'V_E6?X<\1S-<'1=9!BU&+Y59O^6H_
MQ_G75UB>(O#EOKMN#GRKR/F*8=0?0^W\JWA--<D]OR,IP:?/#?\ ,VZ*X[1/
M$]Q9W8T;Q"/)NE^6.=ONR>F3_7O]:[&LZE-P=F5":FKH@N+&TNQBXMH9A_TT
M0-_.L>Y\%Z!==;!8SZQ,4_0'%;]%)2DMF:79QDGP[M(W+V&I7EJQ]"#_ "P:
M9_8'B^QP;+7EG4?PSYY_,'^==M15^VEUU'S,XG^U?&U@?])TF&[0?Q1=?T/]
M*4?$'[-@:GHMW;'H2.?Y@5VM(RA@0P!![$4<\7O$+KL<[;>.M N< W;0D]I8
MR/UZ5L6VJ:?> ?9KVWESV20$U!<^'M'O,^?IMLQ/<1A3^8K&N?A[H<^?*6>W
M/;RY,X_[ZS1^[?=!H=717%?\(5JEF<Z9XBN(P.B29Q^AQ^E)M\>:>.&M;]1]
M,G_T$T>S3VD@MYG;45Q/_"9:Q9<:GX=G4#J\6<?R(_6K5K\0]$GP)3<6[=")
M(\X_[YS2=*?8.5G645S.H^.]$L;=)(IS=L_1(>H^N>E7M!\1V/B&!WM2R21_
M?B?&Y<]#]*3IR2NT*S-BBBBH$%%%% !7.:5J-O=-J,.J7,1F2Y8>1.5 1!]W
M /4>]='6?>Z%IFHR^;=V<<DF,;^5)^I'6@"CX?O?M=[JJPR"2QBE5;<J!M'R
M_,!CMFK?B&\EL- O+F XE1/E/H20,_K5VVM8+.!8+:)(HEZ*HP*@U*]L[*&(
M7N#%/*L(#+E<GIGVXH Y'3M:M],U6W1]<DO;6:-C,9@Q\MQR",\\UV]O/%=0
M)/"X>-QE6'<5DVTOAZZ5VCCL $<H=R(.1_2M>$1"%!"$$6/EV8VX]L4 /HHH
MH **YSQUK%UH/A.YO[.XBMYEDA3SYDWK&&D568C(S@$GK69#XCDTCPCK&O7'
MB*R\116L1>/[)"D05@#A259NI(^E ';45PD6L>)]$UC1HM:N;*_AU@2(([>W
M,)MIEC,BJ#N.]3M*Y.#T-9FC?$&_:*62YD@U*2:TBDAM[:+8T5W(Q46AY.2,
M9)." K$\4 >G451T>"^M])MX]2NA=7NW=-*JA5+'DA0/X1G [X'-7J .3;_D
MKD?_ & G_P#1ZUUE<FW_ "5R/_L!/_Z/6NLH **** "BBB@ HHHH **** ,G
MQ'K"Z+HTUUD>:?DA![N>GY=?PKSQ]*8_V/I,F3=ZC*+FY)/(4\*#^&\_4UT%
MS_Q5?C1;4?-IVF\R>CMGD?B>/H#2Z!_Q.?'>J:H>8;4>3%Z?W1C\ WYUV1_=
M0MUW?Z+]3.G[\W/HMCMU4(H51@ 8 ':EHHKC- HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,UK0K+7+3R;I/F'^KE
M7[R'V_PKSJZ\2Z[X<GET=;R.46S;5D*9., XY[5ZQ7(^(_ \6MWQO8+G[/,X
M D!7<&QQGKUQ75AZL4^6IL<]:G)KFAN6_!_B&77]/E:X15N(&"N5& P/0_H:
MZ.N!'A[6?"6+O1YS>18'VB KRV.X'?\ #FNCT/Q18:VH1&\F['WK>0_-^'J*
MFM33;G3^'\BJ<VDHSW-NBBBN<V"BBB@ HHHH **** "JESIEA> _:;*WFSW>
M,$U;HH3L!YGXQ\$S+<I=:+9[H&7#PQ<E6]<>A]JT_A_X<OM*>XO;Z,PF5 B1
M-UQG))';H*[FBMG6DX<K*YG:P4445B2%%%% !7(^+;&_OKHI"+@PI:,\8BSC
MS0PZ_P# <XKKJY?Q)=S1:O:6\FJMIUG)$S>8@R6<'H>X&#0 >#XMG]H/'#<I
M:O(GDFXSN/R\CTX/>NBNK2WO8##<PI+&3G:PR,UE^'GB9)_*UB34N5R7_@Z_
MS_I6U0!P0ATRW>[^R>'IKVU@E<2SE\8(ZA1W KL].:VDTZW>S4+;,@,8QC -
M8L_A[44EN4T_5OL]G<N7>)HPQ4M][:??\*W+&T2PL8+2,DI$@4$]3CO0!8HH
MHH H:O+?0:>TFGZ?%?SAA_H\DPBW+WPQ!&?K7#R>"M1\1-XDO+^TMM&?5=/2
MRBMH9!+AE)82RE0 3D@#&>!UKT>B@#A[73?$FN:WH<^N:=;:?;Z,6E8QW(F-
MS,8R@*@ ;4&6///04S6?#VK^(AK-YL%I-'$]MI4+/MZX$DK$=&D * ]0O^\:
M[NB@#F/!FCW.D6^H&6R33K>XN1+;Z>DHD%NNQ5/(X&Y@6P..:Z>BB@#DV_Y*
MY'_V G_]'K765R;?\E<C_P"P$_\ Z/6NLH **** "BBB@ HHHH *Q/%6L?V-
MHDLJ-BXD_=P_[Q[_ (#FMNN&_P"1J\;_ -[3M,_)GS_4C\EK:C%.7-+9:F=6
M32LMV6;*W_X13P-<74GRW<D?F,3UWMPH_#(_6K7@33_L/AF&1AB2Y8S-]#P/
MT /XU1\=R/>SZ7H<+'?=3!GQV7H/YD_A78Q1)!"D48PB*%4>@' IU)-QN]WJ
M:1BHP44/HHHK  HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Y[7?"5GJS?:86-I?#E9X^,GW']>M=#150G*#
MO%DRBI*S.)MO$FI^'YULO$<#/$3B.\C&<_7U_G78VUU!>0+/;2I+$W1D.11<
MVL%Y T%S$DL3=5<9%<=<^&-3T&=KWPW<,4/+VDAR#]/7^?O6W[NK_=?X?\ S
M]^GYK\?^"=M17-:-XRM+^3[)?(;&^4[3')PI/L3T^AKI:RG"4':2-(S4E=!1
M114%!1110 4444 %%%% !1110 4444 %<WKEA?2:[;7UIIL%XJ0&-Q,ZXY.1
M@'H1Z^]=)7+^)K2\:^CN+>ZMH8Y;=K9FGEV>7D@EAZG'% &GHOVDQRFXTVVL
MLD;?(96W]<YQZ5=O9+J*V:2TA2:52#Y;-MW#N ?7TK&\,645E+J$=K-&]F9$
M,*I,),?+@DX/&3S5_74GETTQVTFR1G7Y1+Y9D&>5#=B10!C:AK5W=3QBSDO+
M>)$/FK#:B65),_==3T&.AZ'UKH=-DN9=-MWO$V7+1@R+C&#6!8:!=-YUQ(9K
M*X!'V9C-YSH,<AC_ !*3_":Z*UDD\I([EX3=!09!&>,^H!YQ0!/1110 4444
M %%%% !1110!R;?\E<C_ .P$_P#Z/6NLKDV_Y*Y'_P!@)_\ T>M=90 4444
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MB_T^UU.V^SWD(ECSD DC!]01TZU#I>CV.D)(+*-D$N"V7+9QTZGWK0H Y_\
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MM)8W?Y&;"@@8/'WCQP>]1Z5XYT#6;R"ULKJ5FN%9H7>WD2.0KRRJ[ *6 !)
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MKB+W4+O49_.O+B2:0# 9VS@5U8>FV^<N"ZG:_#34+UM2GLB[O:>47()R$8$
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M_P# =?\ "C^Q-*_Z!EE_X#K_ (4 4?\ A-/"O_0S:-_X'Q?_ !5'_":>%?\
MH9M&_P# ^+_XJKW]B:5_T#++_P !U_PH_L32O^@99?\ @.O^% %'_A-/"O\
MT,VC?^!\7_Q5'_":>%?^AFT;_P #XO\ XJKW]B:5_P! RR_\!U_PH_L32O\
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M\7_Q5'_":>%?^AFT;_P/B_\ BJO?V)I7_0,LO_ =?\*/[$TK_H&67_@.O^%
M%./QAX8FE2*+Q'I#R.P546^B)8GH -W)K:JDNCZ6CAETVS5E.01 H(/Y5=H
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MDL$8MR;:2<Q';\P0J?E8-W-=W10!%;*ZVL*R.7<(H9B,$G')Q4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXZ\3R
M>$/"\NKQ6J7+1R(GENQ4'<<=:\I_X:$OO^A?MO\ P(;_  KM_C7_ ,DVNO\
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MB(&XUB>0P(CX_@7/S#/IGKWJ]X1M="T#PW\0-,N+.XNH]/E:.[<2;3<1#?L
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M> 9;B:_\F]AS<[9&F8#"<1H3@'GH/:DJS<K-=?TN-TU8\VJ=+>[2V^VI%,L
M?R_/ (7=C.-WKCM7L_\ PKSP_J^B:NUOX7U;1A:6S2VE]=S'=.0">8R<CIZ=
MZKZS=Z ?@)HA_LJX*2N\=L@FYCN/G!<^H+;CCWH^L)V276PO9-;L\:)+$DDD
MGDD]Z2O<(?A?HNG2:7I%[H&L:E/>1*UUJUO(5BMG;L!TP#Z]N?:O(_$FC/X>
M\2:AI#R>8;28QA\8W+U!_(BKA6C-V1,H.*NS+HKT3X?>&?#NK^%_$>JZ_%<,
MFF^7(&@<A@N"2 .A)QCGUK2\.^$?#GB5=9\1V6B:E+I-GLBM=*BE)EFEV@ME
MLGCD=#ZGVI2K1BVGT&J;=CR^TM)[^]@L[6,RW$[B.- 0"S$X YK63P?X@DU#
M4+!=,D-UIT?FW<>]<Q+C.3S@\>F:]!OO!=IHNN>#=?T^PO=,BO-2CAGT^\;<
M\$@;(P?0@']/6M*72K?5/B3\0C/)<I]GL?-3R)VCR?+'#;2-P]CQ4.OU7]:V
M*5+N>(=:M:;IM[J^H16&G6TES=2G"11CDX&3^E>F^'O .G6_@K3=;U#P_JFO
MW6I$D063E!;1=F..I[UTW@_POI?@WXNR::L%Q*]S9_:=/FD?!AC.0Z..YR,
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M":=(R4C/^T>@ZBJE7*,9[]"5)QV/0_'?Q(B\6^%M*TJWMYH98BLE\[@8ED5
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MYIJ5VE_J=S=QP"".60LD0=GV+V&YB2<#N:AM[>:[N([>WB>6>5@D<:+EF8]
M!W-75T#6'N+NW72[PS6:[[F,0MNA7&<N.P^M5&$8;"<G(WO#?BNST;P5XET6
M>&=[C545870#:I /WLG/?M4W@OQG9Z)I&IZ#K%O=2Z5J!#F2SDV30N,<J>/0
M?E7%5+:VMQ>W,=M:02SSR'"11(69C[ 4.G%WOU!3>AVVH>+?#L>M:!)H]AJ
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M8+^%\SCK_&%%%%=9@%%%% !1110!N>%-/T;4M9$.NW\UI9A"P%O$9))6[(H
M."?7%=?XK\!Z/:>!U\3:1#K-B$N%A>TU6,*[*3C</S'ZUE_#+Q/I/AG5[^35
M?-A%U:F&&\ACWO;L>X'^'H*VM<\8:!<_#K4/#\.LZKJ5^UTEPMW?1G]^=P)Q
MR=H ' /?ZUS3<_:*U[:&T5'EU+^H?#[P/H_B?3='O]0U9IM4CC^SQPA2(V;C
M<[$=">  .W-9&F_#2S_X2WQ'::IJ,L>CZ"GFSSQJ/,D4C<H'H< Y^GO1XH\9
MZ-JOQ'\/:W:RS-8V*0"=FB(8;'); [\5?A^(>@GQQXH-XMQ)X?UZ)8GD1")(
MR$V[MO7NWZ5"]JH]=OU_R*]RYH6D7AY?@QXOE\-W%Z]I)(FZ*]4"2)@4XR."
M",$5Y)H^ESZWK5EI=L5$UW,L2%N@R>I^G6O0F\1^#-'^'>O^&M&NM0N+B\*L
MMQ<0[1*V1P /N@ =^IK@-"U:30M?L-5B0.]I.LH0G&X \C\1FM*2DE+]?0F;
M5T=_J7A/X=V-Y?Z#)K^H6NKV:'=>7"#[.T@ ^3 &>_\ /DXJCI'@_P .Z=X.
MMO$WB^\OE@OI#':6M@!O<#/S$GZ$]N,>M:FI:W\,KS5K_P 2S1:C?7EW&6_L
MJ6/;&LI R2X^GKW-4-.\3>&-?\#V?AKQ3+>6$FG2L]I=VL?F J2?E(Y/?'X#
MFH3GR]?/_@%>[?H/N?ASIL?BGPRMI?3W7A_7F_<RG"RIQDJ>.O(YQZ^E:MI\
M.?!NH>(]5\+6VJZHVLVP>1)2BB%0.B>K$9&3QWQ5&Y\?Z(OB?PG;:?'<1>'M
M ;B25<RRDC!8J/\ /)J/P[XVT73?BYK'B.YEF&G77G>4RQ$L=Q&,KU'2D_:V
MZ[?J'N7-KP];^&(O@;J9OQ>JOVO9?/"J[S,"NT*>Z?=Z^IK%U'0Q<>"?  GU
M&]E@U"Z\IH&<;(06P=@QP?KFH?#7B3PU)X$UKPSKMU=V@NKTW44T$.\M]W [
MX/R]_6FW'C#2)/#'@:P627S]'NQ+=CRCA5W9X/?BA1DI/??] NK?(WO^%<^"
M$\;S^$GU/5CJ4J[X"BKY<(V[@K$\LV,GH!T%<Q8^![)O!_B[4;J:8WVB7'D1
M>6P"-@@$D8_K6E_PFVB_\+N_X2GSIO[*_O\ E'=_J=GW>O6C0O&/AUHO&.D:
MQ+=0:?K=RTT-U#%N9?F)&5Z^A_.C]ZEUZ?\ !#W&_O,9O!]H_P ,-.\00&=M
M3N]1^QB/<-A!+ 8&.O [UT<_@/P/H^KVGAC6-8U,Z]<J@::!%\B%W^ZIR,\G
M_(JCK/B[PY!\/=.T'P])>&YL-26Y1KJ/!DVECO..!DD?+Z5IWGBGX?:_XAL_
M%NIR:G;:G $:;3XXMR2R)]W#>G3N,X[4VZC[VU_X )1,K3OAO!'/XRL]6FE-
MSH=OYL#0D*LF59E)!!X( X^M9%AX6L;GX5:GXG=YA?6MXL"*&'E[3LZC'7YC
MWKH="^)&G77BCQ1<^(8Y[>RUV#R-T"[S H!501W^4]1WJO>>(_"5C\,M2\+:
M-/?7$TETDRRW,6WS\%23Q]T8&,'GCWIWJ7L_+_@BM&VGF;5W\,/#>C6MM'J4
M?B&X$MN)7U6RB62WC8C.-J@MC\.XKR&Y2*.ZFC@F\Z%7(27:5WKG@X/(SZ5[
M!H'CKPKHQL;JQU_7K"V@C FT62,W".0.BNW"CZ$=.U>6>(-3BUGQ%J.IPVXM
MXKJ=I4A'\ )_G547.[YA5%&VAUG@7P;H?B#PSKFK:S>W-K'IK(Q>'!^3!+<8
MY)Q@?6KND>"?#.LG6->MY=7?PU8%(XH8HPUU/(5!8 8X )%9/AGQ-INE_#WQ
M3HUS)(MYJ(06ZJA(..N3VJ[X!\;66C>']4\/:E>7^GPW;B:"_L>9('XSP.<'
M _7UJ9JI[S7]+0<>71,TE\&VFA>*O!FN:2][_9FH7\:B&^CV30.&^ZP_ _E6
MR^G/?^/OB.R:A>6GD6AD(MW"B7]W]UL@Y'^-<[J?C'11XB\-M;:MK6HVVGW2
M3WEW?2,PD(/5(ST.,_R]ZM6WCS0HO%/CB_::;[/K%H8K0B$Y9MF.1VY]:AJ;
M5_+]2KQV*>B^ ]%MO"6FZWXC_MF=M3)^SP:7#O\ )3^^_!^O^-=;X!\):?X0
M^*UUIUQ-<SW?V7S].EV@(T+ AMX[,#Q^=<_H?C[2[OP=I.CZGKNL:%=:8=GG
M:>"5N8^P..AQ@>WXU%H?CW1++XIMKDL^IG2H[5[>)[MVGE.<<^H!.>*)*K)2
M3\_^ "Y$TT<?XVU"TU+Q1<S6-YJ-W;CY%?4'W2 @G</]W).*T;7PC::I\.(]
M<TYIVU2+4%M+F(L"FUR K 8R.67]:Y*YD66[GD7[KR,P^A)-=Y\+/&FF^%;W
M4(-;#G3KI$<!8]^)4;*G'Y\^PK>:E&"Y>AE%IRU-W6OA%96?C/PYI5C<7$ME
M?^8+J0N"R&,9?!QQP>]5;W2-+M_AQJ-Q#J6IG0X->^S_ &=9%(:(,H9\8Y?&
M2.?2K.B_%:RMO#VO_;1(=7EN;F?3F\LG;YHZ9_AP:Y:/Q+IH^#MQX::23^TW
MU#[0%V':4XYW=,\5BE5=E+HU_P .:7AT/0_'L6@0^*/!"6JW*7RO:_9T"@1"
MW\SOC^/--\0>%?"/B7XI:CI%YJ&IC6[M1(AA11##MC!"G/+' SZ=JY[Q#XO\
M*ZU<^%=:2[O$U'36MXY[4P'8(U;+G/<CM@\U!!XVT6/XW2>*6EF_LMLX?RCN
M_P!5M^[UZU$832TO=)C<HW/.KZT>PU"ZLY"&>WF>)B.A*DC/Z5W&C^$O#EAX
M-M/$_BZZOQ!?3&*UMK +O(&06)/T/_U\UQNLW45[KNH7<!)BGN9)$)&"59B1
MQ^-=QI7B3POK?@.R\,>*9[VQ?3IC);75K'OW*2<J1SSR1T]*Z:G-RJWS,H6N
MR.Q^'^D:]XX_LS0=>%SHZV_VJ>Z*_/ @."AX +<CGW]JLGP9X1\2Z5JLG@[4
M-2-_I<1F>*]5=MP@SDJ1TZ?RXYI=.\=^&?#GCA;G0]'ECT)[,V5T"?WLX)!,
MF"< \#CC//K3X/$G@SP9I>L-X5N-0O\ 4M2A-NAN8MB6T9SWP,D?K@5DW4Z7
MZ6_6YHE AC\'^$=/\#:!XFUR]U-%OMPE@M0K-(V3C;G&T  D]>U6;OX6:>/B
M-I.AVVIS+IFI6INXY) /-"C.4'8D\<X]?2L'Q%XETW4?AIX9T*VDD-[I[.9U
M9"%&<XP>_6MS7_&?A;5_$_AN[N$OKBQL;%8)S 6ADCD!X92""<>QH_>;Z]?^
M 'N?D5/&'A+PWHVCW,L-OX@TO4(7VQ1:C 'BN1GJKJ,#CWK1U3PJ=7M_AWIT
MVL79CU* C]^P9;<;5.(Q@=>@!SVJSJWQ!T:W\':QI$.NZGXA>_0QVZ7UN$%L
M#W+D98C@CW K%UCQ;X=U"Q\$V\\=U=0Z5 8[Z*/,3 X4 HW<@C/X4H^T=K^?
MY ^4M^+/ _AG1-.U >3XBTZ[M<BWN+N$2V]V1TPR#Y<^Y&,BM77H?"Z? K12
MBWRB1W:UVJH9[GY@?,]5SN [XQ4C?$;P_I6D:M#!KVKZY#>0-%;:=?6_$!;^
M](W) S[_ -:YE/$?AS4/A+9:!?7=W;:KI<DDUL(XMRS.2Q7)Z ?-STZ4DIM+
MFOHQOE5[&W%\+M LI]-T75Y=;?6+^)7-S:0;K:V9NBL<<\_Y&:R]#^'&G26G
MBT:]?3VTNA3*AFA&Y2O))V]R0.!GO6_)\2- UPV.I:CK_B#2YH8!'=:;9%A'
M.PSRK#IG\.U<SIWC33$\->-K6XDNQ<ZPRFT68F5R!D ._KC'-"]M;6_3\Q/D
M)-6\(^$1X3TWQ7I5UJO]DM>K;7L5P%\X+D[F7'&>.G(YK6^-\6APW.E1VRW*
M:BMK&(T"@0BWRV.G\6:YAO$VFGX.#PUYDG]I?;_/V>6=NS/][I5WXC^(O#?B
MRSTW4["ZNQJT4$=O+:/#A%49).[N<G'!JE&?.F[Z-B;7*['(^&=-AUCQ1I>F
MW+.L%U<I%(4.& )P<5V.G^ ]*NOC#=>$WENAI\6_:P<>9Q&&'.,=?:N)T'4_
M[&\0:=J9C,@M+E)B@/+!3DC\J]9MO&?P_LOB(_BV.[U22>[4AXC;X2W)3!)[
ML3@# Z9)JZSFF^7M^),%%K4P_"WP\TS4M&U75[N+5-06TOGM(['32GFX4_>;
M=UX/05G3>"-,U3QYI^@>'[R^2.Y3?.NH6YCEM<#+ @@;N!V[\9J?PSXA\.6P
MU-IM4U?1-2FNGEAU"S+.CQEB0K1=,\]Q^(K9U?XK6*>+O#FHV23WZ:7$\5U>
M31"*2Z#@!L*.F,9'3DU#=7F=B[0L5]1^'.@WFF:S_P (^VMQW^D(TCG4(-L5
MTJYW%#@>AQ^''->5CD9KUC7?&F@'3-5>S\3>)M1N;S=]FM))7BCMMV<ACT8<
M].>!CWKR>M:/-9\QG4M?0****V,PHHHH **** /1O@C_ ,E'@_Z]I?Y5]-U\
MR?!'_DH\'_7M+_*OINO*QO\ $^1V4/A"BBBN,W"BBB@#S_XS0RW'PZN8X8GD
M<SQ85%)/WO:OFK^R=2_Z!]U_WY;_  K[5HKJHXKV4>6US&I2YW>Y\5?V3J7_
M $#[K_ORW^%']DZE_P! ^Z_[\M_A7VK16WU]_P I'U?S/BK^R=2_Z!]U_P!^
M6_PH_LG4O^@?=?\ ?EO\*^U:*/K[_E#ZOYGQ5_9.I?\ 0/NO^_+?X4?V3J7_
M $#[K_ORW^%?:M%'U]_RA]7\SXJ_LG4O^@?=?]^6_P */[)U+_H'W7_?EO\
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0M9<UK&U.'(K!1116)9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img181340459_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7U"@L# 2(  A$! Q$!_\0
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MJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\
M"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"K
MU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *
MO44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O4
M4 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]
M10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10
M!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU%
M %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %
M'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44
M4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?
M[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1
M_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_L
MJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^
MRH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH
M/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*
M@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_
MOR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#
M^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_
M)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[
M\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\G
MYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR
M?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F
M/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^
M8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_
MPH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC
M_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"
MC^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\
M*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/
M[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH
M_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_L
MJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^
MRH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH
M/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*
M@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_
MOR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#
M^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_
M)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[
M\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\G
MYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR
M?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F
M/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^
M8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_
MPJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC
M_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"
MKU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\
M*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O
M44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ
M]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]1
M0!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU
M% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU%
M%'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44
M 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4
M?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!
M1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_
MLJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'
M^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^R
MH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[
M*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@
M_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ
M#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^
M_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/
M[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\
MGYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_O
MR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?
MF/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)
M^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8
M_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GY
MC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_
M  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/
M\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLO\ Z+:@#WJBBB@ I&941G8@*HR2>PI:Y;XA:M_97@^ZVMB:Z_T=/^!?>_\
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MQ+ ^=K>S+W_SB@#Z/HK)\-:[#XCT.#4(EV,V5DCSG8XZC^OT(K6H *YOQ_\
M\B-JG_7-?_0UKI*YOQ__ ,B-JG_7-?\ T-: /GY59SA02<$X'H.36QX6UV3P
M]K]O?J3Y0.R91_%&>H_K]0*/"2J_BW2T=0R/<*C*>A!X(_6F>)M%D\/Z_=:>
MV2B-NB8_Q(>5/Y<?4&@#Z-BECGA2:)P\<BAD8="#R#7EGQC_ -=H_P#NS?\
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MOP;<7#J/-M622-L<C+!2/H0?T%7? '_(C:7_ -<V_P#0VIGQ#_Y$34_]V/\
M]&+0!XIX9D:+Q3I+J>1>1?\ H8KW3QI>-8^#=4G0D-Y)C!';<0O_ +-7A/AW
M_D9M*_Z_(?\ T,5[?\0(C-X&U11V1'_[Y=3_ $H \$M+=KR]@MD.&FD6,'W)
MQ7TOI]A;Z98065K&(X(5"JH_G]3UKYNTJX6SUBQN7X2&XCD;Z!@?Z5],@@@$
M$$'H10!YA\6=#LHK.WUF*,1W4DXAE*\"0%6()]QMZ^_TKE?AK_R/=A_NR_\
MHMJ[GXO31CPU9PEU$K7BN$SR0$<$X_$?G7#?#7_D>[#_ '9?_1;4 >]4444
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MOH+PKI7]B^&;"R*[9$B#2?[[<M^IQ^% 'E'Q3OFN?&#6Q)V6L*(!VR1N)_\
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MG%_-JTOB]?/#H]A8J2!<3,[8[A ./S8'\*S?@[_Q]ZM_USB_FU3?&.)BNCS
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MTRN/Y&O6*\*^).M1:OXH:.W</#:)Y 8="V26(_$X_"@ ^&"D^-[<CH(I"?\
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MYHF#1R*&5AW!&0:^765D8JP((Z@BO=?AKJW]I^$88G;,MFQ@;_='*_H0/PH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<S735S- &QI7_'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#I/.V]A].P_ 54?X;^&WOC=-:REF?S"GG-MSG/Y4 =;7S1KO_(P:E_U]2_\
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MT:/3HV'G3'C=_LKZD_I7O<44<$*0Q($CC4*JCH . *6...&-8XD5(U&%51@
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M'V@:3J$5];P3&>([D+RD@'UQ0!S7QB_X]-)_ZZ2_R6N8^&'_ ".]O_URD_\
M0:]@UWPYIOB.".+486<1$LC*Y4J3UZ52T7P3HF@7OVRR@D^T!2H>20M@'K@=
M* .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *YFNFKF: -C2O\ CU;_ 'S_ "%7JHZ5_P >K?[Y_D*O4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >9^.?AY=:GJ,FK:/L>67!FMV8*2P&,J3QSW!Q^M<(F
MD>*]%E;R+/5K5FX+0*X!_%>M?0]% 'SW+I_C#7"$N+?6+H9R!.)"H/\ P+@5
MUWA/X7W"7D5[KVQ$C(9;56#%B.FXCC'L,YKU:B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *YFNFKF: -C2O\ CU;_ 'S_ "%7JHZ5_P >K?[Y_D*O4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<S735S- &QI7_ !ZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKF/''BD>&-'#0X-]<92W!&0,=6/TR
M/Q(H T=:\3:1H" ZC>)&[<K$OS.W_ 1S^/2N1F^+VDJY$.G7DBYZL57^IKR2
M::ZU&]:65Y+BZG?DG+,[&NWT[X3ZS=VZRW=Q;V989$;9=A]<<#\Z .PT_P"*
MGA^\D$=P+FS)XW2H"OYJ3_*NUAFBN84F@D22)QN5T.0P]0:\/U?X9:]ID+3P
MK%?1*"3]G)W@?[I'/X9KN?A.9?\ A$IEEW82\=4#=AM7^N: .ZHHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S735S- &QI7_'
MJW^^?Y"KU4=*_P"/5O\ ?/\ (5>H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O?1S3:?<Q6TACG>)
MEC<?PL0<'\#7SP?$OB*&8AM:U(.C8*M<OP1ZC-?1]>!?$+2O[*\8785<17.+
MA/\ @77_ ,>#4 >U^'M3&L>'['4,@M-$"^/[XX;]0:K>+M6;1?"]]>QOMF$>
MR(]P[< _AG/X5ROPCU/S]&N]-=LM;2^8@_V6_P#K@_G57XOZGM@T_2D;EV-Q
M(/8?*O\ -ORH X?3=<\27^JVMK#K>HF6:947-RY&2?3.,5[1XO\ $J>&-$:[
M"+)<2-Y<$;="WJ?8#G].]>9_"K2OMOB9[YUS'91E@?\ ;;@?IN/X5T7Q@MI)
M-+TVY4,8XI71\#@;@,9_[Y- '!7'B'Q-XCO_ "UN[R:63[MO;%@OX*O\Z'MO
M%>@#[0T>J6:CDR#>%_$]/SJQX&\36_AC69+BZ@:2":/RF9/O)R#D>O3I7M>E
M:_I.NQ9T^]AGXRT><.![J>: ,_P-JUWK7A2UO+UM]QED9\8W88@'\JZ.HX8(
M;:(101)%&,D)&H4#)R>![U)0 5X3\3-1:^\93P[LQVB+"H[9QN/ZD_E7NU?.
M7BYF;Q?JY;K]KD'X!CB@#JOA-HT=YK%SJ<R!A9J%BS_?;//X '\Z]CKSKX0;
M?[!O_P"]]IY^FT?_ %Z]%H *0 #H *6B@#CO&_CB/PS&MK:HDVHRKN"M]V-?
M5OZ#_)\AO?$>NZO/FXU&[E9CQ&CD+^"CBHO$&I/J^OWU\[%O-E8K[*.%'X "
MO7_AKH%OIWAN'4#&IO+P%VDQR$SPH]N,_C0!X]]KUC2Y%_TB^M'ZK\[H:[SP
M;\2;H7D6GZY*)89"$2Z(PR'MN]1[]17I.N:-:Z[I,UC=1JRNIV,1RC=F'N*^
M;98VAE>)QAD8J1[B@#ZCKY]UKQ+KL>OZ@J:S?HJ7,@5$N'"@!B   <8KVKPI
M?/J/A73+J1BTCP*'8]V'!/YBO -=_P"1@U+_ *^I?_0S0!UGB3XDZCJ"K::5
M-):VZJ \R\22G')S_"/IS_*N/35-0CE\U+ZY63.=XF8'\\UZO\-O"5A'H\&M
M7,:7%U<9,>]<B)02.!Z\=?\ );\5]&M&T2+5(X42YBF",ZK@LK \'UYQ^M &
M5X>^*4MII%Q%JZO=742_Z,X&#)[,>V/7T]^O'ZSXMUK7+AI+J]D6,GY88F*1
MJ/H.OXY-4]$TW^V-;L]/\SR_M$@0OC.!WKZ$TSP_I>DZ>+*ULXA%C#EE#&3W
M8]S0!X)I/BC6=&N%EM+^8*#S$[ED;V*GBO?- U>+7=#M=1B 7SDRR YVL.&'
MX$&O#/&^E0:/XMO;6V0)!E9(U'10P!P/8$FO1?A'*6\,7<9Z)=L1^*+0!3^*
MVK:CIT^F1V-]<VJNLA;R)2FX@KC.*Y[1OB-?Z3X>N())IKW4))OW3W+EQ&F!
MDY)R>>@_R=7XQ?\ 'WI/_7.7^:US7@+PY;^)-?,-VQ^S01^;(@X,G( 7/;K0
M!CW^O:MJ<S2WFHW,K'L9" /H!P/PK1T'QKK.A72NEU)<6^?GMYG+*P[XST/N
M/UKWH:=9+8&Q%I"+0KM\D( F/I7SWXJTA=#\2WNGQY\J-\QY.?D8!A^AQ^%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S
M735S- &QI7_'JW^^?Y"KU4=*_P"/5O\ ?/\ (5>H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^N;?^AM6?\4O^1+D_P"N\?\ .M#P!_R(VE_]<V_]#:L_XI?\B7)_UWC_ )T
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MMOMD/E06Q)"RSL1O(ZX !)Y[_6I?%'@.[\+Z7%?7%[#,))A%LC4C!*L<Y/\
MNUU'@SXAZ1IGAV#3M1\V&6V!"LD>Y7!)(Z=#S7/^.O' \3B.RLX6CL(7\P-(
M/G=@",^PP3Q0!6^&O_(]V'^[+_Z+:O8/%_\ R)^K_P#7K)_*O'_AK_R/=A_N
MR_\ HMJ]@\7_ /(GZO\ ]>LG\J /GBU_X^X?^NB_SKZAKY>M?^/N'_KHO\Z^
MH: /+_C'_J='_P!Z;_V2L7X2_P#(W3?]>;_^A)6U\8_]3H_^]-_[)6+\)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KF:Z:N9H V-*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD=[VZ0Y1Y0 J'U"^OU)KL:* "L+Q%X2TKQ-$OVV)EG08CGC.'4>GN/8UNT4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,U
MTU<S0!L:5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!&574JZAE/4$9%(B*B[44*/0#%.HH **** "BBB@ HHHH **** "BBB
M@ HHHH *:\:28WHK8Z;AG%.HH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *YFNFKF: -C2O^/5O]\_R%7JHZ5_QZM_OG^0J]
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5S-=-7,T ;&E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5S-=-7,T ;&E?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKF:Z:N9H V-*_P"/5O\ ?/\ (5>JCI7_ !ZM_OG^0J]0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S-=-7,
MT ;&E?\ 'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YFNFKF: -C2O^/5O]
M\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB:,=MTX4R2*H9@6^ZBCU/7\1B@#T6BO&-2?Q]X6MX-2O-0F:)F"D&82A2>S
M\<X_^O7I/AOQ+#K?AE=6EVPF-6%P >$91EOPQS^- &]17CB^(O%WC?69H=$F
M>TMH_F"H^P(N< LW4D^GY"GZ5XN\0^%_$RZ5XAF>> N%D\TAB@;HZMW'/\^A
MH ]6O-2L-."&^O;:UWYV>?*J;L=<9/-600RAE((/(([UQ/Q2TM;[PH;L+F6R
MD$@/?:QVL/U!_"K?PYU<ZKX1@61MTUH3;OZX'W3_ -\D#\* .LHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YFNFKF: -C2O^/5O
M]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!YO\8+@KI&FVP/$D[2'_@*
MX_\ 9JZ;P) +?P3I2#O$7_[Z8M_6N5^,43-8Z5-CY4DD0GW(!_\ 9376^"91
M-X+TE@<@0!?^^21_2@#S;Q)/?Z3\4KK5+:PEN#"Z,J[&*MF(#J/Q_*MJQ^+@
M%T(=5TEH5SAGB?)7ZJ1_6O0(-:TRYFEAAU"V>6)S&\?F#<K X((Z]J\L^+%]
MIEWJ%@EI)#+=QJ_GO$0<*<;02._7CMGWH ]>AFBN8(YX762*10R.IR&!Y!%/
MKG?";-IW@2PEOV,2PVQDD+#[J<L,_P# <5:T3Q1I/B(S+IMR96AP75D92 >A
MY'M0!Y7\.R+OXB-<.,MMFE!/7)X_]F-=A\6HU?PE"Y'S)=H0?JK"N*\,7$?A
MSXEO%>L(8Q-+ S-P!G.T_0G'/O73_%C6+1]&M-.AN(Y)I)Q*RHP;:@4]<=,E
MACZ&@# FNF'P8@CYP;\Q_AEGKM/A9$L?@Q&  ,EQ(Q]SP/Z"N=O-&GB^"UN&
MC/F)(+MEQR%9C@_]\L#6G\*]9L_^$<EL)KF..>"9GVNP&4(!R,^^: .5\98M
M?BIYJ#!\^WDX]<+_ (4[QZ1=_$M;=QN4-!%@],$ _P#LU-OY%\3?%E#9D2PF
MZC 9>04C W'/I\I-2?$N*33_ !U%?;3MDCCE0^I4X(^O _,4 >L>(HUF\-:I
M&PX:TE'_ (X:\V^#TA&I:I%V:%&_(G_&NS\2>)-,7P7>7D-Y"XN;9DA <99F
M7 &.N1GD=L5ROPAM&B@U74I1MA.R-7/3C);\LK0!ZE7B<9%Y\93O&=NHGK_L
M9Q_Z"*].T;QAHNOWLEII]RSS(I?#1LNY1CD9'O7EVKR#0/BRUU<Y2$7BS%L?
MP-@D_J?RH ](^(<:R>!=2##[JHP]B'6O/?#=TT7PN\2J,\2*./\ ;VJ:[+XC
M:Y8IX-G@BNH9);PHL:HX8D;@2>.V!U]ZY_PQHT\OPGUD^62]T7EB&.65 .GX
MJU %WX/1*-+U.7 W-,BD^P4G^IK$^+L:KXELY .7M #^#M5[X2:M:V_]H:?/
M.D<DC++$';&[J#CWZ5E?$2[37_&MO9Z<ZSE(TMP4.09"Q/4?[P'X&@#U#5%%
M]X&NPXYET]F_'R\C]:X7X.W#"?5;8GY2L<@'H06!_F/RKT+6=MEX5O\ G"PV
M4@!^B&O.O@["QO=5FQ\JQQIGW))_I0!ZS1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5S-=-7,T ;&E?\>K?[Y_D*O51TK_CU;_?/
M\A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@_L^CYG5_P#"1V/I+_WR/\:/^$CL?27_ +Y'^-<I11_K)C?+[@_L^CYG5_\
M"1V/I+_WR/\ &C_A(['TE_[Y'^-<I11_K)C?+[@_L^CYG?0RK/ DJ9VN,C-2
M55TS_D&6W_7,?RJU7W=";G2C-[M)GBS5I-(****U)"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQG'4GU- &E1110 4444 %<S735S- &QI7_'JW^^?Y"KU4=*_X]6_WS_(5>H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH Y;QI [6]K. 2J,RM[9QC^5<=7JMS;Q7=M)!,NZ-Q@BN*O\
MPG>P2$V@%Q%VY 8?4&@#GZZ/P;$6U263(PD1&/J1_A69<:'J5K;M/-:LL:]3
MD''X U4MKF:TN$G@<I(AR"* /5:*R]&UJ'5H.R7"CYX_ZCVK4H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6J6\99+8&*8*/NJ<;3] <C\1533_ (I6UIX4BM'MK@ZE# (48 ;"0,!B<Y[
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MV/KUJ:RTZRTV(Q6-I!;(3DK$@7/UQUJU10 C*&4JP!4C!![UD?\ "*>'_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *.L_P#((N/H/YBN+KM-9_Y!%Q]!_,5Q=?"\4?[U#_#^K/9RW^&_
M4****^:/1"BBB@ HHHH **1F"C+$ >]1_:8<XWC\JVIX:M55Z<&UY)LB52$=
M).Q+12 @C(.12UBTT[,L**** "BBB@ HHHH [C3/^09;?]<Q_*K55=,_Y!EM
M_P!<Q_*K5?K&%_@0]%^1\Q4^-^H4445N0%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_$/A
MS.^]L4YZR1*/U'^%=910!Y.CO%(KHQ5U.0P."#7=Z!KZ:D@M[@A;M1]!(/4>
M_M5'Q%X<W[[VQ3YNLD0[^X_PKDD=HW5T8JRG((."#0!ZQ16#H'B!=146UR0M
MT!P>@D^GO[5O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %'6?^01<?0?S%<77::S_R"+CZ#^8KBZ^%XH_WJ'^']6>SEO\
M#?J%%%%?-'HA112,RHI9C@"G&+DU&*NV)M)78$@ DG %4+BY,F53A/YTV>X:
M8X'">E1QQM(VU1S7VV59-#"1^LXNW,M?)>OG^1Y&)Q;JOV=+;\Q%4L<*"3[4
M[RI,XV-^5:$,*PKQRW<U+6&(XHY:C5&%X]V73RV\;S>I4MK4HP=^O85;HHKY
MK&8VKC*OM:KU_!'H4J,:4>6(4445R&H4444 %%%% '<:9_R#+;_KF/Y5:JKI
MG_(,MO\ KF/Y5:K]8PO\"'HOR/F*GQOU"BBBMR HHHH **** "BBB@ HHHH
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M/^O6/^5 &U4<\T5M!)/-(L<4:EG=C@*!U)J2N'^*M[):^$5AC;'VFX6-\=U
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M1:)>2:8F^]6,F%< Y;Z&@#SOXR?\P7_MO_[3KN?"'_(GZ1_UZQ_RKRK7-/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !102 "2< 5Q^O>)C)NM+!\
M)T>8=_8>WO0!-XDU^(126%J0[GB1QT7V'O7']3[TH!)P!DU>M[81X9^6]/2O
M.S#'T,##VD_B>RZO_@&]"A.L^5;#;>UQAY!SV6K=%%?GF-QM7&5/:57Z+HO0
M]ZC1C2CRQ"BBBN0U"BBB@ HHHH **** "BBB@ HHHH **** .XTS_D&6W_7,
M?RJU573/^09;?]<Q_*K5?K&%_@0]%^1\Q4^-^H4445N0%%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8&O^'UU!6N;90MT!R.@D_\ KUOT4 >3,K1N592K*<$$8(-=AX>\
M1^9LLKU_GZ1RD_>]C[^]6]?T!=10W%N MTH^@D'H??WKA71XI&1U*NIP01@@
MT >L45RGAWQ'OV65\_S=(Y3W]C_C75T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39
M)$BC:21@J*,EB< "F7-S#:0--.X2-1DDUP6MZ]-JLAC3,=JI^5.[>YH L:]X
MC>_+6UJ2EMT+=#)_];VK$M[>6ZG6&!"\C' 45)8V,^H7*P6Z;F/4]E'J:] T
MC1X-)@PGSS,/GD(Y/L/04 9*Z#%I>BSRR8DNBHR_9>1P/\:Q*[36?^01<?0?
MS%<77PO%'^]0_P /ZL]G+?X;]0HHHKYH]$**** "BBB@ HHHH **** "BBB@
M HHHH **** .XTS_ )!EM_US'\JM55TS_D&6W_7,?RJU7ZQA?X$/1?D?,5/C
M?J%%%%;D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5AZ]H":DAG@ 6Z4?0./0^_O6
MY10!Y/)&\4C1R*5=3@J1R#75^'?$?W;*^?VCE8_H?\:TM>T!-3C,T.$NE'![
M/['_ !K@I(WAE:.12CJ<,I'(- 'K%%<AX>\1[-EE?/\ +TCE/;V/^-=?0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5:^O[?3K8SW#[5'0#JQ]!46J:K;Z5;^9,<N?N1@\L?\/>O/
MM0U&XU.Y,UPV?[JCHH]!0!-JVL7&K3[I#MB4_)&#P/\ $TS3-*N-5N/+A&$'
MWY#T4?Y[5-HVB3ZM+GE+=3\\F/T'O7?VEI!8VZP6Z!$7]3ZGWH CT[3;?3+8
M0P+_ +SGJQ]35NBB@"CK/_((N/H/YBN+KM-9_P"01<?0?S%<77PO%'^]0_P_
MJSV<M_AOU"BBBOFCT0HHHH **** "BBB@ HHHH **** "BBB@ HHHH [C3/^
M09;?]<Q_*K55=,_Y!EM_US'\JM5^L87^!#T7Y'S%3XWZA1116Y 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>_O$T_3KJ]D5F2WB>
M5@O4A02<?E5BHKFWBO+6:VG7?#,C1NN<94C!'Y4 >=_\+@T__H%7/_?Q:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9-V1@8[#VKT:N(\=>.CX;,=C8I')?R+N8OR(E[''<G^E '*?\*@U?_H(6/\
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M?A;X<67A^]6_N;DWETG^K^3:B'UQDY/O0!T=]JNG>'--ADU&Z6"%0L2D@G)
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M*V@2UM8K>,8CB0(H]@,"I: "BBB@ HHHH **** "JNI68U'2[NQ9]@N87A+
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M?X>:K>ZM%J&NQM%;H^]DE?,DQ'0'VSUS0!Z[!O\ L\7F_P"LV#=]<<U)110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5FZQH\.K6^&PDRCY),=/8^U:5% 'E=W:365R\$Z%9%[>ON*VO#_B%K!A;71+
M6I/!ZF/_ .M74ZOI$&K6^U\+,H_=R <C_P"M7GMW:3V-RT%PA5U_(CU'M0!Z
MDK*Z!T8,K#((.012UP>@>(&TYA;7)+6I/!ZF/Z>WM7=(ZR(KHP96&00<@B@!
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV*)!M5$>154>@ /%2I;_ !"$BD-K^01C=))C\<FO=:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **Q?%&HW.F:2+BU<))YH7)4'C!]:X[_A,-:_Y^$_[]+_A7'7QU.C/
MDDG<[</@*M>'/!JQZ717FG_"8:U_S\)_WZ7_  H_X3#6O^?A/^_2_P"%8_VK
M0[/^OF;_ -DU^Z_KY'I=%>:?\)AK7_/PG_?I?\*/^$PUK_GX3_OTO^%']JT.
MS_KYA_9-?NOZ^1Z717FG_"8:U_S\)_WZ7_"C_A,-:_Y^$_[]+_A1_:M#L_Z^
M8?V37[K^OD>ET5YI_P )AK7_ #\)_P!^E_PH_P"$PUK_ )^$_P"_2_X4?VK0
M[/\ KYA_9-?NOZ^1Z717FG_"8:U_S\)_WZ7_  H_X3#6O^?A/^_2_P"%']JT
M.S_KYA_9-?NOZ^1Z717FG_"8:U_S\)_WZ7_"C_A,-:_Y^$_[]+_A1_:M#L_Z
M^8?V37[K^OD>ET5YI_PF&M?\_"?]^E_PH_X3#6O^?A/^_2_X4?VK0[/^OF']
MDU^Z_KY'I=%>:?\ "8:U_P _"?\ ?I?\*GLO%FKS7]O$\Z%'E56'EKT)^E-9
MI1;M9_U\Q/*JZ5[K^OD>B4445Z)Y@51U32X-5MO*F&''*2#JI_SVJ]10!Y=?
MV$^G7303KAAT(Z,/45HZ%KSZ7)Y4N7M6/([H?4?X5V>IZ9!JEJ89AAARCCJI
MKSS4-/GTVZ:"=<'JK#HP]10!Z;%+'/$LL3AT895AT(I]>?:'KLFERB.3+VK'
MYE[K[BN^AFCGA66)P\;C*L.] #Z*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "B@D 9)P!7'Z_XF,FZTL'PO1YAW]E
M_P : +6O>)1;;K2Q8--T>0=$]A[_ ,JXPEG8DDLQ/)/))I41Y'5$4L['  &2
M37;Z#X<6Q"W-V ]SU5>HC_Q- %70?#.W;=Z@GS=4A/;W;_"NKHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *.L_\ ((N/H/YBN+KM-9_Y!%Q]!_,5
MQ=?"\4?[U#_#^K/9RW^&_4****^:/1"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#N-,_Y!EM_P!<Q_*K55=,_P"09;?]<Q_*K5?K&%_@0]%^1\Q4^-^H
M4445N0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E>
M)K22^\,:G;0@M+);.$4=2<<"M6B@#R'X9>*-+T>"[L-1F6V:6021RN/E/&""
M>W3O[UW]]XV\.V-JT[:M;387(C@D$C-[8'?ZUS_B+X76.J73W>G7'V*:1BSQ
ME=T9)[@=5Y_#VK"@^#U\9/\ 2-5MTCSUCC9CC\<4 -^%:M=^+=3OPFV/R&R!
MT!=P0/T/Y5Z]63X?\/6/AO3OL=BK$%MTDCG+.WJ?\*UJ "BBB@ HHHH *YFN
MFKF: -C2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% 'B_P 5I&B\96TB
M'#):1L#[AWJA_P +,\4_\_L7_?A/\*U/B8,^/M/XZP1?^C&KU[[+;_\ /"+_
M +X% 'AO_"S/%/\ S^Q?]^$_PI4^)GBG>O\ I<3<_=\A.?;I7N/V6W_YX1?]
M\"@6T ((AC!'0A10!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <WXW_P"0"O\ UW7^1KSJ
MO1?&_P#R 5_Z[K_(UYU7SN9_Q_D?2Y5_N_S84445YQZ04444 %%%% !1110
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MT:/[/?\ -^ ?7_[OXGMM%>)>?+_SU?\ [Z-'GR_\]7_[Z-']GO\ F_ /K_\
M=_$]MHKQ+SY?^>K_ /?1H\^7_GJ__?1H_L]_S?@'U_\ N_B>VT5XEY\O_/5_
M^^C1Y\O_ #U?_OHT?V>_YOP#Z_\ W?Q/;:*\2\^7_GJ__?1H\^7_ )ZO_P!]
M&C^SW_-^ ?7_ .[^)[;17B7GR_\ /5_^^C7KF@$GP_8$DDF!>3]*PKX;V*3O
M<WH8GVK:M8T:***Y3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO^N8_E5JJNF?\@RV_P"N8_E5JOUC"_P(>B_(^8J?&_4****W("BBB@ HHHH
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M$.4^U0E!NW#ID#MFO0ZIV>K:;J+LEEJ%K<LHRRP3*Y ]\&KE !1110 4444
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M!-6JJZG_ ,@F\_ZX/_Z":J/Q(F7PL\8HHHKZ(\ **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O7_  __ ,B]I_\ UP3^5>05Z_X?_P"1>T__ *X)_*N#
M'_ O4[L#\;-*BBBO*/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JM?7UOI]LT]P^U1T'=CZ"HM4U6W
MTJW\R8Y<_<C'5C_A[UY]J.I7&IW)FG;_ '4'11Z"@";5M8N-6GW.=D*GY(P>
M![GU-,TS2[C5+CRH1A1]^0]%'^>U3:/HD^K39&4MU/SR8_0>IKO[2S@L;=8+
M= B+^9/J?>@"+3M-M],MA# O/\3GJQ]ZN444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4=9_P"01<?0?S%<77::S_R"+CZ#^8KBZ^%X
MH_WJ'^']6>SEO\-^H4445\T>B%%%% !1110 4444 %%%% !1110 4444 %%%
M% '<:9_R#+;_ *YC^56JJZ9_R#+;_KF/Y5:K]8PO\"'HOR/F*GQOU"BBBMR
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M,@5O:GI-AK%L+?4+6.XB#;@K]CZ@]NM36=E;:?:):V<"0P1\+&@P!WH \9\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ+\CYBI\;]0HHHK<@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "O7_#__ "+VG_\ 7!/Y5Y!7K_A__D7M/_ZX)_*N#'_
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M;_KF/Y5:JKIG_(,MO^N8_E5JOUC"_P "'HOR/F*GQOU"BBBMR HHHH ****
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MA.".'0]5-7:\OL+^?3KI9[=L,."#T8>AKT/2]4@U2U$L1PPX=#U4T 7:***
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M/N H-<_\+-6NK;Q$VDM(QMIT8^63D*Z\Y'IQGZT 1>)"?$OQ433YB?(6=+;
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M9P=%%%>X>,%%%% !1110 4444 %%%% !1110 4444 %%%% %W2?^0E%]&_\
M03715SND_P#(2B^C?^@FNBK\OXW_ -^A_@7YR/KL@_W>7^+]$%%%%?&'NA11
M10 4444 %%%% !1110 4444 %%%% !1110!W&F?\@RV_ZYC^56JJZ9_R#+;_
M *YC^56J_6,+_ AZ+\CYBI\;]0HHHK<@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$^
M*]^UMX5CM4;!NKA58>JJ"Q_4+5[X;68M/!-HV,/<,\S?BV!^BBN=^,9;[-I
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MBBB@ KF:Z:N9H V-*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 <#X\_Y"EM_UP_]F-<I75^//^0I;?\
M7#_V8URE?+X[_>)'UF _W> 4445R'6%%%% !1110 4444 %%%% !1110 444
M4 %=)X(_Y#S?]<&_F*YNND\$?\AYO^N#?S%=.#_CP]3FQO\ N\_0]%HHHKZH
M^1"FNZQHSNP5%&2Q. !3;BXBM8&FG<)&HR6-<%K>ORZHYBCS':@\)W;W/^%
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M?[O+_%^B"BBBOC#W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH [C3/\
MD&6W_7,?RJU573/^09;?]<Q_*K5?K&%_@0]%^1\Q4^-^H4445N0%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK3?^0I:?]=T_]"%7#XD34^!GK]%%%?8'Q04444 %%%% !1110 4444 %%%%
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MJ:[^SLX+&W6"W0(@_,GU/O0!%INFV^F6PA@7D_><]6/O5RBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBOB'_ ,>]A_O/_(5VM<5\
M0_\ CWL/]Y_Y"NC"?QHG/BOX+.#HHHKW#Q@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH NZ3_ ,A*+Z-_Z":Z*N=TG_D)1?1O_03715^7\;_[]#_ OSD?
M79!_N\O\7Z(****^,/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@#N-,
M_P"09;?]<Q_*K55=,_Y!EM_US'\JM5^L87^!#T7Y'S%3XWZA1116Y 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V2*.5-DB*Z
MGLPR*KC3; $$65L".A$2_P"%6J* $ "@!0 !T I:** "BBB@ HHHH *YFNFK
MF: -C2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >0>(/^1AU#_KN
MW\ZS:TO$'_(PZA_UW;^=9M?0T_@7H>#4^-A1115D!1110 4444 %%%% !111
M0 4444 %%%% !7H?P_\ ^03=?]=__917GE>A_#__ )!-U_UW_P#917)C?X3.
MK!_Q4==1117C'KA1110 4444 %%%% !1110 4444 %%%% !1110!S?C?_D K
M_P!=U_D:\ZKT7QO_ ,@%?^NZ_P C7G5?.YG_ !_D?2Y5_N_S84445YQZ0444
M4 %%%% !1110 4444 %%%% !1110 5:TW_D*6G_7=/\ T(55JUIO_(4M/^NZ
M?^A"KA\2)J? SU^BBBOL#XH**** "BBB@ HHHH **** "BBB@ HHHH ****
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M8=J[B=7_ ,)Y?_\ /K;?^/?XT?\ ">7_ /SZVW_CW^-<I16GUW$?S#^H8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#Q!_R,.H?]=V_G6;
M6EX@_P"1AU#_ *[M_.LVOH:?P+T/!J?&PHHHJR HHHH **** "BBB@ HHHH
M**** "BBB@ KT/X?_P#()NO^N_\ [**\\KT/X?\ _()NO^N__LHKDQO\)G5@
M_P"*CKJ***\8]<**** "BBB@ HHHH **** "BBB@ HHHH **** .;\;_ /(!
M7_KNO\C7G5>B^-_^0"O_ %W7^1KSJOG<S_C_ "/I<J_W?YL****\X](****
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MCL0T445W'$%%%% !1110 4444 %%%% !7K_A_P#Y%[3_ /K@G\J\@KU_P_\
M\B]I_P#UP3^5<&/^!>IW8'XV:5%%%>4>F%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >0>(/\ D8=0_P"N[?SK-K2\0?\ (PZA_P!=V_G6;7T-/X%Z'@U/C844
M459 4444 %%%% !1110 4444 %%%% !1110 5Z'\/_\ D$W7_7?_ -E%>>5Z
M'\/_ /D$W7_7?_V45R8W^$SJP?\ %1UU%%%>,>N%%%% !1110 4444 %%%%
M!1110 4444 %%%% '-^-_P#D K_UW7^1KSJO1?&__(!7_KNO\C7G5?.YG_'^
M1]+E7^[_ #84445YQZ04444 %%%% !1110 4444 %%%% !1110 5:TW_ )"E
MI_UW3_T(55JUIO\ R%+3_KNG_H0JX?$B:GP,]?HHHK[ ^*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZG_R";S_K@_\
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M44 %%%% !1110 4444 %%%% !1110!=TG_D)1?1O_03715SND_\ (2B^C?\
MH)KHJ_+^-_\ ?H?X%^<CZ[(/]WE_B_1!1117QA[H4444 %%%% !1110 4444
M %%%% !1110 4444 8%[_P ?LOUJO5B]_P"/V7ZU7KZJ'PH[(_"@HHHJAA11
M10 4444 %%%% !1110 4444 %%%% !7?> _^07<_]=__ &45P-=]X#_Y!=S_
M -=__917?EO^\+YGGYI_NS^1U=%%%?2'S 4444 %%%% !1110 4444 %%%%
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MJ\\.+!L$%[90F#TZ?, <CG/I7H7A3Q3!XET1KTJL$L)*W"9X4@9R#Z$?U]*
M.AHKR:[^('B/7M6DM/#%KMB7.TB,.Y7IN;=PHZ?XU/H/Q#U>TUY=)\2P*I9Q
M&TA38\3'ID#@CD?@<\T >I444CNL:,[L%51DD] * %HKR:[^('B/7M6DM/#%
MKMB7.TB,.Y7IN;=PHZ?XU/H/Q#U>TUY=)\2P*I9Q&TA38\3'ID#@CD?@<\T
M>I45A>+/$L/A?1S=O'YLSMY<,6<;FZ\^P_SUKSE?%_CZZL7U>&'%@F6)2V79
M@=3S\Q P><^M 'L=%<GX'\9#Q3:2QW$:17UO@R*GW74]&&>GN/IZUQ6M2MX/
M^*JWRDBVNF$T@SU1R0_Y$$_@* /8:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *YFNFKF: -C2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP'_R"[G_ *[_ /LHKORW_>%\SS\T_P!V?R.KHHHKZ0^8"BBB@ HHHH ****
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M67"X^I(KR7PKILMUX.\53JA*B",*?7:V]OR"C\Z .I^#T""PU2XQ\[2HF?8
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MTNX;EWMH]Q]2% /ZUJUA>#(S'X-TE6')ME;\#R/YUNT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S-=-7,T ;&E?\>K?[Y_D*O51TK_CU;_?
M/\A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M55U/_D$WG_7!_P#T$U:JKJ?_ "";S_K@_P#Z":J/Q(F7PL\8HHHKZ(\ ****
M "BBB@ HHHH M6USC".>.QJ[P1@\BLBK5O<[<(YX['TKSL5A;^_ [\-B;>Y,
M;<6_EG<GW?Y57K7ZBJ-Q;;,N@^7N/2GA<5S>Y/<6)PW+[\-BM1117H'"%%%%
M !7K_A__ )%[3_\ K@G\J\@KU_P__P B]I__ %P3^5<&/^!>IW8'XV:5%%%>
M4>F%%%% !1110 4444 %%%% !1110 4444 %%%% ' ^//^0I;?\ 7#_V8URE
M=7X\_P"0I;?]</\ V8URE?+X[_>)'UF _P!W@%%%%<AUA1110 445+%$7Y/"
MUI2I3JRY8+4SJU84H\\W9#8XS(?0=S5M5"C '%   P!@5%+-M^5>OKZ5[]*E
M2P5/GF]?ZT1\]5K5L=4Y(+3^M6.EE"<#EJJDDG).32=:*\;$XJ=>5WMV/;PN
M$AAXV6_5A1117*=04444 %=)X(_Y#S?]<&_F*YNND\$?\AYO^N#?S%=.#_CP
M]3FQO^[S]#T6BBBOJCY$**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KBOB'_P >]A_O/_(5VM<5\0_^/>P_WG_D*Z,)_&B<
M^*_@LX.BBBO</&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"[I/_ "$H
MOHW_ *":Z*N=TG_D)1?1O_03715^7\;_ ._0_P "_.1]=D'^[R_Q?H@HHHKX
MP]T**** "BBB@ HHHH **** "BBB@ HHHH **** ,"]_X_9?K5>K%[_Q^R_6
MJ]?50^%'9'X4%%%%4,**** "BBB@ HHHH **** "BBB@ HHHH *[[P'_ ,@N
MY_Z[_P#LHK@:[[P'_P @NY_Z[_\ LHKORW_>%\SS\T_W9_(ZNBBBOI#Y@***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_B9IK:AX.FD0$O:2+.
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M+VG_ /7!/Y5Y!7K_ (?_ .1>T_\ ZX)_*N#'_ O4[L#\;-*BBBO*/3"BBB@
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MJ.NHHHKQCUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQO_P @%?\
MKNO\C7G5>B^-_P#D K_UW7^1KSJOG<S_ (_R/I<J_P!W^;"BBBO./2"BBB@
MHHHH **** "BBB@ HHHH **** "K6F_\A2T_Z[I_Z$*JU:TW_D*6G_7=/_0A
M5P^)$U/@9Z_1117V!\4%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 55U/\ Y!-Y_P!<'_\ 035JJNI_\@F\_P"N#_\ H)JH
M_$B9?"SQBBBBOHCP HHHH **** "BBB@ HHHH **** +-O<[/D?[O8^E7NHK
M(JQ;W'E_(_W?Y5Y^*PO-[\-SNPV)Y?<GL.N+;;ET''<>E5:U^H]JI7%MC+H.
M.XI87%7]R8\3AK>_ JUZ_P"'_P#D7M/_ .N"?RKR"O7_  __ ,B]I_\ UP3^
M55C_ (%ZBP/QLTJ***\H],**** "BBB@ HHHH **** "BBB@ HHHH **** .
M!\>?\A2V_P"N'_LQKE*ZOQY_R%+;_KA_[,:Y2OE\=_O$CZS ?[O *.IP*4 L
M< 9-6HH@@R>6I87"SKRTV[ABL7##QN]7T0V*';\S=?Y5*2%&2<"AF"#)-5))
M#(?;L*]BK6I8*GR06O\ 6K/%I4:V.J<\WI_6B%EE+\#A:CHHKP:E6567--ZG
MT-*E"E'D@K(****S- HHHH **** "BBB@ KI/!'_ "'F_P"N#?S%<W72>"/^
M0\W_ %P;^8KIP?\ 'AZG-C?]WGZ'HM%%%?5'R(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7%?$/\ X][#_>?^0KM:XKXA
M_P#'O8?[S_R%=&$_C1.?%?P6<'1117N'C!1110 4444 %%%% !1110 4444
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MP'_R"[G_ *[_ /LHKORW_>%\SS\T_P!V?R.KHHHKZ0^8"BBB@ HHHH ****
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MYBNG!_QX>IS8W_=Y^AZ+1117U1\B%%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M35JJNI_\@F\_ZX/_ .@FJC\2)E\+/&****^B/ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KU_P_P#\B]I__7!/Y5Y!7K_A_P#Y%[3_ /K@G\JX,?\
M O4[L#\;(-=T*/5(O-BPETH^5NS#T-<#-#)!,T4J%)$.&4]J]7K'US0H]5B\
MQ,)=*/E;LWL:\H],QO#WB,Q%+*^?]WTCE/\ #['V]Z[&O*9H9+>9X9D*2(<,
MI[5T?A[Q%Y&VSO7_ '72.0_P^Q]OY4 =G11G(R** "BBB@ HHHH ***.E !7
M-Z]XD6TW6MDP:?HTG4)]/4U5U[Q-G=::>_'1YA_)?\:Y55:1PB*69C@ #))H
M 1F:1RS$LS'))Y)-=9H/AG[MWJ">Z0G^;?X5:T'PVMGMNKQ0UQU5.H3_ !-=
M'0!P/CS_ )"EM_UP_P#9C7*5U?CS_D*6W_7#_P!F-<I7R^._WB1]9@/]W@%%
M%%<AUA1110 4444 %%%% !1110 4444 %%%% !72>"/^0\W_ %P;^8KFZZ3P
M1_R'F_ZX-_,5TX/^/#U.;&_[O/T/1:***^J/D0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N*^(?\ Q[V'^\_\A7:UQ7Q#
M_P"/>P_WG_D*Z,)_&B<^*_@LX.BBBO</&"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"[I/\ R$HOHW_H)KHJYW2?^0E%]&_]!-=%7Y?QO_OT/\"_.1]=
MD'^[R_Q?H@HHHKXP]T**** "BBB@ HHHH **** "BBB@ HHHH **** ,"]_X
M_9?K5>K%[_Q^R_6J]?50^%'9'X4%%%%4,**** "BBB@ HHHH **** "BBB@
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M]5#X4=D?A044450PHHHH **** "BBB@ HHHH **** "BBB@ KOO ?_(+N?\
MKO\ ^RBN!KOO ?\ R"[G_KO_ .RBN_+?]X7S//S3_=G\CJZ***^D/F HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N9KIJYF@#8TK_CU;_?/\A5ZJ.E?\>K
M?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'D'B#_ )&'4/\ KNW\ZS:TO$'_ ",.H?\ 7=OY
MUFU]#3^!>AX-3XV%%%%60%%%% !1110 4444 %%%% !1110 4444 %>A_#__
M )!-U_UW_P#917GE>A_#_P#Y!-U_UW_]E%<F-_A,ZL'_ !4==1117C'KA111
M0 4444 %%%% !1110 4444 %%%% !1110!S?C?\ Y *_]=U_D:\ZKT7QO_R
M5_Z[K_(UYU7SN9_Q_D?2Y5_N_P V%%%%><>D%%%% !1110 4444 %%%% !11
M10 4444 %6M-_P"0I:?]=T_]"%5:M:;_ ,A2T_Z[I_Z$*N'Q(FI\#/7Z***^
MP/B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "JNI_\@F\_ZX/_ .@FK55=3_Y!-Y_UP?\ ]!-5'XD3+X6>,4445]$> %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7K_A__D7M/_ZX)_*O(*]?\/\
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M0 4444 %%%% !1110!=TG_D)1?1O_03715SND_\ (2B^C?\ H)KHJ_+^-_\
M?H?X%^<CZ[(/]WE_B_1!1117QA[H4444 %%%% !1110 4444 %%%% !1110
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M/_Z":J/Q(F7PL\8HHHKZ(\ **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_D/-_P!<&_F*YNND\$?\AYO^N#?S%=.#_CP]3FQO^[S]#T6BBBOJCY$****
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M **** "BBB@ HHHH **** "N^\!_\@NY_P"N_P#[**X&N^\!_P#(+N?^N_\
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M]Y&!!^OS#\J /7:*JZ9>#4-*L[T8Q<0I+@=MP!_K5J@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N9KIJYF@#8TK_ (]6_P!\_P A5ZJ.E?\
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MCRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\
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M_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU7J*V,"CY6H_\_$?Y?_6H\K4?^?B/\O\
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MCRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\
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M*U'_ )^(_P O_K5>HK4Q*/E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\
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ME_SPC_[^O7544>VJ?S/[P]C3_E7W',0^#[:"421Q1JXS@^8Y]JL?\(][1_\
M?35OT5RU\/2Q$N:M%2?=I/\ ,VIRE35J;LO+0P/^$>]H_P#OIJ/^$>]H_P#O
MIJWZ*Q_L_!_\^H_^ K_(OV]7^9_>S _X1[VC_P"^FH_X1[VC_P"^FK?HH_L_
M!_\ /J/_ ("O\@]O5_F?WLP/^$>]H_\ OIJ/^$>]H_\ OIJWZ*/[/P?_ #ZC
M_P" K_(/;U?YG][,#_A'O:/_ +Z:C_A'O:/_ +Z:M^BC^S\'_P ^H_\ @*_R
M#V]7^9_>S _X1[VC_P"^FH_X1[VC_P"^FK?HH_L_!_\ /J/_ ("O\@]O5_F?
MWLP/^$>]H_\ OIJ/^$>]H_\ OIJWZ*/[/P?_ #ZC_P" K_(/;U?YG][,#_A'
MO:/_ +Z:C_A'O:/_ +Z:M^BC^S\'_P ^H_\ @*_R#V]7^9_>S _X1[VC_P"^
MFH_X1[VC_P"^FK?HH_L_!_\ /J/_ ("O\@]O5_F?WLYA_"%M(Y=XHRQZGS'I
M/^$-M/\ GC'_ -_'KJ**U^K4?Y%]R*^LU_YW][.7_P"$-M/^>,?_ '\>C_A#
M;3_GC'_W\>NHHI_5J/\ (ON0?6J_\[^]G+_\(;:?\\8_^_CT?\(;:?\ /&/_
M +^/7444?5J/\B^Y!]:K_P [^]G+_P#"&VG_ #QC_P"_CT?\(;:?\\8_^_CU
MU%%'U:C_ "+[D'UJO_._O9R__"&VG_/&/_OX]'_"&VG_ #QC_P"_CUU%%'U:
MC_(ON0?6J_\ ._O9R_\ PAMI_P \8_\ OX]'_"&VG_/&/_OX]=111]6H_P B
M^Y!]:K_SO[V<O_PAMI_SQC_[^/1_PAMI_P \8_\ OX]=111]6H_R+[D'UJO_
M #O[V<O_ ,(;:?\ /&/_ +^/1_PAMI_SQC_[^/7444?5J/\ (ON0?6J_\[^]
MG+_\(;:?\\8_^_CU?L-(FTR)HK-HXT9MQ&2V3^(K9HJHT:<'>,4GZ$RKU9JT
MI-KU*/E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HK0R*/E:C_ ,_$?Y?_ %J/*U'_
M )^(_P O_K5>HH H^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7
M_P!:CRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5
MJ/\ S\1_E_\ 6H\K4?\ GXC_ "_^M5ZB@".!95BQ,P9\]14E%% !1110 444
M4 >8?&,M]FTA?X2\I/UPO_UZ['P@R0^"=+?/R+:JQ_+)KG?BW9&?PY;7:C)M
M[@!O96!'\PM:OP[NDO? UDAPQBWPN/HQP/R(H \YT?Q#IM]XWF\0>(9S&J'?
M;Q!&?!Z*.!T4<_7!]:K^.-=L-;\50W]C*TENL4:EBA7D,2>#]:]0_P"%<>$_
M^@5_Y,2__%5YQXU\+1:=XI@M=)TV=;1XT)"!W!8L0>3GVH ]7AO=.\8>'KI;
M*X9K:X1[=G"E64D8/!^H-<;)\'K,QMY6K3A\?*6B!&??FNFU*QD\+^$KI/"U
MEMF1UD2)0TI8EEW<$DGY:XMOBCK_ )1A_L.(773.Q\ _[O7]: ,OP5J>H^'/
M&JZ)+,S0/<-;2Q;B4W9(#*.W('/I7MM>2^!O".J7OB >(-9ADA17,ZB4;6ED
M)SG'4#)S^5;/Q-\2:IH9TV+3+HVYF\QI"J@DXVXZCW- %CXKJS>#T(Z+=(3]
M,,/ZU-\+F5O!40'59Y ?KG/]15N?3KKQ/\/(K:](^VW-JDFYAC]Y@,"<=.>O
MU->;Z%XA\0>!?M.G3:4[H[[_ "Y58;6QC*D=0<#\J )/&J^?\4Q$A^8RVZ<=
MB0O^-)XX_=?$\22?<\RW;GT 7_ UH^#_  ]JNO\ BS_A)-7MWBA63SP70KYC
M_P (4'G:..?;%:/Q0\+7FH2V^L:?;O,\:>7.D8RV <A@._4@_A0!W6OL$\.:
MFS' %I*2?^ &O$/#L+R>&?%#J3A;:('_ +^ _P @:UK[QQXCUO1?[$&FL9Y5
M$<LL<;%Y!W^7L3W_ *5V?@_P6=.\)WMGJ*A;G4D(F7KY:X(4?49)^IH SO@^
MRG2=20?>$ZD_0KQ_(UA_%Y@?$=DN>1: D?\  V_PJCI=WX@^'>K7,4FGM+'+
MA6#*=DF.C*P^I_/D5;T[2=8\?>*TU34K1H;%67>Q0JFQ>B+GJ3_4F@#U[3XS
M%IMK&V=R0HIS[ 5B>/U9_ VJ!>NQ3^ =2:H_$?4=8TW1;>32&EC+38EDB7)5
M<''T&:L^&UOM?\!K#K8?SKF.2)FD3:Q4D@$CUQ_0T 8'P?93I.I(/O"=2?H5
MX_D:P_B\P/B.R7/(M 2/^!M_A5'2[OQ!\.]6N8I-/:6.7"L&4[),=&5A]3^?
M(JWIVDZQX^\5IJFI6C0V*LN]BA5-B]$7/4G^I- $?Q.A>&^T8,3QIZ)SZ@G-
M>PZ:ROI5FZ_=,"$?3:*Y'XE>&;G7-+@NK"$RW5H3^[7[SH>H'J00./K7&VOC
MKQ%::"-#73F,Z1^0DQC;S%7& -OJ!P* &_#-?-\>/(ARJQ2OD=P2!_6M_P",
M0'V+23GGS),?DM7?AIX3N=&@GU+4(C#=7"A(XFX9$SDY]"3CCVK%^,%V'O\
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M444 %<S735S- &QI7_'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKBM4\4>
M(KC5KG3O#NAB?[,^R2YN#A">X'('Z_A0!VM%>?6?CG6-,UN#2_%6EQVIG(6.
M>$\<\9/)!&>N#Q7=W=U#8VDUU<.$AA0N['L ,F@":BO/;?Q9XM\1>9<^'M'M
M5L$<JLETWS/C_@0'Y?G6GX6\93:KJ<^C:O9"RU6$$[%^Z^.N,]#WZG(YH Z^
MBN:\3>([_2[JWT_2=*DO[ZX0NO4(@!QD_P#ZQ]:YR[\8>,O#^RZUW0K;[$SX
M9H&Y7/;(9@/Q'/K0!Z115;3[Z#4]/@OK9BT,Z!T)'.#Z^]<7-XJ\5ZM/,OAW
M0$^RQN4\^Z.-^#C(R5'\Z .]HKAM!\<7\FOC0O$6G+97S\1M'G:QQP.2>O8@
MD5W- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !14-Y<I96-Q=2*S)!&TC!1R0HR<?E7"CQ'XZU-?M.E^'((;0\H+EOG8?BR]
M?I^- 'H%%<CX1\:/KUW<:9J%G]CU.W!+1C.& .#P>01QQ6EXI\36OA?2_M4Z
M&65SLAA!P7;Z]@.YH W**\]DU_X@169U)]#LOLH7>8>?,"]<XWYSCV_"NH\,
M>)+;Q/I(O8%,<BMLEB)R4;^H]#0!M45Q&H>*/$MYJ=U9>'="$J6TC1/<W)PI
M8'!V\@?J?I5?3?'.K6>O0:/XHTR.TEG(6.6(_+D\#/)!!/&0>* ._HJCK&I#
M2-)N+[[/)<&(#$40RSDD  ?B17'2:W\0I(C=P^'[..  L(7;,A'N-X.?P!]J
M ._HKFO!WBV/Q593,T'V>[MR%FBSD<]"/8X/';%=+0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 45B^)==DT&PBE@L9;VYGE
M$,,,8/+$$\X!XXKE+OQ+X^T^W?4+O0+,6:#<ZJ<LJ^IPY(_+C':@#T6BLGPW
MK]OXET=-0MT,>6*21L<E''49[]0?QK&\2>,;BPU>+0]%LA?:K(,E6.$CXR,]
M,\<]1@=Z .OHKSNY\7^*O#DL,OB/2+8V,C;3+:GE3Z?>(_ XSZUVUQJMO!HD
MFK(6FME@-POECEUVY&/K0!>HKS[_ (2+Q[J"?:M.\.6\-J?F1;AOG8?0LI_2
MM7P?XR_X2.2YL;NU^R:E;<R1<X(!P2 >1@X!!]: .LHHKSWQ?\0KS1]5ELM)
MMK><6R@W,LRLP5B>%&"/4?Y% 'H5%5-+NFOM)L[QU"O/ DK*O0%E!P/SJW0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<S735S- &QI7_'JW^^?Y"KU4=*
M_P"/5O\ ?/\ (5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7,UTU<S0!L:5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\U2Z_P!;,1P,G) ]<GO[#I74T44 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KF:Z:N9H V-*_P"/5O\ ?/\ (5>JCI7_ !ZM_OG^0J]0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S-
M=-7,T ;&E?\ 'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***:LB.S*CJQ4X8 YP?>@!U%%9VC:W9:]:RW-@
M[M%'*86+*5^8 $_AR* -&BFO(D2%Y'5%'4L<"G4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S735S- &QI
M7_'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KG]2\7Z?I>H2V<\-RTD>,E%4CD ]V'K705Y5XP_Y&J]_X!_Z M=.%
MI1JS:EV.?$U94X)Q[G5_\)_I7_/O>_\ ?"__ !5'_"?Z5_S[WO\ WPO_ ,57
MG%%=_P!2I'!]<JGH_P#PG^E?\^][_P!\+_\ %4?\)_I7_/O>_P#?"_\ Q5><
M44?4J0?7*IZ/_P )_I7_ #[WO_?"_P#Q5'_"?Z5_S[WO_?"__%5YQ11]2I!]
M<JGH_P#PG^E?\^][_P!\+_\ %4?\)_I7_/O>_P#?"_\ Q5><44?4J0?7*IZ/
M_P )_I7_ #[WO_?"_P#Q5'_"?Z5_S[WO_?"__%5YQ11]2I!]<JGLVFZA%JFG
MQ7D"NL<F<!P >"1V)]*GN)XK6WEN)W"11*7=CT4 9)K'\'_\BK9?\#_]#:L;
MXIWDEKX.*1L5^T7"1-@]1@MC_P =KRJD5&;2Z,]2G)R@F^QEP>(_%OC"ZF;P
MXD.GZ?&=HN+A02Q^I!Y]@./6K27/C[0+F%K];?6+)G5',"_.@)QGA0?QP:Z?
MPK91Z?X5TRWC4+BW1VQW9AN8_F36Q4%A17'>-_$=]ITEEH^C@?VG?MM5B,^6
MI.,_7/?M@U2;P'K?V?SE\7ZC]OVYR9&V9]/O9QG_ /50!WU%<?X#\27NKQ7F
MG:KC^TK"39(V,;QR.?<$$'\*P-2U/Q$_Q,U/2M(NG_>PI&@ED)CMP4C9I O3
M/7M_%0!Z?17EGB32=?\ !]M#KEMXCO+PI(JSI.QVG/L201VQ6E;Z3XA\9VXU
M6]U>?2;:90UI:VI/"GHS$$9S_7MTH ]!HKA/ .L:FVH:IX?U:=KFXL6.R9VR
MQ ;!R3R>Q&?6J7C'6-:L/B#IMMI,LKM+: );&0B-G8R+N9<X..#S_=H ](HK
MSN^\&>)(["2_C\57LFIJI=HU9EC8]=JX/'Y8]A6UX+\4'6_"[WU\RB>U+)<.
M!@' SNQ]/U!H ZJBO-]*BUCX@/<:E/JMUINEI*8[>"U;:S8[D]^OOSG&*='<
MZKX(\5:?IUWJ4VH:3J+;(VG.7C;('7/8LOM@]* /1J*XGXHW]YIWAFVELKJ>
MVD:\52\,A0D;'.,CMP/RJM'X=\2>);8ZCJ.O7&FO,-\%I:DA8E[;L$9/Z^_:
M@#OZ*X;X?:WJ5S+J6BZM*9KK3Y-HE8[F(R003WP1U]ZK:]>W^M>/T\-1ZI-I
MMFD0=F@;:\S%=V ?H<8Z<&@#T*BN:T3PS>Z)J?FKKMY>631D-;W3;R&XP0?_
M *U&O:'K>LZBJ0:VVGZ8L8RMN")7?)SD\8&,=_PH Z6JFJ7PTS2;N_,9D%O"
M\NP'&[:,XSVKSGQ%I^L^!H;;5['7[V[@$PCE@N7+ Y&?I@XQTR,UO^-M.GUC
MPVVI6^J7-I##9R2O!$QV3@KG#8(],=^M &[X;UH>(="M]3$!@\[</++[L88C
MK@9Z>E4?$UEXCN[S3FT.]CMX8W)N YQN&1CL<C@\>]<CX%\,7][H>GZC'XCO
M[:#S&;[)&S!,*YR/O8YQZ=ZU/B'J-[8ZOX;2TO)X$FN&$JQ2%0X#1\''7J>O
MK0!WM%8WBG74\.:!/J!4/(,)$AZ,YZ9]N_X5RFF^%O$'B"PCU/5?$M]:RW \
MR."W)58P>1P" #[8_&@#T2BO/= U;6- \7CPQK=XU[#.FZUN7R6/4C)/.#@C
MG.".N*=\1]7U'2=2\//I\TP+3.S01R%5FP8\*P'4')'XT >@45Y]/X/\47]D
M]]<^)KJ+4R"Z6\#E(D/91@CZ9_G6I\//$%UKV@/]N;?=6LGE._=Q@$$^_;\*
M .MH) &2< 45S7CW5_['\(WDBMMFG'V>+ZMU_)<G\* .)B^(6L'Q-'=O-CP_
M+>- H,2X"C'.[&<@,&ZUZW7F^H^$_+^$L5L(_P#2[=!>MQSNZL/P4D?@*ZCP
M5J_]M>%+*Y9MTR)Y,OKN7C)^HP?QH Z"BO.]5U/5_%/C";P]H]^]A968S<W$
M60Y8'!P1SU.,9'0FM"R\*:[HNJ6MQ9>(;B[M?, N;>[).4[E>3S^7UH U?%O
MB=?"NF0WC6AN?,F$6P2;,9!.<X/I6\K;E#>HS7E/Q4TBYMXAJ3ZK<S03W*JM
MFY/EQ'8>5YQV/;N:[#P]X8O])O1=W/B._OXS&5$$[,5!..>6/2@#IZ*X+3=1
MO9/B]J=D]Y.UHEOE8#(2BG;'R%Z#J?SK;\=7,]GX,U&XM9I(9D5-LD;%67+J
M.".G% '145SGA^74;WP#:207 ;4)+4[)K@EOGYP6/)/ZUDCP)JMRGFWWBW4C
M=L,YA8JBGV&>GTQ0!W->=^(99%^+V@H)&"&W7*@\'YI:M^ ]7U-]1U70=5N3
M=36#X29CEF&2#D]3V.3SS5+Q%_R6+0/^O9?_ $*6@"U\6I'C\*VQC=E)O4!*
MG'\#UVMB2=/MB3DF)?Y"N(^+O_(J6O\ U_)_Z!)2>.Y=3T_P[I.K:;>7$(M2
M@F2.1E5P0,%@.",@#G^]0!W]%5+/48+S28=15@L$L(FR?X01GGZ5QWP^O=1U
MR_UC6KFZN&M))C';0/(2B#.3A<X&!M''O0!WE>=>(M;\33^/5T#1+^&U#1!E
M\R-2"=I8DDJQ[=J]%KS*\N(;7XV0RW$T<42P<O(P4#]T>YH EU#5?'GA6!;[
M4VL=2LE($IB7!7)[D*I'UP17=:/JD&M:3;:C;9\J==P!ZJ>A!^A!%<MX\\4Z
M/'X8N[.*]M[FYN4\M(XG#XR1R<=,5<\*:7J6F_#^"TB*PZBT3NGG?=C9B2N1
MSTR,C% '5T5PP\":K<IYM]XMU(W;#.86*HI]AGI],4> ]7U-]1U70=5N3=36
M#X29CEF&2#D]3V.3SS0!K:C9>(Y?%MC<V5[''I"*!/"3RQR<\8YR",<]JZ.N
M"U[4;V'XJZ)9Q7DZ6LD"EX5D(1CF3DKT/0?E6GX]\23>'=#4V9Q>W+^5"=N=
MOJV/\\D4 =57GG@N61_B#XI5I&91*^ 3D#]X:6V\$^)([5+X>*;L:K@/Y;LS
M19_NG).1^&/:J/PW>ZE\8>('OHUCNVR9D7HK[SD#\: /4*P/%OB=?"NF0WC6
MAN?,F$6P2;,9!.<X/I6_7E'Q4TBYMXAJ3ZK<S03W*JMFY/EQ'8>5YQV/;N:
M/5E;<H;U&:6N8\/>&+_2;T7=SXCO[^,QE1!.S%03CGECTKGA?:SX[U^]MM-U
M*73='LFV&6'(>4].H(SG![\#% 'I%%>9:UIWB'P/ FKV.NW-_:1N%GM[HE@
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M?PE;F5LSVI-O(3U.W&#_ -\D?CFNIKSKX?,;/Q9XGTP?ZM9RZ#TP[#^1'Y4
M>BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5S-=-7,T ;&E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S-=-
M7,T ;&E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S-=-7,T ;
M&E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF:Z:N9H V-*_X]6_WS_(5
M>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !14-Q=6]I'YES<10IG&Z1PH_,TE
MM>VMXI:UN89P.IBD#8_*@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4456?4;*-RCWENK*<$&500?SH LT4R*:*=-\4B2)_>1@13F944L[!5
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M#[$9H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KF:Z:N9H V-*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110
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M\8:UJOB#5XDN@LHC@BD&Y%'7H>N!@#\: .UTSQ=H.L3K!8ZE%),WW8V!1C]
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MN'3+*WOIKZ&UC2ZG 6251RP'3/Y4DVDV%QJ4.HS6D3WD*[8YB/F4<\#\S^=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<S735S- &QI7_'J
MW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HVMX7F69HHVE7A7*@L/H:DHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH CBMX8-WDPQQ[CD[% R?PJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IJHJDE5 +=2
M!UIU% !1110 C(KKM=0P]",TM%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7,UTU<S0!L:5_QZM_OG^0J]
M5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "N9KIJYF@#8TK_CU;_?/\A5ZJ.E?\>K?[Y_D
M*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK48[9NDQ13_7^M=EI>J6>LV$=[83"6!^C 8(/<$'H: +E%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YFNFKF: -C2O\ CU;_ 'S_
M "%7JHZ5_P >K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5YAXM_Y&>\_X!_Z M>GUYAXM_Y&>\_X!_Z M>9FO\%>OZ,]7*/X[]/U1BT4
M45\^?1!1110 4444 %%%% !1110!Z?X2_P"18L_^!_\ H;5M5B^$O^18L_\
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MQ'#\Q RQ'.0 >W7K5S3Y))?@^[29W#2IEY] C ?H!1\+8HT\&1R*BJ\DSEV
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M?U;!Z<>WO7&>-;[7KNZT=M7T>/3T2YS"RSK(225R.#QT% ';?$?_ )$+4_\
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M ,]XO^^Q5'Q%J+:3X=U"^CQYD,+%,_WN@_4BN>_X5;X:_P">5S_W^-7_ ![
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP1SW*M$SK@.-TG(]>H_.CXDZ9?:G;:4MC:2W!CN=SB-<[1CJ:[FB@#EOB/\
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M-J=M$Q\F:U). >>P/&3W Q5FTT?6_%GB>UUG7;(6%A9',%HS9=CUY_'&2<=
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M:_JHC$TY\NV17W;(_?WP%'Y^M '6T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7,UTU<S0!L:5_QZM_OG^0J]5'2O\ CU;_ 'S_ "%7J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M9KIJYF@#8TK_ (]6_P!\_P A5ZJ.E?\ 'JW^^?Y"KU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,UTU<S0
M!L:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***JW^HVVFP>;<R;1_"HZL?84 6J*Y)_&OS_)8
MY3_:DY/Z5KZ5X@M-4/EC,4__ #S8]?H>] &M1110 4444 %%%9'BC49])\,W
M]]:E1/#%E"PR <@9Q^- &O17FW@/QSJ&I:G_ &;K<BN\\>^VEV!-Q&<C@ 'H
M?R-=GXGOKC3/#.H7MJX2>&(LC$ X/T- &M16#X+U.[UCPE8WU]()+F7?O<*%
MSAV4<#CH!6]0 445E>)-:'A[0KC4S;F?R=H\O?MSE@.N#CKZ4 :M%5-+OAJ>
ME6E^L9C%Q"LH0G.W<,XS5N@ HKBOB)X@U+0+?36TVX$+33%9"45L@ <<@^M=
MK0 4444 %%%% !1110 4444 %-5T8D*RDJ<$ ]*I:WJ2:/HEYJ#X/D1%@#W;
M^$?B<"N<^&VG-;^'&U&<EKK4I6GD<]2,D#^I_P"!4 =E6=I^MV.IWU_9VKLT
MUBXCG!4@ G/0]^AKFM=\5ZK+XD_X1WPW;0R7B+NGFF^Z@QG],CGGKC%9%EHO
MCGPS<WFH6ZZ?J#7<OG7,2,<L<DG&0N.IZ?E0!Z6[JB[G8*/4G%.K'\3Z2-<\
M-7ED5_>/'NC]G'*_J,5G?#W6&UCPE;F5MT]J3;R$]3MQM/\ WR1^.: .IHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF:Z:N9H V-*_X]
M6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYKM*** .;\7^$QXKM;:+[:;5X)"X<1[\Y'3&1[=ZQ?\ A =?_P"AZU+\I/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N9KIJYF@#8TK_ (]6_P!\_P A5ZJ.E?\ 'JW^^?Y"KU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,UT
MU<S0!L:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF:Z:N9H G2YFMM
MT<<F!N/84_\ M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
M_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH
M /[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"BB@ _M"Z_P">O_CH_P */[0NO^>O_CH_PHHH /[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\*** #^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"BB@ _M"Z_P">O_CH
0_P *C2#>@;=C/M110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img181340459_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img181340459_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7O"@@# 2(  A$! Q$!_\0
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MJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\
M"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"K
MU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *
MO44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O4
M4 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]
M10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10
M!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU%
M %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %
M'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44
M4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?
M[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1
M_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_L
MJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^
MRH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH
M/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*
M@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_
MOR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#
M^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_
M)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[
M\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\G
MYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR
M?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F
M/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^
M8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_
MPH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC
M_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"
MC^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\
M*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/
M[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH
M_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_L
MJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^
MRH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH
M/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*
M@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_
MOR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#
M^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_
M)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[
M\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\G
MYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR
M?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F
M/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^
M8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_
MPJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC
M_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"
MKU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\
M*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O
M44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ
M]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]1
M0!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU
M% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU%
M%'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44
M 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4
M?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!
M1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_
MLJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'
M^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^R
MH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[
M*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@
M_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ
M#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^
M_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/
M[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\
MGYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_O
MR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?
MF/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)
M^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8
M_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GY
MC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_
M  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/
M\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\
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MZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4=5_P"/5?\ ?'\C11JO_'JO^^/Y&B@ TK_C
MU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 4=5_P"/5?\ ?'\C11JO_'JO^^/Y
M&B@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110
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MZ9!ZY.!^- 'I5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_%UIXJLY'BC,%S"0)86;.,]"#W'6@#HJ**XSQMXXE\*W5M;0623O,AD+.Y
MSC&!0!V=%<IX(\7R>+(+LS6BV\ELR@['R&#9]>G2M?Q%K2>'M#N-3DB,WE;0
M(PV-Q)  SVZT :E%>1'XPW^>-*ML?]=&H_X7!J'_ $"K;_OXU 'KM%>1?\+A
MO\_\@JV_[^-7JFGW:ZAIEK>JNU;B%)0N<X# ''ZT 6:*BN;J"RMI+FYE2*&,
M;G=S@ 5YWK'Q<M()&BTFR:YQP)IFV*?HO4CZXH ])HKQ=OBYKQ?*VFG!1V\M
MSGZ_/5_3_C!<JX&I:7$ZD\O;,5('^ZV<_F* /6:*S=%U[3O$%G]JT^<2*.'0
MC#(?0CM6E0 4444 %%%% !1110 455U#4;/2K-[N^G2"!.KM_(>I]A7G.J?%
M]$D9-*TWS%!XEN&QG_@(_P : /4**\93XNZX'!>RTXIW 1P?SW5UOASXFZ=K
M-U%9WD#65S(0J$MNC=CT&>""?<?C0!W-%%% !17F>N_%233M9N;*RT^*:*W<
MQF5Y#\Q'!P!VSFG>'_BF^IZU;6%[I\4*7#B-94D/RL>F0>N3@?C0!Z51110
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M^O63^5 'SG7LR?"30&16-WJ62 ?]9'_\17C-?0$?C[PN(U!U>+( _@?_  H
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M_P"'8Q,^Z\M<13>I_NM^(_4&O-/B?_R.]Q_URC_]!H [GX2_\BC-_P!?C_\
MH*5WE<'\)?\ D49O^OQ__04K<\7^)H_"^C&YVK)<R'9!&W1F]3[#_ =Z -NX
MN8+2(RW,\<,8ZO(X4#\36;_PE7A_?L_MO3L_]?*8_/.*\!O+_5/$6I*UQ+/>
M74C81!D]>RJ.GT%:C^ /%"6IN#I,FP#)42(6Q_N@Y_2@#WV"XAN8A+!-'+&>
MC1L&!_$5)7S3I.LZCH5Z+BPN'AD!^9<_*_LP[BO?_#.O1>(]#AU"-=CGY)8\
M_<<=1_(CV(H T;B[MK10US<10J>AD<*/UI\4L<T8DBD61#T93D'\:\@^+_\
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M-\K!0".E:8\?>%R<?VO%_P!\/_A0!?\ #_A^S\-Z;]ALFE:,N9"TK L2<>@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4=5_P"/5?\ ?'\C11JO_'JO^^/Y&B@ TK_CU;_?/\A5ZJ.E?\>K
M?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]93_ -RZV_FK?X4 >>>"-,BU?Q=86LZAH0QD=2,@A06P?8D ?C7T,!@8'2O
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MXNU/^U_%6H78;=&92D9_V%^4?F!G\:]=^&^E?V;X/MW=<2W;&X;Z'A?_ !T
M_C7B>DZ>^JZO:6$>=UQ*J9'8$\G\!DU]+PQ)!#'#$H6.-0JJ.P P!0!\Y>*+
MQK_Q3J=PQ)W7+A<_W0<#] *[;PE\0-"\.^'+?3Y;2^:=2S2O'&A#,2>>6';
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MI5EX9T33I!)::5:1R Y#B,%A]">16K0!%=?\>DW_ %S;^5?+U?4-U_QZ3?\
M7-OY5\O4 =C8?#37=1T^WO8'L_*GC61-TI!P1D9XJQ_PJCQ%_P ]+'_OZ?\
MXFO5O"G_ "*.C_\ 7G%_Z"*UZ (K:+R+6&'=N\M N?7 Q7S;K@9?$&I!N6%U
M*#]=YKZ7KY]\>:>VG>,]00KA)G\]#ZA^3^N1^% 'IGPK*GP: .HN9 ?KQ_\
M6KMJ\J^$>M1)]KT:5PKNWGP@G[QP P^N #^=>JT %>$?$UU?QQ=JH&4CC#?7
M8#_(BO<KBXAM+:2XN)%CAC4L[L<!0.]?.'B#5#K6OWNHX(6>4E >H4<*/R H
M [[X.(3-K#]@L0_,O_A7JU<+\*M,>S\,27<BX:\F+K_N+P/UW5W5 !7(?$S_
M )$:[_ZZ1_\ H8KKZY#XF?\ (C7?_72/_P!#% 'EG@#_ )'G2_\ KHW_ * U
M>A?%+P[]OTE-7@0FXLQB3 Y:(_X'GZ$UY[X _P"1YTO_ *Z-_P"@-7T!)&DT
M3Q2*&1U*LIZ$'J* /G#PYK,F@:]:ZA'DK&V)%'\2'AA^7ZXKKOBS-'<ZGI4\
M+AXI+3>C#H06R#7+>*]!?P[X@N+$AO)SO@8_Q1GI^73ZBJEYJDM]IMA:RY)L
MU=$8_P!PG('X'/X8H ]'^#G^IUC_ 'H?_9ZZ'XF?\B-=_P#72/\ ]#%<]\'/
M]3K'^]#_ .SUT/Q,_P"1&N_^ND?_ *&* /#K.UDO;V"TBV^9/(L:;C@98X&?
MSKL_^%4>(O[]C_W]/_Q-<QX=_P"1FTK_ *_(?_0Q7TI0!Y3X8^'&M:3XDLK^
M[DM1! Y=O+D)8\'&!CUKO/%X8^#]7"]?LLA_#'-;55M0M%O]-NK-ONSPO$?^
M! C^M 'S%7TSHY5M$L&3[IMHR,>FT5\TS120320RJ5DC8JRGJ"#@BO>/AYK4
M6K>%+:(.//LU$$JYY 'W3]",?D: .KHHK#\6ZY%H'AVZNG<"9D,<"YY9R.,?
M3K^% 'SW=NLEY/(@ 5I&(QZ$U[C\.8 _@"S1_NR^;GZ%V%>$JK.P5068G  Z
MDU])^']..D^'K"P8 /#"JOC^]C+?J30!\[:GIUQI.I7%C=(5FA<JP]?0CV(Y
MKTGP_P#%B)((K;6[9]R@+]IAYW>[+_AGZ5W&O^%=)\21 7\!\U1A)XSM=?Q[
MCV.17E?BCX;7NA6DM_:7"W=G'RX(VR(/4CH1[C\J /8M-U6QU>U%SI]U'<1'
MC*'H?0CJ#[&KE?._@_6[C0_$EI-%(1#+(L4Z9X9"<'/TSD5]$4 %<C\3 Q\#
M7A'0/&3]-X_^M775C^*].;5?"NI6:+ND>$E%]67YE'Y@4 ?.D1"S(6Z!@37U
M'U&17RS7T)X*UZ'7O#=M(L@-S BQ3IGD,!C/T.,__JH Z*BBH;F\MK-4:YN(
MH0[!%,CA=S'H!GJ: )J^>O&^K?VQXMOIU;,4;^3%Z;5X_4Y/XU[9XKU;^Q?#
M-]>AL2+'MB_WVX7]3G\*^=8XI)I5CB1I)&.%51DD^PH ]U^&^E?V9X/MY'7$
MMV3<-]#PO_CH!_&L;XN:5YVE6>J(OS6\GE2$?W6Z'\"/_'J\O_L+5_\ H%7W
M_@._^%']A:O_ - J^_\  =_\* -7P)JW]D>+K*5FVPS-Y$OT;@?D<'\*^@J^
M6N5;N&!_*OH_PQJHUOPW8WY.7DC D_WQPWZ@T >4?%?_ )'!/^O5/YM7/Z!X
MHU+PTUP=.:-3.%#[TW=,X_F:Z#XK_P#(X)_UZI_-JF^&.@Z7KDFIC4K1;@0B
M+9N8C;G=GH1Z"@#G]8\::]KEN;:\O3]G)R8HT" _7 R?H:?X6\(7_B6]0)&\
M5BK?O;DC@#T7U/\ DU[/;^#/#EJX:+1[4D=-Z;__ $+-;B(L:!$4*JC  & !
M0!';6\5G:Q6T"!(8D"(H[ # %2T44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!1U7_CU7_?'\C11JO_'JO^^/Y&B@ TK_ (]6
M_P!\_P A5ZJ.E?\ 'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 177_'I-_US;^5?+U?4Q (P1D&N9?X>^%7F,ITE
M Q.<"60#\@V* +_A3_D4='_Z\XO_ $$5KU'!!%;6\<$$:QQ1J$1%& H'  J2
M@ K%\7 GPAJ^!_RZ2?\ H)K:ILD:31/'(BO&X*LK#((/4$4 ?+==FOQ1\2JH
M EML 8_U(KU!O 7A=F+'2(<DYX9@/RS2?\(!X6_Z!$7_ 'V_^- 'F/\ PM+Q
M+_SUMO\ OR*]5\'ZO<:YX7L]0NPOGR;P^P8!PY&<?05!_P (!X6_Z!$7_?;_
M .-;EE96VG6<=I9PK#;Q#"(O0<YH X+XC^"YM4/]LZ9&9+I%Q/"O611T8>I'
M3'<?KY/9WEWIEXMQ:326]Q&>&4X(]O\ ZU?3M9&J>%]$UIR]_IT,LA&#( 5?
M_OH8- 'DL7Q3\2QQ;&>UD;^^\//Z$#]*P-:\2:MX@D5M1NVE53E(P J+] /Y
M]:]>/PO\,%]PM[@#^Z)SBM'3_ _AS3'$D&EQ-(#D-,3(0?;<3B@#S/P-X$N-
M9NXM0U&%H]-C(8*XP9_8#^[ZG\![>V@   # '0444 %%%% 'A7Q(T6XTWQ3/
M=LA-M>GS(W[9P-P^H/Z$5+X2^(<_AK3CI\UD+JW#%HR)-C)GJ.AR,_SKVB]L
M;74;9K:\MXYX6ZI(N1_^NN7?X9>%WDW"SE0?W%G;'ZG- 'FOB3Q=JWC%C EN
M8K.%6F-O$2V HR6<]\#Z"JO@3_D=]*_ZZG_T$U[A9>'-'TZPELK2PAC@F4I*
MN,EP1C#$\G\ZJ:=X*\/:3?)>V6FK'<1YV.97;;GT#,10!H:[_P B_J7_ %ZR
M_P#H!KYHKZDDC26)XY%#(X*LI&00>HKFQ\/?"JR^8-)3=G.#+(1^6[% '0VO
M_'I#_P!<U_E7GWQ@_P"0)I__ %\G_P!!->B@!0 !@#@ 51U71M.UNV%MJ5JM
MQ$K;@"2"#TR"""* /&?AA_R.]O\ ]<I/_0:]<\5:)_PD'AVZT\$"5EW1$]G'
M(_/I^--TKPCH6B77VG3]/6&?!7>9'<@'KC<3BMN@#Y?FAN+&[>&9'AN(7PRG
MAE85UH^*'B06 MA+;[P,?:#%F3^>,_A7K6L^%=%UY@^H6222@8$JDJ^/3(Z_
MC6;9_#CPS9S"7["TS Y FD++^70_C0!XI<:?J,FG'6KI9#!-/Y8FD/,CD$DC
M/7H>:[OX/?\ (0U3_KDG\S7IFI:)INKV*V5]:)+;H053E=I P,8QC@FH='\-
MZ1H'FG3+-8#+@.=[,3CIRQ- &K1110!Y;\7]5(%AI"-US<2#\U7_ -FK$^%F
ME?;?%)O'7,=E$7SVWM\J_IN/X5ZIJ_A31-=N4N-2L5FF1=@?S'0XZX^4C/4U
M8TG0M,T*%XM,M$MT<@O@DEL=,DDF@#1HHHH ^??'>D_V1XOO8E7$4S>?']&Y
M/Y'(_"NS^$.J[H;_ $AVY0BXC'L<*WZ[?SKN=8\,Z/KSQOJ=DL[QC:K;V4@>
MF5(IND>%=$T&X>?3;%8)778S^8SG&0<?,3Z"@#G_ (IZ5]N\+"\1<R64@?\
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MG!ED(_+=B@#H;7_CTA_ZYK_*L'QSHT^N>%+JUM5W7"%98T_O%3R/J1G\:Z(
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M#S;XJ^'#<VD>N6T>9(!Y=P .J=F_ _H?:O(J^I'19$9'4,C##*PR"/0US[^
M_#$CL[:/""3D[691^0.!0!C?"8$>$9B1UO'(_P"^4I_Q(\+S:[ID5Y91F2\M
M,_NU',B'J![CJ!]:["RL;73K2.ULX$@@C&%1!@"K% 'S-IFIWNBZC'>64K0W
M$9_/U!'<>U=C/\6M<EMO+CM;**0C!E56)'N 3C\\UZ;JOA'0=9D,M[IT33-U
ME3*,?J5QG\:R%^&'AA7W&WG8?W3.V/TYH \7@@O]<U01Q++=7MP^3SEF)ZDG
M^M>_^%- 3PWH$-B"&F/[R9Q_$YZ_@.!^%7-,T33-&B,>G645N#]XH/F;ZD\G
M\:OT >._%_\ Y&"Q_P"O7_V=JM?!W_C[U;_KG%_-J]"UCPUH^O/&^IV2SO&-
MJMN92!Z94BGZ/X>TG05D&F6:V_F8WD,S%L=.6)/<T :=?,VL?\AN_P#^OF3_
M -"-?3-<Y=> _#-Y=/<SZ6AE=BS%974$DY)P& H 7P)_R)&E?]<C_P"A&NBJ
M&TM+>PM(K6UB6*")=J(O0"IJ "BBB@#YHUW_ )&#4O\ KZE_]#->U_#7_D1+
M#_>E_P#1C5:O/ GAJ_NY+JXTM&FD8L[+*Z9)Y)PK 5M6-C:Z;9QVEG"L-O'G
M:B]!SD_K0!8HHHH BN03:S #)*-_*OEZOJ:N>F\#>&9YFEDTB#<QR=I91^0.
M* /)[+XC>(-/L8+."2W$,$:QH#""< 8%3_\ "TO$O_/6V_[\BO3O^$ \+?\
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MZM;>]MI+:ZA2:"08>-QD&@#YEM+F2SO(+J$@2PR+(F1D9!R/Y5UW_"TO$O\
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M^->D:GX(\.ZM*TMSIL8F;DR1$QDGU.W )^M9\/PQ\,12!VM9I0/X7G;'Z8H
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M/7&>I]Z[:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZK_P >J_[X_D:*
M-5_X]5_WQ_(T4 &E?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CJO_
M !ZK_OC^1HHU7_CU7_?'\C10 :5_QZM_OG^0J]5'2O\ CU;_ 'S_ "%7J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>H_E[T >^457L0ZZ?;"7/F")0V>N<#-6* "BFO(D8R[JH]6.*=U&10 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 4=5_X]5_WQ_(T4:K_P >J_[X_D:* #2O^/5O]\_R%7JHZ5_Q
MZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M96+)$ #N.">O3CV]L5UGQB_X]-)_ZZ2_R6N+\#:%;>(?$L=I=LWV=$,SJO\
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MS@.H(_O#KQU'TH Z7Q?_ ,B?J_\ UZR?RKYSKZ,\7_\ (GZO_P!>LG\J^<Z
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M58>A'<4 ?2]'09->.I\7]6$.'TZS:3^\-P'Y9_K7.:[XTUOQ$/*NK@);D_\
M'O -J'Z]S^)- 'J?Q0C9_!,S+G$<T;-],X_F17D/A:X2U\5:5-(0$6ZCW$]
M"P&:]VFTHZMX.73+K*R36:HQ/\+[1S^##/X5\^7]A<Z7?S6=W&T4\+;64_S'
MM[T ?3M<G\2ITA\#7RL0&E:-%![G>#_(&N0TCXMSVM@D&I6!NID&!,D@4O\
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M_(8'X5TE     P!T%% !1110 5\N2_ZY_P#>-?4=?+DO^N?_ 'C0!]">"/\
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M^(+/4 3LC?$@'=#PP_*OHY'61%=&#(P!4CH10 ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"CJO_ !ZK_OC^1HHU7_CU7_?'\C10 :5_QZM_OG^0
MJ]5'2O\ CU;_ 'S_ "%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=5_X]5_WQ_(T4:K_
M ,>J_P"^/Y&B@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=5_X]5_W
MQ_(T4:K_ ,>J_P"^/Y&B@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/F200X8+R0S'[OUQC\Z &_$>[:?2_#*EB=UEYISW+*G^%>H^&H%M_"^E1*,
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M7&>+_ 7_  E6J0WO]IFU\N$1;/(W@X8G/WAZ_I79T4 >6?\ "F_^H]_Y)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX]5_WQ_(T4:K_P >J_[X_D:* #2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBFR2+%&TCD*JC))["DVDKL-QU%<G>Z]<W#D0,88ATQ]X_4U5BU6^A<
M,+F1O9VW#]:^=J<386-3EC%M=ST(Y=4<;MI,[:BJ&EZFNHQ'*A)4^\N?U%7Z
M]ZA7IUZ:JTW=,X9PE"3C+<****U)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH SIM=TR"9XI;M5=#AAM/!_*F?\)%I
M/_/XG_?+?X5P^L_\AJ\_Z[-_.J- 'HW_  D6D_\ /XG_ 'RW^%'_  D6D_\
M/XG_ 'RW^%><T4 >C?\ "1:3_P _B?\ ?+?X4?\ "1:3_P _B?\ ?+?X5YS1
M0!Z-_P )%I/_ #^)_P!\M_A1_P )%I/_ #^)_P!\M_A7G-% 'HW_  D6D_\
M/XG_ 'RW^%'_  D6D_\ /XG_ 'RW^%><T4 >C?\ "1:3_P _B?\ ?+?X4?\
M"1:3_P _B?\ ?+?X5YS10!Z-_P )%I/_ #^)_P!\M_A1_P )%I/_ #^)_P!\
MM_A7G-% 'HW_  D6D_\ /XG_ 'RW^%'_  D6D_\ /XG_ 'RW^%><T4 >C?\
M"1:3_P _B?\ ?+?X5>MKJ&\@$UO('C.0& KRNO0?"W_( A_WF_F: -FBBB@
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ML1JU@8=GVTQMY^W&=O&S/O\ >KUBQ+MI]LTN?,,2EL]<X&: )Z*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBC5?^/5?]\?R-% !I7_'JW^^?Y"KU4=*_P"/5O\ ?/\ (5>H **** "BBB@
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M6_Y $/\ O-_,UY]7H/A;_D 0_P"\W\S0!LT444 %%%% !1110 4444 %%%%
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M %'5?^/5?]\?R-%&J_\ 'JO^^/Y&B@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %>@^%O^0!#_ +S?S->?5Z#X6_Y $/\ O-_,T ;-%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)P/VZ7W?Y'2T4BL'4,I!4C(([TM?7)W/+"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#S/6?^0U>?]=F_G5&KVL_\AJ\_Z[-_.J- !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Z#X6_Y $/^\W\S7GU>@^%O^0!#_O-_,T
M;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&%)^I%6*** "BBB@ HHHH **** *.J_\>J_[X_D:*-5_X]5_WQ_(T4 &E?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \SUG_D-7G_79OYU1J]K/_(:O/^NS?SJC0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>@^%O^0!#_O-_,UY]7H/A;_D
M 0_[S?S- &S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B?Q'NI;+X
M@I=P,%F@2&1"1G#+R./J*J?\+,\4_P#/[%_WX3_"NT\0>$M5U'XAV.K001O8
MQR0-(QD P%8%N#R>*[[[+;_\\(O^^!0!X;_PLSQ3_P _L7_?A/\ "L>QUR]C
M\41:NCJMVTX=BBA0Q)^88'KSGZU]%?9;?_GA%_WP*!;0 Y$$>?\ <% $M%%%
M !1110 4444 %%%% %'5?^/5?]\?R-%&J_\ 'JO^^/Y&B@ TK_CU;_?/\A5Z
MJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !7H/A;_D 0_P"\W\S7GU>@^%O^0!#_ +S?S- &S1110 4444 %%%%
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MX-UN>R^&&L2*_P"\LV<0DG[NX#'_ (\2: -[7/B;I&D7DEI!%+>S1DJYC("
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M<T,=Q$T4J!T/4&I**4HJ2<9*Z8TVG='(ZGHTED3)%EX/7NOU_P :SX9I+>59
M8G*..A%=\0""",@]JYW5-!QNGLUXZM$/Z?X5\;FF0RHOV^#V6MNJ]/ZN>MAL
M:I+DJ_>7M,UF.] CDPD_IV;Z?X5J5Y]RK=P0?RKH=+U[.V"\;GHLI_K_ (UT
MY3GZJ6HXIV?1]_7_ #,\5@>7WZ>W8Z"BC.1D45]4>8%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YGK
M/_(:O/\ KLW\ZHU>UG_D-7G_ %V;^=4: "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<6\5U"8ID#(?7
MM7*:GI$M@Q=<O >C=Q]:["D90RE6 (/!![UYF9951QT/>TDMG_6Z.G#XF=%Z
M;=C@[>XEM9A+"Y5QZ=ZZO3-7BOU"-A)QU7L?I6;JFA&/=/9J2G5H^X^E80)5
M@RD@@Y!':OD:.(QF35O9S5XOIT?FOZ]3U)0I8N',MST&BL'2]=$FV"\(#]%D
M['ZUO5]M@\;1Q=/VE)_YKU/'JT9TI<L@HHHKK,@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,
M]9_Y#5Y_UV;^=4:O:S_R&KS_ *[-_.J- !1110 4444 %%%% !1110 4444
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M <IK_P 0-)\.ZHVGW<%Y),J!R844J,]N6%9G_"W= _Y\]2_[]1__ !=:^N>
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M;_ 5YIXJUR:7QE<WUM ME=6T[()(B06*D@,<]\#GUJ]_PM+Q-_SUMO\ OR*
M/2-.^'F@:7J$%];13^="V]-TI(S]*ZJO(O#/Q#U_5/$EA8W#0/#-+L<+%@XQ
MUS^M>NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \SUG_D-
M7G_79OYU1J]K/_(:O/\ KLW\ZHT %%%% !1110 4444 %%%% !1110 4444
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M+E976/D(B@9R?H,$]R:]VH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 5Z#X6_Y $/\ O-_,UY]7H/A;_D 0_P"\W\S0!LT444 %%%%
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M.>3@\UUE !1110 4444 %%%% !1110!1U7_CU7_?'\C11JO_ !ZK_OC^1HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >9ZS_P AJ\_Z[-_.J-7M9_Y#5Y_UV;^=4: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KT'PM_R (?]YOYFO/J]!\+?\@"'_>;^9H V:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \D^).HWVK^);;PU9;BJ[,Q@X\R1N
M1GV (_,USGB'P5<>';C3+>XO(I9+YBI\M3B,@J.IZ_>]JZ77=NF_&>SNI^(Y
MVB8$],%?+S^8JS\69A;ZEH$Y!(C:1R!WP4- &!=:=K'PSURTO%N%GMI3@E"0
MLH'56'8X/'6O;4=9$5U.589!]17B7B+Q)=?$#4]/TRPLC"H<A%9MS,QZL?0
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MKR0;Y[IQAIY,9QZ*.PKHZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK.UK55T>Q%TT)E!<)M
M#8ZY_P *F<U"+E+9%0A*<E&.[-&BN._X3Z+_ *![_P#?T?X4?\)]%_T#W_[^
MC_"N7Z_A_P";\SK_ +.Q/\OXK_,[&BN._P"$^B_Z![_]_1_A1_PGT7_0/?\
M[^C_  H^OX?^;\P_L[$_R_BO\SL:*X[_ (3Z+_H'O_W]'^%'_"?1?] ]_P#O
MZ/\ "CZ_A_YOS#^SL3_+^*_S.QHKCO\ A/HO^@>__?T?X4?\)]%_T#W_ ._H
M_P */K^'_F_,/[.Q/\OXK_,[&BN._P"$^B_Z![_]_1_A1_PGT7_0/?\ [^C_
M  H^OX?^;\P_L[$_R_BO\SL:*X[_ (3Z+_H'O_W]'^%'_"?1?] ]_P#OZ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!YGK/_(:O/^NS?SJC5[6?^0U>?]=F_G5&@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *]!\+?\@"'_>;^9KSZO0?"W_( A_WF_F: -FBBB@
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M&9-O?()KUVL:T\6:#?74=K:ZI;RSR'"(IY)K9H **** "BBB@ HHHH ****
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MY5C:>90O2TDMUU7^:\SQ<7!X5^_L^IZ#17GG_"P-0_Y]+;_Q[_&C_A8&H?\
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M6W_CW^-'U*KV#ZY2[GH=%>>?\+ U#_GTMO\ Q[_&NH\,ZU-KEE-//%'&R2;
M$SC& >_UK.IAJE./-(N&(ISERQ-NBBBL#<**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,]9_Y#5Y
M_P!=F_G5&KVL_P#(:O/^NS?SJC0 4444 %%%% !1110 4444 %%%% !1110
M4444 %>@^%O^0!#_ +S?S->?5Z#X6_Y $/\ O-_,T ;-%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5QWC/Q1J>EW-OI.BV33ZA=1[U<+NV#..%[GW/ KL:3 SG
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MTC^VSJ;F5U+PI),YD<?7MGM_2D^(<S2Z9X7!Z?V>'_$JO^%>L^'D$?AK2T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'F>L_\ (:O/^NS?SJC5[6?^0U>?]=F_G5&@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *]!\+?\@"'_>;^9KSZO0?"W_( A_WF_F:
M-FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /LHKSRO0_A__P @FZ_Z[_\ LHKDQO\ "9U8/^*CKJ***\8]<**** "BBB@
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M "%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O*?B'KE_J?B"'PMILC*I*)*%)'F.W0$_W
M0"/U]*]6KP74GU*7XFWG]FX^WF]=(2V.#R >>.E '9P?"#3!:@7&HW;7..6C
M"A ?H03C\:ZFX=/!_@ICYAE%A;;49AC>W1>/<D5YQK=IX[\,6ZZI<ZU++&6
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MW\J_A/U_1'SV;_QH^GZL****]0\D**** "BBB@ HHHH **** "BBB@ HHHH
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MM_R (?\ >;^9KSZO0?"W_( A_P!YOYF@#9HHHH **** "BBB@ HHHH ****
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M=U_D:Z2N;\;_ /(!7_KNO\C7-C/X$_0Z<%_O$/4\ZHHHKY4^N"BBB@ HHHH
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M']:^LR+B2CF"5*K[M7MT?I_E^9XV895/#/GAK#\O7_,JT445]0>0%>A_#_\
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M44 %>@^%O^0!#_O-_,UY]7H/A;_D 0_[S?S- &S1110 4444 %%%% !1110
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M17RI]<%%%% !1110 4444 %%%% !1110 4444 %%%% &OX7_ .1DLO\ >/\
MZ":]2KRWPO\ \C)9?[Q_]!->I5[^5?PGZ_HCY[-_XT?3]6%%%%>H>2%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YY\0/\
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MD,"".H->A?#_ /Y!-U_UW_\ 917V>,:=&Z/%PG\4ZZBBBO'/7"BBB@ HHHH
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MM_R (?\ >;^9KSZO0?"W_( A_P!YOYF@#9HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQO\ \@%?^NZ_
MR-=)7-^-_P#D K_UW7^1KFQG\"?H=."_WB'J>=4445\J?7!1110 4444 %%%
M% !1110 4444 %%%% !1110!K^%_^1DLO]X_^@FO4J\M\+_\C)9?[Q_]!->I
M5[^5?PGZ_HCY[-_XT?3]6%%%%>H>2%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!YY\0/^0M:_\ 7#_V8UR-==\0/^0M:_\
M7#_V8UR->YAOX43Q<3_%D%%%%=!@%%%% !1110 4444 %%%% !1110!<LM0D
MM#M.6B/5?3Z5OPS1SQAXV#*?TKE*FMKF2UDWQGZ@]#7RF>\,TL>G6H>[4_"7
MKY^?WGL9=FT\-:G4UA^*]/\ (W;W3X[M=PPLHZ-Z_6ND\"0R0:;=QR+AA/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRW+*<2 94+G R.O4UT5 !1110 4444 %%%% %'5?^/5?]\?R-%&J_P#'JO\
MOC^1HH -*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7-^-_\ D K_ -=U_D:Z2N;\
M;_\ (!7_ *[K_(US8S^!/T.G!?[Q#U/.J***^5/K@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH U_"_\ R,EE_O'_ -!->I5Y;X7_ .1DLO\ >/\ Z":]
M2KW\J_A/U_1'SV;_ ,:/I^K"BBBO4/)"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \\^('_ "%K7_KA_P"S&N1KKOB!_P A
M:U_ZX?\ LQKD:]S#?PHGBXG^+(****Z# **** "BBB@ HHHH **** "BBB@
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MWM6_Z"-S_P!_#1_;VK?]!&Y_[^&C^UJ?\K#^QZG\R/6**\G_ +>U;_H(W/\
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M 4444 %%%% !1110 4444 >>?$#_ )"UK_UP_P#9C7(UUWQ _P"0M:_]</\
MV8UR->YAOX43Q<3_ !9!111708!1110 4444 %%%% !1110 4444 %%%% !7
MH?P__P"03=?]=_\ V45YY7H?P_\ ^03=?]=__917)C?X3.K!_P 5'75F:GH\
M5\#(F$G_ +W9OK6G17S^(PU+$4W3JJZ9[5.I*G+FB]3@9X);:4Q3(5<=C5_3
M-8EL2(WR\']WNOTKI;VPAOXMDJ\C[KCJM<E?:?/82[9!E#]UQT-?#XS+\3E5
M7V]!^[W_ $?]6/8I5Z>)CR36O];'9P3Q7,0EA<,A[BI*X>ROYK"7?$W!^\AZ
M-76V.H0W\6Z,X8?>0]17TN5YS2QJY):3[=_3_(\_$X25%W6J+=%%%>T<@444
M4 %%%% !1110 4444 <=X^_U%C_O/_(5P]=QX^_U%C_O/_(5P]?-9C_O$OE^
M1]1EO^[1^?YA1117"=X4444 %%%.6*1_NHS?09H;2W ;15A;*Y;I"WX\5*NE
MW!Z[%^IK&6(I1WDB7**ZE*BM)=(;^*8#Z#-2KI,0^](Y^F!64L?0747M(F11
M6XNG6R_P$_4FIEM8%Z0I_P!\UC+,Z:V3)=9'/ $G &34BVT[_=A<_P# :Z$
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MQ'T]:ZRO$OA__H/Q':UC)"'SX?J!D_\ LHKVV@ HHHH **** "BBB@ HHHH
M**** "BBB@"C?3Z5,W]F7T]HS7 V_9IG7,F?13R:SK/P3X<L+L75OI4*S*<J
M69G"GU 8D"O.O'-W'8?%&SO)MWE6[6\K[1D[58$X_*NK_P"%K^'?[E]_WZ'_
M ,50!VMP(# _VD1F$#<_F8V@#G)SQ5;39M,FMRVER6DD(.";5E*@^GR\5R,G
MQ3\-31/%)%>LCJ593"N"#U'WJX7PIXDM_#OBZ06CRMI%U)Y96088*3\K$>JY
M_$9H ]UHHHH **** "BBB@ HHHH HZK_ ,>J_P"^/Y&BC5?^/5?]\?R-% !I
M7_'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MJ=_JEEIBHUY.L0<D+D$YQ]*:3;LA-I*[+E%8W_"5Z'_T$$_[Y;_"C_A*]#_Z
M""?]\M_A5^RJ?RO[B/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
MH()_WRW^%'LJG\K^X/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
MH()_WRW^%'LJG\K^X/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
MH()_WRW^%'LJG\K^X/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
MH()_WRW^%'LJG\K^X/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
MH()_WRW^%'LJG\K^X/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
MH()_WRW^%'LJG\K^X/:T_P"9?>;-%8W_  E>A_\ 003_ +Y;_"C_ (2O0_\
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MNO\ #"3]6Q43:M,?NH@^N36?16T<%07V2E3CV+3:C<M_RT ^@%1-<SMUF?\
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M^0M:_P#7#_V8UR-==\0/^0M:_P#7#_V8UR->YAOX43Q<3_%D%%%%=!@%%%%
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M:\^IYU6_M%2*WO)HHP,A4<@=37/B<0J$.=JYT8;#2Q$^2+L>KT5Y/_;VK?\
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M.:G!374\NI!TYN#Z!1115D!1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)OTKUZO&OA%"6\2WDV.$M"OXEU_P->RT %%%% !1110 4444 %%%% !1110
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M=_\ V45YY7H?P_\ ^03=?]=__917)C?X3.K!_P 5'74445XQZX4444 %%%%
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MUO5]9A?X$/1'R&+_ (\_5A1116YSA1110 4444 %%%% !1110 4444 %%%%
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M_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8S^$_#\CL[:-9%F.
M2?)')K9HH \C^('@Z<ZK:'0=%/V<PX?[-%QOW'KCVQ7H1\-Z>_ARXTF*UBM8
MKF/$@B0#Y\#YO<@@?E6U10!XK8V/C7P/?7$=CI\MQ'+@$QPM-&^.C?+R#^5:
MGA;PGK>K>*5\0^(8FB"2"7;*,-(X^Z-O8#CKZ 5ZM10!P_Q$\(7'B&U@O-/
M:\M@5,9./,0\X!]0?YFN/-[X_FT;^P#IEWY)3R3(;9@Q3IM+GC&.,_K7M%%
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MG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<5\0_\ CWL/]Y_Y"NUKBOB'
M_P >]A_O/_(5T83^-$Y\5_!9P=%%%>X>,%%%% !1110 4444 %%%% !1110
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M_P"^/Y&B@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%%
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M^0M:_P#7#_V8UR-==\0/^0M:_P#7#_V8UR->YAOX43Q<3_%D%%%%=!@%%%%
M!1110 4444 %%%% !1110 4444 %>A_#_P#Y!-U_UW_]E%>>5Z'\/_\ D$W7
M_7?_ -E%<F-_A,ZL'_%1UU%%%>,>N%%%% !1110 4444 %%%% !1110 4444
M %%%% ''>/O]18_[S_R%</7<>/O]18_[S_R%</7S68_[Q+Y?D?49;_NT?G^8
M4445PG>%%%% !1110 4444 %%%% !1110 4444 %=CX!_P!???[J?S-<=78^
M ?\ 7WW^ZG\S79@/]XC_ %T.+,?]VE\OS1W%%%%?3GRH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D'B#_D8=0_Z[M_.O
M7Z\@\0?\C#J'_7=OYUWX#XWZ'#CO@1FT445ZIY@4444 %%%% !1110 4444
M%%%% !1110 4444 :R_ZN/\ W%_D*6D7_5Q_[B_R%+7SL_B9[\/A04445)04
M444 %%%% !1110 4444 %%%% !1110 56N?OK_N_U-6:K7/WU_W?ZFO-S7^
MO7_,]3*?X[]/\B&BBBOGCZ,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MQZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<5\0_^/>P_WG_D*[6N
M*^(?_'O8?[S_ ,A71A/XT3GQ7\%G!T445[AXP4444 %%%% !1110 4444 %%
M%% !1110 4444 =/X$_Y&%O^N#?S%>E5YKX$_P"1A;_K@W\Q7I5>/COXOR/6
MP7\(****XSK"BBB@ HHHH **** "BBB@ HHHH **** "N;\;_P#(!7_KNO\
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M!_:@*F)&N=K,0?E^3///M715XWXYNX[#XHV=Y-N\JW:WE?:,G:K G'Y5U?\
MPM?P[_<OO^_0_P#BJ .PO;6RN;=OM\%O+"@+'ST5E48Y// J'2CI#6['1S9&
M '!-GLVY';Y>*Y.3XI^&IHGBDBO61U*LIA7!!ZC[U<+X4\26_AWQ=(+1Y6TB
MZD\LK(,,%)^5B/5<_B,T >ZT444 %%%% !1110 4444 4=5_X]5_WQ_(T4:K
M_P >J_[X_D:* #2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<5\0_\ CWL/]Y_Y"NUKBOB'_P >]A_O/_(5T83^-$Y\5_!9
MP=%%%>X>,%%%% !1110 4444 %%%% !1110 4444 %%%% '3^!/^1A;_ *X-
M_,5Z57FO@3_D86_ZX-_,5Z57CX[^+\CUL%_""BBBN,ZPHHHH **** "BBB@
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M5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB
MOB'_ ,>]A_O/_(5VM<5\0_\ CWL/]Y_Y"NC"?QHG/BOX+.#HHHKW#Q@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Z?P)_P C"W_7!OYBO2J\U\"?\C"W
M_7!OYBO2J\?'?Q?D>M@OX04445QG6%%%% !1110 4444 %%%% !1110 4444
M %<WXW_Y *_]=U_D:Z2N;\;_ /(!7_KNO\C7-C/X$_0Z<%_O$/4\ZHHHKY4^
MN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#7\+_\C)9?[Q_]!->I5Y;X
M7_Y&2R_WC_Z":]2KW\J_A/U_1'SV;_QH^GZL****]0\D**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SSX@?\A:U_P"N'_LQ
MKD:Z[X@?\A:U_P"N'_LQKD:]S#?PHGBXG^+(****Z# **** "BBB@ HHHH *
M*** "BBB@ HHHH *]#^'_P#R";K_ *[_ /LHKSRO0_A__P @FZ_Z[_\ LHKD
MQO\ "9U8/^*CKJ***\8]<**** "BBB@ HHHH **** "BBB@ HHHH **** ..
M\??ZBQ_WG_D*X>NX\??ZBQ_WG_D*X>OFLQ_WB7R_(^HRW_=H_/\ ,****X3O
M"BBB@ HHHH **** "BBB@ HHHH **** "NQ\ _Z^^_W4_F:XZNQ\ _Z^^_W4
M_F:[,!_O$?ZZ'%F/^[2^7YH[BBBBOISY4**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KR#Q!_R,.H?]=V_G7K]>0>(/^1AU
M#_KNW\Z[\!\;]#AQWP(S:***]4\P**** "BBB@ HHHH **** "BBB@ HHHH
M**** -9?]7'_ +B_R%+2+_JX_P#<7^0I:^=G\3/?A\*"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "JUS]]?]W^IJS5:Y^^O^[_4UYN:_P !>O\ F>IE
M/\=^G^1#1117SQ]&%%%% !1110 4444 %%%% !1110 4444 %%%% 'I?@_\
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M!/\ D86_ZX-_,5Z57FO@3_D86_ZX-_,5Z57CX[^+\CUL%_""BBBN,ZPHHHH
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M5YY7H?P__P"03=?]=_\ V45R8W^$SJP?\5'74445XQZX4444 %%%% !1110
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M]'C75=3NK4Z@X_=QM*O[@'\?O']*W_'\8O\ P'J#6[+*%"2 H<@A7!)X]@:
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MA1110 4444 %%%% !1110 4444 %%%% !7-^-_\ D K_ -=U_D:Z2N;\;_\
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M?_T(UO5@^#_^1;@_WG_]"-;U?687^!#T1\AB_P"//U84445N<X4444 %%%%
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MX_[ZZUZI10!FZ'H=EX?TQ+&Q0B,'<S-RSMW8GUK2HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KBOB'_P >]A_O/_(5VM<5\0_^/>P_WG_D
M*Z,)_&B<^*_@LX.BBBO</&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MI_ G_(PM_P!<&_F*]*KS7P)_R,+?]<&_F*]*KQ\=_%^1ZV"_A!1117&=8444
M4 %%%% !1110 4444 %%%% !1110 5S?C?\ Y *_]=U_D:Z2N;\;_P#(!7_K
MNO\ (US8S^!/T.G!?[Q#U/.J***^5/K@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH U_"_P#R,EE_O'_T$UZE7EOA?_D9++_>/_H)KU*O?RK^$_7]$?/9
MO_&CZ?JPHHHKU#R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ///B!_R%K7_KA_[,:Y&NN^('_(6M?^N'_LQKD:]S#?PHGB
MXG^+(****Z# **** "BBB@ HHHH **** "BBB@ HHHH *]#^'_\ R";K_KO_
M .RBO/*]#^'_ /R";K_KO_[**Y,;_"9U8/\ BHZZBBBO&/7"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#CO'W^HL?]Y_Y"N'KN/'W^HL?]Y_Y"N'KYK,
M?]XE\OR/J,M_W:/S_,****X3O"BBB@ HHHH **** "BBB@ HHHH **** "NQ
M\ _Z^^_W4_F:XZNQ\ _Z^^_W4_F:[,!_O$?ZZ'%F/^[2^7YH[BBBBOISY4**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#
MQ!_R,.H?]=V_G7K]>0>(/^1AU#_KNW\Z[\!\;]#AQWP(S:***]4\P**** "B
MBB@ HHHH **** "BBB@ HHHH **** -9?]7'_N+_ "%+2+_JX_\ <7^0I:^=
MG\3/?A\*"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "JUS]]?]W^IJS5
M:Y^^O^[_ %->;FO\!>O^9ZF4_P =^G^1#1117SQ]&%%%% !1110 4444 %%%
M% !1110 4444 %%%% 'I?@__ )%N#_>?_P!"-;U8/@__ )%N#_>?_P!"-;U?
M687^!#T1\AB_X\_5A1116YSA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=5_X]5_WQ_(T4:K_Q
MZK_OC^1HH -*_P"/5O\ ?/\ (5>JCI7_ !ZM_OG^0J]0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<5\0_^/>P_P!Y_P"0KM:XKXA_\>]A_O/_ "%=&$_C1.?%
M?P6<'1117N'C!1110 4444 %%%% !1110 4444 %%%% !1110!T_@3_D86_Z
MX-_,5Z57FO@3_D86_P"N#?S%>E5X^._B_(];!?P@HHHKC.L**** "BBB@ HH
MHH **** "BBB@ HHHH *YOQO_P @%?\ KNO\C725S?C?_D K_P!=U_D:YL9_
M GZ'3@O]XAZGG5%%%?*GUP4444 %%%% !1110 4444 %%%% !1110 4444 :
M_A?_ )&2R_WC_P"@FO4J\M\+_P#(R67^\?\ T$UZE7OY5_"?K^B/GLW_ (T?
M3]6%%%%>H>2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!YY\0/^0M:_]</_ &8UR-==\0/^0M:_]</_ &8UR->YAOX43Q<3
M_%D%%%%=!@%%%% !1110 4444 %%%% !1110 4444 %>A_#_ /Y!-U_UW_\
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M HHHH **** "BBB@ HHHH **** /2_!__(MP?[S_ /H1K>K!\'_\BW!_O/\
M^A&MZOK,+_ AZ(^0Q?\ 'GZL****W.<**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CJO_'JO^^/
MY&BC5?\ CU7_ 'Q_(T4 &E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *XKXA_P#'O8?[S_R%=K7%?$/_ (][#_>?^0KHPG\:
M)SXK^"S@Z***]P\8**** "BBB@ HHHH **** "BBB@ HHHH **** .G\"?\
M(PM_UP;^8KTJO-? G_(PM_UP;^8KTJO'QW\7Y'K8+^$%%%%<9UA1110 4444
M %%%% !1110 4444 %%%% !7-^-_^0"O_7=?Y&NDKF_&_P#R 5_Z[K_(US8S
M^!/T.G!?[Q#U/.J***^5/K@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOOO]U/YFN.KL? /^OOO]U/YFNS ?[Q'^NAQ9C_NTOE^:.XHHHKZ<^5"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\@\0?\
MC#J'_7=OYUZ_7D'B#_D8=0_Z[M_.N_ ?&_0X<=\",VBBBO5/,"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#67_5Q_P"XO\A2TB_ZN/\ W%_D*6OG9_$S
MWX?"@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ JM<_?7_=_J:LU6N?O
MK_N_U->;FO\  7K_ )GJ93_'?I_D0T445\\?1A1110 4444 %%%% !1110 4
M444 %%%% !1110!Z7X/_ .1;@_WG_P#0C6]6#X/_ .1;@_WG_P#0C6]7UF%_
M@0]$?(8O^//U84445N<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% %'5?\ CU7_ 'Q_(T4:K_QZ
MK_OC^1HH -*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110
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M_P"\2^7Y'U&6_P"[1^?YA1117"=X4444 %%%% !1110 4444 %%%% !1110
M5V/@'_7WW^ZG\S7'5V/@'_7WW^ZG\S79@/\ >(_UT.+,?]VE\OS1W%%%%?3G
MRH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1HH -*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444
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M %P_]F-<C77?$#_D+6O_ %P_]F-<C7N8;^%$\7$_Q9!111708!1110 4444
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M110 4444 %%%% !1110 4444 %5KG[Z_[O\ 4U9JM<_?7_=_J:\W-?X"]?\
M,]3*?X[]/\B&BBBOGCZ,**** "BBB@ HHHH **** "BBB@ HHHH **** /2_
M!_\ R+<'^\__ *$:WJP?!_\ R+<'^\__ *$:WJ^LPO\  AZ(^0Q?\>?JPHHH
MK<YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** *.J_\ 'JO^^/Y&BC5?^/5?]\?R-% !I7_'JW^^
M?Y"KU4=*_P"/5O\ ?/\ (5>H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*^(?
M_'O8?[S_ ,A7:UQ7Q#_X][#_ 'G_ )"NC"?QHG/BOX+.#HHHKW#Q@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Z?P)_R,+?]<&_F*]*KS7P)_P C"W_7
M!OYBO2J\?'?Q?D>M@OX04445QG6%%%% !1110 4444 %%%% !1110 4444 %
M<WXW_P"0"O\ UW7^1KI*YOQO_P @%?\ KNO\C7-C/X$_0Z<%_O$/4\ZHHHKY
M4^N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#7\+_P#(R67^\?\ T$UZ
ME7EOA?\ Y&2R_P!X_P#H)KU*O?RK^$_7]$?/9O\ QH^GZL****]0\D**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SSX@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?K_A6)XATV?7H[=?+D@\HL<^66SG'T]*ZFBJA-P?-'<F<5-<LMCSC_A"9_\
MGO)_X#G_ !H_X0F?_GO)_P" Y_QKT>BM_K=;^;\C'ZI1[?F><?\ "$S_ //>
M3_P'/^-'_"$S_P#/>3_P'/\ C7H]%'UNM_-^0?5*/;\SSC_A"9_^>\G_ (#G
M_&C_ (0F?_GO)_X#G_&O1Z*/K=;^;\@^J4>WYGG'_"$S_P#/>3_P'/\ C1_P
MA,__ #WD_P# <_XUZ/11];K?S?D'U2CV_,\X_P"$)G_Y[R?^ Y_QH_X0F?\
MY[R?^ Y_QKT>BCZW6_F_(/JE'M^9YQ_PA,__ #WD_P# <_XT?\(3/_SWD_\
M <_XUZ/11];K?S?D'U2CV_,\X_X0F?\ Y[R?^ Y_QH_X0F?_ )[R?^ Y_P :
M]'HH^MUOYOR#ZI1[?F><?\(3/_SWD_\  <_XT?\ "$S_ //>3_P'/^->CT4?
M6ZW\WY!]4H]OS.,T'0)]$U W?[R;,93;Y17KCG//I72_;I_^?*3]?\*O45C.
MI*H[RW-80C!6B4?MT_\ SY2?K_A1]NG_ .?*3]?\*O45!91^W3_\^4GZ_P"%
M'VZ?_GRD_7_"KU% %'[=/_SY2?K_ (4?;I_^?*3]?\*O44 4?MT__/E)^O\
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M)_X#G_&O1Z*/K=;^;\@^J4>WYGG'_"$S_P#/>3_P'/\ C1_PA,__ #WD_P#
M<_XUZ/11];K?S?D'U2CV_,\X_P"$)G_Y[R?^ Y_QH_X0F?\ Y[R?^ Y_QKT>
MBCZW6_F_(/JE'M^9YQ_PA,__ #WD_P# <_XUT7A^QGT*TE@\J2??)OW;"N.
M,=_2NEHJ)XBI-<LGH5"A3@^:*U*/VZ?_ )\I/U_PH^W3_P#/E)^O^%7J*Q-B
MC]NG_P"?*3]?\*/MT_\ SY2?K_A5ZB@"C]NG_P"?*3]?\*/MT_\ SY2?K_A5
MZB@"C]NG_P"?*3]?\*/MT_\ SY2?K_A5ZB@"C]NG_P"?*3]?\*/MT_\ SY2?
MK_A5ZB@"C]NG_P"?*3]?\*/MT_\ SY2?K_A5ZB@"C]NG_P"?*3]?\*/MT_\
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MA,__ #WD_P# <_XT?\(3/_SWD_\  <_XUZ/11];K?S?D'U2CV_,\X_X0F?\
MY[R?^ Y_QH_X0F?_ )[R?^ Y_P :]'HH^MUOYOR#ZI1[?F><?\(3/_SWD_\
M <_XT?\ "$S_ //>3_P'/^->CT4?6ZW\WY!]4H]OS/./^$)G_P">\G_@.?\
M&C_A"9_^>\G_ (#G_&O1Z*/K=;^;\@^J4>WYGG'_  A,_P#SWD_\!S_C1_PA
M,_\ SWD_\!S_ (UZ/11];K?S?D'U2CV_,\X_X0F?_GO)_P" Y_QH_P"$)G_Y
M[R?^ Y_QKT>BCZW6_F_(/JE'M^9YQ_PA,_\ SWD_\!S_ (T?\(3/_P ]Y/\
MP'/^->CT4?6ZW\WY!]4H]OS.#'A:<*HWR<*!_J3V&/6E_P"$7G_OR?\ ?D_X
MUW=%<[=W=FZ5E8X3_A%Y_P"_)_WY/^-'_"+S_P!^3_OR?\:[NBD,X3_A%Y_[
M\G_?D_XT?\(O/_?D_P"_)_QKNZ* .$_X1>?^_)_WY/\ C1_PB\_]^3_OR?\
M&N[HH X3_A%Y_P"_)_WY/^-'_"+S_P!^3_OR?\:[NB@#A/\ A%Y_[\G_ 'Y/
M^-'_  B\_P#?D_[\G_&N[HH X3_A%Y_[\G_?D_XT?\(O/_?D_P"_)_QKNZ*
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M'.3G)RENRC]NG_Y\I/U_PH^W3_\ /E)^O^%7J*HDH_;I_P#GRD_7_"C[=/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %'5?^/5?]\?R-%&J_\ 'JO^^/Y&B@ TK_CU;_?/\A5ZJ.E?
M\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(_&M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ:][:131HDIB990 =P /8GCYA0!L4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'5?\ CU7_
M 'Q_(T4:K_QZK_OC^1HH -*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[2MPJPMCYN0<CZ8'\J[BZNH+&UENKJ58H(EW.['  KSNRAN/B)XE35+F)H]
ML6(MXW'^N;/?ZX&?8 >IH [G1HG;PWI\-VN9#:1K*K=SL (/ZU9MK:TTVT$-
MO%%;6\8^Z@"JH]?_ *]6*X[6?ASI>M:A<7L][J"23-N*+(NQ3C' *_UH Y_0
M!%J/Q=O[_2E!L(E;S)(Q\C$H%//NV3[X)KU&O,M+N-0\">*[/P[/+'<Z7>L!
M"XB",I8X!..IS@'.>.:]-H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCZ@?B: ,G'_":^(=0U9QNTC28I([0'I))M/S?U_[YJ[\(O\ D5+K_K^?_P!
MCJ.Q\5^#](\+'2;/5-Q6!DS]GE!=R#DGY>YJC\+-?TRSTQM)N+H)?7%XS11%
M&.X%% YQ@<@]30!ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4=5_X]5_WQ_(T4:K_ ,>J
M_P"^/Y&B@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%%
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M3KJ.XC!P=O!4^A!Y'XU6U[Q+IOAN&&749'43,50(A8G'6@#7HKB_^%I>&O\
MGK<_]^372:-K-GKVG+?6+,T+,5&]=IR.O% &A163K7B72/#Z*=1NUB=QE8P"
MSM^ [>_2L&'XI>&I90CR742_WWAX_0D_I0!VE%0VEW;W]JES:3)-!(,JZ'(-
M34 %%%<_/XST2#6X=(%T9;N601XB7<JL3@ GIF@#H**** "BL7Q5KR^'- GU
M#"M*,)"C=&<]!_,_05=TF:[N=(M)[^...ZDB5Y$C! 4D9QR30!=HK@/'/C?3
MH=%N[#3-4/\ :1*J&MRWR88$_...@(X-=#X8\1:9K5A##:7XN+F&%1,&!#Y
M ).>3SW]Z -ZBN8\2^)+GP[JVE"2*$Z7=2&*>4@[HV['.<8P<].QKIZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH HZK_QZK_OC^1HHU7_ (]5_P!\?R-% !I7_'JW^^?Y
M"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC:I_US7_ -#6H/!6G6-QX*TPS6=O(7B.XO$IS\QZY%3^/_\ D1M4_P"N:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 4=5_X]5_WQ_(T4:K_ ,>J_P"^/Y&B@ TK_CU;
M_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'0?SZ5I?#6&6#P9 DT;QOYLGRNI!^][UUU% ' > K>>'Q3XK>6&1%>ZRK,I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *.J_\>J_[X_D:*-5_P"/5?\ ?'\C10 :5_QZM_OG^0J]5'2O^/5O]\_R
M%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *.J_\>J_[X_D:*-5_P"/5?\ ?'\C10 :5_QZM_OG^0J]5'2O
M^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS)N\SEAG&!C[OOUH Z"BN?N_%"VOC.R\.FT+&YA,GG^9C;PQQMQS]WU[UT%
M!1110 445S,GQ!\+13M"^JJ'5MIQ#(1GZA<4 =-16;I?B#2=:+#3K^&X9>2B
MG# >NT\X]ZTJ "BBB@ HK(TGQ-IFMWMW:6,S/+:G$@9"HZD<9Z\BM>@ HJIJ
M=\NF:5=WS(9%MX6E* X+;1G%5/#>N)XBT2'4D@: 2%AL+;L8)'7\* -:BBB@
M HHHH **** "BJ][>VVG6<MY=RB*WB&YW()P/PKGT^(GA1S@:LH_WH)!_-:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@M/$5B]S:)-'Y<ACDCF3:R, #@_G6)??$73+>]EL[&TO=1FB)5_LT65!'O\
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M?$>VUP6M^+:. QF(QCS#\K#@;L8R1WKTS0_$=KK^G37MO;W4,<3E"MP@5C@
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M?_H0KT^B@ KBOB%X7N=;L[>_TT9U"R)*J#@NO7 ]P1D?C7:T4 ><V/Q5MK>
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M84BC4*B*%51V X H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 4=5_X]5_WQ_(T4:K_P >
MJ_[X_D:* #2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1U7_CU7_?'\C1
M1JO_ !ZK_OC^1HH -*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45G3Z_I5MJ::=
M/?P1WCE0L+-\Q)Z#\:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHI"0H))  Y)- "T5@R^-/#<%QY#ZQ;;\X^5BP!^HXK:@N(;J!)[>:.:)QE7C
M8,I'L10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115
M+4-7T[28P]_>P6RM]WS' +?0=30!=HK)L/%&AZI,(;/5+:64](]^&/T!Y-:U
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45G:O
MKNFZ%!'-J=T((Y&VJ2K-D_0 FKZ.LD:R(P9& *D=P: '4444 %%%% !1110
M45BW/B[P_9W,EO<:K;QS1,5="W*D=147_";^&O\ H,VWYG_"@#?HK.TW7=+U
MAI%T^^BN&C +A#R :T: "BBL36O$UKH>I:993PS2/J$GEQM'C"G*CG)_VA0!
MMT444 %%8FB^)K77-2U.R@AFC?3Y/+D:3&&.6'&#_LFMN@ HHHH **@O+RWL
M+22ZNYDA@C&7D<X [5C_ /";^&O^@S;?F?\ "@#?HK _X3?PU_T&;;\S_A6U
M;7,-Y;1W%O(LL,BAD=3D,/6@"6BBB@ HHHH **** "BL36O$UKH>I:993PS2
M/J$GEQM'C"G*CG)_VA6W0 445Q=[\2-/@U">TL["^O\ [.<32V\>57'7'K]>
M!0!VE%1V\ZW-M%.@8)*@=0PP0",\BI* "BBB@ HHHH **SAKVDG4SIHU"W^V
M@[?)\P;L^GU]JT: "BJ=OJMA=7T]C!=Q274'^MB5LLGUJY0 4444 %%%% !1
M110 45G:EKVE:.\::A?0V[2#*J[<D>M16GBC0KZ58K;5K-Y&X5/- 8_0&@#6
MHHK&N_%F@V-U);7.JV\<T9PZ%N5/H: -FBL.+QEX=GF2*/5[9G=@JC=U)Z5N
M4 %%9.H>)]$TJ4Q7NIV\4HZQ[MS#Z@9(I^F^(='U=]EAJ-O/)C/EJ_S8_P!T
M\T :=%%% !16=<Z]I-G?I8W.H6\-R^,1O( >>GYUHT %%4_[5L!J8TW[7%]M
M*[_(W?-CKT^E)J6KZ?I$22:A=Q6R.=JF0XW'VH NT5@?\)OX:_Z#-M^9_P *
MUK'4+34[5;JRN$G@8D!T.1D=: +-%5K[4;+3(//OKJ&WBZ!I7"@GT&>IK*A\
M:^&IY?*36+8-G'SL5'YG H WJ*165U#*0RD9!!R"*6@ HHHH **1F5$+LP55
M&22> *Q/#'B,>)K:YNHK1H;>*8Q1NS9\T#OC''4>M &Y14%W?6EA#YUY<PV\
M?3?*X4?F:Y+PAXL_M?4]7BN]3MV4792QB)16,>3C'0MQCGF@#M**IZK>OINE
M75[';FX:",R>4&VE@.3S]*AT'68-?T:WU*!=BRCYD)R48'!!_&@#2HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZK_QZK_OC^1HH
MU7_CU7_?'\C10 :5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"IJKM'H]\Z,5=;>0JRG!!VGD5Y=_;&J?]!*\_P"_[?XUZ?K'_($O
M_P#KVD_]!->1UXF:RE&<;/H>[E$(RA*ZZEW^V-4_Z"5Y_P!_V_QH_MC5/^@E
M>?\ ?]O\:I45Y7M)]V>O[*'\J+O]L:I_T$KS_O\ M_C1_;&J?]!*\_[_ +?X
MU2HH]I/NP]E#^5%W^V-4_P"@E>?]_P!O\:/[8U3_ *"5Y_W_ &_QJE11[2?=
MA[*'\J+O]L:I_P!!*\_[_M_C1_;&J?\ 02O/^_[?XU2HH]I/NP]E#^5%W^V-
M4_Z"5Y_W_;_&KFE:KJ,FL6*/?W3(UQ&&5IF((W#@\UC5=T?_ )#=A_U\Q_\
MH0K2G4GSK5[F=2G#D>BV/7*;)(D43R2,%1 69CV ZFG5R/Q(U?\ LOPC/&C8
MFO"+=?H>6_0$?C7UA\>>=7MC=:YI6K^,U9UD2^4Q#N(QQ^F4_P"^37L>AZFF
ML:'9Z@F/W\09@.S=&'X$$5SNCS>&[7P9#HD^M:9A[8QS8NX_O.#N[^I-9?PJ
MU+%OJ&AR2I(UK*9(F1@0RDX.".HR,_\  J .OM_$FG7/B"?1$>1;Z%=S*Z$
MC@\'OP0:T;NZAL;.:[N'V0PH9';T &37GOCE3X?\9:+XFC!$;-Y-QCT'!_$J
M2/\ @-:/Q-U)H?#<6GVYW3ZC,L:A>K*,$X_':/QH ZC1M8M==TY;ZR\PP,Q5
M2Z[2<'!K#U'XB>'M.NGMO/EN9(SA_LT>\+Z\\#\JA\0JWA3X9R6UJVV2*!(
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M/2O,O"/CNQTN]UF35+JZ>.YG#P @O@9;/?C@K7H/A-OM'@[23, ^;5 =PSG
MP/Y5RGPVAB?5?$P>-& NEQE0<?-)0!N>)-1\-7/AZPU#6H&GL9W5X/D;()4D
M="#T!KJ8E1(D6,!4"@*!V':N ^+H \,60 P!>+@?\ >MOQOJ,NF>"+R>!MLK
MQK$K>FX@']": (M3^(OAW3+E[=KF2XE0X86Z;@#]> ?P-:.A^*]'\1;UT^ZW
M2IRT3C:X'K@]1]*H^ M&M=,\*V,L<2>?=1+-++CYFW#(&?0 @5S7C6VB\/\
MC30=9L%$#W$I2=8Q@-@J"<>I5B#]* .[UK7;'0+>&>^9U2641+L7=\Q!/]*Q
M]4^(?A[2KUK22YDFE1MK^0FX(?<]/RS61\7?^19L_P#K\7_T!ZZS2- TS2M(
M6QM[6,PLG[S>H8RGN6]: +&E:O8ZW8K>:?.LT+'&1P5/H1V-7:\W^'"BR\2^
M)M-B)%O#<$(N>!M=U_EC\J](H Q+CPAX?N[F2XGTJWDFE8N[D'+$]37 >$-
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MM&['IF@#S_XA?\C7X1_Z^O\ V>.O0ZCD@AF='DBC=D.4+*"5/MZ5)0!7O_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.J_\>J_[X_D:*-5_P"/
M5?\ ?'\C10 :5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT 6Z*QM4\26ND:SIVG744H^W$K'.,; V<8/.>I'YULT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %'5?^/5?]\?R-%&J_\ 'JO^^/Y&B@ TK_CU;_?/\A5ZJ.E?
M\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %'5?^/5?]\?R-%&J_\ 'JO^^/Y&B@ TK_CU;_?/\A5Z
MJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 5[FQMKP#SX@^.AR0?S%5
M_P"P]._Y]_\ Q]O\:T**YJF#PU27-.G%ONTF:1JU(JT9-?,S_P"P]._Y]_\
MQ]O\:/[#T[_GW_\ 'V_QK0HJ/[/P?_/J/_@*_P A^WJ_S/[V9W]AZ=_S[_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HZK_ ,>J_P"^/Y&BC5?^/5?]\?R-% !I7_'JW^^?Y"KU
M8UM>FTC:,Q;CN)^]BIO[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_
MX_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\
MUJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_
M .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ
M -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^
MF'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X_
M_P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_
MM?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\
M_6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[
M7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'
M_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.B
MLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C
M_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6
MH_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\
MZ8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H
MTZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8
M?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__
M -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U
M_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]
M:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?
M_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^
M/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S
M/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_
M /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C
M^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#I
MA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3
MHK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_
MX_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\
MUJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_
M .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ
M -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^
MF'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X_
M_P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_
MM?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\
M_6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[
M7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'
M_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.B
MLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C
M_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6
MH_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\
MZ8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H
MTZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8
M?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__
M -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U
M_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]
M:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?
M_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^
M/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S
M/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_
M /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C
M^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#I
MA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3
MHK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_
MX_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\
MUJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_
M .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ
M -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^
MF'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X_
M_P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_
MM?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\
M_6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[
M7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'
M_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.B
MLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C
M_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6
MH_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\
MZ8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H
MTZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8
M?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__
M -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U
M_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]
M:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?
M_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^
M/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S
M/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_
M /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C
M^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#I
MA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3
MHK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_
MX_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\
MUJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_
M .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ
M -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^
MF'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X_
M_P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_
MM?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\
M_6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[
M7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'
M_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.B
MLS^U_P#IA_X__P#6H_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C
M_P#]:@#3HK,_M?\ Z8?^/_\ UJ/[7_Z8?^/_ /UJ -.BLS^U_P#IA_X__P#6
MH_M?_IA_X_\ _6H TZ*S/[7_ .F'_C__ -:C^U_^F'_C_P#]:@#3HK,_M?\
MZ8?^/_\ UJ/[7_Z8?^/_ /UJ )=5_P"/5?\ ?'\C15.ZOC=QK&(MIW9SNS10
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>acst-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-06-20T20:12:00.2134+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.acastipharma.com/20240331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acst="http://www.acastipharma.com/20240331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information" id="statement-document-and-entity-information">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets" id="statement-consolidated-balance-sheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" id="statement-consolidated-statements-of-loss-and-comprehensive-loss">
        <link:definition>100030 - Statement - Consolidated Statements of Loss and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Shareholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" id="statement-consolidated-statements-of-cash-flows-">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations" id="statement-note-1-nature-of-operations">
        <link:definition>995455 - Disclosure - Note 1 - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies" id="statement-note-2-summary-of-significant-accounting-policies">
        <link:definition>995465 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements" id="DisclosureNote3FairValueMeasurements">
        <link:definition>995475 - Disclosure - Note 3 - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables" id="DisclosureNote4Receivables">
        <link:definition>995485 - Disclosure - Note 4 - Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGrace" id="DisclosureNote4AcquisitionOfGrace">
        <link:definition>995495 - Disclosure - Note 4 - Acquisition of Grace</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment" id="DisclosureNote5Equipment">
        <link:definition>995505 - Disclosure - Note 5 - Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1" id="DisclosureNote6IntangibleAssetsAndGoodwill1">
        <link:definition>995515 - Disclosure - Note 6 - Intangible assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1" id="DisclosureNote7TradeAndOtherPayables1">
        <link:definition>995525 - Disclosure - Note 7 - Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8Leases" id="DisclosureNote8Leases">
        <link:definition>995535 - Disclosure - Note 8- Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquity1" id="DisclosureNote9ShareholdersEquity1">
        <link:definition>995545 - Disclosure - Note 9 -Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation" id="DisclosureNote10StockBasedCompensation">
        <link:definition>995555 - Disclosure - Note 10 - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShare" id="DisclosureNote11LossPerShare">
        <link:definition>995565 - Disclosure - Note 11 - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1" id="DisclosureNote12IncomeTaxes1">
        <link:definition>995575 - Disclosure - Note 12 - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13DerivativeWarrantLiabilities" id="DisclosureNote13DerivativeWarrantLiabilities">
        <link:definition>995585 - Disclosure - Note 13 - Derivative Warrant Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-13-revenues" id="statement-note-13-revenues">
        <link:definition>995595 - Disclosure - Note 13 - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpenses1" id="DisclosureNote15OtherIncomeExpenses1">
        <link:definition>995605 - Disclosure - Note 15 - Other Income (expenses)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosure1" id="DisclosureNote18SupplementalCashFlowDisclosure1">
        <link:definition>995615 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13FinancialInstruments" id="DisclosureNote13FinancialInstruments">
        <link:definition>995625 - Disclosure - Note 13 - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1" id="DisclosureNote13CommitmentsAndContingencies1">
        <link:definition>995635 - Disclosure - Note 13 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts" id="DisclosureNote14RestructuringCosts">
        <link:definition>995645 - Disclosure - Note 14 - Restructuring Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote22SubsequentEvents1" id="DisclosureNote22SubsequentEvents1">
        <link:definition>995655 - Disclosure - Note 22 - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies" id="statement-significant-accounting-policies-policies">
        <link:definition>995665 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables" id="statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition>995675 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables" id="DisclosureNote3FairValueMeasurementsTables">
        <link:definition>995685 - Disclosure - Note 3 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesTables" id="DisclosureNote4ReceivablesTables">
        <link:definition>995695 - Disclosure - Note 4 - Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables" id="DisclosureNote5EquipmentTables">
        <link:definition>995705 - Disclosure - Note 5 - Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables" id="DisclosureNote6IntangibleAssetsAndGoodwillTables">
        <link:definition>995715 - Disclosure - Note 6 - Intangible assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTables" id="DisclosureNote7TradeAndOtherPayablesTables">
        <link:definition>995725 - Disclosure - Note 7 - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAcquisitionOfGraceTables" id="DisclosureAcquisitionOfGraceTables">
        <link:definition>995735 - Disclosure - Acquisition of Grace (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables" id="DisclosureNote8LeasesTables">
        <link:definition>995745 - Disclosure - Note 8 - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables" id="DisclosureNote9ShareholdersEquityTables">
        <link:definition>995755 - Disclosure - Note 9 - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables" id="DisclosureNote10StockBasedCompensationTables">
        <link:definition>995765 - Disclosure - Note 10 - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareTables" id="DisclosureNote11LossPerShareTables">
        <link:definition>995775 - Disclosure - Note 11 - Loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables" id="DisclosureNote12IncomeTaxesTables">
        <link:definition>995785 - Disclosure - Note 12 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14CapitalAndOtherComponentsOfEquityTables" id="DisclosureNote14CapitalAndOtherComponentsOfEquityTables">
        <link:definition>995795 - Disclosure - Note 14 - Capital and Other Components of Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesTables" id="DisclosureNote15OtherIncomeExpensesTables">
        <link:definition>995805 - Disclosure - Note 15 - Other Income (Expenses) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureTables" id="DisclosureNote18SupplementalCashFlowDisclosureTables">
        <link:definition>995815 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" id="DisclosureNote1NatureOfOperationDetailsTextual">
        <link:definition>995825 - Disclosure - Note 1 - Nature of Operation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" id="statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition>995835 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" id="statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details">
        <link:definition>995845 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives and Rates of Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" id="statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details">
        <link:definition>995855 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsAdditionalInformationDetails" id="DisclosureNote3FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Note 3 - Fair Value Measurements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>995875 - Disclosure - Note 3 - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" id="DisclosureNote4ReceivablesReceivablesDetails">
        <link:definition>995885 - Disclosure - Note 4 - Receivables - Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails" id="DisclosureNote4AcquisitionOfGraceConsiderationDetails">
        <link:definition>995895 - Disclosure - Note 4 - Acquisition of Grace - Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" id="DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>995905 - Disclosure - Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails" id="DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails">
        <link:definition>995915 - Disclosure - Note 4 - Acquisition of Grace - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" id="DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails">
        <link:definition>995925 - Disclosure - Note 4 - Acquisition of Grace - Schedule of Intangible Assets in Process Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" id="DisclosureNote4AcquisitionOfGraceDetailsTextual">
        <link:definition>995935 - Disclosure - Note 4 - Acquisition of Grace (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails" id="DisclosureNote5EquipmentScheduleOfEquipmentDetails">
        <link:definition>995945 - Disclosure - Note 5 - Equipment - Schedule of equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual" id="DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual">
        <link:definition>995955 - Disclosure - Note 5 - Equipment - Schedule of equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual" id="DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual">
        <link:definition>995965 - Disclosure - Note 6 - Intangible assets and Goodwill (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" id="DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails">
        <link:definition>995975 - Disclosure - Note 6 - Intangible assets and Goodwill- Schedule of Intangible Assets in Process Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails" id="DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails">
        <link:definition>995985 - Disclosure - Note 6 - Intangible assets and Goodwill - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails" id="DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails">
        <link:definition>995995 - Disclosure - Note 7 - Trade and Other Payables - Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails" id="DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>996005 - Disclosure - Note 8 - Leases - Supplemental balance sheet information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails" id="DisclosureNote8LeasesSupplementalLeaseExpenseDetails">
        <link:definition>996015 - Disclosure - Note 8 - Leases - Supplemental lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" id="DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails">
        <link:definition>996025 - Disclosure - Note 8 - Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails" id="DisclosureNote8LeasesAdditionalInformationDetails">
        <link:definition>996035 - Disclosure - Note 8 - Leases (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" id="DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails">
        <link:definition>996045 - Disclosure - Note 9 - Shareholder's Equity - Schedule Of Derivative Liabilities At Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails" id="DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails">
        <link:definition>996055 - Disclosure - Note 9 - Shareholders' Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual" id="DisclosureNote9ShareholdersEquityDetailsTextual">
        <link:definition>996065 - Disclosure - Note 9 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" id="DisclosureNote10StockBasedCompensationDetailsTextual">
        <link:definition>996075 - Disclosure - Note 10 - Stock Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails" id="DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails">
        <link:definition>996085 - Disclosure - Note 10 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails" id="DisclosureNote10StockBasedCompensationCompensationExpenseDetails">
        <link:definition>996095 - Disclosure - Note 10 - Stock Based Compensation - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" id="DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails">
        <link:definition>996105 - Disclosure - Note 10- Stock-based compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" id="DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails">
        <link:definition>996115 - Disclosure - Note 10 - Stock-based Compensation - Summary of the non-vested stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails" id="DisclosureNote10StockbasedCompensationAssumptionsDetails">
        <link:definition>996125 - Disclosure - Note 10 - Stock-based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails" id="DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails">
        <link:definition>996135 - Disclosure - Note 10 - Stock-based Compensation - Outstanding and Exercisable Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" id="DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
        <link:definition>996145 - Disclosure - Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails" id="DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails">
        <link:definition>996155 - Disclosure - Note 15 - Other Income (Expenses) - Financial Income (Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" id="DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails">
        <link:definition>996165 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails" id="DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails">
        <link:definition>996175 - Disclosure - Note 18 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails" id="DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails">
        <link:definition>996185 - Disclosure - Note 12 - Income taxes - Income Tax (Recovery) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails" id="DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails">
        <link:definition>996195 - Disclosure - Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails" id="DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>996205 - Disclosure - Note 12 - Income Taxes - Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails" id="DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails">
        <link:definition>996215 - Disclosure - Note 12 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>996225 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual" id="DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual">
        <link:definition>996235 - Disclosure - Note 12 - Income Taxes - Government Assistance (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails" id="DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails">
        <link:definition>996245 - Disclosure - Note 12 - Income Taxes - Government Assistance - Government Assistance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails" id="DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails">
        <link:definition>996255 - Disclosure - Note 12 - Income Taxes - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails" id="DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails">
        <link:definition>996265 - Disclosure - Note 12 - Income Taxes - Government Assistance - (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual" id="DisclosureNote13CommitmentsAndContingenciesDetailsTextual">
        <link:definition>996275 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCostsAdditionalInformationDetails" id="DisclosureNote14RestructuringCostsAdditionalInformationDetails">
        <link:definition>996285 - Disclosure - Note 14 - Restructuring Costs (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" id="DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails">
        <link:definition>996295 - Disclosure - Assets Held for Sale - Summary of Assets Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual" id="DisclosureAssetsHeldForSaleDetailsTextual">
        <link:definition>996305 - Disclosure - Assets Held for Sale (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual" id="DisclosureSubsequentEventsAdditionalInformationDetailsTextual">
        <link:definition>996315 - Disclosure - Subsequent events (Additional Information) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information" xlink:href="acst-20240331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets" xlink:href="acst-20240331.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="acst-20240331.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" xlink:href="acst-20240331.xsd#statement-consolidated-statements-of-loss-and-comprehensive-loss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="acst-20240331.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" xlink:href="acst-20240331.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations" xlink:href="acst-20240331.xsd#statement-note-1-nature-of-operations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="acst-20240331.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements" xlink:href="acst-20240331.xsd#DisclosureNote3FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables" xlink:href="acst-20240331.xsd#DisclosureNote4Receivables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGrace" xlink:href="acst-20240331.xsd#DisclosureNote4AcquisitionOfGrace" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment" xlink:href="acst-20240331.xsd#DisclosureNote5Equipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1" xlink:href="acst-20240331.xsd#DisclosureNote6IntangibleAssetsAndGoodwill1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1" xlink:href="acst-20240331.xsd#DisclosureNote7TradeAndOtherPayables1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8Leases" xlink:href="acst-20240331.xsd#DisclosureNote8Leases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquity1" xlink:href="acst-20240331.xsd#DisclosureNote9ShareholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation" xlink:href="acst-20240331.xsd#DisclosureNote10StockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShare" xlink:href="acst-20240331.xsd#DisclosureNote11LossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxes1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13DerivativeWarrantLiabilities" xlink:href="acst-20240331.xsd#DisclosureNote13DerivativeWarrantLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-13-revenues" xlink:href="acst-20240331.xsd#statement-note-13-revenues" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpenses1" xlink:href="acst-20240331.xsd#DisclosureNote15OtherIncomeExpenses1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosure1" xlink:href="acst-20240331.xsd#DisclosureNote18SupplementalCashFlowDisclosure1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13FinancialInstruments" xlink:href="acst-20240331.xsd#DisclosureNote13FinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1" xlink:href="acst-20240331.xsd#DisclosureNote13CommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts" xlink:href="acst-20240331.xsd#DisclosureNote14RestructuringCosts" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote22SubsequentEvents1" xlink:href="acst-20240331.xsd#DisclosureNote22SubsequentEvents1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies" xlink:href="acst-20240331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="acst-20240331.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables" xlink:href="acst-20240331.xsd#DisclosureNote3FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesTables" xlink:href="acst-20240331.xsd#DisclosureNote4ReceivablesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables" xlink:href="acst-20240331.xsd#DisclosureNote5EquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables" xlink:href="acst-20240331.xsd#DisclosureNote6IntangibleAssetsAndGoodwillTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTables" xlink:href="acst-20240331.xsd#DisclosureNote7TradeAndOtherPayablesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAcquisitionOfGraceTables" xlink:href="acst-20240331.xsd#DisclosureAcquisitionOfGraceTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables" xlink:href="acst-20240331.xsd#DisclosureNote8LeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables" xlink:href="acst-20240331.xsd#DisclosureNote9ShareholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables" xlink:href="acst-20240331.xsd#DisclosureNote10StockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareTables" xlink:href="acst-20240331.xsd#DisclosureNote11LossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14CapitalAndOtherComponentsOfEquityTables" xlink:href="acst-20240331.xsd#DisclosureNote14CapitalAndOtherComponentsOfEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesTables" xlink:href="acst-20240331.xsd#DisclosureNote15OtherIncomeExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureTables" xlink:href="acst-20240331.xsd#DisclosureNote18SupplementalCashFlowDisclosureTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote1NatureOfOperationDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="acst-20240331.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" xlink:href="acst-20240331.xsd#statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" xlink:href="acst-20240331.xsd#statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsAdditionalInformationDetails" xlink:href="acst-20240331.xsd#DisclosureNote3FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="acst-20240331.xsd#DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" xlink:href="acst-20240331.xsd#DisclosureNote4ReceivablesReceivablesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails" xlink:href="acst-20240331.xsd#DisclosureNote4AcquisitionOfGraceConsiderationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="acst-20240331.xsd#DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails" xlink:href="acst-20240331.xsd#DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" xlink:href="acst-20240331.xsd#DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote4AcquisitionOfGraceDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails" xlink:href="acst-20240331.xsd#DisclosureNote5EquipmentScheduleOfEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" xlink:href="acst-20240331.xsd#DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails" xlink:href="acst-20240331.xsd#DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails" xlink:href="acst-20240331.xsd#DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails" xlink:href="acst-20240331.xsd#DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails" xlink:href="acst-20240331.xsd#DisclosureNote8LeasesSupplementalLeaseExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" xlink:href="acst-20240331.xsd#DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails" xlink:href="acst-20240331.xsd#DisclosureNote8LeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" xlink:href="acst-20240331.xsd#DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:href="acst-20240331.xsd#DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote9ShareholdersEquityDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote10StockBasedCompensationDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails" xlink:href="acst-20240331.xsd#DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails" xlink:href="acst-20240331.xsd#DisclosureNote10StockBasedCompensationCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" xlink:href="acst-20240331.xsd#DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" xlink:href="acst-20240331.xsd#DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails" xlink:href="acst-20240331.xsd#DisclosureNote10StockbasedCompensationAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails" xlink:href="acst-20240331.xsd#DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="acst-20240331.xsd#DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails" xlink:href="acst-20240331.xsd#DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" xlink:href="acst-20240331.xsd#DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails" xlink:href="acst-20240331.xsd#DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails" xlink:href="acst-20240331.xsd#DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureNote13CommitmentsAndContingenciesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCostsAdditionalInformationDetails" xlink:href="acst-20240331.xsd#DisclosureNote14RestructuringCostsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" xlink:href="acst-20240331.xsd#DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureAssetsHeldForSaleDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual" xlink:href="acst-20240331.xsd#DisclosureSubsequentEventsAdditionalInformationDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange5Member" xlink:label="acst_ExercisePriceRange5Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AssetsHeldForSalePolicyTextBlock" xlink:label="acst_AssetsHeldForSalePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfOtherAssetsAndPrepaids" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInMay2018Member" xlink:label="acst_WarrantsIssuedInMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" xlink:label="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfAssetHeldForSale" xlink:label="acst_ImpairmentOfAssetHeldForSale"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementCommonStockMaximumAmount" xlink:label="acst_AtthemarketSalesAgreementCommonStockMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RetentionIncentiveAgreementMaximumConditionalIncentives" xlink:label="acst_RetentionIncentiveAgreementMaximumConditionalIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedDecember272017Member" xlink:label="acst_WarrantsIssuedDecember272017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CostRelatedToProspectusSupplementAmount" xlink:label="acst_CostRelatedToProspectusSupplementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WriteOff" xlink:label="acst_WriteOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentImpairmentLoss" xlink:label="acst_ProductionEquipmentImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" xlink:label="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseAgreementMember" xlink:label="acst_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassCMember" xlink:label="us-gaap_CommonClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ContractResearchOrganizationsMember" xlink:label="acst_ContractResearchOrganizationsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfGoodwill1" xlink:label="acst_ImpairmentOfGoodwill1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2034Member" xlink:label="acst_TaxYear2034Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange1Member" xlink:label="acst_ExercisePriceRange1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AdditionalLeaseRenewalTerm" xlink:label="acst_AdditionalLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" xlink:label="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="acst_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange9Member" xlink:label="acst_ExercisePriceRange9Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange3Member" xlink:label="acst_ExercisePriceRange3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="country_FR"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NoOfDaysInvestmentsPurchased" xlink:label="acst_NoOfDaysInvestmentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" xlink:label="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BrokerWarrantsIssuedMay2018Member" xlink:label="acst_BrokerWarrantsIssuedMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetFederalInvestmentTaxCredits" xlink:label="acst_NetFederalInvestmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AdjustmentsToNetAssets" xlink:label="acst_AdjustmentsToNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxRecoveryExpenseAbstract" xlink:label="acst_IncomeTaxRecoveryExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PreFundedWarrantsMember" xlink:label="acst_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionsExercisePricePerShare" xlink:label="acst_StockOptionsExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" xlink:label="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange8Member" xlink:label="acst_ExercisePriceRange8Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange7Member" xlink:label="acst_ExercisePriceRange7Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" xlink:label="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange2Member" xlink:label="acst_ExercisePriceRange2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetBookValueReclassedFromHeldForSale" xlink:label="acst_NetBookValueReclassedFromHeldForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ATMTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommissionCostsRelatedToShareSale" xlink:label="acst_CommissionCostsRelatedToShareSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2035Member" xlink:label="acst_TaxYear2035Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockConversionRateIntoClassA" xlink:label="acst_CommonStockConversionRateIntoClassA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentRelatedDeferredTaxLiability" xlink:label="acst_ImpairmentRelatedDeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2042Member" xlink:label="acst_TaxYear2042Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Taxyear2043Member" xlink:label="acst_Taxyear2043Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Licenses" xlink:label="acst_Licenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="us-gaap_OtherShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" xlink:label="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock" xlink:label="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScheduleOfNonvestedOptionActivityTableTextBlock" xlink:label="acst_ScheduleOfNonvestedOptionActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2033Member" xlink:label="acst_TaxYear2033Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TransactionCostsRelatedToDerivativeWarrantLiability" xlink:label="acst_TransactionCostsRelatedToDerivativeWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx102Member" xlink:label="acst_Gtx102Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx101Member" xlink:label="acst_Gtx101Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" xlink:label="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" xlink:label="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseOfCommonShares" xlink:label="acst_PurchaseOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" xlink:label="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockRedemptionPricePerShare" xlink:label="acst_CommonStockRedemptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShorePharmaLlcMember" xlink:label="acst_ShorePharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseOfPreFundedWarrants" xlink:label="acst_PurchaseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockIssuedSharesWarrantsExercisableShares" xlink:label="acst_StockIssuedSharesWarrantsExercisableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_EffectOfTranslationEffectOnCashAndCashEquivalents" xlink:label="acst_EffectOfTranslationEffectOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" xlink:label="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GrantsAndInvestmentTaxCreditReceivable" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" xlink:label="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromNRCIRAP" xlink:label="acst_ProceedsFromNRCIRAP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2032Member" xlink:label="acst_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability" xlink:label="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2038Member" xlink:label="acst_TaxYear2038Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTable" xlink:label="us-gaap_ConversionOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability" xlink:label="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_OtherTaxCreditCarryforwardMember" xlink:label="acst_OtherTaxCreditCarryforwardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ChangeInTaxRates" xlink:label="acst_ChangeInTaxRates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2041Member" xlink:label="acst_TaxYear2041Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SherbrookLeaseMember" xlink:label="acst_SherbrookLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="us-gaap_ConversionOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementTerm" xlink:label="acst_AtthemarketSalesAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonWarrantAndPreFundedWarrantMember" xlink:label="acst_CommonWarrantAndPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange6Member" xlink:label="acst_ExercisePriceRange6Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SupplementalBalanceSheetInformationTableTextblock" xlink:label="acst_SupplementalBalanceSheetInformationTableTextblock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2039Member" xlink:label="acst_TaxYear2039Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SaleOfStockAveragePricePerShare" xlink:label="acst_SaleOfStockAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LeaseExpenseTableTextblock" xlink:label="acst_LeaseExpenseTableTextblock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2040Member" xlink:label="acst_TaxYear2040Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2029Member" xlink:label="acst_TaxYear2029Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2028Member" xlink:label="acst_TaxYear2028Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockNet" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_InvestmentTaxCreditReceivable" xlink:label="acst_InvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchasePricePerCommonShare" xlink:label="acst_PurchasePricePerCommonShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:label="us-gaap_CashFlowOperatingCapitalTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SalesTaxReceivablesCurrent" xlink:label="acst_SalesTaxReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockVotesPerShare" xlink:label="acst_CommonStockVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2030Member" xlink:label="acst_TaxYear2030Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_May2018PublicOfferingWarrantsMember" xlink:label="acst_May2018PublicOfferingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" xlink:label="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:label="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetBookValueReclassedFromHeldForSales" xlink:label="acst_NetBookValueReclassedFromHeldForSales"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PropertyPantAndEquipmentDepreciationRate" xlink:label="acst_PropertyPantAndEquipmentDepreciationRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfRestrictedShareUnit" xlink:label="acst_IssuanceOfRestrictedShareUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockGross" xlink:label="acst_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NonRefundableFederalItc" xlink:label="acst_NonRefundableFederalItc"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Impairmentofintangibleassetsindefinitelived" xlink:label="acst_Impairmentofintangibleassetsindefinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonSharesHeldByNonAffiliates" xlink:label="acst_CommonSharesHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity" xlink:label="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance" xlink:label="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonClassDAndCommonClassEMember" xlink:label="acst_CommonClassDAndCommonClassEMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DirectorsAndEmployeesMember" xlink:label="acst_DirectorsAndEmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsToCompleteContractsInProcess" xlink:label="us-gaap_CommitmentsToCompleteContractsInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYearTwoThousandFortyThreeMember" xlink:label="acst_TaxYearTwoThousandFortyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GovernmentGrantsPolicyTextBlock" xlink:label="acst_GovernmentGrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange4Member" xlink:label="acst_ExercisePriceRange4Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScheduleOfGovernmentAssistanceTableTextBlock" xlink:label="acst_ScheduleOfGovernmentAssistanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2036Member" xlink:label="acst_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SharesPrice" xlink:label="acst_SharesPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BrokerWarrantsIssuedDecember2017Member" xlink:label="acst_BrokerWarrantsIssuedDecember2017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" xlink:label="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2031Member" xlink:label="acst_TaxYear2031Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NoExpiryMember" xlink:label="acst_NoExpiryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockDividendRatePercentage" xlink:label="acst_CommonStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ReverseStockSplitMember" xlink:label="acst_ReverseStockSplitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques" xlink:label="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ConsultantMember" xlink:label="acst_ConsultantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SsPharmaLlcMember" xlink:label="acst_SsPharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxCreditCarryForwardsMember" xlink:label="acst_TaxCreditCarryForwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_OppenheimerAndCoIncMember" xlink:label="acst_OppenheimerAndCoIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2037Member" xlink:label="acst_TaxYear2037Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GovernmentAssistance" xlink:label="acst_GovernmentAssistance"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredFinancingCostsReclassifiedToEquity" xlink:label="acst_DeferredFinancingCostsReclassifiedToEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2044Member" xlink:label="acst_TaxYear2044Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsFinancingExpenses" xlink:label="acst_DeferredTaxAssetsFinancingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncreaseDecreaseInWorkingCapital" xlink:label="acst_IncreaseDecreaseInWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsOperatingLeaseAsset" xlink:label="acst_DeferredTaxAssetsOperatingLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SoftwareMember" xlink:label="acst_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" xlink:label="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PaymentOfIssuanceCostsCommonWarrants" xlink:label="acst_PaymentOfIssuanceCostsCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_September2023CommonWarrantsMember" xlink:label="acst_September2023CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GuaranteedInvestmentCertificatesAndTermDeposits" xlink:label="acst_GuaranteedInvestmentCertificatesAndTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_EquityIncentivePlanMember" xlink:label="acst_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" xlink:label="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromCommonShares" xlink:label="acst_ProceedsFromCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RKOSupplyAgreementMember" xlink:label="acst_RKOSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock" xlink:label="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx104Member" xlink:label="acst_Gtx104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StateNonIncomeTaxes" xlink:label="acst_StateNonIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CostNetOfImpairments" xlink:label="acst_CostNetOfImpairments"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange5Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 5 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange5Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range 5.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange5Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 5 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lower limit, exercise price (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants or rights exercised during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AssetsHeldForSalePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AssetsHeldForSalePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for assets held for sale policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AssetsHeldForSalePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Held For Sale Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at Canadian Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Fair Value [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of other assets and prepaids.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Other Assets And Prepaids</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment of Other assets and prepaids</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of Assets held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedInMay2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in May 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedInMay2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents warrants issued in May 2018.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedInMay2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued in May 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination, Acquisition Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Acquisition Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liability, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of Grace</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the chief executive officer (CEO) and the chief operating officer (COO).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer and Chief Operating Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited and cancelled, Weighted average grant date fair value (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant other observable inputs (Level 2)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfAssetHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of Asset held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfAssetHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Asset held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfAssetHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of assets held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfAssetHeldForSale_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment of assets held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementCommonStockMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum amount of common stock that can be sold under the at-the-market sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementCommonStockMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_AtthemarketSalesAgreementCommonStockMaximumAmount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementCommonStockMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Sales Agreement, Common Stock, Maximum Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RetentionIncentiveAgreementMaximumConditionalIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum amount of incentives that can be paid upon certain conditions being met under the retention incentive agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RetentionIncentiveAgreementMaximumConditionalIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_RetentionIncentiveAgreementMaximumConditionalIncentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RetentionIncentiveAgreementMaximumConditionalIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retention Incentive Agreement, Maximum Conditional Incentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease Commitment, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedDecember272017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued December 2017 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedDecember272017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents warrants issued December 27, 2017.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedDecember272017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued December 27, 2017 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CostRelatedToProspectusSupplementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Related to Prospectus Supplement Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CostRelatedToProspectusSupplementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Related to Prospectus Supplement Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CostRelatedToProspectusSupplementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost Related to Prospectus Supplement Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification from held for sale to equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Write off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Write off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProductionEquipmentImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Production equipment impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProductionEquipmentImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Production equipment impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred tax liability attributable to taxable temporary differences from convertible debt equity component.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_DeferredTaxLiabilityConvertibleDebtEquityComponent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax basis of unsecured convertible debentures in excess of carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ContractResearchOrganizationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research Organizations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ContractResearchOrganizationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract Research Organizations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfGoodwill1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of Goodwill 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfGoodwill1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Goodwill 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfGoodwill1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfGoodwill1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfGoodwill1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment of goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding an at-the-market offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2034Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2034.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2034Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2034 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2034Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2034</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Machinery and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restructuring cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Incurred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Machinery and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extension of lease term, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AdditionalLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AdditionalLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Effects on Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Effects on Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Write off-of deferred financing costs of at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Write-off of deferred financing fees related to at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount recognized during the period for the write off of deferred financing costs of at-the-market (ATM) program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Write off of deferred financing costs of at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write Off of Deferred Financing Costs of At-the-Market Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the success fees to be paid by the corporation based on the outcome of the strategic evaluation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Fees to be Paid Based on the Outcome of the Strategic Evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange9Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 9 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange9Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range nine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange9Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 9 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range 3.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_FR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FRANCE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_FR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FRANCE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net book value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plan and equipment and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equipment and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets and Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NoOfDaysInvestmentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No of Days Investments Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NoOfDaysInvestmentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No of Days Investments Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible change in fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-deductible change in fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BrokerWarrantsIssuedMay2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broker Warrants Issued May 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BrokerWarrantsIssuedMay2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents broker warrants issued May 2018.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BrokerWarrantsIssuedMay2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broker Warrants Issued May 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetFederalInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net federal investment tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetFederalInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Federal Investment Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetFederalInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Federal Investment Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AdjustmentsToNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to net assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AdjustmentsToNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AdjustmentsToNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments To Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other deductible temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxRecoveryExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income tax (recovery) expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxRecoveryExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax (recovery) expense:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of liabilities and accrued expenses incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee salaries and benefits payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockOptionsExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockOptionsExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Exercise Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockOptionsExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options Exercise Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-deductible items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Trade</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of incentive to be paid if individual continues employment until the earlier of April 30, 2021 or the closing of a merger or similar transaction with third party under the retention incentive agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retention Incentive Agreement, Continued Employment Until April 30, 2021 or Closing Transaction With Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange8Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 8 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange8Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range eight.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange8Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 8 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange7Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 7 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange7Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange7Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 7 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax (benefit) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation nondeductible expense transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetBookValueReclassedFromHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net book value reclassed from held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetBookValueReclassedFromHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net book value reclassed from held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM transaction costs included in trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of ATM transaction costs included in trade and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ATM transaction costs included in trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares upon the exercise of stock options, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommissionCostsRelatedToShareSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of commission costs recognized during the period related to share sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommissionCostsRelatedToShareSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_CommissionCostsRelatedToShareSale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommissionCostsRelatedToShareSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission Costs Related to Share Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Derivative Liabilities at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments discounted incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2035Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2035.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2035Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2035 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2035Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2035</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options Outstanding, Non - vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options Outstanding, Non - vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived Intangible Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short- term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Option, Exercise Price Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockConversionRateIntoClassA_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The rate at which shares are convertible into one share of class A common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockConversionRateIntoClassA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_CommonStockConversionRateIntoClassA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockConversionRateIntoClassA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Conversion Rate into Class A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentRelatedDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment Related Deferred Tax Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentRelatedDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Related Deferred Tax Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentRelatedDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment Related Deferred Tax Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2042Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2042 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2042Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2042 member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2042Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2042</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Taxyear2043Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TaxYear2043Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Taxyear2043Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TaxYear2043Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Taxyear2043Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2043</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Share Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Licenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Licenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income tax (recovery) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guaranteed investment certificate classified as a short-term investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Shares From Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Issuance Of Common Shares From Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Useful Lives and Rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure for useful lives and rates for property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Lives and Rates [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfNonvestedOptionActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Nonvested Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfNonvestedOptionActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure for nonvested option activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfNonvestedOptionActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Option Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total common shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2033Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2033.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2033Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2033 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2033Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2033</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows for operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other equity instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TransactionCostsRelatedToDerivativeWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of transaction costs related to derivative warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TransactionCostsRelatedToDerivativeWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_TransactionCostsRelatedToDerivativeWarrantLiability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TransactionCostsRelatedToDerivativeWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Other income (expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement commitment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling and Marketing Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sales and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx102Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GTX 102 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx102Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GTX 102 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx102Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GTX 102.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding furniture and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Conversion Description [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock available under the plan for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx101Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GTX 101 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx101Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GTX 101 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx101Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GTX 101.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated life (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common shares and warrants from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equipment held-for-sale, impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, related to non-vested share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized compensation cost related to non-vested share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized compensation cost related to non-vested share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent accounting pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Difference in foreign tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Difference in foreign tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Expense on Reclassified Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchaseOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">purchase of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchaseOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">purchase of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized temporary differences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount to be paid per share at which the common stock of an entity is redeemed or may be called at.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_CommonStockRedemptionPricePerShare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Redemption Price Per Share (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Disposal Group, Including Discontinued Operation, Assets, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShorePharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shore Pharma LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShorePharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shore Pharma LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShorePharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shore Pharma LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Trade, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchaseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of pre funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchaseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of pre funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Business Acquisition, Pro Forma Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from shares issued under the at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockIssuedSharesWarrantsExercisableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued Shares Warrants Exercisable Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StockIssuedSharesWarrantsExercisableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued shares warrants exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon the exercise of stock options, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in finite-lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and pre-funded warrants through private placement, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net, Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_EffectOfTranslationEffectOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate fluctuations on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_EffectOfTranslationEffectOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_EffectOfTranslationEffectOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of exchange rate fluctuations on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Costs Recognized for Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance &#8211; end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance &#8211; beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development contracts and contract research organizations agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development contracts and contract research organizations agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development expenses, net of government assistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government assistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GrantsAndInvestmentTaxCreditReceivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government assistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total government assistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of award in non-dilutive and non-repayable funding from National Research Council of Canada Industrial Research Assistance Program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award in Non-dilutive and Non-repayable Funding From NRC IRAP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromNRCIRAP_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the National Research Council of Canada Industrial Research Assistance Program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromNRCIRAP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_ProceedsFromNRCIRAP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromNRCIRAP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from NRC IRAP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, number of options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2032.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2032 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2032</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for new operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use assets obtained in exchange for new operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2038Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2038.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2038Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2038 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2038Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2038</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Right Of Use Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Operating Lease Right Of Use Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statements of Operations and Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Cost Incurred to Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acasti share price (closing share price on August 27, 2021)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_OtherTaxCreditCarryforwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards that are classified as other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_OtherTaxCreditCarryforwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized foreign exchange (gain) loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ChangeInTaxRates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ChangeInTaxRates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Tax Rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ChangeInTaxRates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in Tax Rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of shares that may be issued to one person in accordance with the plan as a proportion of outstanding capital stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2041Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information pertaining to 2041.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2041Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2041 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2041Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2041</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SherbrookLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sherbrook Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SherbrookLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sherbrook Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SherbrookLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sherbrook Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The term of the at-the-market sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_AtthemarketSalesAgreementTerm</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Sales Agreement, Term (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Write-off of deferred financing fees related to at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write-off of deferred financing fees related to at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Debt Issuance Cost, Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonWarrantAndPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrant and Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonWarrantAndPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Warrant and Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange6Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 6 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange6Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange6Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 6 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SupplementalBalanceSheetInformationTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental balance sheet information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SupplementalBalanceSheetInformationTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental balance sheet information [Table TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SupplementalBalanceSheetInformationTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental balance sheet information [Table TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2039Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2039.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2039Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2039 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2039Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2039</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total tax (benefit) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Income tax (recovery) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax recovery</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment,net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on sale of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholder's equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Intangible Assets, Finite-lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering warrants (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right, Outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price per share of warrants or rights exercised during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued during the Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SaleOfStockAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The average price per share received by entity for each share of common stock issued or sold in the stock transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SaleOfStockAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_SaleOfStockAveragePricePerShare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SaleOfStockAveragePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Average Price Per Share (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax (benefit) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax (recovery) expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_LeaseExpenseTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_LeaseExpenseTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease expense [Table TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_LeaseExpenseTableTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expense [Table TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Use of estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant accounting policies, estimates and judgments:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProductionEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Production Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProductionEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents production equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProductionEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Production Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2040Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2040.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2040Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2040 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2040Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2040</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2029Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2029.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2029Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2029 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2029Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2028Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2028.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2028Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2028 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2028Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Goodwill and Intangible Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upper limit, exercise price (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the issuance of common stock, net of issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_ProceedsFromIssuanceOfCommonStockNet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of Common Stock, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_InvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_InvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of investment tax credit receivable as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_InvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested, Weighted average grant date fair value (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options vested, Number of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested, Number of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchasePricePerCommonShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PurchasePricePerCommonShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Price per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingCapitalTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in working capital items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingCapitalTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Capital [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SalesTaxReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales tax receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SalesTaxReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of sales taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SalesTaxReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales tax receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from shares issued under the at-the-market (ATM) program (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from shares issued under the at-the-market (ATM) program (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of votes per one share of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_CommonStockVotesPerShare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Votes Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of year:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Weighted average grant date fair value (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Weighted average grant date fair value (in CAD per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GraceTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grace Therapeutics Inc Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GraceTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related to Grace Therapeutics Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GraceTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grace Therapeutics Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the accumulated depreciation component.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equipment held-for-sale, accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2030Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2030.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2030Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2030 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2030Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_May2018PublicOfferingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2018 public offering warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_May2018PublicOfferingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May 2018 Public Offering Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_May2018PublicOfferingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May 2018 Public Offering Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shareholders equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Receivables, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of each sale that is to be paid to the underwriter under the at-the-market sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment Of The Intangible Assets Indefinite Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of The Intangible Assets Indefinite Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Production equipment (b)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number Of Shares Outstanding Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetBookValueReclassedFromHeldForSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net book value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetBookValueReclassedFromHeldForSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net book value reclassed from held for sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NetBookValueReclassedFromHeldForSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net book value reclassed from held for sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PropertyPantAndEquipmentDepreciationRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PropertyPantAndEquipmentDepreciationRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The depreciation rate of property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PropertyPantAndEquipmentDepreciationRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from shares issued under the at-the-market (ATM) program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfRestrictedShareUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted share unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfRestrictedShareUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Restricted Share Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfRestrictedShareUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Restricted Share Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted prices in active markets (Level 1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted averageexercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and pre-funded warrants through private placement, net of offering costs (Value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common shares and pre-funded warrants through private placement, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares and pre-funded warrants through private placement, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Remaining Contractual Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earning per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Issuance of Common Stock, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance of Common Stock Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common Stock gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NonRefundableFederalItc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable federal investment tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NonRefundableFederalItc_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-refundable Federal ITC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NonRefundableFederalItc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable Federal ITC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NonRefundableFederalItc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-refundable federal ITC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Option, Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Positions taken in the current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Translation effect on cash and cash equivalents related to reporting currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Exercise Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Exercise Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of assets from assets held for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Impairmentofintangibleassetsindefinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ImpairmentOfIntangibleAssetsIndefinitelived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Impairmentofintangibleassetsindefinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ImpairmentOfIntangibleAssetsIndefinitelived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Impairmentofintangibleassetsindefinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonSharesHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">common shares held by non-affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonSharesHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">common shares held by non-affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonSharesHeldByNonAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares held by non-affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of derivative warrants liability reclassified to equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of derivative warrants liability that reclassified to equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value of derivative warrants liability reclassified to equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in unrecognized tax benefits resulting from change in valuation allowance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonClassDAndCommonClassEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class D and Common Class E [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonClassDAndCommonClassEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification of common stock that has different rights than Common Class A, B, or C, representing ownership interest in a corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonClassDAndCommonClassEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class D and Common Class E [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash interest received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, before allocation of a valuation allowances, of deferred tax assets attributable to research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DirectorsAndEmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents directors and employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DirectorsAndEmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors and Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement Inputs and Valuation Techniques</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NotesToFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes To Financial Statements Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NotesToFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes To Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable Remaining Contractual Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset, Held-for-Sale, Not Part of Disposal Group [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment held-for-sale, cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the cost component.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment held-for-sale, cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets (a)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsToCompleteContractsInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsToCompleteContractsInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments to Complete Contracts in Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax losses carried forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYearTwoThousandFortyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year two thousand forty three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYearTwoThousandFortyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year Two Thousand Forty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYearTwoThousandFortyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2043</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Non-cash transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GovernmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GovernmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The accounting policy for government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GovernmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets - acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets - acquired in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange4Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range 4 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange4Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents exercise price range four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ExercisePriceRange4Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range 4 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets in process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfGovernmentAssistanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Government Assistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfGovernmentAssistanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure for government assistance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfGovernmentAssistanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Government Assistance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2036.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2036 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2036</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Process Research And Development Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SharesPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SharesPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SharesPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BrokerWarrantsIssuedDecember2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broker Warrants Issued December 2017 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BrokerWarrantsIssuedDecember2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents broker warrants issued December 2017.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_BrokerWarrantsIssuedDecember2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broker Warrants Issued December 2017 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses, without time limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, not subject to time limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carryforwards, without time limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2031Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2031.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2031Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2031 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2031Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2031</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Functional currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NoExpiryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Expiry [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NoExpiryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No Expiry [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_NoExpiryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Expiry</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage rate used to calculate dividend payments on common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_CommonStockDividendRatePercentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CommonStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ReverseStockSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ReverseStockSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related to reverse stock split.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ReverseStockSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation techniques</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfers of Financial Assets Accounted for as Sale, Valuation Techniques</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ConsultantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ConsultantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents consultant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ConsultantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options forfeited and cancelled, Number of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited and cancelled, Number of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net financial income (expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Other Expense Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SsPharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SS Pharma LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SsPharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SS Pharma LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SsPharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SS Pharma LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxCreditCarryForwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the tax credit carry forwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxCreditCarryForwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forwards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_OppenheimerAndCoIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information pertaining to Oppenheimer and Co. Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_OppenheimerAndCoIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oppenheimer &amp; Co. Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves or liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2037Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Identified as tax year 2037.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2037Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2037 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2037Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2037</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GovernmentAssistance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of government assistance recorded in earnings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GovernmentAssistance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_GovernmentAssistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GovernmentAssistance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Assistance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredFinancingCostsReclassifiedToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs reclassified to Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredFinancingCostsReclassifiedToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of deferred financing costs reclassified to equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredFinancingCostsReclassifiedToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred financing costs reclassified to Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2044Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2044</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2044Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2044 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_TaxYear2044Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Year 2044 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsFinancingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsFinancingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, before allocation of a valuation allowances, of deferred tax assets attributable to financing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsFinancingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncreaseDecreaseInWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in the aggregate amount of working capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncreaseDecreaseInWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">acst_IncreaseDecreaseInWorkingCapital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncreaseDecreaseInWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in non-cash working capital items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_IncreaseDecreaseInWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total changes in working capital items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax losses carried forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_DeferredTaxAssetsOperatingLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Operating Lease Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number Of Shares Outstanding Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of significant accounting policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_SoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Research &amp; Experimental Development Expenditures Investment Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific Research &amp; Experimental Development Expenditures Investment Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PaymentOfIssuanceCostsCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Issuance Costs Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_PaymentOfIssuanceCostsCommonWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Of Issuance Costs Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_September2023CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2023 Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_September2023CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September 2023 Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_September2023CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September 2023 Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GuaranteedInvestmentCertificatesAndTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guaranteed investment certificates and term deposits classified as cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GuaranteedInvestmentCertificatesAndTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guaranteed investment certificates and term deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_GuaranteedInvestmentCertificatesAndTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Guaranteed investment certificates and term deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other taxable temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other taxable temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets acquired and liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in Connection with Public Offering February 2017 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents warrants issued in connection with the public offering in February 2017.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued in Connection with Public Offering February 2017 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ProceedsFromCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RKOSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RKO Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RKOSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the RKO Supply Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_RKOSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RKO Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure for useful life of intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Intangible Assets, Useful Life [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provincial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset and lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets obtained in exchange for new operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value Closing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx104Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GTX 104 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx104Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GTX 104 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_Gtx104Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GTX 104.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant unobservable inputs (Level 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StateNonIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State non income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StateNonIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Non Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_StateNonIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State Non Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CostNetOfImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CostNetOfImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost, net of impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acst_CostNetOfImpairments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost, net of impairments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange5Member" xlink:to="acst_ExercisePriceRange5Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="acst_ClassOfWarrantOrRightExercisedDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AssetsHeldForSalePolicyTextBlock" xlink:to="acst_AssetsHeldForSalePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ImpairmentOfOtherAssetsAndPrepaids" xlink:to="acst_ImpairmentOfOtherAssetsAndPrepaids_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsIssuedInMay2018Member" xlink:to="acst_WarrantsIssuedInMay2018Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" xlink:to="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ImpairmentOfAssetHeldForSale" xlink:to="acst_ImpairmentOfAssetHeldForSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtthemarketSalesAgreementCommonStockMaximumAmount" xlink:to="acst_AtthemarketSalesAgreementCommonStockMaximumAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RetentionIncentiveAgreementMaximumConditionalIncentives" xlink:to="acst_RetentionIncentiveAgreementMaximumConditionalIncentives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsIssuedDecember272017Member" xlink:to="acst_WarrantsIssuedDecember272017Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:to="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CostRelatedToProspectusSupplementAmount" xlink:to="acst_CostRelatedToProspectusSupplementAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaboratoryEquipmentMember" xlink:to="acst_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WriteOff" xlink:to="acst_WriteOff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProductionEquipmentImpairmentLoss" xlink:to="acst_ProductionEquipmentImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" xlink:to="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PurchaseAgreementMember" xlink:to="acst_PurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ContractResearchOrganizationsMember" xlink:to="acst_ContractResearchOrganizationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ImpairmentOfGoodwill1" xlink:to="acst_ImpairmentOfGoodwill1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtTheMarketOfferingMember" xlink:to="acst_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2034Member" xlink:to="acst_TaxYear2034Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange1Member" xlink:to="acst_ExercisePriceRange1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AdditionalLeaseRenewalTerm" xlink:to="acst_AdditionalLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" xlink:to="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" xlink:to="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="acst_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange9Member" xlink:to="acst_ExercisePriceRange9Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange3Member" xlink:to="acst_ExercisePriceRange3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StockOptionPlanMember" xlink:to="acst_StockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_FR" xlink:to="country_FR_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NoOfDaysInvestmentsPurchased" xlink:to="acst_NoOfDaysInvestmentsPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" xlink:to="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BrokerWarrantsIssuedMay2018Member" xlink:to="acst_BrokerWarrantsIssuedMay2018Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NetFederalInvestmentTaxCredits" xlink:to="acst_NetFederalInvestmentTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AdjustmentsToNetAssets" xlink:to="acst_AdjustmentsToNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncomeTaxRecoveryExpenseAbstract" xlink:to="acst_IncomeTaxRecoveryExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:to="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PreFundedWarrantsMember" xlink:to="acst_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StockOptionsExercisePricePerShare" xlink:to="acst_StockOptionsExercisePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" xlink:to="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange8Member" xlink:to="acst_ExercisePriceRange8Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange7Member" xlink:to="acst_ExercisePriceRange7Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" xlink:to="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange2Member" xlink:to="acst_ExercisePriceRange2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NetBookValueReclassedFromHeldForSale" xlink:to="acst_NetBookValueReclassedFromHeldForSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables" xlink:to="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommissionCostsRelatedToShareSale" xlink:to="acst_CommissionCostsRelatedToShareSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2035Member" xlink:to="acst_TaxYear2035Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonStockConversionRateIntoClassA" xlink:to="acst_CommonStockConversionRateIntoClassA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ImpairmentRelatedDeferredTaxLiability" xlink:to="acst_ImpairmentRelatedDeferredTaxLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2042Member" xlink:to="acst_TaxYear2042Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Taxyear2043Member" xlink:to="acst_Taxyear2043Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Licenses" xlink:to="acst_Licenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" xlink:to="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock" xlink:to="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ScheduleOfNonvestedOptionActivityTableTextBlock" xlink:to="acst_ScheduleOfNonvestedOptionActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2033Member" xlink:to="acst_TaxYear2033Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TransactionCostsRelatedToDerivativeWarrantLiability" xlink:to="acst_TransactionCostsRelatedToDerivativeWarrantLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Gtx102Member" xlink:to="acst_Gtx102Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FurnitureAndOfficeEquipmentMember" xlink:to="acst_FurnitureAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Gtx101Member" xlink:to="acst_Gtx101Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" xlink:to="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" xlink:to="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PurchaseOfCommonShares" xlink:to="acst_PurchaseOfCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" xlink:to="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonStockRedemptionPricePerShare" xlink:to="acst_CommonStockRedemptionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ShorePharmaLlcMember" xlink:to="acst_ShorePharmaLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PurchaseOfPreFundedWarrants" xlink:to="acst_PurchaseOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StockIssuedSharesWarrantsExercisableShares" xlink:to="acst_StockIssuedSharesWarrantsExercisableShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" xlink:to="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_EffectOfTranslationEffectOnCashAndCashEquivalents" xlink:to="acst_EffectOfTranslationEffectOnCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" xlink:to="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GrantsAndInvestmentTaxCreditReceivable" xlink:to="acst_GrantsAndInvestmentTaxCreditReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" xlink:to="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromNRCIRAP" xlink:to="acst_ProceedsFromNRCIRAP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2032Member" xlink:to="acst_TaxYear2032Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability" xlink:to="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2038Member" xlink:to="acst_TaxYear2038Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability" xlink:to="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_OtherTaxCreditCarryforwardMember" xlink:to="acst_OtherTaxCreditCarryforwardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ChangeInTaxRates" xlink:to="acst_ChangeInTaxRates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" xlink:to="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2041Member" xlink:to="acst_TaxYear2041Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SherbrookLeaseMember" xlink:to="acst_SherbrookLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtthemarketSalesAgreementTerm" xlink:to="acst_AtthemarketSalesAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonWarrantAndPreFundedWarrantMember" xlink:to="acst_CommonWarrantAndPreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange6Member" xlink:to="acst_ExercisePriceRange6Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SupplementalBalanceSheetInformationTableTextblock" xlink:to="acst_SupplementalBalanceSheetInformationTableTextblock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2039Member" xlink:to="acst_TaxYear2039Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:to="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SaleOfStockAveragePricePerShare" xlink:to="acst_SaleOfStockAveragePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LeaseExpenseTableTextblock" xlink:to="acst_LeaseExpenseTableTextblock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProductionEquipmentMember" xlink:to="acst_ProductionEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2040Member" xlink:to="acst_TaxYear2040Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2029Member" xlink:to="acst_TaxYear2029Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2028Member" xlink:to="acst_TaxYear2028Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromIssuanceOfCommonStockNet" xlink:to="acst_ProceedsFromIssuanceOfCommonStockNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_InvestmentTaxCreditReceivable" xlink:to="acst_InvestmentTaxCreditReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PurchasePricePerCommonShare" xlink:to="acst_PurchasePricePerCommonShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:to="us-gaap_CashFlowOperatingCapitalTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SalesTaxReceivablesCurrent" xlink:to="acst_SalesTaxReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonStockVotesPerShare" xlink:to="acst_CommonStockVotesPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GraceTherapeuticsIncMember" xlink:to="acst_GraceTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2030Member" xlink:to="acst_TaxYear2030Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_May2018PublicOfferingWarrantsMember" xlink:to="acst_May2018PublicOfferingWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" xlink:to="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" xlink:to="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NetBookValueReclassedFromHeldForSales" xlink:to="acst_NetBookValueReclassedFromHeldForSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PropertyPantAndEquipmentDepreciationRate" xlink:to="acst_PropertyPantAndEquipmentDepreciationRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IssuanceOfRestrictedShareUnit" xlink:to="acst_IssuanceOfRestrictedShareUnit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" xlink:to="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromIssuanceOfCommonStockGross" xlink:to="acst_ProceedsFromIssuanceOfCommonStockGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NonRefundableFederalItc" xlink:to="acst_NonRefundableFederalItc_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Impairmentofintangibleassetsindefinitelived" xlink:to="acst_Impairmentofintangibleassetsindefinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonSharesHeldByNonAffiliates" xlink:to="acst_CommonSharesHeldByNonAffiliates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity" xlink:to="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance" xlink:to="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonClassDAndCommonClassEMember" xlink:to="acst_CommonClassDAndCommonClassEMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCreditMember" xlink:to="us-gaap_InvestmentCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:to="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DirectorsAndEmployeesMember" xlink:to="acst_DirectorsAndEmployeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_NotesToFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" xlink:to="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsToCompleteContractsInProcess" xlink:to="us-gaap_CommitmentsToCompleteContractsInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYearTwoThousandFortyThreeMember" xlink:to="acst_TaxYearTwoThousandFortyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GovernmentGrantsPolicyTextBlock" xlink:to="acst_GovernmentGrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceRange4Member" xlink:to="acst_ExercisePriceRange4Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ScheduleOfGovernmentAssistanceTableTextBlock" xlink:to="acst_ScheduleOfGovernmentAssistanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2036Member" xlink:to="acst_TaxYear2036Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SharesPrice" xlink:to="acst_SharesPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BrokerWarrantsIssuedDecember2017Member" xlink:to="acst_BrokerWarrantsIssuedDecember2017Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" xlink:to="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2031Member" xlink:to="acst_TaxYear2031Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NoExpiryMember" xlink:to="acst_NoExpiryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonStockDividendRatePercentage" xlink:to="acst_CommonStockDividendRatePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ReverseStockSplitMember" xlink:to="acst_ReverseStockSplitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques" xlink:to="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ConsultantMember" xlink:to="acst_ConsultantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SsPharmaLlcMember" xlink:to="acst_SsPharmaLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxCreditCarryForwardsMember" xlink:to="acst_TaxCreditCarryForwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_OppenheimerAndCoIncMember" xlink:to="acst_OppenheimerAndCoIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2037Member" xlink:to="acst_TaxYear2037Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GovernmentAssistance" xlink:to="acst_GovernmentAssistance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredFinancingCostsReclassifiedToEquity" xlink:to="acst_DeferredFinancingCostsReclassifiedToEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxYear2044Member" xlink:to="acst_TaxYear2044Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredTaxAssetsFinancingExpenses" xlink:to="acst_DeferredTaxAssetsFinancingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncreaseDecreaseInWorkingCapital" xlink:to="acst_IncreaseDecreaseInWorkingCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredTaxAssetsOperatingLeaseAsset" xlink:to="acst_DeferredTaxAssetsOperatingLeaseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SoftwareMember" xlink:to="acst_SoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" xlink:to="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PaymentOfIssuanceCostsCommonWarrants" xlink:to="acst_PaymentOfIssuanceCostsCommonWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_September2023CommonWarrantsMember" xlink:to="acst_September2023CommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GuaranteedInvestmentCertificatesAndTermDeposits" xlink:to="acst_GuaranteedInvestmentCertificatesAndTermDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_EquityIncentivePlanMember" xlink:to="acst_EquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" xlink:to="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromCommonShares" xlink:to="acst_ProceedsFromCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RKOSupplyAgreementMember" xlink:to="acst_RKOSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock" xlink:to="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Gtx104Member" xlink:to="acst_Gtx104Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StateNonIncomeTaxes" xlink:to="acst_StateNonIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CostNetOfImpairments" xlink:to="acst_CostNetOfImpairments_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_NoTradingSymbolFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfGoodwill1" xlink:label="acst_ImpairmentOfGoodwill1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfAssetHeldForSale" xlink:label="acst_ImpairmentOfAssetHeldForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="acst_ImpairmentOfGoodwill1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="acst_ImpairmentOfAssetHeldForSale" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_12"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" xlink:label="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" xlink:label="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_EffectOfTranslationEffectOnCashAndCashEquivalents" xlink:label="acst_EffectOfTranslationEffectOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability" xlink:label="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfGoodwill1" xlink:label="acst_ImpairmentOfGoodwill1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfAssetHeldForSale" xlink:label="acst_ImpairmentOfAssetHeldForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_InterestReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="acst_EffectOfTranslationEffectOnCashAndCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acst_ImpairmentOfGoodwill1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acst_ImpairmentOfAssetHeldForSale" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:label="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGrace" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8Leases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13DerivativeWarrantLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-13-revenues" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpenses1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosure1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13FinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote22SubsequentEvents1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GovernmentGrantsPolicyTextBlock" xlink:label="acst_GovernmentGrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AssetsHeldForSalePolicyTextBlock" xlink:label="acst_AssetsHeldForSalePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acst_GovernmentGrantsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acst_AssetsHeldForSalePolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock" xlink:label="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock" xlink:label="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAcquisitionOfGraceTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SupplementalBalanceSheetInformationTableTextblock" xlink:label="acst_SupplementalBalanceSheetInformationTableTextblock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LeaseExpenseTableTextblock" xlink:label="acst_LeaseExpenseTableTextblock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="acst_SupplementalBalanceSheetInformationTableTextblock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="acst_LeaseExpenseTableTextblock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScheduleOfNonvestedOptionActivityTableTextBlock" xlink:label="acst_ScheduleOfNonvestedOptionActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_ScheduleOfNonvestedOptionActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScheduleOfGovernmentAssistanceTableTextBlock" xlink:label="acst_ScheduleOfGovernmentAssistanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_ScheduleOfGovernmentAssistanceTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14CapitalAndOtherComponentsOfEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingCapitalTableTextBlock" xlink:label="us-gaap_CashFlowOperatingCapitalTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_CashFlowOperatingCapitalTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTable" xlink:label="us-gaap_ConversionOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="us-gaap_ConversionOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ReverseStockSplitMember" xlink:label="acst_ReverseStockSplitMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseOfPreFundedWarrants" xlink:label="acst_PurchaseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchasePricePerCommonShare" xlink:label="acst_PurchasePricePerCommonShare"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseOfCommonShares" xlink:label="acst_PurchaseOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="acst_ReverseStockSplitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ConversionOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="acst_PurchaseOfPreFundedWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="acst_PurchasePricePerCommonShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="acst_PurchaseOfCommonShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonSharesHeldByNonAffiliates" xlink:label="acst_CommonSharesHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="country_FR"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NoOfDaysInvestmentsPurchased" xlink:label="acst_NoOfDaysInvestmentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonSharesHeldByNonAffiliates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_FR" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_NoOfDaysInvestmentsPurchased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PropertyPantAndEquipmentDepreciationRate" xlink:label="acst_PropertyPantAndEquipmentDepreciationRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_PropertyPantAndEquipmentDepreciationRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_ProductionEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques" xlink:label="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GuaranteedInvestmentCertificatesAndTermDeposits" xlink:label="acst_GuaranteedInvestmentCertificatesAndTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="us-gaap_OtherShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="acst_GuaranteedInvestmentCertificatesAndTermDeposits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SalesTaxReceivablesCurrent" xlink:label="acst_SalesTaxReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GrantsAndInvestmentTaxCreditReceivable" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_SalesTaxReceivablesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_GrantsAndInvestmentTaxCreditReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx104Member" xlink:label="acst_Gtx104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx102Member" xlink:label="acst_Gtx102Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx101Member" xlink:label="acst_Gtx101Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx104Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx102Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx101Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AdjustmentsToNetAssets" xlink:label="acst_AdjustmentsToNetAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_Goodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="acst_AdjustmentsToNetAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WriteOff" xlink:label="acst_WriteOff"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SoftwareMember" xlink:label="acst_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CostNetOfImpairments" xlink:label="acst_CostNetOfImpairments"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetBookValueReclassedFromHeldForSales" xlink:label="acst_NetBookValueReclassedFromHeldForSales"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetBookValueReclassedFromHeldForSale" xlink:label="acst_NetBookValueReclassedFromHeldForSale"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_WriteOff" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_SoftwareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_CostNetOfImpairments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_NetBookValueReclassedFromHeldForSales" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_NetBookValueReclassedFromHeldForSale" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Impairmentofintangibleassetsindefinitelived" xlink:label="acst_Impairmentofintangibleassetsindefinitelived"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentRelatedDeferredTaxLiability" xlink:label="acst_ImpairmentRelatedDeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_Impairmentofintangibleassetsindefinitelived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_ImpairmentRelatedDeferredTaxLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx104Member" xlink:label="acst_Gtx104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx102Member" xlink:label="acst_Gtx102Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx101Member" xlink:label="acst_Gtx101Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx104Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx102Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx101Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfGoodwill1" xlink:label="acst_ImpairmentOfGoodwill1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="acst_ImpairmentOfGoodwill1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInMay2018Member" xlink:label="acst_WarrantsIssuedInMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedDecember272017Member" xlink:label="acst_WarrantsIssuedDecember272017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedInMay2018Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedDecember272017Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockVotesPerShare" xlink:label="acst_CommonStockVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShorePharmaLlcMember" xlink:label="acst_ShorePharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInMay2018Member" xlink:label="acst_WarrantsIssuedInMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockDividendRatePercentage" xlink:label="acst_CommonStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SsPharmaLlcMember" xlink:label="acst_SsPharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedDecember272017Member" xlink:label="acst_WarrantsIssuedDecember272017Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockConversionRateIntoClassA" xlink:label="acst_CommonStockConversionRateIntoClassA"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PreFundedWarrantsMember" xlink:label="acst_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassCMember" xlink:label="us-gaap_CommonClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BrokerWarrantsIssuedMay2018Member" xlink:label="acst_BrokerWarrantsIssuedMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockRedemptionPricePerShare" xlink:label="acst_CommonStockRedemptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseAgreementMember" xlink:label="acst_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonClassDAndCommonClassEMember" xlink:label="acst_CommonClassDAndCommonClassEMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BrokerWarrantsIssuedDecember2017Member" xlink:label="acst_BrokerWarrantsIssuedDecember2017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonWarrantAndPreFundedWarrantMember" xlink:label="acst_CommonWarrantAndPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" xlink:label="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PaymentOfIssuanceCostsCommonWarrants" xlink:label="acst_PaymentOfIssuanceCostsCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementCommonStockMaximumAmount" xlink:label="acst_AtthemarketSalesAgreementCommonStockMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromCommonShares" xlink:label="acst_ProceedsFromCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementTerm" xlink:label="acst_AtthemarketSalesAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockIssuedSharesWarrantsExercisableShares" xlink:label="acst_StockIssuedSharesWarrantsExercisableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" xlink:label="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CostRelatedToProspectusSupplementAmount" xlink:label="acst_CostRelatedToProspectusSupplementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockNet" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommissionCostsRelatedToShareSale" xlink:label="acst_CommissionCostsRelatedToShareSale"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SaleOfStockAveragePricePerShare" xlink:label="acst_SaleOfStockAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockVotesPerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="acst_ShorePharmaLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedInMay2018Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockDividendRatePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="acst_SsPharmaLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedDecember272017Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockConversionRateIntoClassA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_BrokerWarrantsIssuedMay2018Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockRedemptionPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_PurchaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acst_CommonClassDAndCommonClassEMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_BrokerWarrantsIssuedDecember2017Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_CommonWarrantAndPreFundedWarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_PaymentOfIssuanceCostsCommonWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AtthemarketSalesAgreementCommonStockMaximumAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromCommonShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AtthemarketSalesAgreementTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_StockIssuedSharesWarrantsExercisableShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CostRelatedToProspectusSupplementAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromIssuanceOfCommonStockNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommissionCostsRelatedToShareSale" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_SaleOfStockAveragePricePerShare" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightExercisedDuringPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ConsultantMember" xlink:label="acst_ConsultantMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_EquityIncentivePlanMember" xlink:label="acst_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" xlink:label="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionsExercisePricePerShare" xlink:label="acst_StockOptionsExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfRestrictedShareUnit" xlink:label="acst_IssuanceOfRestrictedShareUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_StockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acst_ConsultantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_EquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_StockOptionsExercisePricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_IssuanceOfRestrictedShareUnit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DirectorsAndEmployeesMember" xlink:label="acst_DirectorsAndEmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_15"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_StockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acst_DirectorsAndEmployeesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_StockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SharesPrice" xlink:label="acst_SharesPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="acst_SharesPrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange1Member" xlink:label="acst_ExercisePriceRange1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange2Member" xlink:label="acst_ExercisePriceRange2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange3Member" xlink:label="acst_ExercisePriceRange3Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange4Member" xlink:label="acst_ExercisePriceRange4Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange5Member" xlink:label="acst_ExercisePriceRange5Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange6Member" xlink:label="acst_ExercisePriceRange6Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange7Member" xlink:label="acst_ExercisePriceRange7Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange8Member" xlink:label="acst_ExercisePriceRange8Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange9Member" xlink:label="acst_ExercisePriceRange9Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange4Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange5Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange6Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange7Member" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange8Member" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange9Member" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_September2023CommonWarrantsMember" xlink:label="acst_September2023CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_May2018PublicOfferingWarrantsMember" xlink:label="acst_May2018PublicOfferingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_September2023CommonWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_May2018PublicOfferingWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TransactionCostsRelatedToDerivativeWarrantLiability" xlink:label="acst_TransactionCostsRelatedToDerivativeWarrantLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="acst_TransactionCostsRelatedToDerivativeWarrantLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncreaseDecreaseInWorkingCapital" xlink:label="acst_IncreaseDecreaseInWorkingCapital"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="acst_IncreaseDecreaseInWorkingCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ATMTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredFinancingCostsReclassifiedToEquity" xlink:label="acst_DeferredFinancingCostsReclassifiedToEquity"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity" xlink:label="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="acst_DeferredFinancingCostsReclassifiedToEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxRecoveryExpenseAbstract" xlink:label="acst_IncomeTaxRecoveryExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_IncomeTaxRecoveryExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_IncomeTaxRecoveryExpenseAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_IncomeTaxRecoveryExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" xlink:label="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" xlink:label="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NonRefundableFederalItc" xlink:label="acst_NonRefundableFederalItc"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StateNonIncomeTaxes" xlink:label="acst_StateNonIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ChangeInTaxRates" xlink:label="acst_ChangeInTaxRates"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" xlink:label="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="acst_NonRefundableFederalItc" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="acst_StateNonIncomeTaxes" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="acst_ChangeInTaxRates" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability" xlink:label="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsFinancingExpenses" xlink:label="acst_DeferredTaxAssetsFinancingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetFederalInvestmentTaxCredits" xlink:label="acst_NetFederalInvestmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Licenses" xlink:label="acst_Licenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" xlink:label="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="acst_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsOperatingLeaseAsset" xlink:label="acst_DeferredTaxAssetsOperatingLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_DeferredTaxAssetsFinancingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_NetFederalInvestmentTaxCredits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_Licenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_DeferredTaxAssetsOperatingLeaseLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="acst_DeferredTaxAssetsOperatingLeaseAsset" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2028Member" xlink:label="acst_TaxYear2028Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" xlink:label="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxCreditCarryForwardsMember" xlink:label="acst_TaxCreditCarryForwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2029Member" xlink:label="acst_TaxYear2029Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" xlink:label="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_OtherTaxCreditCarryforwardMember" xlink:label="acst_OtherTaxCreditCarryforwardMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2030Member" xlink:label="acst_TaxYear2030Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2031Member" xlink:label="acst_TaxYear2031Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2032Member" xlink:label="acst_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2033Member" xlink:label="acst_TaxYear2033Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2034Member" xlink:label="acst_TaxYear2034Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2035Member" xlink:label="acst_TaxYear2035Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2036Member" xlink:label="acst_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2037Member" xlink:label="acst_TaxYear2037Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2038Member" xlink:label="acst_TaxYear2038Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2039Member" xlink:label="acst_TaxYear2039Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2040Member" xlink:label="acst_TaxYear2040Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2041Member" xlink:label="acst_TaxYear2041Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2042Member" xlink:label="acst_TaxYear2042Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Taxyear2043Member" xlink:label="acst_Taxyear2043Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2044Member" xlink:label="acst_TaxYear2044Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NoExpiryMember" xlink:label="acst_NoExpiryMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2028Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acst_TaxCreditCarryForwardsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2029Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acst_OtherTaxCreditCarryforwardMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2030Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2031Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2032Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2033Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2034Member" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2035Member" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2036Member" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2037Member" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2038Member" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2039Member" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2040Member" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2041Member" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2042Member" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_Taxyear2043Member" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2044Member" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_NoExpiryMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance" xlink:label="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GovernmentAssistance" xlink:label="acst_GovernmentAssistance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" xlink:label="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromNRCIRAP" xlink:label="acst_ProceedsFromNRCIRAP"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_GovernmentAssistance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromNRCIRAP" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_InvestmentTaxCreditReceivable" xlink:label="acst_InvestmentTaxCreditReceivable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="acst_InvestmentTaxCreditReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2029Member" xlink:label="acst_TaxYear2029Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2030Member" xlink:label="acst_TaxYear2030Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2031Member" xlink:label="acst_TaxYear2031Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2032Member" xlink:label="acst_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2033Member" xlink:label="acst_TaxYear2033Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2034Member" xlink:label="acst_TaxYear2034Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2035Member" xlink:label="acst_TaxYear2035Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2036Member" xlink:label="acst_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2037Member" xlink:label="acst_TaxYear2037Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2038Member" xlink:label="acst_TaxYear2038Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2039Member" xlink:label="acst_TaxYear2039Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2040Member" xlink:label="acst_TaxYear2040Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2041Member" xlink:label="acst_TaxYear2041Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2042Member" xlink:label="acst_TaxYear2042Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYearTwoThousandFortyThreeMember" xlink:label="acst_TaxYearTwoThousandFortyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2044Member" xlink:label="acst_TaxYear2044Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_InvestmentCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2029Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2030Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2031Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2032Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2033Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2034Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2035Member" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2036Member" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2037Member" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2038Member" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2039Member" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2040Member" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2041Member" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2042Member" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYearTwoThousandFortyThreeMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2044Member" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RKOSupplyAgreementMember" xlink:label="acst_RKOSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_OppenheimerAndCoIncMember" xlink:label="acst_OppenheimerAndCoIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ContractResearchOrganizationsMember" xlink:label="acst_ContractResearchOrganizationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SherbrookLeaseMember" xlink:label="acst_SherbrookLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" xlink:label="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" xlink:label="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" xlink:label="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" xlink:label="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsToCompleteContractsInProcess" xlink:label="us-gaap_CommitmentsToCompleteContractsInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RetentionIncentiveAgreementMaximumConditionalIncentives" xlink:label="acst_RetentionIncentiveAgreementMaximumConditionalIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AdditionalLeaseRenewalTerm" xlink:label="acst_AdditionalLeaseRenewalTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="acst_RKOSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acst_OppenheimerAndCoIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_ContractResearchOrganizationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="acst_SherbrookLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsToCompleteContractsInProcess" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_RetentionIncentiveAgreementMaximumConditionalIncentives" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AdditionalLeaseRenewalTerm" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCostsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_FurnitureAndOfficeEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_ProductionEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfOtherAssetsAndPrepaids" xlink:label="acst_ImpairmentOfOtherAssetsAndPrepaids"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentImpairmentLoss" xlink:label="acst_ProductionEquipmentImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:to="acst_ImpairmentOfOtherAssetsAndPrepaids" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:to="acst_ProductionEquipmentImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract" xlink:to="us-gaap_Depreciation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockNet" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockGross" xlink:label="acst_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromIssuanceOfCommonStockNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromIssuanceOfCommonStockGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" xlink:label="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="us-gaap_ConversionOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTable" xlink:label="us-gaap_ConversionOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ReverseStockSplitMember" xlink:label="acst_ReverseStockSplitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseOfPreFundedWarrants" xlink:label="acst_PurchaseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchasePricePerCommonShare" xlink:label="acst_PurchasePricePerCommonShare"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseOfCommonShares" xlink:label="acst_PurchaseOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="acst_ReverseStockSplitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="acst_PurchaseOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="acst_PurchasePricePerCommonShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="acst_PurchaseOfCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonSharesHeldByNonAffiliates" xlink:label="acst_CommonSharesHeldByNonAffiliates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="country_FR"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NoOfDaysInvestmentsPurchased" xlink:label="acst_NoOfDaysInvestmentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonSharesHeldByNonAffiliates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_FR" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_NoOfDaysInvestmentsPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PropertyPantAndEquipmentDepreciationRate" xlink:label="acst_PropertyPantAndEquipmentDepreciationRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_PropertyPantAndEquipmentDepreciationRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_ProductionEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GuaranteedInvestmentCertificatesAndTermDeposits" xlink:label="acst_GuaranteedInvestmentCertificatesAndTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherShortTermInvestments" xlink:label="us-gaap_OtherShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="acst_GuaranteedInvestmentCertificatesAndTermDeposits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_OtherShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx104Member" xlink:label="acst_Gtx104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx102Member" xlink:label="acst_Gtx102Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx101Member" xlink:label="acst_Gtx101Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx104Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx102Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx101Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AdjustmentsToNetAssets" xlink:label="acst_AdjustmentsToNetAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="acst_AdjustmentsToNetAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WriteOff" xlink:label="acst_WriteOff"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SoftwareMember" xlink:label="acst_SoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CostNetOfImpairments" xlink:label="acst_CostNetOfImpairments"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetBookValueReclassedFromHeldForSales" xlink:label="acst_NetBookValueReclassedFromHeldForSales"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetBookValueReclassedFromHeldForSale" xlink:label="acst_NetBookValueReclassedFromHeldForSale"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_WriteOff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_SoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_CostNetOfImpairments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_NetBookValueReclassedFromHeldForSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="acst_NetBookValueReclassedFromHeldForSale" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx104Member" xlink:label="acst_Gtx104Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GraceTherapeuticsIncMember" xlink:label="acst_GraceTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx102Member" xlink:label="acst_Gtx102Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" xlink:label="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Gtx101Member" xlink:label="acst_Gtx101Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx104Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acst_GraceTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx102Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acst_Gtx101Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInMay2018Member" xlink:label="acst_WarrantsIssuedInMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedDecember272017Member" xlink:label="acst_WarrantsIssuedDecember272017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedInMay2018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedDecember272017Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockVotesPerShare" xlink:label="acst_CommonStockVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShorePharmaLlcMember" xlink:label="acst_ShorePharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInMay2018Member" xlink:label="acst_WarrantsIssuedInMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockDividendRatePercentage" xlink:label="acst_CommonStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SsPharmaLlcMember" xlink:label="acst_SsPharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedDecember272017Member" xlink:label="acst_WarrantsIssuedDecember272017Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockConversionRateIntoClassA" xlink:label="acst_CommonStockConversionRateIntoClassA"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PreFundedWarrantsMember" xlink:label="acst_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassCMember" xlink:label="us-gaap_CommonClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BrokerWarrantsIssuedMay2018Member" xlink:label="acst_BrokerWarrantsIssuedMay2018Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonStockRedemptionPricePerShare" xlink:label="acst_CommonStockRedemptionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PurchaseAgreementMember" xlink:label="acst_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonClassDAndCommonClassEMember" xlink:label="acst_CommonClassDAndCommonClassEMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BrokerWarrantsIssuedDecember2017Member" xlink:label="acst_BrokerWarrantsIssuedDecember2017Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommonWarrantAndPreFundedWarrantMember" xlink:label="acst_CommonWarrantAndPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" xlink:label="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_PaymentOfIssuanceCostsCommonWarrants" xlink:label="acst_PaymentOfIssuanceCostsCommonWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementCommonStockMaximumAmount" xlink:label="acst_AtthemarketSalesAgreementCommonStockMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromCommonShares" xlink:label="acst_ProceedsFromCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementTerm" xlink:label="acst_AtthemarketSalesAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockIssuedSharesWarrantsExercisableShares" xlink:label="acst_StockIssuedSharesWarrantsExercisableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" xlink:label="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CostRelatedToProspectusSupplementAmount" xlink:label="acst_CostRelatedToProspectusSupplementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockNet" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_CommissionCostsRelatedToShareSale" xlink:label="acst_CommissionCostsRelatedToShareSale"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SaleOfStockAveragePricePerShare" xlink:label="acst_SaleOfStockAveragePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" xlink:label="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockVotesPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="acst_ShorePharmaLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedInMay2018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockDividendRatePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="acst_SsPharmaLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedDecember272017Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockConversionRateIntoClassA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_BrokerWarrantsIssuedMay2018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommonStockRedemptionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acst_CommonClassDAndCommonClassEMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_BrokerWarrantsIssuedDecember2017Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_CommonWarrantAndPreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_PaymentOfIssuanceCostsCommonWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AtthemarketSalesAgreementCommonStockMaximumAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AtthemarketSalesAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_StockIssuedSharesWarrantsExercisableShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CostRelatedToProspectusSupplementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromIssuanceOfCommonStockNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_CommissionCostsRelatedToShareSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_SaleOfStockAveragePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightExercisedDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ConsultantMember" xlink:label="acst_ConsultantMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" xlink:label="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_EquityIncentivePlanMember" xlink:label="acst_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" xlink:label="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionsExercisePricePerShare" xlink:label="acst_StockOptionsExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IssuanceOfRestrictedShareUnit" xlink:label="acst_IssuanceOfRestrictedShareUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_StockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acst_ConsultantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_StockOptionsExercisePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_IssuanceOfRestrictedShareUnit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DirectorsAndEmployeesMember" xlink:label="acst_DirectorsAndEmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_StockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acst_DirectorsAndEmployeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_StockOptionPlanMember" xlink:label="acst_StockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_StockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange1Member" xlink:label="acst_ExercisePriceRange1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange2Member" xlink:label="acst_ExercisePriceRange2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange3Member" xlink:label="acst_ExercisePriceRange3Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange4Member" xlink:label="acst_ExercisePriceRange4Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange5Member" xlink:label="acst_ExercisePriceRange5Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange6Member" xlink:label="acst_ExercisePriceRange6Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange7Member" xlink:label="acst_ExercisePriceRange7Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange8Member" xlink:label="acst_ExercisePriceRange8Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ExercisePriceRange9Member" xlink:label="acst_ExercisePriceRange9Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange4Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange5Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange6Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange7Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange8Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acst_ExercisePriceRange9Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:label="us-gaap_ImpairmentEffectsOnEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_September2023CommonWarrantsMember" xlink:label="acst_September2023CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_May2018PublicOfferingWarrantsMember" xlink:label="acst_May2018PublicOfferingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_September2023CommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acst_May2018PublicOfferingWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2028Member" xlink:label="acst_TaxYear2028Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" xlink:label="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxCreditCarryForwardsMember" xlink:label="acst_TaxCreditCarryForwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2029Member" xlink:label="acst_TaxYear2029Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" xlink:label="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_OtherTaxCreditCarryforwardMember" xlink:label="acst_OtherTaxCreditCarryforwardMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2030Member" xlink:label="acst_TaxYear2030Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2031Member" xlink:label="acst_TaxYear2031Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2032Member" xlink:label="acst_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2033Member" xlink:label="acst_TaxYear2033Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2034Member" xlink:label="acst_TaxYear2034Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2035Member" xlink:label="acst_TaxYear2035Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2036Member" xlink:label="acst_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2037Member" xlink:label="acst_TaxYear2037Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2038Member" xlink:label="acst_TaxYear2038Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2039Member" xlink:label="acst_TaxYear2039Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2040Member" xlink:label="acst_TaxYear2040Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2041Member" xlink:label="acst_TaxYear2041Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2042Member" xlink:label="acst_TaxYear2042Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_Taxyear2043Member" xlink:label="acst_Taxyear2043Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2044Member" xlink:label="acst_TaxYear2044Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NoExpiryMember" xlink:label="acst_NoExpiryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2028Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acst_TaxCreditCarryForwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2029Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acst_OtherTaxCreditCarryforwardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2030Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2031Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2032Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2033Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2034Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2035Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2036Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2037Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2038Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2039Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2040Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2041Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2042Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_Taxyear2043Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2044Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_NoExpiryMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GovernmentAssistance" xlink:label="acst_GovernmentAssistance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" xlink:label="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromNRCIRAP" xlink:label="acst_ProceedsFromNRCIRAP"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_GovernmentAssistance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromNRCIRAP" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCreditMember" xlink:label="us-gaap_InvestmentCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2029Member" xlink:label="acst_TaxYear2029Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2030Member" xlink:label="acst_TaxYear2030Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2031Member" xlink:label="acst_TaxYear2031Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2032Member" xlink:label="acst_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2033Member" xlink:label="acst_TaxYear2033Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2034Member" xlink:label="acst_TaxYear2034Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2035Member" xlink:label="acst_TaxYear2035Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2036Member" xlink:label="acst_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2037Member" xlink:label="acst_TaxYear2037Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2038Member" xlink:label="acst_TaxYear2038Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2039Member" xlink:label="acst_TaxYear2039Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2040Member" xlink:label="acst_TaxYear2040Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2041Member" xlink:label="acst_TaxYear2041Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2042Member" xlink:label="acst_TaxYear2042Member"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYearTwoThousandFortyThreeMember" xlink:label="acst_TaxYearTwoThousandFortyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TaxYear2044Member" xlink:label="acst_TaxYear2044Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_InvestmentCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2029Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2030Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2031Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2032Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2033Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2034Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2035Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2036Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2037Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2038Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2039Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2040Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2041Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2042Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYearTwoThousandFortyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acst_TaxYear2044Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RKOSupplyAgreementMember" xlink:label="acst_RKOSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_OppenheimerAndCoIncMember" xlink:label="acst_OppenheimerAndCoIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ContractResearchOrganizationsMember" xlink:label="acst_ContractResearchOrganizationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SherbrookLeaseMember" xlink:label="acst_SherbrookLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" xlink:label="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" xlink:label="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" xlink:label="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" xlink:label="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsToCompleteContractsInProcess" xlink:label="us-gaap_CommitmentsToCompleteContractsInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_RetentionIncentiveAgreementMaximumConditionalIncentives" xlink:label="acst_RetentionIncentiveAgreementMaximumConditionalIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AdditionalLeaseRenewalTerm" xlink:label="acst_AdditionalLeaseRenewalTerm"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="acst_RKOSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acst_OppenheimerAndCoIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_ContractResearchOrganizationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="acst_SherbrookLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsToCompleteContractsInProcess" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_RetentionIncentiveAgreementMaximumConditionalIncentives" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_AdditionalLeaseRenewalTerm" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acst_ProductionEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_AtTheMarketOfferingMember" xlink:label="acst_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockNet" xlink:label="acst_ProceedsFromIssuanceOfCommonStockNet"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonStockGross" xlink:label="acst_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acst_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromIssuanceOfCommonStockNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acst_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MachineryAndEquipmentGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="6" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="acst_ImpairmentOfGoodwill1" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="acst_ImpairmentOfAssetHeldForSale" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfGoodwill1" xlink:label="acst_ImpairmentOfGoodwill1"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfAssetHeldForSale" xlink:label="acst_ImpairmentOfAssetHeldForSale"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="acst_EffectOfTranslationEffectOnCashAndCashEquivalents" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acst_ImpairmentOfGoodwill1" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acst_ImpairmentOfAssetHeldForSale" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="16" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="17" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="21" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" xlink:label="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" xlink:label="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_EffectOfTranslationEffectOnCashAndCashEquivalents" xlink:label="acst_EffectOfTranslationEffectOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfGoodwill1" xlink:label="acst_ImpairmentOfGoodwill1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_ImpairmentOfAssetHeldForSale" xlink:label="acst_ImpairmentOfAssetHeldForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="acst_GrantsAndInvestmentTaxCreditReceivable" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="acst_SalesTaxReceivablesCurrent" order="3" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_GrantsAndInvestmentTaxCreditReceivable" xlink:label="acst_GrantsAndInvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_SalesTaxReceivablesCurrent" xlink:label="acst_SalesTaxReceivablesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="5" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="acst_TransactionCostsRelatedToDerivativeWarrantLiability" xlink:to="us-gaap_OtherIncome" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="acst_TransactionCostsRelatedToDerivativeWarrantLiability" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_TransactionCostsRelatedToDerivativeWarrantLiability" xlink:label="acst_TransactionCostsRelatedToDerivativeWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="acst_IncreaseDecreaseInWorkingCapital" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="acst_IncreaseDecreaseInWorkingCapital" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" weight="-1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncreaseDecreaseInWorkingCapital" xlink:label="acst_IncreaseDecreaseInWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="acst_NonRefundableFederalItc" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="8" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="9" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" xlink:label="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" xlink:label="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" xlink:label="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_NonRefundableFederalItc" xlink:label="acst_NonRefundableFederalItc"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acst_DeferredTaxAssetsFinancingExpenses" order="6" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" xlink:label="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acst-20240331.xsd#acst_DeferredTaxAssetsFinancingExpenses" xlink:label="acst_DeferredTaxAssetsFinancingExpenses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" order="1" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="acst_EffectOfTranslationEffectOnCashAndCashEquivalents" name="EffectOfTranslationEffectOnCashAndCashEquivalents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_GovernmentAssistance" name="GovernmentAssistance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_Gtx101Member" name="Gtx101Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" name="AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ConsultantMember" name="ConsultantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2030Member" name="TaxYear2030Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_BrokerWarrantsIssuedMay2018Member" name="BrokerWarrantsIssuedMay2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock" name="ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_TransactionCostsRelatedToDerivativeWarrantLiability" name="TransactionCostsRelatedToDerivativeWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_DeferredTaxLiabilityConvertibleDebtEquityComponent" name="DeferredTaxLiabilityConvertibleDebtEquityComponent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_StockIssuedSharesWarrantsExercisableShares" name="StockIssuedSharesWarrantsExercisableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock" name="PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_CommissionCostsRelatedToShareSale" name="CommissionCostsRelatedToShareSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_NetBookValueReclassedFromHeldForSales" name="NetBookValueReclassedFromHeldForSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_PurchaseOfCommonShares" name="PurchaseOfCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_ExercisePriceRange4Member" name="ExercisePriceRange4Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_Gtx102Member" name="Gtx102Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ExercisePriceRange9Member" name="ExercisePriceRange9Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_SherbrookLeaseMember" name="SherbrookLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxCreditCarryForwardsMember" name="TaxCreditCarryForwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_TaxYear2044Member" name="TaxYear2044Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2040Member" name="TaxYear2040Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_Licenses" name="Licenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ImpairmentOfGoodwill1" name="ImpairmentOfGoodwill1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived" name="ImpairmentOfTheIntangibleAssetsIndefiniteLived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ExercisePriceRange2Member" name="ExercisePriceRange2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_StockOptionPlanMember" name="StockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_SsPharmaLlcMember" name="SsPharmaLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_AdjustmentsToNetAssets" name="AdjustmentsToNetAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_CostNetOfImpairments" name="CostNetOfImpairments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ExercisePriceRange7Member" name="ExercisePriceRange7Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_AdditionalLeaseRenewalTerm" name="AdditionalLeaseRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acst_SharesPrice" name="SharesPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" name="AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" name="IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_AssetsHeldForSalePolicyTextBlock" name="AssetsHeldForSalePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_OtherTaxCreditCarryforwardMember" name="OtherTaxCreditCarryforwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_StockOptionsExercisePricePerShare" name="StockOptionsExercisePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acst_September2023CommonWarrantsMember" name="September2023CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_WarrantsIssuedDecember272017Member" name="WarrantsIssuedDecember272017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_IncomeTaxReconciliationNondeductibleChangeInFairValue" name="IncomeTaxReconciliationNondeductibleChangeInFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_BrokerWarrantsIssuedDecember2017Member" name="BrokerWarrantsIssuedDecember2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2042Member" name="TaxYear2042Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_DirectorsAndEmployeesMember" name="DirectorsAndEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_GovernmentGrantsPolicyTextBlock" name="GovernmentGrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_RetentionIncentiveAgreementMaximumConditionalIncentives" name="RetentionIncentiveAgreementMaximumConditionalIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" name="IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ProductionEquipmentMember" name="ProductionEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_TaxYear2034Member" name="TaxYear2034Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2036Member" name="TaxYear2036Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2038Member" name="TaxYear2038Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ImpairmentOfAssetHeldForSale" name="ImpairmentOfAssetHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity" name="FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" name="WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ExercisePriceRange8Member" name="ExercisePriceRange8Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_PurchasePricePerCommonShare" name="PurchasePricePerCommonShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_SalesTaxReceivablesCurrent" name="SalesTaxReceivablesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ShorePharmaLlcMember" name="ShorePharmaLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_NetFederalInvestmentTaxCredits" name="NetFederalInvestmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2032Member" name="TaxYear2032Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_PropertyPantAndEquipmentDepreciationRate" name="PropertyPantAndEquipmentDepreciationRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_WarrantsIssuedInMay2018Member" name="WarrantsIssuedInMay2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2041Member" name="TaxYear2041Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_DeferredTaxAssetsResearchAndDevelopmentExpenses" name="DeferredTaxAssetsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_DeferredTaxAssetsFinancingExpenses" name="DeferredTaxAssetsFinancingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_CommonStockDividendRatePercentage" name="CommonStockDividendRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_NoOfDaysInvestmentsPurchased" name="NoOfDaysInvestmentsPurchased" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_ImpairmentRelatedDeferredTaxLiability" name="ImpairmentRelatedDeferredTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_NetBookValueReclassedFromHeldForSale" name="NetBookValueReclassedFromHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_GraceTherapeuticsIncMember" name="GraceTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2039Member" name="TaxYear2039Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ContractResearchOrganizationsMember" name="ContractResearchOrganizationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_RKOSupplyAgreementMember" name="RKOSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYearTwoThousandFortyThreeMember" name="TaxYearTwoThousandFortyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_LeaseExpenseTableTextblock" name="LeaseExpenseTableTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_NoExpiryMember" name="NoExpiryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2037Member" name="TaxYear2037Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember" name="ChiefExecutiveOfficerAndChiefOperatingOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_Impairmentofintangibleassetsindefinitelived" name="Impairmentofintangibleassetsindefinitelived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_SoftwareMember" name="SoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_CommonStockConversionRateIntoClassA" name="CommonStockConversionRateIntoClassA" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_ExercisePriceRange1Member" name="ExercisePriceRange1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ExercisePriceRange5Member" name="ExercisePriceRange5Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ProceedsFromCommonShares" name="ProceedsFromCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_CommonSharesHeldByNonAffiliates" name="CommonSharesHeldByNonAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_CommonClassDAndCommonClassEMember" name="CommonClassDAndCommonClassEMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences" name="IncomeTaxReconciliationUnrecognizedTemporaryDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ImpairmentOfOtherAssetsAndPrepaids" name="ImpairmentOfOtherAssetsAndPrepaids" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" name="IncomeTaxReconciliationNondeductibleExpenseTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" name="ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_SaleOfStockAveragePricePerShare" name="SaleOfStockAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" name="ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_Taxyear2043Member" name="Taxyear2043Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_DeferredTaxAssetsOperatingLeaseAsset" name="DeferredTaxAssetsOperatingLeaseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_StateNonIncomeTaxes" name="StateNonIncomeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_TaxYear2029Member" name="TaxYear2029Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_IncreaseDecreaseInWorkingCapital" name="IncreaseDecreaseInWorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_TaxYear2033Member" name="TaxYear2033Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_CommonStockVotesPerShare" name="CommonStockVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acst_TaxCreditCarryforwardNotSubjectToTimeLimitation" name="TaxCreditCarryforwardNotSubjectToTimeLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_IncomeTaxRecoveryExpenseAbstract" name="IncomeTaxRecoveryExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_CommonWarrantAndPreFundedWarrantMember" name="CommonWarrantAndPreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_May2018PublicOfferingWarrantsMember" name="May2018PublicOfferingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_TaxYear2035Member" name="TaxYear2035Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability" name="RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_SupplementalBalanceSheetInformationTableTextblock" name="SupplementalBalanceSheetInformationTableTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_ScheduleOfNonvestedOptionActivityTableTextBlock" name="ScheduleOfNonvestedOptionActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability" name="DeferredTaxAssetsOperatingLeaseRightOfUseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_GuaranteedInvestmentCertificatesAndTermDeposits" name="GuaranteedInvestmentCertificatesAndTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" name="RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_GrantsAndInvestmentTaxCreditReceivable" name="GrantsAndInvestmentTaxCreditReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_CostRelatedToProspectusSupplementAmount" name="CostRelatedToProspectusSupplementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_AtthemarketSalesAgreementTerm" name="AtthemarketSalesAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_PaymentOfIssuanceCostsCommonWarrants" name="PaymentOfIssuanceCostsCommonWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions" name="UnrecognizedCompensationCostRelatedToNonVestedShareOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_InvestmentTaxCreditReceivable" name="InvestmentTaxCreditReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ExercisePriceRange6Member" name="ExercisePriceRange6Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ProceedsFromNRCIRAP" name="ProceedsFromNRCIRAP" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_PurchaseOfPreFundedWarrants" name="PurchaseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_ReverseStockSplitMember" name="ReverseStockSplitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_DeferredFinancingCostsReclassifiedToEquity" name="DeferredFinancingCostsReclassifiedToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_ChangeInTaxRates" name="ChangeInTaxRates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_WriteOff" name="WriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_TaxYear2028Member" name="TaxYear2028Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ScheduleOfGovernmentAssistanceTableTextBlock" name="ScheduleOfGovernmentAssistanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" name="NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_IssuanceOfRestrictedShareUnit" name="IssuanceOfRestrictedShareUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_NonRefundableFederalItc" name="NonRefundableFederalItc" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_CommonStockRedemptionPricePerShare" name="CommonStockRedemptionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acst_Gtx104Member" name="Gtx104Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ExercisePriceRange3Member" name="ExercisePriceRange3Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ProductionEquipmentImpairmentLoss" name="ProductionEquipmentImpairmentLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" name="WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_AtthemarketSalesAgreementCommonStockMaximumAmount" name="AtthemarketSalesAgreementCommonStockMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_TaxYear2031Member" name="TaxYear2031Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acst_ATMTransactionCostsIncludedInTradeAndOtherPayables" name="ATMTransactionCostsIncludedInTradeAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" name="ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" name="SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acst_OppenheimerAndCoIncMember" name="OppenheimerAndCoIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874454248704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 21, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACASTI PHARMA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1359336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001444192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">103 Carnegie Center Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">839-4378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text"> No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,617,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACST<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338257328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,005<span></span>
</td>
<td class="nump">$ 27,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short- term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">24,010<span></span>
</td>
<td class="nump">29,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment,net</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">41,128<span></span>
</td>
<td class="nump">41,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,138<span></span>
</td>
<td class="nump">8,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,300<span></span>
</td>
<td class="nump">79,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade and other payables</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">3,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">5,514<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,557<span></span>
</td>
<td class="nump">11,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">17,862<span></span>
</td>
<td class="nump">13,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,038)<span></span>
</td>
<td class="num">(6,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(211,119)<span></span>
</td>
<td class="num">(198,266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholder's equity</a></td>
<td class="nump">61,743<span></span>
</td>
<td class="nump">67,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">73,300<span></span>
</td>
<td class="nump">79,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Total</a></td>
<td class="nump">261,038<span></span>
</td>
<td class="nump">258,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874439574384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">7,435,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">7,435,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874430386768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Loss and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net of government assistance</a></td>
<td class="num">$ (4,683)<span></span>
</td>
<td class="num">$ (9,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(6,432)<span></span>
</td>
<td class="num">(7,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring cost</a></td>
<td class="num">(1,485)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfGoodwill1', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfAssetHeldForSale', window );">Impairment of assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operating activities</a></td>
<td class="num">(12,852)<span></span>
</td>
<td class="num">(52,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign exchange loss</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(2,728)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income and other expense, net</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(1,833)<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">(14,685)<span></span>
</td>
<td class="num">(51,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">9,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and total comprehensive loss</a></td>
<td class="num">$ (12,853)<span></span>
</td>
<td class="num">$ (42,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share Basic</a></td>
<td class="num">$ (1.35)<span></span>
</td>
<td class="num">$ (5.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share Diluted</a></td>
<td class="num">$ (1.35)<span></span>
</td>
<td class="num">$ (5.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number Of Shares Outstanding Basic</a></td>
<td class="nump">9,529,123<span></span>
</td>
<td class="nump">7,435,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number Of Shares Outstanding Diluted</a></td>
<td class="nump">9,529,123<span></span>
</td>
<td class="nump">7,435,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Asset held for sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Goodwill 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874336246288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholder's Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Class A common shares [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive loss [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,381,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 108,270<span></span>
</td>
<td class="nump">$ 257,990<span></span>
</td>
<td class="nump">$ 12,154<span></span>
</td>
<td class="num">$ (6,037)<span></span>
</td>
<td class="num">$ (155,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(42,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from shares issued under the at-the-market (ATM) program (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from shares issued under the at-the-market (ATM) program</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,435,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="nump">67,955<span></span>
</td>
<td class="nump">$ 258,294<span></span>
</td>
<td class="nump">13,965<span></span>
</td>
<td class="num">(6,038)<span></span>
</td>
<td class="num">(198,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(12,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options, Value</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options, Share</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares', window );">Issuance of common shares and pre-funded warrants through private placement, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts', window );">Issuance of common shares and pre-funded warrants through private placement, net of offering costs (Value)</a></td>
<td class="nump">$ 5,707<span></span>
</td>
<td class="nump">$ 2,744<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 61,743<span></span>
</td>
<td class="nump">$ 261,038<span></span>
</td>
<td class="nump">$ 17,862<span></span>
</td>
<td class="num">$ (6,038)<span></span>
</td>
<td class="num">$ (211,119)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares and pre-funded warrants through private placement, net of offering costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337881936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,853)<span></span>
</td>
<td class="num">$ (42,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of equipment</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of equipment</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfGoodwill1', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfAssetHeldForSale', window );">Impairment of assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">(9,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on disposal</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade and other payables</a></td>
<td class="num">(1,652)<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease right of use asset</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,333)<span></span>
</td>
<td class="num">(15,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(6,554)<span></span>
</td>
<td class="num">(5,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturity of short-term investments</a></td>
<td class="nump">6,569<span></span>
</td>
<td class="nump">18,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">13,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement', window );">Net proceeds from issuance of common shares and warrants from private placement</a></td>
<td class="nump">7,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions', window );">Proceeds from issuance of common shares from exercise of stock options</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from shares issued under the at-the-market (ATM) program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,359<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_EffectOfTranslationEffectOnCashAndCashEquivalents', window );">Effect of exchange rate fluctuations on cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(4,870)<span></span>
</td>
<td class="num">(2,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">27,875<span></span>
</td>
<td class="nump">30,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">23,005<span></span>
</td>
<td class="nump">27,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">3,280<span></span>
</td>
<td class="nump">17,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 19,725<span></span>
</td>
<td class="nump">$ 10,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_EffectOfTranslationEffectOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_EffectOfTranslationEffectOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Asset held for sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Goodwill 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Shares From Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329706176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (12,853)<span></span>
</td>
<td class="num">$ (42,429)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874336176224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874439590320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acasti Pharma Inc. (&#8220;Acasti&#8221; or the &#8220;Company&#8221;) is incorporated under the Business Companies Act (Qu&#233;bec) (formerly Part 1A of the Companies Act (Qu&#233;bec)). The Company is domiciled in Canada and its principal executive office is located at 103 Carnegie Center Suite 300 Princeton, New Jersey 08540.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Class A common shares, no par value per share (&#8220;Common Shares&#8221;), are listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) and, through March 27, 2023, the Company's Common Shares were also listed on the TSX Venture Exchange (&#8220;TSXV&#8221;), in each case, under the symbol &#8220;ACST&#8221;. On March 13, 2023, the Company received approval to voluntarily delist from the TSXV. Effective as at the close of trading on March 27, 2023, the Company's Common Shares are no longer listed and posted for trading on the TSXV.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2021, the Company completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (&#8220;Grace Therapeutics&#8221;), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Company is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and developing and commercializing products that improve clinical outcomes using its novel drug delivery technologies. The Company seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Company for further development may be already approved in the target indication or could be repurposed for use in new indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses and negative cash flows from operations in each year since its inception. The Company expects to incur significant expenses and continued operating losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company implemented a strategic realignment plan to enhance shareholder value that resulted in the Company engaging a new management team, streamlining its research and development activities and greatly reducing its workforce. Following the realignment, the Company is a smaller, more focused organization, based in the United States, and concentrated on its development of its lead product GTX-104. Further development of GTX-102 and GTX-101 will occur at such time when the Company is able to secure additional funding, or enters into strategic partnerships for license or sale with third parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 24, 2023, the Company entered into a securities purchase agreement with certain institutional and accredited investors. Gross proceeds to the Company from this private placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, before deducting fees and expenses. The Company issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,951,371</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, pre-funded warrants (the "Pre-funded Warrants") to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,106,853</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, each at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8481</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share and accompanying common warrants (the "Common Warrants" and, together with the Pre-funded Warrants, the "Warrants") to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,536,391</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares. The Company currently intends to use the net proceeds from the private placement for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, pre-commercial planning, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents, will be sufficient to fund the Company&#8217;s operations into the second calendar quarter of 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will require additional capital to fund its daily operating needs beyond that time. The Company does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Company expects will take several years and is subject to significant uncertainty. To date, the Company has financed its operations primarily through public offerings and private placements of its Common Shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Company can generate significant revenue from drug product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financing or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Company to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy. The Company plans to raise additional capital in order to maintain adequate liquidity. Negative results from studies or trials, if any, or depressed prices of the Company&#8217;s stock could impact the Company&#8217;s ability to raise additional financing. Raising additional equity capital is subject to market conditions that are not within the Company&#8217;s control. If the Company is unable to raise additional funds, the Company may not be able to realize its assets and discharge its liabilities in the normal course of business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with government regulations, protection of proprietary technology, dependence on third-party contractors and consultants and potential product liability, among others.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse stock split</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 29, 2023, the Board of Directors of the Company approved an amendment to the Company's Articles of Incorporation to implement a reverse stock split of the Company's Common Shares, at a ratio of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Reverse Stock Split&#8221;). On July 4, 2023, the Company filed Articles of Amendment to its Articles of Incorporation with the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registraire des entreprises du Qu&#233;bec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to implement the Reverse Stock Split. All references in these financial statements to number of Common Shares, warrants and options, price per share and weighted-average number of shares outstanding have been adjusted to reflect the Reverse Stock Split, which became effective on July 10, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329657056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of significant accounting policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of presentation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). All intercompany transactions and balances are eliminated on consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates are based on management&#8217;s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions include the measurement of stock-based compensation, derivative warrant liabilities, accruals for research and development contracts and contract organization agreements, and valuation of intangibles and goodwill. Estimates and assumptions are also involved in determining the extent to which research and development expenses qualify for research and development tax credits. The Company recognizes tax credits once it has reasonable assurance that they will be realized.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash equivalents</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents comprise of highly liquid investments purchased with original maturities of 90 days or less. Cash equivalents consist of guaranteed investment certificates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equipment</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is recognized on a declining basis over the estimated useful lives of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not yet in service, from the date they are ready for their intended use.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible assets - acquired in-process research and development</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a business combination, the fair value of in-process research and development (&#8220;IPR&amp;D&#8221;) acquired is capitalized and accounted for as indefinite-lived intangible assets, and not amortized until the underlying project receives regulatory approval, at which point the intangible assets will be accounted for as definite-lived intangible assets and amortized over the remaining useful life or discontinued. If discontinued, the intangible asset will be written off. Research and development (&#8220;R&amp;D&#8221;) costs incurred after the acquisition are expensed as incurred.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method, which is a valuation methodology that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The significant assumptions used in the valuation are the discount rate, the probability of clinical success of research and development programs, obtaining regulatory approval and forecasted net sales, including milestone payments and royalty revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews the recoverability of its finite long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not be recoverable. The carrying amount is first compared with the undiscounted cash flows. If the carrying amount is higher than the sum of undiscounted cash flows, then the Company determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the difference by which the carrying amount of the asset group exceeds the estimated fair value of the asset group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeds the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than it's carrying amount, a quantitative impairment test is performed.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's annual impairment test is performed in the fourth quarter of the fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development costs</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and developments expenditures are expensed as incurred. These costs consist of employees&#8217; salaries and benefits related to research and development activities, contractors and consultants that conduct the Company&#8217;s clinical trials, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has in place a stock option plan for directors, officers, employees, and consultants of the Company, with grants under the stock option plan approved by the Company&#8217;s Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant.  The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company measures the cost of such awards based on the fair value of the award at grant date and recognizes stock-based compensation expense in the Consolidated Statements of Operations and Comprehensive Loss on a tranche by tranche basis. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including fair value of the Common Shares at the grant date, expected term, historical volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior in determining compensation expense. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may be required in future periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government grants</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic environment. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company&#8217;s lease expense is recognized in research and development expenses. The Company does not have financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with FASB ASC 842&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;Topic 842&#8221;), components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes comprises current and deferred taxes. The provision for income taxes is computed using the asset and liability method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realized (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Company has the right to set off the amount owed by with the amount owed by the other party, the Company intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses, and tax credits, reduced by a valuation allowance. A valuation allowance is recorded to reduce the carrying amount of deferred income tax assets when it is more likely than not that these assets will not be realized.  tax benefits related to tax positions not deemed to meet the &#8220;more-likely-than-not&#8221; threshold are not permitted to be recognized in the consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings per share</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company presents basic and diluted earnings per share ("EPS") data for its Common Shares. Basic EPS is calculated by dividing the net income or loss attributable to the holders of Common Shares by the weighted average number of Common Shares outstanding during the year. Diluted EPS is determined by adjusting the net income or loss attributable to the holders of Common Shares and the weighted average number of Common Shares outstanding adjusted for the effects of all dilutive potential </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares, which comprise warrants and share options granted to employees. The basic and diluted EPS are the same due to loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment reporting</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable operating segment: the development and commercialization of pharmaceutical applications of its patent portfolio and licensed rights. The majority of the Company&#8217;s assets are located in Canada and the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative warrant liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative warrant liabilities are recognized initially at fair value. Subsequent to initial recognition, derivative warrant liabilities are measured at fair value, with changes in fair value are recognized in the Consolidated Statement of Operations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value measurements</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of the Company&#8217;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below:</span></p><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: defined as observable inputs such as quoted prices in active markets.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions.</span></div></div><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are all invested in accordance with the Company&#8217;s Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which risk is managed by dealing only with highly rated Canadian and U.S. institutions. The Company maintains its cash and cash equivalents at accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent accounting pronouncements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the consolidated financial statements as a result of future adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329696672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair value measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.203%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.435%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.477%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.056%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.435%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quoted prices in active markets (Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Guaranteed investment certificates and term deposits<br/>&#160;&#160;&#160;classified as cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Derivative warrant liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of March 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.058%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.405%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.323%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.024%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.405%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.541%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quoted prices in active markets (Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Term deposits classified as cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,072</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,072</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Guaranteed investment certificate classified as a<br/>&#160;&#160;&#160;short-term investment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f132cd30-7902-4315-8127-ab7bcce7e6f9;"><span style="-sec-ix-hidden:F_c1a9517d-f266-4d79-aeb0-1c8917bd2b32;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> changes in valuation techniques or transfers between Levels 1, 2 or 3 during the years ended March 31, 2024 and 2023. The Company&#8217;s derivative warrant liabilities are measured at fair value on a recurring basis using unobservable inputs that are classified as Level 3 inputs. Refer to Note 10(b) for the valuation techniques and assumptions used in estimating the fair value of the derivative warrant liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329648880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Receivables</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Receivables</span></p><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales tax receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government assistance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government assistance is comprised of research and development investment tax credits from the Qu&#233;bec provincial government, which relate to quantifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874454571872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Equipment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of equipment, net:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated<br/>depreciation</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Write-off</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net book<br/>value</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">608</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated<br/>depreciation</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Write-off</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net book<br/>value</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">512</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">570</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended March 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331911376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets and Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Intangible assets and goodwill</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual IPR&amp;D projects and goodwill are tested for impairment on an annual basis in the fourth quarter, and in between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of each technology or our reporting unit below its carrying value. In April 2023, the Company announced its strategic realignment plan to prioritize resources to GTX-104, from GTX-101 and GTX-102 triggering a comprehensive review as of March 31, 2023. The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of the reporting unit was determined using the projected discounted cash flow model. The impairment assessments resulted in the following activity during the years ended March 31, 2024 and 2023: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.52%;"></td>
        <td style="width:8.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.34%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-104</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-102</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-101</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets &#8211; in-process research and development</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">41,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">41,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impairment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,682</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the intangible assets resulted in a recovery of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,633</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the related deferred tax liability.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.68%;"></td>
        <td style="width:11.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:25.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Goodwill</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,964</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The multi-period excess earnings method models used to estimate the fair value of assets of our IPR&amp;D reflect significant assumptions and are level 3 unobservable data regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Probability of clinical success of research and development and obtaining regulatory approval;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forecasted net sales from up-front and milestone payments, royalties and product sales; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discount rate reflecting our weighted average cost of capital and specific risk inherent in the underlying assets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's IPR&amp;D projects, consistent with others in our industry, have risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. It is not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329646000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and Other Payables</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Trade and other payables</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities and other payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee salaries and benefits payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">501</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,148</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total trade and other payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331891648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8- Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically entered into lease arrangements for its research and development and quality control laboratory facility located in Sherbrooke, Qu&#233;bec. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, the Company renewed the lease agreement effective April 1, 2022, resulting in a commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">556</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month base lease term with an option to renew for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-month term. In April 2023, the Company elected not to renew the additional 48-month option to renew, and terminated the lease on March 31, 2024.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to leases was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.914%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.662%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">463</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, long-term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental lease expense related to leases is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.792%;"></td>
        <td style="width:1.939%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.916%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.939%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.416%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the year ended March 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.235%;"></td>
        <td style="width:6.564%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.202%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows for operating lease</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_35eb60b8-303d-4e25-9601-0886d5998462;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the Company's lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As of March 31, 2024, there were no future minimum lease payments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329649920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 -Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Shareholders' equity</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Authorized capital stock</span></p><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class A common shares ("Common Shares"), voting (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote per share), participating and without par value. As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,399,404</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares issued and outstanding. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class B common shares, voting (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">ten</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> votes per share), non-participating, without par value and maximum annual non-cumulative dividend of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the amount paid per share. Class B common shares are convertible, at the holder&#8217;s discretion, into Common Shares, on a one-for-one basis, and Class B common shares are redeemable at the holder&#8217;s discretion for CAD $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to certain conditions. As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class B common shares issued and outstanding.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class C common shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the amount paid per share. Class C common shares are convertible, at the holder&#8217;s discretion, into Common Shares, on a one-for-one basis, and Class C common shares are redeemable at the holder&#8217;s discretion for CAD $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, subject to certain conditions. As of March 31, 2024, there were no Class C common shares issued and outstanding.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#10147;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Class D and E common shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the amount paid per share. Class D and E common shares are convertible, at the holder&#8217;s discretion, into Common Shares, on a one-for-one basis, and Class D and E common shares are redeemable for the price paid for such shares, plus a redemption premium described in the Company's Articles of Incorporation, as amended, at the holder&#8217;s discretion, subject to certain conditions. As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Class D or E common shares issued and outstanding.</span></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors in connection with a private placement of the Company's securities (the &#8220;Offering&#8221;). Pursuant to the Purchase Agreement, the Company agreed to offer and sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,951,371</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.848</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share and Pre-funded Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,106,853</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at a purchase price equal to the purchase price per Common Share less $0.0001. Each Pre-funded Warrant is exercisable for one Common Share at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share, is immediately exercisable, and will expire once exercised in full. Pursuant to the Purchase Agreement, the Company also issued to such institutional and accredited investors Common Warrants to purchase Common Shares, exercisable for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,536,391</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares. Under the terms of the Purchase Agreement, for each Common Share and each Pre-funded Warrant issued in the Offering, an accompanying five-eighths (0.625) of a Common Warrant was issued to the purchaser thereof. Each whole Common Warrant is exercisable for one Common Share at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share, is immediately exercisable, and will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company&#8217;s product candidate GTX-104 or (ii) five years from the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Offering closed on September 25, 2023. The Offering included the issuance of Common Shares, Pre-funded Warrants, and Common Warrants to related parties Shore Pharma LLC, an entity that was controlled by Vimal Kavuru, the Chair of our Board of Directors, at the time of the Offering and SS Pharma LLC, resulting in proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The net proceeds to the Company from the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,338</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after deducting fees and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-the-Market (&#8220;ATM&#8221;) Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2020, the Company entered into an amended and restated sales agreement (the &#8220;Sales Agreement&#8221;) with B. Riley FBR, Inc. (&#8220;B.Riley&#8221;), Oppenheimer &amp; Co. Inc. and H.C. Wainwright &amp; Co., LLC (collectively, the &#8220;Agents&#8221;) to amend the Company&#8217;s existing ATM program. Under the terms of the Sales Agreement, which had a three-year term, the Company could issue and sell from time to time, Common Shares having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through the Agents. Subject to the terms and conditions of the Sales Agreement, the Agents would use their commercially reasonable efforts to sell the Common Shares from time to time, based upon the Company&#8217;s instructions. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> obligation to sell any of the Common Shares and could, at any time, suspend sales under the Sales Agreement. The Company and the Agents could terminate the Sales Agreement in accordance with its terms. Under the terms of the Sales Agreement, the Company provided the Agents with customary indemnification rights and the Agents were entitled to compensation at a commission rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds from each sale of the Common Shares. The Sales Agreement expired pursuant to its terms on June 29, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares were sold under the ATM program. During the year ended March 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">54,108</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares were sold for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">304</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with commissions, legal expenses and costs related to the share sale amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Common Shares were sold at the prevailing market prices, which resulted in an average price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 9, 2023, warrants issued pursuant to the Company&#8217;s May 2018 Canadian public offering to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">137,370</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at an exercise price of CAD $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As further discussed above, on September 25, 2023, the Company issued Warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,643,244</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares in the Offering pursuant to the terms of the Purchase Agreement entered into with certain institutional and accredited investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Common Warrants issued as a part of the Offering are derivative warrant liabilities given the warrant indenture did not meet the fixed-for-fixed criterion and that the Common Warrants are not indexed to the Company&#8217;s own stock. Proceeds were allocated amongst Common Shares, Pre-funded Warrants, and Common Warrants by applying the residual method, with fair value of the Common Warrants determined using the Black-Scholes model, resulting in an initial warrant liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,631</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of issuance costs allocated to Common Warrants. Accordingly, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,822</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,047</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of gross proceeds were allocated to Common Shares and Pre-funded Warrants, respectively; and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">84</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of issuance costs were allocated to Common Shares and Pre-funded Warrants, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:</span></p><p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.093%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.063%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued during the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,728</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrant liability was determined based on the fair value of warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) five years from the date on issuance.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.806%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.558%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.558%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 25, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected warrant life</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions were prorated based on the probability of the warrant liability expiring on the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 and of it expiring on five years from the date of issuance. The weighted-average fair values of the Common Warrants were determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Warrant, as of September 25, 2023 and March 31, 2024, respectively. The risk-free interest rate at the issue date and on the reporting date of March 31, 2024 was based on the interest rate corresponding to the U.S. Treasury rate issue with a remaining term equal to the expected term of the warrants. The expected volatility was based on the historical volatility for the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, the Company had outstanding Common Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,536,391</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all of which were classified as derivative warrant liability. At March 31, 2024, the Company had outstanding Pre-funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,106,853</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all of which were classified within shareholders' equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants were exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331839056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stock-based compensation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, the Company had in place a stock option plan for directors, officers, employees, and consultants of the Company (&#8220;Stock Option Plan&#8221;). As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">738,725</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> awards available under the plan for issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Stock Option Plan provides for the granting of options to purchase Common Shares. Under the terms of the Stock Option Plan, the exercise price of the stock options granted under the Stock Option Plan may not be lower than the closing price of the Company&#8217;s Common Shares on the Nasdaq Capital Market at the close of such market the day preceding the grant. The maximum number of Common Shares that may be issued upon exercise of options granted under the amended Stock Option Plan shall not exceed 20% of the aggregate number of issued and outstanding shares of the Company as of July 28, 2022. The terms and conditions for acquiring and exercising options are set by the Company&#8217;s Board of Directors, subject to, among others, the following limitations: the term of the options cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and (i) all options granted to a director will be vested evenly on a monthly basis over a period of at least twelve (12) months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period of at least thirty-six (36) months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total number of options issued to any one consultant within any twelve-month period cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s total issued and outstanding Common Shares (on a non-diluted basis). The total number of options issued within any twelve-month period to all directors, employees and/or consultants of the Company (or any subsidiary of the Company) conducting investor relations services, cannot exceed in the aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s issued and outstanding Common Shares (on a non-diluted basis), calculated at the date an option is granted to any such person.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes information about activities within the Stock Option Plan for the year ended March 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.658%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of<br/>options</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average<br/>exercise price</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining Contractual Term (years)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aggregate Intrinsic Value (in thousands)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">740,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.19</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">607,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">614,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.89</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">721,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.08</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">312,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.84</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forfeited and cancelled options were as a result of the Company's restructuring that occurred during the year ended March 31, 2024. On July 14, 2023, the Company's Board of Directors approved the grant of options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">446,502</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.64</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share under the Company's Stock Option Plan. On December 19, 2023, the Company's Board of Directors approved the grant of options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">161,168</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Common Shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Common Share under the Company's Stock Option Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of awards for options granted during the years ended March 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.365%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.225999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.225999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Estimated life (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.62</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.73</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized under ASC 718 related to the stock option plan is summarized as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">467</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total unrecognized compensation cost, related to non-vested stock options, which is expected to be recognized over a remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity incentive plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company established an equity incentive plan (the &#8220;Equity Incentive Plan&#8221;) for employees, directors, and consultants. The Equity Incentive Plan provides for the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,483,140</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> restricted share units, performance share units, restricted shares, deferred share units and other stock-based awards, subject to restricted conditions as may be determined by the Board of Directors. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such awards outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation was recognized for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331926048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Loss per share</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has generated a net loss for all periods presented, therefore diluted loss per share is the same as basic loss per share since the inclusion of potentially dilutive securities would have had an anti-dilutive effect. All currently outstanding options and warrants could potentially be dilutive in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential Common Shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">721,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">740,974</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2023 Common Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,536,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2018 public offering warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share is calculated based upon the weighted-average number of Common Shares outstanding during the period. Common Shares underlying the Pre-funded Warrants are included in the calculation of basic and diluted earnings per share.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329885328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Income taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax (benefit) expense:</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation between tax expense and the product of accounting income multiplied by the basic income tax rate for the years ended March 31, 2024 and 2023 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at Canadian Rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Difference in foreign tax rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible change in fair value of warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible transaction costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible goodwill impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-deductible items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-refundable federal investment tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State non income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in tax rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,263</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net deferred income tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, and 2023 were comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax losses carried forward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,659</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property, plant and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">905</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net federal investment tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,882</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,950</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other deductible temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred income tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other taxable temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,326</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,347</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years&#8217; taxable income, were as follows:</span></p><p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.552%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.302%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.062%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.082%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provincial</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax losses carried forward</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,651</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2031</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,794</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,484</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2033</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2034</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2035</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2036</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,470</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2037</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2038</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,856</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2039</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2040</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,576</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2041</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2042</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,416</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2043</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2044</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No expiry</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136,205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses, without time limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,887</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized tax benefits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect a significant change to the amount of unrecognized tax benefits over the next 12 months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter the timing or amount of taxable income or deductions, of the allocation of income among tax jurisdictions, and these adjustments could differ from the amount accrued. The Company&#8217;s federal and provincial income tax returns filed for all years remain subject to examination by the taxation authorities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government assistance</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government assistance is comprised of research and development investment tax credits receivable from the Quebec provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the years ended March 31, 2024 and 2023, the Company recorded ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, as a reduction of research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized Canadian federal investment tax credits may be used to reduce future Canadian federal income tax and expire as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.403%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2029</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2031</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2033</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2034</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2035</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2036</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2037</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">252</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2038</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2039</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2040</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2041</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2042</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2043</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2044</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331347872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and contingencies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development contracts and contract research organizations agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes contract manufacturing organizations (&#8220;CMOs&#8221;) for the development and production of clinical materials and contract research organizations (&#8220;CROs&#8221;) to perform services related to its clinical trials. Pursuant to the agreements with these CMOs and CROs, the Company has either the right to terminate the agreements without penalties or under certain penalty conditions. As of March 31, 2024, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commitments from CMOs and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of c</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ommitments for the next twelve months to CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raw krill oil supply contract</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 25, 2019, the Company signed a supply agreement with Aker BioMarine Antarctic AS. (&#8220;AKBM&#8221;) to purchase raw krill oil product for a committed volume of commercial starting material for CaPre, one of the Company&#8217;s former drug candidates, for a total fixed value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on the value of krill oil at that time. As of March 31, 2022, the remaining balance of commitment amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,800</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. During the second calendar quarter of 2022, AKBM informed the Company that AKBM believed it had satisfied the terms of the supply agreement as to their obligation to deliver the remaining balance of raw krill oil product, and that the Company was therefore required to accept the remaining product commitment. The Company disagreed with AKBM&#8217;s position and believed that AKBM was not entitled to further payment under the supply agreement. Accordingly, no liability was recorded by the Company. The dispute remained unresolved as of both March 31, 2023 and 2022. On October 18, 2023, the Company entered into an agreement with AKBM to settle any and all potential claims regarding amounts due under the supply agreement (&#8220;Settlement Agreement&#8221;). Pursuant to the terms of the Settlement Agreement, in exchange for a release and waiver of claims arising out of the supply agreement by AKBM and any of AKBM&#8217;s affiliates, the Company and AKBM agreed to the following: (a) AKBM retained ownership of all raw krill oil product, including amounts previously delivered to the Company, (b) AKBM acquired and took ownership of all production equipment related to the production of CaPre, (c) AKBM acquired and took ownership of all data from research, clinical trials and pre-clinical studies with respect to CaPre, and (d) AKBM acquired and took ownership over all rights, title and interest in and to all intellectual property rights, including all patents and trademarks, related to CaPre owned by the Company. Pursuant to the terms of the Settlement Agreement, AKBM acknowledged that the CaPre assets were transferred on an &#8220;as is&#8221; basis, and in connection therewith the Company disclaimed all representations and warranties in connection with the CaPre assets, including any representations with respect to performance or sufficiency. The value of the raw krill oil previously delivered to the Company, the production equipment, and the intellectual property rights related to CaPre were fully impaired in prior reporting periods and had a carrying value of nil as of March 31, 2023. As of March 31, 2024, no liability was recorded by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal proceedings and disputes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes. The Company assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, the Company records a liability in its consolidated financial statements. These legal contingencies may be adjusted to reflect any relevant developments. Where a loss is not probable or the amount of loss is not estimable, the Company does not accrue legal contingencies. While the outcome of legal proceedings is inherently uncertain, based on information currently available, management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to the Company&#8217;s financial position, results of operations, or cash flows.  </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reserves or liabilities have been accrued as at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329839728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Restructuring Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Restructuring Costs</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 8, 2023, the Company communicated its decision to terminate a substantial amount of its workforce as part of a plan that intended to align the Company&#8217;s organizational and management cost structure to prioritize resources to GTX-104, thereby reducing losses to improve cash flow and extend available cash resources. The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,485</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of costs primarily consisting of employee severance costs and legal fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874330229952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of presentation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). All intercompany transactions and balances are eliminated on consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates are based on management&#8217;s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions include the measurement of stock-based compensation, derivative warrant liabilities, accruals for research and development contracts and contract organization agreements, and valuation of intangibles and goodwill. Estimates and assumptions are also involved in determining the extent to which research and development expenses qualify for research and development tax credits. The Company recognizes tax credits once it has reasonable assurance that they will be realized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash equivalents</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents comprise of highly liquid investments purchased with original maturities of 90 days or less. Cash equivalents consist of guaranteed investment certificates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equipment</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation is recognized on a declining basis over the estimated useful lives of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not yet in service, from the date they are ready for their intended use.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets - acquired in-process research and development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible assets - acquired in-process research and development</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a business combination, the fair value of in-process research and development (&#8220;IPR&amp;D&#8221;) acquired is capitalized and accounted for as indefinite-lived intangible assets, and not amortized until the underlying project receives regulatory approval, at which point the intangible assets will be accounted for as definite-lived intangible assets and amortized over the remaining useful life or discontinued. If discontinued, the intangible asset will be written off. Research and development (&#8220;R&amp;D&#8221;) costs incurred after the acquisition are expensed as incurred.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method, which is a valuation methodology that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The significant assumptions used in the valuation are the discount rate, the probability of clinical success of research and development programs, obtaining regulatory approval and forecasted net sales, including milestone payments and royalty revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews the recoverability of its finite long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not be recoverable. The carrying amount is first compared with the undiscounted cash flows. If the carrying amount is higher than the sum of undiscounted cash flows, then the Company determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the difference by which the carrying amount of the asset group exceeds the estimated fair value of the asset group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeds the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than it's carrying amount, a quantitative impairment test is performed.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's annual impairment test is performed in the fourth quarter of the fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development costs</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and developments expenditures are expensed as incurred. These costs consist of employees&#8217; salaries and benefits related to research and development activities, contractors and consultants that conduct the Company&#8217;s clinical trials, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based compensation</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has in place a stock option plan for directors, officers, employees, and consultants of the Company, with grants under the stock option plan approved by the Company&#8217;s Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant.  The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company measures the cost of such awards based on the fair value of the award at grant date and recognizes stock-based compensation expense in the Consolidated Statements of Operations and Comprehensive Loss on a tranche by tranche basis. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including fair value of the Common Shares at the grant date, expected term, historical volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior in determining compensation expense. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may be required in future periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_GovernmentGrantsPolicyTextBlock', window );">Government grants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government grants</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic environment. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company&#8217;s lease expense is recognized in research and development expenses. The Company does not have financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with FASB ASC 842&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;Topic 842&#8221;), components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income taxes</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes comprises current and deferred taxes. The provision for income taxes is computed using the asset and liability method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realized (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Company has the right to set off the amount owed by with the amount owed by the other party, the Company intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses, and tax credits, reduced by a valuation allowance. A valuation allowance is recorded to reduce the carrying amount of deferred income tax assets when it is more likely than not that these assets will not be realized.  tax benefits related to tax positions not deemed to meet the &#8220;more-likely-than-not&#8221; threshold are not permitted to be recognized in the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earning per share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings per share</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company presents basic and diluted earnings per share ("EPS") data for its Common Shares. Basic EPS is calculated by dividing the net income or loss attributable to the holders of Common Shares by the weighted average number of Common Shares outstanding during the year. Diluted EPS is determined by adjusting the net income or loss attributable to the holders of Common Shares and the weighted average number of Common Shares outstanding adjusted for the effects of all dilutive potential </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Shares, which comprise warrants and share options granted to employees. The basic and diluted EPS are the same due to loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment reporting</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable operating segment: the development and commercialization of pharmaceutical applications of its patent portfolio and licensed rights. The majority of the Company&#8217;s assets are located in Canada and the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative warrant liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative warrant liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative warrant liabilities are recognized initially at fair value. Subsequent to initial recognition, derivative warrant liabilities are measured at fair value, with changes in fair value are recognized in the Consolidated Statement of Operations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value measurements</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of the Company&#8217;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below:</span></p><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: defined as observable inputs such as quoted prices in active markets.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions.</span></div></div><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Financial Instruments</a></td>
<td class="text"><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are all invested in accordance with the Company&#8217;s Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which risk is managed by dealing only with highly rated Canadian and U.S. institutions. The Company maintains its cash and cash equivalents at accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent accounting pronouncements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the consolidated financial statements as a result of future adoption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accounting policy for government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329646000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.203%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.435%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.477%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.056%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.435%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.479%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quoted prices in active markets (Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Guaranteed investment certificates and term deposits<br/>&#160;&#160;&#160;classified as cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,725</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Derivative warrant liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets measured at fair value on a recurring basis as of March 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.058%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.405%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.323%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.024%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.405%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.541%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quoted prices in active markets (Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Term deposits classified as cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,072</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,072</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Guaranteed investment certificate classified as a<br/>&#160;&#160;&#160;short-term investment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338171392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales tax receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government assistance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337856448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Reclassification from held for sale to equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of equipment, net:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated<br/>depreciation</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Write-off</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net book<br/>value</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">608</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated<br/>depreciation</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Write-off</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net book<br/>value</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">512</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">570</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337491552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Schedule of Intangible Assets in Process Research and Development</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of the reporting unit was determined using the projected discounted cash flow model. The impairment assessments resulted in the following activity during the years ended March 31, 2024 and 2023: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.52%;"></td>
        <td style="width:8.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.34%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-104</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-102</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GTX-101</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intangible assets &#8211; in-process research and development</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">41,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">9,196</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">41,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impairment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,682</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the intangible assets resulted in a recovery of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,633</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the related deferred tax liability.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.68%;"></td>
        <td style="width:11.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:25.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Goodwill</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,964</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331306976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities and other payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee salaries and benefits payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">501</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,148</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total trade and other payables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329568144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_SupplementalBalanceSheetInformationTableTextblock', window );">Supplemental balance sheet information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental balance sheet information related to leases was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.914%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.662%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">463</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, long-term</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_LeaseExpenseTableTextblock', window );">Supplemental lease expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental lease expense related to leases is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.792%;"></td>
        <td style="width:1.939%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.916%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.939%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.416%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs Recognized for Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the year ended March 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.235%;"></td>
        <td style="width:6.564%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.202%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows for operating lease</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_35eb60b8-303d-4e25-9601-0886d5998462;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_LeaseExpenseTableTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expense [Table TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_LeaseExpenseTableTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SupplementalBalanceSheetInformationTableTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information [Table TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SupplementalBalanceSheetInformationTableTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331834384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:</span></p><p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.093%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.063%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued during the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,728</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrant liability was determined based on the fair value of warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) five years from the date on issuance.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.806%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.558%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.558%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 25, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected warrant life</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329733968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes information about activities within the Stock Option Plan for the year ended March 31, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.658%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of<br/>options</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average<br/>exercise price</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining Contractual Term (years)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aggregate Intrinsic Value (in thousands)</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">740,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.19</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">607,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">614,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.89</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">721,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.08</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">312,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.84</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized under ASC 718 related to the stock option plan is summarized as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of awards for options granted during the years ended March 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.365%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.225999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.225999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share price</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Estimated life (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.62</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.73</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874440080016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule Of Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded the following potential Common Shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">721,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">740,974</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 2023 Common Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,536,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2018 public offering warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874333754464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income tax (recovery) expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax (benefit) expense:</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation between tax expense and the product of accounting income multiplied by the basic income tax rate for the years ended March 31, 2024 and 2023 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at Canadian Rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,891</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,772</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Difference in foreign tax rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">242</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible change in fair value of warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible transaction costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-deductible goodwill impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-deductible items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-refundable federal investment tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State non income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in tax rates</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,263</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total tax (benefit) expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net deferred income tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, and 2023 were comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax losses carried forward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,659</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property, plant and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">905</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net federal investment tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,882</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,950</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other deductible temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred income tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,198</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other taxable temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,326</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,347</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of Tax Credit Carryforwards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years&#8217; taxable income, were as follows:</span></p><p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.552%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.302%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.062%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.082%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provincial</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax losses carried forward</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">571</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,651</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2031</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,794</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,484</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2033</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2034</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2035</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2036</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,470</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,371</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2037</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2038</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,856</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2039</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2040</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,576</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2041</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2042</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,416</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2043</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,568</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2044</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No expiry</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136,205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses, without time limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,887</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrecognized Canadian federal investment tax credits may be used to reduce future Canadian federal income tax and expire as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.403%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2029</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2031</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2033</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2034</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2035</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2036</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2037</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">252</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2038</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2039</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2040</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2041</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;2042</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2043</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">614</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2044</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ScheduleOfGovernmentAssistanceTableTextBlock', window );">Schedule of Government Assistance [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the years ended March 31, 2024 and 2023, the Company recorded ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, as a reduction of research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.463%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2024</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2023</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">412</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ScheduleOfGovernmentAssistanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ScheduleOfGovernmentAssistanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874439781344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Nature of Operation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 24, 2023</div></th>
<th class="th"><div>Jun. 29, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">1,951,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">7,435,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_PurchaseOfPreFundedWarrants', window );">Purchase of pre funded warrants</a></td>
<td class="nump">2,106,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_PurchasePricePerCommonShare', window );">Purchase Price per common share</a></td>
<td class="nump">$ 1.8481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_PurchaseOfCommonShares', window );">purchase of common shares</a></td>
<td class="nump">2,536,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=acst_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PurchaseOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>purchase of common shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PurchaseOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PurchaseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of pre funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PurchaseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PurchasePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price per common share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PurchasePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=acst_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=acst_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329649920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>Vote</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331373104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Fair Value Measurements (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques', window );">Changes in valuation techniques</a></td>
<td class="text">0<span></span>
</td>
<td class="text">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the valuation techniques or other methods used to estimate the fair value of assets obtained or liabilities incurred in transfers of financial assets accounted for as sales. If a valuation model is used, the description would be expected to include quantitative and qualitative information about the assumptions used in the valuation model (for example, but not limited to, discount rates, anticipated credit losses, and prepayment speeds).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338282464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_GuaranteedInvestmentCertificatesAndTermDeposits', window );">Guaranteed investment certificates and term deposits classified as cash equivalents</a></td>
<td class="nump">$ 19,725<span></span>
</td>
<td class="nump">$ 10,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Guaranteed investment certificate classified as a short-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">19,725<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_GuaranteedInvestmentCertificatesAndTermDeposits', window );">Guaranteed investment certificates and term deposits classified as cash equivalents</a></td>
<td class="nump">19,725<span></span>
</td>
<td class="nump">10,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Guaranteed investment certificate classified as a short-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">19,725<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_GuaranteedInvestmentCertificatesAndTermDeposits', window );">Guaranteed investment certificates and term deposits classified as cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Guaranteed investment certificate classified as a short-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_GuaranteedInvestmentCertificatesAndTermDeposits', window );">Guaranteed investment certificates and term deposits classified as cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Guaranteed investment certificate classified as a short-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 4,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_GuaranteedInvestmentCertificatesAndTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranteed investment certificates and term deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_GuaranteedInvestmentCertificatesAndTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874336944816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Receivables - Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_SalesTaxReceivablesCurrent', window );">Sales tax receivables</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_GrantsAndInvestmentTaxCreditReceivable', window );">Government assistance</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_GrantsAndInvestmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GrantsAndInvestmentTaxCreditReceivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_GrantsAndInvestmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SalesTaxReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of sales taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SalesTaxReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329651744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 12,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874535686528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Acquisition of Grace (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (12,853)<span></span>
</td>
<td class="num">$ (42,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 12,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337501184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Equipment - Schedule of equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(608)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_WriteOff', window );">Write off</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_WriteOff', window );">Write off</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_WriteOff', window );">Write off</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(519)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_WriteOff', window );">Write off</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_SoftwareMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_WriteOff', window );">Write off</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331380704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Equipment - Schedule of equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874439800576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible assets and Goodwill (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 12,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">28,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentRelatedDeferredTaxLiability', window );">Impairment Related Deferred Tax Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of The Intangible Assets Indefinite Lived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentRelatedDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Related Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentRelatedDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338218208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible assets and Goodwill- Schedule of Intangible Assets in Process Research and Development (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Beginning Balance</a></td>
<td class="nump">$ 41,128<span></span>
</td>
<td class="nump">$ 69,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Ending Balance</a></td>
<td class="nump">41,128<span></span>
</td>
<td class="nump">41,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx104Member', window );">GTX 104 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Beginning Balance</a></td>
<td class="nump">27,595<span></span>
</td>
<td class="nump">27,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Ending Balance</a></td>
<td class="nump">27,595<span></span>
</td>
<td class="nump">27,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx102Member', window );">GTX 102 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Beginning Balance</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="nump">31,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Ending Balance</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="nump">9,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx101Member', window );">GTX 101 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Beginning Balance</a></td>
<td class="nump">4,337<span></span>
</td>
<td class="nump">10,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net, Ending Balance</a></td>
<td class="nump">$ 4,337<span></span>
</td>
<td class="nump">$ 4,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of The Intangible Assets Indefinite Lived</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx102Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx102Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acst_Gtx101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329675776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible assets and Goodwill - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of the year</a></td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 12,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ImpairmentOfGoodwill1', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of the year</a></td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 8,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ImpairmentOfGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Goodwill 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ImpairmentOfGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337733744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Trade and Other Payables - Trade and Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">$ 1,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other payables</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee salaries and benefits payable</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total trade and other payables</a></td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">$ 3,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331585216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Leases - Supplemental balance sheet information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329735536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Leases - Supplemental lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating cash flows for operating lease</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total lease expense</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329660096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Leases - Schedule of Lease Costs Recognized for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating cash flows for operating lease</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331332992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Leases (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Extension of lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In March 2022, the Company renewed the lease agreement effective April 1, 2022, resulting in a commitment of $556 over a 24-month base lease term with an option to renew for an additional 48-month term. In April 2023, the Company elected not to renew the additional 48-month option to renew, and terminated the lease on March 31, 2024.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional lease renewal term</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874430396496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Shareholder's Equity - Schedule Of Derivative Liabilities At Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance &#8211; beginning of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issued during the Year</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 2,728<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance &#8211; end of year</a></td>
<td class="nump">$ 4,359<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338116528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Shareholders' Equity - Fair Value Measurement Inputs and Valuation Techniques (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative warrant liability, measurement input</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative warrant liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative warrant liability, measurement input</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative warrant liability, measurement input</a></td>
<td class="nump">203.00<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative warrant liability, measurement input</a></td>
<td class="nump">8,594<span></span>
</td>
<td class="nump">8,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874333562944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Shareholders' Equity (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 24, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">7,435,533<span></span>
</td>
<td class="nump">1,951,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_AtthemarketSalesAgreementCommonStockMaximumAmount', window );">At-the-market Sales Agreement, Common Stock, Maximum Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales', window );">At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">7,435,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acst_WarrantsIssuedInMay2018Member', window );">Warrants Issued in May 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acst_AtTheMarketOfferingMember', window );">At-the-market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from shares issued under the at-the-market (ATM) program (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Other Selling, General and Administrative Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_SaleOfStockAveragePricePerShare', window );">Sale of Stock, Average Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_PaymentOfIssuanceCostsCommonWarrants', window );">Payment Of Issuance Costs Common Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ProceedsFromCommonShares', window );">Proceeds from Common Shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536,391<span></span>
</td>
<td class="nump">2,536,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 3.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.003<span></span>
</td>
<td class="nump">$ 3.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acst_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_PaymentOfIssuanceCostsCommonWarrants', window );">Payment Of Issuance Costs Common Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ProceedsFromCommonShares', window );">Proceeds from Common Shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_StockIssuedSharesWarrantsExercisableShares', window );">Stock Issued Shares Warrants Exercisable Shares</a></td>
<td class="nump">2,106,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106,853<span></span>
</td>
<td class="nump">2,106,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acst_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_StockIssuedSharesWarrantsExercisableShares', window );">Stock Issued Shares Warrants Exercisable Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,643,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acst_CommonWarrantAndPreFundedWarrantMember', window );">Common Warrant and Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_StockIssuedSharesWarrantsExercisableShares', window );">Stock Issued Shares Warrants Exercisable Shares</a></td>
<td class="nump">2,536,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="nump">$ 1.848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from shares issued under the at-the-market (ATM) program (Shares)</a></td>
<td class="nump">1,951,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockVotesPerShare', window );">Common Stock, Votes Per Share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="nump">9,399,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockVotesPerShare', window );">Common Stock, Votes Per Share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockDividendRatePercentage', window );">Common Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockRedemptionPricePerShare', window );">Common Stock, Redemption Price Per Share (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockDividendRatePercentage', window );">Common Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockRedemptionPricePerShare', window );">Common Stock, Redemption Price Per Share (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acst_CommonClassDAndCommonClassEMember', window );">Common Class D and Common Class E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acst_CommonClassDAndCommonClassEMember', window );">Common Class D and Common Class E [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockDividendRatePercentage', window );">Common Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acst_CommonClassDAndCommonClassEMember', window );">Common Class D and Common Class E [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_CommonStockDividendRatePercentage', window );">Common Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AtthemarketSalesAgreementCommonStockMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common stock that can be sold under the at-the-market sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AtthemarketSalesAgreementCommonStockMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of each sale that is to be paid to the underwriter under the at-the-market sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_CommonStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_CommonStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_CommonStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share at which the common stock of an entity is redeemed or may be called at.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_CommonStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_CommonStockVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes per one share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_CommonStockVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PaymentOfIssuanceCostsCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Issuance Costs Common Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PaymentOfIssuanceCostsCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SaleOfStockAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average price per share received by entity for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SaleOfStockAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StockIssuedSharesWarrantsExercisableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued shares warrants exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StockIssuedSharesWarrantsExercisableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acst_WarrantsIssuedInMay2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acst_WarrantsIssuedInMay2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acst_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acst_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acst_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acst_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acst_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acst_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acst_CommonWarrantAndPreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acst_CommonWarrantAndPreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acst_CommonClassDAndCommonClassEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acst_CommonClassDAndCommonClassEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338272608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2023</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions', window );">Unrecognized compensation cost, related to non-vested share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of options (in shares)</a></td>
<td class="nump">161,168<span></span>
</td>
<td class="nump">446,502<span></span>
</td>
<td class="nump">607,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_StockOptionsExercisePricePerShare', window );">Stock options exercise price</a></td>
<td class="nump">$ 2.125<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_StockOptionPlanMember', window );">Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock available under the plan for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_StockOptionPlanMember', window );">Stock Option Plan [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_StockOptionPlanMember', window );">Stock Option Plan [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_EquityIncentivePlanMember', window );">Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IssuanceOfRestrictedShareUnit', window );">Issuance of restricted share unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssuanceOfRestrictedShareUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Restricted Share Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssuanceOfRestrictedShareUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued to one person in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StockOptionsExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StockOptionsExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation cost related to non-vested share options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acst_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acst_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=acst_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=acst_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acst_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acst_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874336750976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Activities Within the Stock Option Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2023</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">161,168<span></span>
</td>
<td class="nump">446,502<span></span>
</td>
<td class="nump">607,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited/Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,793<span></span>
</td>
<td class="nump">740,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted averageexercise price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.68<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding Remaining Contractual Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 29 days<span></span>
</td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable Remaining Contractual Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">$ 8,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338227376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock Based Compensation - Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_StockOptionPlanMember', window );">Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acst_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acst_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874439599600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10- Stock-based compensation - Schedule of weighted average grant date fair value of awards for options granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_SharesPrice', window );">Share price</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Estimated life (years)</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">117.94%<span></span>
</td>
<td class="nump">117.56%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337902048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options outstanding</a></td>
<td class="nump">721,793<span></span>
</td>
<td class="nump">740,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_September2023CommonWarrantsMember', window );">September 2023 Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Offering warrants (in shares)</a></td>
<td class="nump">2,536,391<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acst_May2018PublicOfferingWarrantsMember', window );">May 2018 public offering warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems', window );"><strong>Impairment Effects on Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Offering warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">137,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acst_September2023CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acst_September2023CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acst_May2018PublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acst_May2018PublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338276208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Income taxes - Income Tax (Recovery) Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IncomeTaxRecoveryExpenseAbstract', window );"><strong>Income tax (recovery) expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax (benefit) expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax (benefit) expense</a></td>
<td class="num">(1,834)<span></span>
</td>
<td class="num">(9,542)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax (benefit) expense</a></td>
<td class="num">$ (1,832)<span></span>
</td>
<td class="num">$ (9,542)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncomeTaxRecoveryExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax (recovery) expense:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncomeTaxRecoveryExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874328279472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (14,685)<span></span>
</td>
<td class="num">$ (51,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at Canadian Rate</a></td>
<td class="num">(3,891)<span></span>
</td>
<td class="num">(13,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Difference in foreign tax rates</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(1,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible stock-based compensation</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IncomeTaxReconciliationNondeductibleChangeInFairValue', window );">Non-deductible change in fair value of warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts', window );">Non-deductible transaction costs</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Non-deductible goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other non-deductible items</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NonRefundableFederalItc', window );">Non-refundable federal investment tax credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_StateNonIncomeTaxes', window );">State non income taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ChangeInTaxRates', window );">Change in tax rates</a></td>
<td class="num">(486)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences', window );">Change in valuation allowance</a></td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">4,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax (benefit) expense</a></td>
<td class="num">$ (1,832)<span></span>
</td>
<td class="num">$ (9,542)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ChangeInTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Tax Rates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ChangeInTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncomeTaxReconciliationNondeductibleChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncomeTaxReconciliationNondeductibleChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NonRefundableFederalItc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Federal ITC</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NonRefundableFederalItc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StateNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State Non Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StateNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874430284272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Income Taxes - Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax losses carried forward</a></td>
<td class="nump">$ 40,659<span></span>
</td>
<td class="nump">$ 38,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_DeferredTaxAssetsResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability', window );">Operating lease right of use liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_DeferredTaxAssetsFinancingExpenses', window );">Financing expenses</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_NetFederalInvestmentTaxCredits', window );">Net federal investment tax credits</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deductible temporary differences</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Total deferred income tax assets</a></td>
<td class="nump">53,139<span></span>
</td>
<td class="nump">51,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(47,284)<span></span>
</td>
<td class="num">(46,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(11,369)<span></span>
</td>
<td class="num">(12,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_DeferredTaxAssetsOperatingLeaseAsset', window );">Operating lease asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Other taxable temporary differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(11,369)<span></span>
</td>
<td class="num">(12,326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (5,514)<span></span>
</td>
<td class="num">$ (7,347)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DeferredTaxAssetsFinancingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to financing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DeferredTaxAssetsFinancingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DeferredTaxAssetsOperatingLeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DeferredTaxAssetsOperatingLeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Right Of Use Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DeferredTaxAssetsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DeferredTaxAssetsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NetFederalInvestmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Federal Investment Tax Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NetFederalInvestmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874336789872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">$ 3,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2029Member', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2030Member', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2031Member', window );">2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2032Member', window );">2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2033Member', window );">2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2034Member', window );">2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2035Member', window );">2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2036Member', window );">2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2037Member', window );">2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2038Member', window );">2038</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2039Member', window );">2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2040Member', window );">2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2041Member', window );">2041</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2042Member', window );">2042</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2044Member', window );">2044</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">137,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards', window );">Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards</a></td>
<td class="nump">3,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_TaxCreditCarryforwardNotSubjectToTimeLimitation', window );">Research and development expenses, without time limitation</a></td>
<td class="nump">25,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">2,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">3,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">4,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">6,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2038</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">14,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">32,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">23,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2041</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">13,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2042</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">9,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | 2044</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">7,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">136,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards', window );">Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_TaxCreditCarryforwardNotSubjectToTimeLimitation', window );">Research and development expenses, without time limitation</a></td>
<td class="nump">27,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">2,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">3,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">4,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">6,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2038</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">13,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">32,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">23,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2041</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">13,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2042</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">9,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">11,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial | 2044</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">7,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">15,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States [Member] | No Expiry</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax losses carried forward</a></td>
<td class="nump">$ 15,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Scientific Research &amp; Experimental Development Expenditures Investment Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_TaxCreditCarryforwardNotSubjectToTimeLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, not subject to time limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_TaxCreditCarryforwardNotSubjectToTimeLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_Taxyear2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_Taxyear2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_NoExpiryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_NoExpiryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874331303536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Income Taxes - Government Assistance - Government Assistance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_InvestmentTaxCreditReceivable', window );">Investment tax credit</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_InvestmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment tax credit receivable as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_InvestmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874455014080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Income Taxes - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 3,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2029Member', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2030Member', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2031Member', window );">2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2032Member', window );">2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2033Member', window );">2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2034Member', window );">2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2035Member', window );">2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2036Member', window );">2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2037Member', window );">2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2038Member', window );">2038</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2039Member', window );">2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2040Member', window );">2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2041Member', window );">2041</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2042Member', window );">2042</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYearTwoThousandFortyThreeMember', window );">2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=acst_TaxYear2044Member', window );">2044</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYearTwoThousandFortyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYearTwoThousandFortyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acst_TaxYear2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acst_TaxYear2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337698080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Income Taxes - Government Assistance - (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 4,683<span></span>
</td>
<td class="nump">$ 9,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Statements of Operations and Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874338111904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Oct. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities', window );">Reserves or liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsToCompleteContractsInProcess', window );">Commitments</a></td>
<td class="text">no<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=acst_RKOSupplyAgreementMember', window );">RKO Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase Commitment, Remaining Minimum Amount Committed</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember', window );">Research and development contracts and contract research organizations agreements [Member] | Contract Research Organizations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="nump">$ 6,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsToCompleteContractsInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General description of commitments which may be required in performing under a construction-type contract which are outside the ordinary course of business at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsToCompleteContractsInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from estimated policyholder reserves, which will be deductible from future taxable income when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the tax deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=acst_RKOSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=acst_RKOSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_ContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acst_ContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874442233952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Restructuring Costs (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 08, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Severance costs incurred</a></td>
<td class="nump">$ 1,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874337230528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held for Sale (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract', window );"><strong>Asset, Held-for-Sale, Not Part of Disposal Group [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139874329742832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Additional Information) (Details Textual) - At-the-market Offering [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from shares issued under the at-the-market (ATM) program (Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acst_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acst_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acst_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^5A9Y."P =*$#3]!/T%U6:"52$Z0-@VYIM.6PKI,#"!MZ KZ^>J&"LWOIJ<
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MHOXH4M\HOJF^*]QQI7A17:ZI;IZ%$=#O5YRKYQOSJ>+P:6K^+U!+ P04
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MYHQF3%D#>+Z0TNQO[ OJKT;3_P!02P,$%     @ S3O56"%6RS+1!0  M2
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M1ZT%^./9<X/1-F_ZCM5USJ"M2Q,$K6BA5K3H=8^T^3@4\'"X@K\D9X-J?1U
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M'('8&<"?(0EU5V62QRIS"U2*7O=-]TC')*K86%BEC(.U!5QIR)"ZV$[4"K6
MZ'+12(2T]%839"&LQ,IH2\/ER"V@K?9P7.'=M0%W(Z2#/4+'K@AT(](#^O&Q
M0-WRR.>@F8KR;S:6;.$[(! IAE:+ <ENW.WLW9A\DSJ]NR;":FAII<P7&V0Z
M\+'=2S5B<-4%_!3ZL H2:[U52S(?N]YM)II47@2R&A"D7B7.D<R$G*0R=@73
M=*B',><_H,E]C--NPYV8;K24T2X$PC@5:80,[-2##F4I911X=*-6Z*QC(CB_
M*^D]U6X-*DQDO1)X\4/#%?MGFMO&"$Q].AH[ULXR['  '[K^;,03ZG2'5.N3
M&/_1_QB]K/"Y8UT0CGL+/]XG<$M^HY])EHK=5XNBBV;&((?63B+05$@[PC<A
M,I'>QE<L'ZEX2GHEA.PB,QCGUGJ=>(".K]$3K.5()):N)SP4_YF3.0>IOA#_
M*,-EO4 +])M]L29;5=L$_WXSQQ!XH(#1/_D*L>$#JC.RZ(X+(BVO@7D3<M8,
M+!;6:'S^TBG-EI(OV;K?G*6MTKTBV7)L"DA/S1> 2'7&ZB.C^%,%'/?,I'[^
M^,?Q;'H&90] GV5$GL]%?OH\PXS"]"R($[@]=O!4BU$-Z6K</<N( L0NHM\B
MCY:EE"]DY J$ ]],F"_281&=7#E@ ,U1Z_#[QC8)714Z-<<B#8!JR+VQ+8[>
MV%#*6J%'- Q7@+BIES!F?G:H:9#3Q).DNZ1:BBJ2%0T,3M"(;<*(G%&8T&I2
MCP-_MEVV@#[114%>2;"[-IC8 I3X.2 EZ./"F,2J>TR3FA$;^RI+A!?Y..FR
MR#&WMDX%^%OU='*.MA, ,,PMA(BA(ZY6)D.QS]&[[7#L<A,2D2[X ,-@V9IG
M(KBSR??GL\GBZ6R_E9E +S05[,]*=:-#T&3-1S3AZ/WNR>_YR=%C&CBXKFND
MBMPY:CZ939],GITO[AXE+ 48Z9T$>*603=^JV<FSLV<S:8['^WK7)SOIB=Q:
MW]$V[QDTS=VO!V,3ZQD_1AVP*D'FZ&\:>;YX,EE\?\>?^T$19G?D#>#/Y*++
MPL#S'$K) )NA:;T/$V;#T$:TP<I(DVD:XOHZ)K:)PHN[RRDA)W^*]ZYW$<)U
MDIMD,W%OGBVD#Q+1:X/4E-XASWLJ5[H[YBY1]4$I4:AG:$"D<@EG\8-!6PLB
M-^)V81>4SMBQ[Y "+Q:Y<IQ$PVRU5_-RHB&CO<B&R!+U[TL'=DAM,=C@R;Z"
M<EZ@"OO\U)O<'RYLJCE3["J?DS@MS=:+=IPD0(3[\DMOV-:UN<A27O)=RYJ
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MM^,_MX8PV.,!NK]V!#3Q!S;(_W<$;_X'4$L#!!0    ( ,T[U5BVW[ZVT0,
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M9-+H.&J3Y3(11PE\1#H&=/)]+<0G*NH&8<T-Z29%3BXU:&.ISH.ED_&,7!M
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MVH#O2X=+7_]""G9__+C[+U!+ P04    " #-.]585*S]27X"  "I!0  &0
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MF'CLEPT$.DYIKR\K7%5.\G$F%^N, K9C/E40ZJXVYN+)6:/)7Q27YT-O$UT
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M%>G@ '^PW!M6?IQ?O7JD816]Q,03X*?V:;VJ(<ZWVB"L*)K:D05;:BXTD3K
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M9P9>![UI$!P_,-HD&(XGMN3:V:?,6EAM81EI4_3:@/$ 4,V36X>T'FU6"MH
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MON1"K 8^*WC/)9,99P)VEEFD'K,&_GY,C=74)?^\%'O'/'^9V4W.@ZE9AJN
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M!Z#WA:)AZA?.P?C-LOX/4$L#!!0    ( ,T[U5A:,Y.Z?0@  .$4   9
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)U876_;.!9]]Z\@/$71 FIL4=]I
M$J!-ISL%=CJ=MC.+Q6(?:(FVV4JB*])QLK]^SR4E6TGM3#$/EBR*O+P?YYY[
MJ8N=[KZ:M926W39U:RZG:VLWY[.9*=>R$>9,;V2+-TO=-<+BL5O-S*:3HG*+
MFGK&Y_-TU@C53J\NW-B'[NI";VVM6OFA8V;;-**[>RUKO;N<AM-AX*-:K2T-
MS*XN-F(E/TG[Q^9#AZ?97DJE&MD:I5O6R>7E]%5X_CJF^6["GTKNS.@_(TL6
M6G^EAW?5Y71."LE:EI8D"-QNY+6L:Q($-;[U,J?[+6GA^/\@_:VS';8LA)'7
MNOZ7JNSZ<II/62678EO;CWKWB^SM24A>J6OCKFSGY\;8L=P:JYM^,9X;U?J[
MN.W],%J0ST\LX/T"[O3V&SDMWP@KKBXZO6,=S88T^N-,=:NAG&HI*)]LA[<*
MZ^S5>VTE"SE[P=ZUI6XD^RQNI;F86<BF&;.RE_/:R^$GY$#$K[JU:\-^;BM9
MW1<P@U)[S?B@V6O^J,1?17?&HC!@?,[C1^1%>TLC)R]ZQ%+#/FOV5K6B+96H
MV2<KK 3"K&'_>;4PM@-&_GO,=B\Y/BZ9\N;<;$0I+Z=(#".[&SF]>OI3F,Y?
M/J)WO-<[?DSZ51\7>RHNCZX^KEO(S]A8[.B!/5O(5BZ5?<[D+3+?R//)OZ7H
MF*2P,@2E7.^CPDZ]B29/V)/)];;KX-SC8AEG3W_*><A?3M[(I<3,ZL3$9RP,
M\BAFS_&O")*8L^>3QQ3N%_#Q O8*#%)JA+U6PM'!0MJ=E*T3,2P4+7182[;I
M=+4M+=-+L$:IMZU5[8HIOV>#?%>;6D'?Q9V;#E90Y?":Y'6 %0-ANK=W\)$Y
M[C[:C[S%E&'"8$4-CC1_W^'(728LNQ:MJ)1HV4?2XQF+@KP(G3?"*,@R\M\;
MM83/95M*Z$VJ@KW:O>X&4[/,KPBB,,&"][I]@5WA%;6H)0,OE5]?$!U6#&:3
M^[Q;.;P=Y_.'\\NU:%=^+Z$Z=B/JK23W[D37"<J_B/3\?A^D)"1[ B^UP<0,
M[AJ \V#R2NMJI^J:J6:#72BQAZFP(TZBR6\(2,?:^\L4., P6#D6B]JP;2M!
M[Y>RDAW80K4WTMAF0'0)Q*K#!L]8ZI#I.(6V& $"#@WWTJ_WKAB[.\Y3^/O[
M.>0I[UE!X! 4L3!(HX3% 4\'B\A[6#_YK"T4_?&L>(^J7PW9-P*P,$9:ATG$
MZ#X$@P-J=T"0BWZG" >82GCW*$;"G$\>@/<(8M^<W-R!N=;X;U@)E%"^ :<
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MYV=9,O5=]?!@]<9]Q%IH:W7C_JZE@#]I MXOM;;# VVP_ZIY]7]02P,$%
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M/AD0.HT"TB*#LDSQ+45(U&IMCQF\>C$MB[?O H@LH54_,(YZS"'W:M"*K(B
ML/ ,#$^E443JO')>+OL'B;0$UPN!$,]___CE=3&N4IF>ECNQ-GT=NZ%="(./
M,IUW&X(:0PLKD;64CAXC3\ -*HU+O3<?P$?P\:AQRM:]%VAX"<5%-;V,1=>I
MW4),U%'IV%R1OL QMUC)=-KMB"#0ACQ::=@0$'-K6DO1*XII3CVR_$@@#/EU
MDL$@ '(1@U8<3@]*>ST(S'_N@TS+/*Z5#9)R):'CT=O+#/P@?<.&79?D9NE8
MQ"LM6_E:D(\.8E\YD9S])B8X?'\6_P)02P,$%     @ S3O56# [-G"F%@
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MO[FYP@)^X[^,WOOL[P)'65K["1\^5*_.KH"1KG79 H2B?^[U6UW7@$1X? Y
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M()_R9.9W0LYVH]I"K59DAQD)0LLZ9N4V"0B]KUL2B]JHI:E-RS)"W+5;O6"
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MJY2N$K&S*%"^M+5='\3P@.&FXL O(9I,WT#<Z04A;)9?N$_TF9Q":RA)52'
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MK-9N^<^-)H_F\ )]O[)D%<,';)!^=>GU_P%02P,$%     @ S3O56+$ (2-
M P  T @  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULU5;;;A,Q$'W/
M5XP6A*@4NI<DM)0D4L-=HJBT!1X0#\[N;-:JUUYL;P)_S]A[:5JE <$32A3?
M9L[,F1E[,MTH?6T*1 L_2B'-+"BLK4["T*0%ELP<J@HEG>1*E\S24J]"4VED
MF5<J19A$T=.P9%P&\ZG?.]?SJ:JMX!+/-9BZ+)G^N4"A-K,@#KJ-"[XJK-L(
MY].*K? 2[:?J7-,J[%$R7J(T7$G0F,^"T_AD,7;R7N SQXW9FH-CLE3JVBW>
M9;,@<@ZAP-0Z!$;#&E^@$ Z(W/C>8@:]2:>X/>_07WONQ&7)#+Y0X@O/;#$+
MC@/(,&>UL!=J\Q9;/A.'ERIA_"]L6MDH@+0V5I6M,GE0<MF,[$<;AS]12%J%
MQ/O=&/)>OF26S:=:;4 [:4)S$T_5:Y-S7+JD7%I-IYST[/R#L@@C> *O&=?P
MF8D:X0R9J352Z*V!QU=L*= <3$-+YIQ2F+;0BP8ZN0<Z3N!,25L8>"4SS&X#
MA.1G[VS2.;M(]B*>,7T(HW@(292,]^"->O(CCS>Z!^^&\Q!.C4&BRV0&[SE;
M<L$M1]/%(@.JH M,:ZVY7'FI#TKJ?F/!##?P]71IK*9"^[8K6HTOX]V^N,MW
M8BJ6XBR@VV50KS&8/WH0/XV>[V$Z[IF.]Z'/+^DR9[5 4#G\-6M/<A>SO;9W
M,]LR++8,EYUA9B%W?JY]1;KK"S?17OIH,^/84$VD15\4P#2Z@UP)>F[,R>!*
M62;@8TUEGD&E>4I&>/<8T$72U\Z-Q^]QC0+B [CD*\ESGC)I0=D"-:BE<]E=
M E*LZAOIY+9T+>^5'!T,'H+_#!K>@S<UTZ2$Y!27:S36739(45L/9[$)C45=
MTAM3*<,)+7XV/$HFW?#HP7$2)\^[L67*FKCN%]U*]> E:KYF/AH;IIU3MQ(R
M'HXFS^X"-+NMQ3^4[DKM'S,\^E\R?'4K=:F@Q!".XTTK9@K [S4%7OA'-HZ&
MT5'2#7?3]=MBN0//()ZX[_X*(5O'1]UP-V6[GIQPJ\N4J%>^EQ(954O;-)Q^
MMV_7ITV7NA%O>CVE=,6E 8$YJ4:'1Y, =-,_FX55E>]92V6I _II07\Y4#L!
M.L\5I;M=. /]GYCY+U!+ P04    " #-.]58N)HH49@"  "E!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6Q]5$UOVS ,O>=7$&Y1;$!7VW*29FUB
M(.G6K<"Z%4VV'8H=%)N)A<J2)RD?^_>3Y,1U@3072Y3)Q_=$D<.-5,^Z0#2P
M+;G0HZ PIKH*0YT56%)](2L4]L]"JI(::ZIEJ"N%-/=!)0])%/7#DC(1I$-_
M]J#2H5P9S@0^*-"KLJ3JWP2YW(R".-@?/+)E8=Q!F XKNL0IFI_5@[)6V*#D
MK$2AF12@<#$*QO'5I.O\O<,OAAO=VH-3,I?RV1EW^2B('"'DF!F'0.VRQAOD
MW %9&G]WF$&3T@6V]WOT6Z_=:IE3C3>2_V:Y*4;!(( <%W3%S:/<?,6=GI[#
MRR37_@N;VO?R8P#92AM9[H(M@Y*)>J7;W3VT @;1&P%D%T \[SJ19_F)&IH.
ME=R <MX6S6V\5!]MR3'ABC(UROYE-LZDWZ5!Z,('>,0,V9K..6IX-_/K^V%H
M; KG&&8[N$D-1]Z BPG<2V$*#9]%COEK@-!R:PB2/<$).8IX3]4%)/$YD(AT
MC^ EC>#$XR5'!&N82;AE@HJ,40Y30PW:AV8T/(WGVBC[5/X<TEXC=P\CN_:Y
MTA7-<!38_M"HUABD9R=Q/[H^PKO;\.X>0T^GMAWS%4>0"QAGF5Q9NN?@U9S#
M-TF%!BKRO2JQ;!44GGP]889; Q,NL^>#ZH[F/ZS.%B<KFNK *S/IG,)I9TK=
M@S)T:SOXY8$E<1^29-#Y(M>HA+MZH%HS;2QWA*37AVY,.G?"H$UE6J$0]Z!'
M.C],@:I]G/3@[&1 8G+=F4EC:]K.=DD(#"("AZH0MEJG1+7T T*#O]^ZBYK3
M9@:-Z]9[<:\'F%6_9+8,'!<V-+JX[ 6@ZJ%0&T96OA'GTMBV]MO"SE%4SL'^
M7TA;S9WA$C23.?T/4$L#!!0    ( ,T[U5A#9/LQ!0,  ,4&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;(U576_3,!1][Z^X"F@""9;$3;^VMM(V
M-H$$:-H&/" >W.2FL7#L8#LK_'NNG38K4E>A2/'7N<?G7,<W\XTV/VV%Z.!W
M+95=1)5SS5D<V[S"FMM3W:"BE5*;FCL:FG5L&X.\"$&UC%F2C..:"Q4MYV'N
MUBSGNG52*+PU8-NZYN;/)4J]641IM)NX$^O*^8EX.6_X&N_1?6EN#8WBGJ40
M-2HKM *#Y2*Z2,\N,X\/@*\"-W:O#][)2NN??O"A6$2)%X02<^<9.#6/>(52
M>B*2\6O+&?5;^L#]_H[])G@G+RMN\4K+;Z)PU2*:1E!@R5OI[O3F/6[]C#Q?
MKJ4-;]ATV&P60=Y:I^MM,"FHA>I:_GN;A[V :?), -L&L*"[VRBH?,<=7\Z-
MWH#Q:&+SG6 U1),XH?RAW#M#JX+BW/*S=@@C> O7OUK14+8=O'K@*XGV]3QV
MM(&'Q?F6[+(C8\^0I0P^:>4J"]>JP.)?@IB4]?+83MXE.\KXB9M3&*9O@"4L
M.\(W[.T. ]_PB%T+#QINA.(J%US"O>,.O7$+WR]6UAGZ4'X<\MXQ9X>9_>4Y
MLPW/<1'1[;!H'C%:GKQ(Q\GY$=U9KSL[QKZ\PUQR:T4I<AZ^YM+H&BJ4!=#%
M!,LE@M. NT,\I/_H#H?U/U1(_))NKE!K$!;X[O:"+I]V>P,*W=F #BNO^M."
M*VT=7.1Y6[>24ES -R,<OM5E"9^IVOB;.G@)] QN6J.$:PT"5P4QDTM\8H=T
M"J\@'<)K:C)ZIX,K73>M0[,/2C-:GHP#:NAAV> C7VG#G2:Y3\#1)"7$*)T%
MY(A1<_)BRE)V/KC7I=MPDD&+"3WI;#!AC%#C9!K0LX0:EOWK=/C_3O_#Z\Q[
M3<-N_CTYZ#7Q&<DF <6\@^'L&;/3<3#+.D*?G=%T,*%DTNPDZ9+E,Y$F&1SZ
M3N.]TE*C68<":B'7K7)=E>EG^QI]T96F)WA7X"EI:Z$L2"PI-#F=C"(P7='L
M!DXWH5"MM*.R%[H5_6?0> "MEYIN[W;@-^C_7,N_4$L#!!0    ( ,T[U5AC
M0GQ0J@,  -0(   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;(U6VV[B
M2!!]YRM*GFB42 Z^@3$)("4SL[-YR"A*LA=IM0^-74#OM-W>[C8D?[_5;7"(
M FB%1%=?JD[=#L5D(]5/O4(T\%**2D^]E3'U51#H?(4ETWU98T4W"ZE*9FBK
MEH&N%;+"*94BB,,P#4K&*V\V<6</:C:1C1&\P@<%NBE+IEYO4<C-U(N\W<$C
M7ZZ,/0AFDYHM\0G-;_6#HEW062EXB97FL@*%BZEW$UW=#NU[]^!WCAN])X.-
M9"[E3[NY*Z9>:!U"@;FQ%A@M:_R"0EA#Y,:_6YM>!VD5]^6=]5]<[!3+G&G\
M(L4?O#"KJ9=Y4.""-<(\RLVON(W'.9A+H=TW;-JW:>I!WF@CRZTR>5#RJEW9
MRS8/>PI9>$0AWBK$SN\6R'GYE1DVFRBY 65?DS4KN%"=-CG'*UN4)Z/HEI.>
MF?V0!B&%2[BK#*N6?"X0F-9H-+"J@.]2%ALN!)P_,[K2%Y/ $*K5#?(MPFV+
M$!]!B&*XEY59:?A6%5B\-Q"0NYW/\<[GV_BDQ7NF^I!$/L1A/#AA+^ERD#A[
MR1%[>Z'?N-!]^$%T./_VDHNFX-6R2\,%_'4SUT91+_U]*!,MSN PCN77E:Y9
MCE./"*11K=&;??X4I>'UB2@&712#4]9G3\37HJ$8Y (^1 2\@@<E<]0:'@F:
MJ7SE"OP5UT3,FFAF#@5T&O)YA8#:<"('%K!@7,&:B<:Y8.A.82V5L0EL*FY@
MPS01QJ"B/J;WC;8W]EVMY#_$4CHKN,YE4UDQ9WH%"_K1@%(6*/I@T7A9$XKU
MUG6IUE;4!*2)A:1$85J#"RE(T9IWK.?F%8I&[>!>*7P-:+L1[ETF=LWD4D)"
M<M7[_OSG910.H%WC[1K!LS1,],[ ?7H?6?/Y4Q9'T35Y<EEO$Z[V$UZ\);QW
MRP2K<O3?>Q%#//*'XZ'=C\,,HM!/PA&D8S^+PM[=6P8<5'P-YQ#'_HAX=D'B
MT!^/0B?%F9]F='@$)MG!C/UHG,+ 3Y(1#"(_BK-#($?6(\8'QXV?:/5AU^K#
M_]WJ.VH>ZMZ35@[3T;QO,@(XVR5RV]3\0\GWNX_1+I=K5*^M+JDFR1L?A&,*
M30U4B@3#7D!P-N>"6K3?.^OMHCG:&E'LC]/!?H'.*;M9G)ZH<^9'R:&:'JV=
M4X!#A0KV)DV):NGFJ0;'V7;H=*?=R+YI)]7;\W;>$^:25QH$+D@U[(^H6JJ=
MH>W&R-K-K;DT- 6=N**_':CL [I?2)I=VXT%Z/[(S/X#4$L#!!0    ( ,T[
MU5C1"(28E (  +(%   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;'U4
M6V_3,!1^[Z\X"A,"J2S77AAMI'9L HE!M19X0#RXR6ECS;$SVUFW?X_MI%F'
MNK[$/L[Y/G_'YS+9"7FG"D0-CR7C:NH56E<7OJ^R DNBSD6%W/S9"%D2;4RY
M]54ED>0.5#(_"H*A7Q+*O73BSA8RG8A:,\IQ(4'594GDTQR9V$V]T-L?W-)M
MH>V!GTXJLL4EZI_50AK+[UAR6B)75'"0N)EZL_!BGEA_Y_"+XDX=[,%&LA;B
MSAI?\ZD76$'(,-.6@9CE 2^1,4MD9-RWG%YWI04>[O?LURYV$\N:*+P4[#?-
M=3'UQA[DN"$UT[=B]P7;> :6+Q-,N2_L&M]![$%6*RW*%FP4E)0W*WELW^$
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M&V@]5]0S5@/G8//I-/H?4$L#!!0    ( ,T[U5@74XV_#@4  *@+   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*5637/;-A"]\U?L*$[&GI$I?H@?
M<FS-2(K3YI#$8[OQH=,#1*XDC$E"!4#)[J_O J0HVU'40R^B""P6;W??/N[E
M5LA'M4+4\%06E;KJK;1>7PP&*EMAR90KUEC1SD+(DFEZE<N!6DMDN3U4%H/
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MBOX:J)T!G9>**FFU< $V_Z')/U!+ P04    " #-.]58"IZN>[ '  #K$P
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MP!7J@/?SKK.;!YI@^+YW^C=02P,$%     @ S3O56$B$MLVV P  BA$  !D
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M'=Y6%L'+C7&N^5I,5J1@IS;8CQ7S&$X8QY @V&H0[!8A#^PQR9X&>D^X6H!
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MCDQ@JNG[C8&RJEOG3*)IQ/6P,$\E*.M@UA?2-([6L-VX>WRS?U!+ P04
M" #-.]587F92M5L"   7!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6RME5U/VS 4AO^*Y:$)I(U\TC&61H)&8TAL0NW8+J9=N,EI8^'$P78:]N]W
M[(2H:.W4"VX:^_@\;XY?]SA))]6#+@$,>:I$K:>T-*:Y\#R=EU Q?2H;J'%E
M)57%#$[5VM.- E8XJ!)>Z/L3KV*\IFGB8G<J361K!*_A3A'=5A53?ZY R&Y*
M _H<F/-U:6S 2Y.&K6$!YKZY4SCS1I6"5U!K+FNB8#6EE\%%%ME\E_"#0Z>W
MQL3N9"GE@YW<%%/JVX) 0&ZL L/'!F8@A!7",AX'33J^TH+;XV?USV[ON)<E
MTS"3XB<O3#FEYY04L&*M,'/9?8%A/V=6+Y="NU_2#;D^)7FKC:P&&"NH>-T_
MV=/@PQ80Q'N < #"0X%H *)#@7@ 8N=,OQ7G0\8,2Q,E.Z)L-JK9@3/3T;A]
M7MMC7QB%JQPYDWZ3!DA,WI/+_+'EFKO#D"MRK5@.-JPU&-VO*B@(JPMRR]F2
M"TP%;=?;"N/'&1C&A3Y!YGZ1D>.C$W)$>$V^E[+52.G$,UBO?:N7#[5=];6%
M>VK[RM0IB8)W)/3#> <^.QR/=N#9X7CX$O?0Y-'I<'0Z='K1'KTY:*/:W+2*
MUVLRD]HX,S$,:@/DURWFDQL#E?Z]RZI>/-XM;B^'"]W@D4TI=K]3I.G;-\'$
M_[3+N-<4RUY)[(6IT6AJ]#_U]%K*HN-"['*L)R>.M+??)CT/HO/$VVP[<4A2
M]F]2$'Z<Q&-67[JWU87VRL0_T)K7F@A8(>>??CBC1/774#\QLG&-N90&V]P-
M2[RY0=D$7%]);,YA8GM]_!:D?P%02P,$%     @ S3O56-V&]WVP @  B0<
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M&U/MR^,->OWJ#7H59WY>B8TRT6ID:T,I;LSVL_:G:?OD1/N8H#O!]4JA?W@
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M<WS:0-D W%]*;'?MQ";H'LOX'U!+ P04    " #-.]58X]/4G:D"   Z!P
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M;C]#ZV=D^3+)=?TDVS;6<TBVUD:6+1@5E$PT;_K0YF$'X$<O ((6$+P6$+:
ML#;:**MM75%#DXF26Z)L-++909V;&HUNF+"[N# *5QGB3/)-&B!C\I[<*IH#
MH2(GWTT!BLSI(TTYZ*&EXRLPE'%]@D%WBRMR?'1"C@@3Y+:0:XT /7$-BK2_
M<K-6T&4C*'A!T%>J3DGHOR.!%T0]\-GKX>%SN(NIZ?(3=/D):KYP(#^:W$IR
MS005&:.<+ PU@(5L-/EUD6JCL!1_]QEMF*-^9GL\SW5%,Y@Z>/XTJ TXR=LW
M?NQ][+/]G\B>)2'LDA .L2=- 53MMO=9;?!QC;>-8Y/XGC>>N)M="SU!011T
M0<^D19VT:%#:19:I->2$,YHRS@S#W;*5*NM*'9+<\(YVU8SC/<6',1^BN%_P
MJ!,\&A3\J:RX? 0@FG*JGN2F(&#)L*):Q7V"1P=B1IZ_)_@PQO>CLW[%<:<X
M'MY]:;#J3=<$_IW:^'"CX[-H3^IA4!B&^\EU=SJ;O57P>*^8T(3#$F'>Z1BM
MJJ93-Q,CJ[K9I=)@ZZR'!5YNH&P KB\E'NAV8OMG=UTF?P%02P,$%     @
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M 'Y?2.QE[<2VQNXFS/X 4$L#!!0    ( ,T[U5CE,H6N?P(  %X&   9
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M-@W5#3/SY$%I'<SWI3!ML)K8!>I'5/P/4$L#!!0    ( ,T[U5@_> *&(@,
M '(,   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;+5776_:,!3]*U8V
M;:O4D0\2/CI 6DNK]:$3@K9[F/9@D@NQZL2I[4#[[V>;- M?V9C@A<3V/<?W
MGA.'F]Z2\2<1 TCTDM!4]*U8RNS"MD480X)%@V60JI49XPF6:LCGML@XX,B
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MZ(Y%2K:A$9X_K7@J"5O(D:-@G+HW)RS&%.1C<I\9$W;1#6=J)=&4+>BB#N#
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MFE(1K/H;E04K5HK,4)^YU>?V$I'D0D.N_G957=^FUWT;\Q"?JI(N8>+@4ZI
MKL&)/W[P!]Z7+@T.1+:C2-@J$NYCCW^5YL%$&2JM-"T2U*&KWIJD;TG,.V8=
M1X$?C; GZ^U*.L)ZWBCJM6$[.?;:''M[<YQ#B8U88'.,#<BT]NH-E9(6V,';
M*WO8V:>]Q&_MTX'(=C3HMQKTW\>Y_4,J<B"R'44&K2*#_<Y%&2063S:/1CAB
MS1M,'7=5/GAFSJ ?#L*1_\3$S^.\;O]&;:;1WDROZ ,ZUQ^2LEIPML17\]/,
M]UEX+_=;&W8@LAT9AJT,P_>Q\/"0BAR(;$>14:O(Z+ 6'NVQ9EW.\P@_C,+H
MJ8/=K>'##'[XH5TQ_ QP2!'HG43((.MAJEYH4=IY9"$T3C?V,L/Y$Z0)P/-4
MX$S2+,R(TTZT\7]02P,$%     @ S3O56&P8:.:E @  *P<  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3DN>&ULK55=3]LP%/TK5H:F(@WRV8RQ-!)MF<8#
M$^)C>YCVX"8WC85C9[;3EG\_VPFAE+3B82^-[=QS?,YI?)VLN7B4)8!"FXHR
M.7%*I>ISUY59"166I[P&IM\47%18Z:E8NK(6@',+JJ@;>%[L5I@P)TWLVHU(
M$]XH2AC<""2;JL+B:0J4KR>.[SPOW))EJ<R"FR8U7L(=J(?Z1NB9V[/DI (F
M"6=(0#%Q+OSS66SJ;<%/ FNY-4;&R8+S1S.YRB>.9P0!A4P9!JP?*Y@!I89(
MR_C;<3K]E@:X/7YF_V:]:R\++&'&Z2^2JW+BG#DHAP(W5-WR]7?H_(P-7\:I
MM+]HW=5Z#LH:J7C5@;6"BK#VB3==#EL /]X#"#I L N(]@#"#A!:HZTR:VN.
M%4X3P==(F&K-9@8V&XO6;@@S_^*=$OHMT3B5_N *D!^@$W3%,EX!4G@#\F5Z
MCS=H= L97X%X.D:7&_WY2$"C.2A,J#S6E0]W<S0Z.D9'B#!T7_)&8I;+Q%5:
MGMG$S3HITU9*L$>*5G'-F2HENF0YY*\)7.VK-Q<\FYL&!QFOL3A%H?\)!5X0
M#0B:O1\>'I 3]EF'EB_<P_>2,!J)/E+H(OU]L9!*Z,_ZSU!T+7,TS&R.^KFL
M<0831Y]E"6(%3OKQ@Q][7X=L_R>R5R%$?0C1(?9TU@@!3+4I+(!!050?PI#S
MEBZV=*8GK=(@<5?;=MY6>'W%*XWC7N/XH,8Y%*!5YN\7V?*-MR2<^&=AM"-T
MH.K+. J&Q<:]V/B@V'NN,'V_TOA-6$;I;J0#50-*W:V^4X%8VG8L4<8;IMI3
MVJ_V'?_"-KJ=]:F^"=K&_4+37B/Z#"X)DXA"H2F]T\\Z/=&VYG:B>&V[VX(K
MW2OML-2W&0A3H-\77'>X;F(VZ._']!]02P,$%     @ S3O56'4ZG*I6!
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M8R*7CIG+1>JP!K!+)[DKT=Z> KP4R$MCHI>.V2NHZX0"^M))_"JTMZ?@+P4
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M,M,E/G9)2>UP:5"R]D>,1RZA2:)?(-0EB"7"'TMFNC0. 32ECH@O( 2(4T.
MJWCJ%PAU">@N_'2?Z=*8WE2DPN$2P%N<#F^\D.H7"'4)X"UBPEN,X<U2[;I(
M _26I],;KZGZ!0)=DD!O&9/><DQOKK0C$9! ;SF#WFAYU2\0ZA+06\:DMQS3
M6_#,06\)])8SZ(U66OT"H2X-+DG&I+<<TUL)[:"W!'K+&?1&BZY^@5"7@-XR
M)KWEF-XB<225$N M9\ ;S;S] J$F ;QE3'C+,;QMB)..>I$">JL9]$9S;[]
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M03])]7"^MUP??UE^GT2<%Q><TVU%??H+4$L#!!0    ( ,T[U5C62",N]P$
M "LH   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[#,! %T%^ILD6-ZR</
MT6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0D;B;1JWMN1./=%8]OWOV%"?;KNWC
MO%BEY,\8B]6*.AM+YZG/*TL7.IORU_# O*W6]H&8F,T,JUR?J$_3--0H%N>7
MM+2;-DVNMOGGV+A^7@1J8S&YV&T<LN:%];YM*IOR.GOLZT\IT]>$,I\<]\15
MX^-1WE"P+Q.&E>\#7L_=/%((34V36QO2M>WR+K9M64S/+<5R?XDO>G3+95-1
M[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T^^0'YX]E]@7FG;?!^9@G%NCW<6\C
M&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S\_4^N; >YQ'9^#C\CC_.^+W^+_L0
M('U(D#X42!\:I \#TL<Q2!\G('V<@O3!9RB-H(C*44CE**9R%%0YBJH<A56.
MXBI'@96CR"I09!4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR2A19)8JL$D56
MB2*K1)%5HL@J4625*+)*%%DEBJP*15:%(JM"D56AR*I09%4HLBH4616*K I%
M5H4BJT:15:/(JE%DU2BR:A19-8JL&D56C2*K1I%5H\AJ4&0U*+(:%%D-BJP&
M15:#(JM!D=6@R&I09#7_*>N]<^L_CA^?96>;_BV?C?\17+P 4$L! A0#%
M  @ S3O56 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #-.]58U*5)2NX    K @  $0
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M=#(N>&UL4$L! A0#%     @ S3O56(X;EC)E @  8 8  !@
M ("!Q!4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,T[
MU5@/13N5!P4  $$2   8              " @5\8  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #-.]58(5;+,M$%  "U(   &
M        @(&<'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ S3O56.HP&[L6!P  A1\  !@              ("!HR,  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,T[U5@)7>"R2P(  *0%   8
M              " @>\J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #-.]58)MHO#D0"  "*!@  &               @(%P+0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ S3O56#L798*?#
M^1X  !@              ("!ZB\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( ,T[U5A=8/+SDQ4  )I    9              " @;\\
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ S3O56+;?
MOK;1 P  2PH  !D              ("!B5(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #-.]58^*E>M!(#  "_!@  &0
M    @(&15@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M ,T[U5C6?#CR'P,   4'   9              " @=I9  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ S3O56+BZLV5B!P  "!$  !D
M             ("!,%T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #-.]585*S]27X"  "I!0  &0              @(')9   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,T[U5AA\^YNR@0
M ",+   9              " @7YG  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ S3O56$S]/1"_#   *"@  !D              ("!
M?VP  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #-.]58
M"&+&,YP(  "P%@  &0              @(%U>0  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,T[U5@UG- <W ,  +\(   9
M      " @4B"  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ S3O56%HSD[I]"   X10  !D              ("!6X8  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #-.]58Q01IUID(  "M%@
M&0              @($/CP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( ,T[U5@7U$-="P,  (L&   9              " @=^7  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ S3O56# [-G"F
M%@  @4D  !D              ("!(9L  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #-.]58L0 A(T #  #0"   &0
M@('^L0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,T[
MU5BXFBA1F (  *4%   9              " @76U  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ S3O56$-D^S$% P  Q08  !D
M         ("!1+@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #-.]588T)\4*H#  #4"   &0              @(& NP  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,T[U5C1"(28E (  +(%
M   9              " @6&_  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ S3O56('@F,=S P  %@D  !D              ("!+,(
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #-.]58?XN?
MS54$  !&"0  &0              @('6Q0  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( ,T[U5@74XV_#@4  *@+   9
M  " @6+*  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MS3O56*$\714E P  DP8  !D              ("!I\\  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #-.]58"IZN>[ '  #K$P  &0
M            @($#TP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( ,T[U5A(A+;-M@,  (H1   9              " @>K:  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ S3O56%U[NU8$ @
M%@0  !D              ("!U]X  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #-.]58/-TU05T"  #B!0  &0              @($2
MX0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,T[U5B5
ME!3M_ 0  +L>   9              " @:;C  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ S3O56)@_>HNA @  B <  !D
M     ("!V>@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,T[U5@6X?#(V@(  *X(   9              "
M@9KX  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ S3O5
M6.YB,80 !    Q0  !D              ("!J_L  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " #-.]58H(X^";H"   X!P  &0
M        @('B_P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( ,T[U5CCT]2=J0(  #H'   9              " @=," 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ S3O56,<2Q26% @  %0<
M !D              ("!LP4! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " #-.]58Y3*%KG\"  !>!@  &0              @(%O" $
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,T[U5C(B:OX
MR (  *L'   9              " @24+ 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ S3O56)WD)_-* P  J@D  !D
M ("!) X! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #-
M.]58H=G*2W$#  !0"0  &0              @(&E$0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,T[U5@_> *&(@,  '(,   9
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M970U-BYX;6Q02P$"% ,4    " #-.]58T_6&N64#  "F"0  &0
M    @(&X- $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M ,T[U5@DV:,#!P,  -T*   9              " @50X 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ S3O56&P8:.:E @  *P<  !D
M             ("!DCL! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " #-.]58=3J<JE8$  "S#@  &0              @(%N/@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ,T[U5AE3"'E.00
M ) .   9              " @?M" 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ S3O56*C11'#3"   XT0  !D              ("!
M:T<! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #-.]58
M:+(TDS@"   I!0  &0              @(%U4 $ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( ,T[U5B 90(>U0,  *@5   9
M      " @>12 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ S3O56/M 2DZA @  H08  !D              ("!\%8! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #-.]58&(()\@H$   Q%
M&0              @('(60$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( ,T[U5B!$$^K)@(  %($   9              " @0E> 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ S3O56*,=13YR
M @  QP4  !D              ("!9F ! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " #-.]58J,DXXL@"  #@!@  &0
M@($/8P$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( ,T[
MU5@JXG)]4 ,  ,X5   -              "  0YF 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ S3O56)>*NQS     $P(   L              ( !B6D!
M %]R96QS+RYR96QS4$L! A0#%     @ S3O56*6ON?JA!0  ,BX   \
M         ( !<FH! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,T[U5B7
M=W+D+ (  /8H   :              "  4!P 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,T[U5C62",N]P$  "LH   3
M      "  :1R 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !- $T $A4
' ,QT 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>181</ContextCount>
  <ElementCount>296</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Loss and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Loss and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Shareholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholder's Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Note 1 - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations</Role>
      <ShortName>Note 1 - Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Note 3 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements</Role>
      <ShortName>Note 3 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Note 4 - Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables</Role>
      <ShortName>Note 4 - Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Note 5 - Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment</Role>
      <ShortName>Note 5 - Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Note 6 - Intangible assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1</Role>
      <ShortName>Note 6 - Intangible assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Note 7 - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1</Role>
      <ShortName>Note 7 - Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Note 8- Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8Leases</Role>
      <ShortName>Note 8- Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Note 9 -Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquity1</Role>
      <ShortName>Note 9 -Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 10 - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation</Role>
      <ShortName>Note 10 - Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Note 11 - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShare</Role>
      <ShortName>Note 11 - Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 12 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1</Role>
      <ShortName>Note 12 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Note 13 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1</Role>
      <ShortName>Note 13 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Note 14 - Restructuring Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts</Role>
      <ShortName>Note 14 - Restructuring Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Note 3 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables</Role>
      <ShortName>Note 3 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Note 4 - Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesTables</Role>
      <ShortName>Note 4 - Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Note 5 - Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables</Role>
      <ShortName>Note 5 - Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Note 6 - Intangible assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Note 6 - Intangible assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Note 7 - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTables</Role>
      <ShortName>Note 7 - Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Note 8 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables</Role>
      <ShortName>Note 8 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Note 9 - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables</Role>
      <ShortName>Note 9 - Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Note 10 - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables</Role>
      <ShortName>Note 10 - Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Note 11 - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareTables</Role>
      <ShortName>Note 11 - Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Note 12 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables</Role>
      <ShortName>Note 12 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Note 1 - Nature of Operation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual</Role>
      <ShortName>Note 1 - Nature of Operation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Note 3 - Fair Value Measurements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Note 3 - Fair Value Measurements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Note 3 - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Note 3 - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Note 4 - Receivables - Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails</Role>
      <ShortName>Note 4 - Receivables - Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Note 4 - Acquisition of Grace (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual</Role>
      <ShortName>Note 4 - Acquisition of Grace (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Note 5 - Equipment - Schedule of equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails</Role>
      <ShortName>Note 5 - Equipment - Schedule of equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Note 5 - Equipment - Schedule of equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual</Role>
      <ShortName>Note 5 - Equipment - Schedule of equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Note 6 - Intangible assets and Goodwill (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual</Role>
      <ShortName>Note 6 - Intangible assets and Goodwill (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Note 6 - Intangible assets and Goodwill- Schedule of Intangible Assets in Process Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails</Role>
      <ShortName>Note 6 - Intangible assets and Goodwill- Schedule of Intangible Assets in Process Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Note 6 - Intangible assets and Goodwill - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails</Role>
      <ShortName>Note 6 - Intangible assets and Goodwill - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Note 7 - Trade and Other Payables - Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails</Role>
      <ShortName>Note 7 - Trade and Other Payables - Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Note 8 - Leases - Supplemental balance sheet information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Note 8 - Leases - Supplemental balance sheet information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Note 8 - Leases - Supplemental lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails</Role>
      <ShortName>Note 8 - Leases - Supplemental lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Note 8 - Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails</Role>
      <ShortName>Note 8 - Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Note 8 - Leases (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails</Role>
      <ShortName>Note 8 - Leases (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Note 9 - Shareholder's Equity - Schedule Of Derivative Liabilities At Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails</Role>
      <ShortName>Note 9 - Shareholder's Equity - Schedule Of Derivative Liabilities At Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Note 9 - Shareholders' Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails</Role>
      <ShortName>Note 9 - Shareholders' Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Note 9 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual</Role>
      <ShortName>Note 9 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Note 10 - Stock Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual</Role>
      <ShortName>Note 10 - Stock Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Note 10 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails</Role>
      <ShortName>Note 10 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Note 10 - Stock Based Compensation - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Note 10 - Stock Based Compensation - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Note 10- Stock-based compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails</Role>
      <ShortName>Note 10- Stock-based compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996185 - Disclosure - Note 12 - Income taxes - Income Tax (Recovery) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails</Role>
      <ShortName>Note 12 - Income taxes - Income Tax (Recovery) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996195 - Disclosure - Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails</Role>
      <ShortName>Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996205 - Disclosure - Note 12 - Income Taxes - Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Note 12 - Income Taxes - Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Note 12 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails</Role>
      <ShortName>Note 12 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996245 - Disclosure - Note 12 - Income Taxes - Government Assistance - Government Assistance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails</Role>
      <ShortName>Note 12 - Income Taxes - Government Assistance - Government Assistance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996255 - Disclosure - Note 12 - Income Taxes - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails</Role>
      <ShortName>Note 12 - Income Taxes - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996265 - Disclosure - Note 12 - Income Taxes - Government Assistance - (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails</Role>
      <ShortName>Note 12 - Income Taxes - Government Assistance - (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996275 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Note 13 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996285 - Disclosure - Note 14 - Restructuring Costs (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCostsAdditionalInformationDetails</Role>
      <ShortName>Note 14 - Restructuring Costs (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996305 - Disclosure - Assets Held for Sale (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual</Role>
      <ShortName>Assets Held for Sale (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="acst-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996315 - Disclosure - Subsequent events (Additional Information) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual</Role>
      <ShortName>Subsequent events (Additional Information) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1, us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques -  acst-20240331.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="acst-20240331.htm">acst-20240331.htm</File>
    <File>acst-20240331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img181340459_0.jpg</File>
    <File>img181340459_1.jpg</File>
    <File>img181340459_2.jpg</File>
    <File>img181340459_3.jpg</File>
    <File>img181340459_4.jpg</File>
    <File>img181340459_5.jpg</File>
    <File>img181340459_6.jpg</File>
    <File>img181340459_7.jpg</File>
    <File>img181340459_8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="526">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "acst-20240331.htm": {
   "nsprefix": "acst",
   "nsuri": "http://www.acastipharma.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "acst-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "acst-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 245,
   "keyCustom": 51,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 39,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 181,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 722,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 526,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss",
     "longName": "100030 - Statement - Consolidated Statements of Loss and Comprehensive Loss",
     "shortName": "Consolidated Statements of Loss and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "longName": "100040 - Statement - Consolidated Statements of Shareholder's Equity",
     "shortName": "Consolidated Statements of Shareholder's Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_ec51c81d-0491-4f6a-87b8-469f68295a7d",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ec51c81d-0491-4f6a-87b8-469f68295a7d",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations",
     "longName": "995455 - Disclosure - Note 1 - Nature of Operations",
     "shortName": "Note 1 - Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies",
     "longName": "995465 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements",
     "longName": "995475 - Disclosure - Note 3 - Fair Value Measurements",
     "shortName": "Note 3 - Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables",
     "longName": "995485 - Disclosure - Note 4 - Receivables",
     "shortName": "Note 4 - Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment",
     "longName": "995505 - Disclosure - Note 5 - Equipment",
     "shortName": "Note 5 - Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1",
     "longName": "995515 - Disclosure - Note 6 - Intangible assets and Goodwill",
     "shortName": "Note 6 - Intangible assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1",
     "longName": "995525 - Disclosure - Note 7 - Trade and Other Payables",
     "shortName": "Note 7 - Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8Leases",
     "longName": "995535 - Disclosure - Note 8- Leases",
     "shortName": "Note 8- Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquity1",
     "longName": "995545 - Disclosure - Note 9 -Shareholders' Equity",
     "shortName": "Note 9 -Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation",
     "longName": "995555 - Disclosure - Note 10 - Stock Based Compensation",
     "shortName": "Note 10 - Stock Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShare",
     "longName": "995565 - Disclosure - Note 11 - Loss Per Share",
     "shortName": "Note 11 - Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1",
     "longName": "995575 - Disclosure - Note 12 - Income Taxes",
     "shortName": "Note 12 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1",
     "longName": "995635 - Disclosure - Note 13 - Commitments and Contingencies",
     "shortName": "Note 13 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts",
     "longName": "995645 - Disclosure - Note 14 - Restructuring Costs",
     "shortName": "Note 14 - Restructuring Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies",
     "longName": "995665 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables",
     "longName": "995685 - Disclosure - Note 3 - Fair Value Measurements (Tables)",
     "shortName": "Note 3 - Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesTables",
     "longName": "995695 - Disclosure - Note 4 - Receivables (Tables)",
     "shortName": "Note 4 - Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables",
     "longName": "995705 - Disclosure - Note 5 - Equipment (Tables)",
     "shortName": "Note 5 - Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables",
     "longName": "995715 - Disclosure - Note 6 - Intangible assets and Goodwill (Tables)",
     "shortName": "Note 6 - Intangible assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:InProcessResearchAndDevelopmentPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:InProcessResearchAndDevelopmentPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTables",
     "longName": "995725 - Disclosure - Note 7 - Trade and Other Payables (Tables)",
     "shortName": "Note 7 - Trade and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables",
     "longName": "995745 - Disclosure - Note 8 - Leases (Tables)",
     "shortName": "Note 8 - Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "acst:SupplementalBalanceSheetInformationTableTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "acst:SupplementalBalanceSheetInformationTableTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables",
     "longName": "995755 - Disclosure - Note 9 - Shareholders' Equity (Tables)",
     "shortName": "Note 9 - Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables",
     "longName": "995765 - Disclosure - Note 10 - Stock Based Compensation (Tables)",
     "shortName": "Note 10 - Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareTables",
     "longName": "995775 - Disclosure - Note 11 - Loss per share (Tables)",
     "shortName": "Note 11 - Loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables",
     "longName": "995785 - Disclosure - Note 12 - Income Taxes (Tables)",
     "shortName": "Note 12 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual",
     "longName": "995825 - Disclosure - Note 1 - Nature of Operation (Details Textual)",
     "shortName": "Note 1 - Nature of Operation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "longName": "995835 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Note 3 - Fair Value Measurements (Additional Information) (Details)",
     "shortName": "Note 3 - Fair Value Measurements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "995875 - Disclosure - Note 3 - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Note 3 - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "acst:GuaranteedInvestmentCertificatesAndTermDeposits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "acst:GuaranteedInvestmentCertificatesAndTermDeposits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails",
     "longName": "995885 - Disclosure - Note 4 - Receivables - Receivables (Details)",
     "shortName": "Note 4 - Receivables - Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "acst:SalesTaxReceivablesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "acst:SalesTaxReceivablesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
     "longName": "995905 - Disclosure - Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
     "longName": "995935 - Disclosure - Note 4 - Acquisition of Grace (Details Textual)",
     "shortName": "Note 4 - Acquisition of Grace (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails",
     "longName": "995945 - Disclosure - Note 5 - Equipment - Schedule of equipment (Details)",
     "shortName": "Note 5 - Equipment - Schedule of equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual",
     "longName": "995955 - Disclosure - Note 5 - Equipment - Schedule of equipment (Details Textual)",
     "shortName": "Note 5 - Equipment - Schedule of equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual",
     "longName": "995965 - Disclosure - Note 6 - Intangible assets and Goodwill (Details Textual)",
     "shortName": "Note 6 - Intangible assets and Goodwill (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6f23d8ea-d676-4a69-b9d8-7312636e2386",
      "name": "acst:ImpairmentRelatedDeferredTaxLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
     "longName": "995975 - Disclosure - Note 6 - Intangible assets and Goodwill- Schedule of Intangible Assets in Process Research and Development (Details)",
     "shortName": "Note 6 - Intangible assets and Goodwill- Schedule of Intangible Assets in Process Research and Development (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_6f23d8ea-d676-4a69-b9d8-7312636e2386",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d9c4389a-7f67-4bbf-a637-b694aeda8261",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails",
     "longName": "995985 - Disclosure - Note 6 - Intangible assets and Goodwill - Schedule of Goodwill (Details)",
     "shortName": "Note 6 - Intangible assets and Goodwill - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_6f23d8ea-d676-4a69-b9d8-7312636e2386",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails",
     "longName": "995995 - Disclosure - Note 7 - Trade and Other Payables - Trade and Other Payables (Details)",
     "shortName": "Note 7 - Trade and Other Payables - Trade and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails",
     "longName": "996005 - Disclosure - Note 8 - Leases - Supplemental balance sheet information (Details)",
     "shortName": "Note 8 - Leases - Supplemental balance sheet information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acst:SupplementalBalanceSheetInformationTableTextblock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails",
     "longName": "996015 - Disclosure - Note 8 - Leases - Supplemental lease expense (Details)",
     "shortName": "Note 8 - Leases - Supplemental lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acst:LeaseExpenseTableTextblock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acst:LeaseExpenseTableTextblock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails",
     "longName": "996025 - Disclosure - Note 8 - Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)",
     "shortName": "Note 8 - Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acst:LeaseExpenseTableTextblock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails",
     "longName": "996035 - Disclosure - Note 8 - Leases (Additional Information) (Details)",
     "shortName": "Note 8 - Leases (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails",
     "longName": "996045 - Disclosure - Note 9 - Shareholder's Equity - Schedule Of Derivative Liabilities At Fair Value (Details)",
     "shortName": "Note 9 - Shareholder's Equity - Schedule Of Derivative Liabilities At Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_6f23d8ea-d676-4a69-b9d8-7312636e2386",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d9c4389a-7f67-4bbf-a637-b694aeda8261",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails",
     "longName": "996055 - Disclosure - Note 9 - Shareholders' Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "shortName": "Note 9 - Shareholders' Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_1b554ace-39ee-4357-9ded-83838c05db04",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1b554ace-39ee-4357-9ded-83838c05db04",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
     "longName": "996065 - Disclosure - Note 9 - Shareholders' Equity (Details Textual)",
     "shortName": "Note 9 - Shareholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3cca4b1-352c-4004-9c30-f04a2f7b79e5",
      "name": "acst:AtthemarketSalesAgreementCommonStockMaximumAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
     "longName": "996075 - Disclosure - Note 10 - Stock Based Compensation (Details Textual)",
     "shortName": "Note 10 - Stock Based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
     "longName": "996085 - Disclosure - Note 10 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)",
     "shortName": "Note 10 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_6f23d8ea-d676-4a69-b9d8-7312636e2386",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
     "longName": "996095 - Disclosure - Note 10 - Stock Based Compensation - Compensation Expense (Details)",
     "shortName": "Note 10 - Stock Based Compensation - Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_c11690fb-a2e6-428a-b417-46b840d84bbd",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_06ea57a9-3a97-4d7a-9bd1-eecd71be02df",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails",
     "longName": "996105 - Disclosure - Note 10- Stock-based compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)",
     "shortName": "Note 10- Stock-based compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
     "longName": "996145 - Disclosure - Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)",
     "shortName": "Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails",
     "longName": "996185 - Disclosure - Note 12 - Income taxes - Income Tax (Recovery) Expense (Details)",
     "shortName": "Note 12 - Income taxes - Income Tax (Recovery) Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails",
     "longName": "996195 - Disclosure - Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "shortName": "Note 12 - Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails",
     "longName": "996205 - Disclosure - Note 12 - Income Taxes - Net Deferred Tax Assets (Details)",
     "shortName": "Note 12 - Income Taxes - Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails",
     "longName": "996215 - Disclosure - Note 12 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)",
     "shortName": "Note 12 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2de077db-85fa-42b0-920e-a1103a07c7f4",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails",
     "longName": "996245 - Disclosure - Note 12 - Income Taxes - Government Assistance - Government Assistance (Details)",
     "shortName": "Note 12 - Income Taxes - Government Assistance - Government Assistance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "acst:InvestmentTaxCreditReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "acst:InvestmentTaxCreditReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
     "longName": "996255 - Disclosure - Note 12 - Income Taxes - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)",
     "shortName": "Note 12 - Income Taxes - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_407b0177-7169-41e6-882e-472705b1636f",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails",
     "longName": "996265 - Disclosure - Note 12 - Income Taxes - Government Assistance - (Additional Information) (Details)",
     "shortName": "Note 12 - Income Taxes - Government Assistance - (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5dad982-0286-46ce-aa2c-9586c4730f1e",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "acst:ScheduleOfGovernmentAssistanceTableTextBlock",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
     "longName": "996275 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 13 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_140a03c6-59fa-4092-bf9c-59104fc56516",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCostsAdditionalInformationDetails",
     "longName": "996285 - Disclosure - Note 14 - Restructuring Costs (Additional Information) (Details)",
     "shortName": "Note 14 - Restructuring Costs (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_d5755bb0-b1b3-4e1a-b0d2-be4c6caa330f",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5755bb0-b1b3-4e1a-b0d2-be4c6caa330f",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual",
     "longName": "996305 - Disclosure - Assets Held for Sale (Details Textual)",
     "shortName": "Assets Held for Sale (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_779b151d-a506-4172-855a-bc523254a908",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
     "longName": "996315 - Disclosure - Subsequent events (Additional Information) (Details Textual)",
     "shortName": "Subsequent events (Additional Information) (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_312bbb54-59d2-4300-b0d4-eef44282cdc6",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acst-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "acst_ATMTransactionCostsIncludedInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ATMTransactionCostsIncludedInTradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM transaction costs included in trade and other payables",
        "documentation": "Amount of ATM transaction costs included in trade and other payables.",
        "label": "ATM transaction costs included in trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total trade and other payables",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayables1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Payables",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65",
      "r68",
      "r959"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r63"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r152",
      "r553"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated other comprehensive loss",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r82",
      "r159",
      "r548",
      "r570",
      "r571"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16",
      "r26",
      "r438",
      "r441",
      "r488",
      "r566",
      "r567",
      "r874",
      "r875",
      "r876",
      "r884",
      "r885",
      "r886",
      "r887"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r706"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "acst_AdditionalLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AdditionalLeaseRenewalTerm",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional lease renewal term",
        "documentation": "Additional lease renewal term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r749",
      "r1030"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r884",
      "r885",
      "r886",
      "r887",
      "r973",
      "r1033"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r105"
     ]
    },
    "acst_AdjustmentsToNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AdjustmentsToNetAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to net assets",
        "label": "Adjustments To Net Assets",
        "documentation": "Adjustments To Net Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r792",
      "r802",
      "r835"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r805",
      "r838"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r830",
      "r839",
      "r843",
      "r851"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r380"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges, Total",
        "totalLabel": "Net, Impairment",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r40"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "Assets, Total",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r155",
      "r177",
      "r213",
      "r217",
      "r231",
      "r234",
      "r250",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r432",
      "r434",
      "r463",
      "r542",
      "r628",
      "r719",
      "r720",
      "r749",
      "r770",
      "r928",
      "r929",
      "r989"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Abstract]",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r161",
      "r177",
      "r250",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r432",
      "r434",
      "r463",
      "r749",
      "r928",
      "r929",
      "r989"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r739"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset, Held-for-Sale, Not Part of Disposal Group [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_AssetsHeldForSalePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AssetsHeldForSalePolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "documentation": "Disclosure of accounting policy for assets held for sale policy.",
        "label": "Assets Held For Sale Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "totalLabel": "Disposal Group, Including Discontinued Operation, Assets, Current, Total",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r62",
      "r99",
      "r101",
      "r146",
      "r147"
     ]
    },
    "acst_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market Offering [Member]",
        "documentation": "Represents information regarding an at-the-market offering.",
        "label": "At-the-market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_AtthemarketSalesAgreementCommonStockMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AtthemarketSalesAgreementCommonStockMaximumAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of common stock that can be sold under the at-the-market sales agreement.",
        "label": "acst_AtthemarketSalesAgreementCommonStockMaximumAmount",
        "terseLabel": "At-the-market Sales Agreement, Common Stock, Maximum Amount"
       }
      }
     },
     "auth_ref": []
    },
    "acst_AtthemarketSalesAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AtthemarketSalesAgreementTerm",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the at-the-market sales agreement.",
        "label": "acst_AtthemarketSalesAgreementTerm",
        "terseLabel": "At-the-market Sales Agreement, Term (Year)"
       }
      }
     },
     "auth_ref": []
    },
    "acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of each sale that is to be paid to the underwriter under the at-the-market sales agreement.",
        "label": "acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales",
        "terseLabel": "At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r788"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r788"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r788"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of award in non-dilutive and non-repayable funding from National Research Council of Canada Industrial Research Assistance Program.",
        "label": "acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP",
        "terseLabel": "Award in Non-dilutive and Non-repayable Funding From NRC IRAP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "acst_BrokerWarrantsIssuedDecember2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "BrokerWarrantsIssuedDecember2017Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Broker Warrants Issued December 2017 [Member]",
        "documentation": "Represents broker warrants issued December 2017.",
        "label": "Broker Warrants Issued December 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_BrokerWarrantsIssuedMay2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "BrokerWarrantsIssuedMay2018Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Broker Warrants Issued May 2018 [Member]",
        "documentation": "Represents broker warrants issued May 2018.",
        "label": "Broker Warrants Issued May 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r428",
      "r732",
      "r733"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r428",
      "r732",
      "r733"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total common shares issued (in shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAcquisitionOfGraceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisition, Pro Forma Information",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acasti share price (closing share price on August 27, 2021)",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Acquisition Related Costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common shares issued",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGrace"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of Grace",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r429"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and accrued expenses incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability",
        "terseLabel": "Deferred tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets in process research and development",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired and liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "periodStartLabel": "Cash, Beginning Balance",
        "label": "Cash",
        "periodEndLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r546",
      "r595",
      "r623",
      "r749",
      "r770",
      "r871"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r150",
      "r708"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents, beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r92",
      "r174"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r92"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "label": "Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r998"
     ]
    },
    "us-gaap_CashFlowOperatingCapitalTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingCapitalTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in working capital items",
        "label": "Cash Flow, Operating Capital [Table Text Block]",
        "documentation": "Tabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosure1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosure",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "acst_ChangeInTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ChangeInTaxRates",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in tax rates",
        "label": "Change in Tax Rates",
        "documentation": "Change in Tax Rates"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ChiefExecutiveOfficerAndChiefOperatingOfficerMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the chief executive officer (CEO) and the chief operating officer (COO).",
        "label": "Chief Executive Officer and Chief Operating Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r156",
      "r157",
      "r158",
      "r177",
      "r202",
      "r203",
      "r205",
      "r207",
      "r215",
      "r216",
      "r250",
      "r292",
      "r295",
      "r296",
      "r297",
      "r301",
      "r302",
      "r306",
      "r307",
      "r310",
      "r313",
      "r319",
      "r463",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r615",
      "r639",
      "r658",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r862",
      "r881",
      "r888"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "acst_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "acst_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during period.",
        "label": "acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice",
        "terseLabel": "Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Offering warrants (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "acst_CommissionCostsRelatedToShareSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommissionCostsRelatedToShareSale",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of commission costs recognized during the period related to share sale.",
        "label": "acst_CommissionCostsRelatedToShareSale",
        "terseLabel": "Commission Costs Related to Share Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r119",
      "r545",
      "r614"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r286",
      "r287",
      "r693",
      "r925",
      "r927"
     ]
    },
    "us-gaap_CommitmentsToCompleteContractsInProcess": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsToCompleteContractsInProcess",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments",
        "label": "Commitments to Complete Contracts in Process",
        "documentation": "General description of commitments which may be required in performing under a construction-type contract which are outside the ordinary course of business at the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A [Member]",
        "terseLabel": "Class A common shares [Member]",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class B [Member]",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_CommonClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassCMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class C [Member]",
        "label": "Common Class C [Member]",
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": []
    },
    "acst_CommonClassDAndCommonClassEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonClassDAndCommonClassEMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class D and Common Class E [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, B, or C, representing ownership interest in a corporation.",
        "label": "Common Class D and Common Class E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_CommonSharesHeldByNonAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonSharesHeldByNonAffiliates",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "common shares held by non-affiliates",
        "label": "common shares held by non-affiliates",
        "terseLabel": "Common shares held by non-affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "acst_CommonStockConversionRateIntoClassA": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonStockConversionRateIntoClassA",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate at which shares are convertible into one share of class A common stock.",
        "label": "acst_CommonStockConversionRateIntoClassA",
        "terseLabel": "Common Stock, Conversion Rate into Class A"
       }
      }
     },
     "auth_ref": []
    },
    "acst_CommonStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonStockDividendRatePercentage",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on common stock.",
        "label": "acst_CommonStockDividendRatePercentage",
        "terseLabel": "Common Stock, Dividend Rate, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r761",
      "r762",
      "r764",
      "r765",
      "r766",
      "r767",
      "r884",
      "r885",
      "r887",
      "r973",
      "r1028",
      "r1033"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "acst_CommonStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonStockRedemptionPricePerShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid per share at which the common stock of an entity is redeemed or may be called at.",
        "label": "acst_CommonStockRedemptionPricePerShare",
        "terseLabel": "Common Stock, Redemption Price Per Share (in CAD per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74",
      "r615",
      "r634",
      "r1033",
      "r1034"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Value, Total",
        "terseLabel": "Shareholders' equity:",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r547",
      "r749"
     ]
    },
    "acst_CommonStockVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonStockVotesPerShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes per one share of common stock.",
        "label": "acst_CommonStockVotesPerShare",
        "terseLabel": "Common Stock, Votes Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "acst_CommonWarrantAndPreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CommonWarrantAndPreFundedWarrantMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrant and Pre-Funded Warrant [Member]",
        "documentation": "Common Warrant and Pre-Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r134"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r866"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r184",
      "r213",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r719",
      "r720",
      "r928",
      "r929"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r184",
      "r213",
      "r219",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r719",
      "r720",
      "r928",
      "r929"
     ]
    },
    "acst_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ConsultantMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultant [Member]",
        "documentation": "Represents consultant.",
        "label": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ContractResearchOrganizationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ContractResearchOrganizationsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Research Organizations [Member]",
        "documentation": "Contract Research Organizations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ConversionOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ConversionOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock [Table]",
        "documentation": "Disclosure of information about stock converted into another financial instrument in noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "acst_CostNetOfImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CostNetOfImpairments",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "documentation": "Cost, net of impairments",
        "label": "Cost, net of impairments"
       }
      }
     },
     "auth_ref": []
    },
    "acst_CostRelatedToProspectusSupplementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "CostRelatedToProspectusSupplementAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Related to Prospectus Supplement Amount",
        "label": "Cost Related to Prospectus Supplement Amount",
        "documentation": "Cost Related to Prospectus Supplement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r303",
      "r308",
      "r492",
      "r501",
      "r540",
      "r710",
      "r712"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax (benefit) expense",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r883"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Financing Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "acst_DeferredFinancingCostsReclassifiedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredFinancingCostsReclassifiedToEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs reclassified to Equity",
        "documentation": "The amount of deferred financing costs reclassified to equity.",
        "label": "Deferred financing costs reclassified to Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred income tax benefit",
        "terseLabel": "Deferred tax (benefit) expense",
        "totalLabel": "Deferred tax (recovery) expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r140",
      "r883"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r118",
      "r404"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r543"
     ]
    },
    "acst_DeferredTaxAssetsFinancingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredTaxAssetsFinancingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing expenses",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to financing expenses.",
        "label": "Financing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "acst_DeferredTaxAssetsOperatingLeaseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredTaxAssetsOperatingLeaseAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease asset",
        "label": "Deferred Tax Assets Operating Lease Asset",
        "documentation": "Deferred Tax Assets Operating Lease Asset"
       }
      }
     },
     "auth_ref": []
    },
    "acst_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Operating lease liability",
        "label": "Deferred Tax Assets Operating lease liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "acst_DeferredTaxAssetsOperatingLeaseRightOfUseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use liability",
        "label": "Deferred Tax Assets Operating Lease Right Of Use Liability",
        "documentation": "Deferred Tax Assets Operating Lease Right Of Use Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax losses carried forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other deductible temporary differences",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "acst_DeferredTaxAssetsResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to research and development expenses.",
        "label": "Research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets",
        "terseLabel": "Tax credit carry forwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves or liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities",
        "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from estimated policyholder reserves, which will be deductible from future taxable income when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the tax deduction to be taken."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "totalLabel": "Deferred Tax Liabilities, Goodwill and Intangible Assets, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Other taxable temporary differences",
        "negatedLabel": "Other taxable temporary differences",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "acst_DeferredTaxLiabilityConvertibleDebtEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DeferredTaxLiabilityConvertibleDebtEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from convertible debt equity component.",
        "label": "acst_DeferredTaxLiabilityConvertibleDebtEquityComponent",
        "negatedLabel": "Tax basis of unsecured convertible debentures in excess of carrying value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation of equipment",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42"
     ]
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation Expense on Reclassified Assets",
        "terseLabel": "Depreciation expense",
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r41"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13DerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Warrant Liabilities",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r436",
      "r443"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liabilities",
        "label": "Derivative Liability",
        "totalLabel": "Derivative Liability, Total",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r449",
      "r450",
      "r459",
      "r462",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r629",
      "r631",
      "r632",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r712",
      "r976",
      "r977",
      "r978",
      "r1029"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liabilities",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liability, measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liabilities",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r56",
      "r57",
      "r58",
      "r59",
      "r183",
      "r198"
     ]
    },
    "acst_DirectorsAndEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DirectorsAndEmployeesMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents directors and employees.",
        "label": "Directors and Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r372",
      "r373",
      "r375",
      "r735"
     ]
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]",
        "terseLabel": "Reclassification from held for sale to equipment",
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r146"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "terseLabel": "Other assets (a)",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r62",
      "r99",
      "r101"
     ]
    },
    "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the accumulated depreciation component.",
        "label": "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation",
        "negatedLabel": "Equipment held-for-sale, accumulated depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment held-for-sale, cost",
        "documentation": "Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the cost component.",
        "label": "Equipment held-for-sale, cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Production equipment (b)",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r62",
      "r99",
      "r101"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r788"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r788",
      "r831"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings Per Share Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r212",
      "r424",
      "r431",
      "r446",
      "r447",
      "r537",
      "r558",
      "r713"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r202",
      "r205",
      "r206",
      "r207",
      "r212",
      "r424",
      "r431",
      "r446",
      "r447",
      "r537",
      "r558",
      "r713"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earning per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r209"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r208",
      "r210",
      "r211"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation effect on cash and cash equivalents related to reporting currency",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "acst_EffectOfTranslationEffectOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "EffectOfTranslationEffectOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate fluctuations on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of exchange rate fluctuations on cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee salaries and benefits payable",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r145",
      "r167",
      "r168",
      "r169",
      "r185",
      "r186",
      "r187",
      "r189",
      "r194",
      "r196",
      "r198",
      "r214",
      "r251",
      "r252",
      "r272",
      "r321",
      "r413",
      "r414",
      "r421",
      "r422",
      "r423",
      "r425",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r475",
      "r488",
      "r557",
      "r566",
      "r567",
      "r568",
      "r584",
      "r658"
     ]
    },
    "acst_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plan [Member]",
        "documentation": "Represents the equity incentive plan.",
        "label": "Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r420",
      "r863",
      "r864",
      "r865",
      "r969",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment Ownership Percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r792",
      "r802",
      "r835"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r832"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "acst_ExercisePriceRange1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange1Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 1 [Member]",
        "documentation": "Represents exercise price range one.",
        "label": "Exercise Price Range 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange2Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 2 [Member]",
        "documentation": "Represents exercise price range two.",
        "label": "Exercise Price Range 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange3Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 3 [Member]",
        "documentation": "Represents exercise price range 3.",
        "label": "Exercise Price Range 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange4Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 4 [Member]",
        "documentation": "Represents exercise price range four.",
        "label": "Exercise Price Range 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange5Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 5 [Member]",
        "documentation": "Represents exercise price range 5.",
        "label": "Exercise Price Range 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange6Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange6Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 6 [Member]",
        "documentation": "Represents exercise price range six.",
        "label": "Exercise Price Range 6 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange7Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange7Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 7 [Member]",
        "documentation": "Represents exercise price range seven.",
        "label": "Exercise Price Range 7 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange8Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange8Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 8 [Member]",
        "documentation": "Represents exercise price range eight.",
        "label": "Exercise Price Range 8 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ExercisePriceRange9Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ExercisePriceRange9Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range 9 [Member]",
        "documentation": "Represents exercise price range nine.",
        "label": "Exercise Price Range 9 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "FR",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FRANCE",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liabilities",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r459",
      "r739"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r743"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r459",
      "r461",
      "r496",
      "r497",
      "r498",
      "r725",
      "r726",
      "r729",
      "r730",
      "r731",
      "r739",
      "r743"
     ]
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted prices in active markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r332",
      "r337",
      "r450",
      "r459",
      "r496",
      "r729",
      "r730",
      "r731",
      "r739"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant other observable inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r332",
      "r337",
      "r450",
      "r451",
      "r459",
      "r497",
      "r725",
      "r726",
      "r729",
      "r730",
      "r731",
      "r739"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r450",
      "r451",
      "r452",
      "r453",
      "r459",
      "r498",
      "r725",
      "r726",
      "r729",
      "r730",
      "r731",
      "r739",
      "r743"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r460"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued during the Year",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r460"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance \u2013 end of year",
        "periodStartLabel": "Balance \u2013 beginning of year",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r460"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r458",
      "r459",
      "r461",
      "r496",
      "r497",
      "r498",
      "r725",
      "r726",
      "r729",
      "r730",
      "r731",
      "r739",
      "r743"
     ]
    },
    "acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureNoncashTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of derivative warrants liability reclassified to equity",
        "documentation": "The fair value of derivative warrants liability that reclassified to equity.",
        "label": "Fair value of derivative warrants liability reclassified to equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets and liabilities",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r460"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents (Year)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r504",
      "r505",
      "r706"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r706"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-Lived Intangible Assets, Net, Total",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r920"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in finite-lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "totalLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived Intangible Assets Acquired",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange loss",
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r768",
      "r980",
      "r981",
      "r1031"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange (gain) loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r637",
      "r768",
      "r980",
      "r981",
      "r1032"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r839"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r839"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r839"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r839"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r839"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "acst_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Office Equipment [Member]",
        "documentation": "Represents information regarding furniture and office equipment.",
        "label": "Furniture and Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r642"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, beginning of the year",
        "periodEndLabel": "Goodwill, end of the year",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r255",
      "r536",
      "r720",
      "r724",
      "r740",
      "r749",
      "r903",
      "r910"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets - acquired in-process research and development",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible assets - acquired in-process research and development",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r913"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r256",
      "r257",
      "r258",
      "r724",
      "r740"
     ]
    },
    "acst_GovernmentAssistance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "GovernmentAssistance",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of government assistance recorded in earnings.",
        "label": "acst_GovernmentAssistance",
        "terseLabel": "Government Assistance"
       }
      }
     },
     "auth_ref": []
    },
    "acst_GovernmentGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "GovernmentGrantsPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants",
        "documentation": "The accounting policy for government grants.",
        "label": "Government Grants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_GraceTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "GraceTherapeuticsIncMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grace Therapeutics Inc Member",
        "documentation": "Related to Grace Therapeutics Inc.",
        "label": "Grace Therapeutics Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_GrantsAndInvestmentTaxCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "GrantsAndInvestmentTaxCreditReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance",
        "documentation": "GrantsAndInvestmentTaxCreditReceivable",
        "label": "Government assistance",
        "totalLabel": "Total government assistance"
       }
      }
     },
     "auth_ref": []
    },
    "acst_Gtx101Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "Gtx101Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GTX 101 [Member]",
        "label": "GTX 101 [Member]",
        "documentation": "GTX 101."
       }
      }
     },
     "auth_ref": []
    },
    "acst_Gtx102Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "Gtx102Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GTX 102 [Member]",
        "label": "GTX 102 [Member]",
        "documentation": "GTX 102."
       }
      }
     },
     "auth_ref": []
    },
    "acst_Gtx104Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "Gtx104Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GTX 104 [Member]",
        "label": "GTX 104 [Member]",
        "documentation": "GTX 104."
       }
      }
     },
     "auth_ref": []
    },
    "acst_GuaranteedInvestmentCertificatesAndTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "GuaranteedInvestmentCertificatesAndTermDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed investment certificates and term deposits classified as cash equivalents",
        "label": "Guaranteed investment certificates and term deposits",
        "documentation": "Guaranteed investment certificates and term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r788"
     ]
    },
    "us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentEffectsOnEarningsPerShareLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Effects on Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentEffectsOnEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentEffectsOnEarningsPerShareTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Effects on Earnings Per Share [Table]",
        "documentation": "Disclosure of information about the effects of asset impairment charge on per share or per unit basis."
       }
      }
     },
     "auth_ref": []
    },
    "acst_ImpairmentOfAssetHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ImpairmentOfAssetHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Asset held for sale",
        "label": "Impairment of Asset held for sale",
        "terseLabel": "Impairment of assets held for sale",
        "negatedLabel": "Impairment of assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ImpairmentOfGoodwill1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ImpairmentOfGoodwill1",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfGoodwillDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Goodwill 1",
        "label": "Impairment of Goodwill 1",
        "verboseLabel": "Impairment",
        "terseLabel": "Impairment of goodwill",
        "negatedLabel": "Impairment of goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of Intangible Assets, Finite-lived",
        "negatedLabel": "Impairment of intangible assets",
        "verboseLabel": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r880",
      "r924"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r880",
      "r921",
      "r924"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Equipment",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "negatedLabel": "Equipment held-for-sale, impairment loss",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r98",
      "r741"
     ]
    },
    "acst_ImpairmentOfOtherAssetsAndPrepaids": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ImpairmentOfOtherAssetsAndPrepaids",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "documentation": "Impairment of other assets and prepaids.",
        "label": "Impairment Of Other Assets And Prepaids",
        "negatedLabel": "Impairment of Other assets and prepaids",
        "verboseLabel": "Impairment of Assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ImpairmentOfTheIntangibleAssetsIndefiniteLived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ImpairmentOfTheIntangibleAssetsIndefiniteLived",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of The Intangible Assets Indefinite Lived",
        "label": "Impairment Of The Intangible Assets Indefinite Lived",
        "terseLabel": "Impairment",
        "negatedLabel": "Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102"
     ]
    },
    "acst_ImpairmentRelatedDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ImpairmentRelatedDeferredTaxLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Related Deferred Tax Liability",
        "label": "Impairment Related Deferred Tax Liability",
        "terseLabel": "Impairment Related Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "acst_Impairmentofintangibleassetsindefinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "Impairmentofintangibleassetsindefinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImpairmentOfIntangibleAssetsIndefinitelived",
        "label": "ImpairmentOfIntangibleAssetsIndefinitelived",
        "terseLabel": "Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research And Development Member",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets in Process Research and Development",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax benefit",
        "terseLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r123",
      "r127",
      "r538",
      "r555",
      "r715",
      "r719",
      "r890",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r279",
      "r455",
      "r457",
      "r460",
      "r563",
      "r565",
      "r643",
      "r706",
      "r742",
      "r1000"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r279",
      "r455",
      "r457",
      "r460",
      "r563",
      "r565",
      "r643",
      "r706",
      "r742",
      "r1000"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r392",
      "r393",
      "r399",
      "r409",
      "r738",
      "r966"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r392",
      "r393",
      "r399",
      "r409",
      "r738",
      "r966"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxes1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r385",
      "r392",
      "r396",
      "r397",
      "r398",
      "r402",
      "r408",
      "r415",
      "r417",
      "r418",
      "r419",
      "r583",
      "r738"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesIncomeTaxRecoveryExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred income tax benefit",
        "totalLabel": "Total tax (benefit) expense",
        "negatedLabel": "Income tax benefit",
        "negatedTotalLabel": "Income tax (recovery) expense",
        "terseLabel": "Income tax recovery",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r141",
      "r197",
      "r198",
      "r213",
      "r221",
      "r234",
      "r391",
      "r392",
      "r416",
      "r561",
      "r738"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r387",
      "r388",
      "r402",
      "r403",
      "r407",
      "r411",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Difference in foreign tax rates",
        "terseLabel": "Difference in foreign tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r395",
      "r738",
      "r961"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at Canadian Rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r738"
     ]
    },
    "acst_IncomeTaxReconciliationNondeductibleChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IncomeTaxReconciliationNondeductibleChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible change in fair value of warrants",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value.",
        "label": "Non-deductible change in fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Non-deductible goodwill impairment",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r961",
      "r963"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-deductible items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r961",
      "r963"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r961",
      "r963"
     ]
    },
    "acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible transaction costs",
        "label": "Income Tax Reconciliation Nondeductible Expense Transaction Costs",
        "documentation": "Income tax reconciliation nondeductible expense transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r961",
      "r962"
     ]
    },
    "acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IncomeTaxReconciliationUnrecognizedTemporaryDifferences",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized temporary differences.",
        "label": "acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "acst_IncomeTaxRecoveryExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IncomeTaxRecoveryExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax (recovery) expense [Abstract]",
        "documentation": "Income tax (recovery) expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade and other payables",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Trade and other payables",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use asset",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r869",
      "r879"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "totalLabel": "Increase (Decrease) in Receivables, Total",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "acst_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of working capital.",
        "label": "acst_IncreaseDecreaseInWorkingCapital",
        "negatedLabel": "Changes in non-cash working capital items",
        "negatedTotalLabel": "Total changes in working capital items"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r830",
      "r839",
      "r843",
      "r851"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r855"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r855"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r855"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwill1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and Goodwill",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r270",
      "r271",
      "r705",
      "r706"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r920",
      "r921"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Cash interest received",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r1035"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_InvestmentCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCreditMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Tax Credit Carryforward [Member]",
        "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income and other expense, net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r220",
      "r234",
      "r719",
      "r877"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r573",
      "r574",
      "r575",
      "r576",
      "r667",
      "r668"
     ]
    },
    "acst_InvestmentTaxCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "InvestmentTaxCreditReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceGovernmentAssistanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment tax credit",
        "documentation": "The amount of investment tax credit receivable as of the balance sheet date.",
        "label": "Investment tax credit"
       }
      }
     },
     "auth_ref": []
    },
    "acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs (Value)",
        "label": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs",
        "documentation": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs",
        "label": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares",
        "documentation": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares"
       }
      }
     },
     "auth_ref": []
    },
    "acst_IssuanceOfRestrictedShareUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "IssuanceOfRestrictedShareUnit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted share unit",
        "label": "Issuance of Restricted Share Unit",
        "documentation": "Issuance of Restricted Share Unit"
       }
      }
     },
     "auth_ref": []
    },
    "acst_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment [Member]",
        "documentation": "Represent laboratory equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease agreement commitment amount",
        "label": "Lease, Cost",
        "totalLabel": "Lease, Cost, Total",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r748"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs Recognized for Operating Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "acst_LeaseExpenseTableTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "LeaseExpenseTableTextblock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental lease expense",
        "label": "Lease expense [Table TextBlock]",
        "documentation": "Lease expense [Table TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments discounted incremental borrowing rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Extension of lease term, description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r984"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r72",
      "r177",
      "r250",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r433",
      "r434",
      "r435",
      "r463",
      "r613",
      "r714",
      "r770",
      "r928",
      "r989",
      "r990"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities [Abstract]",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r120",
      "r550",
      "r749",
      "r882",
      "r900",
      "r979"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Equity [Abstract]",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "terseLabel": "Liabilities, Current, Total",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r149",
      "r177",
      "r250",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r433",
      "r434",
      "r435",
      "r463",
      "r749",
      "r928",
      "r989",
      "r990"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r974"
     ]
    },
    "acst_Licenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "Licenses",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses",
        "documentation": "Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreements [Member]",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r384",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r960"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4Receivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r896"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment,net",
        "label": "Machinery and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r339",
      "r381",
      "r453",
      "r502",
      "r562",
      "r564",
      "r572",
      "r605",
      "r606",
      "r665",
      "r669",
      "r671",
      "r672",
      "r681",
      "r703",
      "r704",
      "r723",
      "r727",
      "r734",
      "r743",
      "r744",
      "r745",
      "r746",
      "r758",
      "r930",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "acst_May2018PublicOfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "May2018PublicOfferingWarrantsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2018 public offering warrants [Member]",
        "label": "May 2018 Public Offering Warrants [Member]",
        "documentation": "May 2018 Public Offering Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Exercise Price [Member]",
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Expected Term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Price Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Share Price [Member]",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r743"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r743"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r339",
      "r381",
      "r453",
      "r502",
      "r562",
      "r564",
      "r572",
      "r605",
      "r606",
      "r665",
      "r669",
      "r671",
      "r672",
      "r681",
      "r703",
      "r704",
      "r723",
      "r727",
      "r734",
      "r743",
      "r744",
      "r745",
      "r758",
      "r930",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-1-nature-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r142"
     ]
    },
    "acst_NetBookValueReclassedFromHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NetBookValueReclassedFromHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net book value reclassed from held for sale",
        "label": "Net book value reclassed from held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "acst_NetBookValueReclassedFromHeldForSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NetBookValueReclassedFromHeldForSales",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net book value",
        "documentation": "Net book value reclassed from held for sales",
        "label": "Net book value reclassed from held for sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_NetFederalInvestmentTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NetFederalInvestmentTaxCredits",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net federal investment tax credits",
        "label": "Net Federal Investment Tax Credits",
        "documentation": "Net Federal Investment Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss and total comprehensive loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r94",
      "r124",
      "r147",
      "r164",
      "r165",
      "r169",
      "r177",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r204",
      "r250",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r424",
      "r431",
      "r447",
      "r463",
      "r556",
      "r638",
      "r656",
      "r657",
      "r768",
      "r928"
     ]
    },
    "acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common shares and warrants from private placement",
        "label": "Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement",
        "documentation": "Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "acst_NoExpiryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NoExpiryMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Expiry [Member]",
        "documentation": "No Expiry [Member]",
        "terseLabel": "No Expiry"
       }
      }
     },
     "auth_ref": []
    },
    "acst_NoOfDaysInvestmentsPurchased": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NoOfDaysInvestmentsPurchased",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No of Days Investments Purchased",
        "documentation": "No of Days Investments Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r830",
      "r839"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "acst_NonRefundableFederalItc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NonRefundableFederalItc",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable federal investment tax credit",
        "negatedLabel": "Non-refundable Federal ITC",
        "documentation": "Non-refundable Federal ITC",
        "label": "Non-refundable federal ITC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "terseLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "acst_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes To Financial Statements Abstract",
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r722",
      "r891"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operating activities",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r715",
      "r890",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows for operating lease",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r748"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Lease, Right-of-Use Asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r748"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r748"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statements of Operations and Comprehensive Loss",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r719",
      "r720"
     ]
    },
    "acst_OppenheimerAndCoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "OppenheimerAndCoIncMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Oppenheimer and Co. Inc.",
        "label": "Oppenheimer &amp; Co. Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative translation adjustment",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r557"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r640",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpenses1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net financial income (expenses)",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r958"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "totalLabel": "Other Receivables, Net, Current, Total",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed investment certificate classified as a short-term investment",
        "label": "Other Short-Term Investments",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r540",
      "r541",
      "r873"
     ]
    },
    "acst_OtherTaxCreditCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "OtherTaxCreditCarryforwardMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards that are classified as other.",
        "label": "Other Tax Credit Carryforward [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r837"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797",
      "r807",
      "r840"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797",
      "r807",
      "r840"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents (Year)",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r914",
      "r915",
      "r916",
      "r917",
      "r919",
      "r920",
      "r922",
      "r923"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "acst_PaymentOfIssuanceCostsCommonWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PaymentOfIssuanceCostsCommonWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Issuance Costs Common Warrants",
        "documentation": "Payment Of Issuance Costs Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Rent",
        "terseLabel": "Payments for rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Machinery and Equipment",
        "documentation": "The cash outflow for acquisition of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "acst_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid Expense, Current, Total",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r253",
      "r254",
      "r709"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "acst_ProceedsFromCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProceedsFromCommonShares",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Common Shares",
        "documentation": "Proceeds from Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares from exercise of stock options",
        "label": "Proceeds From Issuance Of Common Shares From Exercise Of Stock Options",
        "documentation": "Proceeds From Issuance Of Common Shares From Exercise Of Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "acst_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Issuance of Common Stock, Gross",
        "label": "Proceeds From Issuance of Common Stock Gross",
        "documentation": "Proceeds from issuance of common Stock gross"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, net of issuance cost.",
        "label": "acst_ProceedsFromIssuanceOfCommonStockNet",
        "terseLabel": "Proceeds from Issuance of Common Stock, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of short-term investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r90"
     ]
    },
    "acst_ProceedsFromNRCIRAP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProceedsFromNRCIRAP",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the National Research Council of Canada Industrial Research Assistance Program.",
        "label": "acst_ProceedsFromNRCIRAP",
        "terseLabel": "Proceeds from NRC IRAP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equipment",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "acst_ProductionEquipmentImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProductionEquipmentImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Production equipment impairment loss",
        "label": "Production equipment impairment loss"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ProductionEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ProductionEquipmentMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Production Equipment [Member]",
        "documentation": "Represents production equipment.",
        "label": "Production Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_PropertyPantAndEquipmentDepreciationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PropertyPantAndEquipmentDepreciationRate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate",
        "documentation": "The depreciation rate of property, plant and equipment.",
        "label": "Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r485"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5Equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r135",
      "r138",
      "r139"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r151",
      "r554"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net book value",
        "terseLabel": "Property, plan and equipment and intangible assets",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "negatedLabel": "Equipment and intangible assets",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r485",
      "r539",
      "r554",
      "r749"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r135",
      "r138",
      "r552"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of assets from assets held for sale",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r485"
     ]
    },
    "acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Useful Lives and Rates",
        "documentation": "The tabular disclosure for useful lives and rates for property, plant and equipment.",
        "label": "Property, Plant and Equipment, Useful Lives and Rates [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r119"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r119"
     ]
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r119"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Purchase Obligation, Total",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase Obligation, Total",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "acst_PurchaseOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PurchaseOfCommonShares",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "purchase of common shares",
        "documentation": "purchase of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "acst_PurchaseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PurchaseOfPreFundedWarrants",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of pre funded warrants",
        "documentation": "Purchase of pre funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "acst_PurchasePricePerCommonShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "PurchasePricePerCommonShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price per common share",
        "documentation": "Purchase Price per common share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "acst_RKOSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "RKOSupplyAgreementMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RKO Supply Agreement [Member]",
        "documentation": "Represents the RKO Supply Agreement.",
        "label": "RKO Supply Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r331",
      "r339",
      "r367",
      "r368",
      "r369",
      "r381",
      "r453",
      "r499",
      "r500",
      "r502",
      "r562",
      "r564",
      "r572",
      "r605",
      "r606",
      "r665",
      "r669",
      "r671",
      "r672",
      "r681",
      "r703",
      "r704",
      "r723",
      "r727",
      "r734",
      "r743",
      "r744",
      "r745",
      "r746",
      "r758",
      "r762",
      "r926",
      "r930",
      "r977",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r331",
      "r339",
      "r367",
      "r368",
      "r369",
      "r381",
      "r453",
      "r499",
      "r500",
      "r502",
      "r562",
      "r564",
      "r572",
      "r605",
      "r606",
      "r665",
      "r669",
      "r671",
      "r672",
      "r681",
      "r703",
      "r704",
      "r723",
      "r727",
      "r734",
      "r743",
      "r744",
      "r745",
      "r746",
      "r758",
      "r762",
      "r926",
      "r930",
      "r977",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "totalLabel": "Receivables, Net, Current, Total",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r899"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r832"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r338",
      "r489",
      "r490",
      "r544",
      "r551",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r633",
      "r635",
      "r664"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r489",
      "r490",
      "r491",
      "r492",
      "r544",
      "r551",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r633",
      "r635",
      "r664"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r338",
      "r489",
      "r490",
      "r544",
      "r551",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r633",
      "r635",
      "r664",
      "r988"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r303",
      "r308",
      "r492",
      "r501",
      "r540",
      "r711",
      "r712"
     ]
    },
    "acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development contracts and contract research organizations agreements [Member]",
        "documentation": "Research and development contracts and contract research organizations agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses, net of government assistance",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r706",
      "r719",
      "r997"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r790",
      "r800",
      "r833"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r791",
      "r801",
      "r834"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r798",
      "r808",
      "r841"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Costs",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r278",
      "r281",
      "r285"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14RestructuringCostsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs incurred",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "documentation": "Amount of costs incurred to date for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r280",
      "r282",
      "r284"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restructuring cost",
        "terseLabel": "Restructuring cost",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r280",
      "r282",
      "r284"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r105",
      "r549",
      "r569",
      "r571",
      "r582",
      "r616",
      "r749"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r185",
      "r186",
      "r187",
      "r189",
      "r194",
      "r196",
      "r198",
      "r251",
      "r252",
      "r272",
      "r413",
      "r414",
      "r421",
      "r422",
      "r423",
      "r425",
      "r430",
      "r431",
      "r437",
      "r439",
      "r440",
      "r442",
      "r445",
      "r473",
      "r475",
      "r566",
      "r568",
      "r584",
      "r1033"
     ]
    },
    "acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of incentive to be paid if individual continues employment until the earlier of April 30, 2021 or the closing of a merger or similar transaction with third party under the retention incentive agreement.",
        "label": "acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty",
        "terseLabel": "Retention Incentive Agreement, Continued Employment Until April 30, 2021 or Closing Transaction With Third Party"
       }
      }
     },
     "auth_ref": []
    },
    "acst_RetentionIncentiveAgreementMaximumConditionalIncentives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "RetentionIncentiveAgreementMaximumConditionalIncentives",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of incentives that can be paid upon certain conditions being met under the retention incentive agreement.",
        "label": "acst_RetentionIncentiveAgreementMaximumConditionalIncentives",
        "terseLabel": "Retention Incentive Agreement, Maximum Conditional Incentives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-13-revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenues, Total",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r170",
      "r177",
      "r213",
      "r218",
      "r219",
      "r229",
      "r234",
      "r238",
      "r239",
      "r241",
      "r250",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r463",
      "r538",
      "r719",
      "r928"
     ]
    },
    "acst_ReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ReverseStockSplitMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split [Member]",
        "documentation": "Related to reverse stock split.",
        "label": "Reverse Stock Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset and lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r748"
     ]
    },
    "acst_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for new operating lease liability",
        "label": "Right-of-use assets obtained in exchange for new operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "acst_SaleOfStockAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SaleOfStockAveragePricePerShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average price per share received by entity for each share of common stock issued or sold in the stock transaction.",
        "label": "acst_SaleOfStockAveragePricePerShare",
        "terseLabel": "Sale of Stock, Average Price Per Share (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "acst_SalesTaxReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SalesTaxReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales tax receivables",
        "documentation": "Carrying amount as of the balance sheet date of sales taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Sales tax receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4ReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote7TradeAndOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r706"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAcquisitionOfGraceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote18SupplementalCashFlowDisclosureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash transactions",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income tax (recovery) expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r738",
      "r961"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r420",
      "r863",
      "r864",
      "r865",
      "r969",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r975"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote6IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "acst_ScheduleOfGovernmentAssistanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ScheduleOfGovernmentAssistanceTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Government Assistance",
        "documentation": "The tabular disclosure for government assistance.",
        "label": "Schedule of Government Assistance [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets, Useful Life",
        "documentation": "The tabular disclosure for useful life of intangible assets.",
        "label": "Schedule of Intangible Assets, Useful Life [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ScheduleOfNonvestedOptionActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ScheduleOfNonvestedOptionActivityTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Option Activity",
        "documentation": "The tabular disclosure for nonvested option activity.",
        "label": "Schedule of Nonvested Option Activity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r485"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAcquisitionOfGraceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r107"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote14CapitalAndOtherComponentsOfEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "acst_ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scientific Research &amp; Experimental Development Expenditures investment tax credit carryforwards",
        "label": "Scientific Research &amp; Experimental Development Expenditures Investment Tax Credit Carryforwards",
        "documentation": "Scientific Research &amp; Experimental Development Expenditures Investment Tax Credit Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r599",
      "r601",
      "r603",
      "r666",
      "r670",
      "r673",
      "r685",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r707",
      "r728",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r759",
      "r762",
      "r931",
      "r999",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r237",
      "r239",
      "r717",
      "r718",
      "r721"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Selling and Marketing Expense, Total",
        "label": "Selling and Marketing Expense",
        "negatedLabel": "Sales and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and Marketing Expense [Member]",
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "acst_September2023CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "September2023CommonWarrantsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2023 Common Warrants [Member]",
        "label": "September 2023 Common Warrants [Member]",
        "documentation": "September 2023 Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price",
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock available under the plan for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Forfeited/Cancelled",
        "terseLabel": "Number of Options Forfeited/Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted, number of options (in shares)",
        "terseLabel": "Number of Options Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, Ending Balance",
        "periodStartLabel": "Number of options Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price Ending balance",
        "periodStartLabel": "Weighted average exercise price Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued to one person in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Forfeited/Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted averageexercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r345",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lower limit, exercise price (in CAD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upper limit, exercise price (in CAD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Closing",
        "periodStartLabel": "Aggregate Intrinsic Value Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable Remaining Contractual Term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding",
        "periodEndLabel": "Number of options Outstanding, Non - vested",
        "periodStartLabel": "Number of options Outstanding, Non - vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited and cancelled, Number of options",
        "terseLabel": "Options forfeited and cancelled, Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited and cancelled, Weighted average grant date fair value (in CAD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding, Weighted average grant date fair value (in CAD per share)",
        "periodStartLabel": "Outstanding, Weighted average grant date fair value (in CAD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Remaining Contractual Term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options vested, Number of options",
        "terseLabel": "Options vested, Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested, Weighted average grant date fair value (in CAD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (Year)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "acst_SharesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SharesPrice",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Shares Price",
        "documentation": "Shares Price."
       }
      }
     },
     "auth_ref": []
    },
    "acst_SherbrookLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SherbrookLeaseMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sherbrook Lease",
        "label": "Sherbrook Lease [Member]",
        "documentation": "Sherbrook Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_ShorePharmaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "ShorePharmaLlcMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shore Pharma LLC [Member]",
        "label": "Shore Pharma LLC [Member]",
        "documentation": "Shore Pharma LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short- term investments",
        "totalLabel": "Short-term Investments, Total",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r873"
     ]
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount",
        "label": "Short-Term Lease Commitment, Amount",
        "documentation": "Amount of short-term lease commitment."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r175"
     ]
    },
    "acst_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SoftwareMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Software [Member]",
        "documentation": "Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_SsPharmaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SsPharmaLlcMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SS Pharma LLC [Member]",
        "label": "SS Pharma LLC [Member]",
        "documentation": "SS Pharma LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provincial",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "acst_StateNonIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "StateNonIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State non income taxes",
        "label": "State Non Income Taxes",
        "documentation": "State Non Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r156",
      "r157",
      "r158",
      "r177",
      "r202",
      "r203",
      "r205",
      "r207",
      "r215",
      "r216",
      "r250",
      "r292",
      "r295",
      "r296",
      "r297",
      "r301",
      "r302",
      "r306",
      "r307",
      "r310",
      "r313",
      "r319",
      "r463",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r615",
      "r639",
      "r658",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r862",
      "r881",
      "r888"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74",
      "r78",
      "r79",
      "r145",
      "r167",
      "r168",
      "r169",
      "r185",
      "r186",
      "r187",
      "r189",
      "r194",
      "r196",
      "r198",
      "r214",
      "r251",
      "r252",
      "r272",
      "r321",
      "r413",
      "r414",
      "r421",
      "r422",
      "r423",
      "r425",
      "r430",
      "r431",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r475",
      "r488",
      "r557",
      "r566",
      "r567",
      "r568",
      "r584",
      "r658"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r599",
      "r601",
      "r603",
      "r666",
      "r670",
      "r673",
      "r685",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r707",
      "r728",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r759",
      "r762",
      "r931",
      "r999",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceAdditionalInformationDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r214",
      "r475",
      "r503",
      "r573",
      "r596",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r658",
      "r763"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationAssumptionsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationOutstandingAndExercisableOptionsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r214",
      "r242",
      "r475",
      "r503",
      "r573",
      "r596",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r658",
      "r763"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r836"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program (Shares)",
        "verboseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r73",
      "r74",
      "r105",
      "r578",
      "r658",
      "r687"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common shares upon the exercise of stock options, Share",
        "negatedLabel": "Number of Options Exercised",
        "terseLabel": "Number of Options Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r73",
      "r74",
      "r105",
      "r351"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r73",
      "r74",
      "r105",
      "r584",
      "r658",
      "r687",
      "r769"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r73",
      "r74",
      "r105"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares upon the exercise of stock options, Value",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74",
      "r78",
      "r79",
      "r105"
     ]
    },
    "acst_StockIssuedSharesWarrantsExercisableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "StockIssuedSharesWarrantsExercisableShares",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued Shares Warrants Exercisable Shares",
        "documentation": "Stock issued shares warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "acst_StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "StockOptionPlanMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plan [Member]",
        "documentation": "Represents the stock option plan.",
        "label": "Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_StockOptionsExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "StockOptionsExercisePricePerShare",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercise price",
        "label": "Stock Options Exercise Price Per Share",
        "documentation": "Stock Options Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total shareholder's equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r78",
      "r79",
      "r96",
      "r617",
      "r634",
      "r659",
      "r660",
      "r749",
      "r770",
      "r882",
      "r900",
      "r979",
      "r1033"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Shareholders equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r176",
      "r305",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r444",
      "r661",
      "r663",
      "r691"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other equity instruments",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r662"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r494"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r494"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r494"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote22SubsequentEvents1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r495"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the success fees to be paid by the corporation based on the outcome of the strategic evaluation.",
        "label": "acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation",
        "terseLabel": "Success Fees to be Paid Based on the Outcome of the Strategic Evaluation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Tax Credit Carryforwards",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "acst_SupplementalBalanceSheetInformationTableTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "SupplementalBalanceSheetInformationTableTextblock",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote8LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental balance sheet information",
        "label": "Supplemental balance sheet information [Table TextBlock]",
        "documentation": "Supplemental balance sheet information [Table TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "acst_TaxCreditCarryForwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxCreditCarryForwardsMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tax credit carry forwards.",
        "label": "Tax Credit Carry Forwards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses carried forward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "acst_TaxCreditCarryforwardNotSubjectToTimeLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxCreditCarryforwardNotSubjectToTimeLimitation",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses, without time limitation",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, not subject to time limitation.",
        "label": "Carryforwards, without time limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "acst_TaxYear2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2028Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2028.",
        "label": "Tax Year 2028 [Member]",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2029Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2029.",
        "label": "Tax Year 2029 [Member]",
        "terseLabel": "2029"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2030Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2030.",
        "label": "Tax Year 2030 [Member]",
        "terseLabel": "2030"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2031Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2031.",
        "label": "Tax Year 2031 [Member]",
        "terseLabel": "2031"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2032Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2032.",
        "label": "Tax Year 2032 [Member]",
        "terseLabel": "2032"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2033Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2033.",
        "label": "Tax Year 2033 [Member]",
        "terseLabel": "2033"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2034Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2034.",
        "label": "Tax Year 2034 [Member]",
        "terseLabel": "2034"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2035Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2035.",
        "label": "Tax Year 2035 [Member]",
        "terseLabel": "2035"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2036Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2036.",
        "label": "Tax Year 2036 [Member]",
        "terseLabel": "2036"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2037Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2037.",
        "label": "Tax Year 2037 [Member]",
        "terseLabel": "2037"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2038Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2038.",
        "label": "Tax Year 2038 [Member]",
        "terseLabel": "2038"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2039Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2039.",
        "label": "Tax Year 2039 [Member]",
        "terseLabel": "2039"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2040Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2040.",
        "label": "Tax Year 2040 [Member]",
        "terseLabel": "2040"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2041Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to 2041.",
        "label": "Tax Year 2041 [Member]",
        "terseLabel": "2041"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2042Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2042 [Member]",
        "documentation": "Tax year 2042 member",
        "terseLabel": "2042"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYear2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYear2044Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2044",
        "label": "Tax Year 2044 [Member]",
        "documentation": "Tax Year 2044 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_TaxYearTwoThousandFortyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TaxYearTwoThousandFortyThreeMember",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesGovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year two thousand forty three [Member]",
        "label": "Tax Year Two Thousand Forty Three [Member]",
        "terseLabel": "2043"
       }
      }
     },
     "auth_ref": []
    },
    "acst_Taxyear2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "Taxyear2043Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TaxYear2043Member",
        "label": "TaxYear2043Member",
        "terseLabel": "2043"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r987"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockbasedCompensationActivitiesWithinTheStockOptionPlanDetails",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote13CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "acst_TransactionCostsRelatedToDerivativeWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "TransactionCostsRelatedToDerivativeWarrantLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction costs related to derivative warrant liability.",
        "label": "acst_TransactionCostsRelatedToDerivativeWarrantLiability",
        "negatedTotalLabel": "Other income (expenses)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote3FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation techniques",
        "label": "Transfers of Financial Assets Accounted for as Sale, Valuation Techniques",
        "documentation": "Description of the valuation techniques or other methods used to estimate the fair value of assets obtained or liabilities incurred in transfers of financial assets accounted for as sales. If a valuation model is used, the description would be expected to include quantitative and qualitative information about the assumptions used in the valuation model (for example, but not limited to, discount rates, anticipated credit losses, and prepayment speeds)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesTaxAttributesAndTemporaryDifferencesAvailableToReduceFutureYearsTaxableIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "UnrecognizedCompensationCostRelatedToNonVestedShareOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost, related to non-vested share options",
        "label": "Unrecognized compensation cost related to non-vested share options",
        "documentation": "Unrecognized compensation cost related to non-vested share options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year:",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r400",
      "r737"
     ]
    },
    "acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits resulting from change in valuation allowance.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote12IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Positions taken in the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r737"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of estimates",
        "terseLabel": "Significant accounting policies, estimates and judgments:",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r132",
      "r133",
      "r136",
      "r137"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "acst_WarrantsIssuedDecember272017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "WarrantsIssuedDecember272017Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued December 2017 [Member]",
        "documentation": "Represents warrants issued December 27, 2017.",
        "label": "Warrants Issued December 27, 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in Connection with Public Offering February 2017 [Member]",
        "documentation": "Represents warrants issued in connection with the public offering in February 2017.",
        "label": "Warrants Issued in Connection with Public Offering February 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acst_WarrantsIssuedInMay2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "WarrantsIssuedInMay2018Member",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual",
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in May 2018 [Member]",
        "documentation": "Represents warrants issued in May 2018.",
        "label": "Warrants Issued in May 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number Of Shares Outstanding Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r207"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted Average Number Of Shares Outstanding Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r207"
     ]
    },
    "acst_WriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "WriteOff",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote5EquipmentScheduleOfEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write off",
        "documentation": "Write off",
        "label": "Write off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote15OtherIncomeExpensesFinancialIncomeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program",
        "terseLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program",
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.acastipharma.com/20240331",
     "localname": "WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.acastipharma.com/20240331/taxonomy/role/DisclosureNote9ShareholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Write off-of deferred financing costs of at-the-market (ATM) program",
        "negatedLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program",
        "documentation": "Represents the amount recognized during the period for the write off of deferred financing costs of at-the-market (ATM) program.",
        "label": "Write off of deferred financing costs of at-the-market (ATM) program",
        "terseLabel": "Write Off of Deferred Financing Costs of At-the-Market Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "44",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-44"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-7"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/720/tableOfContent"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0000950170-24-075875-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-075875-xbrl.zip
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M8YPOQU87D4T,CS UMK/^K<<5<KLG!_N* P+2-(E"A94#70(G-G,AD5(;PAB
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MVE6'K947 BKF#*P_U_VY;L[UP5=?B[HG]I[8&V)_;6$$/JUZ1B@-)2(;:#*
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MUQ<GV+C3;L10N$JM-Y/GK7@-B[D01L FKI@)C7*0T]Y3I<+FF( ID!F'PY&
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MPGN=S1H\:=3X23_KKI&1V&OI?!HY?62A8 4&J6\"5]?NDMXG3V@K-^*W&$E
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M0@4C@W)+7AEJB-#SA&^"XD"4IB/;4O?-U)1 Q7-F9]LN>(.. '\<%U 5GE9
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M*X%.S[2R(>5-449DQY5+G.1Z]IQNX>"!B9X9K4BO$<%(^+Q.V!HB^,G6 HC
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M%8=*0@KW?HV[1%SCG/* A8Y2,%CXH.,N: (+9MUNS%$42FBO:247 L9<U%5
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MUZU6=[YCA1;EW!D<F#NT/H=VC4_;KO%X:-<8VC4^TA%_12<G]V><FK]U[93
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M5Z5W:X",@N-83I^"X.,TYUI=ESD]3$KGKAQ3FELXKL<)RN/ZG4P/XM_ZJ7<
M^Y)+PG,0JM/DO:@UL7P:3&I!\B_QU1T@^:_SLF+&F^=!H_7]/Y_E_;\5;!NH
M#B_K>F"5-F'U5M*!)Y\]_G\R<Z;(&/)9LF%U\7?^(=]11SSYQM<X"-,S@;7;
MMD\3?.J<_P$V:IX;RT"X;7@>_0OJ6H<#62GL,!NQ,W@9*G"<0YSBYT#W=5E@
MBI@A&TRV;M1//U\&XJ5?)M>1>Y/?0F%,=*;(EQN4],:1T^[I0F(/?#?F>7-S
M<Y'S=G!!&TXVMP6\>Z?_OK8=3&,WP#MB:\PA'+VNCM;"X_<EW#-@K$-PT3;<
M :'OP(Z$.,S>L^ KH3K7DH'LT@\5(D;F%:SKY\N+V ,:'3TGHYF2Q*-?LF8:
M$P9G9K&UH"2'^"1G(AZ)$5ZQ^.S<K%<6P^CLD'E1M$AN.&ZD@Q7-9A#FT$YT
MRG.9&(>[P5E:MW4M2MOW8&1\<>!OI4"BRKJP<A7D*2L*1[O$2;+H/.#);**<
M0(J8H'[N:>^]8?4K>)K.;2XH<Q(*^[ECTZHX>VQUM'SLGX]=[_8<X/_9K\[5
MMV:REW0/QZX4JJB?'%0309^;]^_)R]*MY"V<[,7([[VG\?J%"?TC H=]O8##
M[@L3^AM8D/?\J[+X/Y\ #?#/)_D_V[)[\4]5^+C;I.XD A5^]PG%+S_1I:V^
MDTM[?7?V-I[4$@/<P?O&:^[L/=->6@FB6.'!5A+_<![/!U^LNC?%G%\=AVN<
MAVQV?O1&1)^J8S1,22<"AW+M.)<'WZDD.3WTD>]!^K#8SMN%E3"U6RE-#'G;
M-V(K$]LP EPE6#<*=[(E+NPHO9MI::BV1"8)MN*A$O4)?R03U&*:.2XJ)6.'
MG<^'PT_H,0T'BM$%OWLC@"TM%0GET2=___8R$-AQ_F(EGUB6CO$Q[4W>%H^K
MIGEA%)[XNR!DFEK)?+M^1?_'U+>X@@C_%7,#MY'3Q1_Y(7#J;=T!>5X7J[\V
M-V#ID=9I+AV1<(-2)--GB]=1E* 8E6=T@V?-L$SGZO"B6 </5,E";!<.IH>Q
M-Y%V+/+1X\[X.&B;'>5C/%]#^'A$9J;/5%]&_.CQZM=L&I'<B<FB9'3-M!!J
M,R)(NK7@2(YFP*W7DTVN-,Q@H98"3N5=>1#_-!9F]OGQQ)H$8#JY(W[*9(=&
M;GR-WDQXW&5WZD%WCI7I_9RA/7@<3_156.=6K)RGP_A5,G+P6B8<O3"]]N.Y
M?:;VXN7FUEIV*@9AFAU/Y])M^8_H1X[U]0X UV:XVW7E]J9T3Z: %P8LH@HH
MAH:;/EEYJ$=5L.,+18O-KE&[TSSK1OF@_7EF0\&R "24V[+<2NSS%VC.TAV1
M__,V,QSX+3!1[G7922]OO#;+4(@#3:+CBQL]7MAK\CUM1^HJH!/P/=V4>##N
MY<8=>M9'M#\&79_U$1W/B]5E?0ROV)JU87D=<,'-T)W:1S?-4!7:G\3@M1/*
M%I6RM"<I)6:3"LQ27>1".Y/QH)@9AO>.;6XDX>)M=.P\:%/<@^W[HXG\WX0)
M\2["/>Q@.T<+%O[*"W[J;J9T1&8D#.),$?<VH_K%^S>9)>)[NUQ5D9<1Y(6X
M1[.)G/^]AN8 !,7&Y@-[R=>T]X,[I8F(K2K!<;"[/QKV(SL3"L"Y&]8X1 $N
M6.1,T.$Y,^"2>>>!3^Q<O\XW+\PSCW GAK47-ZQN%U>KCC=Z'A<K/!T>;<%&
M&P\ ^*L>7[ /6^P\V/>W>6G4(!'.!(P=^GSV.$4;95:KR\XWB'!)X&P&W?%)
M B\.U L'2@0."\![P-0BY/_)]K#NFW//PVB&(Z"W!.D5OFZ7,9Z$6*'*Q790
MNY'+X U^@QV0U22NRX('WH<VE^1!\@/K\'+;+H2*L5'X)YF$(/$%^7-&0A4,
MC_FN:40N^5M\+>H"CVE0OXNR ST-G9G\<FJJ?NJ/04[1'>AE2TAMUSY]P?=@
MQ_WXW.=]WWJMTA)9^8@BPF>Z(Z*(D7'/$D5DOM'F2EX8B9MJAOXQ71[85Q"<
MDF^$YL3R<CXL*WWS'7[&<":NDR$O/<^^Y2UG@[&CEVEE<GJ>J4KPB?!^FB'%
M6397/W1F.C"XZ0'O?G>36 07\-CMD01C\9W\^HB)Y5>>RC-7;PH"7N85';ED
M4>.XGOME=LG&";XL7H18]!1Q&:]>P+XHIVXEHA.E/:=H\-6N68"A'T5F^0'U
M$I(=KF1<U)AWBZNIQ37'@++RM3+%A'/18CP95\<DCC.9*I>T:-7$S@@$8"CX
M?CAO[8-??G=SH[\ZJ:.1/T59O8C*8573@94?9E1#F!/X-^:2VU;-C347@EUV
MI5DD_G' 'R]6O]"&P7GFC9Y'BG!NPB9G7ESJG5YXMM,1\9$P+1=:@AAM%L3V
M^*I47=3QUTRR-*-,B]:Q'+'AZ]/)7%;S.?3:.9'%U.<O5R*#VMDF+!]<L0J9
M#JUK?LM/A9?;B&KO+-,>Y/_^X^GG%Y^9XA\73;>0 :+S?,[3>$]EW_V/IU]=
M_/'<UQ;IFH_N1G^(P.!&<S=G(!F'G620OPFQ#M>0#@*"C0Y1E5)D I@[[Z3%
M1O]/'/[. 8:[7W-DZ#&)X9A)!</4)_V@4DU/;-7?N(K6]YZN?Y<T8*22I1L(
M?S]M0N&0QEAB7!!1S8*+(-8#Q17/A<B;_( ]UM="XH;#P*$EXY;I%?[]V\NH
M2,(""'.%DODQ?F;";#E'[$!W"9%G7#Z]Q@$X)6D6T<7X1YU9V.S9:O<L\F5M
M4:G$P&RF.S5#CODH%ZMGY*PDN 4Z-72%)W2?\V[H';!ZKOX4=W.[WATZIM@C
M6^QS;2T)B=Y9QOR[RD&$Z5=)4MF.7N?1N9JC,C6ET6.CG_LE$1LC_Y%L%;7@
M2' -3>9CHRVFTTLAZJWZE?!+HZM)&(!<4FH-69X]VS9'\TU6*+(;]%_MXL(3
MMYTW6E>1S'NZ$>_1SCU@ D S4G0'F_IQ45:#Q@=\^ !2N!*Y<+J+JLDU>HV)
M/T6KCBS\^=;,9Z@M!)8;B#O/>O5<*/2FG.^;P1J1M6JG D1]Z.U 0^<3/HY"
MX",#NVYEE6_M#M\FG%Y5^5#3M])PVF[#Y]FR]#7=O8V51I<U$W_[A5Q3L(-N
M^?_4X@A<%*-9&U/7GV]J6\S"-G6B2\6/**KC1XV)DR^#?OM?3<3''5[OZ/'A
M6W.=<6 .NGC?TI4Q_ZAGKOIB=3E]5(@$[T_^ON# WRT._(\+#OR^X, _S'"[
MWY6M*+UCVXOK,7Z&D6.RL*V(1K?U&^&_DC#!NWT?3_^^2LV<OWO_.=!2'+RC
MXJ#G7:$-HAVD;*&=]XXB,T%)@<] YLH&#3>O'4R/T0@SL"=6MZHWF/UTBFKJ
MM%IAH>P;U;[OKN_T_G?V9?%]H![_AR3SM2%A95SAS%4QG<C\L3L\QNYPC+)]
M^BC*XG'D5D=%E/ /@3CG/[)@.0,7N1CL%G2T':75+[B V=R@JH!2(44J.",&
MKVE/&&J% 7>,@:&3(I<!YC'^]K9JFH+^=S>T+9('/L+QL&OXSK8E_XJ>.U)0
M2E!RNV#Q!_397@F>Z2T4;@]ZEG!C#)\5/"S=^^-]7CAXHYR2_I9W0)^"@HVF
M-2^5<:*AA)I.JU2N ,9<DJ[.5=O')3VDUA#6*;B;H2J&W%Z_EA\<]4M^KP]$
M[:EU5I8X90+<K/%_F '51&0[/Z1)E4>]L*5Q/GWBI\&$] $ _R2 YNAFU7*G
M)NIM69K4G.%)?2P/+[4)[]K>KT?WSK_DA9ER<<1WL=__$&(;@U4*B+*;@5"V
MCA?5"V>%,M:5T=IAWK.3SNQ;7-9J>FDPD3>NRFT)TFY:*M :J98X:(F#[OOR
M>^,6,&/;A;E^ FT_M+1+E@?:$_9,C=>%/I"N+5;%,9#/V2])]36N<:;2.\P6
MS@-<6JB5'-Q%:C_/O+X#2LJ80;N4,"$]6R-"%;9M4A)MXFC[0]4<;<P,1Y(A
M/?3$JM#CXF\YQ70IQ!5HU;*JC(#0?X<NH>H:/D0,R9IM?' =.JT]4_0S&!=E
M/3#[X.0J;@Q U>W*K11(UWF(5*,(@!O@S."4V\A<TL5BY)A-]V36Z.+^N<PO
M\!FL57?B)','SCR^RTKLK=NT0]E'M^&QQ>&UA]<AG;'9UMO%ZB<YEO7-Q'GC
MOX++CDZC!>XP^Q/:D:I'LD7W 3L"E$,D\C6/G\E=Y/1.&6Z.3@@/A:DHE.P_
M'+"V3$84N!-S'Y/SDWQ!QW'%>!/2GI^=SNKT]D@,1DX'KLH7"#ZC8M+H[:'F
M[GJ)9UG10<\8'5SBM;IS8:QI:&M,(ZZ8Z9F,$'>)U<\'OT'$"W4*[7%%'.<,
MQ]YLFK9@\)$7UCQMZ#.P)MU_H[<87>U<A>V*'ESMFV5VM_F^P:3JL'=M@P8B
M,SINF%F2HWRC4<53H2=;7I?%@'X:7W17DH/,]7%AV*$3S5!M(F26:?EY#)DU
M\)V4KB=;TBKA'K-W9.3,#+_9@2>^OM)Y55L T;W.11B<^E"&$D<P\L-1"*/]
M=@!S;)B1<I_K4CMQ<&:1!VSEY[HJ5GN$(M 6<86S-7_51D-+MZA(<NZ*2UGB
M_B7PN$MHI!-@"P4)QJ"5BB\PD%J^&VGJ8BZXW*!G[;@=RB/FLK65:$TW-_TN
M3.T@3M#<>JZ&,$HRQ!FY)3U8TH/[ODK?D//HQ-R:VVX]SV> SV<I946T8/U&
MQ#$E?984WX3]0>@20HB6K7@S=0Q!R<**Y&_E%8).CZ>*![Q#F!6&)S3_WV',
M0C;KJ#ZK]5JKWUZLOI-B@_B(U0T[!]H[41T^ =& M!T=L?0H.RU,["/UKA$M
M@7JULN#;/6:V[V<>_)WYVD2F!4L*M#ANB\[L ]_L_#W-X\QE7)XV=9FQDQD5
M)V\NILJ,2^7B,G$P90D@YWKC\A<(MET7(MIMFW>F)))Q)(=Q1QE3#.^20I.N
MES*XA3:^V-@P(F2H%4UGGT?Y&<=6DD%IK12HN:-&B*W;:Z(0I6OIRQ7/;Q,X
M\=N=07(I#HKY0RB&[B.C"Z8FT&B%]C&&LDMI6V:(W#T4K?&5KLFXKM:/]>-P
M9GJ4S,Z /6]FJ^I<-9VR=3$+?#(B5VX5$\F$P?(S;'6)I7"*)+4"3B*1^&8S
MM;@9Z^+L/7X#2SO[WFP5=Q'0;4'B?VCPAU)@::+EI@#EHWJZ+>5;>;F7#6;-
M&$7RMU>TFKL^!O3QY$(\8!^.= \,Z\$$6W=%LPYXC2])3=U7DJ<+AC;0/R-D
ML$1Y,O8>]RJU+1=AM3W;$NT%#?:XP5?!9(!_.S5D-> +R)#,?J(Y^7K.OM&:
MX]U\SPWHG<NK?K=1J#^H /#7DV4/Z]IU[/QU6PF$/$KTQ6!OIM_>]*&<,[?M
M"*Q5N0@2BHK";1TFTO3"3ST$T7F1,.KT@M7MIIL49%IWE;=%I=4*>B1ECSMB
M!B+P?#5#3_<DO$PG'G4<K)R1<'\-:5/ Z^Z[M.GM(8 /2]F48OF\;., S(><
MK3L,(KT;-NZWH82[F,N':RYPCD6;W^3<(4H*P4<!C:)%1EG78C&+Q;#%")JH
M&+035C%%)RH#5ZGNSV(G#]M.>" FWQCB.U2+O-Q#WG.JA!:?L=S(]-;1[UF+
M-2W6Q-841]7[IG8]K"0'XR>G*P?R/0EGIT3'V+B^0>R]V-%B1SH-,^I(WZ9T
M>''"?#[::L2D%;U,^;W3*;_//UNF_)8IO[=%JC$M%?$L G=1F*X=S8J$(RPF
M3VA=N5\/X)L>E &]/@8>  8G<B],J]3X,61NOV]:US!+_<S)2G #^-H<=T?I
MGY4=M[R6+J!'[4D7Y132RA-(S9P)T,<@_>>XYK9BJ-3<8#TBA[;IT=.EF[52
MG]Z@ICBAZ+ZZC.G43A3DA&6VU9D'K='-5$&E9+C)!^T3,^^V,G(S$P1R<:=/
M9;OZ;2BNA&0!/.1*,S2]_^P<=ZWGA]^.(2">U?:AE-L_H+["772N>!0H!>\R
M*C)H63*<E*[XZNBU6A5+B$6;%^Y?0[XY9LD,329K@2DWP(]_Z%2J !P]_G@Q
M> "'W1P!L[9? :(-%$%GENTGH>)A([;F$6M(U*!=S/ICN]%O77> "B6'\Z#G
M@&_TT^7>>O:T$<A@H4G*M[6VDP8>-&3!R?&(9#HQS^TCWT SW DW;Z^'JB;+
MTVVIR/?8@;B6P4;\.._[?/-"U4GXA-=E2PZ?_C+4RA@-,E\1QLPF,VH\+=FV
M]*UNC]G(5I'=HP%*&>UCP4PNWMHXY847U/3SE70F64[)TD1@N=FY=%-*1AY7
M\W2-AC QJ$PD6A&F&1,^;MLU)YA<JSP'<JAD9TI0.F7HH/$6WK"H[E&A+@R&
MC\H%"<A%J/ "[2SF1HNC()4-@W/R0INQX!!8QO+)4V#.'?_(YOCL/<0, XR)
MVYT9W!38- /;6?)$KDSYH>C\3)\DR*:>8[B=SG_$KV#RMH6FCX\=WIX^ 7;<
M:LY](XN'[Q318-#OZ3*)K/BV#A ]<29XHZHTM%JV @*3*5OYGA1O4H&6M(>:
M]DW'&&[C^PG][QG8T4P'/0R:X@6Y8MD6[M^-OA.=PY^T2T'6_FW,H/R+Z_S@
MS;,YFA)D58IQ6,00[]^-OO/0^,^8T"GGY2287)59R:;^?9YET;)9QZ[\M-I)
MTZ9(E),ER@[PD [J&3HTD\Z6?3@O\L%8[%L4Y&$RQ+*;CK<.ARE:]8RU<4&%
M!Q3/".R<D'PZ,=-XV84OQ%.$7-IA7LQ3FC&ZM8O4832LEEY6V2MP_79*:3%J
MU_@E4PTU>9BX_RM72RZI3$,CN)93AQ"@="PF,_-<N^EE!SF=V;)6T:RZAJ-&
M;F!IMJ)(\M\H=NN*DFON#VAE?T!+^ZZDVB*B'>@'LK1J?TSD1"-,9>L09?M$
M6*<*M,(K2ZZI4!7M),?E8B,,<YM?-SZUG=G_?#VFA%"C!/>B_3CSY?<WK:5@
M@_L]S!91@MH0]H=C]\O>?>N]^VS;>1Q?)B%@-)5B0RE&8V%9?Z-%JBM4"GA2
M'1NBRI*IEH"0P8A[D.Y!RO054T$=\B,(ORA%(B]0=BI>IFE^Z+=,_ E3J@>J
M@HF4$/] \['6Y2(:H./__8Y\U(X6&O_\]$FRN2N5K;OR=2"EPXZK.9U$#$R\
M8:- ?*H B%]+F/+=MY<H"DU. I^:=+!X=HZ3R'AB+B+%5I$%U.:4RJI.[ZPJ
M]Z7*M)YXCI[#S+-MB9AP<EA_*$]XOJT&9VK<AZ'=[)3S(MH>_)2]J%%$AY?.
M&6/H2V$V]WL(/]88MZ^/1@XA$'Y]4+3@^L'GV*D<,$I4TYU*F<]FB$2TFL9A
M6<2X$<\^^'>*ESZK,H@OF=)@D"(_(348&YE_95R#BU_4*4O'Z"#9LM/V(PZS
MN/6/[4:?S^LI,(-*Y&LB_IO*795=)8SFXAM\[D KM+YR?OXF7J=2R(=)L:08
M[%8[O:&_FW*D^@5)%QQ74T-__=PWK8KJI]DH:Z,G[S!N^S\<\0G3ANLV;2DU
M9K;_-3GA+09]OV>?A0DW_@OM=-P3!RN+KJ[IC_T:X\5MVU7G,.;+*9K>.3L=
M\-#W6M5COS?B&9H</OHQGTBX3[@6CO>5'WC:B*ZP=U><R7%;(N\ZW6G+%DM]
M3R^K+75T**G%X,#P-60F3BKYU5 $)8GHMX'\D6\J&V>IFH\G1U>;\(_UT!Q@
M-B7O)EK71F]T*6M_?#<JA$S,V^1]2J8;_@L_M!RK#ZY==L[1()!K.A0I<EDV
M6U<@=E(5"ZPZ#3\$Z(<>I0\&=.BN K%K4+[I^C2T2'=?6&VO!%D4[.1"^\/K
M$940;+U%<U#IX^"A+!+A&^-9=VV<:;TSQ+HI[$BG!3-%G:.EB894Q*R2,%9)
M_))&1K[WIG<M^S['(?)1^G66EYB ;FK>_)F40:]XVU3TX "]6R;U'C@4>4)F
M .B: L T+BU<ASPFB3!M1Q ^ \2S\ T:^"XX]\6XYHQK7-96M<W-CF6CDM!O
MF0U=;"C,2HPSA=-Y0193<7,GJ:KR==,BXEB&<!;#&AF6JL_X;-,HB5C4[.$-
MW"SS-G<Z;_-DF;=9YFW>9,%>QA(>'9ERWI:-00SG,.IS-9TYP $*2SU@$YSN
M*[35E#V->4V3]UU^S:5US_NKQ75?SI:<>BD(W;\;O1-AB6E?V8M+,$@(^'2I
MY\3D@(8&$KYJE:PYU<J;24D#Q1X3%1YVQP[E7]0Y:S1- KU3V>$W?G;;JM/6
M[E*0^T)W]O'=Z)\G.*HY:-I<W2.!H)SYT".LK@+A66S3KVF<V;QE"G/YN$L<
M,=W')/LS, ](GM]^L7EZ-[O=A-O- *G^\45",G$#:BNTJ='<U5*+7#(R![D0
M+NUO@V!%K[RS@H;G28M4Q*L9K;\<<\$@9>V"J,%UT/I::DN+P06#\[-4T+'P
M6H#>I7ES,^-"4*S!Q6)(BR%%AM34%$^(- +/0BK0*2_H5TQ#Y4<%/4_0;=S9
M8F6+E04K"S5OALM0)(=PB[D6*&V"7"G/'H,-?6Q6&/C)*\7S0T/* Q\7$UM,
M+'9D J/P]K'BS*CR_FO>B,84"E8.XMI2N5G,;3&WV_5@8EBR<'IP83)&NPI4
MD')FPTI/(=*H:GI@3@Q!7ZQOL3ZQ/O%IU[<-W1;#60Q'# ?;6^VNQ'@.PQJS
M:S;])EA@T5!3_@PI09!7TCFPT30(=U44J*O#!'LG%"1 *EX!MXCS+N:WF%_(
M UIWG5?>8W48Y]<-U.:/>29?FG%)<!;/YZ#.D;?HOG2&,17X:YX8J6=+_N[;
MR\=^OH5V;1C&U8*K6:PSM4Y/>U9'"J@L*:<"7S;HIE#J!P^U^6AO]/E\(ZF9
MQ1'[IBU(%SC35&PH>!$L$^"9 /9SH5U%.<!K--%.MGBS> QOJ&T0SZ,CX@:U
M(242=50A4X!6CB#U]S)B),#6RBTMY/MWH^\< R'B3L#'!XL*\\QS3G&3'_*@
M<]FN&*(F<E(Y18,ZTLN4@"E+8,JBPL*$LZ0):JWS1H[@UGA'/IS7^&#L]0T1
M8U6_ PLP3("5ZXO4'/-5M\^K*A.&'+CB[N  %J#0<LY4$P%[(3+>-WW$,A.Y
M]=&,^TEZJD#5PW-F=2/E[.14YL*M5NGOP*:\C9Y9>!BA#5JG1Q Q:V8QQH%T
M9)29%QO^4</#8XAPL0-QDB9W]=2&7H&-6SN])3H.[4)O]/QXE(;VDIVK9>X&
M-)G&CKB?$ SJU5RL_H) 2S)'YG'8KDKR#Z%3(*?C9PLV2F@I]<[&=P,#!*Y'
MCOE$F8V,PH =D)>THWM$1<1=E1OV/.0WZ+D?Q"'EE!6T5RY^T?H=M@4[?M1%
MC<@.4@L)&W6$8-R6"D'AEWKB0FP4U5/3F,3>*2_L@XNQ[+' RU "*M>#S+E&
MSAD0&Z<\29[ZJF(\SM0[GV)<"M%%H :W9K/Z8:^*&\47450!.[6H1:L-=.5\
M!7LF,_;"A?+.T_7%U!V=S6<"./%X.]28&4Z?@IAO8$"ETY9P)MAL JMM[_*]
MX)$<CV(TK= L)#5:. H1U9T]!YU^8U+(,SN5">8FW"1&:BY86!YV]*_7%>$1
M+%O:_;O1.PK!%.,7<\ZE!#@3\H[;41R2GUI=8Z1>RB\MLWWF7==L2BX'\D),
MB=0B!F/92XP\KIH;X(TXXA;S_=AN]+G,SYX"7$9CM4I'-&*(]3[R=V0)XBSG
M+7V&4?%7UJUGVK<194U$!Q<S$/%*B*KB:1R1+HE((%0ZS=C*%WSH4EF,Q?R@
M\N*X^.)QV@G-U=;J2H$ DSP^_95V&*8HJ?MV:0$O)A6U@$&F49@ #\M -D)[
M6D'+8!#",]JNT=]#F+(8SV(\:CQ#+=LA\@LES4)1@T+![1:S&BVEE:MUWK9^
M'/V$WUI,:C$I,2G*[>MF7VXHN,I?U*S'$AJW(%/,O:81*'-[1:YW?1!94\%L
ML'SYG4\/FY2?%JM;K,ZK:>\/5<F=-,D7\I?9RM'?FJ/26NWWY54;2J_,J4'_
M_T9"+OFJHW-5Y;4R<Y'WNV9TP"I?MTU^FV&)A63@'9 ,/%U(!NZ$9&#QF@_-
M:]KF2M[2)?LT?"CXHW60\9 ?VZ:JY'O+IKN83VH^TH[9'%?;:D#":9T/'C\<
MJ[J9,EMA)61@J$P65S(,26BU<Y1%#)/-FMZIY^46"3Z1_& 8O=7?4"*O5;Z>
M"R8+&=MBLVJS-TW[@NQVXQ+5CS(JK:$CVCH-$(<:Y/!H]G)##K5KYB'FAN&T
MPKS8V6)G"K"/&4DW++\4M8]'/6-729H1FA[GNG6+D2U&)D9V"+P2W:YI97A6
MMEK8$]._L^S\M1 #":89$AGY35#[8KY)AGS0N0;0F@SM!,2G*?""DU_,SYM?
M%'#%&L<C [QR32CTY0:+B7(-K\?L)9K)%"<:SM$O'#VGW;^&_ 5K1!P/NX8/
MN:V:II 8<ENV;H'DW^,;?2^89=]]+4WE?@Q68(-=MSF#QUK'W]XXE;U F?!E
M*5*W?B2<%2_@(%%%M('Q>*0<O;BMAP=BHHX3$]5_QI7%E%UAR-= $_Y4Z;2=
M0<@$LG@2?C'1Q'B%(NKX@7@@XAC3L] A?GPW&D.K$]3PK&487%/9AZ"=&J^O
MXOQB4F!L&=@5. %S+0)D3\J?0:.T[$;\G<(-$IT, 1!?#]"EY9X>C%RS@H2@
M+(;OS&-H;4(G'HT9']P8]&;X\0RV*<N:;TY([AJ&C@J]W9G?1U= [W)?#GO/
M"X!G)(#8L$J+D:#=LCX?SOJ,)'1%A%<WHU>L,8]?&^\DV>_9EEBAY59;D_3!
M6%:']JC9S2F:K;A8_2"CP*N_?WN9,+&LOOSLRT?K3Q\]_=0N3SK($0(_4QDM
M75TJ2\7R8>NCXLTAC,BA]6??5/3@%"#+?WGRC14K<QR7GN[0TC^P]DH=BXB8
M^L,T/+X:0\2]\OB6Y_W6Z]9=BR^LZ>4:K,ON8/5(+^>2[EBOXU.1ZOE.=82^
MHX@V6WU+/Y0RZ+.FVSNH:UW2;=K/O_OVF?]YQJ]37]U(GV?Z;OT7O'BM"?S1
MX\?M7AO8TO)"!.) '2/  4B='&6)QU\WE*756^2->&?P13*=O;4Y;$P^Y!O$
M(3*ZX<:/"T^!':5953>L1??0>:7&]$+VB"%735TQO%[A*(6*#0F/XLH8,EA)
M3.K,&!3H^J&0>&C7W(C9RFYD-K3+NS-,!H\Z>M)%T['(6M-2RM)1S%=?];ML
MU3:LC#VA31,QAUK6+S^9H>,A2QM"!]OC[":A"UDUID:+#LM@73:X>1ZG[Y6\
M 3,@+N?I(=E#\W77M.L@#;5NZ GH,?DN6W^J)OQ195'UTF*@K;T3NYYP!;[V
MOR=O25?AHI-0VL:A*"6[=9&WR-<Z[\!TVI4%Y/(*A['M+16RK)!T8G"*Q=!S
M%B%GNURW*MV\3Z38X]D1N?K9R^; (,B?>A5+Q )J'BG2F ['\ETB-P3U5?2?
M59\K)?W,HSC'_$?&E.,AZF N-*9 L[J?3JP(P-J>TIC,D3)@#< JS)+IV[/3
MI:_L<K-IVH(E5[- +8H(1U+UZ3,Y >N^.0WZCP*PWYUX+,'+_;O1NU!F)^>>
M1N(3&Y6]C#Q>[S:[FB[]2B0F4]\1B]?Q#@@V&]]OE J5YC 86G.MLFC;V+[%
M,)X&HEK8TS^Z&T6D188TLIR20@?:M(]PK3Q@S$XMIF'FGDV8%T$!J) _1H;K
MS5/,D=&UR0"*BE#&X20]H=UL7Y&/GDR;P'^'&'F?_X;R/9==;1SE]()(%T_8
M'W$2RE<Y>.OM#[+>:,6XO-WL@A8UYB<?BJ$\F!7Q?51)C V3+97C\9R3(%H0
M5YP"M!AGSFOLY)F8O)3Y8\.A@VT<ZYIAB+VS\6IO4CR@' V&TTFV,D>.I=(R
MJ=UXE#?M5"6*I%Y1.+X!JP0EB2H+CO*<K7EYNL@<FP&B<L28(6&P,'->/#*3
M@>$<<STJA&RG[)JFYICP_.^3$;CHYWW3K)"]FUO8'#=5.DUMU:,Y682H8B I
M\GEW1UZJI8=*S_S?DO6*:YMW9<^3#9->FL\F@ NBO5IF_.=^?'XJ.MYS5[\D
M/V>.X,T,^XX9D%SV].UC6H'EML^_P@G)#^5,%5U39BE'V 30HZ*G;W#WO+H'
MWO!=N84):/2>.\&[B%0%UT9;,'C!@F=456,E7=">J/$I^H:IN+P*&O2ZKJM\
MJ$$1,I]ME5./1A_^%T_31O*0FO]6[BJT6GV!>AA!\KRZ5G)5DR#9F_5[V';O
MP;Z[+*FW<;=3#7.C'1F;==/.EUHSV2_.VO=J+;A2V6@MOLCBX"*SDE Z@BX5
M/F5$B<17O%+0&>*W,=Y!1M+C VZJG#5A3,I+(J,>3#^,A."RJ3-2'"DTG9O?
MI A>P@SFFJ[[ELLM5L*7IT/_;(!FC'M>C'OD\E[AMBYFH<$<S%#V$1T,_3^1
MQ);BO=#!@"IE#Y9._(&[:'3?J &A^4?;9+LW\DV\@&U^C1J7;O6<V6O-#FB0
MJU 5+4JM%_MXP0>1>Q:>YT=#3Z!KZMI55GBTBS9_5OH-/BH[30(JLHDS+0GK
MF7#?8/Z(F&$;N,LR</WWD/?(RSIA/=JZ&R4*DIABHO,[CJKY J6MMWN/KG81
M3KW3F:;/EYFF13CU31:L9T2+(KK9$GQP/4;%Q;O4C+X*[14_,^_G:^7_/L&7
M%!>L;XUNL@9-T/RNH^>56QJKK'?13L"\;'94:SO5PAE3T;:)-@OM/8#X89N@
MY^3/R*>Z6'TWM'#=2.DS(5P5&FG:MC9Z8SFB\@,:=)(3"CO<T/VWJ!K1-I;O
M@:+-PG/CSJ$5VGK:&.AN]%LB\$"6T=;NZ+G1MTY;VW[;':2IQD\1-6=I@MC&
M3X?@B>>CYZ@&NUT=;>EGR1PX=6:^_WW^@J,,REQ0M9 IUH'_,2U\T(VY*XD&
MZ/::]M"T*MU$AW'2F]Q:*VOF[+ 27)Q< !=*BI@Z)Z[H1#8"*D!T3(?*,'B!
MMZ=E3G#\8% H7E3T6>FT!AOM-]:GC"B#XA<VU!Q\2*^[.3)Y(<R('XR+@?:(
M5> 2.45;>_N49RLJZFY5.Y13\O8853.P7'X:'SI%\;,16%LZBPH>HA="UP:S
M)X/MC E85\H@N$&\J:I:$K E ;NCF@;\0M38J <*]IM!ZEX4K)TD+6(W33;-
M8RY2R+,86[*A"&^2&;>B;0&3T?WI+[!R)N6*-UH7[_QIKNY/++\LV@\TQON%
ML7M6Q:  33AEDW)&T@C)/+R&RP)-E7F05>9A1N"1W[S(K_B?'2WF' 5Y2N]H
M'WS\PKF#?(=ID+EOP&%47W;\]XC;-B:5S1BB2ZO2<GJ-'V91?W-5D)'K"<L?
M]7SOB((>%NH#$2KQ9-/459WC@4X%U@5T''U!8)(#9_D"A7QV*16B$@X/YY%*
MJ/=%%ZN_-_7CL<M2VLT9Y&3B)ND91(/0% <-G:#?&*\S=VM<<#"TI0^41AS#
MFQ;5)8G-,&OHZRI;^,G,Y%%6E4.AHLLB;E[ ACCPZESY;WAO#/L'=&B#:T%8
M!CX>[BMUW ^32DV8/N-#[LJU0=O:5*'%0O[0G\JKY%0B-2"/@]7Y*@;EC6F;
M(;JMP$CNMO?".<S3:U8'HS>$=^R!7Q(#GK0;#LD9C!@_<;S4 C-R7H_9D_%Q
M_,R_6CM7<\!:DF5R0D2Y$7"LDZ;;*7L0;*( UD[5HD[TJK C2B]-BXZ<#C7R
MOVS # TC,_;(^2:JO6JCSM+$;:@$&@V8!*OO,_9\_UY^V<7N;EC+D.A%0\=
MHX ^-3VQ$Q,H'2V>;GO4)3;BT,0? VX\QK(;ZIB2[-U-?HPGM"9'22'*)SEN
M90?Y62JD]V#)W,N7'*'X6R?(!31:% ^5I9!P?3E^<&9V^J@J7Z#8U:->,0((
M<[THDQPC_8@!'QP9U#IQ-/J"E:!DD]]$*'EA ^:B4U A*#1@J-E -E*'\13Y
M ?5Z#^ !#\9QWUE3,PB0=,Z]D,C#D[/O6AZF.^F)QC9>N;P82UZK"HD$KY@#
M6?T(J/GJ602+A?G]*!7#7QPER3\YCNKYLTO9WI_\\>LO,I'[>%$W-_5*IQO^
MFO>;W>-?\Y?[G+^+8!\0<W5ET74KJAP1\L7,QP?T_GHYZ+:LE#=*AGF44 5@
M>9=C/6HM5FJ+* ;*M?H!CL3SRNB.U*S[H? X_ANG7D1G/13YTWKOKP%YW2\K
M[V.[T;EX09*&@6NVAZ'M!G>[E>=U?DS;Q(U&B$))VT9=5SUF'B21XFFIN.R=
M][EN",&RN9.-,9CHBV$ 9LO9SR1 X<X]I<>=F#IRA,UF:&6C]'&^AU]&1?9X
M$DIKVHEG.KFI<L=&=]6TVV.L71>K[VG_1#:5B6A*U!B_[5,?,X)A-BY&UD7
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M&)$'2OC9P[2+"NY$GA"(ZT&+(2V&I!O>WH-?>$3:!U&0@!1A"ZDW:K0D*#L
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MIG 4R'0]RY.K#)%(O^6;.*![[34@4NCCWG Y1\X\.C"@I'TWLT:,RPUK M^
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M!+=_"S-<IH#>P130U\L4T)U, 2WN]*&Y4\Z;;(C)]\DI2C2&;-N+F?5;Z2P
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M>5@T+_F)5;+>=ID\.U4DET) *.-;27"FZ);4O?BF]U['@7_)KA('.'(IU(,
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M>$[:I3EG';-D>B,EI_?"N0,"@1)H,(REAA%GA:-=M5IB@/6]#CA804H'I-.
M+E$ZNT$@LJD:!NT:;7FHT&@Q>@;^?G>Z:$LOZKV27_^2OWS/^>ORIN\(!2"M
M(I!2)L O%N^Q,IAQ-564UPK*E;&A/W[W_!E7F?[GXN<+ ["RY,>>TJ#\I0=*
MWH/6PV)/;X7:4?DVD%KZ)J(0/#2MYZ%-BI447S4<Z+.1_)7L&#"]1SEV,<KV
MT>RDO>SF4^"I#8)XD[=2%,] F(IZL!QXWS#OZX9[G[Y2P(!I+?A)\^ W(Z;
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MORKT3G-B% V=NEF>61.V5<2S04'@%G5N;*P.P*.KODIH1E8;ISFEV,+_WTK
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M<P%QODI%I*(8,N(Z<);)CZK9*LJNM6&^=ZDH4F+]4EUODT3,M%DBM,%]D"W
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MQ^<GYX/3:M]1@DL_I.W?LU]N/3LX,XAG094GZ1\=-4?=#-:,)#P&5UR(5QX
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M',DL@S6!4!*C<N<=DPB4>Z,LG=1 ,8YN94(OP2@RCI+ZQ#Q:-3DRR&IK7BP
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M1?HC4^K>0*("#E?8*FI69MUD 70N D)E_VK"!\[=+I8.%[*IY44C8SFP3&4
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M5&B@0].=G/1.!V]4T&++[Q>]DWM^[=_WVWGO\N*I[][SVUGO8HN&/>\=+P?
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M= A7XRU%CH>BP)#[L<A"?4IZ"7@"+:!B$$S$-XGQ^L2S:.%\6( %7IB58T
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MMXZ8O1A[8.;;WEFVHC85X%>7V*P_U[\<ZM-4.RO?<FN&@\T& &(H6ZCO:+?
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MS6F!VW<HV!R*;Y07__8M?+J.TORHW"X"?E\"/EH6\)9\>LQ/,(LK,#^)/77
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M36.4QO2?M^? S>Q?O6$O"S_H-E7+C&I$P7A<LPK1TTD<6(-GOBZL![;J :.
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MTT37WX.-?4'W2FA7T+U/AMV>G@41M^0^8(C;X<[.OO@F(E4B5>+LBT")0(E
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MUE)6[G([_VM4_'S)?_VNIOHR1?2$J'<OFF;XZK:4>':*XG>'Y"MU5!<)0=I
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MB>R/B.S_623W^J&?8MRLC+5@/QFZCDFH0L5]E0FGI^S;RA#4;U=?7Q-/()Y
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MG[L5YG-KN7?R%5#X3_91) E+1S"Q\7.[ HYCWO7G*!7)Z=QF7?^F6(7K)Y.
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M8/6 /\^KN_?CY&+O(<+*_<?*P2%AI2KKOUH3EETM=JPS=-IZAW2&C;GH]0/
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MYD+=$[39N2>-DM!/?1COB7.H*?C<),MWA,#PPPROIB,6W6#RC-)2RSFG+,E
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MN$#$S.(#O"E&DUB%/Z7BNC"0RSER3@@V+<9?.15O.F'92V/9UKF,DI"? #O
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M<Y30E46#+LZOOGU@EW\___KIG'WX?-'>PA4K81\!@ ! ')U0:C,JY*_3T\W
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MX_N>6>VN;3WWRVO,:[9MTWS4EQ\J.C_DSH_K&&Q(5\NIR9/_K5>-/C_<7.:
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M-#5A#W3--KJ6UA_T#<WB/<?T.KU>Q[8W<F._<[9EM2RKVW"V13U(]T1%GJ_
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M NYUB H?I%BM'\4. ^+8X0B2/)JP)D1S%&D2=3XJ.8."0"5VCW](1;N4\X*
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MH'%!XX+&!8UWXD0@6 M-J03.80.H81YH2"*$(N$D"]$^O\/A2F&\QG+ 5-"
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M/T'/?'6?#VQ4&1_',$GE?M-077G=E&J54JU2JE4V:M 1)[R16 .!L8H&G9-
M0JH IL1Y231Q;LV@XP$3)[T&C@L.J.8*&!5O% 1A3KC'1&[6H%N:;C_5[>6T
MU>,_1Z2]C'?$?Z>AU9.Y=V\O?:,WVA50C*0H9X:7<L$"P$,@AP,%8.]$!%Q"
M :5, BID!&!L"5#,!2$H(TBKVP#LE*5$J@C:@0M C0E <R* X8IJ[[3$'!T
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M(IMR9R]]T_\K+J/^X_.OV+/)Y(>_8NEF^G5^X9O:+H[O@=XJIPA@,CG9B>9
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MSDXS76Q Y.]99.[A O]ZK19,!#IATXD/D*&[O;_MU.&G4#UWP^Z=]4#3UV5
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M!_0 3>:573MA:2Y:,R]T;6.Z7M\I0IKNB'P:IS2'UPN;=OZ*LWS^?_.O7:V
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MKL_).<?BJ2]Y^CS4.:/LY:<!Y,"4]V(>N]@6P=>?>=E:&9T,97C9<FS>YUN
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M)4&LE>A?.5/\6YCN^%BQM(IZ<1DIT-D/HO2,+8X4.@'R(HLU091J@KA0"JG
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MCE+C\$:<XS%XW+,(L2#/VD>H)R+:A^+G/2%%@? "X4<"X3%&2V)MD",J=:'
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M:HU-NCUH$5?6(N6(1EX156-64Z_X32G6FE#L#$9&Q@"2'RC2K':IVFSPF)E
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M;_.5&/,^79":--\(.=[E@Y-SQ56?>"5Y8*O\DG'C5Q@ASG+=N?\VDXE)U[P
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M.NKCQ@%:RE)3:=$Y(;$R1DV$*O$# 2&<!,\"P8#;H"@HC+OS6GX* X@4J,'
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MNZR76"I+23VV+JR=9QT[<UQ4H^-C#(E:8_GUX;H7G0.Z'%TP6A-@090:Z)#
M.N^!,L.)#8$$N<8,ZKFVWJ8 S"2'GQ'H5=B&@99;2FF0GJWQVYR?5['J-S3&
M<3(:Q%N^P4I,^ CQX=T3'S1RV>.-0HI,%J>4EY9D!L8KIJ.S2FIZ5WR"Y$D1
M-*O:%LZPJ 0X?!]DZ;51P4HKXD$J[J6XH*1+&=U[9:@IG!@5*O.5@X$N'@T)
M8G"W$5N85Q0EA$NP,67@U@@64G9<K97>/T5"7CKKSS>R]1Y,0EI/?>E63RYZ
M@_3>#989_WG TLZ6;\\\YQ%[HQ^M2]7V3<^GR'=.@FPH :[)* BE1=<0!\YC
M$$N,QQC6QA#]&K7<<S#F;:GJ^P.C/UR(OZ1A&5;S9AAO%S-]2G]NEW5'LD2[
MY'XO0].-B#,_NL8+?G+]LD*]-G!IBQ9OC0DJ1]9M'69)_LXG!2XK&]T5@M47
M?/JF1JUSHA:9UCDJ I(7GO1 #7A-4'8"D4HI#/[6.<6?#%:WFH3F<]5VWBOT
M(.G6I>Z2Z-TB:ZAQT.'CH!T/TUG4W=0COZ..;]\.,1JY[ME%*/)Y44XU+Y*_
MNM.5<C?;7C[,"#6]']W0Q3[>_M7,#_JA;2J>.Q\N_'/6[R!-B"ITWIER\-&B
M(T*EQY#790@A<&<UR2&NQ3G4)Q(U#^!I+H=4O SOI R8*ZEWDDU:;R#=6 #_
MZZR4QZ')6#9X_^A*%=H/UZ7]8/6]VS8=<WW!NV4;UAL#-[5,=)/74%@6-?H"
M#/W7TEN.L8_C%K3FA.?(G&;K0UMW)35/:IO8CNU0L4O3J;AYGOFM*=UJ\K8<
MPIIGXQ(6-AQ8LTDY3G9^]"E=;*Y<7CU9FQO&9=WQW7ZPKL&5XL)RH5(9"T5!
MJ-(,;*P!KJW4WI$LZ-JA%\G*Z)P82->499;Q\,81,"$H*XG #\G#=$2*"R7X
M!1.=2M?<F:6TVJRXYD(]T":Y6FOU#*J9BH\5'[?MZ+C;7+%@>2L<A:6[8KW1
M =W[F!HZH]+$-P\C>H.^\_U!2U_T'E]H56/Q:JE &#:SF6,_-@.P/Z8TO1E&
MW? NMF.I0W-NWI0<-/4)\\S5W?MT#95Q^\U?;K*B=Z.6T>>RI@A9E[U%DKG-
MBJ$'/@I-/M7A][Z?3)_=CN*O2UIL<+TX_L%/]V.IB_B8IA]&L67 [>726]+R
MWZZ>@"^_)Z:V=*24/$T67_;#P(5_P!^AM"A/>A]',0WN-):4">*(LWV\X-V]
MN.[DB4+B(6G*!;K1Y<Q)! ^6. \A*II)F69HUEB>HD9SY&T 2D4"P64":VT"
ME1K*C)QEY'>]ZI]QQ?]>%OQ-+%I6$/?&C=Y5!OA"\4ZU[!<![=R.X_8(PPP'
M$YDJ@]H<-)OI,Z-,"FF87(NCC,^216[ \D(()J@"YX6 Y(AF-A32GM5II[^U
M8][?YL4!TH_EU*15LAWONN@26_+MENGY2=$-MMTPW2Z6X++WIJD_0_0H==&=
MDQ4IJ0\^*PB<<A V!K 2?=I$%;7:BX!_6D,'%EV0Z+\&:2,(A\#@2V<:U\XD
M$0R/4=Y[WC@_95QW6;?I03.L2P3+W40%KSFU21#@))@R9DF!I4F"%=92SS$
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M4/4IST9_JFE9J06.AAFC#/@<2BVPD&#+[#)7Z!TY%YOZ;Y]3@O)<TW*/9=E
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M)H&).8ODC IT#[4/>\*Q=5)G5IL9:@)X!\KS<W_HAH59L5;]GI_N5(NQ6O'
M#?71@LJ*@@B%]]]PQ(>0#>4A!B;7ND:V]WR7"KCC CFJJH6HP%6W] R BW,J
MC$P)@H@(7,YXL"(F2-('Q;GESJV5:FWOZNX+N)C2%;AJHG=[92GD\#E%#,@&
MO?[P4VH'TC7D1P$%N5^+'<Y(EZK%N&TQ!.<Q:85NJQ86A$)7UY;J.)U]=-KH
MY-E61 ^-Q4#]^[E5OU^6VH?6X\=6]W9E+2Z,J7T@%;;JEIX!;'G.@\S4@42
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M7$M]<^I<R$2#UMR"4 HC.Z$%,)%YI,FZ: X2V2E97:0*6W5+SP"V<G3<4:]
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MDH=PD82I+E*%K;JE9P!;UEJ:DF5 T'J7\S<*+A$&6F;*591,*+,&6Y$SIY(
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M#Z@/S ^]DW?=)X+^0N3R#,LN#Y+$?9<,=B6;72_O7J?A3Z8P!R&F)UJ#>JQ
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M',E\&<W#W>:!A80I\Q2%D/-:B09/P#"#O&8<>VJ9L5OF05D>0O(142?R3HE
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M[DL7PM(<+2U-@?I9VY=H1&G(6C17TLI-F;;S"@JMY\W0B+3H2FQD9B^+5(9
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MG.Y0DI =KH)ZA@Z$DY*=D@@^_$'X*(+X0IHHEYW<%^!G0$,/,C%UVC\[0+Z
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MQE:UB3IX'!#AW<4;)G?]#L4N:O1U"$8#F5KCK]1[@HL(%'<(5F,9'U7#RI9
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MV1T1_7&Q,R8'I.&R-2KVU%D*VG<,Q95*+>X$@*Y^%40OE_R+KO[#.FF"R.U
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M'9#-$H2 L7(<RX[ :PFZ(E-."V<O&"BM/T1V".)M5)<0;:WWTWS4(0MLCY:
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M1.)IE_.#V93)BL9/%&,E$W_E!PXKDO%)7ABCK [C5)C?0'7!J<1R5+4N.W*
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M O3A#4T22O-^:)BPCMT<74/PN(O@FHL?"?$$69[[B[^NF1C\R!YFT0M<0?$
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M_V'H^'HK3E,?>G.:4I"4'>*!C("4O<8$%4%/[>";PEHYCZGGI^3<B>,M$TG
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MY7#\N_SX=W/'?[IT4@(L9EGN09<>07?ZU:';YE@*+:@ -%QW@\DOYS":\X7
M')O'*/!*4%%<3>K'1/R:['L18%MPQPN"D#T7*1XI&%.1BS4KDZA"_2/&##$4
M.6MSM_$8(4^M/'K8@^'1#WDJ-_:(\#WQG$"T!/ZJXJ'@UR%CF-W_"8>TA6@
MP)GK&(."D=;/F#%A!ZV.8R=_PP-1O 6T+H LI76":+TXDK'YJB,291@$,MF7
MWB.J.8H'!P=UM]@_QX6^?G3\$!Z>D+S="0 WH5N05D9'08<H!Y8W3ZRQMR08
MX)W;"\/YA:!Q"C3)&Z#Z]HB(IHELFVB-'Y%'"L,"UT^O=^<YCOAU"%EL_W_V
MWKRY<23)$_TJL%ZSG6PSJ3N/ZNJJMV_^H*YL32M%/4E9]6;WCS$(#%+H!!$L
M'%)R/OV&QX4 $ & Q!%!,<VZ*RDR+O>X//SX.9F=?LXY;/8(B6! !Y24<8.J
M^XX]J@Y;9!YV>]@5@6S"X<O$QQ)W<+ZL0DY?QPO$$,$I(/CE=Y[U4_B[[HLM
M6T WDAM% SQ=],O!J=_)KJ6O[>C7[Y2,*0$93Y;Z&7P>PD7H)]L'G]J P-XP
M^Q[N[07O<R,.LUM 2Z.+U+<H VRHNP2_D*MX<;;]FH+O)@N#!#T+I".G,-F#
M0(=#1!/$,_% F%!TX_FRG]&QQ,<GF<\G9'FA%(NN((3A'?3FP94N._2*'B=$
M([HCI^,@VGK>D/<./*!&/U9Z#3LJCWBBI)M[1MGP%('^BAPM\SR#X#TX(^GI
M\,7_'J[S-2E"_I?BG;VV*O<F;TX)R^(/%*K(6/M;(H*)1"\9]G",X!U'^H6K
MU@\"G"RH0IBB1T&4XH:P"C0>/B0KVN DXR997-#A!?XFA)AHFB)E7*V(DW/
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MK+(\+FAC2 D4T!L4>7G*'8C'5[.BC1\N.-C  ,(>;U" #$R0<VD( I030Q#
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MI>>3.DCEFV-!"8Z-AN&(3/?D=MK@!'22BW!)1H7 6?'MT*\WF-KG ,"IQ_M
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M9F2(AWB#K7+ YIU@5T4U7G:X4' % 70ET#%DIP;LG[>W*#O#^)N  09='5I
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MD!H)0LI35:T93L;*0.P?^JW/LUJ6CAVJ.;'"%$UM(I1(\^4-CE=4-<LGJ?W
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M+ONJ,T:A7;K\SO4! +V0H61=_&0Z&79NQ G2I8U4.:0U",Q-IH,=FW""[.*
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MOFTY(0=R9:LFAX6^A!-;PF!P,Q]PC16LWWXL?N-W%$7_C/%K_(#\%).G+7T
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MV,+\8/(9JI5P@MO%>YK)F0*'5Z]LTI>USWU=:$1M G2%[ ]=;%8N_O(DO9W
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M>":G'KK"R2UZ[4;.($V^C4QQ$SZA>S^=+<(H\1-/K(Q[\KIEAUWEI*-P_6$
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M_5P\[M_1'L=7"6W@H_^R[^)N[?H^Z[:U @B79I/XF>SP3+K)A<75-C')[B;
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M$>K9;T^H ]A' 9IUC.\<24YG\^LU@/XK^O KJ,10722WC@_))5)6ZF_GT9=
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MQC._$%<+QI\;&$]PW\_B,/ZU@?',K[G5@O%O#8PGN,_6C$"H]U^C.'Y 6&*
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MVD405R-CV?J[O&&DA)3RTX^(Q!"_V".4K\$K"*(CJ0F3IZ;SLE)D7V'.0CW
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M,I+30^"$"3K3;OY*?:*279ZVZ+.<9#F9GN9-"P^-3U$2/153T.:(M-\]\ \
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M_;86!EF-G-J@K@B=%?2J!Y0 <XD7:)OD/4@0U-$!?(UBUCSJ;5:?SX1'UP-
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M1LE3^OP?I+5LHRW2;TD$'+%M,$ZH3J\8=0:WV><YQEQN^]%.>$Z:1;N17C4
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MG  \I8># T^;7>O)6EQH[JG%B"R.4>P$7V"4'M$YGRGXF%@*R3KG %&X2?8
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M:YSM1(=GAUI2<GT5,\D>/K(V9^S^DGD$0BO=X+W\4<+MW^>MVN PP6E$1=2
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M\!C!/!)=#9J8'$U)3E7J959PW ^5Z^2P$0N)HT&6I+W99;E0Z"#'P4;H<#>
MQ4JF+IRKI!7MZG/#24B%P6X+#L<(.O!T[:/YXK0E1LU],^T7$DBTFM;!R'.V
MSD_Q4N=8)+X36!.M,I H[B.\P5)$\3@RD8@:=V$9HV]1,+!*'/)7-*5]:T))
MAF\/&ASG[#N<E$*/Z+ 5CJQZ#W9I[-+0P\?;+?#P?7%WB6O-Y;3C+#L]%;2F
MR/\R!^X@@(;QAHLD)Y2GQ$E2)-.=:D<*K2CI;"'*0@S*M*XS@_C-3&^ WE10
MMJ[53WBCJF"]7J5_0;K*:OP%Z_BV:194)'A)+Z?@11IFPQ2?^LV)]3K3R%1.
M9NI"JE)O5%T:D24$M1>/U=2&A>%)-4.7B/-NTZ#I*]5T@:CG-TR#JBW== &A
MU=LZ0]D]2"IQ6YFMTR#C6&ML%:LD(PJ_U06?F-F0@R#Z@;U(]-L]S13@B^F4
M:T8Q\I:Z+B4$[W05A:\ $DZ&/6DX6!O_B"3$T*Y(K];"?H&5:LI<$BAB:$DV
M+*-(N(4 R&\&.O7T=COIG[K\VM?J8PHOV[1D^CW88(Z8-:9?\9(W65[6[!'$
M 'T')Z9<@U<01&2Q6PEK<P" V?)<_0GUN'(@/.TB^,.!'MW:/;_Y8[F,:LF>
MW53+F@[T9?YY!G.G[_/R0H'6UNYLN)ZJLK@4$V\5&^?W,F<Z-#E;;DJ4GMJG
MQ9.W&?.A=E%LR.DCX;=M/#W>HGU!Z/Q!1%I98X,&S]-$)*?$>84Y$^6(W7+3
M9+]@O"TE)T%R]Y/4*\Q9)IZD*+=.G#<8-,U,()2<$6ELSN!9(I[<;!B]Q]Y$
M%/%,8M^T>YEN4<W&72E9_81E7GC*:UE7GQAD5\T)?5>KXUZM[MZNYL[)'.SP
M%B97MS#S5!>&G(CZSJ:LB1+D!D/5S*#K_T)]?%WE+J'S?H5?L $FZ0C_8>^4
M/H+RI_A_GIT89#__?_]$L_MOYWCTPUV$?\I_",,H(6\@O^&?0)8N]']\K_<5
M-?\G= YH97ITS)84KYK_WP>D\B7H#,/92%OT^W_]GSA]1N=BDN(W$1"+ICE[
M)/\^DEO>MN1%7IK!B4:$5!4<2O __Y5 ' +CH#=!QT4<:N<$Y!X%TOG9";#B
MCWJ"YR+^BH[*EPCIJ>$A6Q\_3C)+0S9Q^C-CYN8208P[N>3M_4_OOX'#,Y97
M\TG5?LLFXR7P'?Y7_-]>='#\<.3ID+\YP[[ 0N4=B9OP@Q0G6B :0W^1ZWM(
M($D:XBV';_>Y?[RZ>[QX*&;7JZLQ*RJDUJLHC-, $6)27]3V[T8N+)+,_Q=I
MLA]^^OA3??R4!T9.X!)&?P)87$6 \TB!]\TY??CI_:_U"4DT-'*"3^X>>"F^
M";!I#?H>@UT:?/5W8$O*/R#MYS(@%_!E,^[3LPE!4CR:9/?Q"+5/+GA.RGVZ
MVL.!^IB,,V#Z]%2,BQ_B0SP9XZ@EETIF^SR[";78^_EMJ/AKV8-RPW3H4<4A
M)K]-@0)GNDR)O]CLK^02:QRE%]/YQ9 W&,LW\ 6C/I(5FWN?K&-V95EQ8 L;
MVL,3[D%R&45_DF#R1^ &#F+['I:P*N:JDNPE&YNR\X63?TBANW?BQCW()94S
MGBK=T$I(M[BU^0'Z+GC$*0*?ZB(-IX&1H@Q1=#Y0E)\/1@^[#?-OHG7XS>@)
M/>T!?(9HRY/+X^ISH3\S<AIUS\=M[OEHJ3&<-D9.JY;IY;SE@?=QL[3#(\#Z
M9:XX%QE$M!B-# C5;S7F+!0+@J4J^^D30\?]9#;?/(^3I:1_,EM)_XKX8N8C
MS,9]_ML:H8)QFW<V'\9#B_8(/?OI JL_+Z3IY>G<)+\4GECVSC=#XBK!Q!-5
M.P[/Y\IH'VB2/,*,O$JW_%:EBNT>-(TP=Z&'6'"(AH U*X]&2S*]C"$RX19J
MBTD?1'*4V8(AL1=L"$EBG;DA2-$?FCF1^(&$1'P-W,8DV@^,G,!%@K;*-P?^
M"="NV:&7AR_UB7 :F#FA<]+A-D(*>N'^S&?#>&H/+\ VEGN\%F=V5\Z._LP:
M2:'-Q3Z+V-QGPVG1\[,(DZ^9BA""'TZP!?!PID=VB^JZ%:/1;"K-3#YM\20V
M7*"X32$Z^'%06N@A+H;&6IIHZQ0FT=!,2DN2/3@0+DV,CA<O$) FWY'4 W_@
MTK'P%J!U0AL(%UY] 9M=S90YX 641<=-=*]Y41FW;JY$Z_H B><<>(638KM'
M@WK9/Q"?%D RATM>13AI<>81TW;='CKB!\PSJ;9B-A^BP'=/+5>(N)VQ#@\2
MX$0-"J[S"'$[(UF$[CN$BF@"W<,P11R2],-FBE!<$WT>\F.5HC&Q&HYP,BL1
M*, Q(9L&!QEG;+1@F@U]2MS0R%W7VWI3/6@W:8*AQL%>9*F_.6_^(3V@)NC_
M8C+ 8::B;A\S],!O';MU"F(^-I)NZN%6U\#-B/_SAY_>-Y0BF99&3O$*^\LW
MNWS\&_B(P_,+]N5=IU@J>B#?+/7;#CW,$Z%Z5L;+A<U^G>VQ:]"B#$MB;A&]
M;&LC"?_L?/K \DJ9;;[%Q;+B;51>;81+FI$F\47^CC)"1J)E;:<F> ]KGMXU
M$CC=)()8ERLNUVH<)MPF1J[9.0'@"]DS#/U-V,Q8]>T1)%AY( 7X\#]>06G#
MR$68*QQ)GUG;RC:E7M*[NSWZQ @&BQ%M(38=7@\P<@'P8AS[T8(""]%Y:88R
M7%2JM57S)T)(%#+LJIP&1G)+>4F3ZK/OW=U4 _HYJ845"?31DDB@C[^P)O"+
M)1/XE34!L]-QA%R/E'J2Y)"DK3W\L1J:0NR:%0,Y+7REW<:8N8K%C%+]Q#<5
M-O*$XC)=)H^7]W<^SA7(LF5*+]R -Q@#E) HVA<ZED4^B "$R. <>X%VQ MT
M2K]QO[[V8-/V]/\J"@4PF_MQJ@-AQW\K]4Z^O3WZ1Y% 4K@F*JI",\>$VL14
MX8CXP3/3'$#,"KWD?,UU;ICGM#!E_81[\FD?0< *=Z,^,W(G(M&AN+PA1 H\
M"08KO;G5U"YN*VM6K=A19VM&73%C/39R[<ZR+LMR^M%LRVF9*=I(%+T&1PC<
MS*:?73G1R"P5MC?4*5<WT=^%U H#@D9&KN395O^>9<0WNS))Y^J.#,%$U,T:
M3BE3J8^! :6E-=.N:-77_JOO@2Q1_1P2<(XN%C8TE G=1TA/<D[Q^2B/BW.O
M]"WSVU174T$LKN(LF3SEGE:5HFU=X#:VAFIE4N\KLIQ$6WN4XR^H-T#:/72.
M  W(Q;FHC=QP3@LC#Z.S_/8;2[ S.S/\*@I)R^(TW, 7)_3_)N]M^(ZEFAHY
MR<?_MWE*C\?@Q% FV,^-G$Y.6]L?T78?I;$38F:0G+9[-'@J%7);&CE%8BPJ
M;I0L*L\\5QW^O!;&^OKO(S1B___O[MIVVHB!Z">U$-&^5)66 !(231 )\+QQ
MG,1MLAOM!<C?U^.]V.NU8R>$,NXCZ[&);^/Q^,R9;->=)?TKRAF1"NV[3=/A
M1B\-5XPNKM\H$92$59!,!L29\+WU4M;?-<UW3%64@R#-J73!VD#C6%P&6!MH
MO#:')WM4"<<8J=Y=6D!,/YQWCP#*J9VDB^(USG1V%^TKRI^NW- J-KJ\=@_=
M\D4G, F1X3)G%U57X;;\?$=[_]'GS/4JA-L'T_^]%ZX.7:#ND/IP;^00LY:'
MH_'4WPTWR,O=*$TB?F@!)IOFV@ZSBP5SUZYZ(I3"%9S6\L]K_6;C%$2Y:BW@
M^@[S$]ULTXS/T!4#D"+E(R?!C\=6#V?-J^"4*K=S%9TG )Z\:)[WS1R[9$#]
M]D^#KI/E'A*Y86TBG)$R/P,TOHY<J(,]?H_68Z Y2T[>+$H%!![(\4)88Q&W
MQ>*E)<[3)6;POZ- 2.S%\XD3$DH:8Z?N8AW0ZH4)=+81SD;BFF)7O1\.>@X"
MO0#E8G9 E\0W3YA3+8O%4O()V>:VW4@$D51*7^7(-A0%M2PK]]2YS4-_CMM#
MKQ-VWB;/:?8' )/QEA7Q6CFO'7)H)NT !L]!7YGH!2AG3?%3/$$LH7XDVLO5
M66))09<T^Q<ZPYMVM^8,&:7%I)S]IJ28IE.VH7=LPXIFV Q,O![5L*C+PZQK
M;M#L:CM8CR)URZE=1A%#VJ&H,,3!F2[.;FF46[1&:]V7LS4C30B?F8/!2Q1E
M)Z6^O+ I4MR>.1&"-EX\UD95/IX5_$<!VN[ZC0CB@)LT&]%7!R[]W<T$HYS$
M2[;X%J\OJUJ3%:7%;<)5<)4#T_RB>D1%M ^M,A/2*!7 *$@("*U&I& O?$)=
M"90\JZ$=@%-DCHP(*3=EC;J2N-WV#O21_P++=G.;JG?Q+,T@;>;.$D.\1P"E
MQG7<;:4F/33XQU@3RT2[T6ME#,<]A3.C@5H.(7'6@A%X&.'+&OA/^3).<R4@
MX^!JP0Q(RSS1.BO;Q_)AHP$JCA$H>^1?UM$V8^O!5W[G/AMGPS7O<;)4G,?/
MK%A-5RR;W\>9<G1_^/_!,N0>V42%Q<G7C"&Z1P9I*7!*+VDL_?<BD6[S=/%#
M)=_RBV292\LEV@"-HKR>>(JC\8PX1\#*=]MA9]XOI/86"RB\9O4;+QH7N7A(
MZA(FMAYU+]EPYE1]<%4)$#O+EQND3\(@%6XB[8WA/2V$,TY>.N]_475]!,TW
M%\0&-Q&(^@ZF98PV%H6S+F6"P1YKE!ZN:A3I. %14#Z>XFH'NN>45\6JO6#V
M[P,%<"(5'O[)EM]U='R I1CEWC63=>RC0CFD!IJ=[K:_&ZI2\.EW0'.][V@Z
MY<WGTO1%_AW,9I-ON3:2J7/<4=G2\2B)+".^46# B#/;NT\=M)[*D2#Z<4!D
M^$'0G)<@I+,P*A&3)V@KG*TK._A X?F0--;]8\+D*^1^(7S6QPA2*RRXD03U
M&S:3@LAP*4MQ./.FO/X_\ Y420Z-T#D?27UK8T'/B4S/&N]B]QM*7=R_6 U<
M-R_<6!0#B:E$.]]U"5Y=@N'L,9V<99@F"6W=O]VG_!LZRTK>$U>6@L-;0;D@
MK/Y!1=O4Y-%=A^H1%<.S(0<V8IP![J"L:/I+!^)75VU8M[QD+I+#06A#G65(
M)E$[HB8:1> !;B6,BO1,I,': PXK8Q7402?_F8L\>KG!CZCBV"0\]F,:#V;;
M3$I":)Y#CKUI>DGO8S87:7K&R71%QV4!"#B1UWC"_T]!EXQ<OS39Y27RY#UM
M!#-4XRU? 2O*EX8('D][]"=[!#Y5X_SX OW)">C^GW\!4$L#!!0    ( ,T[
MU5@7&/Z3L0(  #,.   /    86-S="UE>#(Q7S$N:'1M[5=M3]LP$/[.K_!
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MM5(?9?I4J7OO"A5W&U*-Q#IM.'V9(R$>2[.02Q]WF)-#?E_I]5<GA_%-I_\
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M%WF5H,>.R;10/"IE!-:*X2-Y)IRS;9(G27Z!O-98-!J4-^OR(^W0/ 0F3B2
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MF#F4DM?D*+'4UY$3G?<[)*>.=%:3CF-[!F)$Z>L=?JG!$<.MM $^?X4.DU#
MKFNF18D44,Z:7'2E"?W-MOTVKN [WG.P&GOL##?^P_')P4,+TQ#BUA*N(#GQ
M>C5N.I67)#U\0>_^BI+H-,3;547?"J;Q^B'-VM<WJ(4^\.=_?4NAGRW=>V^P
M"QT(S4;J).#S)D%,BT7 !RQW$LU0^KC3Y7&,YA$4&?95#?M[B?1 K(UR:9A,
M>JFF'J@$-X4[2*[2E08=#)1^PG98;8DR.!98V ++!AJ,@O["?JOP>CU50V_B
M/TW&07=#HLW3FF72.WJXEAZVGP0]D'J)QU/723=_-_Z%KY29K6J,F4MK#!U3
MSH55*=$=K#-(AK20A:4[P[<^PSN/X R/4*[7L/46"'S)?2LXBJ5-]V&3\!N&
M34G!G!'E<>@K3J MD.5X:$U$S33\M;6SS#U46SB^WQ49?!O/M=V/8?K!NFIH
M7465TAE21C-K%^I229M 2::8[J25*C#(I1)(+$SGTI1/AX:4,;%865^F\RD8
MD;RM:]K<1K-5MG53NGJYN3Z[V&O*\06F9^[Y :>Q>=Z#MD$VYJN&;VHPFB3S
M)J,'-.8EW3.Q?*QYDKZ"BW5HK#M&8XWZMS=<;OKNP:/!#ST+D-2SF&2'!.N0
M8$\8"=8I_-<J_*\>@<)_O=&*-F0/G;N-O ]7IGH(K@#7N1@:ZNM*'^+U&1M:
M(85;9FI(<HV)%RB_@FK@.#I[]Y;'__M'</P;1I=L%_5M58'S1:)<@@U?V)DL
MK+K"LSF,<HE!F\*"4:IZDYS:-/4IK^.6%[$=/[N0F,Q>P8^8J-3D[LWF[IY]
MG;X7L]C39;8*+4TRHH)LV+:8;R/1=G?,;WS,7S^"8W[6=(P[KMLPPX%%GKL@
M+3XI,;\Y&-.FKAG>\;;IGI>5MI;*&NW+Y$28I=;G\FR@*]"G$V0C\ 4=0S&!
M:6WKHHO=@;WQ@?WA\1U8>ZW:) 6PX>6+W-?BHQ3&0F'N5)O\'SCWA$>4KX)R
M*XL$N*'*,QF9"G^V3"@6 #"9FS_M?WC1,[4_?*R)V&W#\S>F7+8Y*.I4:@2C
MWD@Z[HD>\63$C$P%JC\]7R405!1@OIB$.:MA$)JGHIYD=Z)O?*+?/+X379>.
M(>]GK6Q0IACG)D4G;V:R!3?PNCUBD9B-WSN03:4T:"V+1!@X49Y-@+^3,QE[
M[0[8C0_8CX_@@!WEP QC;XV9(L4N$X@_4H$;?OEY%#X+@G7( Z^]4+)T^5X0
M-5F?5DI7#<-#P[',;1!&*E=/B1+K5\U2?WPJ?.&H=A1CR9! #5$^NY+)%5-Z
MK%Z0BZ8J<I,IOY%<IIT[QF:769HYQJ+_<()Z04^I 0EU]\L>N"; <,^Y'.["
MOW]WMP_^?DH(6]R_3[#K[(.! _VSNP+_+((NVX_&5?\LXA'/8I)=T*4+NCSA
MH,L*%/36FWN\2S+8W-G96>.[)(='[-?#LZ.#TU-&V/CC#P\-D&XIQ81Y]ZZ+
MEI);7TG%^ZBH4,X%5E8$-15^'.?H]54(2<I6(N+M;B'O'+X:/!-(_%W<N;][
M37O=\BL\E1D^CB-^NQ5X/Q]^_KK_GO,J'?%4#-^.U;LS68(%^H!JT<HTC0^[
M#<^10->-[3Z!G#T/NZ'T,P5J\'+LL"H*H;"HYNZ#*>;6#?A\1?#3G^%S$)^=
MDO'52@9;U#(ZA_63=EAW=1Z[278.ZV?ML'[[<IS'\W=_>/MR5J;)N_\'4$L#
M!!0    ( ,T[U5@GZU$S.J,  "#/   2    :6UG,3@Q,S0P-#4Y7S N:G!G
M[)IE6%S-EN\;$D((!(*[2W"2X!Y"\.#2T%@2M.D P1T"!+<  8*[TXTV+L$A
M0'!WE\8:;?QRSIT[][SGS)TY<Y^9>[^\U<_Z4,_>NU?]JO:NM?Y5=3=UMP1X
MIBBK( M 0P< T.Y_@+M9@#3@\:-'F(\P'F-B8F)A/7Z"0_04!QL;AYR $(^(
MFH*6AIJ"BHJ.B?LY'0,G(Q45JR ;YXN7?'Q\M,^%Q85>B7'S\KWZRY^@86%A
MX6#CD#U]2O:*GHK^U7^ZW/T$X#]& S[T?X#& $#'1WN CW;7 :"];R<&VE\+
MX%\*&OJ#AQB/,!]C/<&^OP'^#(".]N !^L,'&!@/']Y?];J_#GB(CT% _U+J
M$:'Z!TP&.Z)7OM&9CQG?E+<2:PP?,O%^M/?#>D)"2D9.P<SRG)6-G8]?0%!(
M6$3ZK8RLG+R"HJ:6M@Y05P]D8FIF;F$)MG)P=')V<75S]_\:$!@4'!(:$_L]
M+C[A1V)25G9.;EY^06%11645O+JFMJZ^K;VCLZN[I_?7R.C8^,3DU/3,\LKJ
MVOK&YM;V#O+H^.3T[!QU<?D7+C3  [3_5?Y-+OQ[+O2'#Q\\Q/P+%QJZRU]N
MP'^(0?_R$8&4.N8'.T*&5[Z/B=Y$9Y:W8C'R:AP2?[0??D+"Q+?,C/P+VE_)
M_CDPO_\KLG\%^]]<,P"<!VCW@_< 'R )V.6#<F@BN6M*?3IE"D',4$17"%&)
MK*!@"UDGY [0AE'H,[1<? =8[+H#K!0<DEX'>FK? 3Z0W &&DAI"#SH^LK_)
M#G<>S=IU0WF*BWP?RX%/%A_L?+X#'/I:&9\(6=T!SI$MJ"+)9?2QEJW/XW>
M@U4?I/:<NNZ-38U/JT]TR]C6V;7Q18KD-1THX0:7HN7FVO:6/0KU&LYS2<7O
M<X5:O-9V(5(_K9^_ V#<2IV*B+>0WEK@W0$>D^3> :0#2^\ /I1W@-#LVV=<
M2K=!3XUO;P7O ,2&G41>?W7PS4LERK;S#I#8_@\P=X"OV!IW@,QVX!V@)>(.
MT FTDZ'5ARX>&J_1:F;/(GTV_F,,N0F$RS7I!>:?%']2_$GQ)\6?%/\<A;&;
M#SB_Q-K%CHH!B)]WUK4A#CC/LP)! Z,L;4XI"_8R,"G7/N%<_GUKGO^'K3%*
M+-Z^'*B9<434PC[^QI:=;CWA=XZ"3AR@>([P"H?W4"W'0CY_8*;]8_?ML\'Z
M*'@;,+3)F=( V0BGAEOL:_\=1P]OGNO?S__H3.X//5F/\'KS>[][K_H<BQF&
M[59D7TNMXO.DLQ)Y'F"[OU)5-;%GGJ8S2\%!H'OY1*)&OV6II4<B7ZYFY0[0
MW_</':3^#Z"PE="_>VKY#O"'H=;R^6.W%]=F_:? 6?^.EO;?HVT(9;V<M[D#
M^-T!Z"Y3:1;#[@"\07]B_(GQ)\:?&']B_(GQKQAJ"Z[/-:HKTI9<&W1,B#XM
MD5.FX-P!W!OV3U7OE>0W\8.;SSXW#T<CN8O!QO=IS;NR[QHV?Z7[=NAULSX8
M\"DO;0=L9GWA\BW&VYE:F=BXE?:(5==G5O6&;$P'/G)6<6JN17FF?B(SB.;3
M8]%I?(9O>X-57 -C_&E\1(X$WGS5OP.\L=I#4!DCT_N.9%&22Z7I&VVAK#"3
M'-:L4,#_<^LD4L-,N'Y]>#9@K#"Q;[MOPR12@C_[LQO_=4[*$F[.:B'4T/WA
MF#>'J_?O+<[X,KU!^W*A7U6)3["H#SD@G4E/NUIL\^5L.>V2(5LPW68W[=^O
MSS<RD9)!MO"G<BH351[![\<=;W;2W&.I"MIQH)%>6P]XWD6*"ZY,Y(+!%)T8
M WZJ#'1M!YCDW3".DOJ)DV+R?E)01-4KWY@81:);[8CE03PKDOJFLQKH7*M
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MT1*P^& +_2&'E/.37%,KNP-4IU^^+(#MW&OCA&(A5I\G$F%'W*[8M](2['>
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MD^['@+.1$F:(BE(8<]+E*]89-6@PF*;7XW;MHARBR6NB^2])5G]-GKH,\QW
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M=_F2D]^'2FC)/8S=\5(V&'/T$M14/[N2-W\B4KN-FDPQWKXTAY>VYKOJ=)I
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M@L8]32Q*!"+YXJ(D+;VN^\4?%\]L!!5LS:0LT!T>7Q\<&TZ77YAUVQT8T@1
MI4HMD58OT(N6 C7'=9V(]F,:WV9M2H"BM NSIF=FW5=#CY]23((F>9P8;UKL
MP(6S*MH9C*RDY=VYGWS:W+SXSE^!+'D-IEK90G(CFC]%-NI(GHV!HB*K^FYH
M1G8H"_'BW*BBXS#$E?'#@"Q07>5BR?Z)FL/)$!XQJ?P%"&G\('4TLVG Y\%=
M2 .1)HGN?&A.:*?[%WL9\[7I\2=6E$Y4IC+O<[\3#A%.U+:$:"C11)A=]1*,
MPX:Y%:FHOUY.Z!3F/K5=$5\/V%OOX#J3B>G-MA? GPP-,@SK9)2N.[RYB;52
M$L!H6O.2PO0;SS$QAPL7C=M_C6N,8/RP@H<ESS*2>FI(7R<P(F J==M[H'-+
MHV>D#[+2G ,UE0@"E?E>])Y_I]CAJS7W5ZP*7-JP7-9VV,?0+[0?Z2K+^OX]
M]N(O,ID:;:%PI^4(L^D. ,.[ V0DU?U=O<!3/O&:<T4,_P[ $!!T4W4'&(Z0
M^<.1BX;B.P")4<E2YC7K)4]/W=_IXHZ_6R3_$';+>^$MO]5Z!\#PO ,(W$\&
M]T)9WEUC4G*56KLJ'=>@C_SFVO]7V*3=2A+0F<%!+2QV2RNAN_X=J'OJ)0==
M["_(MY8&X,F TVL_WI1)$K'G!)[BUI+O!;EHTP8CWZ4Z@!:>COTN7$[6RY%L
MDEI72-=>@:E'E!*F12BFS,%%BDN/!+>R"JUJ$'G;0&#4"%F?MW@Q;V%5W#0V
MY/*C5?8[R%3 \AT@WFUS&^16RA[6;BOINSY)1KNGQRP8]OPSVO8%,--2)'1G
MACIW2_A5%[:7QT1LJ#[5&,<OFU&=^OH3OJT!8O^5&[TJ'UR#.5D?[]6^L)O5
MSC= 9\&4,8:U2XJR'0$7TE?Z[0Z$ [2+,N_EBX4'W)PF?'D"'"-XC'Q3%MZT
MEJIXHVSJ+H&YLP;,XR6:7?8QK&:7%(4R7.IQ%"/)=DF5-^3\]'1.0KDP8'=2
M2C4(;QJJ&U8\^4PNLO&T,+2A'*H8FD*5+IT!'_M4FB0#KPLU(6]_^&EIO.C8
M2^ZMQ&-#0;W1FD_!G,"^]&8\G5+IFD3N]Y&N/_CL6<T8:_DU0D'0\*WQ[\GA
MXTG,.3UYR@SMV#W=3T)U;XG7XQ?H)]XWAW7$_M[+-3 DHZ#YE?B3'].)2JPH
M;W06Z14%S$H*+\G\OB[?PSB28OF"(6D#VZO9L9=F-6!NJK?0(>E8\MF,TLH@
MZ:)>3F39=GQN+/B^GYL@18=&19>E@7MK/S9<*XGJ$-&=F,KO))GY11'CSLW=
M,K*6,-&NA/-2I_PMT*<-RN3)BS6C C]_=JUY!?OLL@$N>QJ<">[UF'/I<6.G
M&_]5-P2#,__D$#&XWM[N@PR1FOD? H_YM\D4%.+*N/W\8(6+MU,@'ER&Q;?W
M^G;'P,>EEN6+.$V%4Q3A5M*CUJ(=Y[/P.X"3J2<A2L?BRS50,MQ3I#ZN*YGK
M:_(O(I]ZU"WSH-7QX*/M:B-.%'P%T>1.U)#VRYA] 2OP+3CF%=H9$=H.[WU^
M.#'CU)PI4&H9G_"P1"/APB R0R?6>(;9MQD2W)FA^J)??WT6D81<#$TC'GEO
M^\0R7J?0UL*A0.G':(;Y R9W!P/4Y#Z<%GW:4TR/\DI#6?5*XD/ZC]?0&.\?
M&7ANHXU2.59G&D:Z5L]4K?';?T4=E8Z-B^)1H&RUQB3:S4IF5!U2'@]?2"I>
M[+AXT2[G->7KB4I;L]2=@<E5Y;NI?9Z<>U'^3",M+Q]9@X_L^<\4-0H^>=&Q
M>F#1;/F@Y-]>T2_U\+#-GU%R<6+O?*A4-]_P!*W!2C>'WS_#M44)2531:3I2
M$ATQRZR<4UIP!KT>M9IY9<+,[-H0_C@S# ,M2@.3I?&J(R%? >4+*9R?,5"U
M)2[4MR.PZ0^"NU/S1^M3?J=R[,DG_6@UNJFCTIVTLW@8:P626:@I-&J. C\T
M6X)_O>XXFX/4'(X/#&P&5B'"VI-#Z'0<=KP@M"N<I((T1#%"#&ZD ]*O,GJG
MTR#L'#<>G6S$D2$/DW1B*;YZU"40"#T@4Y\I70GYG5Y9, &=/1!'BV8B<]*A
M^6H*I%_U4ERFAQ_>)G]M'$LV7^Y.H$52^/_4F.?.A$[QK]4X.\<^#-53T1='
M.'30D)0AL=^<<W%JMIXS!U278<(5%5^-C:AH@XU$R^.!(-J DP8OX=*]%=WO
M>(E="OM67,9M]9(A.:$W.7%FTP%I,\JY"8<(@_/@:]'[J09GR[Z7.FKF%-MW
M76KSI;.Y.,)6>03.1;A\.:U/<.GW6G[07&S)BZV!2Y.*7KA7LY HZW8U>IRO
M8PA>+"J.J3=FPR\0I^";LQ":>@[,M+I<2,_6R[:R+^!^P?C SF$1O38*%U(O
M&;0T[Y!O13NCX6 GVJ8;?^"_#80_#@H]X#I=Q#.081[_-G4VR?;%Y\'0V"^@
MZ+;93@1P\-";%K:.K4_N=$"BN^,N&WYI"&],SJNS3?AMK R?09PE24 _,$?F
M<]*K,G(_H#^E":RH6B15/ILZ:8*H>(GL&\<\I^K:G)H4S ,G&8C,=R6O!#-=
M.5942G_>=U;,SZ#Y/@<;?M%WH7719'T?:Y9<^,6>%QN"9ZY<S5=.^2GM:!.M
M'2/BM6\1.D%A\'F=;JU1O@'65J*:@!8?H5]^DH'I@M>,1AAOH[G>:@P>%42X
MB.I8!#NEXZ**95Q-QC06SF@7]1-EN^1H0>!\KDAR=:@J7O_9]BV089RG49T[
MP2X/(4$=>2;\+3_QT_P5%5!UZ4H)08L]K6_%=)-)^) P!O,]N/G9^/I$(S_$
MY45'+>MF)7Z7U7A+<%58\7EYD)KOOMI2=T/*2*R'KM8JT=A<#<@@_@Y@,.K8
MFQUZ=L1*HUH/FQIP6,0W(35Z)HC_(H8U5T&7K<<),VEPD@^AT,P,ZBYHJ]0W
MFODQ)OFZ?231:VG>O6UAI?UML\))0X8V=#_RG=Y^7A$;2VI/H?" HL"H[2OG
MP]@B?80W8?W5TX[HXJJ'&VRR(O@S59ZT63ON7EVY/D7!,2MGK[M8HW[50@<(
M6JN:*$8ZUXXIR-I(3J%/$@3+2UAE^+G2;7Q#6;,RYEA+_%<H:5'R"=(:!V[K
M%Q%P^P+Q0:M)(E";ANK[^R_]CXMT4DO 4-3LZEYS2-% WI;.RT4Q' V]]8^$
MGW=(J2T?S!24LJ#<D!6#G?6A8)'4K"GCWMO"N$JJH-&TP";S>PD_0)Z!'LKZ
M'Q@'K_XDYPDE#WPA4:S"^4NP;NRV[(JUC&',CDAS>DY7A;&A''IY6X+0@'ZH
M[F:(64A[URK[SS5\(P^S+ /7%&/7(*,:>J/G^AQRVQ0F@8P34)2@OK\2RI;X
M].1'Y%P]SJF0&)K.<EZ0&*2&QTT/M.F4)-U3*CDJ9@RKAN?= :ST9'#3BWBY
M*O":?VRI3C0D-\Q"L)W3]EV70]P;4IZH<%&TE9C#@J$GJ1(CR_M<N\NA%L(6
M6H"D9;BU3I\J*I%YHY MDD/IY1HWUD(W3!PQQ+7_OM'7O":..210>VB-(G#S
M77E#(DL=/%2/<+^R@$F=U**0G^V8N6_GLTA"2*.V4_X@5*^=)#EW-N+7<X->
M28G4XJ91[J0[@$)U7;2 V/ C,^H*CGA4W/.$Y5E+U3Y;KC$(+UI;GL, T(=P
M1Z0_)!<E.T66K59AW%\; ;@]@.H;_-HF*[P2AK,L+/I\R_[IGD)*JC[M&@C1
MQPYY!R4"'Z^=;E2H!)$DK'IQM\LW-B8A\1)=."OBT<0?PQ):0<VY!>T%H!V"
MG&.]_H^$!3_=-ZO"YO5E6L:4+$F!2="._G?=7V?3 !+?A15$>;/Q_/*#_;_S
M62VFPP*[(T]%@_,K1FZ'/I7 *L_",D30KAE'8):@H("J/N+1DP:$(TUNL[FM
MAA>$XJ #E)MZFN/-6C:Z6E[+%,<5^XRV S+H:8)4;?W$-'IBS?1+R1HR_CI3
MUKU@!R*:EE*HH8A?F)]4*0IA5L7><2&$)/'.)S)Q)_E%\:Z+"T%;"! 51JYZ
MMGR4?A^. :DKM&+@Q<CQL,SK-\;XV]&ZKAJ]IUCT(1IZW&69N**AY5D[(L8!
MILUAV@UZI3!CQT/]MWJ,9SG6MI;C.J7,PQ"G[:&DOM:SI/5PEY>H9/7:@#I1
MT^XE+XZ,49BGY/*6IFQ-8R CZ:'HD0(BW7W=4>D'7OA'GZ?M3M3A%U<&]O2Z
MW;4#7'G1^?JN]5>R$U "=?<-#Z7 '2\@W_Z>"=8R_9Z9!K"I=/.&H?>[JV97
M]"!.T:5$V94NAZD<3^FJX:S;2W,@?IY(W<\;R/>@GTD8@848[<K<ZC6=#RO-
M7-R_6/&$?+A/J*&ZE6$?'/V6V+K4DFK ?-&K,'>U[SE5\]2&L^15TP-57RK?
MSI*KN'6Z106*B;KX9.259N]HZB->*FX+N7#&W&OZF>IDZ8E&'H8%E(U.\^@/
M&P^L9*8'-Z- 3[3\Q1G]'1?!ZKQA'NYWP_KEO:_=1XUV#1,)C$9RM.)J[@!!
M[_HJPHS'KZUS%XVVS7\KL<YS,V.N?Z-5/ &QQ0Q0X?-5U.=8ONKO!CSYK;*I
M+.(9@O"(RAW0+!_;A0N%5PNJ&] )L0C\?FIO1(>D:113XD[,E,:^B42S$XHM
M]K]F"""9]W,R>7QLX[R[$ZSW ^,!4UI;\=0.2=+W1Q#A$<MVXKG\\-#U S&E
M1_##<_66:F9F77+FX)NMQ<Q'5=?DUM0U7QW'(E\D9^),42L<*'?]VE4O'N#+
MAL-LS_^]XS_!GO)U_^U2AX$FKN/^&98T[F&^S_:A72OJNR+ 3Y"0(=6S_ XN
MB-K5\$S1;)=/J@%?PZ[#1Z?U()<[P,.]SP*K5(Z==D9XDM,+3)-\YLLZJA+T
MNY#J/0/9*I\*;T:PX&IPJ=ILCX=%S4D6Q?PCQGF[=(N++1?B;L\WJ<GRU:/9
MDHU-M;J'XKP#SL2=5NE(7E1TWO1IY"]&WBB'D5 ?XBL\HCN RZ_Z[?-44QV[
M[GSFM.'UDC=B'B;$OU#HLM516L-KDOQQO3.2T^(<53 JGX[\E7B)75!JS4;[
M'6#\K9,RH9Z]"N%QS>)]:_<Y@I'&U\IB>EF6J]^!5V^SIX#6!BJ^=P!"51H$
M1<B&Z'NN58F;K< $KZ"0\^_@<Y_X?,TB/9;L7(/IVE]]Y.H7=KJ2> =&J^TM
MIC_2);IT?(^W1(!  XF$.P"!;8A(@._%^S$&PBY1&VK+R')+]JNX#Q*77E?4
MW58K3O0WI4B6ML$#Z0_XB=W6W;G.)6\*GW]YI&SGC86I-@Z'@@/?CEZHIY_I
M!%LF/[D]R51MN(:+-,EVB2NIU%9^1X^EUTS::$3SHA_E=@R+O8W.^_61[I1C
MIO[80+SGM@T5A_'SPOI4MUHR#_F67X5>?R[%RC,]^P[@9X.JWYUV!:K_H*)E
M*KA,XV"8E=)O"03G[=VLSKJ%W=X!U)60+!K-%$I.DOR=_7:KDTD[4(9GTZW/
MJ)BL6G*E=MA$'#].["WNOVA\6BB0N^RA\VW#$C.6Q7W=%18QQ4 B#NB%,;9+
M(I\C\\JSTQA2;O+P3Q&&$DV.]R$3X6=702*9^W RZ !*G5MTD3+YA7"/!VH5
M^<H&]LM_ETV,^;[7%DD@]<++2F'!W>4(D!%ZM< "7D7/1>X\V[6R.43NBF-%
M-MIK1+1#8-_K2LU1X7B\$!>AFG#]<HYBA5-R!8R4N%TZIO[*P'QF,M&@QX3?
M<23X%B-JV<"X/4>0I#ZM:'6CL>$C7AD?U8G7C$-Z7/.1)&'I&6TX7ZK[R^!\
M2?.Z;L\3EH8,*7),_Y$R,;/[> M&&>TSDT>3#H1?OCK6=-74N!T_'(_K%?;A
MY+@#- KQ8:AZAUN,@V]EQXG4I?K_5L$1_S9RI7TSUBAS4U, NH%M:W%"7LZ%
M1"Z[F]>+L*(5A5%@R#S)> ]X@?&9X@[0_AA.2R 9S.=EA) ;,R-+W;O0$^\Y
M+97*^B+$>#CR/.BMWFE87TA57U<C[SL7OOZI'@G_T*31Y>9$,!+7AXPITH99
M,U@@HJCC?<U$@SOK _]JE'$NBW_)-FFL@H-MX1R\C^#%1Y.>[I&,(0D*PZWS
M:FN[%:CB_J_>&BFK3>Q=O()2Z?^YA?'J=+9)Y]> Q4@)P:7,IUZT6)-7+C/N
M%@CM*AZ2[:3CQF<-LXMR'=5 CO4!\CN XRG-2@V$TN"P.:&T"#[';&-R!]!V
MPIKFM)@.XD.KE+'[N-I)0W)ADVWM\<[XPII@9>/E[<B);5L]%Z/A*'S65E*U
M3N_U\M#AEA>Y*MW0H[A_.5WSU"2 "6?)$8;KH0SL2JJ7]C'C"@RSNG!=$YM[
M(>9-O*CQ,<F9MU U7:Z\K:+;!*GSPI<^H.IV#H"AWC+AE$ZDY&.79<B?%I?/
M\?&S<.TW9YKQ<5?_-I!/L%D@));3ODL@**0Z)K] 8MSEBF%A]DWLN\J0CT&]
MEL-RM<4;((D\W/!3?:Y?MY3C^AJ'G6F9]K^H5^89:3"IE:5S7?MD)N!LG)PP
M[/Y$1HXO*$35.>RY2@42-S-G%J4&ZC.S)HQV<9RGYCT'(D#UL%3K;-?)MFB0
M;%E;Y@JE+&^WNPW[[H^)=';GT;>#KX48J:V$T9X)A0-F588/#(Q*H3M)&S4L
M8<O3'6R?L.H;N]ZD[T>YCQY*5#I 79W,&]]/OE0\[&F/F%7A55L9J6N$R&JL
MRU$O[ZGJC7Z"57F)RJ?"P3##]23M#DNLI<TF/8&DYJ"5O:<LX_D-C4W.5XJT
MIQ]>3@$_D(95*<"S<^5<H4ZIC7C?T]]=3HK#Y@VVC425996P]K-(9KDZE*(;
M+R^UZT1WR3PIH/M='M9'6\9(E:AB X@S15XJ#E#2_*';JVJ Y$+)GHHDB73>
MG)5(?#E&N!WW,A6CL'B@574EI'3>LL9] NK%'-J1G%'E6^X_RU*\<^D_SQ,$
M=>I-$F5$GS.0P#O0+^./WA_Y"B7.KDXV_MU7!_/4L\,+.IE:&#) )$2OTV//
M5@KF6LSV%:#,=_6DB5Q$SHH\I\DCIU9IXM)A$'2$%D5+4'9CI/S'HP5CCK4I
M<?;J!I)LESSP3,19[M/)E+XU=N[IS^XKB5 1[+<CBOJE$F'#E*!P01&C3),"
MU] 50]GK9NM/T.Y?E!/I,"N*]!!.BB&4CM.W.T!QDNP3$XFZ$FM0UZF3(8]*
MD)Z@?<(C$JI>&Z^>/0W(Y7[.T0Q89#,5;WKM/O5UI437VIW3H +/MQ8+'NL8
M*4EG3IQ8R](^W08%OKV,C\],<5IHZFXR=FWD@5JJ0P0GXK,>&?;OULYX1/TN
MX]F-??,L3)6D]R&0XWND3PJQ^&V<1&FF7/ZUH"44AC'2S5KG8J1]T7O-MM#-
MK*A63-9E<^X.'CYH3DYUCG;)-0:G&47S<=D4:7$:MZ. F,OI.."9B<2"[7/U
M'W!LT1KT%=X@<F%,_LKG 1IG$Y-ZAWN#9TZ(KM(CKUZA+1GCPS3_@NT$D8#;
M0DYE)]>?%9WGLJ+C^::G8IXR0O6_7H:M&]X!8!O*-0&>,MPU^0*%/CAG21XD
MH>\E76^[&BY_5B'C0SR*JQ.?3@D^Z91B?-+A!#@ODA :*]W35"X;M;@2.S^G
M 29ALHL7BO;F](;EJ^"JNURK5-?U-MIFSB)\IC7FXM*=V]:]7R]\O9SP"3J]
MFN4R4L5%^;VV);*IKA7#FKR&\+2+,)<&.RX^:W7WC?>8G&41UA!Y!B[(K7L%
M9=/37#2\C@SJ!N7^3EQN.]-P<QAD?PL3M1&7,077YV4O&UI1/S>HAR1SE#V%
MKY[9[L--!\U6E'+*#\?WDG]5UR@BO*ZY*-)X#XR"BK>J00MI$\!AV^ C/">)
MC%'GT$IFA['8%$>KQ4/U/I3^^>(S,75)'+3(%^UIXW,3DD'7PB;+?7KTE0M=
M.O-,,525M [ZQ 3@IJ=;K5T"'@%$ZAI61-KBFEJ5PU47M@>;NEP?R-THL\8F
M:EX:@3H='@0%:N-&BOHO?&'YZW*5OY'/RD$X#<5A'$)W@"G!)>1\I89\>E<5
M"G">25+BCG.APB3DXWYV!X#[AZ+>[+-E-*9Q!)@E,IE]$U3[>6RL[ZJZ2AOH
MJ><9C]_+G+J*I+J_7^++Y;UJ/(2TIW&-T:JQZ%/V"D<O=5%=1B->T[YT%5G8
M072)O-7Y$+ZQ_61OYX7;#<<^?6H&31,BZ!#8UH*'8C%QLBIU\)25&)9DEBO;
M,QP > XB;5>J2R6#;:K$*?;V.*'Z?2[!R[DVUY= ^F7)4&^FP]^%1'L%RF[@
M6K>)X[KW?8OD6U8'G8L8.S0TR("];3^YT0.F5YTB,"V+@N?E,,GV!:JQ:]5B
MZ7QP_"!GQ0N,+Q=J+DQG1&CGN.E>N/GY^L;Z*>UV!+^"IL+'DS*SP,796\XB
M5@+K<%^&0=@C]IM_?]^NER%2>Y:!(TJ6/'_X-8XI3L#C"_DN\>+@2I1SV4*1
MP6+CI8$F^4HE(^"E\.9$0Q%;(7]YRK:LM3!7).$*X(KXMV_1)]M*/4/ODZS-
MC]$3F57PA.[ZP;.($Y6DI^4,,Y@]Q[-7'>Y +R8P.U$T\="I#OFC )F(-UD!
MZD-H7]CK=L/GL0>J3[QP*7\*XH,O52IB>QBK*QMC*:,>PPW%/ K[G!YE)+GG
M!?#_K(F46UZ\R=S3X;Y^(/Z[T/%1UO"VH'U(?K5ZGV">%[LM[50)#8&O-?WL
MTY3A,BU:)ZFB<X.F=]8Z1%>LMY*'N-5[7.95=J[E_,VO%FP$5A?Y=<@_3<K%
M*W/TNNH(L-)UO<*$V\7,#2(?J =V#?72^'\BFAOX=;%W,[P'%*.TI4E8D7P&
M'L+C_OT<&,';AAQ0BH@O62"FVG3M0K2<#G4?+H;2CYS00\RLF3?*'3@:WH1Z
MZSQ'15B!K-(81AL5S&R+#618&R)2E\)]B@!:I&D\D6T[!VHC)\4^N[,6Z#O'
M:"X.OY_:";:07POC19F--18G-^@N'V6: G#.Q<;2QFY2>%R9DKQK]M9,/;6;
MZL8;A26JC[^P-%[Q?0Y<9S!6WX=T%"_F1RD@%T**(#H*UAA?+?"LTQ=,SQGA
M;H'E2U.<,%[K@D>^7]BIO6W=I?2Q1084(XLASD<\GO3U$QG(O2IW1CP!K0\,
MDG-F#\0FH3.H0$2[/0+4^3N1ZJQ<&%+;1=9U4^:%5<HPQ*W?'L*A1T)* .M.
M%A+UPLS]9.1:?;;9EC!#T17=:5_GK!YO+[PVY*S1A]#(Y,B9W7( W0$ZH@@0
M]=\3E L&(/B?NC$:/FE1!Q'/>(HATRI7!BR4#_<+'2MZJ9JMX7/I"%*JN$'/
M4.0&AJ[?"SEUP\6V5/0[@!92T7C6 %NH!"T:EAZ@<TL\6)B!!"NJ%R3-G=^H
M*OIKHP+X(S.9,A2L*,;C>J;:8>S5\#Q4!1?+ZAL/NZ+IW^CM=BEBGH<@F)X^
M9"8_Y*0!<26?K<]L??ZR6D>;,5PKJ-LE>E[)C2OXME.A_^FK]$35PK.BL$J1
ME[KN<4N%72!F:-+)M0JLCT(GX%/-<189O7:,["<<7X3.'BRCR=>B.I$EI%Y$
M0 K&VSTJYV.2U4H9PF7+/>H\V@[53L+RID$86U4KT+9/RIV7\TA:^*COJ<8C
M^H\,+;! "SO5V:>T9 B%8JM7X+.7 WG@2()UGXC*L:A<A=74C]1*R\,-90F.
M0%6*-9K/JG1C+7A!LZ0&+:S*3>O3+_=IW>S4!@^W(Y"ALVJ652XI!@K@\.N?
MFU%6+4Z2TCP+OY,A1I#K8)Z3L"@L)7#IUK?RZJ-A6RAA-K?$(0U<\BLW4!^9
M!X?.YOC]EE\-%7!J97*"'5OMS?K6D+6>Y'7C?(9-96L9RY 14YW+_@K(27*W
MM>6-F/"FA9YEBIV1'NE)N_BZ/,&+5[UM<CJ+'YZ>D;9^=C,GC^_MEY^5V]M$
MG@.6?5H+;6_2'/=9P_.X QC0W@&D^!W^6.=;1C+D_S>=UU67(>YW_#;_NWK"
M0:4;G8_KXLG:+>5/GS*6%I\6#_NCV!W>3DO7E>T],4;/83\CF:/)!Q.EKO8]
MX%OJT3T[OV\P[QS3<2C]CH.DQ[/&A TK(#V28&#C<&>A0]+#Y-5OO#*Q26/M
M ZC&V2\/O4<:IJP^^(K< [R@H;/O<Q[AHZ4$5\K5#9IQ\2\NKCEB#^UN1Y$D
M#5 :]=PC!LG=T.XR)/Z0)V,A6!!'YB:9[UGF3FL]OF&4_TG>B!@OV):NH[_9
MM.5 D-_:/G_#OBV_.D4L;A&VN&$+)$:BLU1'*4UDTXI'],S)G8,:0+\G3M;'
M'2'%I*V$LJ_/Q(OH]CA2B9<VE3MMN&YSB?-")')TW<!8WVC;0]M17N9GMQ3Z
MB7('I4S@68G-T#5]S>;Q$WW)QX]S2-L^$+<R^E*DP7?BJY$SH';;9QUV=#(T
M/[5[[;OF^UD'9[4T]9E13;<K5BN>;H1ZJKD0)%[2K\\5^#==L)E"JWI/4%ZB
MG<F+"Y8W+=((=4RPP5:IZHRFG?[)*:^8>@EST-=]VVP;L[!/NOO]0ODH:641
MXT!.Z-3'-\F+.VXPQ;[V9KHQ[D]\J: 7]4;)+'< 06?/7:]AHY@,--^?N^RY
MEC M$[FDG)N<N!+H[<=)4B3U.W?#_\';>T<UV3W[XE%4% 04Z26((+U)E0[2
M07H)! )2!$)OH1<1Z;UKZ"7T!!!"Z$@7I5<)37JO4B+UY_L]Y]SUON?>=<XZ
M=ZW?_>/Y(WO-/#-[]LZ>/?N9^>S8I<H!9\\8.H8F^"XG;3?8=<)?U,^V@*>O
M0:H@42LK:V1.0W!5B";J<,L]FS]Y%UL<NA.,/Y"IVCD.X&RJY#EHZ9IG/#1(
MYTJL@O ,%Q;&Q8^VJ":.1<?7:".F QT6+RV(4Y>(&$RU/ZA(1,9?L"#]91NG
M%Q4C208\-FDL6]4=<-$J$&>YANJ7L]LI4C%BH)S-HRW39^."CL].)PT'T[KF
MQ(FI*@EED80:+S(N:,^=VNA)5,:X0XM2H4[W).I3@U37 IFP-;:/S?Z:4F*O
M[^\(#'@^*]ORA)9L8H3='E:,I$A'Y*X@=)/*,O8LO4,,E2\)W4L*@I!UM"1-
M#_7FB:JN!P_2<FY163[R/,^V'US,_J53/79)S^S$^G[_2=++H_$5FA/<B&6L
MI7:H%AF)N6SK,V!/3LW>_M$&9XF'E7E"YQT0^4]K89HT=%Y#[_3Z+TO\"R2D
M :48P',ZL\3=6FQ_RUXMVIW^>TA'XI@@M3:TQR4 M!37&,66N_ZO&!@V1/P#
M%T:5WVK_KEIX]8C5=C#@6[;]DVOR[. ;@*20]"5)^J7=?@SOI4K19I_[XH#P
M_+6^A744B+'N'"668[<N&$3FW6:BPY73.>\65/%>CD,U?+AT[9U0VZ+1!L.O
M,=T;P)??03WQ. -?_,OC\1O @93984$_+O(&(.$O?0,(4%/Z=$AR[8WSNSY/
M>T?R3[)_*&&[\+_HX@666"\/#VX 5R?< (:#BF.2WYNE-X"?_FW+2I><DGC7
MOG9!. 9>W,B:O_P-(%L*> -H1?P1&OZ74,F_A,K@_X/N!D P)/.'$IYSC?_]
M6M GY['T>OP?ZOU2VU]2SX*&&$AN  LZP[?^$UU01\VP]'I1\0T@^.@&$ NT
MZ=+\O;QX [C8 HM<_DLRPU^2<_'^V9$;0*A-;M"0NN8- &_U!D C,121\ZNW
M\P9P-E[[=]& _TPH_4^;_LT*_RYZ_X]DP%]4>-?@?^O:!/+)%QK\<+3-A"".
MU;A7)YYI<*B>04M3"/3O8_ O<X"./0^AK3> R'%?5:RC!#9]H0EC^D*&GIR,
M..7?ZQX87Z[ 5Q8/KU.%ZP5'Z-K!<@2SB1=U0:_'5%HB4I4[9H?<D?DUZ"R+
MJ5=C5JU-S(J9=^D-3V^7>KMW"P<RJ72]4'.6N//@Z4?S,%\:KET7V#/$]P#U
MK:Y#RC"DOY(SJ29SU7="YRC;.&H2M-XA?JR#A+1OFIN<9%>W?Q_%XQQNZ69[
MS\G3^:,>\1]61'<BFZ71XD(E&:%J[5MZ(QZ<W/B:%)ZVGMFFBJN9V2M363]Z
M*S>'[:2HJS_#Q:,S,*Z>2E\37VR1(&%PF_C:%ETC&G]7C> ?%0+U':I*6IS&
MIE..$M+%&4VY VGW$W._BP,[2D59K3%\2<4O2Q4-E)<E%!8O-$DVP7<,RO"Z
M_8M4JG^) POALX?$;9[8#V+ ,/(3:A\?Y6]?6HOGTSAC19:(0[GD!C'>A;2I
M8<RAO7)&6G9BO.]Y5VIGW/T\?]B75UCE2@KLZK*<VA2'(!1ZX4G-31Y'09-K
MGGD^Y5O7-*UC>^XPR=BEBIX7WW-/B\SLVPZ2[1[9]EN.[J03?@+QBV#0*L*5
ML,5=)7#2Z*0*_ 9 .J-Z3^NVJ$5 >4Z.UAC^AST*Y=7K,<\G&:5*YYW9GCFR
MRJ?LNJUE4FD;6)#G$8?=-9LSR;0=G*BE/\E8<,:2*]"QH'+=1+(W8G\]D4JE
MYCND=,'VM&*[_!,OCZF/89HE/"QQ5R>/BAN]96^$2]:KSAP@:B<%HEXZ#S8Y
M$^ PZMDJ4P;H^I:F^I@N-:FE6\?WF@=SR"H?EC,[Z(^O/,:^*P\/5;#V$PZU
M.O7MR;EJ<&S\ML8:1EY/S1%2%,#Y:K[=!KZO>8"JC;7GX^3.&F)4<OM404NR
M2_($)V_W9*NZF>)QC8]5X(EQD< FY/;F:=*&F#S\[?@C[_=8QF=/':CQ=8I"
MNI$%$]N8I*T,P<H_4:/'M* S(50D^F$/Z;XH]45+N9S\H2 F#8/U++PCABYT
M;/%U!C!\-#!-]G)'XKX1@=<&C95WD-2L_#& J\-=,#P[.-^[.W0.>:@6<:V8
M/=' 5"\X45FZLNRS?)>J6Z0IT.E*PZO3E#K:# =[3!6%4V<>-B&F$MX3/2[N
M.)]OJ=SP; S+X>+?C!MP%V5@.KT#LG\PZL^),#:2[/*<W!!66A/A!E<WJD8S
M.U!36?'M<<S.KZ?2B7T&38#7E"+\!<R7Q#W4<ONXE#QT>UPV F(U\S;2&N]E
MUAED1-TV^C2H]F0<GB@4*Z;VZTUZ GKT)$)DP*"X/FJ2$NY#\3+A[:<X0$D3
M.G;<?& 0\SR_;-I.&)X"A&5UN?=F.LEE0],;T6&9AXC562W!\/OTU7"#M[\X
M35>Q[&7M*7Q/W_,3&:#'*_:MX;3V'U>3GD22$WOF^-[>P"A#;7-M(B]5#^=V
M;P ?8+'<EYRE,UV!FFCE@N]43FVJ<P<B<94\CAZ.C,W<I=U/Y!.OD.^.ON#M
M!W"6'\Z'PY;,[FW1*"3W8"CODS\,)QP'VFO*?DY7'^;BLN9X^_YN[+=C9N+Q
M6P5_EIF[W!9&>2.5;S%W^A/$621=7,T(3-6%NG=^F0@(#C$)I&UI^%2V?/W:
MOFG*N>S\S@ [6<Q3D+OP/"7Y!91[54?7=4LO+D<5\+N1FCG,>S4TZFL,-<')
M'8_*QMH'*!X)\6)-S_OU25CA9$DO<NI*I@.;G1N <^&6JQWP:6O<<4=[05VD
M\BNE5UTGYZ"Z=V0  ,#C]CN)J26&'B*1=A&SZ6'9T]W7#VO-JZK/G:1:)WHV
M@FI=X%?/)FL_A$W'/:S;4]%T(P$?F45,3J6U/4+7MA*M"XT)&S<FMP-_=+L=
MWSK+U#'<!GNX/XW:&O4@1J3P5TF#C27Y>S5UZ@P\3W^>/%:DE$YU7<#_V52+
MLT0@#]Y:5'RC+7GE7<F+"SZ<TE>W#A#O)**CJ-O31AG)"<:(+4O<DF%0U#:]
M>S"T#+LN1LKFX]*_)>_B6XDH-RD[M8=K!-@O**D"V%@!<+9<8K!9!/BA@(3&
MF5]B5":X8260; AG./_'/66G!^$(;@"+$% ZPQGE4>%1P9\V^]]:^-Q_(0=U
M+OP:W;\!W#*[9/L+BF=Q__<V[ ;PKO*:?/RW]@U@2.BRY'\Q\/Z%^?.' ;O]
M-X:%W[ON_\[@\Q>#X!^':'MD^8?E3VC@'P7XX]86+7!>UWXF?_PWYQ\6AH/J
M9O$_OG(OZ(#\!M#1&,\B_7LMY^QK05_TM4_QU1$;7OI?6$2+?\(,[C\TU']H
MZB,"):!5WJA]U7&N%8IHGA\\%G))TEBY =\;0#+EY2_-BQ60M,U/,Q(C^W3P
MM\W#OA*3UC.X=OV?+8.59R[1MO''?6Z+A@_)=&74*E0OI2:XGU)1T;/; LH:
M0Z_J/MD\GULI)WL<4R-D)-3AC9SJDF(;;99\$AXF<J'P0S<!L$&DIS^=972D
MN.U>/@HK)W(;GX7^JJ@."8F[+[64-^&O7KB!>2P;Y%FMQCNGV]=;BC+CPVDN
MT9(:$(GHADM%?.;6'ZXM/(R=;ZN85P1ROI^LRPB?T]^3ID$IM,F1.(KL548<
MOTT$,CZK8E/\^>4PZEO5H6)BZ1;_#[ I<_KC=0[Q992D?5C=H42:-,G>\::5
M-+;NB);Y]657\KL@CL#JW#_VX5V<HS2LC:8$NY>;?(Z#&.];AQ+' !G1WDC2
M)DE\W0FNXVCAIM9/%J'>?7M0>"#"'&5(F"%*NC2'DPC\ *(OF6U?N@%0;7KR
M\<$[)E_ A$5U-&5LJ^M#VJ\%QW?6S(ES_!BPN4,$%6+!2BS9EJ?[?UR2C65A
MXR%Q:-Y\=]%W5Z+FRE$ADULY)AX5$/N.QMB>4B^?8CL51V@ %:7\"8%XR'%%
M%F7G<A>6HJ%\KL@)QNI<4T.L#=I;2@HB59%^ESNFW3?!XFJE*\VW?N=:KS!)
M_/-O4&9#?LO4E?V9R8H4CSW\;65G>0"E3/V])RZD <T4 !O6*9;6@,J2:T8<
MI:8SR6:U<A@;&9= ?T@*:\$U;)&FK7/.1GUBK?J#@F_)#Z-<A_*0T=QY)*7(
MD.HN?_J'$Y7:7>U42->3/"-+_'#Z&MQDUYC@J.!G895UUJI\Z8=!%F"?,]+"
M= T9;-8C+P9P<8G3]5"&#:06>&VFX>W/F3+9V$3F)-2M0M!)Y2(=D8VVZ-6+
MVVVN@R1YTL>ZZPL5[:.[,?M.9$!]KJG'N[K)C0'$8QIU8QF@]VK;]_<*K F^
M]NO1742=($4ZS:PF!>?X_9AKQGC?0M,&A7\"Q))-Q;FB207C9O1]!FSG+D'C
M:_8RS^:Y+8XL$W^$S2P@\$OC/&R',N2Q 4(GDENC5Y>4?L(9/IQJA:^ID4X"
M3=^EYX2\VH5=AA8?6+8J\,U]6ZG(=+IS,85_@.EI-(L0"A\%4AH6Q_#5-3@+
MD!(C-/-0=:=]S<9+G-LOWWH[U&YXRC\35\IX?53<I_UR0<EZX9+XJJ]"XJZ/
M?2F6N?%3NO+GE.^.>"2?-/^X]H8@EC?#;6G+#/QT#*/UN_C=]Z3OS)G,MSH=
M_QS^GHT(5UTC'=(>\4"*=!^9#$X):+;N4L<M<,?C 2<\W68/BA9?:?!-P *-
M@9\CZ1[?55!>-OT&N)U9@>*OH/(-@2_Y0TO42EJ3<W^H?CO/"$\</GI&![<)
MO1PB\?Y\UNFFSC0C]F#W86QRW+)@@V"#Z33[T8QZY9H7T3/&6Y_TLM]E6F?!
M?Q$VB>?0V#7.[8 $E(BS'QH$&K^AIDP*V+:8ZKES^=(1+)?Q->'+]L( G=9/
MMJ4G3MN:@[UVGSE?Z+]EA@&.$=8$#RP ]'V5G'&#9QW<>=M'LP.L,PS6N:BN
M^)P$5^- GFR(L^F8A)"]0*% X/7F\DLIPUW<2%])&M.<(]+/=\=+)@P0DN 7
M5?KWVF=[8]N=70M,M)2)/=K-S86#'G0M<]9VTGX#.'ZBRD JDOY_"0=FZKKH
M:#&C,HD^=&^[X@3Q*=7:K'']&/"5_#\F0S!!R*?L2\PW%*$R (NT* ";Y%^A
M(D^S",+4SG5+A"+B[,4RL=^5DN]4-YENDU5)CPC4B<PBBIU,GCO/*.8[F84!
M%0^9U;40]]\JIY6A]F*=8/0XFEZQA^C:*>=9K[#B/=4]JDLB@''8)*';[L,7
M/2:K42C^@"V[H>I);ACAQ<5++Y\ZG?NK7[_T42_5L@$$AZ.HJK0>;+E.9OW;
MR;=,70+W=Q.N%Y$?WWPE<V+:UAU1N.62'S64;(2.AH0H.2[8P>]E>2_;90)M
M\5[]1U);%;KMP29\)G)%"=.B>>+EN6X5%5A0N6Q<JX5/!M-\C-.-M;@W*=A]
M TB?T;LZEKNJ[YT_C]H\;K'4G*R8W-=HBEJCN&9V"A^.R[V@:5:PQFZ '>.*
MI0J@-G24( (*4,P;Z7&/H18 ]-\2]1B?/DSN!G"3IY)$UG)FR>T\LCO5@:P#
M5?L1-9M1V?0VK^O;_*B<=PN;XL5SC6ZYXK3N;G'$GE87;<;2+)@9SP@6WW^>
MP.Y<!'4^<117Q3S9HJP"=_E*?+Z+OPD'-"GH5X]7H,7-W<UA1/WXP<P:5($6
MR/^M:!U?9%D]4/*)0BIY9$N#+GVM';]1/ /"W-1;4?F:5@E*&M35,TN8JZ3[
M=&7*A[OV2:-$5<]..)N1+$= V6M]=B-;2S&)W0;/ZC4\T)_=W[[.<,4ST!%R
M7#,@]2EG_*)T+-0[>*QC7K!VZEMJ56-,NX>>R_V+PBEGHBQTD[C<'=>:S&H%
M -SC]&"VRS*;.9%$WS51,\OL:[PY#\2L96%XR9_!\@HC7%-I*N^YQ67^X>4-
M($TN?K)A8;<\B[#S/#WTMC+LR8NP@5?)C2*2[CN<DTF"D>1,"GK:[\KX[BI.
MINV[8(CN./(?,'.(D/3D2#5&+BYP:/N>G<PNGNP_["O&,6E>$ 0508VM:96X
ME.;+ANW8ERLI-L/N6E=516B^X Q>RUF\Y!PQ2A<W1&E:^$XZY;F^79QCV<(9
M%[KVB'SNR7429+]:Y& 7+[8]^4V'RG-E"&EVY"EX]GGS/$5:5#N!&9S<*0;>
M$I,J]BLIJX#7\&DSMD]?"MDK'$(J(WAN #4PB/@.ABO?T"+32KDEHF+76!W(
M>#B.=4A6(:.8-,]_7'<;8ZDSIJD[T:&'T,G0NYK?'SD]X=N#]2&;G_.&K2B)
M?="A,EY=D1<=#$P-7R92VFTEJXG9=+2GTU["FJPHMQ#!DK9O]RI/>" =F=0-
MJ*@9ZSG[OWE32:$CZ<2&(II%69+)'GUT>*9E81XN2CU+Q/0C?]Q,W*"F97^A
M3,(S*GMOU)BSE'OM%2K\#LW[Q+WB/_\>?[X^5S$Y@O0D18(R\609$<L1B;N6
M-GZ+ [)[O(@Z6_Z=,N]426FQ+8=+L>)VHM+N^%TK5QB0=ET//S@>80&=]-63
M>EQ7;?OII/M3_N/27MV)EE"/)%NY3I%6^IPA*(^3]0N3NIWRVV*6HR&=77I.
M&H.#YSRG5]1!76+3D\=$3)K500M;J'SUEE?Q+7"?NO#V:Z$J0_QT\Q*EE:KK
M1\MYQ0LS&]>/)G34I0;VT,9)\A2+-57 0E^"$;0] ]!6D_ZJ1H&9/Q5&]$MQ
M^=_BMB5ZY>&KWL[UR?USE8_;;TEB):"E0M]^-\(^6,_S!.HR;D%;@8</1OS9
MRW_,]T4C&;&"#WW>2GLV23*H5 T[3/;TWZ6>]1(VBB\MHTE_?QP ,H"H+E'\
M"A,)=>#ZN)DX7_E)$M@;O6/=LG$)7EB_5GKLNMCGL7\/ZQU+'H9\V+$'NF;1
M\<$_0 8]V<+K^F4+YL[\%(5#=O>,C;[HN]?4Y[B4-HV<NQ69;F[ZX[@"0M)!
M8Q ,XQ[(=%[[*OQ^-ZM@V)= =&QBCX1XJHD^J_+*YR/%"Z5%Z0BBMU2/-AM3
MC M,%O6GD#HU8TR'DY65=B(<IE@^1X>:X<>7<H>H*<C!27R$8Q+MN/-<UM<-
MEV\!L4:CQTT0!LVX;]\D$WJ'O5C'1X80Y_$_I)Q !WLN<*^HPL\XF'=RP_7(
M9TN;VIR/& 543CN6SI<G%/ BV(L_DC7A:LUR2# =2#""0K>7]1'ZS(1\OO>;
M.OR5$M+C54HA?+A,KS!K?4S^KV)$C]#_0)%1<'<E0M1B!+Y6=Y*F>SF](RY"
MH*27,BF]I(G0)3LAU#%W%GU3\7-&WTE\-[TJN".6W)F_R2Y4)GQGK/J>I@N^
M+.0&T%D9!?:*MTRZ]:!VW((V>RY.CD1?<GMYZS@H^  R<"C<O1OB$$M?Q%34
M[Y5+DB]A<S C<U@/&F>TW4LP=WKVTM^70=ND-?R L)-&_QP"47<-JL9PN250
M2OV$58*XR$B5 6XJNZ9FE9>>!ZCH4LF45WYKL77-";>J&&0TP8!C^R8+CX9=
MY)=7YE8QO+>\OU2&PFBA%2?BY?:A;^&B1B8B6K*5M1*,RUDD/77.4LDNKQ.7
M!X)[Z*4*QN:K_-\>^'7.\[6*?<A^F[4=\/M-#\.6I"W>:AO!M,D6D'-T%TD.
MMVE0;_)[$P*_2+UE. [,!=C_]6$:B=<N(#11UC)P2/5K;:O@AR=JZ[\LR<8S
MJ@,#<XKG9R$SQF4F)G1?KU20'&Q/5/9L[+ L.<@9+IK0QOXHMX8MDLF*:2/C
MS=-$++:K6HZJ(_^TG$P[,/A;I9^=Y??%6* C!*;"E3 7DG5]77^"%/T9M8;_
MWL/H68+C6_-V<L8*>N,>&N'H$J6W?BXZ-CTN_&3 ]5%X$^.1+&3#>%1"NLC6
M_NG8;AH#WVK$ENW$,9&(B3Q$<=KZ<6:IQ&-M7+C^]>!!]QK"Z=LJXQPML2QK
M'DI$8_*DC3C@_2]P@XBO=6[4 #O=EW7,:"F[I).-Z%AX_61.\+C=-=-(,Q,Y
MNO B@7_I9?[K1:4@A!(P(_>SRI(:IW=A2L]H14B1ZQ00'<\6KHVK(>4SRH4(
M)LX^FC#]I3[1S.%<<=RDPBO8-&Y.9]\7.G2<K_)\S>/-G&HJG<5HW%S,!@H6
M.L(T5;GB**?>:,&#-+2QL'G/(4UJ!V0XJ(7S%-LRT?AR:KBXF9R2-SH[2XCF
M0<4>^OK.S<_*>W7UQGB1_[P!4%C5J973^JG91\N0P^U]5#JD?$GL0GZD:A@V
MIHT9&UO7@<Q*LMD.UV)1D %N](>Z>4NGIY9.^UJ<ST29ZJ-]^:R<..-0R1UI
ME/ /Z=HS\D=<MM3O[@3+HLP^#NJ3TV3P-Y]3^1#*/=4*"@U7K;9$( I^Q\VL
MT+_\:9 Z[FP5<\8V4G:@1C 0;8A.@L6D*5CC^1'C-^3NISXD!N9G5N2<# NE
M>E:+RSX5-@:F#DP- ^G&!-4%-,>Y>9%!:!Y><H.Y)0;F*+_2XXH6RY]H=.@'
ML=#NSAG)_JU(VQSA6U*U0.NWFC,&NN'&S]<W7!D(/*)W;7I/'_WX=E#K5^B3
M$E2N12*=?3>  ;$-)@GET4AR>IZ]I.+NZD;)V7P.7Q<TN[^ H_';%>G$VJN<
MGLBDH]RTO/J0\:0;C[R#%G=*I'U>ICZ'ZTYD2&2.J9[314^/%MN-GIDY#YQ[
M"J(9 +)!%6I>]#L)6)/&/E>[@M7$<-_-RMHF1SG5=(U/^-/STKQX5;M1:[ %
M4A-F"AJI*/E&Q(JJ'+&\6G":X-"#N2V#0);Q8R+%WY4/7Q3V,<7Y;'%@DT$V
M<0A5 =>H6<SBT-W8)UHB4R*CIH.)O_FH\<]KC\EMNK(I:5;2S@S.G&T"G!.2
M<]>A6^S8H9C: .(3;IYUYY<Q50IS5;X8A%,GEWM'4D][XCA_U1Z1FEN;  ]?
MX5A1S"Z>7$CG^6M//E+<\ZR9\NHM=?=1?PE,@/D>Q:G"V$JFB>1'!O;DR28P
MF P^CE$D51&JSJC8.#V?3!3.<GE!%_U.29\ICSQ]L?)!+,&:?5-T;TMSHKP%
MB &&+\-9E)^4K-KIL;12.%DB/B'YMP !],^?&@RD=/\#'&[W\-4)WL+K_<@G
M)];D.Q/+R7*<1M[Y2U39BK6323_+'F:5,P[BCS:]Q<4OSA4(S-HP_-JY 2S^
M)S#%+$?ROAM 1\_!^N59_0W@B\T-@$!ZT=+;_=IO-NBGP T@U)V>U4C!+>B@
MNEGTKV,>Z7\=X<3C#.?I;@#99PRXAW]>*D/_]K][#0"6 F+]UQ%5SJ_YY1O
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MROO;[=7H1P)_!L#K/Z-KZ0DAU3T<@?LZWHA/W 7\5$O4UKUO.*X8 3&/$V6
MNHMMI+CD)>YCD31X;'9B82>;#3HV9/;KK8V%.?*:PVC]QM% .K/O-DQ*S AS
MGF9R@Y="B!)_B6%G6$: Q7U@KU:8+"-\I+E-@/XC\7UD_*,-@\#GPWL>&<<L
M\XN>U:9E?H_W9>B\0ENI<#J\)!MG>!J*S;&6]9117<I#4\SG?J#DKV:RAX/%
MRU2$05UM)H],WGGSU;=7:HY(T>#B5>&CDYJT<]\+P%^!XOH1G'SXH=R;(-W%
M&%[SI7+QC'TAH>F'(6?>1R26^R$R0.U#ED5_2(4=>,>-LFJ,]?WH=,IE1;];
M3V/;SHP9]:53_1BL^T(A+/TM-:;6_>@%QX.7^Y.8Y,6'KOX2T1T'6[)6E&KN
MW%.I9U\E7\";EN+#/F\UKM:UY=OS;]+T:]_/]E#__BPX3@$ H\$//8Y_R#UJ
M>_I^DO/3G4K2Y%KA%U]VC?4'O=4ZS^-"H2Y"$*< TZ,E6:8!CEW"X!BV'<Z"
M_U,9&&67*3/F8+=6DUE'DVOH,YL%M;7@:&O$)Q4%2 9+LLL@O\"F$9@DPN%2
MSL+)48V3D9.+MU-Q_@,HVPB\[5LU(:%D&?2B%=W\-N[V E-/"XA<E7+V&VQ4
MI=MT/=\[Q.3/4JF[H!%S ^"3C_6M ;XOPWEU"Y__3KL7NNO\9ZTR<F:=QYO\
M,Z])O<-FNAHI(E<2,+PEBI]GDG]Q$C>#%):"B.8&O)R1&P[5=G4_[FH2BMT
M/,9658SV;';?LHL0Z50/F6RFM[(>FC8P4X[)NA>G&JLC0XGV.+CMN\VP\_A-
M8_O5]ZK)(A\. PDS3X ]C3GXMN>A*?"X@K*>1,C"P!I5PLI3I'$;,902&V5'
M2?%8Q2.+F2FG=S(C2=/T X= "BU8Q&_A?/;[1#._4 !I=Y[YO0)[FH\L]'K+
MQ:,U%0[H+.:M:Z8) Y8FBAD=05%\9]^F974SW:H GE[5)#:6UH^]Z\K\E+=+
M%98RFH3250X=*Q,&$11[+SZNW/$Z+JE!#ZF11/@O@&*<%^0X=[$?TNI\Z]J*
MC+<\20';7"J_.J^?U0A=M <A(4.Y_4..DI_[W*JM'E&6G"[5U4+<()2+*[\*
MG\'"%O/#@^8X-.]<Z$V"&@<3BGR:7T %083I:=_+\7:53Y^X)-MQ*HY.]EU^
MZO8.Z:21*C]]>2SK[NHC\<S$1AP_3ZAS :=I,+9_MR+MHDCZ2W/.MQ8;Q8.6
MU9TI;&J4>I$*7=/.AV+\.4VT0KZ)??4V#6+<X!%D[E[W..M^92.-DJ.$22X\
MNJ6IQ7F[>I5BGFK"">Q2URU/ #9PBI#<QHPT,TN((S;GF3[)[Z_MVYX!7GEV
M.VUP(@?A:>EOB2KWU00GS]0B[TM=;9[?"W>\UXP%13A>]BK'E,FOY+/M*/ A
MHY+513 *3?*G8B92_*T-$WLKF-I@LAI9!U=&8(4=A$FQ;=*?X4Z=F[6QVEK:
ML*H; 5Z,=4X!%%EALNV;G>Q45Q=+",;F'S SE>O!]3&1>\<9CJ23XYL&PZCI
M/9/+H>VZQ$X=1PC[<WO;<RCN5*19*$^%Z*H'6:9)WU/.BV_^-33@KCO<+)+[
M4O":2:7'*73ZB+MW/B'[([FS_!C3:"!C0%B'3S;;KAJ$FL'S5%( XG"N&(7]
M;#KDZ'BZO^C9LZQ/D;9QY(HJ2/)8+[A&.C,-PB0Y=<<JN/VU2^?4K\JY1Y_0
M5!/2/#ES-0U%>4=-R8XQ-692)IEP:?/.)\:;:WLW*:1#AI_78CA8'S+'>[T.
MR310C%QLT3@S5+?I*A+@(B#%3A#K2 113J*V5'=^I;!J:/ 9SY@-P%MI#L6V
M;P!V46I&W$[(CP_, PLD.?T_O[_UYL'&@VU3/V@9UE9*_%!P:O1^0D=2B:09
M?3C2<NL46X?,-<,U[JTM3>1W_I@I>/3XUI92"X]:E6$XU78YZ)+$&%$A6VEL
MY U> +4E6U"1STQ$TN.WZ!WLQ[R9JK2JL1?=Y2&_4Y9,TAJ>5[+JV3"R:^Y1
M62YFQTYX:WPI9E20XN^K#WP+%6HDQT[U]/A9E@+ 1[CE +\3W%IXEH:AI GZ
M.)/-]LYJR!]OM(GA'HY0_D RHQ/1T6,D/3FK[+9_C8=MC&+#2\)EP& V!]M@
M>'_51QE%4 E^R#FH&WTV,%$K4O=YQD21.4R?;6/NOJ3]EV;9"U%-EL*C#;%"
M=MO=1*)O62,7M\6B (N!!)!Y8W_-,9WQNNF07OZXT!?).5]!4^AU,Z)K,D,<
M27]SFG.=71*J4WB6RWZCX'PJ_[\'DU2&0DG @.[Z0^M8^PHB'OL)XWS7VF/\
MX1QP2(]O=T_L8I^3XWU*XFTZ!Y]VRY@I[EQ;X5;F^*Y-S]SF]'ZF= ;^Q\,A
M>KR%4Z@=I#]GD(U@N@N$D5*U0>49_GM-I%TNRE6U^3?]^8XSE.:Z-&_K8%.*
M^:,:/38,W=QSBQ6GKE2\>7K>&]>L1K2B)DA$*B]+_>4456DX[' RP&4X7Z1W
MJWHJ3)&^O>R:[J ;$_[LHYQ@S8"XM0I"U/H8T8\,1/BQ_V)KL6@KIP,BH*A-
M&H6%T+L54W4U"5Q[9#86R2.MJ1OEA<:S.%]ZGM/G28RW>[8"PC@U;]><#&A[
M0&BVM6S[WY-QD7D)9F;&,JD*[LV,'0OX2_[<E>Y,YY\U[A,<4V["^S;-T?J^
M&B7A%00L\'XS,A\@-FC& =6Z_'F^/!I-PF RT\QPD+ 9]HTP@8;VX^#&@:_-
M:'+GF!Q^%[W%Z -28_NO!JNJF2B_":.M%<LA6D7!+/330R#&,N J&K5Y1C#@
M[%:VF<E'-/Y8KY7%T+:5)?T"Z,CA%[T2/T!)\=,Y@F%-LKRD]> L%(E^N8\:
M)?2)=M*WP58$N.KYZU/7--8=:GS<9#)>="*G95R67C3*7A4=*5E6M[<Z&S.-
MEEOW::5J=F2!";UJ\V1G?+.[&W5")"[3@@M89-_YB>%U+NFIF IVV;B.W>"L
M/53$<$HE-'JC@WE[]NLTJ=YDOR_?@E,T8DV.[*58-'=^-J0H4>J?%CJJDN4N
MLR2U^6&.A@]YHS"!^F'QQ4K%0O /_%_7<T3;6K)/ULB/BZ,EA%P/:>4^C]5F
ML>\N?V;8.,-P8UQZ7TD2^?!D'"1W^V9CI#X1%;Z9:>TKXB?A#@(>TWW\.##N
M9G]2/7')$S:Y_>4<,5\JV6?,+N\941G_*<Q%FN;8[P: _F'HK7]B!3?V)E1C
M!U3CXV3+JG"\UX_\U$D'.471G"\)U=TLZ/I$]Y1R=R%W]]J62BM6&^,5T;4U
MD5XY:&$5/&S(Y^B<FK#2\R9C1((:;(GDB1+7H?*Y5"I-&DG\O$KP.4';XKMK
MY@.C<%#_)KOMF8B!EK<TF!=&VV*SV#VPBFY0^X2,8S*;8@AU/]? E,_;UH%9
MPQRL(I<CN,[2"4-CSGI+RV.,04J?HKH51?+8 A9@S8--G=>/Q_Q?CJK853*/
MNKQ-Q0A+WCI&>4'4=>4/:\_185G/?S2C'^5I1"Q/9BW&[TJ*]Z2#)<XS,8?/
MZY- R3B3<U" G*,D[&7!_?'0_ :'P5O-/-B@]R?E+3*1)\9?:516F%[ND05P
M*#=K-8J\.TYT:K,==S(WW,VC2W/Z)-71%+D8M_2 ,=5+Z5FJ^1:1>R-K<"V2
M&#<O;YVM_S5ZT+'CJ1^W$//U4X^W%"TY]D'M+XYI=_W4#QW$#- !IY5UQI^J
M8WP<-SB+)YO5BFP)&6;VA 5S8( ^IBGR0>]:"#208TSHAP.B*8H-SJH<IJ&I
MJL[4B0$E+N!"S&(DK_HU&(,;'BG%X4]FJ%ST?_SFVO)R?_W'+M?^T[;:J"VL
M+#,_:M5\5N]D_9KB\&Y=^,&2>%-R,ED\G6L<:GI1P<%;1_JQQE"IO8CMLWK(
MR'194!E]P[E>/7:MJ@+QK1%]1J_Y7X'X0N66%&MP1EW_R /^9P6O%^B:J\6H
M70ZG?6R6Z/SE#;UEM]$-(/=?-;J5J0R7O\R^U;?] P.QXD503Q!O'SW5O^YX
MZ_'Y9P:"[@;*LM#FWQCC.:1_K[6E2D4!_I\V9 +P &]T1F2(V)!G*0PEA?]+
ML]Q[_YNR_\.FTE<<,6QX&^SC_QT^\?_Y,5&*>B$2URP >*/Z=91\2$-LRMEH
MX4>:](PTMH=NWN$'778(MHQG< WV9JVBJ0 ^)4BOJ3:IT;18GZ3REM;)\4%'
MW_749*T$23[$%DZHY'][3E-@Z%E(%B)>==-5+8HNPX!%T)+Z5P&Y/WL^JOJJ
MK(Z-YU>3E\/Y\F2=JQH\KV)>S3Q_?JXC8S6, F:F<Y?;"%%P!ZNP]6L&:=DM
M,L\V\6;4ZAT+'$211&R-WVI7]VF)A-P(:H!=[4"5%LWR_"9E# ^_A)[S5+\M
M\W]]X92TRRQB$+2)!Z6E\KV8C!)NZ!/[5LRA7OXY/+(99(^R36"N^OX6:33'
M%&U$MI+YJ_:,?,/KZ ?1DUUPHR)W&M^13\'+I8J!(L/964379$(??\"4U9VH
MXB5'V@N_SBE?;T?DLU62 F(%->@T30<Y>X/&6="*9?L2P_UML$?C:Y!6-V&>
M&?>4S9* T36P=9S[&&GY"I-B C%DO^ J<Z/6U.PI.NBG,8L4#*L=/]ZXEV?E
MGQ$Z$_9UPVX6&QXF<3]PL,P"[ISQ/5:M 7@]_G+;"C;<_>JEYY9XW?[JE8<U
M27BMGQDI=B\',G[WR-7U5@""=G-3<^QZVK%T 2I%7J=U6$4I,N6<QOI#7]U,
MOV9"R-A^GV3:M+OL=W2Z851Y9<#$A%WK8TQ+\H4J;8/@]E)N'Y=C*.NL7G9F
M&?*Y2&%:Y/%O[BE+/)WWOSJ.E%XT48K-E_CGH%6.>N\CJ?Q?V%.&[R-_CB_E
MZ#>_8FZ WC,\)Y'5LJW)\M-J'!9*OE=*U!BN5G*.MZ&)U#Y4C%X<8 SLL[PS
M:C?V4/8A/ZG>>8ZLC"A6-7,5*NZ0FN.$]:&A"<Q:?F%^+X?DA\>,-\CZY/>G
MEBWG!V9VX5V-:9]< V&$QK [@XK";;GEZ9^WX*R=/38LD%>T_@+$RM)7=NO-
MDDMS3V1'\FNKU9"JYYKS&N8128.^*Q-L=:AXJ3JIQRFE ]R^E]='1HN'PLE+
M+:;JXFJ4_'9W_3.*G).$@.BL)3.B(014:V'!3@!BGT[)5MU83? A6X9\QMNK
MVW4; Q)V,QJP\7+"$^0_P?K2Y"W'2FMG+ZNT5=6*O/_F_.(G_MT6(G"R3HU$
MZ6ATT2K%PB:JV #U%"TG$=6D=\_S)76W<ES24X\WWWSN:LBB[EY*E]MOLQ0L
M983\V6^EJU$9 VY=+8,9B RT%]7W^BU\5OC"1+&?EO*ZP6=BC/H-)6@K)SL@
MW2A,[2MJWZ$@S?9Z^_'E%12VRV;7"FP>TRJCSF?+?G=:/@*1%1?KE'#CI^-3
MQ&< IR/5IXN9P;Y./O.)BP'.>FD=TH^970VA913B'@Z1'STL#6"$$1Y#409C
M@YL/B8H3&^+P[S4U&YA6+P[PFA[%Y3D\?\&0LG['3Y]];LMB RRU=J:IFU@;
M=]';6+Y%Y.IJDV\L/&,5LPO]P= <4#ZL[5F&4OG2HZ[D[$Q4\>#.XPI7Q;_@
M>0G@*5D#T+%5D"^F7EN!G"7X_V9%^NO1'J).>\ $LN)!R%7JGY6RY3Z,)[&E
MN :.82<?  V\^%4XK]8M9R?K1C+/$-UD(JZ*'!Q?7Z@HN(!,!2?#2OTGQ90;
MQG:8C]8(@GQ.;L.C_1Z+)8:B[+S+N]+/]>?B<A#8Y]V[T\_EP_'PSB=]<65C
M9F.\M1#PDZ(M11:#L$ \.ICN_.=+M25)$5#MR E2:C%P!.J9E^=$+_OS/2=F
MHED<X?V>["*@[*L+09LB0RPD1:=1=%\L*9T9U>11'?TS[Q[ZI[&]WT:21[P'
M%YT5?3%Y98&WF>JP=9HQ84"26KN%>_"&9-EU3C%XTU-[>KKKV?L71R4HM6ZQ
MNBH)??,"0U,EB_3'Z4:%)N'FEX+H9"B-$(U+-+S)0(&!^L>,,0ZC.0ZS#1Q!
MF/!.K\R-4D@20?L.?KWVF+'W\;K;%&>APE_!R0O"'"(F4UT19M Z^ =WG@FX
M\%]PX2#S0NB4P3PE9FROF&75\;(N 1A.MGJ 5 HKY8"]?<EI]OU 0.A!,YM'
M7OZ\*?:W-D_WJV4WR[;)*G^QOC*U4F_(/G$>XCY&P:U%-Z<)CL@#0\'$Q5>1
M2Q >1G>F9.? 9<Z7K T[]IB)0LQ!6[@SK\<V5:=\QGO%^J')E (;*X_%P[H"
MGH"SXU\G?$ &,ISJ;#-I=^EF5<Q.\JJ'MB;Z8#<\\BG-6I:/SQMG*1]2X2]S
M\V6;-$*]T<BD,_VI[GX=\UADN3GH*AG<^L(8R=!^ [ 9L?!>UF%R?_2=.>#K
M&>([,C9;U(_!GB$:F:XI%2:5\WP^8YG644!S8GT\.0==D5EAN;UM< GUG3K?
MRUELDW3<10 #QE$_[N(?3&@2XRK;L7?A,[+,FXP,+7!#C77)(_O2AM%:$DKP
MS/QW,I#KK8L&O=/C,@SG!-U$M9FAM@=<Q^"ZEEUE.8@0JD8/-V/B>L/VJ/1-
MP0+Y"%;-V=61[A1!0WUOU8KND7W8X=N6L'0H?OBQNMC=<:$GJZCQ._E>EI"T
M^**BQ$+P#T450Z8'R;.C20:-+XK%DC)T,)=/!G=/R@=(NLYQ$):M;;VF3$(7
MRI7I'\F;BM4DD8+5EN5V-#5!MB8FA5 ;RG.T[C@#^(2^O,ESI*G(=< E6SQ-
M3=WK51M\TF>'.^M3EUK]_FZWWENOZE"PQB/'MLV:)I,=VL9EN+:IGYAW?->!
M>H"/!%PXE892.3G2Y%9F,A;CC^_C%; H#MU;@=*E$>Q.I ")Y&)3!R,,UM*Y
MX]+)8G)+\1.\!6O1++U,-@<7:NB)T&4UP6KF,$-DYIJ@^_A2X_ +-07AF=D(
MW1@ILO_F/L-BDDCB_Q_O<2+_<JEQJ+X>JBM;7]?PR'B@A,M+R7IWY&<21[\9
MV24O3SI/+H^UH7F]L8]<EYSBP!A3E12ZWR,+28VRUSF<#RZ<GP.;0G:2)G^8
M?'NUJD^B$:")<#T->@(RP(4[$Z7VE^<793WO[N)O1W<2RZYGI]S:J@4Q%%V^
M/A@LA?IY.7LN30XR<HWU4>NU+P/.I,8;I;MR2.Q!3XQG!B3<%?!,?-R[M)K?
M6'U>1P)@QR#RHDO] Q2R%&PX _G>NK,;.O^L9.!J;A[=CW->:D$BKY%OEXRG
M^(N*3@_X.SQ[/G6$,44!3II'X$=#U-Z=!J/[S0KD84BGNT4Y= <R3[_G64A9
M]+Z7+#M-76;/G]P+0I]$FULZ%W9[<4FI$'\(3N->$-W<EP%&*[A?TQS&I2Y5
MBYRZ9E*]8U9__#ID..:$7,T4%[MX R"VX]\\^Z5^6K],2I4?T<#A=RA#[TC>
M-^<O/^QX7,ZM*LK#D]ORZN *3N$FLYT@9I';@$,LVD.$.\[5^AZ*M%_&5I.J
MZ+ZOWW&7H<\B7^<^M&[W=W;.O8I;WODE@V(]RG#QW! ^]YLJ( "P#9#W^&M.
M.3>+_NR#<8NYWMD4M#-![; [>9]KX=LHN)P'=?,2S6V>)5_E.TX^XIHB&$ZU
M*,9SH>]1MQM8CKWW8,?"[PO1;@U$_L=/^7MJ3[#OQ,0X^_:DV+HK<+V=:>"[
MX_FC:S:4G%QW_;OPWA>>GH-T$9>J!_.5?D)(Q'AH+@B:5<#(=%_#S=<SE[@U
M:KFV,G*>9E)(V>/"+S+-Z->I5QIII+#8+BL2)$UQR<(S.H=:NUMT1-W/:N6<
M:1YO!]BSK61G('LZW.R\Q,GMN:=8C;&]_I8HUV21V,?LB6HR/#P-R9^95I/L
M['=.[L?$S0LP-5J*5XEKX6O#.;\W0PY9V(XA>.!A-(#+9ER>4KXWC4#J*'&<
MIJ7,7[%JO)FQW&Q###X]^X.?"PES4HGGNJ<*6WLG21RUS(*+SX-B#+ !<_W)
MIH+:M0-WGJ<26MZM/G.';\!:W'H[S^4;B_(8U92K(%\&^6WQ5*-6/'(B36DG
MG8MJT(TI:G2*YFOR>LHAY3R^8PY2SW%!6N-$29+C E1PVZX#?I^R F:4[Y\Q
M#R5?][H!4!Z3'ZPARC8M_'IJ8QX5L>A;LP)L?D^I+S(\:5\:N$>D<;\PVONV
M/(R)*$YF2'M?AG;\?P(V_2EW*LO4#L@VWFQ<-@,%C<A=99+UVFUW?3EC*7O1
MD*6:F39Z)M3L6K9EP*I6,U9,,1#@NBK43CV]J8<?><)-M/#ZT+'!WH<L?Z&K
M01$__J-GA1DI#@$+('*HK%C[/,7MQ)3T,BJ)/GBKJ$7J9=)1Q_/&4#-_.R-Z
M-X$HS!["PUVA,3GY0U-0IZ!;SL/IC$[^+A%:[SV(N874D4W4]M.QG=WG26I^
MMA9)&I!$ +=.]T,7Q>INFI[H$;TW!,5(.VC!QIE82!XLF-"1?HNV:7CC@_Y+
MYG-R?X.I[XO1IV,?D<,QJ9Q3"T <2D1V&$V["US0'9'0]$!M7WS=(SXAFJ5I
MP8\]0=?%;9UUZDAF?F^PP@0LL)^04P9;>QWR5$P*3SW:?'+KJ5&R4Y]?L$%R
MC-$ ^RN$\GYEV>\,(,W!7D'Q%J:QJ!Q&-N7%018!(@Q>V-9OULS?>F1WB$M6
MBF5MB)),-GXY]#%[_F1DV^L(ZLN]>JQ-;?7^V59( WD/5 <WU 7V]PVMPQ1W
MDQ6(DW*EG$H=%WCM4PK=1ZBSS*_K+PYX#IE57R@T^NCDS0AR\8U@\E!/0-F<
M0Y2S6%S1]=9@'QVA83(G6?26NJ<4Y4$_G'8> IFG;9KI(1(,]HR3O"O0=7X6
M[I" W2JG'R]T=2IM&<)I(0=RU_LWBT6L8[DI>E4_5^$I*5-0, 0*9/7.3MTM
MRM+MI&FYFE@/1PD1]JU:\ ROKPP!? WB@P4O/IY$SVS;LQ]? ?5N<T(SF#$E
M].6%AR(1R9V3;-N$)I#!>4@SX00V/O0(^<H-9E$V,%VY7:JK>/B!IJ[@*AUF
M[OK68\/((LO;=;Y6R+B<@=CV3.P=)NH%:?('&4)@QV<)D<7OAR5U;94#:UMN
M*-+G%U6\9THMSMMB"JT-"'5S6-.W%)CN5\E85OM4$MO-NK,-]U:2S_:T:K%>
MAJE,K>.:'WL4\2R""*9 CE[./M1)6.]5&=<&6J'N&T!'\RARR3[+4J>E)8J\
M[XGJJ[)X\]<X=^M6I^)2K/SDN6-7AF->7P_^8:#@2G)3 ]GJRY?ME;UFNA53
MCBQMP_N.W%])OS_69YVL#Q!1/30H0,S8QH0HC^V.?4]3<&ANK3^N5,E'J" L
MC49TO1Q^Q9- A;&@KD\5QVU\QC/3-X#"-#>OA@W-%M\[Z77#@U4JKJ2J"S#J
M=ZP'* *(>#>-303:$@&67]>&<?JN1Z3X&6A&7G(#8Q%8-<GQJ<;=N5D[S,/U
M.!^ KWYMX<3T$/6W%$C!Q U ^:21HV96X:U=)4Q,L2Q7H.F--2+,=CW6*G)B
MV3SAFQN1E>=L4A1;KOG_;4CP'X_1^7S!57(!Q&QG_DU,E1EXN R,_FP*%?$\
M6K9*Y&.^8D?VI?Z&Q/$,]8*SHF:&EH@$E2S=\O(;0];T\2_&;P D<S,D$=BH
M:8UD\()QQ47"RFV._7=&0KQW%1QA- -T&@<)RXSO) SF4Q>13/)P(X\+P3 5
MJ5\DFJHC]>7E=+6+HB7?SHQ_)VC^W+VWK =1.,:UCA9[RGQA'8^:[;G+K<1U
M^*H)D<AD^LFZVWK&1B?&\C/?I=S2C";)T-V:3J&!_B^?NPE6Z^).^KPSNK*!
MASPQWYQ,O^N@I6 -GP@^U^_B)J=B'5AFH$OJ7.'-8W%+9.O]?[QPS5M@XI(D
M/_:J KEFI"<R1,7,H(JV2A8M'A)5I30[P/>VU,XP.%A-W>T@2U/N^>F7 T8L
M:3X9*)@'0T\-%/?.MY\_JAL)WH>0/NL)?ORJA KP\):A*>O!+JK-+A@E->!S
M:\[9!1DF=TW.,8N%#ZCKUIH6"U48XVJZ)A4[UN5KWXLPD3:M%IP!3V:GP3XT
M5A3)51E6LG08\?IUH4%OS2Z1FH79#;$OBN,.XWQP@=1/X@Q(!V_XY/FO3DS=
MN4,HS[P$(S[^)MRMY;=R46J6@N<- $G\I%L82#'Z-BE 0"NI5W^ET/.UQMHQ
M!V?#0?]YZ$(XU]J$KN-R[\47);,2%&LG37K8,1,]"H%0*=YBNK7>H#XS,^5:
MJ18GGR:4)$(<PU]!+$NVCH[L+)Q)@OHPQ1WR8*B:Q8"QQ>T^9:I\*ST$'22>
M0C6+$,+KQ[L$G!3)_<G/5\S'7%>6L55.$MR5F]BYT[S%*\5IBI.SK^F/5T)V
M MC3YAD/@:E+:O2<X ORKTW,)#4'FWM*"&$4\K&B2<U:28[SL[VFQ2R#Y2X5
MI.W9B*SKRF_N=9Z?!>,@D:58B@OE4> -0/OP^<YY")^Q;;YCF<GQ4HMJ\W;7
MF3ITN=R^1?7;VEK///=D*8'3/4U=>>:9*@OV;H76&\#$X+H2I9Q2#>5 XWZ?
MF> - !UGMZDUYZ+4XD(9*#KUIC9 QMLQKRKF_;[$1PO)4"\*$;4 R[NCI?J?
M\-[YQD1%*B"-6L02TQL;J;-YP[:"".Q>&+'[S).2*^ENG__9E-K17!<CP+98
MHA2X_Z,>4OOOH>WXK2.F:5 ^RF)5LHH*]I&U=*$=%RFRN'V-0U1>8:RBWXSW
M&U!JD6A7^&C3SE0ZUFSKG*4)I7 O7FBPV,_U8R'3F;DXJ;V7ZD%<R=2('780
MXW;6CJ$R?QFI=.8*$IKX.)RAEL9QWI:(U59FMV>J^B_SDO1)(I](AV;^8^=?
M\+>B!A L:.G[1":9="B#PF]*B;LW ,8<\J ?"FW'+*CY^OC_XDAXD':))[C$
M'@.D$1;.]Z@='_6+2;B=2^^S;0@RO=_0TG)X,/Y4F4N(;6*WB-F2C9]VY@ZH
M7,^]G;Z?Y.%7(#M9>;G'TQ/R?H\<*6_G#M^I&"EJ.VS>VQS]1OCS<)\O22^5
M;[EON$(>BC%$P]K(@QP6O#TEA1D+U:P3*\KZS:BH>TLW35O>6CH6@Y7L;>ZX
M&/?P)?;PD>E' 8Y"?D(,UG^&MH6GS7,&@(6,'KY6I$^MJ4W<UAM3/@2B4;V5
M6]AG&Y-8C42A>CDVSZQOCWO$"$[%K*J91VK=V*Q<]%..GY[FDN0T,Q3@DKL:
M>3]4I"N^7U"M:KHP&I=_EZXU]V)*"./Z,\!3\QZNK!\:Y<P+<W=U:DKG!>ZL
M"^T(&PAC \K 6)D$F1Q/0:K;%5KX<=[%[?#KO KO,#]CTL,YZ"/C5U[Q<(4>
MI4U]M'/X_-,)'C0L;MK2J-;>V\+3-3R-OS#O,M;/FBV76*U=!'XU4!UO='#L
MJSK3E<A(>@^J3,4:][Y>^O'L-L4"Y8G!2*WMB5&.FB&6Q04A^_7K$/@47M8(
M@]N1!-8=1F,@L7QF'RN+;/&ZEP^<8SRDB7!!ZE%8^PPKH^S3^9Z?\MM,F25<
M01^\NE46*V_;GWH!B2\\/][QI/3B-PES6<1C2+F8PNAHX6=N-QHT61Z"- _O
M911R7Z6DY5BED][A6VT]'$+[\B'RWQ$L2[%N8,YO "&%56..EQ=AV2S3"5):
M7[+1TR,R0 =_1B_W0]*UK:4^D$J.'(7S4R9:W-=NE\#[!W$%_\*@/YHMC+5W
M.-?(X3U89CZY# VXK_=(=L,.&99A4_3*O+HN:I[%HMO2Y+:FK@Q0O- 6R-<T
M<?F,MUF$/!85\9#_=0T[5,K$Z<NNL2GU@6(Q0Z>CGT(31DWM8CLZ+#82GZ-W
ME3EN8LM#"S_ZA[=7-[C_FF(,37];DF>J<W=-S6>MW&=&$2 CNM80*_#ZD#6R
M62AH\4I$/GC'"9:6B&9Z"M0"]=V!#030*2IRH-.RH,7R(T8SO7><5J?_*-1;
M6E "-),.$7)GC7M7;22U8)LPW<#$GVH22*XO(;+D3&R&LS2M'5$L?EZ4PH5R
M^)!G*GQRY]"T+^JU%GYHVSM_7>?%#';+L3?IVLG&CAK&TGQW(ET[DG7F<'+=
M8O,9R_0&RXIJX@/ZYE'S[59W%JE(NXXK7;K);JW06,<O+3S 96@E#74.;Z6=
MEW7XKW]D>_<.[QY^"7!BQ/_-T"7''.@EOIW-V#[!_@O]?0=N&"T(W?Q>]&=0
M"UW(TV'\^,USUABA*^M.@P":!14QZY1AXY<)?-F*9BDQGN>3GNF+))0FN!"U
MMG'!\FX_/[\(%$M#$VB!B1&0']_8T.W7Y5JA7?8L5($*X'$[2P9H4X23UC%[
M[P4$^BDO3CQ')PJ3BEJH4 N-XNYO12Z*BSN:J5X/UM<IA'^?I_76CIWU&/ X
M_A_M46[3+%G)X7>79,]115:TC?*]I-IPA[0(?(=<G*)V+#U%B[(B,D61*WL*
MS[-JCRH^SW0=\<Y9:RF7'JHI/*L05B%EPZI0<;!]?R%QRU#Z(!'G#HZR9]CE
MA%(HL'TUIK[<5C.LNAX?V=OQ(ONUS$;E*=3NK:DT@HY^X $Q5H^2U%67T@M5
MG'R[\V6BFQ/R<2)S/$4?O?^;!OBP(4-YDM>?TYT-_E(IR^:I:+\-9A'R54'[
M"]X&)XG\05QZKDF?JW6<=8(C+U/:4U^".4EV]:*]J(('BA2).J?7WP:ECV<B
M+!272:NH*T7&G8YO  ^W']M)48_G)8E'OIJ%?IT)L3K1QE9ZSZA?\$8P3@D1
M4HP+)E+%&?:HA%]5@%3R-J6HL^?IE51JT%;F*8F@Q.M[I6".M2=KI5+Z5E,+
M6\X],\L&[=2 GZ>54BVC0CG$WG%GAC5C;R9V41E^G$'(Z!_6+:3UY?M/MFG2
MD#"$M],W87OK:<GQW5"Y'?'1T/T\!(R6<W^T!Q-^J6M3^3NAEZYNRB7^_VOO
M*X/BBK9TFQ@A6$)P38(&#^Z2!(<0M*$;28+3N#9."-HXA"98XTXCP3UX<&C<
MW8-#-T%?,N_]>'?JSKUOWLR=.U63'U^=4V>?4_6MJKW77FOOL_8W/Z-<8W(#
M>*1^]JD-WO2T.H0Y1MXDH+J#70XO,._,L?5XJ\[_O#C;#=VHZ#P]<(]$+JWX
MR\FB\;FZB^H<ZP.-@ +Z_LI^TOTVD..\8!C7H_@K31LLSCE?DAFHS3KZN&T<
M2.EG50=ML0\#)DU#*(&7#!/QUYPQBP:O7H ]3(._K*@-18).5.@Z1 1J=DE3
MW&.^9S*)O2\[X7=\,_WE[6?AF3?S0-:S!96FL08N1[/<8UX21M[P;4*V5/>6
M\MC.X^DV,Z,<W2W2X2=2J*IE +I$:D>O*])9*9RM[;%XV7.&OJ?'HK)4?I8?
MKKN1YHSNX96Y+YO]G)%*:DD:Y:-,$3L_''Y"G"F7]# D$Z<E$BA/C26?!UO<
M%G @H1<WA:,MA<.>>PPD_P 38M4@9\L.SY"?)YMB5R^F(*S)4'-M] N0GY+N
M^3'987_-BZH4#;UBUABQAA\6&;-;3Y75( +K*5DURFN1\L^[XI(Y<OWY\5U6
M#<^^;O3= ! N+P3H54N0+I3>J=8YNG(6%G3Q=SQ9-X0*=3*28C\$L+1I-=ME
MP%A5_OY1\W\'20P05AZANSKO/LUJY*4]0+MHHTEW;"$/.AZ<R)"3?("QX(+?
M\^IAMX/5T(U,Z ,%IECJ $XU\O#:S5GMU##^.265NA$KIQ$\AWEYC8&DO?R3
M(N3+BPZ_5@]\P[9APQ968AY0\PX,A9.3T&U@'V,WL<=,"PCK:):?*$$BUPUK
MF]WC)$';3N*T-+@*0:H?$U!/,4GY$I6O6EQ<T;2D%56CTKH30B\=M!R_\0^-
M]J@:*?(MQL1H&PN^U(!P^WY\\:HT==\(=E2"OSGM7>W(GU/ODR>'[-SH_[C.
M2H4HW&9KGFC0RH5Z]"B5\*_'[\D\L#$Z ^(LBYL2$@5GC?!QO!$'"=#*#'X&
MVHH/9NOS]=D3!8R=0M+G-Q%D(WR$+XHR;'G>T"I0.3XZY<_T<+/-G>IU=7X2
M<3_>L>P'2]GC4%Q[YT_V:R4)D?M&B4$ZJ,7QBJ1PB<5HXMZ*Z%%MU_K1;24X
MJ9]0N)+>J*?1'3B(TY>A*LKZPF1[$6O[KHL$-0K\>LB:#_.E;Z@8%[%>^^H&
M@&/KS]&D%:2-6C188 CVJ\<GT_X$1EF?XKY[K<$I99-VKC5H+<"=:>/1N\SK
M:5:LFF;.HP]^8I'B;]Z/>8M8_RK&9I2QM>=,U?AA&@-,-E685SO:^'K^X$<Q
M\DGCQ[3:$,:0\TR\3WJ$,*=4[$WM)2IE7:[<95RHPGS7!$W HW*]=%U%'G2B
MKJLX/HW^*_I[&D.?HLQ9"=\2B,LXSN.,<#F5X+?9>JLF*MCY;_1B9TS(O!U+
M&+ZW1CQ=]NTL1F.9BU1Z"?U9)G<:RQ[:-[FP63E4'2HF;L'GDCKMTG/)6E E
MA<Z!T.(/G]8ON;D^_CDYW4%=O+0/6[U4R]QZVV^VY$7VQM]@KM2-H5-9[5,W
M$]*AY_M:?$7.FCC_=8SX"QWNN_)/POQ$4:.D4;A@^7?J\N&W;GDL:GX;-P--
M"APGOE"2N?V[6N=_C%+DOR _O['=77]DF@42$!+V[@;@0:U5]THJL4ZLJRT*
M&@]$:6B4'E+Q#RPS5Z7PY'T[02-3<*4F"&$SX''\"H?[8C$<-X"UW-JLRM(D
MV;/(9Y/M-X#WS?Z]0K=7@30=+JT5G^NI*RR8&G?F)+="-2OU96F8E6J;DQ\3
MW]?WW;;<E7:VQ9^KJ,+<IZ7XEQA_W'S;M2J(A [FJ90/+JI"4  K$QQR%.Y1
MJ"+U#V0#?+)"?^Y_B)C45VKD,+(J\E'L5N"2H#/LP$F>VR0C\I?JCZ]F3J,=
MV[1\Q4*?3H%D^%$QN9Y):V%@/4=0K*1[8 4D0UG6V:1S)KB[N<K^I+M:TK=V
M,RBQJZL.Y?PUF1)95HMXA5G=;<")4Y#+MWS[YIPDV%Y-4?$&$+1L"U5J!P6,
ME[MF;!.UN*"_D^M+8\"3%Q.0Z:\5',SRJ!]^%H]>EU8S#JU6CV*0ENH6C;C9
M%+("L;6QQ?-;[EK^\76?[8G5?"FP3"7\:FWQ+("@ZN"@D+VBV#<?C5[,@#-V
M334N5< &G >[G8UW"W^E&[/32NN=#'J9=/8ZF/@F8935:GV=B$;+@SW;I>\D
M:C,J?98^1$<@SBXH*UN2CNT3<\YG"A_L ^4H[N6=>6B)S =9YY&'R9ITOYJN
M9!4P4[14O*+HVU&W\"8<9FJH+*V.,*PGR@#H#DHK']A$G0O$,LY=Y#4U^4@L
M?5FY<T(78' H&!3;#G(')TSC?(A2H(;Q5@95ON=J:X->G"(=KB^NPB_(3@I5
M'+8'W&0MLU=H2+NL8MAA%.0\"']JF+/)ICM)U4?3<7@)[VN]4J*FW:;62C8!
MI\Y=2V*U_SW"_K/ ?:F1+E-B'@M^,<7J?42!K6G_G1_\[;SO?"$P';'J?<W$
M_7WN2PE%<518F*;=3)LU><3]&(8!EXQ%TY23LE3FYH&0Y^9Y-FM0:R8XW_QF
M0)R7/,US2NH%6(.XJX]X%3*KIVP;[G;4AE<4.J>B<] 5$@^. $-"72I'D4VZ
MNY-&V*,>0(Z,_N5(DNG*40GZP.&V*'0W63^=.+Y3$^U!4:+,56>V1YZ"EX^(
MOX7..P";;%'1@+Q"CZ4=2/P&4+RAI(MX-@:6&;(Y)0[N&<I9;,JI9!4V4C R
M7]5R>A^H37%'VWP[QIHO4F*DPEJN4WO+K1"2CF2@:NHVG02X\[NZD J<6W_6
MAI<%+X:X%$2,;4@PH1I$T\6J$[613$EYD0E/J[Q:9D:L76DIZIN;#G93!K+I
MXEVVXLF[5F H#WTKAZ&OL:$&&(_9B1(A1!MXV-/0JR"<W++)_JI]YF>(%V#7
M(%I7XMG$LP-T-.-)GIX?R4.?Q[1^.1RYQA#0+V<&L7P_"9UW+ 1;G%=%2R P
M'%5D1E']6_I1Q<S20URGXNI<C\X"VO18^I$%J3$//:X@E<1O)H98A"O=/ /X
M6RUI:0[QJT.Y^+THP=H7(%:;9.-V[/?Z<TS/F3\4:&@H;I#0!30HT6?W#X9D
MD3WX]N-UJU%-ATO!?;78V @5#F)!^];$P!898G5VE@P8X)^TIM$*8RDVROI-
MX+\:RHXH.(P%(,[6?VE@+,'I1V-POC<H"Q<O4[*95&.^D&U\5F"X-5Z7D@RO
MCBHJK6G1)E%S,=7*K^W\OFXE06<>W4\RHNKL3ARD*F+=^\->WY>\V*A51#8[
M@VJ'*I#C78Q/.MRJ:D%QFR5VPBZ3.#.C%,B[' YLTQZF\C)^)>9O?U]ES]NO
MSO(X:8Y+\V CQ-;YR\F7TU P?%9^7<?+EV\Q]D,)4V;&E8+870N'Q,;=L6QD
M/R+DV4=B,NS?6P0![B3OSCPZ1'R"M5]7$;VR)SSO=0-"<I? HSDS[@%W2>YD
M[/$EW_)BZXM9\K1&ZE65Y,E89$WUJ8O27(#41:LKW9W?+4 %I4=M:#W")7C9
MCOH:3(,K D!$*<AJFW7DYRK3.:-R:)B\0$&G-$"K8-UI\.[D9EV/X1:J_\$=
ME@.;GB:/">7GHDY\G^(:U]YEP)Z3_D>56?]-4+*D$5!U&-#%JT0WR*79!%X_
MH]2AI]#MLI-#N@@XBG=\?JQ $:% KVTLV2J_I;'"]R')5=O4/B>3:4(-0M\^
M9#A[YH#F> &;YS.6E6ZY9#.()8XM<P!JBW6U5C>1C% *\5-1L)^J?62(+TSI
MWR:?R)'=W"SRYXF.DEZ$9>=OHD4:L^"8JN&>XBSCO.^8>^%D2BIDBI]4(X!Q
M3\D)GW8_*U 15[9XJ7DUQVZN[5V6.0U)])@R2#?_\NDH^:'<2WQS-?4* 0M^
M4WO\@TTFB?Z2[6BCO4C>)T"9I1WQ-VW*I.?9TW/*82][L!D]S.8KS0L<;!V%
MAOUIEG^9KI#W?^MAN?XM"9D".B*F?^"?!\1J>EWR?R'.]4^ NOJP%#$]BCUC
MS'@4!:AV8.JTG]4Z9TE38"S]U8SWS_ @?PW_X]SH_S=R?@93,YW.R[[<2'ZK
MKQ6GZ\LQ]'C<ET:&WUAN8%R[I:5E %_D_P0I.6[#U!\T5Q<]VV*WI @S8! 1
M-A;3MV!?G!TI@K\N&?FO4!-NVTFYVQRZ=G =E-:6IT3R=?;[T=S]4O*5FD)O
MNL,PS'G;IOM\'%-L(;NWI2P*.\)X3RU([W<-K0SZ"V^DB%AT:H.(^TA?M#^!
M_DN$/P(?( *+4%@.I37.2ZJS><>K"@0.C.-'$!"88YD7L44^)!<S,DOS2GVV
M/+5Q7.TUETO>896PI'M'A16'4(:=]^?;.Y\U&.!"0*>OK%R%U _>;G8WZBJN
MB'Y<_F7^.\MK)A5![6'V]'!.,O5:<[S0)U?S9,(89!6".$H6E5&[F>W+?)"&
MPY+3_>QUP*JS#,WDHC9)2<C=B7 NOKN^5M45$:MOZ$2KB5Y$MOH*;N:(E76E
M'#U;-%Y=B019U/H^JT5P(S$Z-2WG;^]4:%$E)7T_I9)_7PU3LA!T0_&EZW(+
MM=X 2$!N2^&M8F6%"%@?%A\6(W$W8P3)'#LL=+OK5ED#</G14C/>[ [._=J'
MNZWWOEF5TOA0 F8S2CDN9<T.'<T-3;^1*CFO[YT*=;+9#OKWKN%H]%VO+Z7V
M^#)D9,9 T[N26)GVDK[@C7[^;^'5L/J@*^T8;U*4M0U[469#;6U]Q+A05NR[
MWI/U,M/#KN *BEWC0V#@4D5I;0I'1W_VY!?9'W:X> 3/4\FN1ZX^95Y%]EZH
MHAN;X]:]YJ:$!BLY%@(\P<NYE56'*N@DT@1;NWA\?#^!+5BRKY(311KA*VQZ
M^NSWT*1VPJ6S$[22O>#T'FIRK:Q"T'W%*9(0=(9Y.[Y?.;6W>L&_,PV6)FEK
MK]I,N?] CKE8Q8AJIS?\7D\/>FN?(&'YO1E-7Q 'Z_/%V%ET/\!#AF1MM[![
MT<NGHTJCIW-^G6Y77$CT\3'W]";O];Q005U\$+]Y ]M2O>2"H5SMGK/HG?H7
M*@XZ9FO"W0]4%0&G!6P=-X"EIY%M\SB'>")LEG5>)^JO);KS4G9-&=[51R6O
M.JB"1@ZY I -^.EMRQR4YY>6VD?MC#%@>)1^X#MRGM@(1P3+[3$(=EO34R\'
M#*@:8D^&=EZJNB/@NG@[U::RG0ZO93D5UO0D4JV^\8*D@72@JDR/SW) >G41
M77!-<6"3NDSW$%KI3+&'0.$K&0L,_VH,>M>;DD7D78&U4P&,8,J0"]@[L=9H
M%XP&34/N#0@_N;O'N4P=K!GA.)FJ*"9L9I[ZD''8VLH9PO'L0M61'_FC[[4_
M74/M!VU?\5?2$QQB,CGX+[M\IOHB*>/UB+1@"(FT\12H;*#D$NG9"[>"S1UV
M4,#8S Q?P1HL_TL>*\ZW)UK?3R[F:%?>- V=B+L,G*F2UR".#OA<[ZOV49/2
M,PN3IQ$:C//+\ZG0[FO4#49#'D6WGCYQ(>F264%:CER(8$!#1",*HZ81Y*81
MBZ*=QA<!$]2W=U'58O9Y,Q9-]\<X2ZR]1["CR]*8]^%/I09'8<>-0+GQ!OYT
M<U!3;2$^6*&T)F!!]7F%7,PM;IN2<GK $+9CT5FNAK[7B2JAA=K"?,O#Q+6<
MI%[YT:OA9 <5<RBPO>PL21GN:(.N=AGAKQPK3_Z2;9 IWF4'P6VM-0RAY2)Z
MU-A']&2_W.QL>/%5<X>$()P'#UM#2\]IEAZK&038R_M/=.ZK_ M4@]EG8>8N
M$G0-8YS^MUPN1 L"U.WGX]\<[C:N@I)=W:WG4_.VAJA"BHH!LQH4=^4781N5
MT,I:[Q?R?**A\J:4H'W(9_;[<S,D*=QC?/N/=H;.HM-J1_<KW/ ;.ZI[0H@^
M?9Z9W$@>PLXW/X^!4(KG9!-;4^JU,VC:I%$V&BB(H<NAAJTB)AWK&:U@\0V5
MD:\,-0"LVB\.Q)3?55Z]K3HPBS@Y];B0_Z$L.RX:@NF]M\PCZ)Q&Z% 43F88
M!*H?XU@.6+&66)T1-L)$8'U'K]>P-3Z]9"L\ ZJ5CY[BV#CC9OD=#]9PQK)Q
MJO9 J<^!DA*Y/H0ASE?\#1?B!!O@*8^\UDF3GK GDJV$CE*T6S+ P/M(OE,_
MO.#,2$N3KW;82&@1B._X4G#4\\WT0 Z_DJXI! B&XS[4%:)R?W3ZBTB!"YGC
M7-&ZQW,.98?/:O2WUUDVVVC"W2K<G::Q@QN>YDGG+_3;%S;U+O&MQ>AUU>\A
M[A%FJUD;J@>U30<TD!U+33310P1JY^"!/&[3JK]&.%J$S2^^K:H)-\690U2W
M(2S8>,',T<Z$3)F,GBKRC@<0VX(NF%^2,#?X2?E81 GW<>S;ZR'<^QLY Q\]
M/OB*NQL2M9"%, \K$U&\_WKQ/I;^KH.L1(/F->UXQB%I *2@[7$'32O\_D;T
M@&2V/7>OV+QD(CA;J\:'@$V1>-6F>P#?\9$E<*6E"6^H:*466C*NG<)A<I05
MIYD:)6@)P%"R]? )_1J@V_%H%WL]BT3/<<[AG'1W)NX^$9'5#1(E:2)ST*_)
MN:!N/M5-S$_8QF!CL*K!:*:8C#D:!D K_AOK&F*Q7666"P?E[+85%H:[(._$
M"0DI,>7T:Y.NFGZ+[<2QIL82*+9Z>=07&TY&AMMA=.QK\J?WJK-1MN!EYZ:"
MI_TQ6TA<A=05KF1OK=[>12\-I;.D''V+_.:VSK5]6K$;0%=%49: >(2C%)EA
MI_8Y6="E7"%H"T E+M<3PQ^U;LJ /WLB=I*KLC+X2'?;I8K,FQ17(B-KDE7O
M4XQP>[)G@[9-]I*^I0\.-'% E,>L?@P.);/[F4F0*YE>G E&V18WF"T5;K[C
ML#9G/%Z0=&3[*$5BU>!]H+MC.'-N_[41)9"0$7#9$24Y.^FQD<TO9H'4$8\;
M:$[C@"=Y/.N,E9- ^U?/'9-5648@%Z^4=,8N=6[=CSD2-:V(B^P9I!.2F,IN
M#FV_YJPH&[;E4_VQ:90HS+EG\+:GA<#.USU:BI(7V@9L'MU?/$ 'QX\G>OQT
M?=PM&=_XK5NGRX$M[L"[Y-:6^Z/:D6E=6_[Z@+">5?YZ!\?]+? X_/=^]"F-
M]GB;K$A*W&E+374<(^Y:N3,A8FI?EY(YH$$:OR2P_S1*=[<RH;C8K_3IHX\M
MM+-#]Q8/<X-M3QN-W@PWB-)\'V$^0EC8"+ =)G/16#SN0%/.SE/47O<S09*Z
M.7IZVOF+\NZ_[S*(BT[?GEY/6+8EHY&4L5:<.WT<R2E5%%GA/&@9KWQ@4Y;;
MNS25&VZ<>J$.N=AGORQS\ST0M_^6AKMPD +!E%OV9D'M.3^@]@PH5F-6WMEE
M2G)1)VO51P;;=6=N/=Z"^WGLZBI)V_)E\$LU0^MI?36;*(;W?U@U*,=S$T/J
MM]9\S?8+60 35#> ^P09==B!)9Q.4&><BM$8-J2 :>>)47+^]4$:P4H;@BM6
M<VQCV)E-Q]J9)?,QUIUEG=57LX^VMO3U[1"X0Y03.C6CP#92$&-99&\(V7I*
MI$-7&NW8W-\LKL;&-I5<QFS[H+%#;P"O^+%#<B+VEU.#.)"Z!AY*'B'%+D?J
M/#58C3P06_TSGW1HD/;U2",XN_ZH76:Q%OHU,TU416^HX6G&F</S^#<5D\=A
M2GP1!@H216Y\6.OS% =K888X):?CQR:C6>6U[8/T1*%P<C4$-DGA,I4_'<XE
MG^</"MKVYX2]7O-7.\TC?.*2"L/Q"I5!I(H4GM6B7\ECI =')T0)6Q<>M#PQ
M*?]2(,\ $ZAQB'[H(/!<" 3H'.'SH".#]K;? &8ZBFE;=1:KJGE('K9KB'[#
MSA>_*L"T!L?@/];T8PNJ@7$H&BO08(BP3@L0G$/,M8?4\>IGEBHOF4+4V4)Q
M,^_X$^1S27*?(/>#KJF2VB2H!4:ZJ'GZ>0>&.AW*;,0X/1;?WG.IIN\X?-,J
M'^\4DC7+0ZA.2-)O04D05^3)D]1!&= 7I!OSW,:D\?B[N8FZ768R@/L>VVCV
M<%'.^-(X+8_MTY!TN5D[XE/R7_%\$"U%W:AQ0TQW5Q)S$F-=7R]N,P9VV\_\
M=KA'Q2'[-$GC7I);D>4G)86UK\<->?3XWZ(''2!$/><_/6D<LQ5X=:>J@^$]
M/JP.R_=UCCY>\79"QDY+[IB[GXX*"KY5HC[H6F.'HRJ4-2ZR\E<]U$P6;0DF
M+8#3>I3NN%3C"WSL[?E"V[Q#0]@4Q5"(W $F4HS:J9*;+_X-Y:R\_+N'EY/,
M)8V.(-/4@K,DZ='*A).=Y\4&%M66CRWQJ>'9"K?7-NOM48VBJF?V2_V":I6C
M3_V6]G8-/7GZ[8YX[,/P$(C1Z@4"3_Z\;?7Y0=.E7.N1#NJ^:&4O?:R6-((W
MY$R'!(U+7O3M0 5G2Z=,NU8*U7AG;J$!N?EO+84&CU$_*FQ#SZ_@J?3D9*J^
M/TUZW5Z7_91U)SC#% _J'B#"BZ? TW/3NTJVI_BXY/.<+X[B5C5%"/U.5/$7
M5#QR9AI<>3OIX7)QR378PL+;7INW$P\%HJV+/;6'?Y0HAT.NDO@BB;YK*@22
MXT=D)K:A/&FRYA:@=:@ELQA4R_?R@!SK4A,>Q>,=@VRF<!/.6H*OA[$>>!RW
M)%9\PQQD)1]$S$B/[)J-F@8R$>91S])TK0MU+74 W'*#]CEMXI?ZCOL9OE96
MS"1\6?NN?L_+7?.:=(C/A_C,3&W\4EHLQI+#40BQV*>%='D!X)+D!-RK+Y3$
M,4?3*X*A-++PHJI:!Y=[.ZF@[#Q/T8/Y[/Q>'_ZL4(95OL,.7@9'.N!;._/;
M'^L%)9X<?J;4^BI3;(%.-':889P;><G4W1(;V>"A21F>DYY[*7EH$C<*+[2E
M/OAB_:26E\JJIB?&W8MME#_UGKG[JDNAH[F1A\S,G:J!#]")B_3X9 \-8 OE
M'6^ZI-=*'%4:I6Z^CDVR=ZC+G9F?^0ISR.YY$%)98N#?$A8/]A/(;TMR;^G%
MY406S$)Y1L"!$V^J:Z/5?7;S^9GF]1!93N@.#T5S[4<[^ 7!D=/36#8Z5=+2
M,R3!J?AB7#28:>T.M!O"O(JGS%=2+_BX&@EPH$2'^^2?1:P?(JW%7OL-,,+[
M;?'4=:OF%0DNZC[I3WS<WW4FQ-'M-;?QS+HGIE>U19S?<@?3(0@ZX PH7@C=
M^<((VS&#HV:4AWE+3*QSH\$@FR2S+!T9(Z-;;=8/6Y^ATW#U_W9U34%0>TCJ
M_^OQP-Y_D?K9]]M=_^6#?Y4+!O$Y_E9B^GTAQ@I?YB( 0V-PA8ISX$\ASC0H
M\N"UJ-7;T:@JMU^1[<JI9-"!_G:\2&!*T7:=6#544.D]M]:7\RCI%@QYH>2!
MG\6CS7.7>,CZS(S.+++'VJHB@D#!0;J;.;\8 0,<JQ*#=,Y&NJ8Y4^XV#)PK
M[W*<= IH:I*W&H<)Z! @XL;/8EOA"'JP+N7Z=@^Z/Q0T#U+X*A]"_L3>[_[V
M?>00@,$72]S"_'9<Z<&OS-(D7SI/Q;E0*3\WWM7>_2)ER$G-%W"[BC4EM0TB
M;X,$78#&3D5%!0@A)FY"YIGT>P< CH@IIGI+EMO/>MO0:(EGHY5Y:W&YS?*H
MUQ\$BEL^1O#.UVYY4TKQZ\MIC%Q*%VU-@/SGK5LJ4UZ6=@KLLD6(NU],V,L
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M$:VQ#SKA1<C_*VYCRN-EJ/2<Q+T3/!B3)CS@6UVFA$=H[+DP8!I#XHS& /Z
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M<*.9-'BWWL]*X\XA8(&@^L* DJE&UL.MVFNK<WF3ILD.B>(6DJK)%K/-VN!
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M8>F0MN!&J&&*(Y7]S6G3CRZ&O+U#,Q\K088)S_B]Q@YU^T)G&0:R!%^6LC*
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ME:S_FH$07F5-,9G>U#GNM% 3>0,)S]G=;;IV>D@9J8;-3XP(JV['G.9@CEZ
M7DL+8#*V.79HXG5'DAMF8RI9AN)\\KT/R9NC0?!.UPBQGVL#]R1UN;&W_62^
MG<;V0[VWG;MP6V8+OAB"B5'UAL1V[ ^S<SR;@"LZ]CI'D)QRO?&+]4F+7"1
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M+.#CM+_L\T@3JB5=TR&VUPFO<T[6K.E0AKB)INN12$ARRE?-(FJ+%C*/Q;
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MPK[GU_!HCG8:1BWM";_1NB*C,:BQIEP+.AV0+?(P59RD,ZOW_USP8ET&%[A
M9!5;9JKV>E.FAPU/6MF:?F-Q^@##32N9"5O,$ MYM?V\.T,^(ORA3$CHR,N;
M*2 BM?A==I5L192CXG!ZH=6YUT3N5(E*V=W9;&6"-%,5JWFZ'\.9B>*OGN@&
M+:P+[:Y@ 9.0<=7^/>BF\.N8_#U];6'G;W6']/ZN#F.>?.TZJT5@?W0A5&ET
M]S3)OGSJ92F+DV./Z3;8JQ9$Y&0S$ ,FE$FN7;J=]EU+*V%I#BA;E[@\0F?V
MU;A/"K9>:965I- ]JK'$SBYO4W7,A^/V1%N7%NF">V4BB>\/N'[3)J>RP8FV
M#HH1B&XL 'K[H?O1SRX%9$::1 DLZLQ&@4.BH&=A8[9WPEL\=T?XX9!'Q-"]
M5EMO]P$GX",@TGKAD'?+,%"US_X^ZL1$_L68TZ>0 E=:LZ1-X] 6F4;V5C%1
MR,'P^L+/1+K^C*7T*$) !Y,WCV]<W;1Y^NB,DLYGMV*J2!/'#S9SY#Q.L'(;
M#XC 01]925. ;TRF[F;\@+U946FYG7B2Q'AB?)QYX8Q/ZOF=./ZH7_EG>)7Z
M&0G\C9?Q>6,JYV[ZC76T R4?3CGU_)-ZHM5RGYA[EZP9L-UX"0#@ 0@@[+VX
M-Y*HP:ZJE4O6>-\#_2*[JRA%T]B^DH(W98%G98&\D$M>0(DLKX0FC.]']],T
M$"O+!0=9?HL@.32YHIGXE(J%[U[.2V4WYJ^03:[WW"XSFE45_B;!7AQ8 /^.
MEE4N>R]$",3%3:W4FZSF^^$EHQ\?L0KTW[_"G(R@7M6IB&("S;@"$% M)R5'
M=TLH8[J7A-:SIXLY30V&-,Q=G*/1K!5^]'*D=[;\S8P[@]="AK\HJTNKAY>Z
M7RY;3H(BE9=LX.D<B=ZNBJW;4I9I/-..// ?4Q9>*?-*C2%"S!%2H3K$.;]T
MYJ5?0%O09V:^/4__ [GJ?Z ZE3XX4!S1C"E(T!C9$PQ]5E&O]8+S[@T]/"9<
M$FIO9G[;0K2YL#=!.V SOR^3 \.YG_XX%*W\0$(&ILYC9:4J\'K\N2+%LJU*
M6/B%V,"/ (\DNWTP9)\Y1#3&+ C1%,;'KB80?E.FH$#L#N7-8DT;(;WDF+ZM
MP>:*1&6)JLJ&7B_#*//,Z>O47A+J1_&2B@QJ-@^$V^I\XWPDUPI$XAVDX[TC
ME*%:(1&6B/H4&W_!/JL2=WM>:8XNW&]2\@?R]#)#@S\2*:XZ.7D4",_?&W$E
MG*R+IB*97?ML7_'BK,/%15T]VKV6M%4EUI.6O/I76VBK&*CQK''UH0#?S[L#
M82]7)B>+P;R!+K\K*R?F&/9L7N'!:>\3<6J%Z!_O"_IGQ,527.#0C5]G^+UK
MN[^]YJ\W\@;%$94V/E+([;9=[8=%55>O=^T\Z#@&R&I3.ZZHW9W*ZA?ZUU90
M\.]9R])D@S<&.V/6$&'3/VU]^XW!3'9#O P\DB_41I358ZO-U-I4L^&69 BG
M46_@L*$I8X3+[0V3OF-DQ:5/>/Q'1TNZ0I_8-RT9G[W[7PQ*RA>+L==%P\J,
M/V<J8P;9A5>=4^^/KHT)Y+_]44'OW?DF.$+W\0\I5'']C(@K(;LMZ^T.CKUW
M1$0<'639+&O]!AP/<^75])Z9)B7\K*.M*FU9E<O@DW/U%I8,/H! 9/QS-QTJ
MW%3V>"]2(G2;<BKR<C98BJ:>MZKD\GB\8MTTW<90CIY5DQK\]![&X9];E21Q
ML6P62E%N9.-D[[O%5Y=HK5GM+;U8M8VX8I^[AQ5T8.ONVOI?W<@&X5QHIU"#
M[ )E:X-MQ<IH5L4P%]>I^V@4U9Z1>+Q,C^A%L1@;SLCQVC!!/+\7<6%!%+/T
M@%>FZ7%\*CSQAFK3VS!J)7#+M%"ADQW+QY6X6HO@JOU+Y#79==8?+)( LI:O
MZC<6F5O3TXVYO.P<O"\W2T6[;R+)_QKE#C9PV%YBV#.+24&[=(&S;4844[4;
M^W2\%#@X./HT5UL+YZ?:\G05K458V+6A  ='+;;\7TAY>=U=E3$!F-+3GF)N
M\L]O%1\.Q,2H;-'3_QBAMRR351<2WO<^Q>D:9#&Y_I"!.[\&.X\>"%;OZ46E
MXN$.KD*:363*/@:GM#?3GBT7;/L^&#F#=M:ELI-J7:VSXJI-XK]-75@4%S>^
M;%0+Y$]J 3R$0?*VV2%S&3 G C(G?,8-UO&)I 4<) ?D$V6*B=:$6JDQW/H4
MU;4"&5??2'#0@>#KOM(;*TTKW$1ZS97IS1=66%UU(KM$F"['[%PX"1N?"4PM
M+=A3WN#SU'=AO$3&D<4F;NOGJ<?8=AALHD<&]#P>O:[2Q8MBSAY'F'G'77I1
M5Y_?.=S_Z)!H4*Y_NR^(V<3=ZR-*:X)L3EYRKG_E<^:=JYJ\IBUZ/?L\#S$U
M.WN!GG<U:O(?G;K!O_<@]#<KXW<@S1/H2(ZIBWN=S_GT1!A>&;0GFG\>]8R>
MTJO' CPS;T_$@4 $(>2R+^\"BI_IBE34)0LX3<D460HUSKEHU9^\.(,3;D%F
M_?1J[GV][XGC,DP+R*0LE+K\2,Z?Y$JJB,:1$+#"3$;9G^PBEMZND,RM6-6?
MVR6/;:(;F]07JY&],I0?Q(B9YH[^J6UZU,K)K';F,)O&M\5&;=.^-2."V^*4
MY=70E6(0 A4)'E9EJB?E[PU3)7=.=I.*JU31UX7,Q0E3C"AH[R>\_(7>CJU:
M_]6;_=A:(3PV38^6M6V /75[0R=:,LCI2YA7<C0P80/23 )?U68X.TQ#UG7\
ME\$!;GQ@+P/1]E7I3$PB*,TTQ:KS!P>MWI$]CWSPN/'LQ)(\RP,H-W'Z0&I[
MF9W4(G3=*NT/3.X(S/$,R550(%6"5@;!3EWCJ6?6)*8O@](U7 #O"%S?;BOH
M-3XX1(EIJ#F&K%>6F!)J'@9$%<[2A 91L0 ]EVVSFRI-Y0[7OV68%RVVASTW
M<ZXMW4J<R$B0*(9N0EJ'U<]#"),:PWPLV\3LZIF=#)E^1X6GK]CFT@?D5 T7
M<5? =YO9^JR'^MCGDJ]PB>+<BZS!E"BF#,49'*P[]1U>O7KDF:J_:BE^OYG;
M;BA[:BB[*M$$WZ:GW,3QHS9;^B#834F"F\ Z[Q7G0;JBXFBQ"XRW#,+)I1=J
MG,3*4KB52C=V&MJS7TS27GY?U+)[!]>Q/RB>L,N.,'+],V=HS],7BQ^KU4*#
M&3UP9>N%U%S7)#E,;EA@CU1(C\VM_'K#--Z^LV(S?5!)M\S4/QW_2JZ%=;Y3
M*PE':12:4H\G:)5$GO1)R;(*4I0L&7!"8I5<;SPRO2LW R4YV-'3^%/O+C^U
MJ3J<VW$FE(9G>1@IC)CQ3?]\.R?10[1^:V8T:QPMGKL]^<7 @.F;<6=KR<=)
MP4(0[7'C01Z7(#FQ148MC*Q2B6-2I_R*>[D<5"-$_L.)4UA[C)O;FPU):.WH
M>-N&_&G06O 0[374-X0L\<>VRN??*94VD\=\$B]RE;)17DCDHHGYG60O4OD.
MR(1 DJ3%V.YDJ?W;U8<.&I>?M*W2>TZ<B008\SFT&M2J<@7M%Y4(YD75NZ.E
MG^[-,:WFG9\6'J&<P9$@'V:N@)%!A00<Y#^ JBJ-Q\Q]Z\)_S7"?=*OZ=6I2
M]HRU%J&Y3=$3-;G[4Q+'-E4Q2WM 4*IGT<C$>N?U4.IO3&4AB <7^$0.@4G>
MNL:YAL;[=-HMES(E+G9V3UR^7J__P=0Q[18O9OOW6W:;2!2'=*JR<\P.CAE?
M9^U!OS70T_7TM!C\OF.V@,.X<4$Y5YK/SHX4PUE2>'A,D9V5>?E*Q>$%ZOX@
MZ\+,_U(H@WG_42BYSZ.L\[8^@6NTA!;9 $+$=**%X^KK7C:*Z4JUPN0']NL6
M\'>_L #C< ;H]9?[INZ2SI,[\A0?C8E"+E\S74>=?-%+508+YH-H1_=Y"T<Q
MFI5-!HT$$*TX:.:43_2 KLFLWOTI44&CMX?[:5F&8%>KB&=_2*ZL/K*8S%G2
M=?8/8=C_3PE#QF1;G4]J"4\^J4A=@MNR$5-J@Q;.KJ\FGCZZ,J/"_?<%'Z)!
M/'=NA\0F.C,IK[0B\.=*+EE=TT=C!*72=KVGZ%1EZ2051A/7O>-]8F+YG&3-
M5(R%8>%W'>CS5P^6Q9F!SE#3*HYB+."S0(J"U5IMA-I(9RD/,],:':=7"-EJ
ME4DJ1=B,4XC[-9$1AASS"0N0R,$"FG.J6$;>\[A4C.5^D+>G]E?IBHKXS  9
MSDC*9ZTG>Q[[Q)7RF<^IJ(?$C>]M(E\Z!+Z*3C%_@VQ%40AH@ @*G@,H >IY
MV>R]>F7YQENJS>4AA@&^)9FZ.VY]=[;K98IK;-\[*R?(5R3)8OI<[<M^FTC<
MW;B5"_0WQ%'G7[DR279*-J>^5IFYUD*)AJGO;>,^X['BLNIL/7T$#31.+\KH
MH7M3,U=;/EK)EMM_-NG(0386JFJX/R^C%8.;E*!X:ZZ1B6Q*VZ'$=-BB+='E
M4JX5<_#7M<_@BD>GB.@0WU'Y^56)9_BO7K7HNI2F9%O%4W,]((^](>QSSLJU
MH*[K[GM[&+%A'<;W1F<U*.T64&'+*BN7>?^K(N%K%958\OAI,H%&^BZ9ZN=3
MKYG4G/J5=2-KB^9D6R \V4Z3I"^/Y+JXC'W2(Q&<Z?]&D+NX!*E:U&,U<02Y
M3N93KE54V=2KRJ0#<=IR7\&[I4NVO'JQ2NZ$^!^ZOM'8FDA>0RU"1-=@"ZH-
M@H_!4R((0Z1H^:+!O1E9O*G9V\^J\<2_7B5N_OP)<,O."&17=!/38%?#!5=[
M5W-<8$=);:2XY(FNB<3BN=3W<\%@VT5)@E^U#WN>F'->=0W.7L(F%4$$3@H]
M,>H/9+)J<\D6TJ7E1[D%]/BA%D5/>?0#WB<GP_W-#5$TTDVUUM/X3RU$C0GW
M;E]S9OU7H@_A]_N<D:B'&SUUF\R'#G- &$/#'(ZGY=FD$N,8QB='B?LQPEQ'
M0J,+D/E_(QC;HL9YO01)(6L&7&:;&)HQ ;X!2_P3RG?=&\ZF8P(#1JW36I5L
M\=LW6;9P:E8G$@Z9RHCX\W\ (ZW,W>L$CK4]T\?RAXB8C+X-R$^(G9\\C2,#
M6,&W9*F85^_=Q1<&@?OX#_?>>VDUXDK&15/Z&41J:.J8QQ#YO*+DGC4UZ&=-
MM7^J\87AOY'""E4%-2=W\]%,Y5A/ZT)>QHP0=NK_XU]@_:O]J_VK_?^W.6(!
MI)6$ _RMMHZFKMP5\UZ\WZA:6O8,_!T6*("KBO:7J,C+"=GEU_%=,?!6\V7[
M2Z(%^$(O<(GO2/@:S[[Y8,U$U4!(YK'% IK%D 4+^+YW<8W.Q#SB?00?=KO"
M8+2>D>G>F:K& O 3@ILWQ7VP #@;C@3TM2^<TC7A*GQ<,(CBE9LM%O"?^ 9]
M,4B"'W[S2,)\JEZX.(Y$O6U0P@)>S1Q<_=:)537[UW/_]=S_%SX7=M%F\/I$
M_=#;77B2;W;0,NIM-&WRK9^(IAKX9RS@F*D+"S B_7,FUJRV0!.+/9U?+2_#
MG#YD2^O 7B#J1=+M3%,);3U]^W;[W[=FX)/VFS:;6  )+54F%$\5T77GNCP?
M"QBZ'KI&"\#?;\-/L !G7#<>J&8T\FC^0C'8JO].FS?$3(UC 1N8#0R&&ECE
M"OR-!=3BNA>0-R++L4L_G7L";&C\3_U$:/Z2K 2OPSUA5Y;J6$#:5=H5RNHO
M#C-!M(4_8#9I_9CCB_/!7"P > &\.!SY[_X$94)$M=^=3P"_7:\=[*6 ,?!]
M^,%2YG_W9A-.YH1HV2N \U_U+<R(I:&Q@%DL8*%-]K^[FZ!F6S/X-*.!L;Q(
M:/[+""+_F[\" =7>>KRJ?/30 >]?!\#P%X<:5IEQ;L3_"LF_0O+_:$AV4@E2
MH6D/.IB/&R(,FBQ%):'I".C/M&/.-BS @.'WI**A@5%X6OK:7@.WT!5CB0BJ
M9'G.LO6'=7B6OBQ^RJQ\$^-OP'W7$MD2.M3)GRU2O-<N,;\)"MA%LP:_U;]9
M@2_9>XQA_(2P !1!VI(LFON &CXLLX %W%!'<P9FU#<FB]/.CNZ[,QQ6-UCC
M8(T&CKX#/LS$4%R$ S>9[+& #_D8\K81V?+ =^L)SC58@'_C"OCRW@P6L,@!
M]_^[%8(^1#)9'$^@/J7K;\]A^R<KAU/5W:5?HMFS^\#_<>\B+8E:!G@V<,2#
M$-:9=DJ" ].?&E@ P=_-]"7)8")N1-;NXI$HO7D!'!*'-V-NYJ)4_]EL:3-S
MJNV'LV+M++QU_BCW^C8.] _)@:U_-],F!M$/TGU*-!A<^5L4R/YN5./%=NZP
M2_NOT/TK=/_?#UV:)HI!LP&)ILNU$3[F2E!_8FFN\CTYM;6.>M67$@OH$1\%
M[D1A </AKA,;8'G^ G'&C! .F?_H7 3R-F\=+""*NWEG&;AC,/!7:2#]1QKX
MCX#(QYW]_U=K$W+)E*R+"T?(=*=9JM9TD'CB+RGR.&4:[1'-P#M*QV;4/(&F
M-T/F[ D,!>QL[05F>D@4O]HBXF8_]CR!(<GQ9[7^^589R<DE(#KH" N8;&^^
M)'<G;T.SXD9%#[Q$)6 !KQ'+M99'_!GBC CA96'TQ[WFG>I3P2EMFB,:S,OS
MA;.92^HZAG;9N[:8-?7A$P6VC$;IDY\9(6R _]6M<-HBRK6@M\^NH/1[?W2W
M6P:QFDVX:YU_2I]/:)L6C?;[I[!H/2M+)N;2TYL93E5!VVVJFKSLG-FV%'N-
M4;)73*_#?CNA/E#!ON[UL6YHNM(1P&A<ZT-T$+M?%\'XW7C#$1EUBCHN250"
M>RS+DF+V4JS"PC35Y'9N2_5N!=0^Q4.!9R)/ZJQRQRIO&L.Y+YAN=:WS<3X3
M7L#@;X()[T8[*F;:8';&8-6N^;TC6I6<TL;YL]./TEAD7OJ\E* NU,MU=>Z*
MU3=;OG@%(E-G_G/PQUGD37AW"?&U"WS#@-O9\#8NY(8,?[YS'*R#'!>@WU\S
M\&(!+KF;S8Q_KW;G'$<+D<"CG0S<^Y('?LF51@5MY1^6=UAEA)PJO_O?$?F,
M$.GA83QUZ\.K]L=5%!>EV;$.LZS?'J=X1)4:Z3]2A[=6'3U&X%+ETSTLH#/K
M*%J:V?"A7N"+5I>:MAJ##FW/GEN-^D<6H4OBX'M6U12/]^T,YZ7Q*6J$C1I:
M>)R/HT;+UN-3?4%3M,CZ)5OMMJ@9^;PN0,2&0_#2-S,MSK!CJ8S20@0R0(H2
MI<AP<@3# M*+G00=;8OEK7!A3/\S(QC WB^P@&CW+/@D$^[/U#N%42A3+(#Y
M0 X+0,CB<EAP4CL!&)SB.(7[M=KS_VB,")KE+G0P#GB,2/YLUX<&H$JQ@*=Z
M\,EV.+* @92L2H(GA V1F?S?CFW):!1N3:4=J8#C5X<T2-]+<YB[S\4'&,3K
MFPL^RV8USG;N+P=Y=7Y;QH&B1_3FEE?\)UO+^Q^"UMY])S9Y2:/TS@,N/[J,
MRGS@WS!L0^VFG\XH%O4CF?90+GM@CCAV"6?+V4:>UA&N0&-+)/F:^2UWXE-_
MAJ?'-_[L^]'O0$;F[?BR3CP=JZB2)]5VK]0G9K:D/%V93OQ2]&Y$;QC%V9Y
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MKYBH2=R;0_]<DU^\%3$Q8+/]>"D@(C-C6_NE#Q^GJ* D$)']S%;)FMOX\"+
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MB_$WZ'# %4L<1Y.-Q#3AGCA<6(/01;_=C.CF_.M*I)MF)UH&"_@B67WMA@E
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M@U^OMS&JFA'P&.O+I5E&W1AEN[7&#!N]0M?D9_T\BU-$&6M#)L,.D\];Q\^
M#U<1AK-TR*<\2!IFDI=$4K3KZ6IW +P ]A@=.TN@AFZ;6DO3X:N?9 O% ;]B
M49NR\Q@<N#!/C"#NW)6V<%U]I+@CV(AW[G./'\V+ -UWC6U9$T>A9E= ><4Y
M2MN^83:JI3Z'+"WS-8UH#<E:0N/9D<FD3_.<XJ2PB1'OD2?#RY,I-M#$B,Q)
M([Z8P"" V,T1!.N\ [SW7AW%N97K.%>L:"YN<B?ZLG)#=V4^UPU/LL<3<DCJ
MB5 E @BP=MP#0] J*I'?")V_,O(X<AYY'*B]A+J*M'7]<I?O=2L)6ZK%+IBX
M9?]ALFUL?9'N];G9-92Z<&J]X0Z@O 1!5QW9=QI8B#4@=G0E[*WI%0O3;H$5
M! HR\9UL!_P,5\**!%",8F 4<Q=.!5CEF@<\N/U>WPA65UK34..$3#%U_ 2%
M8]AJA8WXH0;,>]J]QM#6V!Q<RT!1)'!T,R-U>R[I<:0>''VIJ>JT.G'F"_$I
M?/2P@J$>.(V#N27!1>PB8+J?KK?KTS6I,BC6W7D S#S[0.=WXY@SP3YIB0Q(
MF8V,]XR1L R9,[6+JO5]=[L3IUF]2FQU! ^1F:4I: R56/%,>D0N*9D9H2V(
M6P)7#J_4>7%<G/R&N@F/L*X\)A<SUQ.MML^WRN_?Y6Q?</X0AK^X_SX"='5N
MQL_*''ZSY3$LO]_T80!^K6B;SQ7=H"H46ZDZS5@RIM_F"R\JB;/HG0V'7#S%
M^RP[0N^RA8$A4V&L&9O35B>]/W1?/YQ]WZ"-X\U-D!(\9ZU%JB(\8G.A*HP>
M9Z$IF.GY[N4)]_<SBKHQCQGA'L-J3[S(RV>%UL_DFMO/%K9Y6>TH"44#NG%'
M@C4F*?3RR)L*:D=3K+AU,TNG[0>Y=R8'3YL*%,GU<>HHMABEWT'YHV0I)]Y,
M\?/P5/,>&NL 7==3N$,%'<?WAJ]="W8NCWJ)<0T=O*(][<X;WN0'+"="P!_1
MGMMM' ?'78N]*?!)N0/HQ&@W/EXP-#.-":E=N['LYP;MU+0_,)Q;6C0QW)&L
M+T_AK3]<[0(@NKI+V1*3I-9$AI_DV=\!"-H?&&E8O4VT2]\6#9]W$DUEZHZ0
M#G?6.*YD(NRGC'.N,'2XE88%2/D[^@LGS8315D2\C53_IN;$F)9+K-6*J(^T
M7\D !IC*]&;-Z$(-22 ?FI99:LQFUA@J$J9:K?B*UC1P=_;>5-C]A.X(&2\J
M;_P:3Q:7)J.VK?>IM'L+A##@=/KM6VD'DDWKIFRNU%BAJ\#EY1/*3TU_(N&C
MT:W*!8X6) 'WL5.]"4\3EH0&15J<53K-R3^O<=#T0P'>Z;(=]E7SNPG&A>67
MP'%HA@^ JL_G?/.+07\ZQS6KM_'^J+"HUS2_@T*QV;I.@T/IWH>)IAQ"9*3*
M<7]TJZ-]U5*OE=2NA4/<0ZD7M1^I']T<9F&YB6(M?36V:89/M,5%@MA;6Z+R
MYA,I^U8[]I/P<HDU)J5];?TKYNQ3F_4K"DT7T8'8>;A/9"7#F;-=?\"\.T@J
M@4='O)4>629Z:I1SWJZO #XK3LM)2BI'L9,EB/;PTKWTEUE%OK13P[#PUB$O
M TI[\!NKL(:=SAK)XWF7[?-+*+AF;5BYNR&EX8LJ[R>!\N8OUI).VA8NI\,
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ML$Q2V<JF,! F3_ ^T#01J=\1)ZW 'YGQ,N7H)6BK^^? :UBQW?<(0- ><-M
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MX6$^(/4!#BG!XJCN&5'G)=8:EV5!.IJWFDB9P,$;(V028\4_M_&6<QQV*[:
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M#JW"OFIW+?36+QX<HK8>&V\LS:;QMTYG&;S&=C'F,ZR%9$ZL=L%M_4')02#
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M[UWF$KY^]L"0TB5>E7&U4,!4E-#5=(T-P6%,IC6>4SK< >)#<@(J+2DO$<,
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M/4X\FRE>[/-AZ>&Z%OBL\? =4[(N88CC.9QBD/.69JXPEGXCX/$+"A5-RFB
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M6<#T9?Q6Y?=\\6]D?ONH#@L/Y=YN;.0:S&B9[<V/PG;3S4799W_^=&5M51P
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MQ615 6+D5#BO!.F@4L[EY6!LOF+XYP6]=XKX@]V3[U4?T]]C^]0G6QP7N"R
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M>V&X!S@'%J^!I2MD.7Q16U _F_"U@^?"4O<;7I)YYV$+R%#_0FSV_P?)]'^
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M$2Y?^G69?&Q0XN,!+2QT6R$M6JCAO\@42I @KR#H,@)W&8R)L/FY5P%?W .
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MK!E,D;WU+\A"F)D./]0I7>#UH.-%332J9944=G@!77KL*@^V3 =>*)3[O97
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M,?NL$AU_&?);V""N5^A*A_MX1.F->$@#W(;-ON&YJPNO='K40D/#RNBU0 _
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MY![M"A4 \U'#_\9YYY_R3_G_@R#=S_U?4$L#!!0    ( ,T[U5A?KH7Z*S0
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MO[![E"I/1D%QQG"WXYXUZ<P0N@CWFY_8LQ>%^VLZ!4EK>2;1N$"9"^]/\@>
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M)*=LAI/N!8XR,;$/6^*]U($;"@G3:O?BQ>.?'ZG1IX6S89^H CRM68JP/CB
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M_$T-^//MK=C;PN?_J'-A0IA3/YOT<-L(#7HG+^B=1LGC+I<BQ+-JJ#98T?X
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M6]!%IQ/\P!LW.Q=P!!U^!5W=/@!P\/7IP>5[B=O[])N+!V"R-!X*K'_YK/H
M_-IZ )H?T9;#X++;^YJ[HS]H]"/Z "R]5+BZ\[E9SGD /FMAUD3;+!P<H!J>
M=CIQH/\%QHZX]P'=7^+ZM%&";N]:[@X9<K)\>5LNWQL] .DUC]VB@ Z#.Q\
ML(// D6]]*-C/78DSG)U&W-_A?OX>^U_A_AHD5(?(6G0U<TCA)>9NWFT%20:
M79'0)0.P0D?^M2 8_/#[_P!02P,$%     @ S3O56(O?EH2$Y0  +@P! !(
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M+?CAH3N3Y@8$]HA0G;V%0B!)4AN4FIF<XB25DS&[NB+"IP4M>3[R<5WOFX%
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M+$*O,&;:[+M7=R7=>&^3@RXR_&SQA+C(EC+RV\PSS^2#<00QB)))T2@V=;U
MGR^B1'N)KS**<AJ^U4Y$+2HJ#1<YB%,<PL5*0S6;WM[6I%59G'<H0@8E!0@B
MB???AXC%R#><D5LSKJ9DA*ED5,%W?"^^,$3_18X%G=;J&K>NFQF6T+S['HZ
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MU9X0!;N.GU71_3EHZU_TT[Z);LS@2=)C_,"-;A,_-1:-<&UQUTL;C'OL7>.
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M0*)6"FHZHQ=9B,L>]EUU6L21\Y&AU\GC;XW$(KY+JHT\ <IFJ"5%S0*_[OF
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M)A>_7^)^] KO@FU#7%VP)%7[!&BU^)=!C?<3P-##R@XFQ2G\AP.)5D=NX1=
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M)!U2PM5XKPJU$94LK]GX]GG<3FK:YEP)STVVZGJ6<[8YHFA/&L<1JUV&;+3
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MNC7*B&B9:*/Y?-9<&[[Y^@_I,IWL?*3'LQAP(Z*Z53["A5G8(/O#M#OI@R>
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M;J5J&Y^6_XCK%(O%1S7^KO0^*MV/9U2GBZ<EWU%/KV6RY/6$0$GR]2LQBD2
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M0UR5W2][QV!6ONG*';4-YJVMQ)@P"I4#EB%\PN4!@ _52Y/6UF.WE,(RFZ0
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M2%$V\59\!VI+4!*=77:E*%2:5^^4W4\O3XW>='\PA/EA;:@S@H<-\+3R[YX
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M^2APL-C_(I;+2;WG&;O1819N7D0U+^+U;_SM6*N> 'I7 M$6-:,"V]_/RW&
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MBXB[P(G4#.VK-!,QDM.OE13QUR6K-]LUUA>Z+:I>3H0_]>?>-[ER^Z5]F.Y
MIP@33>#-[J+<06H!47L:V4,<GP!U\3UN]')$OS.K+.Y^%1L-14=O8)I[3YUZ
M]LD Y_<9VQ6:JT.WT@E1:#4MP$(=-'CQV/)>%:)MQ^=7<*L$!BIZXHG%NLV1
MJTMS";-&+<.^<"IM1$Z![(6MOY*6LO+V]5-RTW6^],U[))+U"B20GFQ1WMTL
M()#TG:BA:.%TS[]VTZKQ8WID&9ER=_@\0H2O@P'6\7\L0Z!UTN$0"[#P*.[
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M-TI,$];GL\HY\*7\*>X!LR7* VB.E>WU]_",=/TJ&<9[PH12>""!RY3^V74
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M]X4$)D!0^>)Q\T[[0:0=4UQ2&Y4E+[+[T_^'DQ"%,>!XNPOJM% -%S$<)HG
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M88*X57P$M'4<XMJ13P#O^P]XAA53.XYU=VS*EEBL;QL%-6+&_T#=U7F#/!#
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MZ'9*!?4.F\-@R3J2(/ID_6;F8@W]0*ZHQ/@1+[IIYS4]"TWWMBG"TW010_3
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MZA*[P UL*?3V\!>CL5K,3H$ >5H+LFY2VGS'(P&T/O5#=3?0NRE0EQ>.N(5
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MUT!-]RK0/ZCX=TB]D&/HB92-8_';)GO"1)&\'CDH$L1"!LW8DRYN,(AKLN%
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M+-:YEHM]GQ2\XX3'D+_^(TE",5ZT+P.IFA#9P3!WT6<,J:A$5R-X+\W7HS+
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M#0-X_C,YU@N$7UC;&Y[LOZQEH?IV5@<B-OMUD!5_\P0PGVKR;RZPC3&K@<6
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ML*23QB!R*0'](A'%@:HMJLPE1VQ?M)'N><+!T=-35?,MO^U8G7D(F:.<\D<
M^IE"JYDADV"8C07[#V>P,QXT L'%T(L<C$BBR7.;W%=,,JQM(QPEG)GOP.I
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M<FL(*W>:Y)KID1'YO_X_[7UE4)S=MN9+< \$UQ @$#00W G!0G"G(3C!&Y<
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MS0<]\)5 V<\]2IS/6:&X9A6,8;7S6QASZ<1NP14G)%='@0,'JPD%1%-*!3!
M1=Z>+>^:9NY9;(\MWRG.LI>O]D3A)$1/K3UYK.$M">.OSD[D-ADK[&^31G8/
MR;%F&^E#([*S5I%,.8F?XYA?I\:L?<? -H$,W!&6]_<SZXSI9&F'#<3K7&S<
M\@[C6",W#-#XHLW?J94&O+D;^26 :H0  S@8/K$4*.(VU[_O*6*T#"@R7G<*
MC[]KN[A5:9RRG(*(<*72>"R_\/XOFJ!.1,_R6+A#,H),L7-%O0,\?6.I44='
MD_V!ZDWI!(+8E$P@:Z?IA8F?-G0[ZX%,"X29JKEI&D,:GZ]MBRI#RB8ZU4%Y
MH(BKJ/,G-'^E<GF6FO!:1=EXY<ZW2T X)L5FQZ*1!XD]\&=(IYC0J>'>)@;F
MV<->K_-!/<#P"]6D^4[=\:#XC1#U6Z%>;WHRI[""Y$>-LZRH$U$Q>FZ\6<_C
M'?R8  UR>G<2FK3%H)ZFL8@ )*](?[.6N<!)I@K%8^Z**]&'.-\9Q2C>ZL/F
MM8<KO!)VQY'&-AZC#"KV3V-=G@D'92&-#=[\N4);=ADM6S%>>Y'^MWWZ1)WN
MQ@)=MW/"PMSY<PGUR3DQW'E!XS^M9TO^:#VGCDY$+5D\^SU8A)<\\D1G8RQ]
M#2CT,?H. Z2 @]+\'XRNC8EUZN;<#%4TICSCW4GB$;#DBL77MW7?;(Y%?-X7
MGO;!2BI4+3O"XOX8O,X@^XX>7J%?L%^Q^:P9JE 8!@,8&<( TG:71Y12<YUK
ME)"2ZYM'4>*!W=5=R8LOO7H4#Y]UQ7.K0P0O?QO<M(4,JB9Y9U2&!+SIKCAR
MRCY,,^Z++2L>[!0:\,.(0P7L46Q1BLPE>15I-<T&</0RY&P RRK?B-9.+HP>
M)$F;A0V-/Y\D3:RM+7F-;25'2(3-&TD6]87N'G)=;.C_N%SVZPPH!-M)7+BD
M@9Y]L9\)KEL(S!@F'P6N>!)==-HU9VK#/]5/_-G\.O7'F8VY;@GJ[7P+PDK:
M3-/)#&![4I@IG&7\<4!FRTS8)#X1W:OE:XV8(%3I5?EJ_)KP3ON<1[=V=BM!
MC$?]34XCFOQ20Y*C<&!#4(QDN8UQB>"3L83&H5M;WTM B;R<'=D+SE:K@+EV
M1)-?H983@@CMC*\#>ST,8K\\26S6UK3-O3:6.F:?I7/%&(V\VZ-A-4=, )&=
MKT4D>KTZ=W2J%6D\N6[^W1,U8#BDICKR\XL$R\T:H)N]_8N;8&'T9KP#OHOP
M>HQ(9&G+>;"E)ZA';<?%KC_:[^V93N"FBF^/1U-!N@KFS\A?3*ES-FQ;5:3K
M6)"Y)\4[7P)QBIH942%\PU6;<#3$3_JYFLTEVTE"=.>EU(@PP+;M.>C9W?09
M2W'JKGUS82.4&F6_-W_Z&H](G7I5R_Q+NPY4_QK,R!*+:P$#E.$34EM[N!#5
M/Z3TQ1+8ZGAR\9)99:#]]JT]&WMZ[UM%@O!KK-4?#I'+4)("IZ^JERSXO?J7
M; P Z]Y&X:$I4HMJ@1TVJ[%MR@2;9[H<>7NT7,-A4;OX];X)TUER_>:Q[)KN
MN)\Q>TAP\N]J0?V;=LWFG8]"B ':A)OY,QEYXZ4.92MVAN>;=^UJR9C4W5]%
M@$KAJ177R()<&%LVMW3CU@=&[1VBTME WQ@IXZBLW+E\&Q^'U?@-+S;.2H.'
M79)4BP;[7>D$U]^,.?T;)LYGE._3J%J"S^8^@K8@J-!=]6,SR&GAQSO&[F13
MO,HGS7)@G_[N);]A_&M35H]-E/YL , +[!2223,[M[$*L37'7KK&Y/Z8'-<X
M\+H]K/*=--GPG=,FID!'/17K)&2AMZ#'Q5'FL^MKXVZ$Z9]1/KM-G%\>_,Z]
M?#6G=Z)R5U>P.>E.D9#CCY/ISL!'(LRF#FSO!736#']F1,<T6Y^W2X'PC.D?
M,@8N?[Z^_X1DA$C9T.\H#KEZX[47 =K>])-X23_B>P63?J.[L)'!IVAF5F/O
M+#[;MUY2H/!,!E/BIH+BAN_=*?$!H+=[)ZZ3X(+D\ "F?86S7?UY5M850FNF
M4A+'G<:^Y;UZ1>NP$S]&AW/J7LS-F3J@N6@NM3A#G-.EZCNX8W6OT=-N/. #
M\YU;>5I6:BCPO9N&"S\&A>O/1W.PQ^&.@\>]O5E!92$,P#,A3KNZG[S*?]9B
MD!S-?CR=4%R?RA'U"7^7\\V[^\;.)];\\_J8*Q@ 2;]K#E?!U?NS?#TD?".+
M4D$LC+:!,W*I?</,BW&X#P;@$S O])O.O\O_$'TNT$WUNBUZ32D\MP9I0*I"
MX>FSY&VO2]]/B^PL*[OM.;[H9NQO&IVEB_->>=TI/C3-@J'>J$PNGWGBWHJI
M"E8$]64*JJ(^QZQB\F]I3',:VA.=;2,L)08MG[&.B;/?Q<J?AV3&YGH%;/"Q
MWCL&5<:A+J+%1STDR%$MS];'MNB6VRSN!FU\\U?@+>:@4:VU<PP,W[/M\R+I
M-W4>R%M@V+QW\#TXN L342A+2R/N.6J.)5BZ\^RAHLJ2;VDB#:Y-#W+ODT4V
MPHW/M-N+$J?KWQBQ6I.:JOT-,?[DCD$3\0N'*G4]P7=K*NV2\)$ 1.8GGKQ*
MVS"'-O#5L#$?"R%AC26^3]CM1,713O>7E^[-5P<E?1##X,G:K2Z6N/:PF6O6
M.ZW8OI*),/X53J<C=>;!I6L>B!..TB9VE FA+YAC3[FEWFLS<S% ,6,G$+F!
M)L9N+-I=_LHIUL#_*4[E,VV=RJ^.YA<-LJ$M5T*/%MMC $W=Q(X1)T]73.5X
M';@9LA>;Y+%J"+CM,!NQ!9:"'^5M.K\(!F)O51W)%%2T#3&VM7X(D[G+XQO[
M9G9VT[AQE$&[NP<5&XYM%CJ(#YQ#M/ L@W+<A5&'07S]\3],,<Q 4N=<EJ3F
M%[&<$X/&2/N$77M=,L5?),C:.@QP:PX#3(#U EB^JHAL14VM'FG:Q)E(%:)?
MJ4E%!SHG=I!JH![KRWZGGZI76GJ8KA>BGTL]H,*["R$.Y_.-QE>;8IQT_T'L
M:JCL0H)A$11X]-/'9]8?!N@9.KA^/*;KIB)/UTWHK%L>VD.9QOG\CF0O3FYC
MLO$437__=HT@MZG^7"</;*?C7'<0W?3#F!\W>OV*O.JZ/-I<Y:P/O*6B8\S8
MDY)),K,55[OYQUN]>?MD41I>:(_JGH!%Z_[F8 \&P.+PUKMV>N75ZV=L^?FT
M<,7VEG^L6L]:,^KRUA!!#+NA0G4CLZA K"BB:)P7U:$HL%M4U<OB4?K+-D#^
MWH?:I'8M.(!QSMWWV%QY^C1%$U)-(^/W2IHB_LL\>2 "G>B,1"#HJ$45!C!5
M@ %J)K\3:,UE3U=L78J8(GH=SO49L,]FLX\D&@QHV&2J+,ERDPM2N!_/SSBA
M^;T/ZEGTJ"Q5^F3O-B(6_JB<Z'@)0$R,POCX\?;(1'U+J%*<VJNLI\G_NST[
MWZ-]=_V7YO2?_A)>[>&5D@UGT7V)9QQ',I#P]"W;/>52(6MZD=@ .-.NB,G"
M)!@@;?;B!,W%QX,%U+75G(#J;NB$LJ:4_?Z1[':X\RAJB^091':50:=3,\>;
M[O"A2Y5[<4,@#S?H!.6/Y&9;P+CCU>R=9_5M?WV=,XNHIBU77WD/EQ!:_LLH
M%;KE^R.!:<_.>XJP(&/F["J65S.$O]R]TT8:\=AX,!UK-%GY => %;@K[)+H
MD^% H&X4VBE#H ;W7S1$XF2=Q9#\Y)0X.;&6/&R*();N96TA/Y$\U?S^ J5"
M@]9@.6;'B:^1WMO8/5#W(AG>Q7D=6<NY,#?@$BN0-8-[UA!H[XTK^K'<BX2$
MLJ%L:DG2W?YF#J>?#:O90(B ^]<5S72MN@>1+%;&>B7& 7'N1??[FJ\[ 7^^
M42D^\TR=@8%'Z"J*$\><X-R&^CBSO"1IYB=,O=PPAI4EQ 2NVBQ4+Y!4 S":
M4QX"20W%",_B%X,3C81PA!6,E,F5_C9S? @V1W51<U(?D[Y+:Y<18!;PZ!K(
M<<^U36D*:<MQ-T.<2[Z[L')#2D06I5J>)FL/N1(+D-^><6L&-M*1R,5S=_A8
M3RU"BO/S9X?9HAK\!'(-5SN]7R79$HXT>7\>C$>R,,+](F>/K[%@DV:2[NGL
M:6GFY.3LXLH;GXWY>M1;[+[L2GWX,21>ZJ6N..83NF;U1?>JM!Y(=GM'>7D(
M@I/)C"@XN*TG3O8@.C-:_CG"9H.@\!^]N@8ZID5Q-Z(USBM.W428*RAV\KG6
MJZX%C^YF$_<?[--T;S3UEC(D;$QKO,V'.H3Z5C/LC@GN\Q]"XJ4?B96%Y6Y4
MYS]"1Y?J_RR]&K86[)]+PXHHR*![I)\WS!!Q7*NQ)^?ZN45M8@<<D1I2E?%=
M:F!/BB$LC*-A'+<J!74IY8#&@1]@@(Y\&(",F&>>EV-AP=!VUGE1OY."Z!R#
MWCF*)=9,V]T!66$N1P]B++YZ3+#C-XU8^2(!V9KJ,M Z)M<6<Y<QN@PLX55O
MO?>*#U33U:KK&B,7?1MH,TVOG46_\-RL4ZF@IXJ$IN/8"A,EY;P;M]4ANHFO
M&D*)P^Q?ON:MS+5U*JLHGR7:4Y.$."IBKIN3C(V_1)##VG>9[6N)G8]L1OF2
M?[I&]=<3JAR&=QW4ZIE)'O$_:),_P0<FJ+YC4@&'?CQ813WK2W3A8*L582JD
M]E!EPVN7<HWMJC_BA.(9(T.###RA2(QW,V5B'[K5.-@JP16*YIZ)+&W+5Z/8
M!#O#UW%)R3W" 6$%MCRJ_%E%2TL*GUUYW@<J_4P<J]2\GT(.<S,KR]"S36Y?
MI#]Y5(@BY8ER?W V<-/8]>\:*"D^\"!KK5QP)Y=WS%XF'TI%P(@)>Y5E:0XL
M7.BWM827="+IDB'I*C[J*"-0]P1B=>&@T$0%S9;8IO&GYLG1^SA$$46P.CJC
M(6'X?V"Y)C#^\XJC;(,:&Y@"="\Y($KA*>Y/I?7K\<%?.P?;T$0N(GY%26#*
M4RL.;]!&^ 6?_Y(=,^F$\5(.^$I9VM^TDKM63C=)8C;BB/_*@JS1RDD+:U)2
MRM+6MCQ+;]Y?2R:&(VQR>/0NKYBO$0K(?HT/9G6*DS0U)'A?D:.^B?_67 M(
M9BSA,_]PUA:4;^2?ISKQ!US8)SJ0H]:]#S2(]+M8W!B,)%YD2"DQ7EHQF3=<
M-C*DZ*8/1Y=US<1VE%'U-[,M,1 #7]?J\I_>YB4A_)V^2?-_S&W%\<Z@(2*J
M!0=$=36X0;2,(['*F7;^IN\FW>\T* U5OQ[C[(A._];\XQ,YF9O%6^E[R,JJ
MUQ?;94(5;H!R!:1_?+WBJ(.#82TT(-Y(6D;6%E0 '&<C P<3.^<LYVJ-3KWT
MF\B-L36Y1:>CI4;;)SJV&3\@<H9D/?DFA2-0"PW<CN@EOI_<G<F;L?A5[R#%
M%=S()%"\_1F$K[M?\'?.'KV?XG0G]Y?:[4)U8C_?'MU'+\22Q794$= ==P/[
M( 5I__IZPBNDSF)M>R,F8S,AQW-").L1GVTKC,A)E%2TM$CWL_W[#_9K,16=
MF1:ZC6>/=2,['YF"X0[S8;?[JGWY[=D9@OL"WS6U:DADFF.*6=XB>V&&-2:X
M00BW*U#6/P!"E9Y[D";TXV"6Z*;08X7S>Z!GEN;]2PJP_JKFN<;$5IRQ_NK[
M++ZX:^CZ(U.OFT!HC/0!;3PWDJ//=<H+OZN>N._&&+ZW MV)[1,)XW1,V$5%
MH+:Z5#%:]D? 6T#!RQBY_:3 _C62*?]?,V__]PRA'P:PX;PGKHU]>'!ZAB]=
M\G)=WX[K;E</&K$TBJV76.V?!0>,FUYPVE)?WZP](+G7F6**DLTF7V3 +WE'
MZV6,S5$;'$=-V_0=@V^$EIT$<H7:PW'O@-)-9S$9GOG+*_3OI2W,FYAW &H8
MVY0K[2PEY\10)<8@\2H88']*^6X2<,X8U+'/@0T-HY38Y'Q*5GWE_Y=L*BS-
MG A0?M-L8G,@*GTN.]?=QNZ$/51@;#2TPRH[N^<J_X>[F)ARC'3$LO,\3;#R
MA'=%M]LG.C/_!\YBY>A%5=],WRO4 :'R%4E"&,#6D+);L![1_[W*AVDZ!0E;
M)4 'A:$CM3J^5JG;L57;2-\.Q[.]6QO177+3:<3NV4U!GI&M<&2)18S52@/<
M3ZI76$(50]HP0)S,Z?/G1!A DF]'0.+"E2CK^A!T):U;9M=^@=(* U3@@?89
MJLI(2F1Z'1,Y,&M/_+;.CI3.**&)GHS?.#9##ZQ[)$\,1 LGYGUW6_,Z%CF#
MKLJ 0Z=HPPF2S*BBN1[QDLH_7;SZ#B]C@\1QQD5E-IZE_$V5(T_T3NKHA#Y*
M'2-3D%V+M*,O'&1BSEQ58B\4Y#36IWR25>4FZ =E$[8QV/[N.[WB*:#$KQ92
MRHJ2\CWZ\22QT?QL,CD-?3AD"^DOAE.E-M+5W<@B/\AD&6><X3U;7RJY!&]W
MN'WDB<WY QP3Q_%J[W[ #JZX>M:Y(4<?X#!1( (E_<1!ILHW)SGJE3LK1.4H
M/"^L1V0G2O4P>H?289YBCYUM=C]9(LNLI&18Z=SGL&0\HB01G;48W\,[AKYF
M;$3*/T(FKO-&$$T)Z43A*":IJL)/HV[\R5@@+'_BY,21B(^+W+6UP$--"JF_
MC>=8+PM JWU64<2$X+KZ,>OC-RA#634K=(KZ+;)# ]W1MMJ&:J9ZW>^OWQLU
MVW:CZ_ML>H]'TXOOG-3J9N)"0D?$/9,B-GPP*'" AET@O,0><;J&<3Y,VBW%
MZ5R-(0)P\V>*."\20:%;PN%:.QB@MF$9;LFAP=\O$A_ZP0P&.%IZ20.U@RF@
MS(TCFD;;RWC(I+U+>' *7WLWX4;>:JX6(:!(.UCJ)AXF)JOZP9:7.F*H0N\(
MK8ERVZ?N1\CVU&7C=F<G>I]K)E?D;N63?BEP#>=:!>4N$AMC7N_$E#<W@F'1
M^3:=9-1UK@BL?O?N3* G"^\Y$VJX/ZQ2?6B>\L,[:$_"I-:7J=0!4JIP#0.$
M8GGLY.%O8$="#+-P#YV-;6]O^Z ;RG-1O<E+-BX(Y_W9!\:<W;Y@-!")5Z88
MIU)#;9."ZJ)E\M:P/O:/E5?B)BY Y/7",C/S4N"#^\RRNHG12G$HL: MRMI/
MK+O")ZY(I5ABKQL20_MJ4EQR,9*6+]2CI>7:>U/OE:GB[S.H<L[=R74;?YV=
MAIVZ5]F!0'QM'E$4%&8?Y!K[@* NJ,24J&Z>B<FB'+TND8W!YJ01LC*\SRTR
M<MIE>U ;W40+5Y'=@TZ].U$&B'+"@QC9<9T PWH:Q^LV_XS(W8G$:\WT5W2B
M0C+J!+4C0@UE]Q7BHU6AV\?&)+!CZV#44DW;[DY17^B,VP'#I!][L8E1=W(:
MT^AV!+(L&W&[J#G$'8IR#DZ)OHK@=#!+6)6WN-@-E4X(*^X\0:G@7$=C.HO)
M7\<<\9&4>&\0M,Y)U$:+  U(O.=CJ5W_/JTSBZ*HJ^N;V2U#H$O:H"Y# /C_
MV> RRO:%=5HQG.WJ<%;ER!UEDEP(K@; B-KOM=3@BSL0?A7D9JR4$_% V!$4
M9AGJT]5_?=U5,F\BBG=1VZ:2>'VO[IU]8!!:X%"\,O\"0W6BJ1DN$^O;'Y^!
MLI%"6<[ZI"/9!ZI@CNI9'$H%7;OEI/N./JZLG%[,_]B;H4#\S[VTM39YJ2^4
M*U1+R0R!S*H$(VMH+W)X//VMWS8K![ZQ.9 76WS4#CS!%(XDM_?@N<I 5QK_
MF(#)TD<NG^]P4L4!)]@'E(ID<FC5LW==S ILX2PW25]ZQIL%)KA,.K#H/6Z1
M/@&MT,F5# FKZ^LB6;55OJ$Q::,?!.HP%>XPE,^7QTLK3/".H"T<7S4S.;SV
M6/V-MT[4Q_.@"?KE5GG<?ISU2_*YH-YIT>/I[N5ZBPCS7B1E:]? *+1SLKVN
MO2Z@$_LF>:7==NERBZ0OX*<:+R43$+1$VX5]3-L<,%6_U\<5]2P()F/Z2^5U
MS?@1;[0ZWID<O@B<W@& =U0#&[+R5N66CH.H0.Z\G4.)@6WR[&U4IJ$2@9F"
M$5R,R&<)ENG<+%$P,"0^A#I(5(BH\1E"%>^8%G/)F)D=U' M.,IS&EE?M$_V
M(='3U=VLJ-/)V<U5-+X"(XS^\B[10$MMA[$9G0Y9]TPW]'JIRKW$YF:.F'*'
M13O]4);G;C:C,-7<O.@;NI+\QUHT+6DR)".J%NTF)I=$'7NV>B9;88;4',/6
MMA1SS'R.I05:(_CY/I"B8])+Z,F&FXR#B;Y:8=)$.#<\9(W6VORE@.)>1E8H
M@;H,X/^^J:T82ULZ3BT+RJ><"NVW[7YAR*:(8<7R71@+!YM%GLNT%%-([VP/
MO'7I;,9*!0-U5@ 2QP+08!MXN__T2)G'8GI;15;$/90'__,D;XYBQORZ9[&;
M[V-S<W/#"=5*,ET(+D*C-QUV9EA,4H3'^,@FI1 EP=#-;S2A#F;(6,#]U8-.
M6*B%@A,D3)UCR_DRE4*0WL*OJ$(L5A&P_Y\?&+)DYGC-QK'2&-4X#/UD>I@9
M!/95,^NJ#?I\Y<:TUN'^3A94L_^(Z6@U5BJ?AGA[GNL=GX>#I9@@<C[*RJER
M[KMFYY'FUV2??#%:WIMQ!D 0Q7#-4CQ(DBH& )#?B6A2K9(RQ.A&D,G7[#22
MLF9B8=L5,^1^SYB/L,F-S/X/5TG9)KKQ?[.6TF+4<'4@S#:B9^$?&B2MUT[0
M:&/>6L2[#$NT!G55-OZ^*;QKU^0>Y;VB[\7!?DO=M];5/G<4N7(&C>,=PK$@
M;4K'YO&],<U^*>HN"PS<CYIX,_*H(^YO3$LF<\C<IO?*?#FG"]/X6[>)$GL2
M_;-_;CA,#5&M< <TEDX ?>I2W&_\/_#]Q%*0Z2:$7L1W8]LC&%NJS;CM3-L/
M>Z-S/TU(W!H^84L;;C)K?VXE-5!R'/L- V3NJGUWL@6CZ]QR&;]+[-C8<DXR
M6RVHD)9L!2J=TBKGZV)HQ\$ B'E/SK$5K)4%7WO["946WUC7&*>M(!DX_BPG
M4%<W6NZV15!U9I'!VW)M[" 5/#*VLJC50$@S>(E.T#L<R#2J*V6-XE=;@FI9
MP]V/PG%BU2QV&]<@K,,44]S:8PW29?U<>"/0$'NK)O6Q]?V<\V*%N@*KR'*X
MPN_:F7+H66XD"_K_[JT%?-+K"L.^M.C=%">;&T].W/AY_K<N@%O"Z:I%'B/5
M'FZ=T=YT1JP]A.?%S>$W3!OYZW]@@/5T-85I7>8[D.'T:46ATK>##!W1P(L8
MURMP-]\0:&AGX.$M#("VU4(LV.3-B%L;8$'S)R!OMZ*MS>E(\(=O=7K3Y:5(
M(_.05L0$@U>GP&WJ31PHY-7JBWKE(C^' 1SD8 !\#4EHOE;2&H:,B?8I#_$'
M@?F!YM!S"+OX)*6U1O@'"VY"-T:["M^2$QDE3R!_BC7[<!JTC!D!I9K7:P4&
M@)-4RF=JF76"$'6S62P:QB_HGL9?.SV_@O"AT[=7>U&+1I4@DXB55?/9-?F(
MR0CV<:O7ET@K<A;KE^=I3"/$4! ;64_[M;(&3#*$ L"B-53-^319XVA#D_9M
MG45R""SE/U,ZQQC76NW[H>7^K$6HP@E*BV+VKC/JJBOS[@3JQH62_V^33GI0
M)I<TI,Y7'Y>1WFY]%JN*-R24UOOEH/3!UY()'7<(C^N$:]0& 8-5()+7_[ Y
MK_:^'L<##UM&0I!Q^N$3Q.T>0L2#7;/T_(/K(FM8Y,>)PP+)%L6G8L(T;#S;
MLT;K)?CR1"22E5  %YWH%WG2:W &6V@5HMLE/0PPOOB%NNT6ZM4- X"P[]3_
MM:J=Q@1?][AVOX7]_*)^9?^YIF.3C;9T"MJ+DK@]@P%"9%PY"NNJ^2"0FE'B
M;=WO(8S+6Y&MRLDVZQ'Y25VY%PK96#JCHX>WFI'N&F9U;1E9MPW&2P./#??A
M?[QZC<^>:-GEM-SJ;<P3C"[ 84)"HE CYP.U?8%CLD',\C:MA^AQ;Q= <)B(
M)W9 EL%!\;]57.7/3EJQLA..$%1)5GA' %91-G4J88[:RF*OKRU?^3X5LUI>
MR0E*(=A?AG5AR16[.^W/*LU9T9(6RJE4K2.A"V*V!V6_M+[Z80"?#N9S$CD\
MH7Q<; I"8N=V K!DDK?,@5@I2!6"*(VV3G38WRB^6ZF9_BUQ9S[-3I%9*:#0
M)(B_A.];&Q@G9FO8GB4*T-H\6T"@E?PWTO_.U\OQ)C_)39:05"UOQQTP/[L^
MH,"G6AL.?+:S?H/2*!X4N6M+$1"!.\-WE__=VA4RG'JSC3T<.]B*U[#VJ@=S
MY<_*!"[RI@(T:4$W-;'W65O+]W<=]+*,# ;P':PS0'I]H"3C4_2Z[VAV5;:$
M,^7B?I#!R,.Y\_D=WXR^T;=F)@[DI]IW\T^LZ><X363E[*R<"Y&X6,09RXZ(
M4%+JV *CLV[C6A[Z&+ MN<.WG<Y1!4??P#C6KBX5C>$R=24% U/Q=N\%=5>S
M+8Y%2B1G& #7;41:\VQ=">?"VZ5, 3XJ54[R'@_3@\"<[[3+$4_#& OM^XR\
MH%BJG&Q=0_5$^7'%[F4%;82.@D3+NW()TKMZ*&[XGQYG5,LTY>K,KV\>]\1;
MSHVU+8\,,&-:,7!-9?7-4BV-G >.K\10BI"I?$>,\35XMNW2:SB71E/X)\9P
M&80(A!.XXF1E\(RZ">+EZ(LK60FC]=8;^SZ+>1'2P,D".BJ(^WPX*HN]\J0:
M?L7W*# (,&V^0G9VO4:@#A690"E1')EW9]@@+W!MZN"M_9J</1Y18:847&^K
MIGRH;\Y^B?,W>!JL0XSQ]=(W/;) &!7LB&;!V7Y5M&<36;<U#X^Z/L+:HRS,
M^JO[H_@N#GQ B?;A%XH,>O>_F * J_;O#@J:GTOUJIC3FFAA-:-\7K*K+Q$%
MMY.PH0Y0?^$[J+P%X9HX;:8;ZTRNI&NU*N6\N:I>LC?R5CLF,04[[V*R\2[I
M+GUX2)O0+0;OJIT!1Q^2<_:\?;7@J+H3Z^DJ6ST(.^\4+[KZYM1G?IT;DJCT
M-"+6(V=*H!WG-H4"F4YQ.^J]>G*68K]';3\XF_(9I&LT12=,.9:Y3Y\&)T%\
M3B]X/\( &LQ6J0['VQFC1+P<JK](B\$<M)F]'#1)]!%S/O+D.V;S>Y.-*Y+7
M0^U([^NI+>NG*RSE"] O&?H221"M2S>;;:8<6)OM(=PN1K.09TP8 $MJW.;&
MIAO+#&M-YS[V$NSS=1G)#^[+*T#)475,%4_Q*4-7A=P+,+)D&,4^ZSWH6E%O
M<F5V%^=&_N'^-^ZY-,5Y4FJ=@!RUBHN@>^,A+Y+^V#XW23*5\#J"RJFH0IM@
M $GC'\+.)?SYE3F[N^Z'ZH4_*2'"JG>&BV'/".R@T\(7CI?8<#JDOL*H@P':
MTI^ H\Y*D5=M)7+WJL2/TOA/_;DP0-?J-&B?% @#^ O<3<  Z)X:,$"V0^7N
MVI:)>Z21^K6BQ"#G,87J)50N%]2U/ T#[%/:WM??3;YLS$CL4UO# +&@:.]]
M@N-:?XW8BV^/<OA/,$#\/O59/9_J _("#+"UMJ4HSGX8!C5B@P'.3\\KQ9>4
MZA=C2]6A:MXQC/<P -W^"A941?-]35L2(957=Y+)UUI6_"X*+SDE&* "ONZH
MIS@A7?ZAE-NEB.@A7]<779\3[_AX"QC>1R0EA/"4J'9 ?8%-?3UK^DPRXU/\
MGS9>!:=%72S97JJ@2U73;I.FH]YE3H\P')_6#CA:<"7[)>Y05&H(BO6W"AA^
M2F-?JG@>3$_YE"Q$$07WN[A%F&OC41P'+_4UEA;%S\".;$Q%IF*.4_8_[&^:
MFE-?UT<HB<9\)E"#7S&6M 2^&1DN(^"JV/,0A=.?=1XK&4ZYK>)5*UEQL-M*
M>B'K_MM6Y+-G((XI?YE'6O03'GN+G'_2-^;UFV33FU;BNX"B;PE @8H/<UI4
MWTAOL]&I*+33^C5D276F'0.1H4UDL[4>7#^VA1+HJF(K<YYD68D[*R9M/:/Z
MV=S)?V8]V@!MH"=/5).%$K@PP*Q$ 4#O_VE2KE2X-\C.QVC65B!ATAQ+U^.M
MY,%:@4GN]]S\GR;#MK4G40[([Q/EE +9)Y=YR[%TQ +?/:F"[2=D5(2=BPA1
M6.F%%'Y?*GU^$4N_6>SXF8OU6YL3&G>,L-3#I,2_/[*^KZZ)7!77X>M3U?#-
MZIF)9/&F&QEQD/,$(A%H:^'! #8#RHUA0VIT_=*)B6DY1,4CA#K']-[LD8H3
M(=^) /X;09WY'1"%0$4F,>8OZMKV$S,G]8.3"%PL*(]Y"($ZQ>\8D-AU6[WS
M:E*/9PPL-=2X.AB*I!2CKOMY*\%?#)AR?R 1J+_['PTS401+4*QLY$G&J4S_
MSE/EFV%+S,FU=6J:WAR"DS;UEUX?Z>>U'MU4KU9W2FK92TC9AC<TG;>*UW;P
MO3/$^=C(.]CH;"I*>ZE^%RA9/*URGRI,^6?RH#[%QS)A=> ,FV-5];O@*MS8
M1MH11&0(4T+1EH^V:O&7GK%S_*5?\V<1U\@]/U+'7Z9KP@-_:I@^@R>$*+#M
MCACJ0W<Y6;P2]'XC XOI:+8I=$=<-:*^FY\5@2144WPIEVMLZUO;3*=8C.0(
M"Y(S<CH+6]+\YWWU,=X'.E%-_19_9E$J8^)=H5.JJD/Z6-]8'XU \?/5%@,D
M9^P[*]F>\DR1OU'KA0(%F"+-SQ T7>T:=&UF$B)TV<GP]&QZG]K+-*WZ(+__
M4@#H!21]Z#?X>@,%:O>IQ9,CQ'6XC^5L712+"I7U5]@.N=%=Y-_G9>+/"E!P
MSWHDWR2;L#74H#O36?13]"I$FSINAC0Y+BW6AM4:E8J8FAX][ MIV&E$)1<?
M'FZ##OLG2V8:8("9V (?05#X=F;W_O^$;R^IWR\-9?T'DIF^T_WBM?<O8+L'
MG5/G;%M+=,96[H]Z$GQJPL:Z4U([Q\C9HI*)DVAI<KZ(<D<_!#: ,.]D)Y4<
MN.633MZ\5M]V;=,9@WCH]$WEWWL&R*6'#+%^HMVK/AEC[A72@GA .<ZBZ])+
M]'NMX@WZN:L^7>)Q8]M/\P<0UY-P&_=UMTT92..C=O_<K0PN4\PK:I9CI6P6
M )"]U)_T4:4X.S&OO"H.UZ2K@C$38NSF;HPKI).'$!8+-E/>"^Y<4_>,B35,
M<CA KU0"ES%F>%"-SDVJ'=C'=S(4XV]5"UQ]H+$V<7S#;*^$76<CO9(8K5CN
M2#6_?3?^X\,9?'=6F H#&"'9S\J%](ER%6$_?&(U:;%K[TDI$Z_!!)/X< ZP
MQ"2@3'5(7+X@&V;IM=84:&L -*<@<<6CGXXQZY>7M^)]3OKI8G1_)C*9ZDO,
M=YM5N1N^[+I+1/BW./*2'\7.>Z4W^5$WEG:9\6.9GJJC2AXB'5-%A3U#'7:;
M,IG60S''.'^@L00^GTJ^(R/V]+CA3U@Q5H[K1$M)D!-$0W8U(NP=&8LX,6]K
M"96O'4CWS_@>+AEWDZ9^]#QS/'T9]69F&,K:I#348,).R[!F;4V+8T47SQMT
MK24FG.G\;1CU-^O/1X'6MZ\0$R\NQ\[J6Q%!53! S,NO^[T_**1UG^XYZ\F]
M%088NR= F3K3ZTOT/"TV>F&:;D-/FB#TF#*:9R\HY-OZVCWB"FCNN1\:Q=?\
MF0?!O+CS*<86(SGRG0O<=<$_7O3^/[!<T[L'IUOD2S[V]^WG5VLGV+LV\ :A
MH%;L9S=H:&&Q]>,X##"GNF_[EB%[0O) &84=>@4#7+\PWVO-:2(8P ?TL ^*
M*]F')Z^\NTEYGM*H7"$DG'OR58(>E.B>1+YC)U!7_I__ER7X]I9+>2#->+A4
M6)C[(]0>$V"<*.)%NJU+?(X"RM5S[!R.SAILXBE9P;X/,@&MJ;]PI?: UP74
M&UP>=)#B_$GVL4_<Z\9N8SC12W_I87H)^TG+^DX7*N$H<10'=9^>(]_P+2&Z
MV'I^M=/N)FQ__7*=3;%U Q*[U)[WC#  H2D[FLN.Z6ZLHH8NGQD,H,6B.!JF
M[HP# T2XPP#/CZ90EJSG?-^#VRWH_(NS1Q/!;P9CO!6,?E=-5!@:S 9TEZH4
MA:4:R$32.RQ]I_CJ0Z6B/YV\]LX):]'0T$B^VNZU4N7H@J7#\%ZCT&A [3./
M&GKY(?B&=2OY6^ K^7N1RP^S[N&YB<H)2H;[$YQ:-:)(<LMF<WP':A\6L\$:
MFBDL_L2JG#T3,V[!,Y:_/!L;@A>,OH7@U"$&P_/7%^_6OQ2^.N))H7Q> XCZ
M=O14P095KR#E%4@C#7$RO.:%"VHY3]'NX[NMJ;VL;FSJ,H23[_[SW.B_P8H)
M#& "MY5U3\DG\7#TC.2Y P/T!(3%_X0!7HFWYXDA=Z&^Z0]D,]='BZI7M>(;
MN=.9.6WQ=??V_?R']]8*@YBE7Q#]N'-LP]@S<(/+BZ53[Z(S:Q\=_T-;0_TX
MF)*-73N?O:$TMF7[6KRPH4!W8;IX]N3H7$Q8S],DA.3W?OE:9HA3.-?"81L%
MC]0Q?5W_L$QLA7^O-YN JUQT]=L'LNM/?+'5$2=7%^'=;SRV Z\(=Z$,7BG&
MJ 14:C;5\R>NQGH8IFRMWV>C-D8NVFVQG116P+W?])LUL\0B;LL^ Z=Z&Q);
MPSOHKRH"?I+,U6X0C]^+V_:N\#LJE*F*G'A_<(WCZ66_J;A5Z\<*D#DZ 1)P
M\?Y)"Q@5"V^Y5CGQW0OYX,=>F/4"/9^J6EZ&#&UA^M^8-#>J#:5OU;_U<EKO
MG@B0U"Y_9ZB&?+L& TCQ6>6L)M>!Z4>K^M(S5F+@HQ(3@#R?V)6E%BW'%CG$
M1U"D3.P#?V$I[,6.-L 7&2NYVQ3$2M6]+C]^HS/2>?@F#N0&0LLJ^<.RFN/)
M&,E!I*">*!L=).FX+]ED-A#??XNL;?*L:J:$R.S$MA\8GC2\QN7Z^RA6,G/U
MJN.7I- ;?U^!5L3/ :83K?O]IBES-;[C<L@[S^2K@0A8[9R55K?9,>V<^ZLP
MP-Y3),KV4UMK^MI?PE22\J\>?T,-''C]/)IE#]I>(7%E!KXA_QZK'MES5GH\
MN7O;_.-%M^[6,V/$(#2M,ER_ RDFY-63.^12A2,?:*C!*:09=*0=9#[8M/1A
M_-@2J]*?+AFP_9">7L5^TS"[F+B0;Z.O)JYW/6)N%R"BPG$QN6ACOB+BUX/_
M6+!/\F@=.S99==T<\7K.;US!4OMHV4?#U);?H.?&L]HM^$20^HBX8O8&.6NT
M+G=]T76^K\6:8%I >.WXX,63*%!JOCA-ACR5%)X/7(**2]/SRDAFA#L;KO#O
MFE!1!XW/>OYP138"NKH&;S*&AR>6"?J@6.?C7,C3 "#1CJ@(.,S.F*C)=)O#
MZU'5ZA8RFNWUU0H0;D[S; NJWX,!,KF@5K\<.>BJ:Y,WK7N<F3W,7X)<84>.
M*84I.RA2RX,4[Q+9LM%<YANDF+^CF%+K[.20=&UI[.JRIIE+1?N]ABD&;RAZ
MD&3;NO!?YVL08YA2#^M-R[^LXGI[GTZAE*F&G3WBIGB4M"08%Y]LW+"@:Y+/
M-!W"?SH"200"C^;3-%R_.1BZFD/QF&MB7PMO"0J.%0(_=5T[L=^NLP:%JL_/
MO4[>0<Q_+1+I/'<_/3O'B1$8>BVWY?$6TYPL,?H9G-QVTER992JME>@A(CJA
MST_\7JE:EEY "F@ "9Y.ZM? POJK6*W^&Y2C)O0?6HZ=/DTR]V$J9R0-1GEG
M?+NGJAW/EC<5DV5%LLCXSCV*0D>S/L,XB\OWXZKP!4 4$^A8*@0[CN=*MK?&
M=>Q<?-]/3*JORAG&'ZFXZ[(H/!;1_JHW HV9W9/Q.,, 8F';-C>552;=PVL#
MUWETL[_^8^=(OZE(;$[!L>G'A_;4ILAB0^13RKZ,^",]TA?-E-E]P6NU?KZ'
M/3#QWQLTLMS'<\/#F45ZT<"-N-21I1TZ#]^D?)()U0D90 ZE]+VZ+?/^1[\5
M!<;R]\4EK"7D]P7EZ>@I"D\EAB(O103X-8>%M:!@\XLFUOHW=-114I[PR@E.
M@3-[)'IO&<--G4Q'<D4Z M3YT+'*YJ(>_HB"F'0?<+\E7@L7NZGBJ'?-3K7:
MMZNEX$BAK(VB:\H>3A[>N6T=>5ERXLC1(EGRVY5UX#[*,O8C%NN$J(W$IO7&
MFBKD-PR0:]+2YU7D+ZU'](<N*1+1=0#Y5<.E/+.9MQ/P^CZC@=A:??'&M/Q#
M95?[^>/+/3(*NZPH;#1%_<I1A.&R*O^;<A186AD?&B__QS=YXV_VBL&^ELJO
M5*1&$UK=86?;,IGY?BVN%$#.]8QINV)@:&I82_Q93I0QD2*25'4=R-VQU=/T
M]99_'/>^ >SQ\7UD.7KISR_>%,XF(=3!HV6WI]OM="+=15#F5I',.";PW=^Z
MU765+ VU1>0331+]Q::6/SBC IGF@>*F(E3BVOS N%:<P=QT,Z#\K^E,JW^;
MNC1!VA(<7A5M#W9/V% +$"0\A6SZ9-0O0ME;] 8>#:H>F#"?66N0.709M[U3
M?PIMH=PFB,EVD;#SWCE\)*>-@&=ZT)"TQ&Q=;[0?'"RRH<MA!+]I;M3P@7=-
MRRFM*QX8,N-E91!<Q6(=W)W=:RM96C$D2PMYE+,[#E$/^LUW.1=)]:@Q1Y?&
MP&J_?2*T@7(4>7WOALKAT+U\B)_^M=%B;!"[:+*EN>=,P;S8/US6T_$0'-=Z
MH0)46,W7@DR/MFC9J'0NY%\SWVQ^U]"(?)@.<.F/_%P(%G4O?9UYNZ%Z3^BV
M]K#.:E75POQ"$!7_((AAG?]$$'*,>0<W<P85X&*COLF5;_>O]4F7=F30(>]&
M 12SRO477E\-OPF-LMD[YD> 1Q4RDJ :,, ?K.Y&BJM>-]VWA@?$+@/NYC;U
M":DZC#(TO[]@3<IZ=VPFFV+TU'%]\S8\CB=R$H,!=DJLV#K/YQ/O/,I'HF*\
M88!-@SSWYS_6"V&R5T7,]DW")#M1QPG<)$D2<T>K/[H%T"2:\C/)VZFWE-_G
MNS_]31R@N^3;/$H0U<BI) 55>Z+O.$#.M+_&%P;(NF"B"WJ1!?7M+P4*[5=A
MJ-@_F(."^LP)= F5 3C=.7@<.)TZO]R#_A'@K&Y8*&\W#&"<#P.,1]M-DKPH
M19UVR0^%?:YXU&K,TP!=_)+1<6 LS7'4"\$<ET6>8]9T%Y.JKGR6$-45I[/P
M^'@\.L5T]W5<%=ZT^]*!Q-[3I/^L_)GV",/AY]ERY5P#.)K?W0VHX*V##+BE
M['4UB*Y-<S@/QP.(Y#FI+T;RM#=U$RJ.I5(2G))UTJTH&A!&A5T*P7$-E/KP
M%V&!+1(,6;I#+Z(<03-;10=1&JC'U^CPB5\TM%AIJ6?+;&;Y%U4B@D;TC>=K
M$P@?5[/BH)#ZZN#/%R&<'L9LM89'3IJ!C8\R3ZV^]V1D(0EV_,1$KH2O0U>&
MQM_NRVVI[=^@YA],+ 8U7C;IPV>4[U7" *5%C^_??10$^&H\E]MSO42FB='9
MR/-A6M$K?#**9AJBVY99.3?@%[>W5]=,^C 73CNQ"XE.\8ZO5X+V^*-C^\$
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MC7*86BX'P@">N/9Q@&.CS)*RY8/9&A-N'L!G5*<#8_:=[;>RRE&"%>RSJD3
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M7&GH.E0[\)^==7K^&WMO'10'T^6-#H% 2)#@#B&XNVM"<"=!!PG!F0P$'W2
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M]SV*;0N)]N9V3TS\U\GS# _A++^*LVH#&7[AD2LM\_A,(^=W I3_B=A(@5W
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MIW86WY<4;M+S X1ZE]?#F-?A\XOHQZDI-KRO4*8X#L6'K7)VBJN)(L[I@D(
M:;AR3VPS?O4@=#/[>/QC55E5XNX&G*+\O=]".3.>M] 3O87<*DT$0QPZ2,$Q
M\6/;\8:.U7;0HBAZ@](RE\]"S[P)YSJ;WXPYW8LHG9C'F]@2YFVR*#:@PS_@
MKKT5P$!"N:0)RLV$+'524I]@'L0EI>G>?U>96!PZW 5&B4O.]&'8_S&-'$\K
MJ(^]&.[@P(78+ZF,\8D82"BV*+\__"LH M)$3-3FRVG/PF++CQ?;#CL]U"\;
MY(L';NXG1J_SM >D:C!X)JCT  ,!W8:L4S9.,XX<V#/"VU?1[VBOM)4*&56"
MO#&.:&BW *::)B<\'=JIN)3LXXU"X/N EVBUP*2,BF8L6BYOKDIR;_G>;H7)
M8\H45PNK-6H'"U$VNV*#_A=1W#D?F&O-AM7<23O'*T/E)2S0>6O&#^/5^/$8
M9I64Z.8-?I+9)8^@2:]BDQFTYEDF:@6 S:_@E9@.Y/4_NA@U.)&Z 7$FJ;Y5
MC7R%H/@Q(ST07+"\OM)),Q&-XWE;9,IH.>!DGG1=5!6%0?;X(/>G!P-[?L8K
M.MV<FL#%S:%O:=BQ7I]ST[OM!A6/^_HNI[4FX;U.EHW,_<1EP9KSM+A0$LDE
M3M52/<#!G53!8,:VB\ EW+,K751!M 'H1+?^11+9^YO0^B5)B?A1ESC;\<%F
M+$,@KR<3[_W[71']68.*?N06Y&]F2/YNJU7-=% ;:!N!P[TWN]?X)D/2I>K%
M@\H1K/\1 "+82!P*S%Z@C[9;@:*#SN3!>7/#+GE+TEP1;^QBU;98'7KAG%R2
ME/?4=GB_VA(XG?T%42X'(8\ 7W:^G?-' !74$C@;[.#BOB7JT% _6(89]&(#
ML T1G]S7W$BE! Z*'W4G$G3%YK%.QPNX5(_?)_\R"QUYCG1CPU %,(-H=WJQ
MC#83[B06UP04K8_RWK[;3"@)FE<*ODK!QP (=:FHL)1/7LR1W"DNZZ(F8+9.
M#(P!]17DHF:(I<QD\]%0*\#G#1?WJ4._OI8\?P1<\G1>VC)>)UW"XFWU;S_2
MCUT@%WBPVYE\T^HC(I+M$_2^3]#&OE^$;#4!](Q((3"M$\*&C&U2BN#>;/T7
M\-W3C:BWV?:H -IRH4N 4_'1<TCZG6;&H(.=Q:7('#"?]3!MJ98VS[7U4(@@
M83GI58,J(63*/5@W/6A+7=9O_7V&)HY/+$/><#9#^U-,>07%#>[7+1Z 7TR4
M!ZJ5G--]>R)7%VE8J__5FN=_R, )W?PE)=%D*1O,]%AWD!4<LA*+CD:EKI_K
MUTR/\-J2'F6[,/":OOVR.87'*8K-%X.;[0TG8\BQ1&[.*.,3Z7U[XA]@73_!
MWRNL E2UK!%;Q'^MV1)@^W%/:>K.924<RS!83%O'=W&]9(V09%9[TO=[I:>=
M) 4!0>K-950BP^6X-7^[TNRF9^$ I>&2_D-L;.:=Y'%)4UX)+&?O]:#SGYB?
MA=3?4.T;O(=7)"G8"(9!E$+'0SYY.; "$.'EU5=D5UG:/+%7GRDRYU=KM4ZJ
MJY?0&S5+I;S"7<WRE3&S=H,D0Q1\[+JP4<XD*6ND[6^@'52O#'>_[7"!XGY;
M8__ \?TV'/:)GS]Z'],*U$P_ZL&#X@ B_:$5S#1'_#7.X:$O)!KQ$C"5\?N\
M%&?[9C/Q)BPI;VY>C]ZC5[.,IMM@ME7??;6"=^FG%^[D!>]XD5.#JTT6W9?W
M)!]^.&M(8B)( 3O;)<Z>'UK7PBMZB]O*Z'^-5R=LF"&@%W--7*>K5:Q5H2+J
M8WA:%0U!(#2IMT.Y&W">:,3GAT](;D%_&DY*_?<=@09?MK1\1<A:$%<16]R/
M@/K:>2B2-J\$CA4E;06HF/*!I5:S6DBJ3R 3N4="79+4\:-9)'7@1F1U!I.Y
MN+=3"=4?H]?%'L;0(KW[@H7LFL9(L$F@CDVU0;HI;=CZ(^ B#[D^H\[DA*:U
MOP!JGN(U?B!N$3NQOW2_@)B#=54Z00FV]3#:*+0_U51&M%F\HFYE?$%"V1C!
M*92&&<1"\^Y$/'C5DBY)=N)MO4[25Q][$NQ;!4F:TP)#DLG5)^HF>ZNH=O*\
M.A,#S!2M]H(ZW-*AE:+Z_(X1.2NC;A"O.Y7XA.#D]U@5A*$>KB/M_WY7.'8>
M=>5\4$3_9-K?0PC">F%@2,SN',#I/;2;6_<2'7E/D@+SXZ3C^62E^X*PK&G8
M(9I/BEN>V9O(ZVF*-5L25R] N.'Q4#9^,-T\3G;'9T%FTY?M:"WJ>P9KG-*L
MW2]1Y=->"E/&4@:DZUAQ]IS*6MA$L+1HO02@W)YH[_4Z<I#VK@[_O GA7V0A
MA'LF^564!<W@.&=P#^T/<'-ZI3 _ NYHX<F<"/3/TQD3:Q-'IOZ[IXS/V/I"
M%U#%]4W(W=30LD?UNS)/\-KT%/LI#NO Y!$#(_+$& ,EM?,O *G<0CO26QU&
M+W04P11#+>8Y&X1R/5_:09YC<BB,XH@TK-2@X;IIWGXQA6[5VL90]J,KSSB:
M*8-,!BI)T/O_\/X<%R\,\UT6Y+O^Y&JJ;+PV)/7#9_[T4/X03\\]FW]-+HF?
M$B6[;UIE4;R]U]M5YI\<,QW[HXX3RU,U<R%Z%I9 \%_]&?"_*E\0+0\?BET>
M6L\> =O5I1(UP9)&LQ6;0-O?*6\J<,(1UW./@/1K6!AHDOW@<W-%ZM@F%RU>
MUVC/CS7[LE9R=]+-MPB3Y6W;-_7A4C]XR11DFP:,8P#$.<YQ?W9E+)%COA]
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M@&]VDN2EWQ5*#PC6^&A10>K>;JE?2MS;X2&7;K#.>RG%:)Z.DA-Y*D'J[.N
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M4>3HYW1A-D0'$:Y3617&XM]8^Z&J0JM7K<'G.ORCSSUH?"]FT@,Y=U=OOWZ
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M!WCP.92H[+$U<KG^+*_?-)+,2B8?01TD^+Z\A-NY.HPQN]M'':8[[A$AR^B
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M<Z8+G%6ZF,M7V?DH9165[%M !'_Y?.&M@3)AC1 U?=A+>T!105<NI,:94X=
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MP\.I-97-TOGA%=L0JU\I(9OYEFW#EX.!DHC@*+AVQ,.&B/"ZN<5&[4KVT6C
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ME;>(3K? '@'$XN$X7\:3[M1#$#X,B,;<VYZN/(][B0*2%U#D>GT)N!CF\\"
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MCS,S$T3BRA*IO%]?^#QYPD6]+UN!B:.^(&.&"(Z7"HZXS V^=1Q[W^+PII.
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M   2    :6UG,3@Q,S0P-#4Y7S8N:G!G[+ME6!S=NC;8!/?@+D$"">YN28
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MD4]W4SISVV&P]LF%8M)/[4SJ]%:M57WG)G)! "@IZ=@+@&%_"M2\)_\__A^
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M@O=<G(?D-C)PM\450:O;\?/G]8SBZWL/7!#8!_-FE>]#6A1?K=Z\M6C)P=I
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M@+S*Y@S(*'R^R!JE$?=3R&1;.+4+37AFR@<XY+=ECY"+%J,1NBNX&5+71#:
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M*I&J]^'YP GNX0? D_D[5LS!,>5/<URJFM(T_\=77X#=UE"C&[(ZASO<R =
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M@'%^,.HUU[2Q-2="EF6%93')E]CAVB_Q\<\YZ4:]ZP. QOK]GI#%GPT@S@/
MY@%@3G,NG]O(];-CQ6G9$6/]K9 +:/0QA._S,B\?^W)!#SA?^LH@E&)2F>,'
MZRQ2:#+=)WK-7=;0:7J($Z!&SR 07_'IBVKHL!]0=48_@7AVJOMG+R:E651"
M[#RDJ9QD@Y)<*]PM7<=5X$WDYSI;L_JZ-SS!E,;G6XCQ3S.Z_#$\6_ R:DH$
M1ZB;'H7\IX9*RIVW;^CCM43!3&=YL)F[CO(N!:8/)4AAZ2D4H_;2DM65;D&F
ME]UEXC0[([9I0K;FM_M.KP/D7%C$'6O!,'Q3?;8 ?IF9:]- 2/NQJIG0-[BH
M]_>F2(9HB(N096^1:P?Y>-F2I_?4FDK& D0TNAWO<$ 8]&38S VL(-_JD],'
M?:G7XZT5NCHTATCZF%C1"CY[@N&RY2SV&4!5M%7JMNUPX+@3\F>M;_T(\WQ)
MGH<&R]J?=DIW@:Q0<0H4@IBQ#%B*BKD8\:3KXG.!>:- 3MGU%WWYT[J+,(^$
M'X%5=&*FE$]E).YP*6<I:,*I:>I;:F=C@]&%^LI\I!962&E_!G29H66T"9:0
M._2ZG_$N\!YQB"HJS16\7]:C#WU/F6:<Z[XG_EI>LCP%U2%^2L/#$9E)X,M9
M"$M13BA;7.C)7UYY%7&F'+'^J5J ##N/L*OKKL_$5W"Z[,*!!J;)?PESLF5M
M],S,-2&-G?DB]A:!DUQ6GM@0F[4$TW0/K\/S&'U[X7'R )@O_3N7VRJTZCCI
M0'V?K<\G5[Y=_+.W4^;>;)&ZW@;L)P<%OH&OUW/]"2:/'_D[\'CN$;D$3*.M
M%NW=6(:ZBH=L&L[5,5\(#_LI*!KS_SJ3^YK%A=HC$[@D.M+:X/B3Y9EIV#1]
MQX5M^/J]TC>'WMX"-/P.2PL!,K ::W1R/Q9_SR]XJ:[@+R.*AF9N;,K=Z,:#
M<?TYU> U'^OY$_8AYOURME;>7$]&%0JC/7PC^6(C$7<A'[F/?+"F*MS*%5$7
M2$7#'^BP7B8&<EQI4H/M0CC;CB.=/CA/;??)S"V>LA E3N(@T@6LV4!-GM#C
MC8IJ;OAI=I;SX6V,7&8EQK3@W7@Y^6[L Z">LT[N\+RW:M+56DW1EG2-_F=G
M_.A!OSCA/,^*X)G>Q1Z'U<+YZ%=V&D/DB4.NP5Y54L0KG\C 77ZR8&)T]R7]
MADSR'G@D>/)CMBKONZ+V[T( 5@9_^MX.8HI^X**SEP4GYV&[X_A-VY^56'"^
M1<^F]@8\[$<=G?%VO4]''=NJ<:^4HP =Y7E>L1)]F[BHS"X%:-_[FR%@RM5L
MB@<,;VLH?CFB (G)%]WOHY=N_J76N>ZV"2JNI$18Q.($;)3+*H)2QT"!^M*,
M'X;P7@Q2P9V06KJ9!#Q^DE1\0 )/'3=1=>7(H8AU_6_R1*YGA*1B;0>!,P[/
MLXOU5[&LV(.G2/ Z6TRCJ(=$6?;ZK=L=#A",N9&Z5&T-L87\G;?1NHIN)*4E
M+]HGQ];_Z$>Y'MM.T,/M0[_EV&%U>UMTY-0WCO:2Y!F2@/4S1 7&H9#6 ES2
M,AJ</'A5#3N=$5:UHS[Q>NRO"D&8 7%R;R7NXMK2 9>GA-X!7E\M7[(%A8<
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MN3UQ\^!(".N U5;/W,KX5MWOJ++%'X>4X'U02JR#7U**/X,/J[V7'3',%OH
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M$1NFRTD*(^\%?;:^61E6>CG#96]^'4YFV!YVEGM5[ 9[ *"+]J/.R%IIK!X
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MS:XP=,H+U43]DOY8P 5K#T\#3OT%LI#GL350^N#],4N.?A;Q8VHXRAL2X<D
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M_()H852EE.7)'3*5?NX608#!@&5Y.$K;UU)'G;32L:$.!)W?O9(9_F6C;5F
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M4J1:BNNK'&?$2\%V3F[5%@'EKGV$),KMD'7Z$WKRL#RQH0V,!_KCOD(1#_'
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MGRPW...!R  ;TH P"LCP,=PAF[C(L>U(>-O\=$<8%^* U49 5\TGVG:FS+'
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M-14NFO.@DNB%5=*T+D+P\*H^;A 9-#75C3#?W,(#Q)<+J$TQHN4T7,',4%M
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M/_*-',?R7H4-_P0DE"?,5:<$'U(<-U[10TK''D'H$LS5G]S5HO)XVI&;\$2
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MF3G Q*!3L?X$0)G-"ESD--H%@WUSEBG68]3GV*,YM&9NL9!:01D]'IX,P?
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MPXLGGF<_YW?>]SKO];S7V7N?W_[C\\?$W>M>:WW6=P57"&7MF6'$WNC<W?E
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M7TF3C2_VXS?L/!FJ7\U.>Y'L"SO!\-@E!9=!\<>7K ,_9V_A6PK'B>>"'"9
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M@+MR^:76<-+5^D;&C3/[;RO?Y=CPCS>"-[APY70C>!(D^Z=+X'N058_&7[W
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M]/TI8C&FOUE7KL%KCZA]7Z55K,JQ=O(]>,?@%2S8U$;EV5MP&KT;X\P[+%2
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M/B6NGZ\DD6P+'6EZVRV$_J]MQG7NV:+JP,[7P (3J-U/I/^_W'C!*J_LC9\
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M1K:XUX%SJFOL^[RB%ROKMC_*Y*A<:LKUN_L-)4_E$'@.^(9:#;40M'>?:Z2
MV7HHS7[$03\!GH/_53?CKR2>O_!/0]@P-%G=L@740%BV91-:)P'Y_FN*BN4W
MN%HA7CF^HK&VW9</?F*$+:\0^V6P]SP)1MB,&+2G$5EPE:>'IX.="&='V?%(
M;@L<P$P4%U@_S0C2%$G/<O# S!%K'&:4[^]E4NU<7<GJ5E+(07*,GNR\KVM,
MUEV7PLWQ*\RP%[GB#=_?S"2PZFE(U3$++/_V@=,^^"?_*<<C!'Y&>X4O*=S7
MAE<AY7G]\TI#FT=9VXP4;4BGC#SVJI:Q77Z^)RU5P6LFC]\_]?>#1.D K
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M0H#VBL8:J=2^A< -SP(NP?Y+6,> X]$,.VG%U!?9RCGC[96$X/9N"Z_X=77
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M[MIZMZF+2J2T7J4K3,?,ZP[M]6X6<,2'1>Q ;%S'VCON.Z^B"8S@#YF!>AS
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M.%+X+T-[D[!>3:?[MMA>V!<T\2@.J$.G3BIZ)/W'R)5/. !BACT6@]DT?<.
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MJS"^_6BT:CG5,:5=$YH!C.XCYD0<;[1?74]R*"Y"5U$ORPV3*-0]6HN1>=!
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M_>H4+="GKWTH\NDV2I7G&[Z_#N UVEFA#AU2.&MF[S[ IUS>M2ZJ:O&H(!4
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MTNA(GM=$?*7Y)L%<UDT7EU*4JOK?,!L.'X\5Y[%/@M$N'Z%5.%JK>IL,U2.
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M,"7S4JV9XBSW6=(Q6W!S18C72KIT?PKF0KST+DXA+M$VHJH67:4?>J [C$Z
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MD;U4DF]ADI,S>8N5FNN6LO#4V%*GZ4>C1%*>219O0R1E-,D6&^U:=UAFG%.
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M CI9G=+RD6<VZ_:BQ6/^]668M>@FG\9UEW#V+CSO:J4-OI.F5WWN4S^D[4K
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MOA>LBCF5S;4S =[?=X9,$+W%B1?N1X[!\[("1(KE9J&.+K30]IHIW%(\8^O
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MNB!!^70'AU6!$R$TJD $"Z39NX,0ZGU5+"Z&&1F:\=+'HYUW3#W)W6Y+[\8
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MO)!N\R%>$<(VO-[],W^?51MEB7Z2BN:LDLD57^AL=IT*+0IZ2:_Q9C1NCV$
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MLHP7%N3XCV;GF[=8WC\7X?#W$\L8TMK[+^;/Z#(\"'[<*'D6U)E'Y,J;/-R
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M%QC?'\M3&2D4?WNEGYC)PNITD'Q)BKDS(\);!.)=XW;Q75E,<%R])"LJDP.
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M];)_XB)859O,VO'WNQ: /1<XK:5HQ\Z-R%RJ.*&Y"']9D%2K>4VQ'RIXR4=
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M3)^>,[RJ"F;Y-+;<X@!&=)&%H?Z$.%-T8.[R7-.;EQF[?!+:L!B7ASD'(7\
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MW8$/ZY%\/8A.*R_'EW*_"C5Q!OLD9&Q >9^_GL0Y:8R^C9O.=69-D-":RKK
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M*1ZR\W'X=Y0T5TIL1N=T^?[.9AMEG7P5_-++4SMZEH%!=XGC+\+47[W*Z+#
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MLWSH[NOPO#=RW(FV+X:2":/LV><L(NO:257N>:^\=A]Y7N; B<2#<!]_.]+
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M@'X)T(4FP4V9+TA(KT^% -CG96&NK)8T8P-N(._");%!T6=>F^)H:MT77+2
M009*!3.$-.D1.V*07K+G\,W)>@A"/$+S3-B OK6XV3*'^9L5V)_>NF>4SV&M
M#B)7W ?/Z7=>&.1ZAYK6(_:3^'/=Z5()]9[N_/;%,07WAL"TMS)=&7Z(?/>,
MAS*6@H4T?IDYQ?A+76>'G!'+&BJXVF4W[[W>HK5^<?DB28[6=BV'Y@,%&J4L
M&L/E7"(AM">[>)VQ[K-!A-@#"KRXI$R*3T4WTY8$IUOX66J0^N\QRCWV 3<'
M6-R')3B95BX-H)TB7@^5I/F9'E!)2AZ_4)2GPF$\&?^Y?2;N=/8BJ@#\%!<+
M/%O#4)M4CSJ)TOED'VYG9&$!<@"B/36&^O(%$5X%JYIE1]=G36MTR[0C0HW@
ME>?B 5XYF+\ZE&KA,ZK*-3=%%4Q8?C@?("#8T):_* 8G59YIM$_4F5 G=WGS
M\WV#$\H#OK?GM^SLAZ3L+PWJFX,Y@OOH&*SI5^J<PJ-LV[! M\','0,;(E[S
MEYVG)).!CZ"DF+GII6$<O/+;W>3L[^(4BMG7$3(_G)GXG7XG1&(8IW3W:)BW
M#IEZWMAR(E*.*R 1F/L-2*8(-O/5RHK\P\6./H2B?+_59"!U#%(';(/ +)_D
MV 2T9T).BD%C_W]HS_(OT"[EYG5LWH'-[?WX45>)LG"</J)Z<PMG)4?+;)$Z
MG(V,'ODK:2R\9X1,UMO7SB<"S6J\B49=I\C77IT>O$HQ ][LQP*L1:B9HC%3
MR*RN7WLW.GYYS_<J'8YY\P'2=;\2,I* >:J!S,/<YG/#^$,.N2%QO@%4D%=:
M^UB [)#LG^2CKRTB'#BK1RLJ*G6L!YM=UQE>13$D6)EN]OBIZ>A5?QFOW54I
M4-E<%(ELU 4!CC+AZI 5T?DQ\UB67&KJT2,[M6%'I\K\.Y[5AC\[;0E[-!6K
MH:>@&XT)D4W$3<OA";,O;1WW\BD4HX6^2SYD#AY9-?.@?D*7S92]O]D]+631
MR2X>J&FD+1^^(,&>X/\&6<7;C/"L;[KJBW"R?SCF*)#L)&JPKKN9=<ES^^1&
M:V8T\-8E7ZO<I5A7CEK7'7"GWN0IW&TCF#G@=X\3K>-C1<(^L#EE"Y^[Q&;W
MLRVULD8#:WE(IRC1FWGA0UT&#QU?,)ET:>EZK03G#*>O>7[T*_6V6[I[U\CQ
ME4FO:Q+_&HU5+,;:P/8I\/AU>9K85D>XX22Y'X,!J-+0GIXF02/JK?NL!X\M
M_":[BW63?ZXZ,(@A=TO0,H]Z"OAX11<@E6)J#<BW=(R,%':6=*$9&V_A87UR
M=",GE1&]+O/]B*F5]HR]:B<*1*,5RYP"O$VY?W>N^58G$A*1$%5+4ZWR3H<G
MRO+U97.X(EG]32BICD+Z&C!6;GY71E*9XMYZ3%+$;"SQ2OQ/3%WUZ@'-\J+]
M"'2WR=5HYYYX;EQ-0I_+Y.G@ $?9W"):KKH^?JS6GBB/_IT1&M$(:KP;#@&X
M^R-:!$O(R(?6P.0:1,M-;Z-I9=<?TV), SE3Y*C1!E"[Z[!8CP1'P(TJU\Q2
MYE,P7ZP8I9"=FU]Z!= <<^B87_TK%4],F61=.Z]++C\'+RI-/#5^U=G: ?;)
ME_%W^TR'&-[<TRC249M*NSK^F#K!KGQ0SWP_ZX9XH+3>'!=H!(Y,C^$3= I8
MV8V)">Y,7OCR^)R';/K3:BN!T62+_M*#F543 [UYI[>2\;>.MH,TS%W]_KHM
MVKE-:O3$2-1,O$=21#9@*IV,?#V15)$@L)QP]X=!ZV2+T5J%K"I1 *D9*X$B
M#>6PRFO:7[KD9#)@IJDM74T"3L1.UX$Z(LOSK/[0Y#N'6\W3SD[9U,>=<V97
MZ;$M:FYNMKR:&E(BVI(K$D*" S(HT<4Q.0;Q7A*A2]W1WVM?:M,VGC8N#%'L
MLS@XVC=>>[S5-J;M]#F/X::9M.0.CD82NB27EE>-S!\*YVR]MI&^6$#+7N5I
MRGS0U]3SFX>C5F!-"/?^%I34:@TO;CIWY;+,3X(]^[7W0+Q@LG.WM#XL8C5Y
MN=O7E))-B=?3A2V/F/I%$+F]XO4P+3*%%B;^2C-5KVO3I(P2(W^]ZFKG&3W;
MUA,=(K%20&XC^>(_\A<X2+]DC^=-UWC_H(,.W$7JLL,SQ@4EXT?JMG$A/:/7
M&&_9\W"9F7Q[3RG](\NY80#T"%,WMV0\C,%MJ#7\L"#V88RPXSSFW+!_1K3Q
M*>"Z3,;K6'M V.GDX\1.>9/A?9*S'%\_]80:L1>Y"FXI_2.JO))]PDZJ"^OR
M;:):V]:NY)*L:U]@ ^IMD?ILI@;W]I=QWE"5X=]1#9&,)6G!L',R;;36-(S@
MH+PTQ^>U)^L^=-G1U*S'K7YIU6!)&@1#*X>#;AVUDZ-,C,9;%)?8$7U,1C>%
MYQE<-9963@A*&-TFYO]:C:P%G7>;^^$]A/N@V\3W%.\$<"3S!;7C[-9%=L&J
M:AG9[>%D,[.#Q5_PVZ XJ%4\X0AJ1N7:& OC M:J\.<9.3;E/NK41R6DB)9P
M D<_F83\@J._VN;M!O(B92J_5LX2$1&Q?>"CJ_GM>X2"L\.AM%4*GX,DVJ/F
M'/9+5LN\WSJ\:DQUHO[VI#G2+%[X/,G,([/&<#[O!IV5IOQO%QVM:V4).A[:
M YLB16">R9T,9]QCPI6@N''7OYKK)41)OCHM<BC@B\N'X4M]&F8SW:/=N5:C
MH$=.D5C@\)X=Y'0("R@6N&(8IELT5J_P?ZC'\5>]Y)7?RU[XA Q%\P5YHZ_U
M>-9[0JUY"LT68&5%\]&-_T=4 [_SC@9G?-!4%8F11I&WO?K7)K64[AMEE?*=
MQP-K08\TB+>:VBK6BI#JS0ZGVJ7Z<[/!Q"TOK)F";O@>JORP0+:'']0]>%L7
MQU \^?LN=S[\NZ9;0K%,\_J,U;6Y5:/F>XAHXYWP=DC<8BD^MM0$N-7"3RYF
MM')-=](S;7+TOZI*I;E%:GVM\[/>K+"]W@'.KBO^Z^1L7""OO39M=FF%VLC
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M]:S096,4V\-GPS3LPG+(\^C?HOTEV?\WP<+_2Y+]7;!_R#4-T)&3D91'S@1
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M>KZD3NG6&Z#72)"]^S1W]2 7'!R^R//Z^4=]WJJ<!!XJ$)KM?-!HP:928F2
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M+TIPJDON#.98]UN?Z\:%]-Y]3N"C4?C6JBY4Z)P$\;/*AKETDLH(*-:0D@B
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M!5MB;Y*25OP\!DLJ<FG,1-&/,2MH.?9,->OF.@%834<J3 "1[@T_"ULV>D-
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M#;#-S>3_U%QB)?N5 Y >6"7Y:D4"R<?E S@ZI1GP"#U]&PJ1Q>\/;S%8"!%
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M<5GN1_+JY(HH*UE>[D\#;^3VE<6UC+J,:87DE/![Q<*+-6)K,F*Y9_ZEF13
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MXZCU)C$IR?<I%"RE-YA>?..M5#P2;'Q<\N&>S@=G,Q_FX)D762HG]D]AY/V
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MYT,>!43MRE?Y&/-C+="]KLQ;U[J]7;16Z21DL>^2:J;V#06917$5P=X>X@L
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MMO6K#$VAQ]# $FJXNH+R-=%0\83^(Y@0,B0= Y@@:Q9B[(GFSIYX*\\RG0R
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M6@![7S[GFVT%8[H1J#D;ZRD;Z*3//K6]'AP*=,#7@K;K^+(N8H<=^1B&NC&
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M,LZ5(2$2M!1T/N%IW2^]_M!!@WQ@Z$LHQU84YS\FH__[T??)8/A6PF+<CL;
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MPID1^K%#WK5GT)@U([O8+[OETGGL7^K?1?]J'O8'[_O'>%^?&^S;,?A^I;+
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M<43<)&YG#S%+.*-!0^,\QU"=9+9TII=(P]=2'.FKGZ7[7SQ^M^O.C[4F3C"
M%U'><_[#2,=$#KYO8TWMPH8M%H2UL:."K)3#  $L;7&EEB_DWJHK$Z]VO;AV
MU7'&_O2FEB+<T7;RR%?\>+WTL&7I;)0GG!5J:6G<&(L!OJO@Y4_U56I&S[ W
M]]!5,;::?1[ED?F4:3#WH+,R<*6C"$LHQPEH:4G4MJT_EBL]FKB?&G["A+LY
M+7*1W,B- 3(!=]<WAUA+-@[H$^TX'7)1T4]Z5W^$-/6_\O7P5!?G&@(MX"-,
M"Z;48YFI*%JJ2]3?2.J?W/21I1I"W9P^]GY)4E_#>?$ B2Y77+K&-*6KO;?<
M>$")E8]XW$K>L= K/C69R)O+\W'9>;\)SW91VT<#+QA-NQ&/IGJSNK-*/:YR
MFK,Y0;9LZK;7SI<Z]-7G]C7<3PO>IQW'#D='S6MG6H5(J"5\-DYK]R*6T_O1
M=6!_+] CHBWU[:Y3",VI&@MYPH()& /$R:Z V\!L\P65;0_5/AR\OM:118\!
M"L&3?U/X:.C:_1>2GYSWC[XLA\3ZFLDKD*=GTU*E7JKI5#\,L#;5@0&N*&,
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MSR#M$OKJ2-3M,W ^%\T-0T6#%R$XP%+A)[^-XS"YN3B@_Z :@S%!9IZJJ>$
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M0+(8MH. .F<$2$:T@"A$,+=;$VBJ><_>)TR?*JH5Z\CVWOKMTQ/_HAG.1N*
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M'*# P2Y9U,^)68,ZI0KWPM3H8N%+WFV8_N%RZ>*")YU&#L>9 U8E+LKP\*U
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MV'@]M)SOK.L#B!P.H(\4YI=%-5.!*YJ+N$)*U&:3.5!F<(^*?EX<(#K=@U6
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MAAMR!9JZHH282.3R@Z;.+!;LH7& ^#Z,3%_!;DY*8/JQW9V\)Z;YYN=@0BJ
M^3%7^^OY/(YPSUC25<#R 8@W'\O1+]WJ)V5;!+UR#,8&(9F*3=FO[<VA7L;]
MR((^G/BK#"?33SK^-MC"1,VJU_$.)MG2L LB)YG<5XY0"^43:!O]'$_R-9='
M+ZD9\ICV+6]?@XL'4V@;@T17M9?.E@/O%IV$]DLQ=&$A#@B&SLUNFX!GTW%
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M2+@EX8"=@O#P"6'K#BMH3395'8DB%WNLW\8G! 7J=.=(\R1YH;#TC[_WA7#
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M'CIH*KH'A'RO.QQP!  6X5^SX <5-(HR@HRI;Q_7QY6*KS',W9J8J E>E7W
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MH/7,->,#T):ZT8UW-2_RKN2!6+'&$0NW:QX1&,0V[INL]M]Y'#730O7^TI;
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M77,(IQR_3[@E?R5HW%CIH7^O'#2@DS>-9=QF<_U*N,&^;K_F'OPQSK@1#[R
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M%XQ7B7JA"P/J>P<18=KY7Q<SGF/YUFQ':0E/5A%[?[4=SF8P0<0O2>.J3?!
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M/' Z30\/Y&EBDQ*HZ@T0V3*RMZU7IGC*ZDZ%%)0D,'PH:0B<"%ZZ[F)\0_^
MT'FR6!/$:T%,GSIMYGP-P_HUL9ES$/J[ZN>JYVQ>PF:*E,>-PEIR_5D5>"D8
M.-B#@.3DA6-ZR['/^VFWPTM(.0[IEW+D9_.N@"S+[Q6ESVWE5QJ;*-X>\[UW
MEV@@:Z%CUDT+5%^T2QU4>2VU'OZV4?"3<'B%X3,O"=S-069I]YI0O<320-/5
M.[1-QTUY_4.(=V* 2KDSIZMZ53,M]![#K<[N#:UF3+J-^>S<JTAQC&#H\N.E
M\)6B,4AK*#5Y7EOR<9[\4I<4W:>56[A+_?!'G)8RH)0"%OC;!.QC;N+[I7F!
M,<'OQC&%K5[6CF>C&31[T]GA" LLI"B/I]]Q3\@X*$(U8_APMD@J3YJ)@*6R
M+#U=>#,>8$DXY/O>@QQ-=S5,.)AWU\&GXRZ&3'UOG:%F[-9\U"0>..JA.CX,
M5?*>VPG;7;#T:Y)Y21_N<ON(!JD)1MOP3.46'J"\US=N,RH:',V!,06RO)1%
MB @H'WFZ?/2]6;*ELUMEON>:=9K%SM$C8(.[A2*@XQ=R/7.)31PAT/NO)HNB
MO.[*UCQG=\S& _[]$1?&/J4ILIDUY*Z*V_O>I&[Q*OJT+>B*@T;'6QI6W^NJ
ML#$P[_:6<8+2$VP)VG-%L$7(E(-WVF<RD&"UU@EB5LF.<:-7B0MYV98%1BJO
MAW5=KVJWEAH< X@CEC[R/JO  Y&#!)5DE(8'%*N<$<;H.?$]>YLI^1-L#&@^
MH[/=D]5!GY<:[(]?$2;Y"$CB@>:,>';T53V2Y-3/[Q^LB6+C=<QN'[!+EL,#
M;F_D:* M&8YXP+@##R0HW\)QX(&6]G'UG6WP#HL#$0+CUZ#EQ5(8YEX4HQ2U
MJ4C/6Q97=<C>#GNIHD!3+G'<\$I_6[C,-"DLG0? +J0A'*O$+Q3H#ZO4I3]0
M.K#L9+.IW%W&"FEBU(,'K"0'UPTD%L4,(SI>BF7ZILW,NK!"R8!EA]U=3[4Z
M\D$5F98SABVC,S7WQ[W8"(U (%=V=O# Y\D<_L><\(/Z!]Q4V4%;7=FC 36K
MHI@*7'7-IBLWT$>8?(6S-1OST&=%7?J8MR<\3, !IXM<[ET:9LFN#72AK-VA
MA1(;+.=]F5^*A/EU YOZVD/)]QJ'3A=6TSK-@?;)ZV;;7NH&:U 4X!P3AY72
M>FD/E?/(<FD+(;T15C^TGAG/TE\SSMYUI]<_:Y OU3=9;-';-A;'\ &KTAO:
M'_IZ3HR/[9J6Z6>_K:>^8"'M5=%!RWY!RW*KHA#P_%BHB;$'Q3UO/L1+[+G"
MXE*8KO!@XUE&<M]99E9/2 ]O4R4MCLMX21VC//'6!8N>WDM8I99H%B%*1'.I
ME72)RG)H=2>J0IJ>3=TUK/@PYN<S&DF="ZE&DSY9Q$J:LVQ9BH3R/@CBUK:7
M=B.;SO8XD37O-LE4$Y276 JQ?V%U&\3>S"%#A9V(W9+-2O]G0^,M&>AURO!S
M.EP#E9L*N7>9S9ZXN9<!\'+\;+FUN1/WB+$XTC7\:D5$38=77SW$2*"\%POV
M9#$ZUD>9W;]<[?&^Z"8#&*Q0NX#1@M73JON>\Y$]'4Z].]MY:)1RH5@J-R][
M8&"N%7(Z=O!T^*$]]% ]%W&?NK'>\X;J<SU889:+8RJB;:/S2\@3]]BJZ\IJ
M]HTK#S>-(SC4&6RYW?\!N*,U>8#!S>O\-4!:"XTTG-7S#TM+,9JS&QJX4CSM
M(&TJK49RF=7K10[T,7250P^*4 &O"^L9"1?ZKM0Q)<2??MI:XGJ#8_EM!CO,
MK1UCC@=.B:;M.3S% PHB1/U7IKF-Y$.F;A;WL11+DZ$_8S5YL9>+^\'Y>5'=
M!^"FW!Y-VSJF% XS8'_W<ZY3H]CH0=#.!GCGW"QQ=J=C4[_#MO7TF[*>!NN;
M.2T#EP'6437HE5HX4N2&H2I58++Q_3J.@,B#)Z$4!Z "PMJ$KGYO/A:\&?C2
MZ%J$M=&[%\3;(;"F;,R9#\P@4LM@,I_IV@))4$.;D/WV!"KAL(SLA#NET\8B
MVY%%QX,SBVLAQVK?O]M<E\B-KQQ$LD#N(&LHYYT6BJ>F/TVYE6I=I<:ZP)JJ
MSGA+UGS96"HT$XH0)8#6_@245IR)[5B.0+NYS4F7,"3Z;$>;V^1-'!@/1##?
MQ .Y$#R0F&/GQ20G!:7454[-C8F^!QY6X1HEYLHSPO4",6:9%L;'1^JOL1FF
MH)]RJG9=@'F!5Q($-QKU,9E$3^4/FC(_;@&CR#ZC\OQ2NE9R1:VN+QK-(XAG
MPJFCA!$G%N(E:R="M$"-+["CBQ+O>:N=#<*2I2V(:W!M/7A@IFD0M\>/N=Z&
MLBSWZ.&['_Z.^?(M@!B@A1 0MK^E#1ZXL&2,(RA@5,[2O?<)*,6-9W;O3\+4
M7:*&IN T$9&>:F ] (D]DL(5)$J^0K<@F%-?N'LG=%N1W13E-G:4M!.1,&HQ
M8)ULL5FBI?&>/.2H!H6[WZ?=H"DOALNP,620TF39P]%P<']%$+ &(GZ)E9W(
MT:X_QR&:)W3I^#K'(?7>Q)E9WIZL]G/YCNBZ<:2DSJGMEI4GOO!>7-2< ]'S
MO+D;"WIWWC[&J;(OR[P_!1+F<F1!QZSEV%P@@/0)&[*!.=2B@A#C/4ESN=N3
M,1LQ:W!FZ'L%5-Z>H_K><6[BKO0OFZ36L)9LIH7(2"?$W[4\N)J7?@XVF;.-
MT$8B2F%U>LD#T73D3N^,$DQBO4[D7L0N8T;32&?9)?! C34TSNT"$$(3;D'L
M@[&T21S"W!5D.=9M3&)3N*+1$=?,ZMHD&#;L/EV^:T5W]6TOVTY_T_'SAA0/
MT.>'6\-=B<,2[/O+#/7'X_P;WU=U+;_N7BXH=35^"+HMH(T"^]]"=3PIJA)O
M!*.",8$-JP)RBLW773CMAXY2&]GO  ^PBOF,(V15$JV#2W&R3V3PP$1JED*=
M5/#]>+H>Z^$2Z8LT'5G\']2G>=3IO3U.9UO/;9ZM62?6@9*W@@[64E\0\?84
MEF>-^@OD0/Q/H;]L4@K]AH.K@SYF0LL9XLIP2TGEM!K , 7Z5)ZW1\P/7:F'
M^KNS,O0HT,Z^CI1<N-.G]<H\#'IWOF:=HHK X90X^OT%AD4' AP;H%TTV3B^
M)6._RWB+ %C,5O8P-JCD_84\DR38TA$GZO3FL@GXOB]]_55ZJ(7J&T\EV0X6
M7&,?=/:$.Q[P8L9R[R_P?II-WKUHZ#<ON.PRLWD^"P_(MX[NHD;'M45".:X'
MZ[V)O":U1&/-<>^>OS<@\)Z+87[]NLNV*(3R=E+<,L-[EY6Z2)>G:H_U3V6E
MZ^5;!$H,4=_J,*DEX*L\0RN&6J=X6TLT2*,G2?^:\X5*QB=BST-MIT$&--A
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M>>F-%6_#S;=;$Z1K6.5\!/58Z/F=YH9XKOCY;IV[I67#=.5C$J,G6S;FP5)
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M5 >P0.?404+A'Y@HCWO>T(/:M[)V.>Y,;BST0+V"YJ1(LY#")]7\!06;O(-
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M^66585Z7-_W10O=17Y)T9*W6[3]#C!9T$K0L%C/5/GQ8H)?G!18H*[O^.D*
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M*322IHZDB9B?[(S"XL^/L8"O6S75OK >YYG2^=^/])P69\/G$# *%*9E.JX
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M4PH@J-L$_UE(1@R.$&.A=SR:]E"OJ6JA'>$I/4KW]P>_E(V+A;4["94%Z'R
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M+3(P,C0P,S,Q+GAS9%!+ 0(4 Q0    ( ,T[U5@7&/Z3L0(  #,.   /
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M   /              "  90[!0!A8W-T+65X,S)?,BYH=&U02P$"% ,4
M" #-.]58;@PFMS@;  "YZ@  #P              @ 'K0 4 86-S="UE>#DW
M7S$N:'1M4$L! A0#%     @ S3O56"?K43,ZHP  (,\  !(
M ( !4%P% &EM9S$X,3,T,#0U.5\P+FIP9U!+ 0(4 Q0    ( ,T[U5CMQV.-
M@S@  (Y*   2              "  ;K_!0!I;6<Q.#$S-# T-3E?,2YJ<&=0
M2P$"% ,4    " #-.]58;2XL+_5% 0#*BP$ $@              @ %M. 8
M:6UG,3@Q,S0P-#4Y7S(N:G!G4$L! A0#%     @ S3O56%^NA?HK-   OCD
M !(              ( !DGX' &EM9S$X,3,T,#0U.5\S+FIP9U!+ 0(4 Q0
M   ( ,T[U5B+WY:$A.4  "X, 0 2              "  >VR!P!I;6<Q.#$S
M-# T-3E?-"YJ<&=02P$"% ,4    " #-.]58G[6$Q??(  #(V@  $@
M        @ &AF @ :6UG,3@Q,S0P-#4Y7S4N:G!G4$L! A0#%     @ S3O5
M6,05$Y<8C0  0:$  !(              ( !R&$) &EM9S$X,3,T,#0U.5\V
M+FIP9U!+ 0(4 Q0    ( ,T[U5B;4#-C=X<!  VF @ 2              "
M 1#O"0!I;6<Q.#$S-# T-3E?-RYJ<&=02P$"% ,4    " #-.]58*H4%MN->
M 0"K@@( $@              @ &W=@L :6UG,3@Q,S0P-#4Y7S@N:G!G4$L%
3!@     3 !, I@0  ,K5#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>acst-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:acst="http://www.acastipharma.com/20240331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acst-20240331.xsd" xlink:type="simple"/>
    <context id="C_b74594a6-c75b-40ac-87aa-02fea55113f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_02572285-4b65-41c8-8fa4-f3dc4a164d60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b9938b6f-8e2c-45cd-b9a7-e5a38fc58fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2023-09-24</startDate>
            <endDate>2023-09-24</endDate>
        </period>
    </context>
    <context id="C_1b554ace-39ee-4357-9ded-83838c05db04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8c949238-1cb2-49d3-a7a9-6006bf23a15b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_6bab073f-8e03-425b-882d-ee0197687a29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_3487dee3-4575-436c-8773-9c3b4bf9b897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_189b018a-6b9e-4d85-84a9-062a43fb0c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_84420b03-d4bf-41a4-a1dc-c3a81a813802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">acst:RKOSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_76b72763-8a2d-4d7e-aea2-4b623c8e60f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_91f3906a-c565-4e1c-b09c-103612aaa49a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e235b4c9-4adf-47cc-a3e3-c01fd379a76e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_a0ba7fe9-844a-4c36-9819-69617b6b15f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-12-19</instant>
        </period>
    </context>
    <context id="C_f34c5198-014f-4f67-a218-f5719b424883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7597480c-39df-45e1-9922-7010d9c4c72a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1eefc74f-a703-4dea-ae7e-ea4e331b81be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_407b0177-7169-41e6-882e-472705b1636f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYearTwoThousandFortyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_16d16afb-4a44-408e-a2a5-100f7c0b1fbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_faccd42d-8b25-4802-9d19-2b48cbbde167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:May2018PublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_dce797e5-6a6c-417b-b7d7-6195591f7d0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_f4f8e9bd-4546-4f0a-afa5-60be369c087e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3c9a0299-cb67-4749-8a76-c93fb0ab71bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2023-12-19</startDate>
            <endDate>2023-12-19</endDate>
        </period>
    </context>
    <context id="C_349e1080-b426-4ed9-a578-476efce50cf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5f7e0aa5-ee77-4502-b721-627acdac5133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2024-06-21</instant>
        </period>
    </context>
    <context id="C_99120ca0-a7fe-43e2-936c-fcfed03ae232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_05adfb7b-9ddc-4cc6-873f-b2dd8d56c9c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_70f162d2-db64-4bf0-91a3-884865073097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_1be0d73c-b1f4-423e-aa12-2a42820f8ecb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acst:WarrantsIssuedInMay2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="C_039d64a4-88b3-4aa8-9f0d-bfbbffcaad9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8187204f-303d-4869-a819-a4eb7d6028a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_dc813500-db81-42bc-be45-0769d86cdfbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_705dbe6d-a676-4e14-8f68-1447dd74db79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:September2023CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_0a51f099-2623-4ca7-bec5-744e473c2a07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_572273b4-60a1-4bad-97f2-b3aeeca1fc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0cece337-a016-4efc-9a7d-ad4598442843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1a24fef3-a068-4ca4-8dac-1a23822d569c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_06ea57a9-3a97-4d7a-9bd1-eecd71be02df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f9bbd593-6189-421e-8104-e8b8f59ded6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_23c5dc6d-7785-4018-a4a0-3981b25c8bab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5c543260-cf22-4eb7-a1f7-51cc4741bc47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2f8fe5fb-ef11-4634-a474-acca8f534421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3475cb4c-b4fd-423d-8077-b5c595ff8757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_fea751d3-7614-4442-a3db-d6540fa51879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_96f34336-bce0-4b05-bf5a-f6a008568ba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0238deb6-4fe5-4dd5-8a50-1ee0d936549a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="C_d43202e2-7d88-42ec-9006-9b5d92669112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f4272963-8b80-42bd-8469-469e87f57dc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_f61b02f5-57f3-4c12-8cf6-ac25efbcbdaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_95d10643-bfd0-4043-b9c9-ff71cc4ed89f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_6f23d8ea-d676-4a69-b9d8-7312636e2386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_50bbc2ae-76a4-43e0-848e-139f93c827d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d9c4389a-7f67-4bbf-a637-b694aeda8261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_c869cf00-c0af-4b98-825d-27c8d211e38b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9de35410-3114-4f88-8550-bba2bee392fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_ece0ac7f-6585-46e8-9205-a30ad7140159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7a4ddfce-2b5b-46d2-8208-60d8a22d52e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f166744b-f3f7-45e1-bdd4-2768e6ef6d20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8b87163d-8c7c-418f-bf82-a0fb5e3ddc84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acst:CommonClassDAndCommonClassEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_b2555b6e-b437-4ba8-9563-def690c61ff9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_4e7ece24-7a7f-426a-bbb4-52d87842bae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:Taxyear2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2c54e8e1-ca7e-47f6-aaac-354c7f5c59dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_4cc0c4ab-5764-4050-862c-4ecc5ff57375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_af2c1513-5cb1-454d-9540-187ad7be9278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3c620743-7648-4a40-9f52-ad9e1ce7c425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_31aacf07-7739-466d-9474-24f3d1e9ad89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c4d697ac-eda3-4464-bee3-640ff429e5f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_dc8f5eed-e387-4957-ae1f-a00211fe78a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f3eda1d7-9329-4b09-81c9-72ab4a9683c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b8860ddc-a67b-4cbc-b6fe-22b8b851fe21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_212e94e2-e50a-4b7d-b58b-26d56a137061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c73f5261-e930-4ac2-9ecb-307f85b47d05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2022-03-14</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d6ef368e-0ee3-4ea0-acc8-95b6fb55d6e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_ee140fde-ec8b-4597-a458-9c1426a405b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_f8fa8a4a-743c-49ee-8a05-07e36d9b8934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d5755bb0-b1b3-4e1a-b0d2-be4c6caa330f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="C_46a52c6b-9951-44a8-8b8a-3cb9cb3e2439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_58a0300e-46b5-4e90-9cfb-76e05e952710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_2b3364b9-6260-4b70-b7c1-3323e1ed6f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1661c524-65aa-434f-8b9c-ae631dd5b8bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_312bbb54-59d2-4300-b0d4-eef44282cdc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_64eefdf8-8725-4487-9627-312c2276a125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_32f95ce9-670d-452f-9fc1-58e64efe3142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2f539434-13da-4ff9-88f7-5a546b91d0a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_ebcea23f-4694-41c8-85d2-30c548c5e8cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-09-24</instant>
        </period>
    </context>
    <context id="C_ae60a243-9e5e-4f54-9f15-fb2ec877bb50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_88cfac6a-e085-4d1e-9bee-16ee91a78d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_d3cca4b1-352c-4004-9c30-f04a2f7b79e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_ec4dd3d8-0001-4568-9915-fb4ca638ab8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_36c24d42-fa01-40ca-a916-10d853ad79e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6b745745-fcfd-4873-8e48-fa848811c654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_3d32a6e4-7a1f-4468-9246-d1db4a2f87d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_56f5d179-a218-4d6e-93bf-c19733becaf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_684d5200-1c42-4272-8ca3-5608277c5be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2b13b7d2-4aec-4346-9923-ef74e0f85053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_422f9f9e-ac11-4222-817c-49c40bebb380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d8143206-01c5-47e6-bf77-ccbbaa1a348e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_177feeb1-7b04-48ce-809a-866ea0b27de7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0d061b65-1b50-45f5-aae5-b793fa09c563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx102Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_c53e60b0-79a5-4d64-a657-f5b786c9594d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_43242c92-e78b-4540-8623-9f75dbf73cb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:NoExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_4875e2a5-c34c-4bb6-b0fb-5d1c12cb8c02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7da55c0e-6ba5-4e9e-acd7-dac4568958a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8a918cbd-dff3-4510-9992-8767c4195fdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_46e5f6eb-b6a7-4f98-a854-ed3f302b7714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-25</endDate>
        </period>
    </context>
    <context id="C_f6847874-0331-463a-bd4c-c694ab172b42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">acst:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="C_f8a2346d-c203-40c2-a5ab-e2216e6c3d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_60ef9157-75f4-4a1e-b25c-2842ef0acc4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_b1b778e5-8b0d-438a-a6f2-684bd8df12a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_f20daba8-2053-470f-8d6f-36c41659af0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_c74a6eaf-0060-4554-9488-83e6d43a52c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_77630b6d-9f63-49f0-aacd-228e5510fa1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7db0708e-187a-44e4-abc2-9ab65651e41b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2023-07-14</instant>
        </period>
    </context>
    <context id="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_ec22031c-0a4b-4387-bbb7-0033acfa1768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5eeacd49-7941-4477-961d-d7f222f3cc8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_ac3b545c-c1db-46c4-aa78-4fb7c590da00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_d5433bae-dcf1-457b-9735-b5bec1fca459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c54d6f0f-6fce-44a5-ad0b-79bf1eed26d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fe78ca06-1c34-4828-b4ae-24b1dc14563f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_057790a0-605f-41ca-8ce9-91d483af8647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4d2dbb68-f420-44ed-9aef-e0dcbd842219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_269f269e-95bb-4430-b89f-d436cbeaad91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_15d1ffe6-b2f5-4746-93b3-3b9ddcb8c862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6a6f8b28-b6c2-44d2-94e9-944ce97688d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_054f3d0b-11e9-4f9b-8d91-3b83f491df0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_61d31cb9-015a-447b-92c1-edb57605af5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_0e9c3508-8c04-4935-ae0d-c619d66df6eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acst:CommonClassDAndCommonClassEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b379b9ec-28ea-4a40-b95f-8839111c5b29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8030229f-2b04-4173-a95b-ae174f4c06f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_779b151d-a506-4172-855a-bc523254a908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_10f930e5-d54c-408c-9930-ba4f2a0de948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acst:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e835e3c2-21d5-4811-900e-7ca8a2f1e162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5a12b334-af4e-4c1d-ad64-bc70258d8ef0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_84b40618-5675-4dc0-9e64-a517f28f6d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_158d50e3-c6b0-4b7c-9cec-bc5c37a93fe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_b3dbe7f3-a4f8-4b41-ba66-ea50c892e380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2023-07-14</startDate>
            <endDate>2023-07-14</endDate>
        </period>
    </context>
    <context id="C_4cec2bdb-71d8-4eef-a7e4-2a57bd60925d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0a03babd-18d1-4097-a9d4-1044dab8ecf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_7f5f8bdc-5660-4849-adbb-453fc624895a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_d2dac555-c59d-4a9e-b6eb-37a8e4c83dd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_140a03c6-59fa-4092-bf9c-59104fc56516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3acbfd2e-cc52-456d-8a30-89f859728e78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_7d5eb575-72d3-4658-845e-185baceef441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acst:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">acst:ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c04ee66d-800b-4148-956d-a12fb82c62b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3d6702e5-9571-48ee-81a7-d74ef46344e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_ecbe80f6-d6d3-483e-97b0-82b3081bda3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acst:CommonClassDAndCommonClassEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b4569b27-2312-4bd8-be26-e61127f1dfc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_893afca7-27f1-4faa-8652-ebeea1283a01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b91b8c0b-647a-4df0-b491-de3b7226a402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:September2023CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_2de077db-85fa-42b0-920e-a1103a07c7f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5ede5bf9-460b-4689-8dc5-21171a08b231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_940b8ef1-f85d-4c61-b94a-bffc507b9e8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5e0b6d2b-f94b-4c26-b5cb-495d338020d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ba9a56ec-eeb4-420e-a520-410844ea86c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_f951dabc-33fe-47d3-a362-7aa2e816d7cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:CommonWarrantAndPreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_e2b01b48-402b-4dc7-b752-a7f73d31bb54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_6e6bc244-b6c6-4d8b-a073-be202a4ef494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c11690fb-a2e6-428a-b417-46b840d84bbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_67401b5c-e353-4b98-9f09-f2f145bc81df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fe4fb9d8-fe31-4fd9-9a01-c7618803d7a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e5dad982-0286-46ce-aa2c-9586c4730f1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_545ec182-f542-4e2b-9855-4b55b11f191b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-25</endDate>
        </period>
    </context>
    <context id="C_1756eb23-2e0b-48cb-9d20-d1c0db7eddbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_d951ff5b-4e5d-465a-855a-f551e8825d5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0f687fe2-5a55-4bed-a8a0-8cc695040f45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="C_8bf52d38-93c0-4416-ab44-ea0729cc861e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2023-09-25</endDate>
        </period>
    </context>
    <context id="C_7da7b073-43df-4431-96b2-512ccdc4cb73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acst:Gtx104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ec51c81d-0491-4f6a-87b8-469f68295a7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_9d1b1042-fd07-435a-9f9e-ae6291bd7e13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acst:May2018PublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_005474d3-953e-419e-8e1d-8a618e56041f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_97daaea2-edbc-4684-b715-e135f9491b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acst:Taxyear2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1bc7c602-b685-4c20-b95a-4e946d0e035c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">acst:RKOSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="C_bd8d29d2-fb73-44c0-8b8f-697d5ef239fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001444192</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acst:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="U_CadShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Vote">
        <measure>acst:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_28f1112b-def6-4587-b528-3cebd6c76aa4">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_30be03b4-e4f4-4dce-949c-e09978481870">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_a31b75df-fbc8-4aa6-92e5-db9704015b28">0001444192</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_7f7405dd-efe9-4caf-811f-fdb52e358109">--03-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      id="F_5b47b599-a873-4c0c-821a-222ef6337cf1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      id="F_728ff52a-c3c5-4df3-8d06-ae1526751ba6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_f132cd30-7902-4315-8127-ab7bcce7e6f9">0</us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques>
    <us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      id="F_c1a9517d-f266-4d79-aeb0-1c8917bd2b32">0</us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      id="F_35eb60b8-303d-4e25-9601-0886d5998462">P0Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <dei:DocumentType
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_f94b48a7-9f50-44b4-a7d8-23e21f3ee6a9">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_754da8a7-dd2a-4c14-8828-6e00f3f3be56">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_301b23d0-e74f-4da5-8764-fea95244e4dc">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_2b5498ba-66d3-458d-b977-782b9d2d70ad">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_56988faa-83af-49e3-a290-db268700ab03">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_044395f7-c0e5-4b88-a85e-ed56d74d5ae3">001-35776</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_881789a4-04e2-4516-93f1-06ac18820cfb">ACASTI PHARMA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_187d0bde-4b37-42dc-9903-f7ae2fdf2c78">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_a7a33f2d-1d33-468f-ad37-a48702fc3146">98-1359336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_8f0fb4ef-102d-45e5-aa8d-313c8fd89b8e">103 Carnegie Center Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_9beb0724-e718-43d3-adb1-38e5ded54a22">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ea5f32f2-b350-4de8-b5b6-d9a895204654">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_c29f70c2-91c3-4560-ad6f-9db64f31d2f3">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_4db0e6ed-2cc5-4b33-8c7a-1950d1aafb99">818</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_31ff6fcd-a7cb-4f10-90ff-6199218f80bb">839-4378</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_647e4899-67d6-45fc-bbb5-4fce133be173">Common Shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_590a15bc-3e42-40be-bc1e-c5ab9883fa44">ACST</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_f3ce4ebd-b258-4576-ae4c-0131272fcb45">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_3c6ac46e-58ea-4bf6-88ba-16ce6ad1e6dc">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_86a6f8fa-4ce7-4b97-ae56-c287eff40efd">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_483c7efd-36cf-48c6-b33c-2c4f2c2e3999">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_f7f31a44-298e-4304-8862-3698782b9a2e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_4b8ca543-8ee3-47b5-bf9f-f0d13170bb47">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_96227b4d-db2e-412a-898e-043ba48a714e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_24cfae39-7561-400f-aa9f-c495cf96937b">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_57190108-c82c-456c-9bbe-838d1e63074b">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_5423cb69-f9f7-408a-8df5-144c61295096">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ec62fee9-def4-4291-808f-5da6d7dc66a5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_d6ef368e-0ee3-4ea0-acc8-95b6fb55d6e2"
      decimals="0"
      id="F_cef15303-644e-4215-a272-3c44ade39d26"
      unitRef="U_USD">17617435</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_5f7e0aa5-ee77-4502-b721-627acdac5133"
      decimals="0"
      id="F_6c38179b-0864-4f48-8562-40794ce9a1d3"
      unitRef="U_shares">9399404</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_f619f8e7-a6dc-4e47-8f6e-7b281c1833ba">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_417424aa-1a2a-41c1-828f-b9526c270c56">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_4ffa285d-334a-4df8-a105-a7af42ceeb8b">Philadelphia, Pennsylvania, United States</dei:AuditorLocation>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d"
      id="F_7aa17690-c5e9-411c-9877-775c4fa8307b">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d"
      id="F_f7a5ec93-3749-45cc-b42c-bec11e258a09">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d"
      id="F_79d57a1d-61f6-4556-a914-dca7eea3620b">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_ec51c81d-0491-4f6a-87b8-469f68295a7d"
      id="F_c97924e7-cc8e-4deb-94cf-aa2930c041fe">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e8b6e2f9-fac6-4dfc-8041-5795d6fd541f"
      unitRef="U_USD">23005000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_cbea8ab7-7e54-4078-a853-7d045efaa28d"
      unitRef="U_USD">27875000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_ce28fee2-b8be-4fe3-a787-cf5b295a57a6"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_33067008-7d00-4242-8c4f-9f5408f0f1ed"
      unitRef="U_USD">15000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_daa0ba1d-8783-422b-b792-5e2a0367907c"
      unitRef="U_USD">722000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_f81f7ff2-237f-4544-a181-24752cfc5c4a"
      unitRef="U_USD">802000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_1a0bc188-42db-4bfd-8028-8d4413ddc0c1"
      unitRef="U_USD">283000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_3c57f66b-3ea2-4396-8324-4ee88a224ee8"
      unitRef="U_USD">598000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_3fe6e41c-8f16-4e86-b1b4-62ea2592c055"
      unitRef="U_USD">24010000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_a0a997bb-f94e-4c2f-a71a-916101b4574c"
      unitRef="U_USD">29290000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_2ceebdd0-857b-4a53-b434-2e059ac05af5"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_90bdaa39-4951-4b43-82e0-f71e0937fccf"
      unitRef="U_USD">463000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e15d70b2-682e-481f-abf4-edea795b056a"
      unitRef="U_USD">24000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_dc902d1a-260c-4591-90d0-9de9b4ea09be"
      unitRef="U_USD">104000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_512f8538-c335-4bdb-9fdb-cedc02856e28"
      unitRef="U_USD">41128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_1b70f597-6a81-41e1-9a23-4b5ac45d4741"
      unitRef="U_USD">41128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_a767e75a-7974-4d9a-9ff8-fef612159eff"
      unitRef="U_USD">8138000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_32ff4297-079e-4f23-8de5-8244b11ae4b7"
      unitRef="U_USD">8138000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_a409fbee-8aa5-40f7-828b-748d3a9413d5"
      unitRef="U_USD">73300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_8d79115a-072b-40d5-b679-8875c52cafd5"
      unitRef="U_USD">79123000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_0de51f18-b51c-4f32-a035-f2608c14f691"
      unitRef="U_USD">1684000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_aead05b2-e490-4163-8981-3a7c2f577544"
      unitRef="U_USD">3336000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_b58dff05-0f99-47bb-bff5-0c560e287b81"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_425a5ccc-e88f-405e-95c2-1fce1ea34ae6"
      unitRef="U_USD">75000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_a2b397c6-8fb9-49c1-8fe8-dac2acfb6564"
      unitRef="U_USD">1684000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_b1dad234-1939-4ccf-8e63-5fdb6bacb048"
      unitRef="U_USD">3411000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_8451d809-9657-4bf7-97a4-10ccf6df9398"
      unitRef="U_USD">4359000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_5769ccb1-09fb-416c-a316-1a3970270786"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_7a6a03bf-686c-4be6-b674-fc51445dddd5"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_fd32b2fd-f9b1-4054-b8f2-7df4c2c4395c"
      unitRef="U_USD">410000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_8f8d0c2c-762c-41e5-9170-301e260b0330"
      unitRef="U_USD">5514000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_d90e15e2-146a-4124-8ddd-8b26b7f20247"
      unitRef="U_USD">7347000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_0ee3cfcd-6a55-4146-b9ba-0698d412b541"
      unitRef="U_USD">11557000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_d5da3a21-027c-4350-a8bd-61d72ccf3d75"
      unitRef="U_USD">11168000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="0"
      id="F_65c912b5-f55b-4144-9f98-c93599fc8208"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="0"
      id="F_8ac6fecc-85b4-4cce-9fed-5b0158884c53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="0"
      id="F_34abc4b5-5986-4a2c-82fb-7cf4d540e54b"
      unitRef="U_shares">9399404</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="0"
      id="F_ca05976c-246d-41d6-851b-051ff4dde384"
      unitRef="U_shares">9399404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="0"
      id="F_9b356fff-634d-4dd7-9f2a-fc8936317972"
      unitRef="U_shares">7435533</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="0"
      id="F_d175764e-8a0a-4896-a081-3de06981ceb8"
      unitRef="U_shares">7435533</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e"
      decimals="-3"
      id="F_69394f00-5da5-4d5f-a1bb-145b2a15fc53"
      unitRef="U_USD">261038000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_fe78ca06-1c34-4828-b4ae-24b1dc14563f"
      decimals="-3"
      id="F_0a0cffcf-c29e-4953-bb89-79f84fce093e"
      unitRef="U_USD">258294000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459"
      decimals="-3"
      id="F_f9a67e0b-f0f6-43c5-b157-89b155a9a03b"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_61d31cb9-015a-447b-92c1-edb57605af5b"
      decimals="-3"
      id="F_03b8f92d-3092-4c1b-9c95-84f9f333273e"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_cc43b150-6f96-432d-97d7-15d27bbb41d8"
      unitRef="U_USD">17862000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_5d7d4b86-c60d-4c1b-a1c4-37beee7a4d56"
      unitRef="U_USD">13965000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_9da5cfbd-a113-426a-9a4b-8b787091135d"
      unitRef="U_USD">-6038000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_fe502441-1ef3-443d-91a8-0ff8243d098c"
      unitRef="U_USD">-6038000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_2910d2da-7fd8-4601-a432-9cfc77a50ab6"
      unitRef="U_USD">-211119000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_d03f4c15-9567-4c26-8fa2-91bb4fc98bfd"
      unitRef="U_USD">-198266000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_5aeecff8-390c-4cf7-8855-0b7e0255bfe6"
      unitRef="U_USD">61743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_170bc865-1dcf-4593-a40e-f2b6870096b5"
      unitRef="U_USD">67955000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_f335ddae-3a0a-4d6b-b83b-02231e683fce"
      unitRef="U_USD">73300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_f94a8842-7872-4607-a394-e07b37c72560"
      unitRef="U_USD">79123000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_a393acfd-7e5f-4bb1-a4a2-e4fa1bce4711"
      unitRef="U_USD">4683000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_c171a54d-b429-430e-8178-c546d34cad7e"
      unitRef="U_USD">9972000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_935e7797-acd3-41a3-a505-b1ba8088e890"
      unitRef="U_USD">6432000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_90f73755-d1ae-4e81-9b2f-46a1f8b71ac3"
      unitRef="U_USD">7614000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_35728812-3994-473d-9b5f-bf2535e53da5"
      unitRef="U_USD">252000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_f3dd8f4c-f66a-4607-9709-9c264c59bd46"
      unitRef="U_USD">661000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_00a4f209-d014-460a-975f-96971da7a6d9"
      unitRef="U_USD">1485000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_ac51bc97-b288-4b81-9585-3ee9dca5f6e9"
      unitRef="U_USD">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_396a5d42-823e-439d-99d4-41237b5c4222"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_03e34163-46ee-461d-924f-a8fc68a27977"
      unitRef="U_USD">28682000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <acst:ImpairmentOfGoodwill1
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_d14643ff-03d0-48d0-8e1b-762ede3220b8"
      unitRef="U_USD">0</acst:ImpairmentOfGoodwill1>
    <acst:ImpairmentOfGoodwill1
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_c2653a6a-fee4-443e-9dc6-3dadc1f064dd"
      unitRef="U_USD">-4826000</acst:ImpairmentOfGoodwill1>
    <acst:ImpairmentOfAssetHeldForSale
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_99e9d8f3-b1d1-4871-a552-b240524f4a15"
      unitRef="U_USD">0</acst:ImpairmentOfAssetHeldForSale>
    <acst:ImpairmentOfAssetHeldForSale
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_78de28b7-fff0-4b0e-800e-e7cd0abbf319"
      unitRef="U_USD">-400000</acst:ImpairmentOfAssetHeldForSale>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_fcaa3478-2e89-405b-8efe-f420633b4e49"
      unitRef="U_USD">-12852000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_e511a3a8-000f-4cdc-8917-f8ee241a024a"
      unitRef="U_USD">-52155000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_87354a79-68ad-4674-819a-159e2bba1817"
      unitRef="U_USD">-16000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_86526664-2d6f-4877-9a84-c100ac19d3ac"
      unitRef="U_USD">-72000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_90d92c18-bd29-4885-b8f8-100a63f1a618"
      unitRef="U_USD">2728000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_4b5668c4-3efe-41a6-b2e9-77909fdd1dec"
      unitRef="U_USD">-10000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_20542c4d-4c2c-4d0f-9921-ce59c67f1976"
      unitRef="U_USD">911000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_a0d46f15-3ac5-4531-97eb-23c19afcf443"
      unitRef="U_USD">246000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_5b08487c-6e08-452f-8a34-35c3c2e7315c"
      unitRef="U_USD">-1833000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_a38c5468-3049-4335-a4bc-72726423ccbd"
      unitRef="U_USD">184000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_95fc2343-895c-4484-a176-e119e1f303da"
      unitRef="U_USD">-14685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_d1810b8b-1fde-4400-86a4-11fbb1a32563"
      unitRef="U_USD">-51971000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_ef04568a-57c1-4b38-ac14-c43acca8e743"
      unitRef="U_USD">-1832000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_5db507f8-2cb0-4660-b563-6ff3eb05185b"
      unitRef="U_USD">-9542000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_cfd8a552-da2a-4b78-8af6-688767662832"
      unitRef="U_USD">-12853000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_06f2168f-2b39-4e0e-9100-8f24fc99f4a3"
      unitRef="U_USD">-42429000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_eb270ec0-318d-4ee1-a029-3fe1bab9429d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_7b95d840-d1ce-4b54-b215-9e50116b466f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="2"
      id="F_dd81ffd0-f4bb-46f5-beb3-fe608b5f88c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-5.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="2"
      id="F_cb0ee9c3-11a7-4ce7-8a7f-a083261d14ab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-5.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="0"
      id="F_42225bb8-a9e8-4a47-a23e-c17e2a0dc8bb"
      unitRef="U_shares">9529123</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="0"
      id="F_79e6c010-0839-43b8-bcfd-29c764fc1614"
      unitRef="U_shares">9529123</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="0"
      id="F_e8676243-e2c1-4c0e-8ccd-7ccbc65868ba"
      unitRef="U_shares">7435472</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="0"
      id="F_04799b2e-e1b9-43a5-918a-9b6ca70566a7"
      unitRef="U_shares">7435472</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf"
      decimals="0"
      id="F_ab3092f6-982d-43ec-80c5-8e5dd9c03746"
      unitRef="U_shares">7435533</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf"
      decimals="-3"
      id="F_71412c82-1eb4-48ed-adc8-3cc4ac0df2bd"
      unitRef="U_USD">258294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2f539434-13da-4ff9-88f7-5a546b91d0a2"
      decimals="-3"
      id="F_c3ed298c-ce79-479c-89f2-b5a704c7f57b"
      unitRef="U_USD">13965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1b778e5-8b0d-438a-a6f2-684bd8df12a6"
      decimals="-3"
      id="F_1b0e6af8-2b11-454a-bc49-dbe2a5b8bdf2"
      unitRef="U_USD">-6038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_70f162d2-db64-4bf0-91a3-884865073097"
      decimals="-3"
      id="F_ea6cf7ad-1e1e-4119-86ec-6eafa700429f"
      unitRef="U_USD">-198266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_efb39ac6-6635-4769-9adb-c83b2a765c15"
      unitRef="U_USD">67955000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_c54d6f0f-6fce-44a5-ad0b-79bf1eed26d3"
      decimals="-3"
      id="F_590b42a5-d061-4ff6-910b-3a7d3f5568fd"
      unitRef="U_USD">-12853000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_a336dfa3-cbb2-4235-95da-f5e3b46f4186"
      unitRef="U_USD">-12853000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2"
      decimals="-3"
      id="F_1b04aab5-45dd-4216-89bd-359b41d0d4e2"
      unitRef="U_USD">913000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_b7d2e839-dce5-4af6-82d1-e6055ad6a992"
      unitRef="U_USD">913000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares
      contextRef="C_0cece337-a016-4efc-9a7d-ad4598442843"
      decimals="0"
      id="F_23d7ad6b-d557-4d79-bbff-a1a3db317ebe"
      unitRef="U_shares">1951371</acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares>
    <acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts
      contextRef="C_0cece337-a016-4efc-9a7d-ad4598442843"
      decimals="-3"
      id="F_c53a4233-2f19-4c4f-b34d-d17460d34bab"
      unitRef="U_USD">2744000</acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts>
    <acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts
      contextRef="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2"
      decimals="-3"
      id="F_d284088d-0f23-48bd-b1bd-b205048b64b0"
      unitRef="U_USD">2963000</acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts>
    <acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_63e1efe8-df07-48a9-815c-3712e4530584"
      unitRef="U_USD">5707000</acst:IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0cece337-a016-4efc-9a7d-ad4598442843"
      decimals="0"
      id="F_4fe1e1ee-1842-4659-9a6b-1486f969f83e"
      unitRef="U_shares">12500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a07bb7ed-62ec-4dc0-b219-9fe84ad13ee2"
      decimals="-3"
      id="F_5a39db27-3fd8-48dc-8640-b47a8e07aaee"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_ee04366e-1c58-4e66-a480-e8080d985305"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesOutstanding
      contextRef="C_1eefc74f-a703-4dea-ae7e-ea4e331b81be"
      decimals="0"
      id="F_6eac8188-85fc-45c7-89fb-3cf34d7d524a"
      unitRef="U_shares">9399404</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1eefc74f-a703-4dea-ae7e-ea4e331b81be"
      decimals="-3"
      id="F_d7e6231d-800b-4523-bef9-2d6bbcc18d9a"
      unitRef="U_USD">261038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cc0c4ab-5764-4050-862c-4ecc5ff57375"
      decimals="-3"
      id="F_06ca39c3-841c-4a6d-ad87-003d2804bda3"
      unitRef="U_USD">17862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f4f8e9bd-4546-4f0a-afa5-60be369c087e"
      decimals="-3"
      id="F_8b1833ed-0f1e-4ffc-a819-20713d3af0dc"
      unitRef="U_USD">-6038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f9bbd593-6189-421e-8104-e8b8f59ded6a"
      decimals="-3"
      id="F_f2cc1d4f-54e2-4690-9d54-cfaadc3ccd80"
      unitRef="U_USD">-211119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_32a7a448-dd2b-4b5e-a030-917d85f8629a"
      unitRef="U_USD">61743000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf"
      decimals="0"
      id="F_6cce119d-4671-4f48-a575-27d62e90422e"
      unitRef="U_shares">7381425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f4afbce0-5bdc-49e7-af1f-23d3ef8415bf"
      decimals="-3"
      id="F_722a45ce-0c51-4aa6-a2a7-74619297ae4f"
      unitRef="U_USD">257990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5e0b6d2b-f94b-4c26-b5cb-495d338020d6"
      decimals="-3"
      id="F_6108cdaf-33b6-4360-8ab8-497079a7a0ef"
      unitRef="U_USD">12154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f20daba8-2053-470f-8d6f-36c41659af0c"
      decimals="-3"
      id="F_4f851220-ad57-4f9b-a63f-a9b2089074ab"
      unitRef="U_USD">-6037000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7f5f8bdc-5660-4849-adbb-453fc624895a"
      decimals="-3"
      id="F_e80ecb25-ae67-413a-9dee-f46b7aec1063"
      unitRef="U_USD">-155837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261"
      decimals="-3"
      id="F_e884d014-2bed-45dd-aa37-4c5d3a7f49be"
      unitRef="U_USD">108270000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_95d10643-bfd0-4043-b9c9-ff71cc4ed89f"
      decimals="-3"
      id="F_c0e4cca5-6ea2-46a8-9ec0-bc4d8c0c1286"
      unitRef="U_USD">-42429000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_f7b4d33e-b5d6-43ba-986b-5dc652d54f82"
      unitRef="U_USD">-42429000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_212e94e2-e50a-4b7d-b58b-26d56a137061"
      decimals="-3"
      id="F_12a9e382-0bcf-4d96-a4d1-bd04a15ea7f3"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_aa97c3de-5496-4fad-ae1c-8174cc98c51e"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_f4272963-8b80-42bd-8469-469e87f57dc8"
      decimals="-3"
      id="F_fd375725-a618-40b2-814a-afbc867d30f5"
      unitRef="U_USD">1811000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_2126bf56-0e0b-49d0-a7e1-9b73d6e3a08c"
      unitRef="U_USD">1811000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_572273b4-60a1-4bad-97f2-b3aeeca1fc06"
      decimals="0"
      id="F_00957bbb-30ef-462a-9e3b-54e425e5ebef"
      unitRef="U_shares">54108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_572273b4-60a1-4bad-97f2-b3aeeca1fc06"
      decimals="-3"
      id="F_7976509c-f302-49a7-b64a-58ec0af96954"
      unitRef="U_USD">304000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_957d4a05-4849-43a2-b7c9-18e55f0aff11"
      unitRef="U_USD">304000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf"
      decimals="0"
      id="F_6187ea08-ea04-42ba-8f0e-8c6c98d1d642"
      unitRef="U_shares">7435533</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8a918cbd-dff3-4510-9992-8767c4195fdf"
      decimals="-3"
      id="F_46c5dbc0-f30e-4765-9927-fb0ca10565cd"
      unitRef="U_USD">258294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2f539434-13da-4ff9-88f7-5a546b91d0a2"
      decimals="-3"
      id="F_803a9196-9613-46fe-ad76-879d26772c81"
      unitRef="U_USD">13965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1b778e5-8b0d-438a-a6f2-684bd8df12a6"
      decimals="-3"
      id="F_f3650c96-b1f5-42f6-bcd4-7b1cf4e10d62"
      unitRef="U_USD">-6038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_70f162d2-db64-4bf0-91a3-884865073097"
      decimals="-3"
      id="F_956254cf-30c8-490e-b319-e092c4109d61"
      unitRef="U_USD">-198266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_1fd2959b-c206-49e0-a781-d27dba2cc9c4"
      unitRef="U_USD">67955000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_2a41cbbe-9e97-4c57-b54e-f9d5f4bf51c5"
      unitRef="U_USD">-12853000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_ff7682ff-0143-442c-a118-fab780748bf7"
      unitRef="U_USD">-42429000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_1fe34ff0-3c99-4215-9603-194dff18a36d"
      unitRef="U_USD">11000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_7a4df0cc-40f7-4b81-a3b2-6c9b7a519802"
      unitRef="U_USD">124000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_a658bff5-02a7-4463-b5d0-f6d76ed9a997"
      unitRef="U_USD">59000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_6736bd66-96b9-4a65-8a6f-18a450afda7c"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_7907314a-a8d5-4f69-a393-70181723642c"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_8d8b03c7-bfc5-4831-bfce-fd56b60b328e"
      unitRef="U_USD">28682000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <acst:ImpairmentOfGoodwill1
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_589929ed-a65e-4e06-ae89-011902e3d5f7"
      unitRef="U_USD">0</acst:ImpairmentOfGoodwill1>
    <acst:ImpairmentOfGoodwill1
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_a6a9a72e-b5b5-4a98-b9ff-8cedd837f6ea"
      unitRef="U_USD">-4826000</acst:ImpairmentOfGoodwill1>
    <acst:ImpairmentOfAssetHeldForSale
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_237b34c7-5b2e-4b71-88f3-a8fb22b30e9f"
      unitRef="U_USD">-0</acst:ImpairmentOfAssetHeldForSale>
    <acst:ImpairmentOfAssetHeldForSale
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_bce967e9-87de-48c4-8618-d9584d37816a"
      unitRef="U_USD">-400000</acst:ImpairmentOfAssetHeldForSale>
    <us-gaap:ShareBasedCompensation
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_b84b7168-2a28-49d9-ae97-d0ae57442e62"
      unitRef="U_USD">913000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_da4cdb14-46f3-4016-874c-76946e1b69fb"
      unitRef="U_USD">1811000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_fa3108da-de96-42af-8c2f-d5075917b828"
      unitRef="U_USD">2728000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_eb3150cf-f7d4-4250-a8a5-24dd2e8011d7"
      unitRef="U_USD">-10000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_49493f1a-467b-46c5-94dd-3f7a1d8d56b5"
      unitRef="U_USD">-1832000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_8aef0335-2abd-4a9a-9541-2b93ff2238b9"
      unitRef="U_USD">-9542000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_a476df59-d139-4f4e-98ed-ceca003c9064"
      unitRef="U_USD">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_85660b60-05aa-4d2e-b2c7-8f99d1406d8f"
      unitRef="U_USD">-5000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_c996dc32-1da9-41b6-82a1-2bf96fa4140f"
      unitRef="U_USD">-39000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_ed835153-6c1b-4b2b-b1e6-397af1ac7946"
      unitRef="U_USD">-39000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_02a46509-cfba-4f4b-a6cb-f0989397b1f6"
      unitRef="U_USD">-80000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_6fb715b6-abe0-439e-bdd0-2b36f357e330"
      unitRef="U_USD">302000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_7ef3c4fc-4c03-4d58-9941-202c50914fff"
      unitRef="U_USD">-315000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_84fba7b3-8968-4141-9627-37f55222a688"
      unitRef="U_USD">-72000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_7fd9cefd-bace-434e-b794-307e5064f2b0"
      unitRef="U_USD">-1652000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_016e9183-4bb3-4081-86c8-535a37f7409a"
      unitRef="U_USD">411000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_da710870-05b0-4d06-8159-19729418c3f9"
      unitRef="U_USD">-23000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_e401705f-9371-443c-b430-b2faddbc569a"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_0158e332-bdc3-48db-a7de-52d1b40721ff"
      unitRef="U_USD">-12333000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_bffeb912-5271-460b-8051-45b38fdfc206"
      unitRef="U_USD">-15913000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_2f7ece7b-e32c-4f11-bd9f-127f07e5cbab"
      unitRef="U_USD">22000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_df86e38d-01cd-4e16-b1c7-d68074a7acf3"
      unitRef="U_USD">17000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_c19b7458-7f25-43ed-8acc-421bc8958f7f"
      unitRef="U_USD">111000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_c647b55b-05d1-451c-b86c-595d889dc25f"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_94c0a30a-1f5f-4da9-85ed-fcbfba0f6694"
      unitRef="U_USD">6554000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_c68746b9-5557-4f2e-9618-a0245367e901"
      unitRef="U_USD">5015000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_8c9efc1d-5f73-4a3f-8e7f-dfcf78ddff98"
      unitRef="U_USD">6569000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_eb6c5c9a-4490-44a3-bea8-097189e67f19"
      unitRef="U_USD">18185000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_7cd913eb-49bb-4929-bf60-d4d8e222bc1c"
      unitRef="U_USD">104000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_119e8790-5cd0-4239-a69a-56b406484bbd"
      unitRef="U_USD">13153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <acst:NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_2de1275d-504b-453f-9ac8-5616b4b75fe6"
      unitRef="U_USD">7338000</acst:NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement>
    <acst:NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_cd088a98-76c8-481c-9595-98c4bfe10453"
      unitRef="U_USD">0</acst:NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement>
    <acst:ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_8e8b0838-224e-457d-8d78-576fcce504a6"
      unitRef="U_USD">21000</acst:ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions>
    <acst:ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_0cf9bae8-1042-4e7a-a90c-741720ec562f"
      unitRef="U_USD">0</acst:ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_dd669dd3-ef7b-44ee-a414-00f343cf4506"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_7ad8db12-df24-4fc0-9ff3-931f19d9f5d6"
      unitRef="U_USD">304000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_13ccfd91-0f21-496e-81d5-3a5f397500a6"
      unitRef="U_USD">7359000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_1290b572-2ef3-4370-a4b5-6b49f1f55b91"
      unitRef="U_USD">304000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <acst:EffectOfTranslationEffectOnCashAndCashEquivalents
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_8d0666ab-01b6-4ec1-bed3-c35a3a01b75f"
      unitRef="U_USD">0</acst:EffectOfTranslationEffectOnCashAndCashEquivalents>
    <acst:EffectOfTranslationEffectOnCashAndCashEquivalents
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_0cd88749-6b7a-40ad-8d91-1ce4f45ea878"
      unitRef="U_USD">-8000</acst:EffectOfTranslationEffectOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_d7710c4d-38c9-4c4a-a0b1-3dcdf39b0f85"
      unitRef="U_USD">-4870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_26fd3b1a-ac8c-4f20-8f0a-9260f5a7d253"
      unitRef="U_USD">-2464000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_3d7eb82a-7229-4fd8-8049-243de83a3dd3"
      unitRef="U_USD">27875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261"
      decimals="-3"
      id="F_ed780434-4458-4788-82c3-95df774531a9"
      unitRef="U_USD">30339000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_a48e5d56-cbd0-486e-96f2-2baea2a72ef2"
      unitRef="U_USD">23005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_22c40f7b-e5fa-4fdb-98d2-19207c5a7504"
      unitRef="U_USD">27875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:Cash
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_bf3c451b-8149-4008-9f87-3f63994b9938"
      unitRef="U_USD">3280000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_bb9bf14a-0fd3-4d36-81d5-c046149015af"
      unitRef="U_USD">17803000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_9b2453b4-ea0b-47ff-bb6a-2576aa8a971e"
      unitRef="U_USD">19725000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_b035eb0f-3d98-458d-9745-cd67c19b6a85"
      unitRef="U_USD">10072000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:NatureOfOperations
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_80ec9d93-58fa-43a6-aded-d2d676a07399">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Acasti Pharma Inc. (&#x201c;Acasti&#x201d; or the &#x201c;Company&#x201d;) is incorporated under the Business Companies Act (Qu&#xe9;bec) (formerly Part 1A of the Companies Act (Qu&#xe9;bec)). The Company is domiciled in Canada and its principal executive office is located at 103 Carnegie Center Suite 300 Princeton, New Jersey 08540.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Class A common shares, no par value per share (&#x201c;Common Shares&#x201d;), are listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) and, through March 27, 2023, the Company's Common Shares were also listed on the TSX Venture Exchange (&#x201c;TSXV&#x201d;), in each case, under the symbol &#x201c;ACST&#x201d;. On March 13, 2023, the Company received approval to voluntarily delist from the TSXV. Effective as at the close of trading on March 27, 2023, the Company's Common Shares are no longer listed and posted for trading on the TSXV.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2021, the Company completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (&#x201c;Grace Therapeutics&#x201d;), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Company is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and developing and commercializing products that improve clinical outcomes using its novel drug delivery technologies. The Company seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Company for further development may be already approved in the target indication or could be repurposed for use in new indications.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred operating losses and negative cash flows from operations in each year since its inception. The Company expects to incur significant expenses and continued operating losses for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company implemented a strategic realignment plan to enhance shareholder value that resulted in the Company engaging a new management team, streamlining its research and development activities and greatly reducing its workforce. Following the realignment, the Company is a smaller, more focused organization, based in the United States, and concentrated on its development of its lead product GTX-104. Further development of GTX-102 and GTX-101 will occur at such time when the Company is able to secure additional funding, or enters into strategic partnerships for license or sale with third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 24, 2023, the Company entered into a securities purchase agreement with certain institutional and accredited investors. Gross proceeds to the Company from this private placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, before deducting fees and expenses. The Company issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,951,371&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares, pre-funded warrants (the "Pre-funded Warrants") to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,106,853&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares, each at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8481&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Share and accompanying common warrants (the "Common Warrants" and, together with the Pre-funded Warrants, the "Warrants") to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,536,391&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares. The Company currently intends to use the net proceeds from the private placement for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, pre-commercial planning, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents, will be sufficient to fund the Company&#x2019;s operations into the second calendar quarter of 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will require additional capital to fund its daily operating needs beyond that time. The Company does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Company expects will take several years and is subject to significant uncertainty. To date, the Company has financed its operations primarily through public offerings and private placements of its Common Shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Company can generate significant revenue from drug product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financing or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Company to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy. The Company plans to raise additional capital in order to maintain adequate liquidity. Negative results from studies or trials, if any, or depressed prices of the Company&#x2019;s stock could impact the Company&#x2019;s ability to raise additional financing. Raising additional equity capital is subject to market conditions that are not within the Company&#x2019;s control. If the Company is unable to raise additional funds, the Company may not be able to realize its assets and discharge its liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;compliance with government regulations, protection of proprietary technology, dependence on third-party contractors and consultants and potential product liability, among others.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse stock split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 29, 2023, the Board of Directors of the Company approved an amendment to the Company's Articles of Incorporation to implement a reverse stock split of the Company's Common Shares, at a ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1-for-6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Reverse Stock Split&#x201d;). On July 4, 2023, the Company filed Articles of Amendment to its Articles of Incorporation with the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Registraire des entreprises du Qu&#xe9;bec&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to implement the Reverse Stock Split. All references in these financial statements to number of Common Shares, warrants and options, price per share and weighted-average number of shares outstanding have been adjusted to reflect the Reverse Stock Split, which became effective on July 10, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3"
      decimals="-3"
      id="F_6cec8059-ee9e-4e1f-979b-946a0b7592e5"
      unitRef="U_USD">7500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ebcea23f-4694-41c8-85d2-30c548c5e8cd"
      decimals="0"
      id="F_00472827-c20b-4281-ab50-115659bb94c1"
      unitRef="U_shares">1951371</us-gaap:CommonStockSharesIssued>
    <acst:PurchaseOfPreFundedWarrants
      contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3"
      decimals="0"
      id="F_5a8e1877-3bc7-4622-bcdc-fa0f5af08408"
      unitRef="U_shares">2106853</acst:PurchaseOfPreFundedWarrants>
    <acst:PurchasePricePerCommonShare
      contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3"
      decimals="4"
      id="F_1d42e8ef-f05a-465d-b41b-0791d50e56af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.8481</acst:PurchasePricePerCommonShare>
    <acst:PurchaseOfCommonShares
      contextRef="C_f21c94f8-89d0-43d9-9f7f-2cc6cf4735f3"
      decimals="0"
      id="F_dd6bce94-c818-4f99-88f2-c7ff770614aa"
      unitRef="U_shares">2536391</acst:PurchaseOfCommonShares>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_f6847874-0331-463a-bd4c-c694ab172b42"
      id="F_25a88d5f-f706-45d9-9852-8c6674c45b93">1-for-6</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_b725ae7b-bab1-4a35-9335-cad2e1cfb693">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of significant accounting policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). All intercompany transactions and balances are eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates are based on management&#x2019;s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates and assumptions include the measurement of stock-based compensation, derivative warrant liabilities, accruals for research and development contracts and contract organization agreements, and valuation of intangibles and goodwill. Estimates and assumptions are also involved in determining the extent to which research and development expenses qualify for research and development tax credits. The Company recognizes tax credits once it has reasonable assurance that they will be realized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents comprise of highly liquid investments purchased with original maturities of 90 days or less. Cash equivalents consist of guaranteed investment certificates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation is recognized on a declining basis over the estimated useful lives of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not yet in service, from the date they are ready for their intended use.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible assets - acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In a business combination, the fair value of in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired is capitalized and accounted for as indefinite-lived intangible assets, and not amortized until the underlying project receives regulatory approval, at which point the intangible assets will be accounted for as definite-lived intangible assets and amortized over the remaining useful life or discontinued. If discontinued, the intangible asset will be written off. Research and development (&#x201c;R&amp;amp;D&#x201d;) costs incurred after the acquisition are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method, which is a valuation methodology that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The significant assumptions used in the valuation are the discount rate, the probability of clinical success of research and development programs, obtaining regulatory approval and forecasted net sales, including milestone payments and royalty revenues.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews the recoverability of its finite long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not be recoverable. The carrying amount is first compared with the undiscounted cash flows. If the carrying amount is higher than the sum of undiscounted cash flows, then the Company determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the difference by which the carrying amount of the asset group exceeds the estimated fair value of the asset group.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeds the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than it's carrying amount, a quantitative impairment test is performed.  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's annual impairment test is performed in the fourth quarter of the fiscal year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and developments expenditures are expensed as incurred. These costs consist of employees&#x2019; salaries and benefits related to research and development activities, contractors and consultants that conduct the Company&#x2019;s clinical trials, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has in place a stock option plan for directors, officers, employees, and consultants of the Company, with grants under the stock option plan approved by the Company&#x2019;s Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant.  The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company measures the cost of such awards based on the fair value of the award at grant date and recognizes stock-based compensation expense in the Consolidated Statements of Operations and Comprehensive Loss on a tranche by tranche basis. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including fair value of the Common Shares at the grant date, expected term, historical volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior in determining compensation expense. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may be required in future periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Government grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;economic environment. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company&#x2019;s lease expense is recognized in research and development expenses. The Company does not have financing leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with FASB ASC 842&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;Topic 842&#x201d;), components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes comprises current and deferred taxes. The provision for income taxes is computed using the asset and liability method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realized (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Company has the right to set off the amount owed by with the amount owed by the other party, the Company intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses, and tax credits, reduced by a valuation allowance. A valuation allowance is recorded to reduce the carrying amount of deferred income tax assets when it is more likely than not that these assets will not be realized.  tax benefits related to tax positions not deemed to meet the &#x201c;more-likely-than-not&#x201d; threshold are not permitted to be recognized in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company presents basic and diluted earnings per share ("EPS") data for its Common Shares. Basic EPS is calculated by dividing the net income or loss attributable to the holders of Common Shares by the weighted average number of Common Shares outstanding during the year. Diluted EPS is determined by adjusting the net income or loss attributable to the holders of Common Shares and the weighted average number of Common Shares outstanding adjusted for the effects of all dilutive potential &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Shares, which comprise warrants and share options granted to employees. The basic and diluted EPS are the same due to loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable operating segment: the development and commercialization of pharmaceutical applications of its patent portfolio and licensed rights. The majority of the Company&#x2019;s assets are located in Canada and the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Derivative warrant liabilities are recognized initially at fair value. Subsequent to initial recognition, derivative warrant liabilities are measured at fair value, with changes in fair value are recognized in the Consolidated Statement of Operations and Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain of the Company&#x2019;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: defined as observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentration of credit risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are all invested in accordance with the Company&#x2019;s Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which risk is managed by dealing only with highly rated Canadian and U.S. institutions. The Company maintains its cash and cash equivalents at accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_5c259ea7-0066-4418-9f9b-c8c173f9ad5a">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;These consolidated financial statements of Acasti Pharma Inc., which include the accounts of its subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). All intercompany transactions and balances are eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_e64e5c19-bcd0-48e8-a1bf-be57b24bb436">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates are based on management&#x2019;s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates and assumptions include the measurement of stock-based compensation, derivative warrant liabilities, accruals for research and development contracts and contract organization agreements, and valuation of intangibles and goodwill. Estimates and assumptions are also involved in determining the extent to which research and development expenses qualify for research and development tax credits. The Company recognizes tax credits once it has reasonable assurance that they will be realized.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_67dbe5fe-e7ee-494e-8b67-e9df96aa2c5e">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents comprise of highly liquid investments purchased with original maturities of 90 days or less. Cash equivalents consist of guaranteed investment certificates.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_7f876a62-7b0b-41e3-b99c-451ffc34642a">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition. Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation is recognized on a declining basis over the estimated useful lives of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not yet in service, from the date they are ready for their intended use.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_9679d4bb-39a5-437b-b47d-911a42473dbe">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible assets - acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In a business combination, the fair value of in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired is capitalized and accounted for as indefinite-lived intangible assets, and not amortized until the underlying project receives regulatory approval, at which point the intangible assets will be accounted for as definite-lived intangible assets and amortized over the remaining useful life or discontinued. If discontinued, the intangible asset will be written off. Research and development (&#x201c;R&amp;amp;D&#x201d;) costs incurred after the acquisition are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method, which is a valuation methodology that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The significant assumptions used in the valuation are the discount rate, the probability of clinical success of research and development programs, obtaining regulatory approval and forecasted net sales, including milestone payments and royalty revenues.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_e774c604-7d67-4404-a9c5-1a59c570fe15">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews the recoverability of its finite long-lived assets whenever events or changes in circumstances indicate that it is carrying amount may not be recoverable. The carrying amount is first compared with the undiscounted cash flows. If the carrying amount is higher than the sum of undiscounted cash flows, then the Company determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the difference by which the carrying amount of the asset group exceeds the estimated fair value of the asset group.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeds the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than it's carrying amount, a quantitative impairment test is performed.  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's annual impairment test is performed in the fourth quarter of the fiscal year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_6be5a000-2d91-4598-8747-5771e4af0f95">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and developments expenditures are expensed as incurred. These costs consist of employees&#x2019; salaries and benefits related to research and development activities, contractors and consultants that conduct the Company&#x2019;s clinical trials, laboratory material and small equipment, clinical trial materials, stock-based compensation expense, and other non-clinical costs and regulatory fees. Advance payments for goods and services that will be used in future research and development are recognized in prepaids or other assets and are expensed when the services are performed, or the goods are used.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_6fdd032e-3665-4bfa-92ee-c217e66c00e0">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has in place a stock option plan for directors, officers, employees, and consultants of the Company, with grants under the stock option plan approved by the Company&#x2019;s Board of Directors. The plan provides for the granting of options to purchase Common Shares and the exercise price of each option equals the closing trading price of Common Shares on the day prior to the grant.  The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company measures the cost of such awards based on the fair value of the award at grant date and recognizes stock-based compensation expense in the Consolidated Statements of Operations and Comprehensive Loss on a tranche by tranche basis. The fair value of options is estimated for each tranche of an award that vests on a graded basis. The fair value of options is estimated using the Black-Scholes option pricing model, which uses various inputs including fair value of the Common Shares at the grant date, expected term, historical volatility, risk-free interest rate and expected dividend yields of the Common Shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior in determining compensation expense. If the actual forfeitures differ from those estimated by management, adjustment to compensation expense may be required in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <acst:GovernmentGrantsPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_0ae27b0a-e97d-46a3-b2ef-59c7382b7758">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Government grants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.&lt;/span&gt;&lt;/p&gt;</acst:GovernmentGrantsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_45d51790-a41a-4db2-9389-68aa18f4e0f5">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;economic environment. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company&#x2019;s lease expense is recognized in research and development expenses. The Company does not have financing leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with FASB ASC 842&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;Topic 842&#x201d;), components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_27be16ec-393d-4f46-88a0-e4ab6e41a236">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes comprises current and deferred taxes. The provision for income taxes is computed using the asset and liability method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts (tax base) of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax assets and liabilities are measured at the tax rate expected to apply when the underlying asset or liability is realized (settled) based on the rates that are enacted at the reporting date. Deferred tax assets and liabilities are offset if the Company has the right to set off the amount owed by with the amount owed by the other party, the Company intends to set off and the offset right is enforceable at law. A deferred tax asset is recognized for unused tax losses, and tax credits, reduced by a valuation allowance. A valuation allowance is recorded to reduce the carrying amount of deferred income tax assets when it is more likely than not that these assets will not be realized.  tax benefits related to tax positions not deemed to meet the &#x201c;more-likely-than-not&#x201d; threshold are not permitted to be recognized in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_6ebb31c3-3014-4468-b7aa-88db6557cbae">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company presents basic and diluted earnings per share ("EPS") data for its Common Shares. Basic EPS is calculated by dividing the net income or loss attributable to the holders of Common Shares by the weighted average number of Common Shares outstanding during the year. Diluted EPS is determined by adjusting the net income or loss attributable to the holders of Common Shares and the weighted average number of Common Shares outstanding adjusted for the effects of all dilutive potential &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Shares, which comprise warrants and share options granted to employees. The basic and diluted EPS are the same due to loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_19d00885-54dd-4d70-8433-01768adbe09e">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable operating segment: the development and commercialization of pharmaceutical applications of its patent portfolio and licensed rights. The majority of the Company&#x2019;s assets are located in Canada and the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="0"
      id="F_fdff9c43-7d69-4c4d-89b4-063ea832a471"
      unitRef="U_Vote">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_da4419ac-4431-4405-aaf3-5049ba0f3c73">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Derivative warrant liabilities are recognized initially at fair value. Subsequent to initial recognition, derivative warrant liabilities are measured at fair value, with changes in fair value are recognized in the Consolidated Statement of Operations and Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_c36f0f2d-a4f0-4c8b-8510-45cee84aab52">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain of the Company&#x2019;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: defined as observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, short-term investments and trade and other payables) approximate their fair value given the short-term nature of these instruments. The Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_d85ce098-efbd-415f-aff1-281698feeddb">&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentration of credit risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-0.013%;padding-left:0.013%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are all invested in accordance with the Company&#x2019;s Investment Policy with the primary objective being the preservation of capital and the maintenance of liquidity, which risk is managed by dealing only with highly rated Canadian and U.S. institutions. The Company maintains its cash and cash equivalents at accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_677ac61f-77cc-4515-b095-cb23a25a8289">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_42ad632b-b375-45d3-8c7a-fec47c42e16f">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Fair value measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.435%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.056%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.435%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Quoted prices in active markets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Guaranteed investment certificates and term deposits&lt;br/&gt;&#160;&#160;&#160;classified as cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Derivative warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets measured at fair value on a recurring basis as of March 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.058%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.405%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.323%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.024%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.405%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.541%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Quoted prices in active markets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Term deposits classified as cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Guaranteed investment certificate classified as a&lt;br/&gt;&#160;&#160;&#160;short-term investment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f132cd30-7902-4315-8127-ab7bcce7e6f9;"&gt;&lt;span style="-sec-ix-hidden:F_c1a9517d-f266-4d79-aeb0-1c8917bd2b32;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; changes in valuation techniques or transfers between Levels 1, 2 or 3 during the years ended March 31, 2024 and 2023. The Company&#x2019;s derivative warrant liabilities are measured at fair value on a recurring basis using unobservable inputs that are classified as Level 3 inputs. Refer to Note 10(b) for the valuation techniques and assumptions used in estimating the fair value of the derivative warrant liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_2fef1530-7154-4dd3-9773-8fbc25066e3b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.435%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.056%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.435%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.479%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Quoted prices in active markets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Guaranteed investment certificates and term deposits&lt;br/&gt;&#160;&#160;&#160;classified as cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Derivative warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets measured at fair value on a recurring basis as of March 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.058%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.405%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.323%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.024%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.405%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.541%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Quoted prices in active markets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Term deposits classified as cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Guaranteed investment certificate classified as a&lt;br/&gt;&#160;&#160;&#160;short-term investment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_f7723e47-a56e-4be6-bb22-779ed52e9119"
      unitRef="U_USD">19725000</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768"
      decimals="-3"
      id="F_fd842b07-69d4-45a2-99b0-637d2d25961f"
      unitRef="U_USD">19725000</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed"
      decimals="-3"
      id="F_2b5e912a-10c6-4bd1-a248-39926e0454c6"
      unitRef="U_USD">0</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278"
      decimals="-3"
      id="F_edba0203-cbd3-4f0d-9842-6cec9e620682"
      unitRef="U_USD">0</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_03ba9a99-86da-417e-9451-1f7b7ababb26"
      unitRef="U_USD">19725000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768"
      decimals="-3"
      id="F_ac570e2a-59b6-4f54-955e-7488d33e4968"
      unitRef="U_USD">19725000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed"
      decimals="-3"
      id="F_6c16def0-d7a5-4a02-859b-d753d06eea45"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278"
      decimals="-3"
      id="F_44540058-a391-4fec-9715-e97bf3e15745"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_caf8a656-4e7f-417f-aa93-f18db75d6131"
      unitRef="U_USD">4359000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768"
      decimals="-3"
      id="F_0a8e54f2-4a12-48e0-9f65-b7c12c9b4159"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed"
      decimals="-3"
      id="F_e415c239-1d00-49a6-88d5-2e6dc408f20c"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278"
      decimals="-3"
      id="F_c79e0ddb-48e7-4319-831b-b994bb57e2f5"
      unitRef="U_USD">4359000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_a2a69737-96d5-47fe-a6a7-5c44ebe725ea"
      unitRef="U_USD">4359000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_ec22031c-0a4b-4387-bbb7-0033acfa1768"
      decimals="-3"
      id="F_096004b5-bacb-4a3e-9ae7-561fcdb66e80"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_04d7ced9-bf3d-4b73-8054-c83f40a853ed"
      decimals="-3"
      id="F_e1db195b-3589-4ed5-9ff2-2a76456e289d"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_af2c1513-5cb1-454d-9540-187ad7be9278"
      decimals="-3"
      id="F_885056be-521e-4442-8452-033ac151a647"
      unitRef="U_USD">4359000</us-gaap:LiabilitiesFairValueDisclosure>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_e13c5d88-8f1a-47f1-84af-c7702c27a991"
      unitRef="U_USD">10072000</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970"
      decimals="-3"
      id="F_bf48f553-93e3-418d-a451-3166722a0500"
      unitRef="U_USD">10072000</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_3475cb4c-b4fd-423d-8077-b5c595ff8757"
      decimals="-3"
      id="F_acf5e38b-3a41-4c35-844c-5bc4ccb345d9"
      unitRef="U_USD">0</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <acst:GuaranteedInvestmentCertificatesAndTermDeposits
      contextRef="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c"
      decimals="-3"
      id="F_d82e6e3c-0c92-4431-89ab-2663a3e5805a"
      unitRef="U_USD">0</acst:GuaranteedInvestmentCertificatesAndTermDeposits>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_17506f3c-f0be-48ee-95d6-35dfe4a64359"
      unitRef="U_USD">15000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970"
      decimals="-3"
      id="F_900f02bb-a6e1-42f7-9067-a97588f8a34a"
      unitRef="U_USD">15000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_3475cb4c-b4fd-423d-8077-b5c595ff8757"
      decimals="-3"
      id="F_7dc9f73c-3f26-4614-86b3-79e27ce51fc1"
      unitRef="U_USD">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c"
      decimals="-3"
      id="F_469b92a0-6b9c-44e1-8994-962971e68645"
      unitRef="U_USD">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_a81c8e58-c071-4305-ab7a-e814ad636eb8"
      unitRef="U_USD">10087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c3d1f9b7-539c-4a82-93f3-bd3cf0c17970"
      decimals="-3"
      id="F_0c24cd06-b4ac-44f3-94e9-3983a1902ddc"
      unitRef="U_USD">10087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3475cb4c-b4fd-423d-8077-b5c595ff8757"
      decimals="-3"
      id="F_fba3f056-1499-46f4-97b6-a4e9fe2b1ffa"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_12a9a6c2-5331-4a9a-8180-e413ebcb602c"
      decimals="-3"
      id="F_0a7f795f-6d70-4361-b950-c22a53020677"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_5a67e05b-e3d9-421c-b07c-3f105ad0e87e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales tax receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government assistance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government assistance is comprised of research and development investment tax credits from the Qu&#xe9;bec provincial government, which relate to quantifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.&lt;/span&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_00751df3-3ea4-4b24-a170-e94234ad03f6">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales tax receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government assistance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <acst:SalesTaxReceivablesCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_c284f9e1-ed45-464a-895b-9b08d1e27c2f"
      unitRef="U_USD">316000</acst:SalesTaxReceivablesCurrent>
    <acst:SalesTaxReceivablesCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_df88d46a-cd8d-49d1-9a1a-249f97286584"
      unitRef="U_USD">338000</acst:SalesTaxReceivablesCurrent>
    <acst:GrantsAndInvestmentTaxCreditReceivable
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_1dd115e4-2e9d-4092-9a41-0522a9cef1d0"
      unitRef="U_USD">356000</acst:GrantsAndInvestmentTaxCreditReceivable>
    <acst:GrantsAndInvestmentTaxCreditReceivable
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_616012ab-ee5e-4770-b620-1a574f4c61f8"
      unitRef="U_USD">412000</acst:GrantsAndInvestmentTaxCreditReceivable>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_3d99bc33-8148-4277-afe1-a93a97977663"
      unitRef="U_USD">15000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_fea952e6-cdf2-49d8-a93c-26938e514655"
      unitRef="U_USD">52000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_1e59b84f-3ecf-4669-b2d2-c8f8a1e76abf"
      unitRef="U_USD">35000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_f9cf3f61-2291-4588-8e32-3f73c902bd4f"
      unitRef="U_USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_610729d6-1b22-4a62-b620-7d5877766fd4"
      unitRef="U_USD">722000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_a30fda9f-3037-4cba-aab9-5bf6d6623c1a"
      unitRef="U_USD">802000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_0411cb57-7abf-4e96-9e38-2cb785fd397b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following is a summary of equipment, net:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net book&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net book&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_95af6580-dd2a-434f-90c8-850747b24b73">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following is a summary of equipment, net:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net book&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Write-off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net book&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd"
      decimals="-3"
      id="F_b046a7cc-4d5b-434b-b5cc-bb3547f85a11"
      unitRef="U_USD">18000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd"
      decimals="-3"
      id="F_ec1015bc-213e-4a86-9a12-cb81726e310d"
      unitRef="U_USD">13000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd"
      decimals="-3"
      id="F_c19e8e98-fdde-468e-966b-6bec217617cb"
      unitRef="U_USD">-4000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_dc813500-db81-42bc-be45-0769d86cdfbd"
      decimals="-3"
      id="F_f4b5818c-a2b8-4819-9780-59e058cf44e7"
      unitRef="U_USD">1000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4"
      decimals="-3"
      id="F_ea13c184-75c0-4c9c-8a74-7eed3ba9c701"
      unitRef="U_USD">114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4"
      decimals="-3"
      id="F_76bc1df2-b5cc-413b-ba86-99ae915f3ee6"
      unitRef="U_USD">76000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4"
      decimals="-3"
      id="F_de3d0dfd-4bfb-46e2-b683-1cb4ccdb141d"
      unitRef="U_USD">-34000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_50bbc2ae-76a4-43e0-848e-139f93c827d4"
      decimals="-3"
      id="F_d023ad50-6481-41bd-81c2-aadf0beaad28"
      unitRef="U_USD">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1"
      decimals="-3"
      id="F_aca4f77c-7588-4bed-b6c4-7b962075344e"
      unitRef="U_USD">571000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1"
      decimals="-3"
      id="F_39e3eb7b-5c02-4ca5-85fc-af3519ed82f0"
      unitRef="U_USD">519000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1"
      decimals="-3"
      id="F_d87309f4-844a-458b-bd02-014fbac77eee"
      unitRef="U_USD">-52000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_96f34336-bce0-4b05-bf5a-f6a008568ba1"
      decimals="-3"
      id="F_a6f54433-d3d7-4861-9574-c76f1643eb65"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897"
      decimals="-3"
      id="F_54356db1-0e83-4605-af80-d02343b930eb"
      unitRef="U_USD">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897"
      decimals="-3"
      id="F_8e43ca8a-19d2-493c-98ac-c39074460821"
      unitRef="U_USD">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897"
      decimals="-3"
      id="F_a2a32f02-dfdf-461d-bec3-b8066cec96b9"
      unitRef="U_USD">0</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3487dee3-4575-436c-8773-9c3b4bf9b897"
      decimals="-3"
      id="F_fc5cf637-f250-40a8-8616-becf48a8b64b"
      unitRef="U_USD">19000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_205041de-d661-41c7-928e-150a2c2a66e0"
      unitRef="U_USD">722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_7cca200e-8804-4d69-ba71-6f0269a38c71"
      unitRef="U_USD">608000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_2f1bfb36-40eb-4a91-8847-77fd4b31f6bd"
      unitRef="U_USD">-90000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_b0272365-6bf5-41b2-999b-ba5154718e5d"
      unitRef="U_USD">24000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78"
      decimals="-3"
      id="F_2600502f-f188-4986-a9b4-e0c60d72e62e"
      unitRef="U_USD">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78"
      decimals="-3"
      id="F_c8ea8292-5120-4bbe-82c2-648fc6b673f6"
      unitRef="U_USD">11000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78"
      decimals="-3"
      id="F_212b07a1-2585-4cec-a817-adfd97022237"
      unitRef="U_USD">-1000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3acbfd2e-cc52-456d-8a30-89f859728e78"
      decimals="-3"
      id="F_6e322f95-7ddf-49d4-8540-002da5740af6"
      unitRef="U_USD">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159"
      decimals="-3"
      id="F_050cc712-09b0-47d0-8d4c-4205b8f62969"
      unitRef="U_USD">108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159"
      decimals="-3"
      id="F_b28aab32-8853-4908-af1e-36dd8de7683c"
      unitRef="U_USD">47000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159"
      decimals="-3"
      id="F_be93c53c-b0bd-47dd-a2ef-1a82a02ddd42"
      unitRef="U_USD">-22000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ece0ac7f-6585-46e8-9205-a30ad7140159"
      decimals="-3"
      id="F_ced1ffc8-cf1b-42a8-9e78-8d91f5d853f5"
      unitRef="U_USD">39000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654"
      decimals="-3"
      id="F_19b3b4e2-d8fc-46c1-87aa-d5ac8c4cd0f5"
      unitRef="U_USD">586000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654"
      decimals="-3"
      id="F_a04b1b25-774d-4484-8aad-ddee9c22ac02"
      unitRef="U_USD">512000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654"
      decimals="-3"
      id="F_fffb1f6a-c18b-4a07-8533-c43f319eb7b1"
      unitRef="U_USD">-16000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6b745745-fcfd-4873-8e48-fa848811c654"
      decimals="-3"
      id="F_7f0e7c79-8b86-4a58-b353-16b4cfce7e38"
      unitRef="U_USD">58000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_679f4231-d50a-4908-9c5d-e1ed5b9e77f2"
      unitRef="U_USD">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_12e5f409-8969-4c76-bd8c-90f02033e282"
      unitRef="U_USD">570000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <acst:WriteOff
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_a8d7d751-7e55-4f62-8eff-d736c0314cfa"
      unitRef="U_USD">-39000</acst:WriteOff>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_4529ff8f-bd51-4107-ae6a-3af0679df53b"
      unitRef="U_USD">104000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_9c40fa15-0f97-409c-a641-897a2176066d"
      unitRef="U_USD">11000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_c6d69755-6fae-495b-aa8c-f85e91fc892d"
      unitRef="U_USD">124000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_37cd78ab-9819-4744-bada-4ff3ea975808">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Intangible assets and goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Individual IPR&amp;amp;D projects and goodwill are tested for impairment on an annual basis in the fourth quarter, and in between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of each technology or our reporting unit below its carrying value. In April 2023, the Company announced its strategic realignment plan to prioritize resources to GTX-104, from GTX-101 and GTX-102 triggering a comprehensive review as of March 31, 2023. The estimated fair values of identifiable intangible assets were determined using the multi-period excess earnings method. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair value of the reporting unit was determined using the projected discounted cash flow model. The impairment assessments resulted in the following activity during the years ended March 31, 2024 and 2023: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GTX-104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GTX-102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GTX-101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible assets &#x2013; in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;27,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;9,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;4,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;41,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;27,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;9,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;4,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;41,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the impairment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,682&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the intangible assets resulted in a recovery of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,633&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the related deferred tax liability.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:25.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;8,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;8,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The multi-period excess earnings method models used to estimate the fair value of assets of our IPR&amp;amp;D reflect significant assumptions and are level 3 unobservable data regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Probability of clinical success of research and development and obtaining regulatory approval;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Forecasted net sales from up-front and milestone payments, royalties and product sales; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A discount rate reflecting our weighted average cost of capital and specific risk inherent in the underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's IPR&amp;amp;D projects, consistent with others in our industry, have risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. It is not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;amp;D projects may vary from their estimated fair values.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ba8197c4-b282-44be-b0d3-31d41ea2712f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair value of the reporting unit was determined using the projected discounted cash flow model. The impairment assessments resulted in the following activity during the years ended March 31, 2024 and 2023: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GTX-104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GTX-102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GTX-101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intangible assets &#x2013; in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;27,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;9,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;4,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;41,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;27,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;9,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;4,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;41,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_c4d697ac-eda3-4464-bee3-640ff429e5f1"
      decimals="-3"
      id="F_584549cc-ec87-4318-b6f0-c46aee6f26a2"
      unitRef="U_USD">27595000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_99120ca0-a7fe-43e2-936c-fcfed03ae232"
      decimals="-3"
      id="F_67d8690a-1c7b-48bb-8c19-d81860362d84"
      unitRef="U_USD">31908000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_e2b01b48-402b-4dc7-b752-a7f73d31bb54"
      decimals="-3"
      id="F_02940392-f4a9-4e60-9fed-48d01709931e"
      unitRef="U_USD">10307000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261"
      decimals="-3"
      id="F_50c017fc-8715-436d-b2b1-e43a48c2c363"
      unitRef="U_USD">69810000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_7da7b073-43df-4431-96b2-512ccdc4cb73"
      decimals="-3"
      id="F_56f78b73-44f8-4a85-8a95-2c6a401efe80"
      unitRef="U_USD">0</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_16d16afb-4a44-408e-a2a5-100f7c0b1fbb"
      decimals="-3"
      id="F_fd28ed4f-eee4-4830-a5e4-a1e04db997c6"
      unitRef="U_USD">-22712000</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_2c54e8e1-ca7e-47f6-aaac-354c7f5c59dd"
      decimals="-3"
      id="F_9c94791f-026d-47bd-b6b5-11b3a9ec4052"
      unitRef="U_USD">-5970000</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_a40435e1-9588-4c44-883f-3628faa8131b"
      unitRef="U_USD">-28682000</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_8c949238-1cb2-49d3-a7a9-6006bf23a15b"
      decimals="-3"
      id="F_8df05f7e-025b-43a5-8ee3-ae0cc5583652"
      unitRef="U_USD">27595000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0d061b65-1b50-45f5-aae5-b793fa09c563"
      decimals="-3"
      id="F_4c904fb3-a2ed-4b3a-82ca-ecb4d1d865e0"
      unitRef="U_USD">9196000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_189b018a-6b9e-4d85-84a9-062a43fb0c41"
      decimals="-3"
      id="F_0de7b709-3cf7-420a-b204-1a5cb4b12bc1"
      unitRef="U_USD">4337000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_ca5b14ec-6228-4fca-a053-fe35d46b8fd4"
      unitRef="U_USD">41128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_f3eda1d7-9329-4b09-81c9-72ab4a9683c2"
      decimals="-3"
      id="F_ac3d3bf4-d0c2-4236-91e3-34a8a84c29b2"
      unitRef="U_USD">0</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_58a0300e-46b5-4e90-9cfb-76e05e952710"
      decimals="-3"
      id="F_7ee587e9-bc8f-47cd-9d82-340cb8e0d9bb"
      unitRef="U_USD">0</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_67401b5c-e353-4b98-9f09-f2f145bc81df"
      decimals="-3"
      id="F_b29b39dc-4901-4790-9760-7c793e609b9d"
      unitRef="U_USD">0</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_c2201893-8c2f-420e-b707-821c0438706a"
      unitRef="U_USD">0</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_5c543260-cf22-4eb7-a1f7-51cc4741bc47"
      decimals="-3"
      id="F_47771f4e-ee7d-4e8d-88c9-816c08026dca"
      unitRef="U_USD">27595000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_b8860ddc-a67b-4cbc-b6fe-22b8b851fe21"
      decimals="-3"
      id="F_9f9043db-8d98-40c2-b535-5f9d6505c035"
      unitRef="U_USD">9196000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_5eeacd49-7941-4477-961d-d7f222f3cc8f"
      decimals="-3"
      id="F_790c340f-049f-48ed-8063-8dc3759910e2"
      unitRef="U_USD">4337000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_f92bbd71-e350-494d-89e5-6f783ef10143"
      unitRef="U_USD">41128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_7ae3d634-09e9-48e4-9f99-bee81d6cd39c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the impairment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,682&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the intangible assets resulted in a recovery of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,633&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the related deferred tax liability.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:25.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;8,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;8,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_d08c83e9-843f-4b57-8d19-c1ceb3da11eb"
      unitRef="U_USD">-28682000</acst:ImpairmentOfTheIntangibleAssetsIndefiniteLived>
    <acst:ImpairmentRelatedDeferredTaxLiability
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_07a76a05-60e5-42c7-aea8-fe093a628ec1"
      unitRef="U_USD">8633000</acst:ImpairmentRelatedDeferredTaxLiability>
    <us-gaap:Goodwill
      contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261"
      decimals="-3"
      id="F_57ff17a6-56ea-4370-acaa-6131ced19bd0"
      unitRef="U_USD">12964000</us-gaap:Goodwill>
    <acst:ImpairmentOfGoodwill1
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_a707a420-a376-4cd8-9992-d8e5b5e4b2d7"
      unitRef="U_USD">-4826000</acst:ImpairmentOfGoodwill1>
    <us-gaap:Goodwill
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_04db077a-2427-429d-9e59-f22ce0a21535"
      unitRef="U_USD">8138000</us-gaap:Goodwill>
    <acst:ImpairmentOfGoodwill1
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_81071468-52ef-4fd0-8f8a-abac857db10c"
      unitRef="U_USD">-0</acst:ImpairmentOfGoodwill1>
    <us-gaap:Goodwill
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_ab9d40f0-42ae-443a-9da0-5726b81e6298"
      unitRef="U_USD">8138000</us-gaap:Goodwill>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_d5591cf4-030a-4f11-b2be-23e4c65e0a20">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued liabilities and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee salaries and benefits payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_863d2812-d061-42c9-b741-bf5309a38ace">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued liabilities and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee salaries and benefits payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e1a1d112-95bc-4ef5-a172-c8e3d67564e1"
      unitRef="U_USD">1007000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_ad71fe9b-53b8-4e69-84a8-1110442412f5"
      unitRef="U_USD">1242000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_561ccd08-8fe1-41d1-9e5e-ccb88edb1713"
      unitRef="U_USD">176000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_91bd0fd2-aaf1-4504-a26d-22a92f2ec3ca"
      unitRef="U_USD">946000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e7cc40ad-fc70-444f-8289-d0fd702fe3f6"
      unitRef="U_USD">501000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_9e148ec4-2973-4f79-967f-9aed4d224bc0"
      unitRef="U_USD">1148000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_2659f050-f9eb-4163-b17d-7f4d028ca433"
      unitRef="U_USD">1684000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_13ceec25-ad8c-4a30-8019-9eef433b6fc0"
      unitRef="U_USD">3336000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ab33d169-65d4-469f-9974-712967085d97">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has historically entered into lease arrangements for its research and development and quality control laboratory facility located in Sherbrooke, Qu&#xe9;bec. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2022, the Company renewed the lease agreement effective April 1, 2022, resulting in a commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-month base lease term with an option to renew for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-month term. In April 2023, the Company elected not to renew the additional 48-month option to renew, and terminated the lease on March 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental lease expense related to leases is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.792%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.939%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.916%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.939%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.416%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the year ended March 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.564%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.202%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows for operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_35eb60b8-303d-4e25-9601-0886d5998462;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As the Company's lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. As of March 31, 2024, there were no future minimum lease payments.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_10c309e4-777a-472f-b8a6-870edb6d5365">In March 2022, the Company renewed the lease agreement effective April 1, 2022, resulting in a commitment of $556 over a 24-month base lease term with an option to renew for an additional 48-month term. In April 2023, the Company elected not to renew the additional 48-month option to renew, and terminated the lease on March 31, 2024.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:PaymentsForRent
      contextRef="C_c73f5261-e930-4ac2-9ecb-307f85b47d05"
      decimals="-3"
      id="F_9d1f278a-b1a8-4a28-94b1-35086364f21d"
      unitRef="U_USD">556000</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_0238deb6-4fe5-4dd5-8a50-1ee0d936549a"
      id="F_b934036a-3c52-443d-86f4-e0d3a4e798a4">P24M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0238deb6-4fe5-4dd5-8a50-1ee0d936549a"
      id="F_18d4d07f-1c55-459e-a1a7-3e00bc5a25d6">P48M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <acst:SupplementalBalanceSheetInformationTableTextblock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_9fc3ee98-75de-4cbb-a6a6-88f9ec97cf6d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.914%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acst:SupplementalBalanceSheetInformationTableTextblock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_3e0542e2-ca3a-4a1f-a5d2-91d0250a47f4"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_b4891581-281c-45d8-80c6-37ea51ea5d04"
      unitRef="U_USD">463000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_2e81e2e4-7e19-4b31-88ad-19bb5394b2e8"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_4f1fc8b7-5602-4fe7-aecc-6f8cc824c015"
      unitRef="U_USD">75000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_1b108ce8-6a49-44b4-a92a-947b96f2be1d"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_2f4fa3b4-0657-414b-8a56-50a791732f03"
      unitRef="U_USD">410000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_ac05bc6c-eddc-4cc5-a783-7924645add4a"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_7c7cde41-cbe9-46f3-bed0-e425dd22badd"
      unitRef="U_USD">485000</us-gaap:OperatingLeaseLiability>
    <acst:LeaseExpenseTableTextblock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_13becb46-7267-408a-b935-eec3348dc7ae">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental lease expense related to leases is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.792%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.939%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.916%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.939%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.416%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acst:LeaseExpenseTableTextblock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_79cb0979-a860-4fea-901e-b5dfdb9d3c7d"
      unitRef="U_USD">93000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_9c45c387-949a-4c22-a1e9-ac373ee5942b"
      unitRef="U_USD">206000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_fd4b7bac-bd0e-4b5a-9f76-3dfba16f6f1b"
      unitRef="U_USD">93000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_1ca2c7d0-d913-453f-99db-0a660f36a273"
      unitRef="U_USD">206000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_faec340f-b632-4906-9d4a-e3b094ff3904">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the year ended March 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.235%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.564%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.202%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows for operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_35eb60b8-303d-4e25-9601-0886d5998462;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_9c5161fb-5324-41e9-832d-2f12a6b7240a"
      unitRef="U_USD">93000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="3"
      id="F_9d9d86de-aa35-4938-9622-a4b5902846db"
      unitRef="U_pure">0.043</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_80656a46-cb17-48f1-9fec-a1fc4245b81d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Shareholders' equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Authorized capital stock&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x27a3;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Class A common shares ("Common Shares"), voting (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote per share), participating and without par value. As of March 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,399,404&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x27a3;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Class B common shares, voting (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; votes per share), non-participating, without par value and maximum annual non-cumulative dividend of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the amount paid per share. Class B common shares are convertible, at the holder&#x2019;s discretion, into Common Shares, on a one-for-one basis, and Class B common shares are redeemable at the holder&#x2019;s discretion for CAD $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, subject to certain conditions. As of March 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Class B common shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x27a3;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Class C common shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the amount paid per share. Class C common shares are convertible, at the holder&#x2019;s discretion, into Common Shares, on a one-for-one basis, and Class C common shares are redeemable at the holder&#x2019;s discretion for CAD $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, subject to certain conditions. As of March 31, 2024, there were no Class C common shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x27a3;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Class D and E common shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the amount paid per share. Class D and E common shares are convertible, at the holder&#x2019;s discretion, into Common Shares, on a one-for-one basis, and Class D and E common shares are redeemable for the price paid for such shares, plus a redemption premium described in the Company's Articles of Incorporation, as amended, at the holder&#x2019;s discretion, subject to certain conditions. As of March 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Class D or E common shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Private Placement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional and accredited investors in connection with a private placement of the Company's securities (the &#x201c;Offering&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to offer and sell &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,951,371&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares, at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.848&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Share and Pre-funded Warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,106,853&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares at a purchase price equal to the purchase price per Common Share less $0.0001. Each Pre-funded Warrant is exercisable for one Common Share at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Share, is immediately exercisable, and will expire once exercised in full. Pursuant to the Purchase Agreement, the Company also issued to such institutional and accredited investors Common Warrants to purchase Common Shares, exercisable for an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,536,391&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares. Under the terms of the Purchase Agreement, for each Common Share and each Pre-funded Warrant issued in the Offering, an accompanying five-eighths (0.625) of a Common Warrant was issued to the purchaser thereof. Each whole Common Warrant is exercisable for one Common Share at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Share, is immediately exercisable, and will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company&#x2019;s product candidate GTX-104 or (ii) five years from the date of issuance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Offering closed on September 25, 2023. The Offering included the issuance of Common Shares, Pre-funded Warrants, and Common Warrants to related parties Shore Pharma LLC, an entity that was controlled by Vimal Kavuru, the Chair of our Board of Directors, at the time of the Offering and SS Pharma LLC, resulting in proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The net proceeds to the Company from the Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,338&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, after deducting fees and expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;At-the-Market (&#x201c;ATM&#x201d;) Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2020, the Company entered into an amended and restated sales agreement (the &#x201c;Sales Agreement&#x201d;) with B. Riley FBR, Inc. (&#x201c;B.Riley&#x201d;), Oppenheimer &amp;amp; Co. Inc. and H.C. Wainwright &amp;amp; Co., LLC (collectively, the &#x201c;Agents&#x201d;) to amend the Company&#x2019;s existing ATM program. Under the terms of the Sales Agreement, which had a three-year term, the Company could issue and sell from time to time, Common Shares having aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through the Agents. Subject to the terms and conditions of the Sales Agreement, the Agents would use their commercially reasonable efforts to sell the Common Shares from time to time, based upon the Company&#x2019;s instructions. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; obligation to sell any of the Common Shares and could, at any time, suspend sales under the Sales Agreement. The Company and the Agents could terminate the Sales Agreement in accordance with its terms. Under the terms of the Sales Agreement, the Company provided the Agents with customary indemnification rights and the Agents were entitled to compensation at a commission rate equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross proceeds from each sale of the Common Shares. The Sales Agreement expired pursuant to its terms on June 29, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares were sold under the ATM program. During the year ended March 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,108&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares were sold for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;304&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with commissions, legal expenses and costs related to the share sale amounting to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Common Shares were sold at the prevailing market prices, which resulted in an average price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 9, 2023, warrants issued pursuant to the Company&#x2019;s May 2018 Canadian public offering to acquire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,370&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares at an exercise price of CAD $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; expired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As further discussed above, on September 25, 2023, the Company issued Warrants exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,643,244&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares in the Offering pursuant to the terms of the Purchase Agreement entered into with certain institutional and accredited investors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Common Warrants issued as a part of the Offering are derivative warrant liabilities given the warrant indenture did not meet the fixed-for-fixed criterion and that the Common Warrants are not indexed to the Company&#x2019;s own stock. Proceeds were allocated amongst Common Shares, Pre-funded Warrants, and Common Warrants by applying the residual method, with fair value of the Common Warrants determined using the Black-Scholes model, resulting in an initial warrant liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of issuance costs allocated to Common Warrants. Accordingly, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,822&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,047&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of gross proceeds were allocated to Common Shares and Pre-funded Warrants, respectively; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of issuance costs were allocated to Common Shares and Pre-funded Warrants, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.093%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.063%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issued during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The warrant liability was determined based on the fair value of warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) five years from the date on issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.806%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.558%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.558%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 25, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected warrant life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions were prorated based on the probability of the warrant liability expiring on the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 and of it expiring on five years from the date of issuance. The weighted-average fair values of the Common Warrants were determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Warrant, as of September 25, 2023 and March 31, 2024, respectively. The risk-free interest rate at the issue date and on the reporting date of March 31, 2024 was based on the interest rate corresponding to the U.S. Treasury rate issue with a remaining term equal to the expected term of the warrants. The expected volatility was based on the historical volatility for the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At March 31, 2024, the Company had outstanding Common Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,536,391&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, all of which were classified as derivative warrant liability. At March 31, 2024, the Company had outstanding Pre-funded Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,106,853&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, all of which were classified within shareholders' equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the years ended March 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants were exercised.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <acst:CommonStockVotesPerShare
      contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e"
      decimals="0"
      id="F_19e19a8a-dfd5-4f5f-881d-2983902aa5ee"
      unitRef="U_Vote">1</acst:CommonStockVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e"
      decimals="0"
      id="F_16885fc0-72dc-46d8-a853-afe8fcac6684"
      unitRef="U_shares">9399404</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d9cd2f0d-c88c-4807-bdcd-aee8f1691d2e"
      decimals="0"
      id="F_d2e35779-9d40-4b59-9fb3-2b3c45460c77"
      unitRef="U_shares">9399404</us-gaap:CommonStockSharesOutstanding>
    <acst:CommonStockVotesPerShare
      contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459"
      decimals="0"
      id="F_a5b9b467-7475-46fd-b792-eeb13cc166dd"
      unitRef="U_Vote">10</acst:CommonStockVotesPerShare>
    <acst:CommonStockDividendRatePercentage
      contextRef="C_7da55c0e-6ba5-4e9e-acd7-dac4568958a6"
      decimals="2"
      id="F_b291eccb-18e2-4814-b3fa-5ff48893fc3c"
      unitRef="U_pure">0.05</acst:CommonStockDividendRatePercentage>
    <acst:CommonStockRedemptionPricePerShare
      contextRef="C_7da55c0e-6ba5-4e9e-acd7-dac4568958a6"
      decimals="2"
      id="F_cda849be-1ba2-4d57-b6fe-24029b5699ce"
      unitRef="U_CadShare">4.8</acst:CommonStockRedemptionPricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459"
      decimals="0"
      id="F_3aefeff5-bb1e-4bdd-9e98-6e772dd8396a"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d5433bae-dcf1-457b-9735-b5bec1fca459"
      decimals="0"
      id="F_2227e7d4-cd34-4c78-a93e-1011dee774bf"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <acst:CommonStockDividendRatePercentage
      contextRef="C_940b8ef1-f85d-4c61-b94a-bffc507b9e8b"
      decimals="2"
      id="F_1d54c5e4-80f3-4dc5-870a-165ff1419ad5"
      unitRef="U_pure">0.05</acst:CommonStockDividendRatePercentage>
    <acst:CommonStockRedemptionPricePerShare
      contextRef="C_940b8ef1-f85d-4c61-b94a-bffc507b9e8b"
      decimals="2"
      id="F_4f1c3f8a-f605-4f90-8bf0-5ab6d446033e"
      unitRef="U_CadShare">1.2</acst:CommonStockRedemptionPricePerShare>
    <acst:CommonStockDividendRatePercentage
      contextRef="C_0e9c3508-8c04-4935-ae0d-c619d66df6eb"
      decimals="3"
      id="F_9fa7f6cf-7b2f-47cd-a844-67fec8cdf342"
      unitRef="U_pure">0.005</acst:CommonStockDividendRatePercentage>
    <acst:CommonStockDividendRatePercentage
      contextRef="C_ecbe80f6-d6d3-483e-97b0-82b3081bda3a"
      decimals="2"
      id="F_80aeda92-656f-4e58-90bc-efbf2e10dcd9"
      unitRef="U_pure">0.02</acst:CommonStockDividendRatePercentage>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8b87163d-8c7c-418f-bf82-a0fb5e3ddc84"
      decimals="0"
      id="F_5f3ea7ee-ca2e-42e2-a3d4-f036de88f8f8"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e235b4c9-4adf-47cc-a3e3-c01fd379a76e"
      decimals="0"
      id="F_e98117c0-417b-4450-a62b-d77f5471c235"
      unitRef="U_shares">1951371</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_f951dabc-33fe-47d3-a362-7aa2e816d7cb"
      decimals="3"
      id="F_b54dd909-2a6e-4c73-baf4-d918e28d5158"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.848</us-gaap:SaleOfStockPricePerShare>
    <acst:StockIssuedSharesWarrantsExercisableShares
      contextRef="C_ee140fde-ec8b-4597-a458-9c1426a405b4"
      decimals="0"
      id="F_907538a8-78df-4825-8e8e-38c0dc861dbc"
      unitRef="U_shares">2106853</acst:StockIssuedSharesWarrantsExercisableShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ee140fde-ec8b-4597-a458-9c1426a405b4"
      decimals="4"
      id="F_3ac9b014-3cec-4b45-adc0-0e308a67629c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acst:StockIssuedSharesWarrantsExercisableShares
      contextRef="C_f951dabc-33fe-47d3-a362-7aa2e816d7cb"
      decimals="0"
      id="F_8d282019-fe01-4852-8eba-37d97d1fc2a0"
      unitRef="U_shares">2536391</acst:StockIssuedSharesWarrantsExercisableShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ac3b545c-c1db-46c4-aa78-4fb7c590da00"
      decimals="3"
      id="F_d36413c2-fafd-4314-9275-6f91fb0fe876"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_46e5f6eb-b6a7-4f98-a854-ed3f302b7714"
      decimals="-3"
      id="F_a7afb694-0392-4366-ae1c-8a3eca189249"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromWarrantExercises>
    <acst:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_545ec182-f542-4e2b-9855-4b55b11f191b"
      decimals="-3"
      id="F_95dd7046-4310-44a5-b2c0-3786e5637dfc"
      unitRef="U_USD">7338000</acst:ProceedsFromIssuanceOfCommonStockNet>
    <acst:AtthemarketSalesAgreementCommonStockMaximumAmount
      contextRef="C_d3cca4b1-352c-4004-9c30-f04a2f7b79e5"
      decimals="-3"
      id="F_3e49c9a1-16e4-42ee-a09f-c6e7c2c39c50"
      unitRef="U_USD">75000000</acst:AtthemarketSalesAgreementCommonStockMaximumAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_312bbb54-59d2-4300-b0d4-eef44282cdc6"
      decimals="0"
      id="F_ce25f896-a1de-40da-be30-1a8c7247ce09"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <acst:AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
      contextRef="C_f8a2346d-c203-40c2-a5ab-e2216e6c3d61"
      decimals="3"
      id="F_05186156-45b0-458b-8a7a-c3f326f116ef"
      unitRef="U_pure">0.03</acst:AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b379b9ec-28ea-4a40-b95f-8839111c5b29"
      decimals="0"
      id="F_fdac8770-2c49-4ace-9abb-128309cc0c54"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d"
      decimals="0"
      id="F_0c2fbded-ed25-40d3-ae02-8b627da96571"
      unitRef="U_shares">54108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <acst:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d"
      decimals="-3"
      id="F_408e6049-2b61-4035-9def-39842cefa368"
      unitRef="U_USD">304000</acst:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d"
      decimals="-3"
      id="F_9c8c728f-4d2e-480a-abd4-08b4289dcdba"
      unitRef="U_USD">10000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <acst:SaleOfStockAveragePricePerShare
      contextRef="C_c53e60b0-79a5-4d64-a657-f5b786c9594d"
      decimals="2"
      id="F_d277fd60-53dc-4c18-b704-ac056663f377"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.7</acst:SaleOfStockAveragePricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_1be0d73c-b1f4-423e-aa12-2a42820f8ecb"
      decimals="0"
      id="F_6fc3cf13-bd9f-415b-b9af-ccc3a970fcd1"
      unitRef="U_shares">137370</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1be0d73c-b1f4-423e-aa12-2a42820f8ecb"
      decimals="2"
      id="F_4492d757-2728-47c5-9a39-77303fd2a72b"
      unitRef="U_CadShare">62.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acst:StockIssuedSharesWarrantsExercisableShares
      contextRef="C_0f687fe2-5a55-4bed-a8a0-8cc695040f45"
      decimals="0"
      id="F_6349346e-afe1-4697-a898-37957ba0f41f"
      unitRef="U_shares">4643244</acst:StockIssuedSharesWarrantsExercisableShares>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3"
      decimals="-3"
      id="F_e3ce7134-7725-44cb-90ab-cd61f0cac685"
      unitRef="U_USD">1631000</us-gaap:FairValueAdjustmentOfWarrants>
    <acst:PaymentOfIssuanceCostsCommonWarrants
      contextRef="C_8bf52d38-93c0-4416-ab44-ea0729cc861e"
      decimals="-3"
      id="F_ff548283-8d26-46fa-9b9c-bf212545825b"
      unitRef="U_USD">45000</acst:PaymentOfIssuanceCostsCommonWarrants>
    <acst:ProceedsFromCommonShares
      contextRef="C_d2dac555-c59d-4a9e-b6eb-37a8e4c83dd5"
      decimals="-3"
      id="F_551bcbf6-c313-49dc-956e-e16197b4c49d"
      unitRef="U_USD">2822000</acst:ProceedsFromCommonShares>
    <acst:ProceedsFromCommonShares
      contextRef="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3"
      decimals="-3"
      id="F_b7319e40-30c8-4576-91e5-94991b3cc60d"
      unitRef="U_USD">3047000</acst:ProceedsFromCommonShares>
    <acst:PaymentOfIssuanceCostsCommonWarrants
      contextRef="C_d2dac555-c59d-4a9e-b6eb-37a8e4c83dd5"
      decimals="-3"
      id="F_daa2e5f9-4ccc-4dfd-8f17-f42fa8505515"
      unitRef="U_USD">78000</acst:PaymentOfIssuanceCostsCommonWarrants>
    <acst:PaymentOfIssuanceCostsCommonWarrants
      contextRef="C_d7c69b9c-114e-435e-999e-6e9b014ff5d3"
      decimals="-3"
      id="F_0b3468a7-4c15-4597-ad9e-2a9c14d24804"
      unitRef="U_USD">84000</acst:PaymentOfIssuanceCostsCommonWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_03ef08bb-81cf-4cd8-924e-b449c7d6be20">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.093%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.063%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issued during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6dd2e2eb-a9cb-4425-b134-c44667fd7eb6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_d746cbeb-7243-47ec-9e29-08b9c61aa68e"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_d9c4389a-7f67-4bbf-a637-b694aeda8261"
      decimals="-3"
      id="F_f5667fc5-ed46-4e02-9475-32cfa7b87ac8"
      unitRef="U_USD">10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_5d828868-bfc3-4945-9314-a0518334a72b"
      unitRef="U_USD">1631000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_7ba49b4d-ee1a-4100-989e-9b8cbe6c95e8"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_0114d19e-6f70-440e-bdb4-d3be58837d85"
      unitRef="U_USD">2728000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_8d5b5456-bec4-46e8-a32d-0a1665dec66e"
      unitRef="U_USD">-10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_722db4e3-2bb4-4fda-aa86-9430a89813c0"
      unitRef="U_USD">4359000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_df4c70dc-23f7-4288-9330-58149e802f26"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_1d0339a6-2442-439e-af2c-295eec604dff">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The warrant liability was determined based on the fair value of warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) five years from the date on issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.806%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.558%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.558%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 25, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected warrant life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_1756eb23-2e0b-48cb-9d20-d1c0db7eddbb"
      decimals="0"
      id="F_ecdc3257-0028-4710-a19f-62ca53254a06"
      unitRef="U_USD">500</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_3d6702e5-9571-48ee-81a7-d74ef46344e1"
      decimals="0"
      id="F_5050435c-ed16-42bb-970b-efbe6e970490"
      unitRef="U_USD">469</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_6bab073f-8e03-425b-882d-ee0197687a29"
      decimals="0"
      id="F_1c7b3fae-382a-40af-969b-4934b6a8b523"
      unitRef="U_USD">178</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_1b554ace-39ee-4357-9ded-83838c05db04"
      decimals="0"
      id="F_2ccdc7e6-f912-4155-9406-7e2c2e937ec9"
      unitRef="U_USD">343</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_dce797e5-6a6c-417b-b7d7-6195591f7d0e"
      decimals="0"
      id="F_2de062e5-9442-4883-a61e-f0ddb7c5196f"
      unitRef="U_USD">254</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_0a51f099-2623-4ca7-bec5-744e473c2a07"
      decimals="0"
      id="F_ddb1c87f-fc42-4447-b0a8-c84f8465dcd9"
      unitRef="U_USD">203.00</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_9de35410-3114-4f88-8550-bba2bee392fb"
      decimals="-2"
      id="F_3de93ea5-e3f7-4075-bac6-bdd8adadb5be"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_684d5200-1c42-4272-8ca3-5608277c5be4"
      decimals="-2"
      id="F_73eb6b89-448a-454d-a293-e12a54796947"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_15d1ffe6-b2f5-4746-93b3-3b9ddcb8c862"
      decimals="0"
      id="F_8822377b-29b7-4251-b937-189750368863"
      unitRef="U_USD">8090</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="C_77630b6d-9f63-49f0-aacd-228e5510fa1f"
      decimals="0"
      id="F_b407157c-81be-408e-a090-6896ef040e9f"
      unitRef="U_USD">8594</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_b9938b6f-8e2c-45cd-b9a7-e5a38fc58fcd"
      decimals="2"
      id="F_5390b8d0-1f6d-44ad-bf46-26b10aae63bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="2"
      id="F_cc1f4499-dc5c-4cfa-935f-cc4aa3506f01"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_2f8fe5fb-ef11-4634-a474-acca8f534421"
      decimals="0"
      id="F_332a6fbe-c1b5-4341-a44a-d60b5a6ad302"
      unitRef="U_shares">2536391</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2f8fe5fb-ef11-4634-a474-acca8f534421"
      decimals="3"
      id="F_90e3156a-9ce7-4b78-8b65-429caf1e9746"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_bd8d29d2-fb73-44c0-8b8f-697d5ef239fa"
      decimals="0"
      id="F_5c277107-0ec7-4cf2-a507-cbd5483c861a"
      unitRef="U_shares">2106853</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_bd8d29d2-fb73-44c0-8b8f-697d5ef239fa"
      decimals="4"
      id="F_0d34ab21-a4fe-4a8c-be22-589e78f2e190"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acst:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="INF"
      id="F_f732fd72-aa18-4ffd-ba85-9fc187876fa2"
      unitRef="U_shares">0</acst:ClassOfWarrantOrRightExercisedDuringPeriod>
    <acst:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="INF"
      id="F_a7ed3d3a-77ed-411e-956e-c0026ae79398"
      unitRef="U_shares">0</acst:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_30e5ebfd-56af-47ef-be6e-1f2850a61e6a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At March 31, 2024, the Company had in place a stock option plan for directors, officers, employees, and consultants of the Company (&#x201c;Stock Option Plan&#x201d;). As of March 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;738,725&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; awards available under the plan for issuance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Stock Option Plan provides for the granting of options to purchase Common Shares. Under the terms of the Stock Option Plan, the exercise price of the stock options granted under the Stock Option Plan may not be lower than the closing price of the Company&#x2019;s Common Shares on the Nasdaq Capital Market at the close of such market the day preceding the grant. The maximum number of Common Shares that may be issued upon exercise of options granted under the amended Stock Option Plan shall not exceed 20% of the aggregate number of issued and outstanding shares of the Company as of July 28, 2022. The terms and conditions for acquiring and exercising options are set by the Company&#x2019;s Board of Directors, subject to, among others, the following limitations: the term of the options cannot exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and (i) all options granted to a director will be vested evenly on a monthly basis over a period of at least twelve (12) months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period of at least thirty-six (36) months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total number of options issued to any one consultant within any twelve-month period cannot exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Company&#x2019;s total issued and outstanding Common Shares (on a non-diluted basis). The total number of options issued within any twelve-month period to all directors, employees and/or consultants of the Company (or any subsidiary of the Company) conducting investor relations services, cannot exceed in the aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Company&#x2019;s issued and outstanding Common Shares (on a non-diluted basis), calculated at the date an option is granted to any such person.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes information about activities within the Stock Option Plan for the year ended March 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.09%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.658%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remaining Contractual Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;740,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;607,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;614,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;721,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.84&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Forfeited and cancelled options were as a result of the Company's restructuring that occurred during the year ended March 31, 2024. On July 14, 2023, the Company's Board of Directors approved the grant of options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,502&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Share under the Company's Stock Option Plan. On December 19, 2023, the Company's Board of Directors approved the grant of options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,168&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Common Shares at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Common Share under the Company's Stock Option Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of awards for options granted during the years ended March 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.365%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.225999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.225999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Estimated life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.62&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized under ASC 718 related to the stock option plan is summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;467&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of total unrecognized compensation cost, related to non-vested stock options, which is expected to be recognized over a remaining weighted-average vesting period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity incentive plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company established an equity incentive plan (the &#x201c;Equity Incentive Plan&#x201d;) for employees, directors, and consultants. The Equity Incentive Plan provides for the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,483,140&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; restricted share units, performance share units, restricted shares, deferred share units and other stock-based awards, subject to restricted conditions as may be determined by the Board of Directors. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such awards outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock-based compensation was recognized for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_64eefdf8-8725-4487-9627-312c2276a125"
      decimals="INF"
      id="F_522d0f12-26b0-41c0-8d2c-06d0707366cb"
      unitRef="U_shares">738725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_c11690fb-a2e6-428a-b417-46b840d84bbd"
      id="F_16a26f4a-c701-4066-92e7-af928dca8385">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson
      contextRef="C_10f930e5-d54c-408c-9930-ba4f2a0de948"
      decimals="2"
      id="F_8f2e9dfc-9d14-4e53-bbb3-811984c6ffb0"
      unitRef="U_pure">0.02</acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson>
    <acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson
      contextRef="C_5ede5bf9-460b-4689-8dc5-21171a08b231"
      decimals="2"
      id="F_9e9bd747-4684-427c-b859-cb87ebeb08ba"
      unitRef="U_pure">0.02</acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_96deb89c-cf0f-4d0e-9a0a-e7560ee6d4ed">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes information about activities within the Stock Option Plan for the year ended March 31, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.09%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.658%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remaining Contractual Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;740,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;607,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;614,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;721,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.84&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="INF"
      id="F_0470be4d-3601-4701-94c4-da3e42fb157f"
      unitRef="U_shares">740957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="2"
      id="F_d1bed01f-af21-4e19-8c14-ad15f4abec3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      id="F_13069142-830c-446d-bcc4-7e96d8fa2bd5">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_810feec9-badf-403f-ae76-0795ade0af51"
      unitRef="U_USD">8121000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="INF"
      id="F_292843b9-d909-4744-b505-6303c05ae846"
      unitRef="U_shares">607670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_2dae2363-919b-43e4-87f2-23b3ba6e521f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="INF"
      id="F_f62f86f3-e301-4978-8bb7-e576fea508e4"
      unitRef="U_shares">12500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_c4308a96-32f8-4190-acbb-c8e4028aa40c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="INF"
      id="F_26a36488-5c72-4018-88c8-40ac7aff6bb5"
      unitRef="U_shares">614334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_31c4aec7-788c-4688-b56e-3b73c13f80e9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="INF"
      id="F_1a01ddb0-649a-4c97-ac94-264ea3f9aa46"
      unitRef="U_shares">721793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="2"
      id="F_94fd98ea-31f7-4868-baa6-c08f232d7552"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ec819210-e5a3-428a-81b3-4b9e0b7730dd">P9Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_ce72484a-5c36-49a8-948f-f0cd48a2cf32"
      unitRef="U_USD">527000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="INF"
      id="F_965aef49-d047-492b-9f3f-bf6e16de1bd6"
      unitRef="U_shares">312924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="2"
      id="F_e2256f74-5f41-45f7-9f20-d715fbc9bf17"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_2e084d6f-2049-42ae-9bba-0a62c32067ff">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_03bfb341-9da8-4167-8718-ecdb9047c6a7"
      unitRef="U_USD">188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b3dbe7f3-a4f8-4b41-ba66-ea50c892e380"
      decimals="INF"
      id="F_95ac1ca4-f443-4581-bb23-c9f49739fc4f"
      unitRef="U_shares">446502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <acst:StockOptionsExercisePricePerShare
      contextRef="C_7db0708e-187a-44e4-abc2-9ab65651e41b"
      decimals="2"
      id="F_bb608872-7bf6-4d86-bef1-e905dfbf2709"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.64</acst:StockOptionsExercisePricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_3c9a0299-cb67-4749-8a76-c93fb0ab71bc"
      decimals="INF"
      id="F_b9ba785a-0272-4859-8e75-d3d3f3d2c669"
      unitRef="U_shares">161168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <acst:StockOptionsExercisePricePerShare
      contextRef="C_a0ba7fe9-844a-4c36-9819-69617b6b15f6"
      decimals="3"
      id="F_cce1b0e3-865f-4c60-887b-7c03d229ab04"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.125</acst:StockOptionsExercisePricePerShare>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_97a2f332-c9ed-49e8-b6b6-af87d5d5caab">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of awards for options granted during the years ended March 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted-average assumptions for the options granted:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.365%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.225999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.225999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Estimated life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.62&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_4f940eee-b29d-4f72-9679-f8dbe064ecb3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="2"
      id="F_57b61dce-7413-408d-94eb-c0c9b0da33e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_5d410b1c-dc22-4a2c-84b4-9ea8af57e1e2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.5</acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="2"
      id="F_3c51dc73-47de-46d4-ae55-42e9a8e566cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.1</acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <acst:SharesPrice
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_6a145051-715a-49bb-909f-095a77f5f610"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.5</acst:SharesPrice>
    <acst:SharesPrice
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="2"
      id="F_823c3bd9-874e-486d-9096-b81c6cc03087"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.1</acst:SharesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="2"
      id="F_cf8f4898-bd87-445d-b5f2-060c3cd926da"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="2"
      id="F_15721004-9f9c-4f7b-b36c-cb9e3907cfde"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="4"
      id="F_e2dac9e8-7de5-48a7-ba33-0eeb8854ab50"
      unitRef="U_pure">0.0395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="4"
      id="F_06324bcc-ccf1-43c8-a84f-008ee5855fec"
      unitRef="U_pure">0.0328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_e1198380-9720-4be8-8169-8a331754c0ce">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      id="F_23b3ab7e-ffa3-4944-b412-114eefe2e85a">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="4"
      id="F_dd74c782-44c0-4586-b6fa-8bfee3b33644"
      unitRef="U_pure">1.1794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="4"
      id="F_5d5bf154-7863-4d69-9c53-2a0ac3e98a71"
      unitRef="U_pure">1.1756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_aeb6ee98-e530-4e0b-a4a0-43b84c07511c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized under ASC 718 related to the stock option plan is summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_06ea57a9-3a97-4d7a-9bd1-eecd71be02df"
      decimals="-3"
      id="F_484adae7-ef82-4650-9976-449e5cc150d5"
      unitRef="U_USD">198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_05adfb7b-9ddc-4cc6-873f-b2dd8d56c9c5"
      decimals="-3"
      id="F_812b5e1b-30cb-462f-b9f4-a521dfd33265"
      unitRef="U_USD">591000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_057790a0-605f-41ca-8ce9-91d483af8647"
      decimals="-3"
      id="F_3e412656-610a-4048-9470-e78b2263e9b1"
      unitRef="U_USD">697000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_60ef9157-75f4-4a1e-b25c-2842ef0acc4f"
      decimals="-3"
      id="F_42f97f13-85e4-406b-8869-55c60cf86a9a"
      unitRef="U_USD">1123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1661c524-65aa-434f-8b9c-ae631dd5b8bf"
      decimals="-3"
      id="F_17f830ce-a7b7-4c0f-8327-c03e39a9c85f"
      unitRef="U_USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ba9a56ec-eeb4-420e-a520-410844ea86c8"
      decimals="-3"
      id="F_eea97d6f-eccd-4915-9f5f-c0f24c7341e0"
      unitRef="U_USD">97000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c11690fb-a2e6-428a-b417-46b840d84bbd"
      decimals="-3"
      id="F_63d34cb2-d5a4-473c-8b73-544e4ff15ac3"
      unitRef="U_USD">913000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_158d50e3-c6b0-4b7c-9cec-bc5c37a93fe6"
      decimals="-3"
      id="F_2d8e7475-b217-4879-8bf2-9830050be4d3"
      unitRef="U_USD">1811000</us-gaap:AllocatedShareBasedCompensationExpense>
    <acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_25ae8449-c375-4d37-8586-59af6b036efa"
      unitRef="U_USD">467000</acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c11690fb-a2e6-428a-b417-46b840d84bbd"
      id="F_8790623a-24a4-4c92-a471-7bc28e0b2da3">P1Y2M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <acst:IssuanceOfRestrictedShareUnit
      contextRef="C_177feeb1-7b04-48ce-809a-866ea0b27de7"
      decimals="0"
      id="F_371a7a72-9da0-42c4-aaf5-c90302554fbe"
      unitRef="U_shares">1483140</acst:IssuanceOfRestrictedShareUnit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_2b3364b9-6260-4b70-b7c1-3323e1ed6f70"
      decimals="INF"
      id="F_1ca698cd-dd09-4cc9-bf66-7e8f721aa6d6"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_177feeb1-7b04-48ce-809a-866ea0b27de7"
      decimals="-3"
      id="F_870c3b04-8853-4fa9-b148-956658bb2207"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_af51f1f3-f0d1-4730-9fc6-47b2d110a98f">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has generated a net loss for all periods presented, therefore diluted loss per share is the same as basic loss per share since the inclusion of potentially dilutive securities would have had an anti-dilutive effect. All currently outstanding options and warrants could potentially be dilutive in the future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded the following potential Common Shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;721,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;740,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 2023 Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,536,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;May 2018 public offering warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per share is calculated based upon the weighted-average number of Common Shares outstanding during the period. Common Shares underlying the Pre-funded Warrants are included in the calculation of basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_91c24cda-deef-4752-b205-7879b2d93ce8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded the following potential Common Shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;721,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;740,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;September 2023 Common Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,536,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;May 2018 public offering warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="0"
      id="F_625fe63d-8baa-4f1f-8173-61be353da0b3"
      unitRef="U_shares">721793</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="0"
      id="F_e4019089-c329-47d2-b224-5ea8ac0716e3"
      unitRef="U_shares">740974</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b91b8c0b-647a-4df0-b491-de3b7226a402"
      decimals="0"
      id="F_df2a4074-bdb5-4f2d-9992-71a2946c77e1"
      unitRef="U_shares">2536391</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_705dbe6d-a676-4e14-8f68-1447dd74db79"
      decimals="0"
      id="F_352cb096-4430-417c-a7d5-6a7ebd7b4fa5"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_9d1b1042-fd07-435a-9f9e-ae6291bd7e13"
      decimals="0"
      id="F_654d5580-812a-4b4a-82b8-bb39860c55f6"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_faccd42d-8b25-4802-9d19-2b48cbbde167"
      decimals="0"
      id="F_85c2a17a-4969-409d-80fc-df653ed68448"
      unitRef="U_shares">137370</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_862e7ab9-3a34-4d19-a3f2-9b5b562b0e0d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Income taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax (benefit) expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation between tax expense and the product of accounting income multiplied by the basic income tax rate for the years ended March 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax at Canadian Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Difference in foreign tax rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible change in fair value of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible goodwill impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other non-deductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-refundable federal investment tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State non income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in tax rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net deferred income tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024, and 2023 were comprised of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax losses carried forward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right of use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net federal investment tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other deductible temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other taxable temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024, the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years&#x2019; taxable income, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.552%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.302%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.082%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provincial&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax losses carried forward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No expiry&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;136,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses, without time limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Scientific Research &amp;amp; Experimental Development Expenditures investment tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company does not expect a significant change to the amount of unrecognized tax benefits over the next 12 months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter the timing or amount of taxable income or deductions, of the allocation of income among tax jurisdictions, and these adjustments could differ from the amount accrued. The Company&#x2019;s federal and provincial income tax returns filed for all years remain subject to examination by the taxation authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government assistance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Government assistance is comprised of research and development investment tax credits receivable from the Quebec provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; For the years ended March 31, 2024 and 2023, the Company recorded ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, as a reduction of research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investment tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrecognized Canadian federal investment tax credits may be used to reduce future Canadian federal income tax and expire as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.403%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ef10f918-2889-4654-89a5-8ce35373b322">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax (benefit) expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_466102b6-644a-412f-93a0-a0484271c850"
      unitRef="U_USD">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_d0978d29-704f-44ca-bfe4-59402d0594b6"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_322ca3b1-71eb-4c97-8ffc-4068c75ff74d"
      unitRef="U_USD">-1834000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_963f901f-7e5e-4d45-9d85-c8e45e7d567d"
      unitRef="U_USD">-9542000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_f0fb6690-9bcc-4f71-8966-cefe4b434371"
      unitRef="U_USD">-1832000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_f46350b9-8752-4d8b-9c85-38201db7b234"
      unitRef="U_USD">-9542000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_5692daf5-8440-42bb-81c0-5d9d609de661">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation between tax expense and the product of accounting income multiplied by the basic income tax rate for the years ended March 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax at Canadian Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Difference in foreign tax rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible change in fair value of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-deductible goodwill impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other non-deductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-refundable federal investment tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State non income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in tax rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_cc016227-10dc-4636-aa4b-30633ab1da54"
      unitRef="U_USD">-3891000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_060e2710-94ab-469f-af5d-abc151a36aad"
      unitRef="U_USD">-13772000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_89d3def7-610e-4f99-bf23-ce830902ba07"
      unitRef="U_USD">-77000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_69ccffe6-51a2-45d2-abae-0d148e73b24c"
      unitRef="U_USD">-1315000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_9e39ee98-2d37-42b3-a867-058087540b5b"
      unitRef="U_USD">242000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_f9f40f38-9b9a-40e1-ac9e-7908b5cd37de"
      unitRef="U_USD">480000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <acst:IncomeTaxReconciliationNondeductibleChangeInFairValue
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_49507995-bc5e-426b-8239-bd1761a892db"
      unitRef="U_USD">3000</acst:IncomeTaxReconciliationNondeductibleChangeInFairValue>
    <acst:IncomeTaxReconciliationNondeductibleChangeInFairValue
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_209038bb-61e9-467a-b1a7-24855688f644"
      unitRef="U_USD">-3000</acst:IncomeTaxReconciliationNondeductibleChangeInFairValue>
    <acst:IncomeTaxReconciliationNondeductibleExpenseTransactionCosts
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_96cbc6fd-9e7c-4d66-8421-827bddd96701"
      unitRef="U_USD">723000</acst:IncomeTaxReconciliationNondeductibleExpenseTransactionCosts>
    <acst:IncomeTaxReconciliationNondeductibleExpenseTransactionCosts
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_7e3f0496-6c3a-4ecc-97b6-f958e0eb9a16"
      unitRef="U_USD">-0</acst:IncomeTaxReconciliationNondeductibleExpenseTransactionCosts>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_84a611c8-ab29-4c5b-8b12-2031ede759dc"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_51cf58ca-cd82-4ff3-8403-36288083918d"
      unitRef="U_USD">1453000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_015ee501-cbd4-4ba8-97f7-76a2e5bdb964"
      unitRef="U_USD">15000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_9b37270c-29f8-44ce-adff-c2a5aff6a284"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <acst:NonRefundableFederalItc
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_220f7619-f6f1-4a9e-97ba-b0eb51b1110d"
      unitRef="U_USD">0</acst:NonRefundableFederalItc>
    <acst:NonRefundableFederalItc
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_5842937c-13e1-44a1-9f76-a0ed39042d1a"
      unitRef="U_USD">-642000</acst:NonRefundableFederalItc>
    <acst:StateNonIncomeTaxes
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_1e37e043-bfd2-4d01-89b8-6eb22ae9c8be"
      unitRef="U_USD">1000</acst:StateNonIncomeTaxes>
    <acst:StateNonIncomeTaxes
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_41e342fd-dc08-480b-acb2-999abca94a61"
      unitRef="U_USD">0</acst:StateNonIncomeTaxes>
    <acst:ChangeInTaxRates
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_77aa42d1-b398-4521-90b5-48895b4ff6ad"
      unitRef="U_USD">-486000</acst:ChangeInTaxRates>
    <acst:ChangeInTaxRates
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_2d45d34e-f984-40db-b013-058dafe61091"
      unitRef="U_USD">0</acst:ChangeInTaxRates>
    <acst:IncomeTaxReconciliationUnrecognizedTemporaryDifferences
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_003df1ef-5c42-4de6-b290-296372e3312e"
      unitRef="U_USD">1635000</acst:IncomeTaxReconciliationUnrecognizedTemporaryDifferences>
    <acst:IncomeTaxReconciliationUnrecognizedTemporaryDifferences
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_d3b1598e-9498-47b2-a269-c83fd741de1d"
      unitRef="U_USD">4263000</acst:IncomeTaxReconciliationUnrecognizedTemporaryDifferences>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_5c672d5f-d767-4e68-b261-807809237022"
      unitRef="U_USD">3000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_23949054-8d71-4597-98bf-770950add215"
      unitRef="U_USD">-6000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      decimals="-3"
      id="F_bcb845de-9223-4a77-a285-a62aa4b8bf24"
      unitRef="U_USD">-1832000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_431b2e53-4771-47e2-aed2-1c7e2f3e85a6"
      decimals="-3"
      id="F_93a9b9a3-2093-4520-8ada-9b13812568af"
      unitRef="U_USD">-9542000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_2210309b-533a-4792-9fa5-f63986a09702">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net deferred income tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024, and 2023 were comprised of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax losses carried forward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right of use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net federal investment tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other deductible temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other taxable temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_5dbc0412-71b7-475a-b78f-8ddd3fe5bd6d"
      unitRef="U_USD">40659000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_8f2dd6d9-3b66-46af-9988-57b58c88b12b"
      unitRef="U_USD">38628000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <acst:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_32a57028-81da-4ffa-8a42-6a08000c9ed7"
      unitRef="U_USD">8522000</acst:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <acst:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_6be1afca-1cde-459a-a5ec-8a79041fe190"
      unitRef="U_USD">7672000</acst:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e91a906b-1d0a-4d53-94ee-80564108bd54"
      unitRef="U_USD">523000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_985f9c98-88b6-49ac-9771-dbf3ff9c5f56"
      unitRef="U_USD">905000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_1a4251fa-a13c-4d9a-a7ec-ac04d712f6ce"
      unitRef="U_USD">328000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_7cccfb39-7ffd-4de1-992e-1a3ad3db46a3"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <acst:DeferredTaxAssetsOperatingLeaseRightOfUseLiability
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_2f173424-0f5b-4ba8-b7bf-4e2e2330f466"
      unitRef="U_USD">0</acst:DeferredTaxAssetsOperatingLeaseRightOfUseLiability>
    <acst:DeferredTaxAssetsOperatingLeaseRightOfUseLiability
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_a4d50446-2cff-42cf-aa8e-8dff4ea86c10"
      unitRef="U_USD">129000</acst:DeferredTaxAssetsOperatingLeaseRightOfUseLiability>
    <acst:DeferredTaxAssetsFinancingExpenses
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e9381bd9-6f61-4c77-a83d-bcf813cdc25b"
      unitRef="U_USD">169000</acst:DeferredTaxAssetsFinancingExpenses>
    <acst:DeferredTaxAssetsFinancingExpenses
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_331485ee-c4d1-4a8b-94de-e5bc63393aa4"
      unitRef="U_USD">267000</acst:DeferredTaxAssetsFinancingExpenses>
    <acst:NetFederalInvestmentTaxCredits
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_433de766-5749-4677-99ac-7fbda787eb2d"
      unitRef="U_USD">2882000</acst:NetFederalInvestmentTaxCredits>
    <acst:NetFederalInvestmentTaxCredits
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_b33c5f1a-5eb2-47e7-8425-2ec7e6aeaa30"
      unitRef="U_USD">3950000</acst:NetFederalInvestmentTaxCredits>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e7f520d3-e98f-4b40-8ce5-6a4e831c569d"
      unitRef="U_USD">56000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_d92c162e-96d1-4d25-ade3-70655854b61c"
      unitRef="U_USD">92000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_8ccb6f08-44ad-45e9-8f6a-b343d31ce0a5"
      unitRef="U_USD">53139000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_042819bb-25c1-4553-9de9-11db6ce6de2b"
      unitRef="U_USD">51643000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_ed707819-1ecc-42b5-a916-908474fc5fbc"
      unitRef="U_USD">47284000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_06390abc-06a5-4526-9856-503341375046"
      unitRef="U_USD">46664000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_15edd0d0-8bb8-447a-b001-ca4e623949e5"
      unitRef="U_USD">11369000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_040f707b-b53f-4f54-8d37-f364a1cdb2d6"
      unitRef="U_USD">12198000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <acst:DeferredTaxAssetsOperatingLeaseAsset
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_e475003a-3d0a-48ff-bcc3-c063ebd1ecbc"
      unitRef="U_USD">0</acst:DeferredTaxAssetsOperatingLeaseAsset>
    <acst:DeferredTaxAssetsOperatingLeaseAsset
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_a63e1d30-a46d-4785-a1b8-0d2d8125df98"
      unitRef="U_USD">123000</acst:DeferredTaxAssetsOperatingLeaseAsset>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_636dc255-d3a3-4393-8752-47bf52a5d998"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_b58711d8-b3ec-41ac-80bb-c7bd9253fad3"
      unitRef="U_USD">5000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_32eaa2d0-2223-4f56-a805-d3c76b43f56c"
      unitRef="U_USD">11369000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_7b3836c6-e73a-4509-b682-f9b05ece7217"
      unitRef="U_USD">12326000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_93452294-71ee-406f-ab94-312ce52a2491"
      unitRef="U_USD">5514000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_1150a054-e245-4efb-81fc-8e6051044257"
      unitRef="U_USD">7347000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_ea58e452-c9c3-4623-b5b4-c5f63efcdc23">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024, the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years&#x2019; taxable income, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:1.427%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.552%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.302%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.082%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provincial&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax losses carried forward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No expiry&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;136,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses, without time limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Scientific Research &amp;amp; Experimental Development Expenditures investment tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrecognized Canadian federal investment tax credits may be used to reduce future Canadian federal income tax and expire as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.403%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_422f9f9e-ac11-4222-817c-49c40bebb380"
      decimals="-3"
      id="F_00bff84b-8021-496c-bf3d-9d624b1a98e3"
      unitRef="U_USD">571000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b2555b6e-b437-4ba8-9563-def690c61ff9"
      decimals="-3"
      id="F_815aeaab-9b34-483d-b26f-ac780d989ccb"
      unitRef="U_USD">571000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4d2dbb68-f420-44ed-9aef-e0dcbd842219"
      decimals="-3"
      id="F_3d065580-d918-4a59-82cb-b59308d0d90c"
      unitRef="U_USD">1302000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_84b40618-5675-4dc0-9e64-a517f28f6d53"
      decimals="-3"
      id="F_e20bbce0-3ed8-4881-a0fc-eba023a04c99"
      unitRef="U_USD">1297000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_31aacf07-7739-466d-9474-24f3d1e9ad89"
      decimals="-3"
      id="F_3df05750-edeb-4068-be62-d9ba1172545b"
      unitRef="U_USD">1657000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c74a6eaf-0060-4554-9488-83e6d43a52c0"
      decimals="-3"
      id="F_fda3a1b6-7999-42d0-b9a9-aeb7e2e50a76"
      unitRef="U_USD">1651000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_02572285-4b65-41c8-8fa4-f3dc4a164d60"
      decimals="-3"
      id="F_66419725-6338-4a5b-8ff4-fe7028c6d0b1"
      unitRef="U_USD">1810000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_005474d3-953e-419e-8e1d-8a618e56041f"
      decimals="-3"
      id="F_1463a0a0-8205-4414-b6be-ce9d20bece1a"
      unitRef="U_USD">1794000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_36c24d42-fa01-40ca-a916-10d853ad79e5"
      decimals="-3"
      id="F_a9770955-5715-47a9-9fee-8b83158c913c"
      unitRef="U_USD">1484000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_3d32a6e4-7a1f-4468-9246-d1db4a2f87d2"
      decimals="-3"
      id="F_9991ee92-0203-4551-ae02-75f136d52468"
      unitRef="U_USD">1461000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b4569b27-2312-4bd8-be26-e61127f1dfc1"
      decimals="-3"
      id="F_2bc8fe74-4ae8-4574-8d85-199ed3015615"
      unitRef="U_USD">2879000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_7597480c-39df-45e1-9922-7010d9c4c72a"
      decimals="-3"
      id="F_24148da4-5172-4967-9d07-54e0e2324c65"
      unitRef="U_USD">2879000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5a12b334-af4e-4c1d-ad64-bc70258d8ef0"
      decimals="-3"
      id="F_2fd95855-5df7-4a0a-8590-5a41bf00a9f8"
      unitRef="U_USD">3678000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1a24fef3-a068-4ca4-8dac-1a23822d569c"
      decimals="-3"
      id="F_8b1c4483-1605-4bea-baaa-130c780dee31"
      unitRef="U_USD">3568000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_76b72763-8a2d-4d7e-aea2-4b623c8e60f6"
      decimals="-3"
      id="F_6cf2c1ae-1f18-4ddd-93ed-a09de4ea04cc"
      unitRef="U_USD">4397000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0a03babd-18d1-4097-a9d4-1044dab8ecf4"
      decimals="-3"
      id="F_2246d5b6-5069-4948-b33b-b4c725b5bcc4"
      unitRef="U_USD">4397000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d951ff5b-4e5d-465a-855a-f551e8825d5b"
      decimals="-3"
      id="F_6e117e19-a064-403f-b1d8-5609dbb2592b"
      unitRef="U_USD">6470000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_269f269e-95bb-4430-b89f-d436cbeaad91"
      decimals="-3"
      id="F_0693be59-69e7-4c3c-9613-815203b7e985"
      unitRef="U_USD">6371000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_f166744b-f3f7-45e1-bdd4-2768e6ef6d20"
      decimals="-3"
      id="F_2b5eb55c-f156-42fc-9be1-f2aa564d807c"
      unitRef="U_USD">401000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d43202e2-7d88-42ec-9006-9b5d92669112"
      decimals="-3"
      id="F_994d3ad0-e40b-40ea-91ad-538bb958fa48"
      unitRef="U_USD">396000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_dc8f5eed-e387-4957-ae1f-a00211fe78a5"
      decimals="-3"
      id="F_b11d2ede-91b1-427a-ae30-d76f7ac89963"
      unitRef="U_USD">14856000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_039d64a4-88b3-4aa8-9f0d-bfbbffcaad9d"
      decimals="-3"
      id="F_4ef4976d-65c9-43e2-80b1-baa932065aa5"
      unitRef="U_USD">13821000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_91f3906a-c565-4e1c-b09c-103612aaa49a"
      decimals="-3"
      id="F_a3415dbe-e0a3-4d5a-8c27-72636bf00c93"
      unitRef="U_USD">32424000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_32f95ce9-670d-452f-9fc1-58e64efe3142"
      decimals="-3"
      id="F_3a3f1917-73ad-4e6d-bd86-7c97e3e574f1"
      unitRef="U_USD">32381000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c869cf00-c0af-4b98-825d-27c8d211e38b"
      decimals="-3"
      id="F_267ecc56-6fd2-4264-acfa-8d6312884272"
      unitRef="U_USD">23576000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_893afca7-27f1-4faa-8652-ebeea1283a01"
      decimals="-3"
      id="F_e8325669-44cb-4fc8-b7d0-de310508a985"
      unitRef="U_USD">23439000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_8030229f-2b04-4173-a95b-ae174f4c06f6"
      decimals="-3"
      id="F_38d49d49-f55f-4be2-8931-04d38c7fcbd7"
      unitRef="U_USD">13999000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_56f5d179-a218-4d6e-93bf-c19733becaf9"
      decimals="-3"
      id="F_39087ccc-59db-4baa-b826-f2fbcdb80b96"
      unitRef="U_USD">13999000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4cec2bdb-71d8-4eef-a7e4-2a57bd60925d"
      decimals="-3"
      id="F_34b20b56-ec9a-4ace-949a-37325210333d"
      unitRef="U_USD">9417000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c04ee66d-800b-4148-956d-a12fb82c62b1"
      decimals="-3"
      id="F_00d3d89c-75e5-4a5d-a4b5-c2aaea459c52"
      unitRef="U_USD">9416000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4e7ece24-7a7f-426a-bbb4-52d87842bae5"
      decimals="-3"
      id="F_a1433b98-2097-4d52-9a93-c01d66f102e5"
      unitRef="U_USD">11568000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_97daaea2-edbc-4684-b715-e135f9491b08"
      decimals="-3"
      id="F_2b67d918-aba2-4c72-b2eb-cca198acea72"
      unitRef="U_USD">11558000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_ec4dd3d8-0001-4568-9915-fb4ca638ab8e"
      decimals="-3"
      id="F_6e9b7de3-78b2-46c3-a319-343ccbf0a92b"
      unitRef="U_USD">7206000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_054f3d0b-11e9-4f9b-8d91-3b83f491df0f"
      decimals="-3"
      id="F_4b8f95c5-b7b0-4382-9f44-0202c5b505bd"
      unitRef="U_USD">7206000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_43242c92-e78b-4540-8623-9f75dbf73cb9"
      decimals="-3"
      id="F_061f6c13-939c-4333-835b-73691635a655"
      unitRef="U_USD">15443000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2de077db-85fa-42b0-920e-a1103a07c7f4"
      decimals="-3"
      id="F_db346469-1519-4f64-ae31-ce6a2111bf54"
      unitRef="U_USD">137695000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b74594a6-c75b-40ac-87aa-02fea55113f7"
      decimals="-3"
      id="F_370e0cb6-4dc8-4347-b8d1-3b3fc6c02cc6"
      unitRef="U_USD">136205000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6a6f8b28-b6c2-44d2-94e9-944ce97688d9"
      decimals="-3"
      id="F_44f1a04d-ab5b-4e67-a2a8-dcde12fe9d61"
      unitRef="U_USD">15443000</us-gaap:TaxCreditCarryforwardAmount>
    <acst:TaxCreditCarryforwardNotSubjectToTimeLimitation
      contextRef="C_46a52c6b-9951-44a8-8b8a-3cb9cb3e2439"
      decimals="-3"
      id="F_3db7e90f-9a2d-4ee7-bf52-591d9cde8bcc"
      unitRef="U_USD">25708000</acst:TaxCreditCarryforwardNotSubjectToTimeLimitation>
    <acst:TaxCreditCarryforwardNotSubjectToTimeLimitation
      contextRef="C_f8fa8a4a-743c-49ee-8a05-07e36d9b8934"
      decimals="-3"
      id="F_a45b06c8-ddb5-45f8-98be-27024136eaa7"
      unitRef="U_USD">27887000</acst:TaxCreditCarryforwardNotSubjectToTimeLimitation>
    <acst:ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards
      contextRef="C_2de077db-85fa-42b0-920e-a1103a07c7f4"
      decimals="-3"
      id="F_97ab70cf-3f66-48de-876f-54e663e74e4c"
      unitRef="U_USD">3922000</acst:ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards>
    <acst:ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards
      contextRef="C_b74594a6-c75b-40ac-87aa-02fea55113f7"
      decimals="-3"
      id="F_237d0d44-da18-487f-b3dc-487c4436e512"
      unitRef="U_USD">0</acst:ScientificResearchExperimentalDevelopmentExpendituresInvestmentTaxCreditCarryforwards>
    <acst:ScheduleOfGovernmentAssistanceTableTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_120e1218-7603-4dcc-8d04-6ae0ca2348ef">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; For the years ended March 31, 2024 and 2023, the Company recorded ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, as a reduction of research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investment tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acst:ScheduleOfGovernmentAssistanceTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e5dad982-0286-46ce-aa2c-9586c4730f1e"
      decimals="-3"
      id="F_b4b53243-b9a1-4c80-a9ba-86b632fa71c4"
      unitRef="U_USD">55000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_88cfac6a-e085-4d1e-9bee-16ee91a78d75"
      decimals="-3"
      id="F_3551d3c3-344e-49ac-a2c8-799d2043bed5"
      unitRef="U_USD">165000</us-gaap:ResearchAndDevelopmentExpense>
    <acst:InvestmentTaxCreditReceivable
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_8b380a90-2b22-486c-b398-1c3bab1326d6"
      unitRef="U_USD">356000</acst:InvestmentTaxCreditReceivable>
    <acst:InvestmentTaxCreditReceivable
      contextRef="C_6f23d8ea-d676-4a69-b9d8-7312636e2386"
      decimals="-3"
      id="F_bbf656be-72ce-4374-93fe-73093a2d3b32"
      unitRef="U_USD">412000</acst:InvestmentTaxCreditReceivable>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_3c620743-7648-4a40-9f52-ad9e1ce7c425"
      decimals="-3"
      id="F_0ba9341e-3dcd-4c8f-99cf-087ca8042f82"
      unitRef="U_USD">9000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_349e1080-b426-4ed9-a578-476efce50cf6"
      decimals="-3"
      id="F_b8ab8348-293b-468e-b889-b51e859ec3a9"
      unitRef="U_USD">23000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_23c5dc6d-7785-4018-a4a0-3981b25c8bab"
      decimals="-3"
      id="F_6ef14aa8-7540-4201-8736-af891556d935"
      unitRef="U_USD">36000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_fea751d3-7614-4442-a3db-d6540fa51879"
      decimals="-3"
      id="F_e9cc4717-be8c-463b-94dc-851ea7e235c1"
      unitRef="U_USD">345000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_f61b02f5-57f3-4c12-8cf6-ac25efbcbdaf"
      decimals="-3"
      id="F_1654673d-4eb2-42b5-be1c-b3f2c979d4e0"
      unitRef="U_USD">353000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_8187204f-303d-4869-a819-a4eb7d6028a3"
      decimals="-3"
      id="F_9dbdf802-3283-4e9a-8030-56000f06a4f6"
      unitRef="U_USD">348000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2b13b7d2-4aec-4346-9923-ef74e0f85053"
      decimals="-3"
      id="F_dcd4efc7-78ba-4790-a759-3525b7f8f6b5"
      unitRef="U_USD">415000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_4875e2a5-c34c-4bb6-b0fb-5d1c12cb8c02"
      decimals="-3"
      id="F_2a8cb890-e8d6-4f0c-a9a1-04b2b0d2fda6"
      unitRef="U_USD">229000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6e6bc244-b6c6-4d8b-a073-be202a4ef494"
      decimals="-3"
      id="F_c4140a65-13e2-494b-ab27-fc1463b7b71d"
      unitRef="U_USD">252000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_7a4ddfce-2b5b-46d2-8208-60d8a22d52e4"
      decimals="-3"
      id="F_3df023c2-dd40-4186-b939-c8340c2a39ad"
      unitRef="U_USD">259000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e835e3c2-21d5-4811-900e-7ca8a2f1e162"
      decimals="-3"
      id="F_66094681-b8f3-4e6d-a73f-714024d5968c"
      unitRef="U_USD">355000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_f34c5198-014f-4f67-a218-f5719b424883"
      decimals="-3"
      id="F_a83e580a-1ef2-467d-8167-2419c7998c79"
      unitRef="U_USD">226000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_ae60a243-9e5e-4f54-9f15-fb2ec877bb50"
      decimals="-3"
      id="F_a112cd4c-ba55-4614-89f9-108234316481"
      unitRef="U_USD">146000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_fe4fb9d8-fe31-4fd9-9a01-c7618803d7a7"
      decimals="-3"
      id="F_9d454996-a2df-4f5c-b0bf-12b46127f19e"
      unitRef="U_USD">312000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_407b0177-7169-41e6-882e-472705b1636f"
      decimals="-3"
      id="F_a9d28030-d999-4336-94e5-a045973daf1a"
      unitRef="U_USD">614000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d8143206-01c5-47e6-bf77-ccbbaa1a348e"
      decimals="-3"
      id="F_7a3f80d7-0327-4221-994b-d47dc7e819fb"
      unitRef="U_USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_7b149d98-d84d-4697-bd7d-09aa7cef1f43"
      unitRef="U_USD">3922000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_a088edfa-6943-41d7-ab43-0b859ea9f84b">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and development contracts and contract research organizations agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company utilizes contract manufacturing organizations (&#x201c;CMOs&#x201d;) for the development and production of clinical materials and contract research organizations (&#x201c;CROs&#x201d;) to perform services related to its clinical trials. Pursuant to the agreements with these CMOs and CROs, the Company has either the right to terminate the agreements without penalties or under certain penalty conditions. As of March 31, 2024, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; commitments from CMOs and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,020&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of c&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ommitments for the next twelve months to CROs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Raw krill oil supply contract&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 25, 2019, the Company signed a supply agreement with Aker BioMarine Antarctic AS. (&#x201c;AKBM&#x201d;) to purchase raw krill oil product for a committed volume of commercial starting material for CaPre, one of the Company&#x2019;s former drug candidates, for a total fixed value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; based on the value of krill oil at that time. As of March 31, 2022, the remaining balance of commitment amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. During the second calendar quarter of 2022, AKBM informed the Company that AKBM believed it had satisfied the terms of the supply agreement as to their obligation to deliver the remaining balance of raw krill oil product, and that the Company was therefore required to accept the remaining product commitment. The Company disagreed with AKBM&#x2019;s position and believed that AKBM was not entitled to further payment under the supply agreement. Accordingly, no liability was recorded by the Company. The dispute remained unresolved as of both March 31, 2023 and 2022. On October 18, 2023, the Company entered into an agreement with AKBM to settle any and all potential claims regarding amounts due under the supply agreement (&#x201c;Settlement Agreement&#x201d;). Pursuant to the terms of the Settlement Agreement, in exchange for a release and waiver of claims arising out of the supply agreement by AKBM and any of AKBM&#x2019;s affiliates, the Company and AKBM agreed to the following: (a) AKBM retained ownership of all raw krill oil product, including amounts previously delivered to the Company, (b) AKBM acquired and took ownership of all production equipment related to the production of CaPre, (c) AKBM acquired and took ownership of all data from research, clinical trials and pre-clinical studies with respect to CaPre, and (d) AKBM acquired and took ownership over all rights, title and interest in and to all intellectual property rights, including all patents and trademarks, related to CaPre owned by the Company. Pursuant to the terms of the Settlement Agreement, AKBM acknowledged that the CaPre assets were transferred on an &#x201c;as is&#x201d; basis, and in connection therewith the Company disclaimed all representations and warranties in connection with the CaPre assets, including any representations with respect to performance or sufficiency. The value of the raw krill oil previously delivered to the Company, the production equipment, and the intellectual property rights related to CaPre were fully impaired in prior reporting periods and had a carrying value of nil as of March 31, 2023. As of March 31, 2024, no liability was recorded by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal proceedings and disputes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes. The Company assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, the Company records a liability in its consolidated financial statements. These legal contingencies may be adjusted to reflect any relevant developments. Where a loss is not probable or the amount of loss is not estimable, the Company does not accrue legal contingencies. While the outcome of legal proceedings is inherently uncertain, based on information currently available, management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to the Company&#x2019;s financial position, results of operations, or cash flows.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reserves or liabilities have been accrued as at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsToCompleteContractsInProcess
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_e9589f0c-c89f-40e9-b9af-ed2062611ed3">no</us-gaap:CommitmentsToCompleteContractsInProcess>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_7d5eb575-72d3-4658-845e-185baceef441"
      decimals="-3"
      id="F_ca84f847-746d-452e-b252-e1724f974c98"
      unitRef="U_USD">6020000</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PurchaseObligation
      contextRef="C_1bc7c602-b685-4c20-b95a-4e946d0e035c"
      decimals="-3"
      id="F_ae27e377-5e52-4fed-a64b-c478965dc240"
      unitRef="U_USD">3100000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="C_84420b03-d4bf-41a4-a1dc-c3a81a813802"
      decimals="-3"
      id="F_df902af5-e549-4476-b707-1e309d05d6d3"
      unitRef="U_USD">2800000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities
      contextRef="C_140a03c6-59fa-4092-bf9c-59104fc56516"
      decimals="-3"
      id="F_b626f744-09b3-4e6a-b5dd-b379f52530ea"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_779b151d-a506-4172-855a-bc523254a908"
      id="F_9321f402-d6da-4101-b818-ae5c27ac6e17">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Restructuring Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 8, 2023, the Company communicated its decision to terminate a substantial amount of its workforce as part of a plan that intended to align the Company&#x2019;s organizational and management cost structure to prioritize resources to GTX-104, thereby reducing losses to improve cash flow and extend available cash resources. The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,485&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of costs primarily consisting of employee severance costs and legal fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="C_d5755bb0-b1b3-4e1a-b0d2-be4c6caa330f"
      decimals="-3"
      id="F_0508ab2d-cde0-44fa-bdbf-bfa6d90bd73b"
      unitRef="U_USD">1485000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
